<SEC-DOCUMENT>0001104659-26-031274.txt : 20260318
<SEC-HEADER>0001104659-26-031274.hdr.sgml : 20260318
<ACCEPTANCE-DATETIME>20260318172635
ACCESSION NUMBER:		0001104659-26-031274
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		80
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260318
DATE AS OF CHANGE:		20260318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Marker Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001094038
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				880277072
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37939
		FILM NUMBER:		26770583

	BUSINESS ADDRESS:	
		STREET 1:		2450 HOLCOMBE BLVD
		STREET 2:		TMC PARTNERS OFFICE 1.311
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77021
		BUSINESS PHONE:		(713) 400-6400

	MAIL ADDRESS:	
		STREET 1:		2450 HOLCOMBE BLVD
		STREET 2:		TMC PARTNERS OFFICE 1.311
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TAPIMMUNE INC.
		DATE OF NAME CHANGE:	20170629

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TAPIMMUNE INC
		DATE OF NAME CHANGE:	20070628

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENEMAX CORP
		DATE OF NAME CHANGE:	20020718
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mrkr-20251231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.2.0.5 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 3/18/2026 8:29:22 PM -->
<!-- iXBRL Library version: 1.0.9448.42501 -->
<!-- iXBRL Service Job ID: 00000000-0000-0000-0000-000000000000 -->
<html xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:mrkr="http://www.tapimmune.com/20251231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" name="us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" id="Hidden_rTRE-7XNW0K4cyqC2oQcTw">http://fasb.org/us-gaap/2025#RelatedPartyMember</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" name="us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" id="Hidden_93Ikgu4vrE69qFMe0Zr1Lg">http://fasb.org/us-gaap/2025#RelatedPartyMember</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" xs:nil="true" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" name="us-gaap:PreferredStockValue" id="Hidden_88CJo7lppUKf_UurEb1KRQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" xs:nil="true" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" name="us-gaap:PreferredStockValue" id="Hidden_WjgPJmQyyEWPfo3nuOI25g"></ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" name="us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" id="Hidden_dTBoH9MfTE64AKs-oLTQIA">http://fasb.org/us-gaap/2025#RelatedPartyMember</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" name="us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" id="Hidden_SzDJsYRNAk-RRfM_aKodzg">http://fasb.org/us-gaap/2025#RelatedPartyMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:EntityCentralIndexKey" id="Tc_bZHKzMsyNEK5R2EWwRW9hQ_2_1">0001094038</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:CurrentFiscalYearEndDate" id="Tc_-1MWiyMaqUCculqnyPQZKw_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:DocumentFiscalYearFocus" id="Tc_wyaARvKeb0qHDOA5Lg-8VQ_4_1">2025</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:DocumentFiscalPeriodFocus" id="Tc_u5ge9XNLPUCKcLAEGhMKsw_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:AmendmentFlag" id="Tc_YaiGqrT_bkCiR0_lboPU5w_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Hidden_8t_mC5yobUSo0_SotysiiQ">62159</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="As_Of_12_19_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PrivatePlacementWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_On3uaIjHpUqZni5K7dWfLQ" decimals="3" name="us-gaap:SharesIssuedPricePerShare" id="Hidden_vlSFv0gqUE-B3bsGUvHgiw">3.199</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="mrkr-20251231.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2025_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember__a5PjJFdNkGHBThsnBK4rA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_jAeiudl5qEe8J-4VzRHRzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XT2HAsu1XEKincjWBVb39A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_19_2024_To_12_19_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8VZRCOP4d0-aokYe1ivjTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-19</xbrli:startDate><xbrli:endDate>2024-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gV71OOam90epk_Du2IQJ0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HXX7qp5MoUuH8nof-BnwCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E0qy7Vq1QkiOgpqHJZmV-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ewnb_9qGskmiSR_2gvsz1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_84AY7Y29u0Wa9RpjQCDF4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oPOrqZBAU0ezQq1EPL4X1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_QeGMQYKwNUKt8wiYv26-mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_26_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_pn_qg4MJb0i_SQXgwMffCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_19_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_NdnoCXF10U2RaVtcYYPkIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_H1iRzvGfK0C3IBU4YuN-sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IyxgTtJMsUeI7g0JQzRu5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tksY2KuphU-6mtLP78kkWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_12_2025_To_2_12_2025_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_RyHxP5Ri-UCIy9cqONYc_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentiveAward2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-12</xbrli:startDate><xbrli:endDate>2025-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_M_rPwQol10ywKLcDBKqTtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_17_2025_To_11_17_2025_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_0n8Ce_-UXUS8UIExWuVJBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentiveAward2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-17</xbrli:startDate><xbrli:endDate>2025-11-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_12_2025_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_br-AgiIl10O-PTuaEnCrgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentiveAward2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_12_2025_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_-zpixAd6L0ukz7Q5PRFHjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentiveAward2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_19_2020_To_5_19_2020_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_-5xby4R-iU6ab24NiQ858Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-19</xbrli:startDate><xbrli:endDate>2020-05-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2025_To_11_1_2025_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_m9FesoReQ0m7x7fy6w2Hag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentiveAward2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-01</xbrli:startDate><xbrli:endDate>2025-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_31_2025_To_10_31_2025_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_qkF9ZLP_WkaIr8Qab56IzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentiveAward2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-31</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_Y5VZDx-btUSB5iQ3XO7H4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_26_2025_To_8_26_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_dZBSMZhgiU-56Poy6Ff-Yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-26</xbrli:startDate><xbrli:endDate>2025-08-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_17_2025_To_7_21_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_bAz_p3gArkWolV47xKRr_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-17</xbrli:startDate><xbrli:endDate>2025-07-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_23_2024_To_12_23_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_uXfGzxM0uEOSkZZ_6NldVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-23</xbrli:startDate><xbrli:endDate>2024-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_19_2024_To_12_19_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_O2p_zKEtQUqaRKBbLOCA1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-19</xbrli:startDate><xbrli:endDate>2024-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_us-gaap_GrantMember_6LnqjjsZJEiYA6ZxeN_-8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_CpritPancreaticGrantMember_YmkzplPQXEqeidRVY8TO_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:CpritPancreaticGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_tIJI_NC6ykGWgCWOPj17jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_GrantMember_UiYnDW3Fo0WMqnl0BxBg_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_RRTLLDVCo0iNI2tLPudd5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_CkarEX95-0qd9acV3OWC_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_dJoyNhvuRUeMzzqqNeKOvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_qobRXgqC6kWkIYzc8lU_ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthNationalCancerInstituteGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_AKZHg4JWuUyRUOYrneJE0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:FdaGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_bMeEXnqqVEGomKtJCoNZAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_L0Z_1a2Gv0qiuiDAeZfKZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_7bCo5DiTM02jrNls_29_eA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_Wv20gcHvB0KjVifO_1x-LQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCoAndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_F38uZMcfxU2b3xquA6y5bA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_mrkr_CellReadyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_AVpatNJHyUqIpBAODzA4gA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CellReadyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_mrkr_CellReadyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__-jgDBmfiUmEu0GZmK8-5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CellReadyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_SpvmUFoDl0q5J75fLE_V5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ESA9zEAYIUOC4PrJsuQIKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_18qBhBV9dU2bbek_wtQbrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_1TeDARXsOkC9hEbasgXmxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_Ek7VnObDF0qwBQZljA5lrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_CellReadyMember_EXj1TZHoG0iefhOIN4rydg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:CellReadyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_y1zLnl6EqUepjN6-dcbOxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_CellReadyMember_4FOpwyVQrECS-MHeaC1tvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:CellReadyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Sob6q5KlDEqJgHe6539l1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Odf2gYh8fUCDHWMqpklBpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalTaxJurisdictionOtherMember_X-zB0CIm-UCdX3pra_QnCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalTaxJurisdictionOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_stpr_TX_Rjqllw7i7k-FAGtEiFvgPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:TX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalTaxJurisdictionOtherMember_RP8A9ma7LU69CXCfisa1tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalTaxJurisdictionOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_stpr_TX_B-Dm5j-e00KX7oWR9bXJxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:TX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_hpcaPdhzZESFYUuK8cOwRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_XnQVMZBaJUW4WC5UTNTybw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_ka9khI5BP0KG3WlDMZO44g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_irhoM80iL0yHiHWgBsAv_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mrkr:NationalInstitutesOfHealthNationalCancerInstituteGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_FdaGrantMember_faf3JBchfUmF26_0A8acNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mrkr:FdaGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_mrLGat3Upk2fb1jB4KArIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mrkr:CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_-Zh_8JjoQEG-VAt8uJFkjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_mMsw9pTVxUmPUqQGanMoDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_WeW3pJ_MmkC27F7VxYyoRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mrkr:NationalInstitutesOfHealthNationalCancerInstituteGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_YiV5PV-xXEmJq6NEHauChA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mrkr:CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_X_oxJZvmIEKv7qs6HvnyNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_cca_sB7gSU6dxZHLZj013g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PrivatePlacementWarrantMember_cafAhZMIDkSljx-lvFkWag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mrkr:PrivatePlacementWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_Nng2hqeyCUeMaAu9fclCqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mrkr:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_19_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PrivatePlacementWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_On3uaIjHpUqZni5K7dWfLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mrkr:PrivatePlacementWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_19_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8uiS2_V-yU681VJlw1Q9uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mrkr:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PrivatePlacementWarrantMember_A7nPIRhbOkCSTYcVdsqkJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mrkr:PrivatePlacementWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_jieysXAEz0G_tGMRFzVAhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mrkr:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_jtXp7bckLE2CuJhkJ9PNfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_MqvvcKTOj0eV0u3Nau83Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aSuKfM4-akyKvKZsn6tCGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_aIjiS1PliUO1FmEZTPTlFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_B2nRyEV--0GS0eskNh548A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Ey1Xk4v6f0yORZDZoGT7FA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1iM8joIEOEKotgV079FgPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_j5D-je0g6E6fJSRo58Oxow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Cf4uLI9Y-kqC1zLcm3sQTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pYHphuyyu066BcjVFoJ8QA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xtMtVYunjEei0jSpfl8XCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C8n1YFIWQkCqU7lJuKSmFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_oLyCD0BiIEeiK_BggHiIyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_17_2025_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_XfMX7dcV3UWRP3Ne6O4l6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentiveAward2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_12_2025_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_K5BoRY6DdkuHU8WoQnkViA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentiveAward2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_FwxvILLeMU2KaVIewcISUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_at2LqTEclEeq_pEAvIINhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_22_2024_To_2_22_2024_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_66lUgXxPyUi3q214hjo-SQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:CellReadyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-22</xbrli:startDate><xbrli:endDate>2024-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineLicenseAgreementMember_Eej9dmqQ10SaSsQkQOu8NQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrkr:BaylorCollegeOfMedicineLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineLicenseAgreementMember_mKK3QAV17UG31xtSaZ_jxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrkr:BaylorCollegeOfMedicineLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_WilsonWolfManufacturingCorporationMember_SnKdFpBTG0ewLmW3QKOiwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_zGmyKdpTO0WFcYUPxTzPtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:CellReadyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineMember_ip2nTF_Fk0CYXX-yEMZW9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrkr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mrkr_WilsonWolfManufacturingCorporationMember_88XPTdVeZEeIbHu_8g-p9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_c3M_pD1k30WAzZa10zvfBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:CellReadyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineMember_-usF9LGyt0GIxeKFzPNwug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrkr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_K0kZGOM0S0iI7apUnHkXog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrkr:CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2024_To_8_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_he6YWLaAFUG7GJ38OI7D1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2024_To_8_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember__Ch-QALgtkqd7AZY24MzHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_WnNM8CWplk24UBwBqIF4_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_MnQUj6Ma20ugl93GMps1dw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:FdaGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_us-gaap_RelatedPartyTransactionAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_AFB5466R20GWPhFeBp81GQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrkr:CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_mjoYIWkR20GbZX_dLT8n1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthNationalCancerInstituteGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_J7SfSASjZE-svWLtQE3gbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrkr:CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_27_2025_To_3_27_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_CellReadyAgreementMember_JD_kClq_cE2FGVMW6U031Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrkr:CellReadyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-27</xbrli:startDate><xbrli:endDate>2025-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_ziCCxC0XiEqj3xjfTYljxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_670n_eqWFEyvZOe0MstmvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_v3gveAJvr0u79DQtC91MKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_qnTBapqjVEaOu5WEAR6N1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthNationalCancerInstituteGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_ZoSbOHwhNE-hXUpvIJbwbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:FdaGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_AdditionalCpritGrantMember_nxUvKve8xkGalcxFRXPFew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:AdditionalCpritGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2024_To_11_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_nPc36OB43EulxDCPK9rlUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCoAndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_Rn5SiIOVNEaGW-wHHWjNLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_U2becBy6kUyXW95FuWcLrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mrkr:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2025_To_12_31_2025_Ivl427bMU0uiB1nIEy7zew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_7SBk-9LcdEuP16DOVYgcxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_16_2026_adwy4cFtS0uxZ5Iqr7vnRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 15pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:47.07pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c02812c5_654a_4ae3_bdd7_6d1b3a889694"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:DocumentType" id="Narr_cW-lt-6BGESoOgExXsfKlA"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ac7c0859_eda2_4f03_8547_effe1ab84986"></a><a id="Tc_Zl1QIP4Gv0aY2X5dPiM2ww_0_1"></a><a id="Tc_JgoUEAf2IUyps95ybvKhrQ_2_0"></a><a id="Tc_tKuzt3PfAEWN6YeQcQMnnw_4_0"></a><a id="Tc_xNMjn9zGiUqlpkLFZahopA_6_1"></a><a id="Tc_I0Cxink0ck2ax6uIARvABw_8_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style=""><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:DocumentAnnualReport" id="Tc_BU7EjmJXYUeFsiXijaGYuw_0_0"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr><tr style=""><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">For the Fiscal Year Ended </b><ix:nonNumeric format="ixt:date-monthname-day-year-en" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:DocumentPeriodEndDate" id="Narr_VidWjcGnZkq90dJCi8gO5Q"><b style="font-size:7pt;font-weight:bold;">December 31, 2025</b></ix:nonNumeric></p></td></tr><tr style=""><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt:fixed-false" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:DocumentTransitionReport" id="Tc_iQ1NGIm8WkST-eEs3UduaQ_6_0"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr><tr style=""><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">For the transition period from _______________ to ______________.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:EntityFileNumber" id="Narr_gS8P3WhvOkm26eJHl37zyw"><b style="font-size:7pt;font-weight:bold;">001-37939</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><img src="mrkr-20251231x10k001.jpg" alt="Graphic" style="display:inline-block;height:47.07pt;width:177.72pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:EntityRegistrantName" id="Narr_LsLoK0LDX0qEx-W28Ge3Bw"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MARKER THERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_11ec842d_d288_4c27_b8c1_6be4f6168352"></a><a id="Tc_mhJbGt9UwE-dZjC3c84E9w_1_0"></a><a id="Tc_H_R8RKByvUKc_s2cYjfwPw_1_2"></a><a id="Tc_b9kX9kDXXECjJ1UtQNdeRA_3_0"></a><a id="Tc_NcnbtNQuqEe12dkdCtQjRw_4_0"></a><a id="Tc_ZRgdnPrbEk-phOH4wBnLUA_4_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style=""><td style="vertical-align:bottom;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:EntityIncorporationStateCountryCode" id="Tc__z8gOWLMIUujU1vBW5so1w_0_0"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:top;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:EntityTaxIdentificationNumber" id="Tc_2ScVrPbnnkW8pCYiJHGS2g_0_2"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">45-4497941</b></ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(State or other jurisdiction of<br/>incorporation)</p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(IRS Employer Identification No.)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:EntityAddressAddressLine1" id="Narr_TwQp7eXGaUq0o1aB_UnqTw"><b style="font-size:7pt;font-weight:bold;">2450 Holcombe Blvd, TMC Partners Office 1.311</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:EntityAddressCityOrTown" id="Narr_HjRROSup5kyvc95eEXhNzw"><b style="font-size:7pt;font-weight:bold;">Houston</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:EntityAddressStateOrProvince" id="Narr_boyqoD_xwU6OKHqr1UwzTQ"><b style="font-size:7pt;font-weight:bold;">Texas</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:EntityAddressPostalZipCode" id="Tc_MOf6ur2NvUuwv2COBR7Q-g_3_2"><b style="font-size:7pt;font-weight:bold;">77021</b></ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(Zip code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:CityAreaCode" id="Narr_GHakC3a0ak21fxttkg_S2w"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">713</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">) </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:LocalPhoneNumber" id="Narr_G9e8r8P24UuvZzZO3S5I3w"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">400-6400</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">(Telephone Number)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.91%;"><tr style=""><td style="vertical-align:top;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(Former name, former address and former fiscal year, if changed since last report)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;text-transform:uppercase;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_30fd9b93_e51f_4292_9f56_eefebf830d65"></a><a id="Tc_p7-2rA4hREyLstKA13Y6Xg_0_0"></a><a id="Tc_jr2Yn8SXX0WeYr-kq0obHg_0_2"></a><a id="Tc_iSB2VGRh2U6Hz5PvlpKW1A_0_4"></a><a id="Tc_VaKV_0wV_0C9P3LKTIrorQ_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style=""><td style="vertical-align:bottom;width:35.52%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:0.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:top;width:29.07%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:top;width:0.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:top;width:33.78%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr style=""><td style="vertical-align:top;width:35.52%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:Security12bTitle" id="Tc_frmzYKUC2k6Koo-9ixCziA_1_0"><span style="font-size:7pt;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:0.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:29.07%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:TradingSymbol" id="Tc_VMLt_vG8pkO4gnCyQg5wvA_1_2"><span style="font-size:7pt;">MRKR</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:0.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.78%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;">The </span><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:SecurityExchangeName" id="Narr_tR_8331b50OIYzWw7JtmvA"><span style="font-size:7pt;">Nasdaq</span></ix:nonNumeric><span style="font-size:7pt;"> Stock Market LLC</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;">&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_otiVyJxaD0qpDdFoRucp5g"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 of Section&#160;15(d)&#160;of the Act. Yes </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;">&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:EntityVoluntaryFilers" id="Narr_L7wrfVJX8USN4EpW9urVYQ"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant (1)&#160;filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:EntityCurrentReportingStatus" id="Narr_d_hi4FfSwUW_wO4-r5HauQ"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span><span style="font-size:7pt;">&#160;No </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:EntityInteractiveDataCurrent" id="Narr_GvfnUgIqlEG3M0jFp_UigQ"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span><span style="font-size:7pt;">&#160;&#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; accelerated filer&#8221;, &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8328f2dc_9b0a_4e2e_92e1_9eeb50d1cfd8"></a><a id="Tc_a_eRCQgdJUqiXok99fMM-Q_1_0"></a><a id="Tc_J5NYU54Y2EyfnXic2tx5Wg_1_1"></a><a id="Tc_Q5-8UCV-6kyTObPFOxIUvg_1_2"></a><a id="Tc_ROxSnMFFtEGF9hJTh5aEqw_1_3"></a><a id="Tc_0cbKdcpf_EqhOy_C1m6r3g_2_1"></a><a id="Tc_DYijTt2TC0K7mggZr6AyTw_2_2"></a><a id="Tc_l9ybKVrUFEebxVCIZeTmgA_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:32.29%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:32.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:32.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:EntityFilerCategory" id="Tc_vRGKFz588k6yPNRdKbtHkw_2_0"><span style="font-size:7pt;">Non-accelerated filer </span></ix:nonNumeric></p></td><td style="vertical-align:top;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt:fixed-true" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:EntitySmallBusiness" id="Tc_tKeigqAj4kS6h_p6fN2yaQ_2_3"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:top;width:32.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt:fixed-false" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:EntityEmergingGrowthCompany" id="Tc_3t3owbm8WUilkEUfsitfQw_3_3"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:IcfrAuditorAttestationFlag" id="Narr_YjWuHgfUjUuE7r_VgJrOPQ"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_rW4n31Hfp0WZPqnlEsYl9Q"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;">Indicate by checkmark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:EntityShellCompany" id="Narr_pX9FSev7gkWW8hGbzymHWg"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;No </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June&#160;30, 2025 (the last day of the registrant&#8217;s most recently completed second fiscal quarter) based on the closing sale price of $1.53 as reported on the Nasdaq Capital Market as of that date was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_6_30_2025_7SBk-9LcdEuP16DOVYgcxw" decimals="0" name="dei:EntityPublicFloat" id="Narr_SpVhx60BzE6tVNaUmY9Aew">17,312,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">The registrant had <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_3_16_2026_adwy4cFtS0uxZ5Iqr7vnRw" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_OcOGn227ekS3S6QI8T1jPw">16,673,127</ix:nonFraction> shares of common stock outstanding as of March 16, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Documents Incorporated By Reference</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="Tb_H2llRE63FEqvchuwT7LraA" escape="true"><span style="font-size:7pt;">Portions of the registrant&#8217;s proxy statement relating to registrant&#8217;s 2025 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;) to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than 120&#160;days after the close of the registrant&#8217;s fiscal&#160;year, are incorporated by reference in Part&#160;III of this Annual Report on Form&#160;10-K. Except with respect to information specifically incorporated by reference in this Annual Report on Form&#160;10-K, the Proxy Statement is not deemed to be filed as part of this Annual Report on Form&#160;10-K</span></ix:nonNumeric><span style="font-size:7pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:justify;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:0pt;text-align:center;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f5eb9221_261f_495a_a6e5_a1635223cbbd"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#FORWARDLOOKINGSTATEMENTS_197689"><span style="font-style:normal;font-weight:normal;">FORWARD&#160;LOOKING&#160;STATEMENTS</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">ii</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTI_513007"><b style="font-style:normal;font-weight:bold;">Part I</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM1BUSINESS_525596"><span style="font-style:normal;font-weight:normal;">Item 1.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1BUSINESS_525596"><span style="font-style:normal;font-weight:normal;">Business&#160;</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS_686864"><span style="font-style:normal;font-weight:normal;">Item 1A.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS_686864"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">26</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_521175"><span style="font-style:normal;font-weight:normal;">Item 1B.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_521175"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">62</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM1CCYBERSECURITY_814205"><span style="font-style:normal;font-weight:normal;">Item 1C.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1CCYBERSECURITY_814205"><span style="font-style:normal;font-weight:normal;">Cybersecurity</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">62</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM2PROPERTIES_338462"><span style="font-style:normal;font-weight:normal;">Item 2.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM2PROPERTIES_338462"><span style="font-style:normal;font-weight:normal;">Properties&#160;</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">64</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM3LEGALPROCEEDINGS_282506"><span style="font-style:normal;font-weight:normal;">Item 3.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM3LEGALPROCEEDINGS_282506"><span style="font-style:normal;font-weight:normal;">Legal Proceedings&#160;</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">64</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURE_456568"><span style="font-style:normal;font-weight:normal;">Item 4.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURE_456568"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosure&#160;</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">64</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTII_862782"><b style="font-style:normal;font-weight:bold;">Part II</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:top;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"><span style="font-style:normal;font-weight:normal;">Item 5.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"><span style="font-style:normal;font-weight:normal;">Market For Registrant&#8217;s Common Equity, Related Stockholder Matters And Issuer Purchases Of Equity Securities&#160;</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">65</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM6RESERVED"><span style="font-style:normal;font-weight:normal;">Item 6.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM6RESERVED"><span style="font-style:normal;font-weight:normal;">[Reserved]</span></a>&#160;</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">65</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-style:normal;font-weight:normal;">Item 7.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion And Analysis Of Financial Condition And Results Of Operations&#160;</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">65</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-style:normal;font-weight:normal;">Item 7A.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-style:normal;font-weight:normal;">Quantitative And Qualitative Disclosures About Market Risk&#160;</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM8FINANCIALSTATEMENTS_684464"><span style="font-style:normal;font-weight:normal;">Item 8.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM8FINANCIALSTATEMENTS_684464"><span style="font-style:normal;font-weight:normal;">Financial Statements&#160;</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-style:normal;font-weight:normal;">Item 9.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-style:normal;font-weight:normal;">Changes In And Disagreements With Accountants On Accounting And Financial Disclosure&#160;</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM9ACONTROLSANDPROCEDURES_136839"><span style="font-style:normal;font-weight:normal;">Item 9A.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9ACONTROLSANDPROCEDURES_136839"><span style="font-style:normal;font-weight:normal;">Controls And Procedures</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM9BOTHERINFORMATION_833436"><span style="font-style:normal;font-weight:normal;">Item 9B.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9BOTHERINFORMATION_833436"><span style="font-style:normal;font-weight:normal;">Other Information&#160;</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">78</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9CDISCLOSUREREGARDINGFOREIGNJURISD_4"><span style="font-style:normal;font-weight:normal;">Item 9C.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9CDISCLOSUREREGARDINGFOREIGNJURISD_4"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">78</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTIII_534190"><b style="font-style:normal;font-weight:bold;">Part III</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-style:normal;font-weight:normal;">Item 10.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers And Corporate Governance&#160;</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">79</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_899018"><span style="font-style:normal;font-weight:normal;">Item 11.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_899018"><span style="font-style:normal;font-weight:normal;">Executive Compensation&#160;</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">79</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><span style="font-style:normal;font-weight:normal;">Item 12.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><span style="font-style:normal;font-weight:normal;">Security Ownership Of Certain Beneficial Owners And Management And Related Stockholder Matters&#160;</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">79</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-style:normal;font-weight:normal;">Item 13.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-style:normal;font-weight:normal;">Certain Relationships And Related Transactions, And Director Independence&#160;</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">79</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"><span style="font-style:normal;font-weight:normal;">Item 14.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"><span style="font-style:normal;font-weight:normal;">Principal Accounting Fees And Services&#160;</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">79</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTIV_855523"><b style="font-style:normal;font-weight:bold;">Part IV</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM15EXHIBITSFINANCIALSTATEMENTSCHEDULE"><span style="font-style:normal;font-weight:normal;">Item 15.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM15EXHIBITSFINANCIALSTATEMENTSCHEDULE"><span style="font-style:normal;font-weight:normal;">Exhibits, Financial Statement Schedules&#160;</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">80</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM16FORM10KSUMMARY_680075"><span style="font-style:normal;font-weight:normal;">Item 16.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM16FORM10KSUMMARY_680075"><span style="font-style:normal;font-weight:normal;">Form 10-K Summary&#160;</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">83</p></td></tr><tr style=""><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_412578"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">84</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f9bd6a35_a042_4ae4_aaa0_03cdd21fc0bd"></a><a id="FORWARDLOOKINGSTATEMENTS_197689"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This annual report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part&#160;I, Item&#160;1:&#160;&#8220;Business,&#8221; Part&#160;I, Item&#160;1A: &#8220;Risk Factors,&#8221; and Part&#160;2, Item&#160;7: &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; but are also contained elsewhere in this annual report. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;expect&#8221;, &#8220;plan&#8221;, &#8220;intend&#8221;, &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;predict&#8221;, &#8220;potential&#8221; or &#8220;continue&#8221;, the negative of such terms or other comparable terminology. These statements speak only as of the date of this Annual Report and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.&#160;We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations.&#160; Forward-looking statements in this annual report include statements as to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to continue as a going concern;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, progress and results of clinical trials of multi antigen recognizing (&#8220;MAR&#8221;)-T cell therapies (formerly known as multi-tumor associated antigen-specific T cells, or multiTAA) and our other product candidates, including statements regarding the timing of initiation and completion of preclinical studies or clinical trials or related preparatory work, the period during which the results of the trials will become available and our research and development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of any submission of filings for regulatory approval of product candidates and our ability to obtain and maintain regulatory approvals for product candidates for any indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully commercialize product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the potential benefits, activity, effectiveness and safety of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the size of the patient populations, market acceptance and opportunity for and clinical utility of product candidates, if approved for commercial use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our manufacturing capabilities and strategy, including the ease, scalability and commercial viability of our manufacturing methods and processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the scope of any approved indications for product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential benefits of and our ability to maintain our relationships and collaborations with the Baylor College of Medicine (&#8220;BCM&#8221;) and other collaboration or strategic relationships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to manufacture our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to use the MAR-T cell platform to develop future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional funding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to identify, recruit and retain key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to protect and enforce our intellectual property position for our product candidates, and the scope of such protection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our financial performance;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitive position and the development of and projections relating to our competitors or our industry; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of laws and regulations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">You should refer to &#8220;Item&#160;1A. Risk Factors&#8221; in this annual report for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this annual report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this annual report represent our views as of the date of this annual report. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">You should read this annual report and the documents that we reference in this annual report and have filed as exhibits to this annual report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In this report all references to (i) &#8220;Marker&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the &#8220;Company&#8221; mean Marker Therapeutics, Inc. and its wholly-owned subsidiaries, Marker Cell Therapy, Inc. and GeneMax Pharmaceuticals, Inc., which wholly owns GeneMax Pharmaceuticals Canada Inc., unless the context otherwise requires; (ii) &#8220;SEC&#8221; refers to the Securities and Exchange Commission; (iii) &#8220;Securities Act&#8221; refers to the United States <i style="font-style:italic;">Securities Act of 1933</i>, as amended; (iv) &#8220;Exchange Act&#8221; refers to the United States <i style="font-style:italic;">Securities Exchange Act of 1934</i>, as amended; and (v) all dollar amounts refer to United States dollars unless otherwise indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">iii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:124.53pt;"><a id="_25c49343_e8da_41c3_8f46_98e863928194"></a><a id="PARTI_513007"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PART I</b></p><a id="ITEM1BUSINESS_525596"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 1. BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage immuno-oncology company specializing in the development of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Harnessing millions of years of immunologic evolution, Marker&#8217;s Multi Antigen Recognizing (&#8220;MAR&#8221;)-T cell technology is designed to recognize and kill highly heterogeneous tumors without the need for genetic modifications. This approach selectively expands natural tumor-specific T cells from a patient&#8217;s/donor&#8217;s blood that are capable of recognizing a broad range of tumor associated antigens, or TAAs. Unlike other T cell therapies, MAR-T cells are able to recognize hundreds of different epitopes within up to six tumor-specific antigens to produce broad spectrum anti-tumor activity. Targeting multiple antigens simultaneously exploits the natural capacity of T cells to recognize and kill tumor targets via native T cell receptors (&#8220;TCR&#8221;), while limiting tumor adaptation/escape by antigen-negative selection or antigen down-regulation. When infused into a patient with cancer, the MAR-T cells are designed to kill cancer cells expressing the TAA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We licensed the underlying technology for MAR-T cell therapy from Baylor College of Medicine, or BCM, in March 2018. BCM had utilized the therapy in seven exploratory clinical trials. In these studies, BCM treated over 150 patients suffering from a variety of cancers including lymphoma, multiple myeloma, acute myeloid leukemia, or AML, acute lymphoblastic leukemia, or ALL, pancreatic cancer, breast cancer and various sarcomas. In those studies, BCM saw evidence of clinical benefit, expansion of infused cells, and decreased toxicity compared to other cellular therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We anticipate to continue to advance two product candidates for 3 clinical indications as part of our MAR-T cell program for:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Off-the-Shelf (&#8220;OTS&#8221;) product in various indications (e.g., MT-401-OTS in AML or MDS)</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not genetically engineer our MAR-T cell therapies and we believe that our product candidates are superior to T cells engineered with chimeric antigen receptors, or CAR-T, for several reasons including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Multiple targets &#8594; enhanced tumoricidal effect&#8594; minimized tumor immune escape</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical safety &#8594; no treatment-related side effects, including immune effector cell-associated neurotoxicity syndrome (ICANS) or other severe adverse effects (SAEs), were attributed to the use of MAR-T cell therapies to date</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-genetically engineered T cell products &#8594; selective expansion of tumor-specific T cells from a patient&#8217;s or donor&#8217;s blood capable of recognizing a broad range of tumor antigens &#8594; no risk of mutagenesis and reduced manufacturing complexity &#8594; lower cost</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mrkr-20251231x10k002.jpg" alt="Graphic" style="display:inline-block;height:124.48pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:511.43pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For these reasons, we believe our endogenous T cell receptor-based therapies may provide meaningful clinical benefit and safety to patients with both hematological and solid tumors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that the simplicity of our manufacturing process allows additional modifications to expand MAR-T cell recognition of cancer targets. For example, we are assessing the potential of combining MAR-T cell products with other products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Company-Sponsored Clinical Development of MAR-T Cell Therapies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">MT-601 for the Treatment of Lymphoma</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We developed MT-601, a MAR-T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are evaluating the safety and efficacy of MT-601 in a Phase 1, multicenter, open-label study (APOLLO) in participants with relapsed lymphoma who either failed or are ineligible for anti-CD19 CAR-T cell therapy. MT-601 is a MAR-T cell product that specifically targets six different tumor antigens upregulated in lymphoma cells (Survivin, PRAME, WT1, NY-ESO-1, SSX-2, MAGEA-4). Although CD19-targeting CAR-T cell therapies have gained acceptance as treatment for patients with lymphoma, 40-60% of patients relapse within the first year of treatment (<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Chong et al, N Engl J Med, 2021; Neelapu et al, Blood, 2023</span>.). These post-CD19 CAR-T relapsed patients currently have no approved standard of care, illustrating a high unmet medical need and urgency for new therapies. In addition, CAR-T cells are associated with severe side effects such as CRS or ICANS and may increase the risk for secondary malignancies (<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">U.S. Food and Drug Administration, November 28, 2023</span>). Data from clinical trials to date have demonstrated that MAR-T cells are well tolerated with no evidence of ICANS. In addition, Marker&#8217;s non-engineered MAR-T cell approach selectively expands natural tumor-specific T cells from a patient&#8217;s blood that can recognize a broad range of tumor antigens, minimizing the risk of mutagenesis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2022, the FDA cleared our IND application for MT-601 for the treatment of patients with relapsed non-Hodgkin lymphoma who have failed or are ineligible to receive anti-CD19 CAR-T cell treatment. The Phase 1 APOLLO trial was initiated in January 2023. In June 2023, we reported first enrollment in the dose escalation stage of the Phase 1 study. In August 2025, the Company provided an update on the progress and clinical observations from the Phase 1 study, with a data cutoff date of June, 2025. In this update, clinical data was available for a total of 24 B cell lymphoma patients from 7 clinical sites across the United States, including 15 patients with Non-Hodgkin Lymphoma (&#8220;NHL) and 9 patients with Hodgkin Lymphoma (&#8220;HL&#8221;). At the time of the data cutoff, 12 NHL and 9 HL patients have been assessed. Study participants showed objective responses and a favorable safety profile with and without lymphodepletion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Key findings from the APOLLO study include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Safety</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; The dose escalation portion of the study tested doses ranging from 100x10</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">6</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">-400x10</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">6</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> cells. Infusion of MT-601 was well tolerated in all study participants, with no observation of immune-effector cell associated neurotoxicity syndrome (ICANS) and two reported Grade 1 cytokine release syndrome (&#8220;CRS&#8221;) events (fever; no treatment was required). No dose limiting toxicities (&#8220;DLTs&#8221;) or immune effector cell-associated neurotoxicity syndrome (&#8220;ICANS&#8221;) have been reported to date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Efficacy and Duration of Response</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; Eight out of 12 NHL patients achieved objective responses (66%), with 6 patients demonstrating complete response (&#8220;CR&#8221;) as best response (50%). Durable responses were observed (range 3-24 months) with 5 NHL patients showing continued response over 6 months, including 3 patients with over 12 months durability. Seven out of 9 HL patients had objective responses (78%), with 1 patient demonstrating CR (11%) highlighting the versatility of MT-601 across multiple histologies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on these favorable safety and efficacy outcomes, the study has advanced to the dose expansion phase, evaluating MT-601 at the highest dose level in patients with Diffuse Large B Cell Lymphoma (&#8220;DLBCL&#8221;) who have relapsed after anti-CD19 CAR-T therapy or are ineligible for CAR-T treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">MT-601 for the Treatment of Pancreatic Cancer</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">We reported data for a Phase 1/2 clinical trial (TACTOPS) conducted at Baylor College of Medicine demonstrating encouraging objective clinical responses and a disease control rate of 84.6% when combining MAR-T cells (targeting five TAAs) with frontline chemotherapy in patients with pancreatic cancer. To date, no cytokine release syndrome or neurotoxicity have been observed in this trial (Musher BL, Vasileiou S, Smaglo BG et al, Nat Med, 2026). </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:212.08pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In January 2022, the FDA granted orphan drug designation to MT-601 for the treatment of patients with pancreatic cancer. The FDA cleared our IND application for MT-601 in November 2022 to initiate the PANACEA study, a Phase 1 multicenter clinical trial in locally advanced, unresectable or metastatic pancreatic cancer to assess the safety and efficacy of MT-601 in combination with front-line chemotherapy. The PANACEA trial will include a dose escalation portion followed by a dose expansion portion. In 2024, the Company was awarded a $9.5 million grant from the Cancer Prevention &amp; Research Institute of Texas (&#8220;CPRIT&#8221;) and a $2 million grant from the National Institutes of Health (&#8220;NIH&#8221;) Small Business Innovation Research (&#8220;SBIR&#8221;) program to support the clinical investigation of MT-601 in patients with metastatic pancreatic cancer. With the support of these grants, we will be able to advance MT-601 in pancreatic cancer without affecting our operations in the ongoing study of MT-601 in patients with lymphoma. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">MT-401-OTS Program</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Since January 2024, Marker has been advancing MT-401 in an OTS program in patients with AML or MDS in the Phase 1 RAPID study. MT-401-OTS has the potential to provide a fast treatment option for patients with rapidly progressing diseases. The Company believes that using commercially available leukapheresis material from heathy donors can facilitate large-scale manufacturing and expedite treatment as fast as 72 hours, while also enabling broader scalability and accessibility of cell therapies at a lower per-dose cost. We have established a cellular inventory manufactured from heathy donors, and anticipate that a single donor could provide treatment for approximately 40 patients. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In October 2025, the Company announced that the first patient has been treated in the OTS program, with encouraging preliminary safety data. This observation is consistent with the favorable safety profile and tolerability previously reported for MAR-T cells. The OTS product will be initially investigated in patients with AML or MDS, with the potential to be expanded to other indications. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">With the grant support from the FDA Orphan Products Grant program, NIH Small Business Innovation Research (&#8220;SBIR&#8221;) program and the Cancer Prevention and Research Institute of Texas (&#8220;CPRIT&#8221;), the Company will be able to advance the OTS program without affecting the investigation of its lead asset, MT-601, in patients with relapsed lymphoma. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Pipeline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our clinical-stage pipeline is set forth below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mrkr-20251231x10k003.jpg" alt="Graphic" style="display:inline-block;height:212.08pt;width:423.69pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cp_text_1_99"></a><a id="_cp_text_2_108"></a><a id="_cp_text_1_109"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our MAR-T cells are designed to enhance the capacity of non-engineered T cells to identify and kill cancer by increasing the diversity and quantity of naturally occurring cancer killing T cells within the patient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our goal is to become a leader in the development and commercialization of transformative immunotherapies for the treatment of hematological malignancies and solid tumors. We are developing a portfolio of highly differentiated T cell therapies utilizing the MAR-T cell platform that we believe has the potential to significantly disrupt the current cell therapy landscape, while substantially improving survival and quality of life for patients with cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The key elements of our strategy include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Expedite clinical development, regulatory approval, and commercialization of our lead product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on the encouraging clinical data from the Phase 1 APOLLO study, we are prioritizing the advancement of MT-601 in patients with relapsed lymphoma and plan to advance the OTS program initially in patients with AML or MDS, with the potential to be expanded to other indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We intend to initiate future additional clinical trials in other tumor types based on emerging data.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Continue to collaborate with our partners and increase our clinical activities to improve and develop adoptive cell therapy technologies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We intend to continue to contract and collaborate with third-parties to perform a wide variety of services to ensure the continuation of our research and development efforts, with the goal of optimizing our manufacturing process, product quality and commercial scalability. Marker previously optimized the MAR-T cell manufacturing process by decreasing the number of manipulations, semi-closing the system and reducing the total manufacturing time from the original 36 days (BCM studies) to nine days. We believe the improved manufacturing process enables products with increased antigen specificity and diversity, both of which have a strong linear correlation to anti-tumor activity and has resulted in a four-fold increase in potency in vitro.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Invest in our platform to maximize the beneficial outcomes for cancer patients.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to explore new product opportunities by increasing and/or customizing the antigens we target to expand the indications in which the MAR-T cell products will be efficacious, including hematologic malignancies or solid tumors. Additionally, our research and development efforts may include the exploration of different doses and/or frequency of dosing and the relationship of these factors with potential therapeutic benefit.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Leverage our relationships with our founding institutions, scientific founders and other scientific advisors.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our world-renowned scientific founders and scientific advisors have made seminal contributions to major discoveries in the field of immuno-oncology, and have significant experience in oncology, immunology and cell therapy. We intend to significantly leverage the knowledge, experience and advice of our scientific founders and advisors, as well as the institutional expertise of BCM and our other major institutional partners, to advance our therapies through the clinic and into commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Background and History of Cancer Immunotherapies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Despite advances in options for treatment, cancer continues to be one of the main causes of death in developed countries. Historically, cancer therapy has been constrained to surgery, radiation, and chemotherapy. More recently, advances in the understanding of the immune system&#8217;s role in cancer surveillance have led to immunotherapy becoming an important treatment approach. Cancer immunotherapy began with treatments that nonspecifically activated the immune system and had limited efficacy and/or significant toxicity. In contrast, newer immunotherapy treatments activate specific, potent immune cells, leading to improved safety and efficacy. Within the immunotherapy category, treatments have included vaccines, cytokine therapies, antibody therapies, and adoptive cell therapies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In 1996, Dr. Dana Leach, Dr. Matthew Krummel and Dr. James Allison reported that monoclonal antibodies, or mAbs, blocking CTLA-4 could treat tumors in animal models. Subsequently, mAbs that targeted CTLA-4 and PD-1 became known as immune checkpoint inhibitors, or ICIs. Immune checkpoints are a means by which cancer cells inhibit or turn down the body&#8217;s immune response to cancer. By interfering with these cloaking mechanisms, ICIs have shown an ability to activate T cells, shrink tumors, and improve patient survival. Recent clinical data from checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab have confirmed both the validity of this approach and the importance of T cells as promising tools for the treatment of cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Despite these many advances, there persists a significant unmet need in cancer therapeutics. We believe that the use of human cells as a therapeutic modality to re-engage the immune system will be the next significant advancement in the treatment of cancer. These cellular therapies may avoid the long-term side effects associated with current treatments and have the potential to be effective regardless of the type of previous treatments patients have experienced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">T Cell Therapy Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The field of adoptive cell transfer is currently comprised primarily of chimeric antigen receptor (&#8220;CAR&#8221;) and T cell receptor (&#8220;TCR&#8221;) engineered T cells and has emerged from principles of basic immunology to become a paradigm-shifting clinical immunotherapy. T cell therapy, which we believe has evolved as one of the most promising branches of immunotherapy. T cell immunotherapy involves the infusion of T cells into a patient. Immune cells used for immunotherapy treatments can either be collected from the patient (autologous) or harvested from a donor (allogeneic). The cells are retrieved and either genetically modified to express tumor-specific CARs or TCRs or stimulated with specific antigens. The cells are then cultured to proliferate, and the proliferated cells are infused into the patient. Upon infusion, the cells can target and eliminate cancerous cells. Unlike chemotherapy, which is unable to distinguish between healthy and malignant cells, T cells produced for immunotherapy can selectively attack cancer cells that express the target antigen(s). This leads to a more effective treatment platform with fewer side effects. Some of these infused T cells may remain in the body for long periods, providing immunological memory, thus leading to longer and more durable responses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">TCRs and CARs have distinct signaling properties and antigen sensitivities. TCRs recognize peptide fragments from proteins expressed either inside the cell or on the cell surface, which are presented to T cells via major histocompatibility complex (&#8220;MHC&#8221;) molecules. CARs are programmed to recognize a specific cell surface protein. Because CARs are specific for a single antigen, or more precisely a single epitope within the single antigen, they are very narrowly focused and have limitations. When a CAR-T cell product is applied to a specific antigen of a heterogeneous disease, CAR-T cells may leave behind tumor cells that do not express the target antigen, which can lead to tumor relapse due to immune escape.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our approach is to avoid genetic engineering by relying upon the native T cell receptor, which has evolved over millions of years to provide T cells with an exquisite capacity to recognize and kill cancer cells. Use of the native T cell receptor is the bedrock of our versatile immunotherapy, which is intended to provide a cost-effective and non-toxic strategy to target multiple tumor antigens and lead to durable responses. The process entails expanding tumor-specific T cells from patients (autologous), or a patient&#8217;s hematopoietic stem cell donor (allogeneic). This is achieved by&#160;<i style="font-style:italic;">in vitro</i>&#160;manipulation consisting of co-culturing a patient&#8217;s or donor&#8217;s antigen presenting cells with patient (or donor) peripheral blood mononuclear cells, or PBMCs, respectively. As a source of antigen, we use overlapping peptide libraries spanning each of several immunogenic target antigens that are typically associated with certain types of cancer. These peptides are at least 15 amino acids in length, overlapping by approximately 11 amino acids and span the entire length of each of the target antigens. This typical footprint of peptides allows us to induce both CD4<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup>&#160;(helper) and CD8<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup>&#160;(cytotoxic) T cells. Following manufacture, these cells are frozen and stored for later infusion. Once infused, the natural characteristics of T cells take over and the T cells multiply in quantity, forming an army of T cells that kill the targeted cancer cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MAR-T Cell Therapies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are advancing two MAR-T cell therapies through clinical development:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Autologous MAR-T cell therapies &#8211; </i>The autologous product targets the NY-ESO-1, PRAME, MAGE - A4, Survivin, WT1 and SSX2 antigens (MT-601). We recently reported updated clinical data from our Phase 1 clinical trial investigating MT-601 for the treatment of patients with lymphoma who have relapsed after CAR-T therapy. In addition, we received an Investigational New Drug (IND) cleared by the U.S. FDA to investigate MT-601 in a Phase 1 trial in patients with pancreatic cancer in combination with frontline chemotherapy.</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:171.38pt;"><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Off-the-Shelf (&#8220;OTS&#8221;) MAR-T cell therapies &#8211; </i>The OTS product targets WT1, NY-ESO-1, PRAME, and Surviving antigens (MT-401-OTS). Enrolled patients are matched to the pre-manufactured inventory of MT-401-OTS products based on their human leukocyte antigen (&#8220;HLA&#8221;). Because the MT-401-OTS product inventory is pre-manufactured, the T cell product is delivered to the patient in a significantly shorter amount of time than a patient-specific T cell product. </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While the blood source and the antigens for stimulation differ between our autologous and OTS products, the manufacturing process for each product is identical.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cancers are heterogeneous in their expression of antigens. Tumors generally consist of individual cancer cells expressing different antigens, and each of those antigens can be present at a different level that can change over time. Therapies targeting only a single antigen are vulnerable to evolutionary escape mechanisms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mrkr-20251231x10k004.jpg" alt="Graphic" style="display:inline-block;height:171.38pt;width:332.2pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While single-antigen specific therapies can eliminate all the tumor cells expressing the targeted antigen, the residual tumor cells that do not express that antigen may survive and expand. In addition, tumor cells may also downregulate or mutate the targeted antigen, thus becoming invisible to the T cell therapy. Both phenomena create a transformed tumor that is impervious to that therapy. This process is referred to as antigen-negative tumor escape.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our solution to the problem of tumor heterogeneity is the development of T cell products that are intended to simultaneously attack multiple tumor-expressed antigens and thereby enable more complete initial tumor targeting, thus minimizing the subsequent opportunity for the cancer to engage escape mechanisms. We believe that by targeting up to six tumor-specific antigens, our MAR-T cell approach facilitates robust killing of targeted cancer cells and minimizes tumor escape.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mrkr-20251231x10k005.jpg" alt="Graphic" style="display:inline-block;height:152pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:328.45pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe our proprietary MAR-T cell platform may have meaningful advantages over current CAR and TCR-engineered cell therapy approaches. Compared to current gene-modified T cell therapies, the MAR-T cell product candidates are characterized by the following:</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Clinical benefits observed in early-stage clinical trials in multiple cancer indications.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on our observations in clinical trials in AML, pancreatic cancer, lymphoma, ALL and MM, we believe that the MAR-T cell therapies have the potential to mediate a meaningful anti-tumor effect, as well as significant in vivo expansion of T cells. For example, in BCM&#8217;s Phase 1 clinical trial in lymphoma (TACTAL), there were complete responses, or CRs, in six of the fifteen evaluable patients with both Hodgkin lymphoma and non-Hodgkin lymphoma with active disease. Significantly, no patient with a CR has subsequently relapsed with disease, whereas typically 30% or more of patients with CR in reported CAR-T studies relapse within one year (Vasileiou et al., J Clin Oncol, 2021). In patient results to date in this trial, observed therapeutic responses appear to be highly durable, with some patients being relapse-free beyond five years. In 2023, Marker treated the first patient in the Phase 1 APOLLO trial investigating the safety and efficacy of MT-601 in patients with lymphoma. Marker recently provided an update on the progress and clinical observations from the study highlighting durable objective responses and a favorable safety profile in relapsed lymphoma.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Non-genetically modified T cells.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unlike CAR and TCR-based approaches, the MAR-T cell therapy does not require genetic modification of T cells, a costly and complex process that significantly complicates the manufacturing of a patient product. We believe our MAR-T cell therapy represents a safe alternative to CAR-T cells and can be manufactured at a fraction of the cost of a gene-modified T cell product, with substantially reduced complexity of manufacturing.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Low incidence rate of adverse events.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of February 2026, the infusion of MAR-T cells was generally well tolerated by the patients across clinical trials in hematological and solid tumor indications, and no dose limiting toxicities or neurotoxicity were attributed to the use of MAR-T cells to date. This appears to compare favorably with published CD19 CAR-T studies that have been associated with substantial tolerability and safety concerns, and investigations by the FDA regarding the risk of CAR-T cell therapies to potentially induce secondary cancers.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Capable of addressing a broad repertoire of cancer cells.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While CAR-T and TCR therapies generally target a single epitope, our manufacturing process selects for T cells that are specific for multiple peptides derived from several targeted antigens. Deep gene sequencing of our products shows that a typical patient dose usually consists of approximately 4,000 unique T cell clonotypes, some of which target up to six different tumor-associated antigens. The six antigen targets can be recognized by a very wide range of T cells, and we believe that this multi antigen approach facilitates robust killing of targeted cancer cells and minimizes tumor escape.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical Development of Our MAR-T Cell Therapies by BCM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following clinical trials were conducted by BCM pursuant to our strategic alliance. In each trial, correlative studies showed significant expansion of MAR-T cells in vivo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Lymphoma</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">BCM evaluated MAR-T cells (5 TAA product) in a Phase 1 clinical trial for the treatment of patients with lymphoma. A total of 32 patients received two protocol-specified infusions of MAR-T cells, 14 with Hodgkin lymphoma, or HL, and 18 with aggressive non-Hodgkin lymphoma, or NHL. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:280.53pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As reported in a publication by Vasileiou et al., BCM had treated 15 patients with active disease (active lymphoma group), all of whom had completed a follow-up period beyond three months post-infusion. These patients were heavily pre-treated and had failed a median of five prior lines of therapy (range four to eight) for the HL patients and a median of three prior lines of therapy (range three to four) for the NHL patients. As illustrated below, in the active lymphoma group, six patients achieved CR and nine patients had experienced stable disease. None of the patients in CR had relapsed, and the range for the duration of CR in these patients was between two and over five years after being infused with MAR-T cells with the exception of one patient who died of an unrelated pneumonia while in a CR. Responses in all six patients who entered CR were associated with an expansion of infused T cells, as well as induction of broad-based antigen spreading across many tumor-associated antigens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="mrkr-20251231x10k006.jpg" alt="Graphic" style="display:inline-block;height:280.28pt;left:0%;padding-bottom:0.25pt;position:relative;top:0pt;width:503.93pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:280.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">BCM also treated 17 patients, including one patient who was treated a second time after a relapse, in remission (adjuvant lymphoma group). Like the active lymphoma group, these patients were heavily pre-treated with seven patients with HL treated with a median of 4 prior lines of therapy (range: three to five) and 10 patients with NHL with a median of three prior lines of therapy (range: one to five). As illustrated below, in the adjuvant lymphoma group, all 17 patients had entered CR, with 14 patients in continued complete remission, or CCR, without relapsing. The duration of responses ranged from approximately nine months to over five years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="mrkr-20251231x10k007.jpg" alt="Graphic" style="display:inline-block;height:280.8pt;width:507.25pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In both treatment groups, the MAR-T cells were well tolerated, with no drug-related serious adverse events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Pancreatic Cancer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2020, we reported interim data from an ongoing Phase 1/2 clinical trial investigating MAR-T cells for the treatment of pancreatic adenocarcinoma being conducted by BCM. In 2020, we reported that in this trial, BCM administered MAR-T cells to a total of 31 patients with advanced or borderline resectable pancreatic adenocarcinoma in three arms: 13 patients in Arm A, which included patients with unresectable/metastatic disease who were responding to standard first-line chemotherapy; 12 patients in Arm B, which included patients with progressive disease or therapy intolerance; and eight patients in Arm C, which includes patients with surgically resectable disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Overall, we have observed a clinical benefit correlated with the detection of tumor-reactive T cells in patient peripheral blood (Arms A, B and C) and within tumor biopsy samples (Arm C) post-infusion. No cytokine release syndrome or neurotoxicity has been observed in any arm of the trial to date.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Arm A was designed to evaluate the safety and potential efficacy of using MAR-T cell therapy as part of first-line treatment for patients with pancreatic cancer. These patients in the chemo-responsive arm have completed at least three months of standard-of-care chemotherapy (gemcitabine/nab-paclitaxel or FOLFIRINOX), which is the period during which a response to chemotherapy would typically occur, before receiving up to six administrations of MAR-T cell therapy in conjunction with chemotherapy. </p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">&#9679;</span>Out of the 13 evaluable patients (best overall response):</div><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four patients experienced objective responses after administration of MAR-T cells;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one patient experienced a radiographic complete response occurring at month nine after starting chemotherapy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three patients experienced partial responses per RECIST occurring at six-nine months after starting chemotherapy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six patients experienced stable disease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one patient experienced a mixed response.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Patients had durable cancer control with nine of the 13 patients exceeding historical control of overall survival;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Five patients enrolled in the study were not administered MAR-T cells, either because of disease progression (four patients) which made them ineligible for treatment, or because insufficient starting material from the patient was available for manufacturing (one patient);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evidence of epitope-spreading was observed in all responders, suggesting that the MAR-T cell therapy triggered the recruitment of a broader endogenous immune system response for improved anti-tumor activity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">No infusion-related reactions, cytokine release syndrome or neurotoxicity was observed;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In patients responding to therapy, significant expansion of the infused MAR-T cell therapy was observed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Acute Myeloid Leukemia</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, available treatments for post-transplant AML patients are limited and include donor lymphocyte infusion, which has an approximately 15% overall response rate but a 30% to 50% risk of severe and debilitating graft-versus-host disease. The five-year mortality rate for patients who receive an allogeneic HSCT exceeds 50%, and patients who relapse after a transplant have a survival expectation of approximately 4.5 months. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">BCM conducted a Phase 1 AML/MDS clinical trial investigating MAR-T cells for the treatment of patients with post-transplant AML. In this trial, patients in remission with high risk for relapse, as well as patients with active disease post-transplant were treated. As reported in a 2021 publication by Lulla et al., 11 of the 17 patients in the adjuvant disease setting dosed with the MAR-T cell therapy after receiving an allogeneic HSCT did not relapse during the follow-up period of the study, with 11 of 15 patients (two patients were each treated during two different remissions) remaining alive (estimated two-year overall survival of 77%) at a median follow-up of 1.9 years post-infusion which compares favorably with HSCT outcomes for risk-matched AML/MDS patients post-HSCT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, eight patients were treated for active disease that was resistant to salvage therapy post-HSCT with a median of five prior lines of therapy (range: four to ten). One of the eight patients crossed over from the adjuvant group while two patients enrolled twice, but all three patients had active AML that failed another line of salvage therapy after their first MAR-T cell infusion. Two of the eight patients achieved objective responses with one complete response and one partial response, with six patients continuing with stable disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In this trial, the infusion of MAR-T cells was well tolerated, with no drug-related serious adverse events and no instances of greater than Grade 2 acute graft-versus-host disease or moderate-severe chronic GVHD. The maximum grade treatment-related adverse event was seen in one patient in the adjuvant disease group who had a possibly drug-related Grade 3 elevation of liver enzymes but was treated </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">with prednisone with complete resolution. After discontinuing treatment and receiving decitabine, the patient relapsed and later re-enrolled in the trial in the active disease group and entered CR for 13 months and survived for 2.5 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Process Development and Manufacturing of the MAR-T Cell Therapies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the manufacturing process, blood is drawn from either the individual patient (in the case of the autologous T cells) or from healthy donors/commercially available leukapheresis material (in the case of the OTS program). Although the T cells that are selected and expanded by our process exist in a patient&#8217;s circulating blood, these T cells are often present at very low frequencies. Researchers at BCM believe that these T cells are adversely affected by the suppressive tumor microenvironment. It is a well-accepted concept that cancers not only evade immune detection but often actively suppress the function of the human immune system. Our manufacturing and culturing process is intended to (1) identify the T cells specific for the antigens that we intend to target, (2) restore these T cells to functionality with respect to their anti-tumor capability and (3) expand the population of those T cells specific for our targets to achieve the required patient dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">After blood is drawn, PBMCs are isolated and used to manufacture a patient-specific product. These cells are placed inside a cell culture device and combined with an experimentally optimized mix of GMP-grade cytokines that is used to restore and enhance the functional capability of the cultured T cells. In addition, libraries of overlapping peptides, which we refer to as peptide pools, are added to the cell culture. Each peptide within a peptide pool represents a small segment of a target antigen, which a T cell might recognize. Each library represents the entire protein sequence of a target antigen, with each peptide overlapping significantly with the peptides adjacent to it within the antigen&#8217;s protein sequence. This overlapping structure allows us to isolate, activate and expand any T cell that is specific for any segment of the antigens that we target in the unique genetic background of every patient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inside the cell culture device, PBMCs, including T cells and antigen-presenting cells, are exposed to the stimulating peptide pools. This results in the selective expansion of T cells that specifically recognize the target antigens. At the end of the manufacturing process, the resulting product is a mix of helper (CD4+) and cytotoxic (CD8+) T cells that recognize the targeted antigens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Once cell manufacturing is complete, the product is tested for identity, sterility, phenotype and functionality before it is released for infusion into a patient. Sampling of product indicates that, on average, approximately 4,000 different T cell clonotypes are present in a typical 5-antigen-specific patient product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon release of the final patient product, the cells are frozen and transported to the site where the cells will be administered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Manufacturing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our manufacturing process was originally developed at Baylor College of Medicine, where we initially conducted our clinical trials. We continue to contract and collaborate with BCM and others to perform a wide variety of services to ensure the continuation of our research and development efforts, with the goal of optimizing our manufacturing process, product quality and commercial scalability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 22, 2024, we entered into a Master Services Agreement for Product Supply (the &#8220;MSA&#8221;) with Cell Ready for the provision of various products and services by Cell Ready. Cell Ready, which is owned by one of our former directors, Mr. John Wilson, is a contract development and manufacturing organization (CDMO). On March 27, 2025, we mutually agreed with Cell Ready to terminate the MSA. In connection therewith, we entered into a settlement and release agreement with Cell Ready pursuant to which we paid Cell Ready approximately $453,000 and we provided one another with mutual releases of all claims associated with any and all agreements between Marker and Cell Ready.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While BCM continues to supply us with products as we continue our clinical trials, in anticipation of the commencement of our larger pivotal trial for lymphoma in 2026, as well as the eventual need for commercial scale production, on June 16, 2025, the Company entered into a Statement of Work (the &#8220;SOW&#8221;) with Cellipont Bioservices (&#8220;Cellipont&#8221;), a leading cell therapy Contract Development and Manufacturing Organization (&#8220;CDMO&#8221;), for the manufacturing of MT-601, the Company&#8217;s lead MAR-T cell product. Pursuant to the SOW, Cellipont will provide technology transfer and cGMP manufacturing services to support the scale-up and production of MT-601 for Marker&#8217;s APOLLO study. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">However, there is no guarantee that we will or have properly estimated our required manufacturing capacities or that the third parties on which we rely to manufacture our products will be able or willing to perform on our proposed timelines or to meet our manufacturing </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">demands, if at all. If any of our third-party vendors experience disruptions, or otherwise cease or substantially reduce the amount of products they are willing to supply us, our business and operations could be adversely affected. See &#8220;Risk Factors&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the years ended December 31, 2025 and 2024, we incurred $0.8 million and $5.8 million, respectively, in expenses related to Cell Ready services and manufacturing costs, as well as $0.5 million during the year ended December 31, 2025 in connection with the termination of the MSA as noted above. During the years ended December 31, 2025 and 2024, we paid $2.6 million and $5.5 million, respectively related to Cell Ready invoices received. During the years ended December 31, 2025 and 2024, we incurred $3.2 million and approximately $7,000, respectively, in expenses related to BCM services and manufacturing costs. During the years ended December 31, 2025 and 2024, we paid approximately $3.0 million and $0.1 million related to BCM invoices received, respectively. During the years ended December 31, 2025 and 2024, we incurred $0.7 million and nil, respectively, in expenses related to Cellipont services and manufacturing costs. During the years ended December 31, 2025 and 2024, we paid $0.6 million and nil related to Cellipont invoices received, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face competition from numerous pharmaceutical and biotechnology companies, as well as from academic institutions, private and public research institutions, and government agencies. Treatment of relapsed patients with lymphoma remains a challenge with relatively low overall survival rates. To date, there are four CD19-directed CAR-T cell therapies (Yescarta, Kymriah, Tecartus, and Bryanzi) approved for patients with relapsed lymphoma. However, up to 60% of CD19 CAR-T cell treated patients will relapse, particularly in the third line setting (Chong EA et al, N Engl J Med, 2021). This highlights a significant unmet medical need for alternative and more effective treatments. Our MAR-T cell drug candidates may compete with product candidates from a number of companies, which are developing various types of immunotherapies to treat cancer, including non-CD19 targeting CAR-T cells that target different antigens beyond CD19, multi-targeted CAR-T cells as well as NK-CAR therapies. In addition, bispecific antibodies represent promising therapies for patients with lymphoma and provide competition in the oncology space. To date, MT-601 is the only natural T cell product that targets multiple tumor antigens being explored for CAR relapse patients with lymphoma. Therefore, MT-601 fills a void in the market by providing much needed treatment option to the lymphoma patient population. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that our non-engineered T cell therapy approaches will be synergistic and may improve therapies being developed by potential competitors. Many companies and institutions, either alone or together with their collaborative partners, have substantially greater financial, technical and human resources, and significantly greater experience than we do in the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">drug discovery;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">undertaking preclinical testing and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining FDA and other regulatory approvals of products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing, marketing, distributing and selling products.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA and other regulatory approval or commercializing products that compete with our drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, any drug candidate that we successfully develop may compete with existing therapies that have long histories of safe and effective use. Competition may also arise from:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other drug development technologies and methods of preventing or reducing the incidence of disease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new small molecules; and/ or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other classes of therapeutic agents.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face, and will continue to face, competition from other companies for collaborative arrangements with pharmaceutical and biotechnology companies, for establishing relationships with academic and research institutions and for licenses to drug candidates or proprietary technology. These competitors, either alone or with their collaborative partners, may succeed in developing products that are more effective than ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to compete successfully will depend, in part, on our ability to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop proprietary products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop and maintain products that reach the market first, are technologically superior to and/or are of lower cost than other products in the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attract and retain scientific, product development and sales and marketing personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain patent or other proprietary protection for our products and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain required regulatory approvals; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacture, market, distribute and sell any products that we develop.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In a number of countries, including in particular, developing countries, government officials and other groups have suggested that pharmaceutical companies should make drugs available at a low cost. In some cases, governmental authorities have indicated that where pharmaceutical companies do not do so, their patents might not be enforceable to prevent generic competition. Some major pharmaceutical companies have greatly reduced prices for their drugs in certain developing countries. If certain countries do not permit enforcement of any of our patents, sales of our products in those countries, and in other countries, could be reduced by generic competition or by parallel importation of our product. Alternatively, governments in those countries could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products in those countries, thereby reducing our product sales, or we could respond to governmental concerns by reducing prices for our products. In all these situations, our results of operations could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">BCM Exclusive License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 16, 2018, we entered into an exclusive license agreement, or the BCM License Agreement, with BCM, under which we received a worldwide, exclusive license to BCM&#8217;s rights in and to certain intellectual property rights, including European patent EP 2470644 (estimated expiration date August 24, 2030), to develop and commercialize MAR-T cell product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Exclusive License to BCM&#8217;s Subject Technology:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">1. &#8220;Generation of CTL Lines with Specificity Against Multiple Tumor Antigens or Multiple Viruses&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">2. &#8220;Pepmixes to Generate Multiviral CTLs with Broad Specificity&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">3. &#8220;Immunogenic Antigen Identification from a Pathogen and Correlation to Clinical Efficacy&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">4. &#8220;T cell performance assay as a prognostic factor for clinical outcome&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In partial consideration for the exclusive rights granted under the BCM License Agreement, Marker Cell Therapy, Inc., an entity that is now our wholly owned subsidiary, issued shares of its common stock to BCM valued at approximately $5.0 million at the time of issuance. Such initial equity issuance was exchanged into merger consideration of 149,081 shares of our common stock and warrants to acquire 54,064 shares of our common stock in connection with the merger we completed in October 2018, each as adjusted to reflect the reverse stock split that we effected in January 2023. Additional consideration includes a royalty paid on net sales by us to BCM according to the royalty schedule in the BCM License Agreement. The royalty fee schedule is based on aggregate net sales in four different ranges: (1) less than $500 million, (2) $500 million to $1.0 billion, (3) $1.0 billion and over, and (4) $2.0 billion and over. The </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">corresponding royalty percentages range from 0.65% to 5.0%&#8201;-&#8201;increasing in proportion to the aggregate net sales. The royalty fee may be reduced in the event that we must pay additional royalties with respect to third-party owned patent rights or technology necessary for the use, manufacture or sale of a licensed product. We also agreed to pay BCM up to an aggregate of $64.85 million in milestone payments upon the occurrence of nine particular milestones relating to completion of the first dosing in the first Phase 3 clinical trial for a first and second distinct product, receipt of approval from the FDA and the achievement of certain net sales goals. We are also responsible for sublicensing fees. In addition, under the BCM License Agreement, we are responsible for reimbursing BCM for patent-related expenses. BCM is responsible for filing, prosecuting and maintaining all patent applications and patents included in the licensed patent rights, and we have agreed to reimburse BCM for all such related legal costs incurred after the date of the BCM License Agreement, except such legal costs shall be reduced on a pro-rata basis on a patent or patent application basis should BCM license such patent or patent application in additional fields of use to any third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, upon a liquidity event (as defined in the BCM License Agreement) of the Company, BCM will receive a liquidity incentive payment of 0.5% of the liquidity event proceeds (as defined in the BCM License Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have agreed to indemnify BCM and certain persons affiliated with BCM against claims and liabilities directly or indirectly related to or arising out of the design, process, manufacture or use by any third party of the licensed products, even though such claims and liabilities result in whole or in part from the negligence of the BCM indemnified parties or are based upon doctrines of strict liability or product liability, but not claims or liabilities arising from the gross negligence or intentional misconduct of any such BCM indemnified parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unless terminated sooner, the license will expire on a licensed product-by-product basis and country-by-country basis, on the later of&#8201;(1)&#160;the date of expiration of the last valid claim of patent rights to expire that covers the sale of such licensed product in such country, or (2)&#160;the first date following the tenth anniversary of the first commercial sale of first licensed product by us in such country. After such expiration, but not termination, the licenses granted to us shall survive and become a perpetual, paid-in-full license in such country with respect to such licensed product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have the right in our sole discretion to terminate the BCM License Agreement upon 60 days&#8217; written notice to BCM. BCM has the right to terminate the agreement upon material default or failure of us of our overall obligation to perform any of the terms, covenants or provisions of the license agreement, including failure to make timely payment, taken as a whole, and which default or failure remains uncured thirty days after written notice from BCM of such material default or failure to correct such default or failure. Notwithstanding the foregoing, if a material default or failure is not susceptible to cure within the 30-day cure period, BCM&#8217;s right to terminate shall be suspended if, and for so long as, (1)&#160;we have provided BCM with a written plan that is reasonably calculated to effect a cure, (2)&#160;such plan is reasonably acceptable to BCM, in its sole but reasonable discretion, and (3)&#160;we commit to and do carry out such plan; provided, however, that, unless mutually agreed to by the parties in such plan, such suspension of BCM&#8217;s right to terminate shall not extend beyond 60&#160;days after the original cure period. In addition, either party&#8217;s right to terminate the license agreement shall be tolled for so long as dispute resolution procedures are being pursued by the allegedly breaching party in good faith, and if it is finally and conclusively determined that the allegedly breaching party is in material breach, then the breaching party shall have the right to cure within 30 days after such determination. BCM also has the right to terminate the agreement if we shall (1)&#160;become involved in insolvency, dissolution, bankruptcy or receivership proceedings affecting the operation of our business, (2)&#160;make an assignment of all or substantially all of our assets for the benefit of creditors, or (3)&#160;if a receiver or trustee is appointed for us and we, after the expiration of 30 days following any of the enumerated events, are unable to secure a dismissal, stay or other suspension of such proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event of termination of the BCM License Agreement, but not expiration, all rights to the subject technology and patent rights thereunder shall revert to BCM, except to the extent necessary to exercise any surviving right or license thereunder. We may sell any licensed products actually in our possession at the effective date of termination, provided that we continue to pay to BCM royalties on all such sales in accordance with the license agreement, otherwise comply with the terms of the license agreement and sell all such licensed products within six months after the effective date of the termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In furtherance of the BCM License Agreement and as contemplated by the terms thereof, we entered into a Sponsored Research Agreement, or the SRA, with BCM, which provides for the conduct of research for us by credentialed personnel at BCM&#8217;s Center for Cell and Gene Therapy.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have entered into additional agreements with BCM with respect to a strategic alliance to advance pre-clinical research, early-stage clinical trials, and Phase 2 clinical trials with respect to our product candidates, as well as continued access to our clinical data, and product manufacturing and support, including personnel and space at the institution for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cancer Prevention and Research Institute of Texas</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2021, we received notice of a Product Development Research award totaling approximately $13.1 million from CPRIT to support our clinical investigation of MT-401 (the &#8220;CPRIT AML Grant&#8221;). In December 2024, we received notice of an additional $9.5 million grant from CPRIT to support the clinical investigation of MT-601 in patients with pancreatic cancer (the &#8220;CPRIT Pancreatic Grant&#8221;). Both CPRIT grants contain identical terms surrounding intellectual property and revenue sharing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Per the CPRIT grant agreements, we will retain ownership over any intellectual property developed under the contracts (the &#8220;Project Results&#8221;). With respect to non-commercial use of any Project Results, we agreed to grant to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with the right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, solely for academic, research, and other non-commercial purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our products become commercially saleable, we are obligated to make payments to CPRIT, with respect to net sales of any product covered in the contract, equal to a percentage of revenue ranging from the low-to-mid single digits. These payments will continue up to and until CPRIT receives an aggregate amount of 400% of the sum of all monies paid to us by CPRIT under the grant agreements. If we are required to obtain a license from a third party to sell any such product, the revenue sharing percentages may be reduced. In addition, once we have paid CPRIT 400% of the monies received under the grant agreements, we will continue to pay CPRIT a revenue-sharing percentage of 0.5% for the remainder of the Revenue Term as specified in the grant agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our commercial success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions, improvements, and know-how related to the business; to defend and enforce proprietary rights, including any patents that we may own in the future; to preserve the confidentiality of our trade secrets and other intellectual property; to obtain and maintain licenses to use intellectual property owned by third parties; and to operate without infringing valid and enforceable patents and other proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell, or importing our products may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities&#8201;&#8212;&#8201;for example, the rights obtained under exclusive license arrangements such as those pursuant to our BCM License Agreement. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed in the future, nor can we be sure that any of our existing patents or any patents that may be granted in the future will be commercially useful in protecting our commercial products and methods of manufacturing the same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To achieve this objective, a strategic focus for us has been identifying and licensing key patents and patent applications that serve to enhance our intellectual property and technology position. Currently, all of our MAR-T cell intellectual property rights are licensed from BCM. Our intellectual property portfolio currently includes patent applications having: (1) claims directed to methods of generating multi-antigen specific T cell products; and (2) claims directed to therapeutic uses of such multi-antigen specific T cell products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe our patent portfolio, together with our efforts to develop and patent next-generation technologies, provides us with a substantial intellectual property position. However, the area of patent and other intellectual property rights in biotechnology is an evolving one with many risks and uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Patents and other proprietary rights are vital to our business operations. We protect our technology through various United States and foreign patent filings and maintain trade secrets that we own. Our policy is to seek appropriate patent protection both in the United States and abroad for our proprietary technologies and product candidates. An enforceable patent with appropriate claim coverage can provide an advantage over competitors who may seek to employ similar approaches to develop therapeutics, and so the future commercial success of products, and therefore our future success, will be in part dependent on our intellectual property strategy. We reassess the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">value of each patent at the time maintenance fees are due, and in cases where maintaining the patent is judged to be of no significant strategic value, we decline to pay the maintenance fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There can be no assurance that our patents, and any patents that may be issued, assigned, or licensed to us in the future, will afford protection against competitors with similar technology. In addition, no assurances can be given that any patents issued, assigned, or licensed to us will not be infringed upon or designed around by others or that others will not obtain patents that we would need to license or design around. If existing or future patents held by third parties and containing broad claims over technology used by us were upheld by a court or other authority of competent jurisdiction, the holders of such patents could require us to obtain licenses to use such technology. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patent coverage may also vary from country to country based on the scope of available patent protection. Moreover, in the United States, patent term may be adjusted to account for delays by the United States Patent and Trademark Office, or USPTO, during prosecution. There are also opportunities to obtain an extension of term for patents covering a product in certain jurisdictions, which adds further complexity to the determination of patent life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The effect of the issued United States patents is that they provide us with patent protection for the claims covered by the patents. While the expiration of a product patent normally results in a loss of market exclusivity for the covered product or product candidate, commercial benefits may continue to be derived from, for example: (1)&#160;later- expiring patents on processes and intermediates related to improved methods of manufacture of the active ingredient of such product; (2) patents relating to the use of such product; (3)&#160;patents relating to novel compositions and formulations; and (4) in the United States and certain other countries, other types of market exclusivity that may be available under relevant law. The effect of patent expiration on our product candidates also depends upon many other factors such as the nature of the market and the position of the product in it, the growth of the market, the complexities and economics of the process for manufacture of the active ingredient of the product and the requirements of new drug provisions of the Federal Food, Drug and Cosmetic Act or similar laws and regulations in other countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Our pending patent applications cover a range of technologies, including specific embodiments and applications for treatment of various medical indications, improved application methods and adjunctive utilization with other therapeutic modalities. The coverage claimed in a patent application can be significantly reduced before the patent is issued. Accordingly, we do not know whether any of the patent applications we own, will acquire, license, or will license will issue as patents, or, if any patents are issued, whether they will provide significant proprietary protection or will be challenged, circumvented or invalidated. Because unissued U.S. patent applications are maintained in secrecy for a period of eighteen months and U.S. patent applications filed prior to November 29, 2000 are not disclosed until such patents are issued, and since publication of discoveries/inventions in the scientific or patent literature often lags behind actual discovery/invention, we cannot be certain of the priority of inventions covered by pending patent applications and whether potentially relevant earlier patent filings exist. Moreover, we may have to participate in opposition proceedings in a foreign patent office, or for United States patent applications filed before March 16, 2013, in interference proceedings declared by the USPTO, to determine priority of invention, or in United States inter partes review or post-grant review procedures, any of which could result in substantial cost to us, even if the eventual outcome is favorable to us. There can be no assurance that the patents, if issued, would be held valid by a court or other authority of competent jurisdiction. An adverse outcome could subject us to significant liabilities to third parties, require disputed rights to be licensed from third parties, or require us to cease using such technology.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">We have patents and patent applications in other countries, as well as in the European Patent Office, that we believe provide equivalent or comparable protection for our product candidates in jurisdictions internationally that we consider to be key markets. Because of differences in patent laws and laws concerning proprietary rights, the extent of protection provided by U.S. patents or proprietary rights owned by us may differ from that of their foreign counterparts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Trade Secrets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also rely on trade secrets and know-how relating to our proprietary technology and product candidates, continuing innovation, and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of immuno-oncology. However, trade secrets can be difficult to protect. We also plan to rely on regulatory protection afforded through orphan drug designations, data exclusivity, market exclusivity and patent term extensions when available, as well as contractual agreements with our academic and commercial partners.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We require each of our employees, consultants and advisors to execute a confidentiality agreement upon the commencement of any employment, consulting or advisory relationship with us. Each agreement provides that all confidential information developed or made known to the individual during the course of the relationship will be kept confidential and not be disclosed to third parties except in specified circumstances. In the case of employees, the agreements provide that all inventions conceived by an employee shall be our exclusive property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Trademarks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In 2024, the USPTO has accepted the Statement of Use filed for the trademark application &#8220;Marker Therapeutics.&#8221; We also have rights to use other names essential to our business. Federally registered trademarks have a perpetual life if they are maintained and renewed on a timely basis and used properly as trademarks, subject to the rights of third parties to seek cancellation of the trademarks if they claim priority or confusion of usage. We regard our trademarks and other proprietary rights as valuable assets and believe they have significant value to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that our patents, the protection of discoveries in connection with our development activities, our proprietary products, technologies, processes and know-how and all our intellectual property are important to our business. There can be no assurance that any of our patents, licenses or other intellectual property rights will afford us any protection from competition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biologics such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices, or GLP, regulation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial may commence;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparation of and submission to the FDA of a biologics license application, or BLA, after completion of all pivotal clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with Good Clinical Practices, or GCP; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preclinical and Clinical Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prior to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1&#8212;The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2&#8212;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 3&#8212;The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so- called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">BLA Submission and Review</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. The submission of a BLA requires payment of a substantial application user fee to FDA, unless a waiver or exemption applies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Once a BLA has been submitted, the FDA&#8217;s goal is to review standard applications within ten months after it accepts the application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-marketing studies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Expedited Development and Review Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast-track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast-track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast-track product has opportunities for frequent interactions with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A fast-track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast-track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any marketing application for a biologic submitted to the FDA for approval, including a product with a fast-track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. For products containing new molecular entities, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date (compared with ten months under standard review).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The regenerative medicine advanced therapy, or RMAT, designation is intended to facilitate an efficient development program for, and expedite review of, any drug that meets the following criteria: (1) it qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. Like breakthrough therapy designation, RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through the submission of clinical evidence, clinical studies, patient registries, or other sources of real-world evidence such as electronic health records; through the collection of larger confirmatory datasets; or through post-approval monitoring of all patients treated with the therapy prior to approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fast track designation, breakthrough therapy designation, priority review, accelerated approval, and RMAT designation do not change the standards for approval but may expedite the development or approval process.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Orphan Drug Designation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Post-Approval Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal of the FDA to permit the import or export of products; or</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Biosimilars and Reference Product Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Healthcare Laws and Compliance Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program; federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to the federal government, including federal healthcare programs, that are false or fraudulent; the Health Insurance Portability and Accountability Act, or HIPAA, which created additional federal criminal statutes which prohibit, among other things, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters, and which, as amended by Health Information Technology for Economic and Clinical Health Act, or HITECH, also imposes certain </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">requirements on HIPAA covered entities and their business associates and covered subcontractors relating to the privacy, security and transmission of individually identifiable health information; the U.S. federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the federal government, information related to payments or other transfers of value made to physicians (as defined by the Physician Payments Sunshine Act), other covered physicians and teaching hospitals, as well as ownership and investment interests held by health care professionals and their immediate family members; and U.S. state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. In addition, certain states require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and certain states and local jurisdictions require the registration of pharmaceutical sales representatives. If their operations are found to be in violation of any of such laws or any other governmental regulations that apply, they may be subject to penalties, including, without limitation, significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Coverage and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. In the United States, for example, principal decisions about reimbursement for new products are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. As a result, the coverage determination process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which the company receives regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product. No regulatory authority has granted approval for a personalized cancer immunotherapy based on a vaccine approach, and there is no model for reimbursement of this type of product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Healthcare Reform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In March 2010, the ACA was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contained a number of provisions of particular importance to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. There have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, the Tax Cuts and Jobs Act was enacted, which, among other things, removed penalties for not complying with ACA&#8217;s individual mandate to carry health insurance. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including, among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is also unclear how such challenges, other such litigation, and the healthcare reform measures of the Biden administration will impact the ACA and our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><span style="font-weight:normal;">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2%, which due to subsequent legislative amendments, including the Infrastructure Investment and Jobs Act, will stay in effect per fiscal year through 2031, except for a temporary suspension from May 1, 2020 through March 32, 2021 due to COVID-19 relief legislation, unless additional Congressional action is taken, and reduced payments to several types of Medicare providers. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. Congress is also considering additional health reform measures as part of other reform initiatives. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump Administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#8217;s proposals. As a result, the FDA concurrently released a final rule and guidance in September 2020 providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January 1, 2023. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. As a result of litigation challenging the Most Favored Nation model, on December 27, 2021, CMS published a final rule that rescinded the Most Favored Nation model interim final rule. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. However, it is </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">unclear whether these or similar policy initiatives will be implemented in the future. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Product Liability and Insurance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. We have not experienced any product liability claims to date. We currently carry products and clinical trial liability insurance policies. There can be no assurance that liability claims will not exceed such insurance coverage limits, which could have a materially adverse effect on our business, financial condition or results of operations or that such insurance will continue to be available on commercially reasonable terms, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Human Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, we had 5 full-time employees: 1 clinical and 4 in administrative support. None of our employees is subject to a collective bargaining agreement. We consider our relationship with our employees to be good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Consultants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have consulting agreements with a number of leading academic scientists, clinicians and regulatory experts. They serve as important contacts for us throughout the broader scientific and clinical communities. They are distinguished individuals with expertise in numerous fields, including cellular biology, molecular biology, oncology, clinical, manufacturing and regulatory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We retain each consultant according to the terms of a consulting agreement. Under such agreements, we pay them a consulting fee and reimburse them for out-of-pocket expenses incurred in performing their services for us. In addition, some consultants hold options to purchase our common stock, subject to the vesting requirements contained in separate award agreements. Our consultants may be employed by other entities and therefore may have commitments to their employer or may have other consulting or advisory agreements that may limit their availability to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Human Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of equity-based compensation awards. We strive to create a diverse environment, and our commitment to diversity, equity and inclusion begins with our leadership team of diverse backgrounds and experiences. 100% of our executive officers are women or self-identify as a member of an underrepresented minority group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Corporate Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We were incorporated under the laws of the State of Nevada in 1991 under the name &#8220;TapImmune, Inc.&#8221; and reincorporated in Delaware in October 2018 under the name &#8220;Marker Therapeutics, Inc.&#8221; Our principal executive offices are located at 2450 Holcombe Blvd, TMC Partners Office 1.311, Houston, Texas, and our telephone number is (713) 400-6400. Our common stock is listed for trading on the Nasdaq Capital Market under the symbol &#8220;MRKR&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Available Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our website is located at <i style="font-style:italic;">www.markertherapeutics.com</i>. We make available free of charge on our website our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and amendments to those reports, as soon as reasonably practicable after we electronically file or furnish such materials to the Securities and Exchange Commission. Our website and the information contained therein or connected thereto are not intended to be incorporated into this Annual Report on Form&#160;10-K.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_71abb148_aa2f_497d_8788_d9761b70e92e"></a><a id="ITEM1ARISKFACTORS_686864"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 1A. RISK FACTORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">An investment in our common stock involves a high degree of risk. You should carefully consider the risks described below before making an investment decision in our securities. These risk factors are effective as of the date of this Form 10-K and shall be deemed to be modified or superseded to the extent that a statement contained in our future filings modifies or replaces such statement. All of these risks may impair our business operations. The forward-looking statements in this Form 10-K involve risks and uncertainties and actual results may differ materially from the results we discuss in the forward-looking statements. If any of the following risks actually occur, our business, financial condition or results of operations could be materially adversely affected. In that case, the trading price of our stock could decline, and you may lose all or part of your investment.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Associated with Our Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Our business is subject to numerous risks that you should be aware of before making an investment decision. These risks are described more fully in this &#8220;Risk Factors&#8221; section and include, among others:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are a clinical stage company with a history of operating losses, and we expect losses to continue for the indefinite future. These factors raise substantial doubt regarding our ability to continue as a going concern.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All of our product candidates are in clinical development. If we are unable to successfully develop, receive regulatory approval for and commercialize our product candidates, or successfully develop any other product candidates, or experience significant delays in doing so, our business will be harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The results of earlier preclinical and clinical trials may not be predictive of future clinical trial results.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our preclinical studies and clinical trials may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory approval and commercialization, increase our costs or necessitate the abandonment or limitation of the development of some of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are dependent on third-party vendors to maintain and support our manufacturing and cell processing. If any of our third-party vendors experience disruptions, or otherwise cease or substantially reduce their operations, our business and operations could be adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our strategic relationship with BCM is dependent, in part, upon our ongoing relationship with key medical and scientific personnel and advisors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients, healthcare payors and the medical community.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The biotechnology and immunotherapy industries are characterized by rapid technological developments and a high degree of competition. We may be unable to compete with more substantial enterprises.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to protect our proprietary rights, we may not be able to compete effectively or operate profitably.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are subject to extensive regulations, which can be costly, time consuming and can subject us to unanticipated delays. Even if we receive regulatory approval of our product candidates, we will be subject to ongoing quality and regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The price of our stock may be volatile.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to our Financial Position and Capital Needs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a clinical stage company with a history of operating losses, and we expect losses to continue for the indefinite future. These factors raise substantial doubt regarding our ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage immunotherapy company with a history of losses, and we may always operate at a loss. We expect that we will continue to operate at a loss throughout our development stage, and as a result, we may exhaust our financial resources and be unable to complete the development of our product candidates. We anticipate that our ongoing operational costs will increase significantly, and our deficit will continue to grow, as we continue conducting our clinical development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have no approved products or product candidates pending approval. As a result, we have not derived any revenue from the sales of products and have not yet demonstrated ability to obtain regulatory approval, formulate and manufacture commercial-scale products, or conduct sales and marketing activities necessary for successful product commercialization. We have no sources of significant revenue to provide incoming cash flows to sustain our future operations. Our ability to pursue our planned business activities depends upon our successful efforts to raise additional financing, which may be adversely impacted by potential worsening global economic conditions, including decades-high inflation and concerns of a recession in the United States or other major markets, and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide. Weaknesses and volatility in the capital markets and the economy in general could also increase our costs of borrowing. Such additional financing may not be available on favorable terms, or at all. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have sustained losses from operations in each fiscal year since our inception, and we expect losses to continue for the indefinite future due to the substantial investment in research and development. Based on our lack of recurring revenues, anticipated uses of cash and historical recurring cash losses from operating activity, and cash and cash equivalents as of December 31, 2025, we anticipate that we will be able to fund our operating expenses and capital expenditure requirements through the fourth quarter of 2026, assuming no additional grant funds are received. These factors raise substantial doubt regarding our ability to continue as a going concern. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently plan to raise additional capital through the issuance of common shares and receipt of additional grant funds, which could enable us to fund our operating expenses and capital expenditure requirements beyond the fourth quarter of 2026, although no assurance can be given that such capital or existing awarded grants will be earned or future grants will be awarded. Our future cash requirements are based on our clinical and research and development plans, timing expectations related to the progress of our programs, and are subject to our ability to effectively manage our costs, raise additional capital, and receive additional grants. We expect to spend substantial additional sums on the continued administration and research and development of licensed and proprietary product candidates and technologies with no certainty that our approach and associated technologies will become commercially viable or profitable as a result of these expenditures. If we fail to raise a significant amount of capital, we may need to significantly curtail operations, allocate limited financial resources among our product candidates, or cease operations in the near future. If any of our product candidates fail in clinical trials or do not gain regulatory approval, we may never generate revenue. Even if we generate revenue in the future, we may not be able to become profitable or sustain profitability in subsequent periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The substantial doubt regarding our ability to continue as a going concern may create negative reactions to the price of our common stock. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our financial statements, and it is likely that investors will lose all or a part of their investment. Further, the perception that we may be unable to continue as a going concern may impede our ability to pursue strategic opportunities or operate our business due to concerns regarding our ability to discharge our contractual obligations. In addition, if there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Development of our Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">All of our product candidates are in clinical development. If we are unable to successfully develop, receive regulatory approval for and commercialize our product candidates, or successfully develop any other product candidates, or experience significant delays in doing so, our business will be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We are early in our development efforts and all of our product candidates are still in clinical development. Each of our programs and product candidates will require additional preclinical and/or clinical development, regulatory approval, obtaining manufacturing supply, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">capacity and expertise, building a commercial organization or successfully outsourcing commercialization, substantial investment and significant marketing efforts before we generate any revenue from product sales. We do not have any products that are approved for commercial sale, and we may never be able to develop or commercialize marketable products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to generate revenue from our product candidates, which we do not expect will occur for several years, if ever, will depend heavily on the successful development, regulatory approval and eventual commercialization of our product candidates. The success of our MAR-T cell product candidates or any other product candidates that we develop or otherwise may acquire will depend on several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timely and successful completion of preclinical studies, including toxicology studies, biodistribution studies and minimally efficacious dose studies in animals, where applicable, and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effective investigational new drug applications, or INDs, from the FDA or comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment and completion of clinical trials, including under the FDA&#8217;s current Good Clinical Practices, or GCPs, and current Good Laboratory Practices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful development of, or making arrangements with third-party manufacturers for, our commercial manufacturing processes for any of our product candidates that receive regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of timely marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching commercial sales of products, if approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of the benefits and use of our products, including method of administration, if approved, by patients, the medical community and third-party payors, for their approved indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of adverse events experienced by our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability, perceived advantages, cost, safety and efficacy of alternative therapies for any product candidate, and any indications for such product candidate, that we develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to produce and manufacture our product candidates, which is dependent on third-party vendors and their willingness to support our manufacturing and cell processing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent, trademark and trade secret protection and regulatory exclusivity for our product candidates and otherwise protecting our rights in our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining compliance with regulatory requirements, including the FDA&#8217;s current Good Manufacturing Practices, or cGMPs, and complying effectively with other procedures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining third-party coverage and adequate reimbursement and patients&#8217; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining a continued acceptable safety, tolerability and efficacy profile of the products following approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize the product candidates we develop, which would materially harm our business. If we do not receive marketing approvals for any product candidate we develop, we may not be able to continue our operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because we have limited financial and management resources, we must focus on development programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications for these product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any immunotherapies that we may develop are not likely to be commercially available for at least three years. Any delay in obtaining FDA and/or other necessary regulatory approvals in the United States and in countries outside the United States for any investigational new drug and failure to receive such approvals would have an adverse effect on the investigational new drug&#8217;s potential commercial success and on our business, prospects, financial condition and results of operations. The time required to obtain approval by the FDA and non-U.S. regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not previously submitted a biologics license application, or BLA, to the FDA, or similar approval filings to comparable foreign authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the product candidate&#8217;s safety and effectiveness for each desired indication. The BLA must also include significant information regarding the chemistry, manufacturing and controls for the product. We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of cell therapies for cancer. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained, and the FDA or non-U.S. regulatory authorities may disagree with the design or implementation of our clinical trials or study endpoints.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may also experience delays in completing planned clinical trials for a variety of reasons, including delays related to:</p><div style="margin-top:14pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of financial resources to commence and complete the planned trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reaching agreement on acceptable terms with prospective clinical research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining approval by an independent institutional review board, or IRB, at each clinical trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recruiting suitable patients to participate in a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">having patients complete a trial or return for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trial sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adding new clinical trial sites; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing sufficient quantities of qualified materials under cGMPs and applying them on a subject by subject basis for use in clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Further, the performance of our CROs may also be interrupted by health epidemics or other disruptions, including due to travel or quarantine policies or prioritization of resources toward such health epidemic or disruption. We could also encounter delays if physicians face unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRB for the institutions in which such trials are being conducted, the Data and Safety Monitoring Board or Committee for such trial, or by the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">FDA or other regulatory authorities due to a number of factors. Those factors could include failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preclinical studies and clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome. Further, we may encounter substantial delays in completing the development of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All of our product candidates are in clinical development and their risk of failure is high. The clinical trials and manufacturing of our product candidates are, and the manufacturing and marketing of our products, if approved, will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test and market our product candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. In particular, because our product candidates are subject to regulation as biological products, we will need to demonstrate that they are safe, pure and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Because our product candidates are based on new technologies and manufactured on a patient-by-patient basis for our MAR-T cell product candidates we expect that they will have substantial manufacturing costs. In addition, the initial estimates of the clinical cost of development may prove to be inadequate, particularly if clinical trial timing or outcome is different than predicted or regulatory agencies require further testing before approval. For example, we previously experienced temporary delays in enrollment due to the COVID-19 pandemic and in satisfying certain FDA requirements for our clinical study of MT-401 for the treatment of post-transplant AML, and any further delay to our planned timelines for our trial may impact our cost estimates for this trial. In addition, costs to treat patients with relapsed/refractory cancer and to treat potential side effects that may result from our product candidates can be significant. Some clinical trial sites may not bill, or obtain coverage from, Medicare, Medicaid, or other third-party payors for some or all of these costs for patients enrolled in our clinical trials, and we may be required by those trial sites to pay such costs. Accordingly, our clinical trial costs may be significantly higher per patient than those of more conventional therapeutic technologies or drug products. In addition, our proposed personalized product candidates involve several complex manufacturing and processing steps, the costs of which will be borne by us. Depending on the number of patients we ultimately enroll in our trials, and the number of trials we may need to conduct, our overall clinical trial costs may be higher than for more conventional treatments. Further, delays and interruptions to ongoing trials related to global pandemics, as experienced with COVID-19, can increase the duration and costs of such trials. We outsource some of the management of our clinical trials to third parties. Agreements with clinical investigators and medical institutions for clinical testing and with other third parties for data management services, place substantial responsibilities on these parties that, if unmet, could result in delays in, or termination of, our clinical trials. If any of our clinical trial sites fail to comply with FDA-approved good clinical practices, we may be unable to use the data gathered at those sites. If these clinical investigators, medical institutions or other third parties do not carry out their contractual duties or obligations or fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols or for other reasons, our clinical trials may be extended, delayed or terminated, and we may be unable to obtain regulatory approval for, or successfully commercialize, agents. We cannot be certain that we will successfully recruit enough patients to complete our clinical trials nor that we will reach our primary endpoints. Delays in recruitment, lack of clinical benefit or unacceptable side effects would delay our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We, or our regulators, may suspend or terminate our clinical trials for a variety of reasons. For example, in the fourth quarter of 2019 the FDA placed a clinical hold on our IND of MT-401 for the treatment of patients with post-transplant AML and requested certain information regarding quality and technical specifications for two reagents supplied by third-party vendors that are used in our manufacturing process but not present in the final product infused to patients. In January 2021, the FDA lifted the clinical hold, permitting us to initiate a Phase 2 clinical trial for the treatment of post-transplant AML, with a safety lead-in portion. We completed the safety lead-in portion of the trial in June 2021, and we initiated the remainder of the Phase 2 trial in July 2021. We may voluntarily suspend or terminate our clinical trials at any time if we believe they present an unacceptable risk to the patients enrolled in our clinical trials or do not demonstrate clinical benefit. For example, in November 2019 we elected to suspend our Phase 2 clinical trial of TPIV200 </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">for the treatment of platinum-sensitive advanced ovarian cancer based on an unblinded review of interim results conducted by an independent Data and Safety Monitoring Board, or DSMB. Although the DSMB did not express any safety concerns with respect to TPIV200, we elected to suspend the trial because it did not meet the threshold for probability of clinical benefit based upon our pre-specified criteria. In addition, regulatory agencies may order the temporary or permanent discontinuation of our clinical trials at any time if they believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements or that they present an unacceptable safety risk to the patients enrolled in our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our clinical trial operations are subject to regulatory inspections at any time. If regulatory inspectors conclude that we or our clinical trial sites are not in compliance with applicable regulatory requirements for conducting clinical trials, we may receive reports of observations or warning letters detailing deficiencies, and we will be required to implement corrective actions. If regulatory agencies deem our responses to be inadequate, or are dissatisfied with the corrective actions we or our clinical trial sites have implemented, our clinical trials may be temporarily or permanently discontinued, and we may be fined, we or our investigators may be precluded from conducting any ongoing or any future clinical trials, the government may refuse to approve our marketing applications or allow us to manufacture or market our products, and we may be criminally prosecuted. The lengthy approval process, as well as the unpredictability of future clinical trial results, may result in us failing to obtain regulatory approval for our product candidates, which would materially harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The results of earlier preclinical and clinical trials may not be predictive of future clinical trial results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Failure can occur at any time during the clinical trial process. The results of preclinical testing and early clinical trials of our product candidates may not be predictive of the results of larger, later-stage controlled clinical trials. Product candidates that have shown promising results in early-stage clinical trials may still suffer significant setbacks in subsequent clinical trials. Our clinical trials to date have been conducted on a small number of patients in a single academic clinical site for a limited number of indications. We will have to conduct larger, well-controlled trials in our proposed indications at multiple sites to verify the results obtained to date and to support any regulatory submissions for further clinical development of our product candidates. Our assumptions related to our product candidates, such as with respect to lack of toxicity and manufacturing cost estimates, are based on early limited clinical trials and current manufacturing processes and may prove to be incorrect. Several companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles despite promising results in earlier, smaller clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses. We do not know whether any Phase 2, Phase 3, or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication for use sufficient to receive regulatory approval or market our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our products may be delayed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, we may estimate the timing of the accomplishment of various scientific, clinical, regulatory, manufacturing and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of preclinical studies and clinical trials and the submission of regulatory filings, including IND submissions. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are, and will be, based on a variety of assumptions. The actual timing of these milestones can vary significantly compared to our estimates, in some cases for reasons beyond our control, including with respect to challenges related to enrollment, manufacturing and our reliance on third parties to conduct, supervise or monitor some or all aspects of our clinical trials. We may experience numerous unforeseen events during, or as a result of, any future clinical trials that we conduct that could delay or prevent our ability to receive marketing approval or commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may experience difficulties in patient enrollment in our future clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Accordingly, we cannot guarantee that our clinical trials will progress as planned or as scheduled. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing clinical trial and planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our preclinical studies and clinical trials may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory approval and commercialization, increase our costs or necessitate the abandonment or limitation of the development of some of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are safe, pure and effective for use in each target indication, and failures can occur at any stage of testing. Preclinical studies and clinical trials often fail to demonstrate safety or efficacy of the product candidate studied for the target indication. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to side effects caused by the product candidate, the administration process or related procedures also can cause adverse side effects. If any such adverse events occur, our clinical trials could be suspended or terminated. If we cannot demonstrate that any adverse events were not caused by the drug or administration process or related procedures, the FDA, EMA or foreign regulatory authorities could order us to cease further development of, or deny approval of, our product candidates for any or all targeted indications. Even if we are able to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to not initiate, delay, suspend or terminate any future clinical trial of any of our product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from personalized cell therapy, as with our MAR-T cell therapy products, are not normally encountered in the general patient population and by medical personnel. Any of these occurrences may harm our ability to develop other product candidates, and may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our product candidates are associated with side effects in clinical trials or have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses in which the side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. The FDA or an IRB may also require that we suspend, discontinue, or limit our clinical trials based on safety information, or that we conduct additional animal or human studies regarding the safety and efficacy of our product candidates which we have not planned or anticipated. Such findings could further result in regulatory authorities failing to provide marketing authorization for our product candidates or limiting the scope of the approved indication, if approved. Many product candidates that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, if one or more of our product candidates receives marketing approval, and we or others identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw approvals of such product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require additional warnings on the labels;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients or other requirements subject to a REMS;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to achieve or maintain third-party payor coverage and adequate reimbursement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation and physician or patient acceptance of our products may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or foreign regulatory agency in a timely manner or at all. Moreover, any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not obtain or maintain the benefits associated with orphan drug designation, including market exclusivity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Generally, a product that has orphan drug designation and subsequently receives the first FDA approval for the disease for which it has such designation is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications to market the same drug or biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA has granted orphan drug designation for MT-401 for the treatment of AML after receiving an allogeneic stem cell transplant and for MT-601 for the treatment of patients with pancreatic cancer. In 2023, MT-401 was also granted orphan drug designation by the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) for the treatment of patients with AML. We may seek orphan drug designation for other indications or product candidates. Even if we were to obtain orphan drug designation for a product candidate, we may not obtain orphan exclusivity and that exclusivity may not effectively protect the drug from the competition of different drugs for the same condition, which could be approved during the exclusivity period. Additionally, after an orphan drug is approved, the FDA could subsequently approve another application for the same drug for the same indication if the FDA concludes that the later drug is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusive marketing rights in the United States also may be lost if the FDA or European Commission (on the basis of the opinion of the European Medicines Agency, or the EMA), later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. The failure to obtain an orphan drug designation for any product candidates we may develop, the inability to maintain that designation for the duration of the applicable period, or the inability to obtain or maintain orphan drug exclusivity could reduce our ability to make sufficient sales of the applicable product candidate to balance our expenses incurred to develop it, which would have a negative impact on our operational results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Manufacturing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on third-party vendors and contract manufacturing organizations to maintain and support our manufacturing and cell processing operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not operate our own cGMP manufacturing facility and instead rely on third parties for the clinical and, once approved, commercial manufacture of our product candidates. Our manufacturing process was originally developed at Baylor College of Medicine and we continue to contract with BCM to perform a wide variety of services to ensure the continuation of our research and development efforts, with the goal of optimizing our manufacturing process, product quality and commercial scalability. We continue to order products from BCM and BCM continues to supply us with products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 22, 2024, we entered into a Master Services Agreement for Product Supply (the &#8220;MSA&#8221;) with Cell Ready for the provision of various products and services by Cell Ready pursuant to work orders that may be entered into from time to time. Cell Ready, which is owned by one of our former directors and current shareholders, Mr. John Wilson, is a contract development and manufacturing organization (CDMO). Under the MSA, Cell Ready previously performed various services for us, including research and development, and manufacturing in support of our clinical trials. However, on March 27, 2025, we mutually agreed with Cell Ready to terminate the MSA. In connection therewith, we entered into a settlement and release agreement with Cell Ready pursuant to which we paid Cell Ready approximately $453,000 and we provided each other with mutual releases of all claims associated with any and all agreements between the Marker and Cell Ready.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While BCM continues to supply us with products, as we continue our clinical trials, in anticipation of the commencement of our larger pivotal trial for lymphoma in 2026, as well as the eventual need for commercial scale production, on June 16, 2025, the Company entered into a Statement of Work (the &#8220;SOW&#8221;) with Cellipont Bioservices (&#8220;Cellipont&#8221;), a leading cell therapy Contract Development and Manufacturing Organization (&#8220;CDMO&#8221;), for the manufacturing of MT-601, the Company&#8217;s lead MAR-T cell product.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Furthermore, we intend to evaluate additional potential third-party manufacturing capabilities to provide potential multiple sources of clinical and commercial supply. However, even if we can secure multiple sources of clinical and commercial supply, third-party manufacturers may not be willing or able to meet our needs concerning timing, quantity, or quality and/or may cease or substantially reduce their business. If we are unable to contract for a sufficient supply of needed materials on acceptable terms, or if we should encounter delays, difficulties or disputes with regard to in our relationships with manufacturers, our clinical trials may be delayed, thereby delaying the submission of product candidates for regulatory approval or the market introduction and subsequent sales of any approved products. Any such delay may lower our revenues and potential profitability. If any third-party breaches or terminates its agreement with us or fails to conduct its activities in a timely manner, the commercialization of our product candidates could be slowed down or blocked completely. It is possible that third-parties relied upon by us will change their strategic focus, pursue alternative technologies, or develop alternative product candidates, either on their own or in collaboration with others, as a means for developing treatments for the diseases targeted by our collaborative programs, or for other reasons. The effectiveness of these third parties in marketing their own products may also affect our revenues and earnings. Also, if we enter into additional third-party agreements in the future, we may not be able to negotiate such agreements successfully and, even if established, these relationships may not be scientifically or commercially successful. In the event our relationship with a third-party manufacturer is terminated or substantially reduced for any reason, it is possible we will not be able to identify an alternative third-party manufacturer within a reasonable period of time, if ever, which would have an adverse effect our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, our manufacturing capabilities could be affected by cost-overruns, unexpected delays, equipment failures, labor shortages, natural disasters, power failures, competition with other clients, transportation difficulties and numerous other factors that could prevent us from fully realizing the intended benefits of our manufacturing strategy and have a material adverse effect on our clinical development, commercialization plans and/or general operations. In addition, the manufacturing process for any product candidates that we may develop is subject to the FDA and foreign regulatory authority approval process, and we may need to contract with manufacturers who can meet all applicable FDA and foreign regulatory authority requirements on an ongoing basis. If our contract manufacturing organizations, or CMOs, are unable to reliably produce products to specifications acceptable to the FDA or other regulatory authorities, we may not obtain or maintain the approvals we need to commercialize any approved products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CMOs will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Further, we may be required to establish multiple manufacturing facilities to expand our commercial footprint for any approved products, which may lead to regulatory delays or prove costly. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our clinical development and/or commercialization plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our manufacturing process is reliant upon specialized equipment, and other specialty materials, which may not be available to us on acceptable terms or at all. We, our vendors, and contract manufacturing organizations rely or may rely on sole-source vendors or a limited number of vendors, which could impair the manufacture and supply of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We depend on a limited number of vendors for supply of certain materials and equipment used in the manufacture of our MAR-T cell therapy-based product candidates. For example, in the past, we purchased equipment and reagents critical for the manufacture of our product candidates from Wilson Wolf (a company controlled by our former director, John Wilson), Almac and other suppliers. As previously disclosed, Mr. Wilson resigned as one of our directors on January 24, 2025. Some of our direct or indirect suppliers may not have the willingness or capacity to support commercial products manufactured under cGMP by biopharmaceutical firms or may otherwise be ill-equipped to support our needs. We also may not have supply contracts with many of these suppliers and may not be able to obtain supply contracts with them on acceptable terms or at all. Accordingly, we may not be able to obtain key materials and equipment to support clinical or commercial manufacturing. Further, the FDA may determine that our manufacturing process, or the materials required for the manufacture of our product candidates, are not acceptable, which would require us to find alternative suppliers or processes, which may not be available on favorable terms, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For some of this equipment and materials, we may rely, and may now and/or in the future rely, on sole-source vendors or a limited number of vendors. An inability to continue to source product from any of these suppliers, which could be due to regulatory actions or requirements affecting the supplier, adverse financial, or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands, or quality issues, could adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our operating results or our ability to conduct clinical trials, either of which could significantly harm our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The manufacture of our product candidates is complex and we may encounter difficulties in production, particularly with respect to process development. If any of our third-party suppliers encounter such difficulties, the supply of our product candidates for clinical trials, or our product candidates for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our product candidates are biologics, and the process of manufacturing our product candidates is complex, highly regulated and subject to multiple risks. For example, the manufacture of our MAR-T cell therapy-based product candidates involves complex processes, including drawing blood from patients/donors, manufacturing the clinical product, and ultimately infusing the product into a patient. As a result of the complexities, the cost to manufacture biologics is generally higher than traditional small molecule chemical compounds, and the manufacturing process is less reliable and is more difficult to reproduce. Our manufacturing processes will be susceptible to product loss or failure due to any of the following: logistical issues associated with the collection of blood cells, or starting material, from the patient or a donor, shipping such material to the manufacturing site, shipping the final product back to the patient, and infusing the patient with the product; manufacturing issues associated with the variability in patients&#8217; or donor&#8217;s starting cells; interruptions in the manufacturing process; contamination; equipment failure; improper installation or operation of equipment, vendor or operator error; inconsistency in cell growth; and variability in product characteristics. Additionally, transferring manufacturing responsibilities from one manufacturer to another also involves various risks, which could result in delays and additional costs. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If for any reason we lose a patient&#8217;s or a donor&#8217;s cells, or later-developed product at any point in the process, the manufacturing process for that patient will need to be restarted and the resulting delay may adversely affect that patient&#8217;s outcome and/or the results of clinical trials. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because our autologous MAR-T cell therapy-based product candidates, MT-601, is manufactured for each particular patient, we will be required to maintain a chain of identity with respect to the patient&#8217;s blood cells as it moves from the patient to the manufacturing facility, through the manufacturing process, and back to the patient. Maintaining such a chain of identity is difficult and complex, and failure to do so could result in adverse patient outcomes, loss of product, or regulatory action including withdrawal of our product candidates from the market. Further, as product candidates are developed through preclinical to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in order to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are working to develop commercially viable processes for manufacturing our products. Doing so is a difficult and uncertain task, and there are risks associated with scaling to the level required for advanced clinical trials or commercialization, including, among others, cost overruns, potential problems with process scale up, process reproducibility, stability issues, lot consistency, and timely availability of raw materials. As a result of these challenges, we may experience delays in our clinical development and/or commercialization plans. We may ultimately be unable to reduce the cost of goods for our product candidates to levels that will allow for an attractive return on investment if and when those product candidates are commercialized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">No assurance can be given that we will be able to develop a new, FDA-compliant, more efficient, lower cost manufacturing process upon which our business plan to commercialize MAR-T cell-based product candidates is dependent.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In cooperation with our current contract manufacturers and suppliers, we developed and have implemented a new nine-day MAR-T cell manufacturing process for our current as well as future clinical trials using a patient-specific manufacturing approach or using products manufactured from healthy donors (&#8220;Off-the-Shelf&#8221;). The new manufacturing process marks additional manufacturing improvements compared to the processes used in the BCM Phase 1 and 2 trials (36-day manufacturing time) and our previous AML trial (20-day manufacturing time). The new nine-day manufacturing process enables increased antigen specificity and diversity, which has exhibited a strong linear correlation to anti-tumor activity in vitro. The new process produces a patient product that is four times more potent, with the potential to greatly improve tumor killing. This new, scaled-up, pharmaceutical manufacturing process is new and subject to uncertainties. We cannot guarantee that we will be able to more efficiently and cost effectively, and in a more automated manner produce, measure and control the physical and/or chemical attributes of our product candidates in a cGMP facility. We also have never manufactured our adoptive T cell therapy product candidate on a commercial scale. As a result, we cannot give any assurance that we will be able to establish a manufacturing process that can produce our product candidates at a cost or in quantities necessary to make </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">them commercially viable. Moreover, we and our third-party manufacturers will have to continually adhere to current cGMP regulations enforced by the FDA through its facilities inspection program. If these facilities cannot pass a pre-approval plant inspection, the FDA premarket approval of our product candidates will not be granted. In complying with cGMP and foreign regulatory requirements, we and any of our third-party manufacturers will be obligated to expend time, money and effort in production, record-keeping and quality control to assure that our product candidates meet applicable specifications and other requirements. If we or any of our third-party manufacturers fail to comply with these requirements, we may be subject to regulatory action. No assurance can be given that we or our partners will be able to establish and operate such a production facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cellular products are not considered to be well characterized products because there are hundreds of markers present on T cells, and even small changes in manufacturing processes could alter the cell subtypes. It is unclear at this time which of those markers are critical for success of T cells to combat cancer, so our ability to predict the outcomes with newer manufacturing processes is limited. The changes that we may make to the existing manufacturing process may require additional testing, which may increase costs and timelines associated with these developments. In addition to developing a multi-antigen T cell-based therapy on existing adoptive T cell therapy technology, we are currently evaluating the desirability of conducting clinical trials of our product candidates in combination with other existing drugs. These combination therapies will require additional testing, and clinical trials will require additional FDA regulatory approval and will increase our future cost of development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to our Reliance on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on third parties for the clinical and, if approved, commercial manufacture of our product candidates. The third-party manufacturing facilities on which we rely may have limited capacity or fail to meet the applicable stringent regulatory requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not have any cGMP manufacturing facilities. Following the termination of our MSA with Cell Ready, we rely on BCM for the cGMP manufacture of our product candidates for clinical development. While BCM continues to supply us with products, as we continue our clinical trials, in anticipation of the commencement of our larger pivotal trial for lymphoma in 2026, as well as the eventual need for commercial scale production, on June 16, 2025, the Company entered into a Statement of Work (the &#8220;SOW&#8221;) with Cellipont Bioservices (&#8220;Cellipont&#8221;), a leading cell therapy Contract Development and Manufacturing Organization (&#8220;CDMO&#8221;), for the manufacturing of MT-601, the Company&#8217;s lead MAR-T cell product. However, there is no guarantee that we will or have properly estimated our required manufacturing capacities or that the third parties on which we rely to manufacture our products will be able or willing to perform on our proposed timelines or to meet our manufacturing demands, if at all. Also, if we must increase production capacity for any reason, we may need to make considerable investments that could lead to significant financing needs or require us to enter into subcontracting agreements in order to outsource part of the production.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the third-party contract manufacturing organizations on which we currently or in the future rely ceases or reduces its business or the products it supplies to us or experiences capacity constraints, other disruptions, or delays in manufacturing our MAR-T cell therapy-based product candidates, our planned clinical trials and necessary manufacturing capabilities will be disrupted or delayed. Third-party manufacturers may not be able to meet our needs concerning timing, quantity, or quality. Additionally, our third-party manufacturing partners may engage, be engaged by, or otherwise enter into arrangements with our competitors. If we are unable to contract for a sufficient supply of needed materials on acceptable terms, or if we should encounter delays or difficulties in our relationships with manufacturers, our clinical trials may be delayed, thereby delaying the submission of product candidates for regulatory approval or the market introduction and subsequent sales of any approved products. Any such delay may lower our revenues and potential profitability. If any third-party breaches or terminates its agreement with us or fails to conduct its activities in a timely manner, the commercialization of our product candidates could be slowed down or blocked completely. It is possible that third parties relied upon by us will change their strategic focus, pursue alternative technologies, or develop alternative product candidates, either on their own or in collaboration with others, as a means for developing treatments for the diseases targeted by our collaborative programs, or for other reasons. The effectiveness of these third parties in marketing their own products may also affect our revenues and earnings. We intend to continue to enter into additional third-party agreements in the future. However, we may not be able to negotiate any additional agreements successfully. Even if established, these relationships may not be scientifically or commercially successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The facilities used by our contract manufacturers to manufacture our product candidates must be inspected by the FDA. We do not have control over a supplier&#8217;s or manufacturer&#8217;s compliance with laws, regulations and applicable cGMP standards or similar regulatory requirements and other laws and regulations, such as those related to environmental health and safety matters. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, we may be unable to obtain regulatory approval of our marketing applications. In addition, we have </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supply of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully, if approved. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed, or we could lose potential revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our strategic relationship with BCM is dependent, in part, upon our ongoing relationship with key medical and scientific personnel and advisors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our MAR-T cell therapy has been developed through our collaboration with the Center for Cell and Gene Therapy at BCM, founded by Malcolm K. Brenner, M.D., Ph.D., a recognized pioneer in immuno-oncology. Our strategic relationship with BCM is dependent, in part, on our relationship with certain key employees and advisors, some of whom serve on our Scientific Advisory board, and in particular Dr. Vera, our founder, President and Chief Executive Officer and Principal Financial and Accounting Officer. If Dr. Vera discontinues his employment with us, our relationship with BCM may deteriorate, and our business could be harmed. We may also be dependent on BCM facilities and personnel to conduct research and development and manufacturing activities in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although we have an exclusive license agreement with BCM under which we received a worldwide, exclusive license to BCM&#8217;s rights in and to three patent families to develop and commercialize the MAR-T cell product candidates, we will need to enter into additional agreements with BCM with respect to (i) a strategic alliance to advance preclinical research, early stage clinical trials, and clinical trials with respect to our product candidates, as well as continued access to our clinical data, and (ii) support, including personnel and space at the institution for the foreseeable future. Any delays in entering into new strategic agreements with BCM related to our product candidates could delay the development, manufacture, and clinical trials of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">An important element of our intellectual property portfolio is to license additional rights and technologies from BCM. Our inability to license the rights and technologies that we have identified, or newly developed MAR-T cell technology that we may in the future identify, could have a material adverse impact on our ability to complete the development of our product candidates or to develop additional product candidates. No assurance can be given that we will be successful in licensing any additional rights or technologies from BCM and others. Failure to obtain additional rights and licenses may detrimentally affect our planned development of additional product candidates and could increase the cost, and extend the timelines associated with our development of such other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to establish or maintain the third-party relationships, including strategic collaborations, that are necessary to develop, commercialize and/or market some or all of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect to depend on collaborators, partners, licensees, clinical research organizations and other third parties to support our discovery efforts, to formulate product candidates to manufacture our product candidates and to conduct clinical trials for some or all of our product candidates. We cannot guarantee that we will be able to successfully negotiate agreements for or maintain relationships with collaborators, partners, licensees, clinical investigators, vendors and other third parties on favorable terms, if at all. Our ability to successfully negotiate such agreements will depend on, among other things, potential partners&#8217; evaluation of the superiority of our technology over competing technologies and the quality of the preclinical and clinical data that it has generated, and the perceived risks specific to developing our product candidates. If we are unable to obtain or maintain these agreements, we may not be able to clinically develop, formulate, manufacture, obtain regulatory approvals for or commercialize our product candidates. Management of any third-party relationships will require significant time and effort from our management team, coordination of our research and development programs with the research and development priorities of our collaborators and effective allocation of our resources to multiple projects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we continue to enter into research and development collaborations at the early phases of drug development, our success will in part depend on the performance of our corporate collaborators. We will not directly control the amount or timing of resources devoted by our corporate collaborators to activities related to our immunotherapies. Our corporate collaborators may not commit sufficient resources to their research and development programs or the commercialization, marketing or distribution of their immunotherapies. If any corporate collaborator fails to commit sufficient resources, our preclinical or clinical development programs related to this collaboration could be delayed or terminated. Also, our collaborators may pursue existing or other development-stage products or alternative technologies in preference to those being developed in collaboration with us. Finally, if we fail to make required milestones or royalty payments to our collaborators or to observe other obligations in our agreements with them, our collaborators may have the right to terminate those agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our strategy includes eventual substantial reliance upon strategic collaborations for marketing and commercialization of our product candidates, and we may rely even more on strategic collaborations for research, development, marketing and commercialization of our other immunotherapies. If we are unsuccessful in securing such strategic collaborations, we may be unable to commercialize any approved products as we have not yet licensed, marketed or sold any of our immunotherapies or entered into successful collaborations for these services in order to ultimately commercialize our immunotherapies. Establishing strategic collaborations is difficult and time-consuming. Our discussions with potential collaborators may not lead to the establishment of collaborations on favorable terms, if at all. Potential collaborators may reject collaborations based upon their assessment of our financial, clinical, regulatory or intellectual property position. If we successfully establish new collaborations, these relationships may never result in the successful development or commercialization of our immunotherapies or the generation of sales revenue. To the extent that we enter into co-promotion or other collaborative arrangements, our product revenues are likely to be lower than if we directly marketed and sold any products that we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to: comply with the laws of the FDA and other similar foreign regulatory bodies, provide true, complete and accurate information to the FDA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws, or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that our business arrangements comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or in asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to develop our business. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Commercialization of our Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients, healthcare payors and the medical community.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we obtain regulatory approval for our product candidates, they may not gain market acceptance among physicians, healthcare payors, patients or the medical community. Market acceptance of our product candidates, if we receive approval, depends on a number of factors, including the:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efficacy and safety of our product candidates as demonstrated in clinical trials and post-marketing experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical indications for which our product candidates may be approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance by physicians and patients of our product candidates as safe and effective;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential and perceived advantages of our product candidates over alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety of our product candidates seen in a broader patient group, including our use outside the approved indications should physicians choose to prescribe for such uses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product labeling, or product insert requirements of the FDA or other regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timing of market introduction of our product candidates as well as competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cost in relation to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pricing and the availability of coverage and adequate reimbursement by third-party payors and government authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relative convenience and ease of administration; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectiveness of any sales and marketing efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our product candidates are approved but fail to achieve market acceptance among physicians, patients, healthcare payors and the medical community, we may not be able to generate significant revenues, which would compromise our ability to become profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The market for any products that we successfully develop will also depend on the cost of the product. We do not yet have sufficient information to reliably estimate what it will cost to commercially manufacture our current product candidates, and the actual cost to manufacture these products could materially and adversely affect the commercial viability of these products. Our goal is to reduce the cost of manufacturing our therapies. However, unless we are able to reduce those costs to an acceptable amount, we may never be able to develop a commercially viable product. If we do not successfully develop and commercialize products based upon our approach or find suitable and economical sources for materials used in the production of our products, we will not become profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we are successful in getting market approval, commercial success of any of our product candidates will also depend in large part on the availability of coverage and adequate reimbursement from third-party payors, including government payors such as the Medicare and Medicaid programs and managed care organizations, which may be affected by existing and future health care reform measures designed to reduce the cost of health care. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement, which could be costly and divert our resources. If government and other health care payors were not to provide adequate coverage and reimbursement levels for any of our products if approved, market acceptance and commercial success would be reduced.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our MAR-T cell therapy may be provided to patients in combination with other agents provided by third parties. The cost of such combination therapy may increase the overall cost of MAR-T cell therapy and may result in issues regarding the allocation of reimbursements between our therapy and the other agents, all of which may adversely affect our ability to obtain reimbursement coverage for the combination therapy from third-party medical insurers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. In the United States, for example, principal decisions about reimbursement for new products are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. As a result, the coverage determination process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to establish or sustain coverage and adequate reimbursement for any product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future success is highly dependent upon our key personnel, and our ability to attract, retain, and motivate additional qualified personnel. We will also be required to establish sales and marketing capabilities or enter into agreements with third parties to market and sell any approved products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific, and medical personnel. We are highly dependent on our management, scientific, and medical personnel and consultants, including in particular Juan Vera, M.D., who plays multiple roles as our President, Chief Executive Officer, and Principal Financial and Accounting Officer, as well as others. The loss of the services of our executive officer, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm to our business. We have a priority to quickly train additional qualified scientific and medical personnel to ensure the ability to maintain business continuity. Any delays in training such personnel could delay the development, manufacture, and clinical trials of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our ability to attract and retain highly skilled personnel is critical to our operations and expansion. We face competition for these types of personnel from other biotechnology companies and more established organizations, many of which have significantly larger </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">operations and greater financial, technical, human and other resources than us. We may not be successful in attracting and retaining qualified personnel on a timely basis, on competitive terms, or at all. If we are not successful in attracting and retaining these personnel, or integrating them into our operations, our business, prospects, financial condition and results of operations will be materially adversely affected. In such circumstances, we may be unable to conduct certain research and development programs, unable to adequately manage our clinical trials and development of our product candidates, and unable to adequately address our management needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not currently have an organization for the sale, marketing and distribution of any approved products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products approved by the FDA or comparable foreign regulatory authorities, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate product revenue and may not become profitable. We will be competing with many companies that currently have extensive and well-funded sales and marketing operations. Without an internal commercial organization or the support of a third - party to perform sales and marketing functions, we may be unable to compete successfully against these more established companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The biotechnology and immunotherapy industries are characterized by rapid technological developments and a high degree of competition. We may be unable to compete with more substantial enterprises.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The biotechnology and biopharmaceutical industries are characterized by rapid technological developments and a high degree of competition. As a result, our actual or proposed immunotherapies could become obsolete before we recoup any portion of our related research and development and commercialization expenses. Competition in the biopharmaceutical industry is based significantly on scientific and technological factors. These factors include the availability of patent and other protection for technology and products, the ability to commercialize technological developments and the ability to obtain governmental approval for testing, manufacturing and marketing. We compete with specialized biopharmaceutical firms in the United States, Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to their operations. Many biopharmaceutical companies have focused their development efforts in the human therapeutics area, including cancer. Many major pharmaceutical companies have developed or acquired internal biotechnology capabilities or made commercial arrangements with other biopharmaceutical companies. These companies, as well as academic institutions, governmental agencies and private research organizations, also compete with us in recruiting and retaining highly qualified scientific personnel and consultants. Our ability to compete successfully with other companies in the pharmaceutical field will also depend to a considerable degree on the continuing availability of capital to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Potential competitors in the market for treating hematological malignancies include numerous pharmaceutical and biotechnology companies, as well as academic institutions, private and public research institutions, and government agencies. Treatment of relapsed patients with lymphoma remains a challenge with relatively low overall survival rates. To date, there are four CD19-directed CAR-T cell therapies (Yescarta, Kymriah, Tecartus, and Bryanzi) approved for patients with relapsed lymphoma. However, up to 60% of CD19 CAR-T cell treated patients will relapse, particularly in the third line setting (Chong EA et al, N Engl J Med, 2021). This highlights a significant unmet medical need for alternative and more effective treatments. Our MAR-T cell drug candidates may compete with product candidates from a number of companies, which are developing various types of immunotherapies to treat cancer, including non-CD19 targeting CAR-T cells that target different antigens beyond CD19, multi-targeted CAR-T cells as well as NK-CAR therapies. In addition, bispecific antibodies represent promising therapies for patients with lymphoma and provide competition in the oncology space. To date, MT-601 is the only natural T cell product that targets multiple tumor antigens being explored for CAR relapse patients with lymphoma. Therefore, MT-601 fills a void in the market by providing much needed treatment to patient population. Current and potential competitors may have substantially greater research and development capabilities and financial, scientific, regulatory, manufacturing, marketing, sales, human resources, and experience than we do. Many of our competitors have several therapeutic products that have already been developed, approved and successfully commercialized, or are in the process of obtaining regulatory approval for their therapeutic products in the United States and internationally. While these universities and public and private research institutions primarily have educational objectives, they may develop proprietary technologies that lead to other FDA approved therapies or that secure patent protection that we may need for the development of our technologies and product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Even if we obtain regulatory approval for our lead product candidate, the availability and price of competitors&#8217; products could limit the demand and the price we will be able to charge for our therapy. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from other methods of treatment to our product, or if physicians switch to other new therapies, drugs or biologic products or choose to reserve our product candidates for use in limited circumstances. We are aware of certain investigational new drugs under development or approved products by competitors </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">that are used for the prevention, diagnosis, or treatment of certain diseases we have targeted for drug development. Various companies are developing biopharmaceutical products that have the potential to directly compete with our immunotherapies even though their approach may be different. The competition comes from both biotechnology firms and from major pharmaceutical companies. Many of these companies have substantially greater financial, marketing, and human resources than us. We also experience competition in the development of our immunotherapies from universities, other research institutions and others in acquiring technology from such universities and institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, certain of our immunotherapies may be subject to competition from investigational new drugs and/or products developed using other technologies, some of which have completed numerous clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA often approves new oncology therapies initially only for use in patients with relapsed or refractory metastatic disease. We expect to initially seek approval of our product candidates in this setting. Subsequently, for those product candidates that prove to be sufficiently beneficial, if any, we would expect to seek approval in earlier lines of treatment and potentially as a first line therapy. There is no guarantee, however, that our product candidates, even if approved, would be approved for earlier lines of therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers in a position to receive second or third-line therapy, and who have the potential to benefit from treatment with our product candidates, are based on our research and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research by third parties, and may prove to be incorrect. We do not have verifiable internal marketing data regarding the potential size of the commercial market for our product candidates, nor have we obtained independent marketing surveys to verify the potential size of the commercial markets for our current product candidates or any future product candidates. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of treatable patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates and may also be limited by the cost of our treatments and the reimbursement of those treatment costs by third-party payors. For instance, we expect our lead product candidate to initially target patients with lymphoma who have relapsed after anti-CD19 CAR-T cell therapy or who are ineligible to receive anti-CD19 CAR-T cell treatment. Even if we obtain significant market share for our product candidates, because the potential target populations might be small, we may not achieve profitability without obtaining regulatory approval for additional indications, and we may spend large amounts of money trying to obtain approval for product candidates that have an uncertain commercial market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">New regulatory pathways for biosimilar competition could reduce the duration of market exclusivity for our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, there is an abbreviated path in the United States for regulatory approval of products that are demonstrated to be &#8220;biosimilar&#8221; or &#8220;interchangeable&#8221; with an FDA-approved biological product. The ACA provides a regulatory mechanism that allows for FDA approval of biologic drugs that are similar to (but not generic copies of) innovative drugs on the basis of less extensive data than is required by a full BLA. Under this regulation, an application for approval of a biosimilar may be filed four years after approval of the innovator product. However, qualified innovative biological products will receive 12 years of regulatory exclusivity, meaning that the FDA may not approve a biosimilar version until 12 years after the innovative biological product was first approved by the FDA. However, the term of regulatory exclusivity may not remain at 12 years in the United States and could be shortened. A number of jurisdictions outside of the United States have also established abbreviated pathways for regulatory approval of biological products that are biosimilar to earlier versions of biological products. For example, the European Union has had an established regulatory pathway for biosimilars since 2005.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The increased likelihood of biosimilar competition has increased the risk of loss of innovators&#8217; market exclusivity. Due to this risk, and uncertainties regarding patent protection, if one of our late-stage product candidates or other clinical candidates are approved for marketing, it is not possible to predict the length of market exclusivity for any particular product with certainty based solely on the expiration of the relevant patent(s) or the current forms of regulatory exclusivity. It is also not possible to predict changes in United States regulatory law that might reduce biological product regulatory exclusivity. The loss of market exclusivity for a product would likely materially and negatively affect revenues from product sales of that product and thus our financial results and condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent to the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection laws. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of investigations by regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a diversion of management&#8217;s time and our resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exhaustion of any available insurance and our capital resources; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any product candidate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could inhibit or prevent the commercialization of products we develop, alone or with collaborators. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no insurance coverage. While we obtained clinical trial insurance for our clinical trials, we may have to pay amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to protect our proprietary rights, we may not be able to compete effectively or operate profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our commercial success is dependent in part on our ability to obtain, maintain, and enforce the patents and other proprietary rights that we have licensed and may develop, and on our ability to avoid infringing the proprietary rights of others. We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates, proprietary technologies and their uses that are important to our business. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims are directed to the technology. There can be no assurance that our patent applications or those of our licensor will result in additional patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">can there be any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. This failure to properly protect the intellectual property rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with relevant employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of the premises and physical and electronic security of the information technology systems. While we have confidence in these individuals, organizations, and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, trade secrets may otherwise become known or be independently discovered by competitors. To the extent that the consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although we have patents and patent applications in other countries, we cannot be certain that the claims in other pending U.S. or European patent applications, international patent applications, and patent applications in certain other foreign territories directed to methods of generating MAR-T cell product candidates, or our other product candidates, will be considered patentable by the USPTO, courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued licensed European patent will not be found invalid or unenforceable if challenged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Most of our intellectual property rights are currently licensed from BCM, so that the preparation and prosecution of these patents and patent applications was not performed by us or under our control. Furthermore, patent law relating to the scope of claims in the biotechnology field in which we operate is still evolving and, consequently, patent positions in our industry may not be as strong as in other more well-established fields. The patent positions of biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent applications may not result in any patents being issued;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors, many of whom have substantially greater resources than us, and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use and sell our potential product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The patent prosecution process is also expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license from third parties. We may also require the cooperation of our licensor in order to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by our licensor have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and it is uncertain how much protection, if any, will be given to the patents we have licensed from a licensor if either the licensor or we attempt to enforce the patents and/or if they are challenged in court or in other proceedings, such as oppositions, invalidations, or like proceedings, which may be brought in foreign jurisdictions to challenge the validity of a patent. A third - party may challenge our patents, if issued, or the patent rights that we license from others in the courts or patent offices in the United States and abroad. It is possible that a competitor may successfully challenge our patents or that a challenge will result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical products, or limit the duration of the patent protection of our products and product candidates. Moreover, the cost of litigation to defend the validity of patents and to prevent or remedy infringement can be substantial. If the outcome of litigation is adverse to us, third parties may be able to use our patented invention without payment to us. Moreover, it is possible that competitors may infringe our patents or successfully avoid them through design innovation. To stop violation of our patent rights, we may need to file a lawsuit. These lawsuits are expensive and would consume time and other resources, even if we were successful in stopping or remedying the violation of our patent rights. In addition, there is a risk that a court would decide that our patents are not valid and that we do not have the right to stop the other party from using the inventions. There is also the risk that, even if the validity of our patents was upheld, a court would refuse to stop the other party on the ground that its activities are not covered by, that is, do not infringe, our patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Should third parties file patent applications, or be issued patents claiming technology also used or claimed by our licensor(s) or by us in any future patent application, we may be required to participate in interference proceedings in the USPTO to determine priority of invention for those patents or patent applications that are subject to the first-to-invent law in the United States, or may be required to participate in derivation proceedings in the USPTO for those patents or patent applications that are subject to the &#8220;first-inventor-to-file&#8221; law in the United States. We may be required to participate in such interference or derivation proceedings involving our issued patents and pending applications. We may be required to cease using the technology or to license rights from prevailing third parties as a result of an unfavorable outcome in an interference proceeding or derivation proceeding. A prevailing party in that case may not offer us a license on commercially acceptable terms or on any terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If we, our licensing partners, or any potential future collaborator initiates legal proceedings against a third - party to enforce a patent directed to one of our product candidates, the defendant could counterclaim that the patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, non-obviousness or enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they are no longer directed to our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents or those of our licensor invalid or could prevent a patent from issuing from one or more of our pending patent applications. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found. There is also no assurance that there is not prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. Furthermore, even if our patents are unchallenged, they may not adequately protect our intellectual property, provide exclusivity for our product candidates, prevent others from designing around our claims or provide us with a competitive advantage. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">perhaps all, of the patent protection on our product candidates. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection could have a material adverse impact on our business development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The use of our technologies could potentially conflict with the rights of others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our potential competitors or other entities may have or acquire patent or proprietary rights that they could enforce against our licensor. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, reexaminations,&#160;<i style="font-style:italic;">inter partes&#160;</i>review proceedings and post-grant review, or PGR, proceedings before the USPTO and/or corresponding foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Such potential third-party patents or patent applications could limit our ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair our competitive position by requiring us to alter our product candidates, pay licensing fees or cease activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As the biotechnology industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published we may be unaware of third-party patents that may be infringed by commercialization of any of our product candidates, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently-pending patent applications that later issue as patents that our product candidates may infringe. If our product candidates conflict with patent rights of others, third parties could bring legal actions against us or our collaborators, licensees, suppliers or customers, claiming damages and seeking to enjoin manufacturing and marketing of the affected product candidates. If these legal actions are successful, in addition to any potential liability for damages, we could be required to obtain a license in order to continue to manufacture or market the affected product candidates. We may not prevail in any legal action and a required license under the patent may not be available on acceptable terms or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As is the case with other biopharmaceutical companies, our success is dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. For example, on September 16, 2011, the Leahy-Smith America Invents Act, or Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#8220;first inventor to file&#8221; system in which the first inventor to file a patent application will be entitled to the patent. Third parties are allowed to submit prior art before the issuance of a patent by the USPTO and may become involved in post-grant proceedings including post grant review, derivation, reexamination,&#160;<i style="font-style:italic;">inter-partes&#160;</i>review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. In addition, recent U.S. Supreme Court rulings on several patent cases have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. While we do not believe that any of the patents owned or licensed by us will be found invalid based on these decisions, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing its inventions in all countries outside the United States, or from selling or importing products made using its inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For example, the complexity and uncertainty of European patent laws have also increased in recent years. In Europe, a new unitary patent system was introduced by the end of 2023, which significantly impacts European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications will have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court, or UPC. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As is common in the biotechnology and pharmaceutical industries, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. We have received confidential and proprietary information from third parties. We employ individuals or engage consultants who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we fail to comply with any obligations under our existing license agreements or any future license agreements, or disputes arise with respect to those agreements, it could have a negative impact on our business and our intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a party to license agreements with BCM that impose, and we may enter into additional licensing arrangements with third parties that may impose, diligence, development and commercialization timelines, milestone payment, royalty, insurance and other obligations on us. Our rights to use the licensed intellectual property are subject to the continuation of and our compliance with the terms of these agreements. Disputes may arise regarding our rights to intellectual property licensed to us from a third - party, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sublicensing of patent and other rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ownership of inventions and know-how resulting from the creation or use of intellectual property by us, alone or with our licensors and collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope and duration of our payment obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our rights upon termination of such agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope and duration of exclusivity obligations of each party to the agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If disputes over intellectual property and other rights that we have licensed or acquired from third parties prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. If we fail to comply with our obligations under current or future licensing agreements, these agreements may be terminated or the scope of our rights under them may be reduced and we might be unable to develop, manufacture or market any product that is licensed under these agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under our license agreement with BCM for our MAR-T cell therapy technologies, we are currently required to pay both substantial milestone payments and royalties to BCM based on our revenues from sales of any approved products utilizing the licensed technologies, and these payments could adversely affect the overall profitability for us of any products that we may seek to commercialize. In order to maintain our license rights under the BCM license agreement, we will need to meet certain specified milestones, subject to certain cure provisions, in the development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, upon a liquidity event (as defined in our BCM license agreement with BCM) of the licensee under the BCM license agreement (which, the licensee shall be the Company), BCM will receive a liquidity incentive payment of 0.5% of the liquidity event proceeds (as defined in the BCM license agreement) received by such licensee or its stockholders in the liquidity event, thereby diluting the amount of proceeds available to the licensee or its stockholders in a liquidity event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be subject to competition from competitive products, including biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide sufficient rights to exclude others from commercializing products similar or identical to our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain of our technologies are in-licensed from third parties, and the protection of those technologies is not entirely within our control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have a world-wide exclusive license from BCM of the rights in and to three patent families to develop and commercialize MAR-T cell product candidates in the field of oncology. As a result of these in-licenses, we could lose the right to develop each of the technologies if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the owner (s) of the patent rights underlying the technologies that we license do not properly maintain or enforce the patents and intellectual property underlying those properties,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BCM seeks to terminate our license in contravention of the license agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we fail to make all payments due and owing under any of the licenses; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we fail to obtain on commercially reasonable terms, if at all, in-licenses from BCM or others for other rights that are necessary to develop the technology that we have already in-licensed.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If any of the above occurs, we could lose the right to use the in-licensed intellectual property, which would adversely affect our ability to commercialize our technologies, products or services. The loss of any current or future licenses from BCM, or the exclusivity rights provided by such license agreements, could materially harm our financial condition and operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely upon patents and licensed technologies to protect our technology. We may be unable to protect our intellectual property rights, and we may be liable for infringing the intellectual property rights of others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to compete effectively depends on our ability to maintain the proprietary nature of our technologies and the proprietary technology of others with whom we have entered into collaboration and licensing agreements. We own or hold licenses to a number of issued patents and U.S. pending patent applications, as well as foreign patents and foreign counterparts. Our success depends in part on our ability to obtain patent protection both in the United States and abroad for our product candidates, as well as the methods for treating patients in the product indications using these product candidates. Such patent protection is costly to obtain and maintain, and sufficient funds might not be available. Our ability to protect our product candidates from unauthorized or infringing use by third parties depends in substantial part on our ability to obtain and maintain valid and enforceable patents. Due to evolving legal standards relating to the patentability, validity and enforceability of patents covering pharmaceutical inventions and the scope of claims made under these patents, our ability to obtain, maintain and enforce patents is uncertain and involves complex legal and factual questions. Even if our product candidates, as well as methods for treating patients for prescribed indications using these product candidates are covered by valid and enforceable patents and have claims with sufficient scope, disclosure and support in the specification, the patents will provide protection only for a limited amount of time. Accordingly, rights under any issued patents may not provide us with sufficient protection for our product candidates or provide sufficient protection to afford us a commercial advantage against competitive products or processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, we cannot guarantee that any patents will be issued from any pending or future patent applications owned by or licensed to us. Even if patents have been issued or will be issued, we cannot guarantee that the claims of these patents are or will be valid or enforceable or will provide us with any significant protection against competitive products or otherwise be commercially valuable to us. The laws of some foreign jurisdictions do not protect intellectual property rights to the same extent as in the United States and many companies have encountered significant difficulties in protecting and defending such rights in foreign jurisdictions. Furthermore, different countries have different procedures for obtaining patents, and patents issued in different countries offer different degrees of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">protection against use of the patented invention by others. If we encounter such difficulties in protecting or are otherwise precluded from effectively protecting our intellectual property rights in foreign jurisdictions, our business prospects could be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patent positions of biotechnology and pharmaceutical companies, including our patent positions, involve complex legal and factual questions, and, therefore, validity and enforceability cannot be predicted with certainty. Patents may be challenged, deemed unenforceable, invalidated, or circumvented. Our patents can be challenged by our competitors who can argue that our patents are invalid and/or unenforceable, or that the patent claims should be limited or narrowly construed. Patents also will not protect our product candidates if competitors devise ways of making or using these product candidates without infringing our patents. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our technologies, methods of treatment, product candidates, and any future products are covered by valid and enforceable patents or are effectively maintained as trade secrets and we have the funds to enforce our rights, if necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The expiration of our owned or licensed patents before completing the research and development of our product candidates and receiving all required approvals in order to sell and distribute the products on a commercial scale can adversely affect our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensor, which could be expensive, time-consuming and unsuccessful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may face legal claims involving stockholders, consumers, competitors, entities from whom we license technology, entities with whom we collaborate, persons claiming that we are infringing on their intellectual property and others. The biotechnology and pharmaceutical industries have been characterized by extensive litigation regarding patents and other intellectual property rights, and companies have employed intellectual property litigation to gain a competitive advantage. Competitors may infringe our intellectual property rights or those of our licensor. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court may decide that one or more of the patents which we own or in-license is not valid or is unenforceable, and/or is not infringed. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In addition, litigation may be necessary to enforce our issued patents, to protect our trade secrets and know-how, or to determine the enforceability, scope, and validity of the proprietary rights of others. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on any issued patent and/or pending patent applications will be due to the USPTO and foreign patent agencies in several stages over the lifetime of our patents and/or applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensor. Should third parties file patent applications or be issued patents claiming technology also used or claimed by us, we may be required to participate in interference or derivation proceedings in the USPTO to determine priority of invention. We may be required to participate in interference or derivation proceedings involving our issued patents and pending applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially acceptable terms.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The costs of litigation or any proceeding relating to our intellectual property or contractual rights could be substantial even if resolved in our favor. Some of our competitors or financial funding sources have far greater resources than we do and may be better able to afford the costs of complex legal procedures. Also, in a lawsuit for infringement or contractual breaches, even if frivolous, we will require considerable time commitments on the part of management, our attorneys and consultants. Defending these types of proceedings or legal actions involve considerable expense and could negatively affect our financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers, and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain licenses needed for the development of our product candidates, or if we breach any of the agreements under which we license rights to patents or other intellectual property from third parties, we could lose license rights that are important to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to maintain and/or obtain licenses needed for the development of our product candidates in the future, we may have to develop alternatives to avoid infringing on the patents of others, potentially causing increased costs and delays in product development and introduction or precluding the development, manufacture, or sale of planned product candidates. Some of our licenses provide for limited periods of exclusivity that require minimum license fees and payments and/or may be extended only with the consent of the licensor. We might not meet these minimum license fees in the future, or these third parties might not grant extensions on any or all such licenses. This same restriction may be contained in licenses obtained in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, the patents underlying the licenses might not be valid and enforceable. To the extent any product candidates developed by us are based on licensed technology, royalty payments on the licenses will reduce our gross profit from such product sales and may render the sales of such product candidates uneconomical. In addition, the loss of any current or future licenses or the exclusivity rights provided therein could materially harm our business financial condition and our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are subject to extensive regulation, which can be costly, time consuming and can subject us to unanticipated delays. Even if we receive regulatory approval of our product candidates, we will be subject to ongoing quality and regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All of our current and future product candidates, cell processing and manufacturing activities, are subject to comprehensive regulation by the FDA in the United States and by comparable authorities in other countries. The process of obtaining FDA and other required regulatory approvals, including foreign approvals, is expensive and often takes many years and can vary substantially based upon the type, complexity and novelty of the products involved. In addition, regulatory agencies may lack experience with our technologies and product candidates, which may lengthen the regulatory review process, increase our development costs and delay or prevent their commercialization. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No adoptive T cell therapy using MAR-T cells has been approved for marketing in the U.S. by the FDA. Consequently, there is no precedent for the successful commercialization of products based on our technologies. In addition, we have had only limited experience in filing and pursuing applications necessary to gain regulatory approvals, which may impede our ability to obtain timely FDA approvals, if at all. We have not yet sought FDA approval for any adoptive T cell therapy product. We will not be able to commercialize any of our potential product candidates until we obtain FDA approval, and so any delay in obtaining, or inability to obtain, FDA approval would harm our proposed business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we violate regulatory requirements at any stage, whether before or after marketing approval is obtained, we may be fined, forced to remove a product from the market and experience other adverse consequences including delay, which could materially harm our business development. Additionally, we may not be able to obtain the labeling claims necessary or desirable for the promotion of our products. We may also be required to undertake post-marketing trials. Prescription drugs may be promoted only for the approved indications in accordance with the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label may be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatment but the FDA does restrict manufacturer&#8217;s communications on the subject of off-label use of their products. In addition, if we or others identify side effects after any of our adoptive T cell therapy products are on the market, or if manufacturing problems occur, regulatory approval may be withdrawn, and reformulation of our products may be required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a risk evaluation and mitigation strategy in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and cGCPs for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of our product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of any approved product candidates will be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any relationships with healthcare professionals, principal investigators, consultants, customers (actual and potential) and third-party payors in connection with our current and future business activities are and will continue to be subject, directly or indirectly, to federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could&#160;face penalties, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business operations and activities may be directly, or indirectly, subject to various federal and state healthcare laws, including without limitation, fraud and abuse laws, false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. These laws may restrict or prohibit a wide range of business activities, including, but not limited to, research, manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These laws may impact, among other things, our current activities with principal investigators and research subjects, as well as current and future sales, marketing, patient co-payment assistance and education programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Such laws include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal civil and criminal false claims laws, including the federal civil False Claims Act, and civil monetary penalties laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, which also imposes obligations, including mandatory contractual terms, on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity as well as their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other health care professionals)(such as physician assistants and nurse practitioners) and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous state, local, and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third - party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures or drug pricing; state and local laws that require the registration of pharmaceutical sales representatives; state and local &#8220;drug takeback&#8221; laws and regulations; and state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. While our interactions with healthcare professionals have been structured to comply with these laws and related guidance, it is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws. If our operations or activities are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, any sales of our product once commercialized outside the U.S. will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recently enacted and future legislation in the United States and other countries may affect the prices we may obtain for our product candidates and increase the difficulty and cost to commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the United States and many other countries, rising healthcare costs have been a concern for governments, patients and the health insurance sector, which has resulted in a number of changes to laws and regulations, and may result in further legislative and regulatory action regarding the healthcare and health insurance systems that could affect our ability to profitably sell any product candidates for which we have obtained marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For example, the ACA was enacted in the United States in March 2010, with the stated goals of containing healthcare costs, improving quality and expanding access to healthcare, and includes measures to change health care delivery, increase the number of individuals with insurance, ensure access to certain basic health care services, and contain the rising cost of care. There have been judicial, Congressional and executive branch challenges to certain aspects of the ACA. For example, Congress considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. Additionally, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is also unclear how such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, other federal health reform measures have been proposed and adopted in the United States. For example, as a result of the Budget Control Act of 2011 and subsequent legislative amendments thereto, including the Infrastructure Investment and Jobs Act, providers are subject to Medicare payment reductions of 2% per fiscal year until 2031, unless additional Congressional action is taken. Under current legislation the actual reduction in Medicare Payments will vary from 1% in 2022 to up to 3% in the fiscal year of this sequester. Further, the American Taxpayer Relief Act of 2012 reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. The Medicare Access and CHIP Reauthorization Act of 2015 ended the use of the statutory formula, also referred to as the Sustainable Growth Rate, for clinician payment and also introduced a quality payment program, or the Quality Payment Program, under which certain individual Medicare providers </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">will be subject to certain incentives or penalties based on new program quality standards. This Quality Payment Program provides clinicians with two ways to participate, including through the Advanced Alternative Payment Models, or APMs, and the Merit-based Incentive Payment System, or MIPS. In November 2019, CMS issued a final rule finalizing the changes to the Quality Payment Program. It is still unclear how the introduction of the Quality Payment Program will impact overall physician reimbursement under the Medicare program. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, for example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented but it is likely to have a significant impact on the pharmaceutical industry. In addition, the Biden administration released an additional executive order on October 14, 2022, directing HHS to report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;), which was signed into law on July 4, 2025, includes provisions that will impact the United States healthcare system in various ways. For example, the OBBBA is expected to significantly reshape the Medicaid program, including by introducing new work and eligibility requirements and changes to Medicaid payment and financing. Although the full impact of the OBBBA on the healthcare system and our business is uncertain, we may face increased costs and complexity in completing clinical development of and commercializing any product candidates for which we may receive regulatory approval, which could adversely affect our business and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The combination of healthcare cost containment measures, increased health insurance costs, reduction of the number of people with health insurance coverage, as well as future legislation and regulations focused on reducing healthcare costs by reducing the cost of, or reimbursement and access to, pharmaceutical products, may limit or delay our ability to commercialize our products, generate revenue or attain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As described above, the ACA and potential regulations thereunder easing the entry of competing follow-on biologics into the marketplace, other new legislation or implementation of existing statutory provisions on importation of lower-cost competing drugs from other jurisdictions, and legislation on comparative effectiveness research are examples of previously enacted and possible future changes in laws that could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect that additional state and federal healthcare reform measures will continue to be adopted in the future. While it is not possible to predict whether and when any such changes will occur, changes in the laws, regulations, and policies governing the development and approval of our product candidates and the commercialization, importation, and reimbursement of our product candidates could adversely affect our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to stringent and changing laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the ordinary course of our business, we may collect, receive, store, process, generate, use, transmit, disclose, make accessible, protect, secure, dispose of, share (collectively, processing) personal data and other sensitive data, including proprietary and confidential business data, intellectual property, trade secrets, data regarding clinical trial subjects, and sensitive third-party data. We may rely on third parties (such as service providers) for our data processing-related activities. Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations that govern the processing of personal data by us and on our behalf.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, and consumer protection laws. For example, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information. Additionally, the California Consumer Privacy Act of 2018, or CCPA, applies to personal data of consumers, business representatives, and employees, and requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights. The CCPA provides for civil penalties of up to $7,500 per violation and allows private litigants affected by certain data breaches to recover significant statutory damages. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA increases compliance costs and potential liability with respect to other personal data we maintain about California residents. In addition, California Privacy Rights Act of 2020, or CPRA, expands the CCPA&#8217;s requirements, including by adding a new right for individuals to correct their personal data and establishing a new regulatory agency to implement and enforce the law. Other states, such as Virginia and Colorado, have also passed comprehensive privacy laws, and similar laws are being considered in several other states, as well as at the federal and local levels. While these states, like the CCPA, also exempt some data processed in the context of clinical trials, these developments further complicate compliance efforts and increase legal risk and compliance costs for us and the third parties upon whom we rely. Outside the United States, an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation (&#8220;EU GDPR&#8221;), the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;), Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or &#8220;LGPD&#8221;) (Law No. 13,709/2018), and China&#8217;s Personal Information Protection Law (&#8220;PIPL&#8221;) impose strict requirements for processing personal data. For example, under the EU GDPR, companies may face temporary or definitive bans on data processing and other corrective actions, fines of up to 20 million euros or 4% of annual global revenue, whichever is greater, or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are also bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. For example, certain privacy laws, such as the CCPA, require our customers to impose specific contractual restrictions on their service providers. We publish privacy policies, marketing materials and other statements, regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators or other adverse consequences. Obligations related to data privacy and security are quickly changing, becoming increasingly stringent, and creating regulatory uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources, which may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims); additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: interruptions or stoppages in our business operations (including clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to our Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The price of our stock may be volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The listing of our common stock on Nasdaq does not assure that a meaningful, consistent and liquid trading market currently exists or will exist in the future. The trading price of our common stock may fluctuate substantially. The price of our common stock that will prevail in the market may be higher or lower than the price at which our shares of common stock, depending on many factors, some of which are beyond our control and may not be related to our company or our operating performance. These fluctuations could cause you to lose part or all of your investment in our common stock. Those factors that could cause fluctuations include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">price and volume of fluctuations in the overall stock market from time to time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations in stock market prices and trading volumes of similar companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the thinly traded nature of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated changes in our net loss or fluctuations in our operating results or in the expectations of securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of our preclinical studies and clinical trials or delays in anticipated timing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuance of new equity securities pursuant to a future offering, including issuances of preferred stock, or sales of large blocks of our stock and sales by insiders and our institutional investors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of new collaboration agreements with strategic partners or developments by our existing collaboration partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of acquisitions, mergers or business combinations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitive developments, including announcements by competitors of new products or services or significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic conditions and trends, including changes in interest rates, and other national and global conditions, including pandemics and related global economic uncertainty;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">major catastrophic events;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">departures of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">events affecting BCM, our CDMO or any future collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of new product candidates or technologies, commercial relationships or other events, including the results of clinical trials, or variations in our quarterly operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory developments in the United States and other countries, including changes in the structure of healthcare payment systems, or other positive and negative events relating to healthcare and the overall pharmaceutical and biotechnology sectors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure of our common stock to maintain listing requirements on Nasdaq;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the outcome of any litigation to which we are a party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in accounting principles; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discussion of our company or our stock price by the financial and scientific press and in online investor communities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The stock market in general, and the Nasdaq Capital Market, or Nasdaq, and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors, including potentially worsening economic conditions, may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. Due to the potential volatility of our stock price, we may therefore be the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#8217;s attention and resources from our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Sales of additional equity securities may adversely affect the market price of our common stock and your rights may be reduced. Our stockholders may experience dilution in the future and it may adversely affect the market price of our securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect to continue to incur drug development and sale, general and administrative costs. Until such time, if ever, as we can generate substantial product revenue, we expect to fund our cash requirements through a combination of equity offerings, debt financings and potential collaboration, license and development agreements. We do not currently have a committed external source of funds, but have entered into the ATM agreement under which we may sell shares. To the extent that we sell equity securities or convertible debt securities, including under the ATM agreement, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. The sale or the proposed sale of substantial amounts of our common stock or other equity securities in the public markets may adversely affect the market price of our common stock. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, we had 16.7 million shares of our common stock issued and outstanding. Those outstanding shares represent a minority of our authorized shares, meaning that the ownership position of the current stockholders could be diluted significantly were we to issue a large number of additional shares. In addition, as of December 31, 2025, there were outstanding options for an aggregate of approximately 1.8 million shares of common stock at a weighted average exercise price of&#8201;$7.77 per share. Further, as of December 31, 2025, there were outstanding warrants for an aggregate of approximately 7.7 million shares of common stock at a weighted average exercise price of $2.62 per share. We have registered the resale of the shares issuable upon exercise of our outstanding warrants, and as a result the shares issued upon exercise will be tradable by the exercising party. Upon such registration, the holders may sell these shares in the public markets from time to time, without limitations on the timing, amount, or method of sale. If our stock price rises, the holders may exercise their warrants and options and sell a large number of shares. This could cause the market price of our common stock to decline and cause existing stockholders to experience significant further dilution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We do not intend to pay cash dividends.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not declared or paid any cash dividends on our common stock, and we do not anticipate declaring or paying cash dividends for the foreseeable future. Any future determination as to the payment of cash dividends on our common stock will be at our board of directors&#8217; discretion and depends on our financial condition, operating results, capital requirements and other factors that our board of directors considers to be relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">From time to time, we may become involved in legal proceedings. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We are not currently a party to any material legal proceedings that we believe could have an adverse effect on our business, operating results or financial condition. However, from time to time, we may become involved in legal proceedings, including those arising in the ordinary course of doing business. For example, we may be subject to claims from our employees, consultants, vendors and other third </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">parties with whom we have a contractual relationship. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, or are perceived to have been compromised, we could experience adverse consequences, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the ordinary course of our business, we and the third parties upon which we rely, may collect, receive, store, use, transmit, disclose, transfer, disclose, make accessible, protect, secure, dispose of, transmit, share, or otherwise process proprietary, confidential, and sensitive data, including personal data (such as health-related data regarding clinical trial subjects), intellectual property, and trade secrets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cyberattacks, malicious internet-based activity, and online and offline fraud and other similar activities threaten the confidentiality, integrity, and availability of our sensitive information and information technology systems, and those of the third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation-states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we, the third parties upon which we rely, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services. We and the third parties upon which we rely may be subject to a variety of threats, including, but not limited to, malicious code (such as viruses and worms), social engineering attacks (including through phishing attacks), malware (including as a result of advanced persistent threat intrusions), denial of service attacks (such as credential stuffing), credential harvesting, software bugs, server malfunctions, software or hardware failures, unauthorized access, natural disasters, fire, terrorism, successful breaches, personnel misconduct or error, or human or technological error, war and telecommunication and electrical failures. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In particular, severe ransomware attacks are becoming increasingly prevalent and severe, and can lead to significant interruptions in our operations, loss of sensitive data, reputational harm, and diversion of funds. Extortion payments may alleviate some of the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Additionally, future pandemics could pose increased risks to our information technology systems and data if our employees are required to work from home, utilizing network connections outside our premises. Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We rely on third parties (such as service providers and technologies) to process sensitive information in a variety of contexts, including without limitation third-party providers of cloud-based infrastructure, encryption and authentication technology, employee email, and other functions. Our ability to monitor these third parties&#8217; cybersecurity practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised. Any of the previously identified or similar threats could cause a security incident or other incident during which our information technology systems or data could be compromised, which could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our data; it could also disrupt our ability (and that of third parties upon which we rely) to operate our business, including conducting our clinical trials. For example, if a compromise were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. Similarly, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may expend significant resources or modify our business activities (including our clinical trial activities) in an effort to protect against the compromise of our information technology systems and data. Further, certain data privacy and security obligations may require us to implement and maintain specific security measures, industry-standard or reasonable security measures to protect our information technology systems and data. While we have implemented security measures designed to prevent our information technology systems and data from being compromised, there can be no assurance that these measures will be effective. We may be unable to detect vulnerabilities in our information technology systems because the threats against these systems change frequently, are often sophisticated, and may not be detected until after a compromise has occurred. Despite our efforts to identify and remediate vulnerabilities, if any, in our information technology systems, our efforts may not be successful. Further, we may experience delays in developing and deploying remedial measures designed to address any identified vulnerabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we (or a third - party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, including: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing data (including personal data); litigation (including class actions); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Additionally, applicable data privacy and security obligations may require us to notify relevant stakeholders; such disclosures are costly, and the disclosures or the failure to comply with such requirements could lead to adverse consequences. Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from claims related to our data privacy and security obligations. We have cybersecurity insurance for a breach event covering expenses for notification, credit monitoring, investigation, crisis management, public relations and legal advice. We also maintain property and casualty insurance that may cover restoration of data, certain physical damage or third-party injuries caused by potential cybersecurity incidents. However, damage and claims arising from such incidents may not be covered or may exceed the amount of any insurance available. Additionally, we cannot be sure that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">As a result of being a public company, we are obligated to develop and maintain proper and effective internal controls over financial reporting, and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are required, pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. We are also required to disclose significant changes made in our internal control procedures on a quarterly basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To comply with Section 404, we have engaged in the costly and challenging process of compiling the system and processing documentation necessary to perform the evaluation needed to comply with Section 404. Our compliance with Section 404 requires that we incur substantial professional fees and expend significant management efforts, and we may need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge and compile the system and process documentation necessary to perform the evaluation needed to comply with Section 404.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the evaluation and testing process of our internal controls, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition or results of operations. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by the Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to use net operating losses and certain other tax attributes to offset future taxable income may be subject to limitation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our net operating loss, or NOL, carryforwards could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. Our federal NOLs generated in tax years beginning before January 1, 2018, are permitted to be carried forward for only 20 years under applicable U.S. tax law. Our federal NOLs generated in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal tax law. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, under Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, or, the Code, if a corporation undergoes an &#8220;ownership change,&#8221; its ability to use its pre-change NOL carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited. A Section 382 &#8220;ownership change&#8221; generally occurs if one or more stockholders or groups of stockholders who own at least 5% of our stock increase their ownership by more than 50 percentage points (by value) over their lowest ownership percentage over a rolling three-year period. We may have experienced ownership changes in the past and may experience ownership changes in the future as a result of shifts in our stock ownership (some of which are outside our control). As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset such taxable income may be subject to limitations. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Consequently, even if we achieve profitability, we may not be able to utilize a material portion of our net operating loss carryforwards and certain other tax attributes, which could have a material adverse effect on cash flow and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Catastrophic events may disrupt our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event of a major hurricane or other serious weather event or catastrophic event such as fire, power loss, cyberattack, war, terrorist attack or epidemic or pandemic that impacts the facilities of any third parties on which we may rely, we may be unable to continue our operations and may experience delays in our manufacturing process and shipment of clinical supply to trial sites or interruptions in our clinical trials and research activities, all of which could delay our development plans and materially harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business and operations could be adversely affected by the effects of health epidemics, including pandemics. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business and operations could be adversely affected by the effects of health epidemics, as was recently experienced in connection with the COVID-19 virus, which was declared by the World Health Organization as a global pandemic. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Remote work policies, quarantines, shelter-in-place and similar government orders, shutdowns or other restrictions on the conduct of business operations related to the pandemics or other health epidemics may negatively impact productivity. For instance, the COVID-19 pandemic disrupted our ongoing research and development activities and delayed certain of our clinical programs and timelines. In addition, although our employees are accustomed to working remotely, changes in internal controls due to remote work arrangements may result in control deficiencies in the preparation of our financial reports, which could be material. Such orders may also impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain and could affect our ability to conduct ongoing and planned clinical trials and preparatory activities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Health epidemics may also affect the conduct of our clinical trials. We previously experienced temporary delays in enrollment due to the COVID-19 pandemic and in satisfying certain FDA requirements to move forward with the trial, which together resulted in a delay in our overall timelines for this trial. Our ongoing and future clinical trials may also be affected by future pandemics. Patient enrollment and clinical site initiation, while ongoing, may be delayed due to prioritization of hospital resources toward pandemics or other health emergencies, if they arise. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, we may be unable to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to health epidemics, which would adversely impact clinical trial operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The extent to which future pandemics impact our business and operations, including our clinical development and regulatory efforts, will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the continued geographic spread of the disease, the duration and effect of any future business disruptions in the United States and other countries to contain and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">treat patients with the disease. Accordingly, we do not yet know the full extent of potential delays or impacts on our business, our clinical and regulatory activities, healthcare systems or the global economy as a whole. However, these impacts could adversely affect our business, financial condition, results of operations and growth prospects and may also have the effect of heightening many of the other risks and uncertainties described in this &#8220;Risk Factors&#8221; section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unfavorable global political or economic conditions could adversely affect our business, financial condition or results of operations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, in recent years the COVID-19 pandemic, decades-high inflation and concerns about an economic recession in the United States or other major markets resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. The Federal Reserve recently raised interest rates multiple times in response to concerns about inflation and is expected to continue to raise rates. Higher interest rates, coupled with reduced government spending and volatility in financial markets, including with respect to foreign exchange, may increase economic uncertainty. A severe or prolonged economic downturn, such as the global financial crisis, could result in a variety of risks to our business, including our ability to raise additional capital when needed on acceptable terms, if at all. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. In addition, military conflicts such as between Russia and Ukraine could disrupt or otherwise adversely impact our operations and those of third parties upon which we rely, although we have not experienced any such disruption to date. Related sanctions, export controls or other actions have been or may in the future be initiated by nations including the United States, the European Union or Russia (e.g., potential cyberattacks, disruption of energy flows, etc.), which could adversely affect our business and/or our supply chain, our CROs, CMOs and other third parties with whom we conduct business. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs. Any significant increases in inflation and related increase in interest rates could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in tax laws or regulations could materially adversely affect our company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;"><span style="font-style:normal;font-weight:normal;">New tax laws or regulations could be enacted at any time, and existing tax laws or regulations could be interpreted, modified or applied in a manner that is adverse to us, which could adversely affect our business and financial condition. For instance, the United States recently passed the Inflation Reduction Act, which provides for a minimum tax equal to 15% of the adjusted financial statement income of certain large corporations, as well as a 1% excise tax on certain share buybacks by public corporations that would be imposed on such corporations. In addition, it is uncertain if and to what extent various states will conform to federal tax legislation. The impact of such changes or future legislation could increase our U.S. tax expense and could have a material adverse impact on our business and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_37f3314d_c20c_4a48_b8fa_963a22af997f"></a><a id="ITEM1BUNRESOLVEDSTAFFCOMMENTS_521175"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 1B. UNRESOLVED STAFF COMMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_b259895d_c971_4e90_9912_2b46d6f62e95"></a><a id="ITEM1CCYBERSECURITY_814205"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM 1C. CYBERSECURITY</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="Tb_hlO_rRF38U6Cu1innGqY4g" continuedAt="Tb_hlO_rRF38U6Cu1innGqY4g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We operate in the biotechnology sector, which is subject to various cybersecurity risks that could adversely affect our business, financial condition, and results of operations, including intellectual property theft&#894; fraud&#894; extortion&#894; harm to employees or customers&#894; violation of privacy laws and other litigation and legal risk&#894; and reputational risk. We have implemented a risk-based approach to identify and assess the cybersecurity threats that could affect our business and information systems. Our cybersecurity program is aligned with industry standards and best practices, such as the National Institute of Standards and Technology (&#8220;NIST&#8221;) Cybersecurity Framework. We expect the <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="Narr_9DwI1SofM0mp5gAWgbZU6g">third-party vendors</ix:nonNumeric> that provide our IT services to use various tools and methodologies to manage cybersecurity risk and to monitor and evaluate our cybersecurity posture and performance on an ongoing basis through regular vulnerability scans, penetration tests and threat intelligence feeds. <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" format="ixt:fixed-true" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="Narr_3Tte3TeNvEO0HFMQMkaRog">We expect to require third-party service providers with access to personal, confidential or proprietary information to implement and maintain cybersecurity practices consistent with applicable legal standards and industry best practices.</ix:nonNumeric></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_hlO_rRF38U6Cu1innGqY4g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business depends on the availability, reliability, and security of our information systems, networks, data, and intellectual property. Any disruption, compromise, or breach of our systems or data due to a cybersecurity threat or incident could <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="Narr_Z18Kq6VX_kOYzTddN7SIWA">adversely affect</ix:nonNumeric> our operations, customer service, product development, and competitive position. They may also result in a breach of our contractual obligations or legal duties to protect the privacy and confidentiality of our stakeholders. Such a breach could expose us to business interruption, lost revenue, ransom payments, remediation costs, liabilities to affected parties, cybersecurity protection costs, lost assets, litigation, regulatory scrutiny and actions, reputational harm, customer dissatisfaction, harm to our vendor relationships, or loss of market share.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cybersecurity Governance and Oversight</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="Tb_mRn91iVOlUGa0Ad2g_dqHA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_9byzhs_OX0qwR74nHpJY7Q" escape="true">board of directors</ix:nonNumeric> addresses our cybersecurity risk management as part of its general oversight function.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="Tb_HegNGGY990u_Q5hDC4y5yg" escape="true"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="Tb_A2BLiH9JXU2_V6IOiKf8_A" escape="true"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="Tb_2gN6k0_6PUCktf9n2sTf0g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our cybersecurity <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="Narr_nf2IInDCO0qfMgj6vHedUA">risk assessment and management processes</ix:nonNumeric> are implemented and maintained by various members of our management team, third party service providers and other employees, who we believe have a combination of relevant expertise, experience, education and training.</p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="Tb_4gzHWrSeP028KfrYd7Ah0A" escape="true">members of our management team</ix:nonNumeric> are <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="Narr_sw9eeOHTjE6CZ4ZXVeDMhg">responsible </ix:nonNumeric>for hiring appropriate personnel and third-party IT service providers, helping to integrate cybersecurity risk considerations into our overall risk management strategy, communicating key priorities to relevant personnel, approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="Tb_bAvuC0xiqEyM5uu-kHzeMg" escape="true">Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including in some cases to our executive team. Our cybersecurity incident management team, and other individuals as needed, work to help us mitigate and remediate cybersecurity incidents of which we are notified. In addition, our incident response processes include a procedure for reporting certain cybersecurity incidents to the board of directors</ix:nonNumeric>.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb__H_a-9_z-ESHnFD-2o3pFg" escape="true"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="Narr_cmIXVEyI-EialjQpg2CfuQ">The board of directors receives regular reports from management concerning our cybersecurity risk management program</ix:nonNumeric>.</ix:nonNumeric> The board also receives various summaries and/or presentations related to cybersecurity threats, risks and mitigation.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4005a772_941c_49f6_92cc_faf53a1007fd"></a><a id="ITEM2PROPERTIES_338462"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 2. PROPERTIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We do not own any real estate or other properties. We utilize office space at 2450 Holcombe Blvd, TMC Partners Office 1.311, Houston, TX 77021, which is also our principal business office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_0c6973d6_d034_40c1_a24a_2020f83bc0c5"></a><a id="ITEM3LEGALPROCEEDINGS_282506"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 3. LEGAL PROCEEDINGS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">From time to time, we may become involved in legal proceedings, including those arising in the ordinary course of our business. We are not currently a party to any material legal proceedings that we believe could have an adverse effect on our business, operating results or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6886ed40_8bc6_48f0_99f2_fc0b647e57b7"></a><a id="ITEM4MINESAFETYDISCLOSURE_456568"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 4. MINE SAFETY DISCLOSURE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Not Applicable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_08b73108_2358_4ce2_8c7b_b0e14dd7916f"></a><a id="PARTII_862782"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PART II</b></p><a id="ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Market Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our common stock is listed for trading on the Nasdaq Capital Market under the symbol &#8220;MRKR&#8221;. As of March 16, 2026, we had 39 stockholders of record, whom are holding shares. The price of our common stock on March 16, 2026 was $1.41 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No dividends have been declared or paid on our common stock. We have incurred recurring losses and do not currently intend to pay any cash dividends in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Sales of Unregistered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Issuer Repurchase Of Equity Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We did not repurchase any equity securities.</p><a id="_6c23898e_3bb1_42ef_b852_3c243ec032ca"></a><a id="ITEM6RESERVED"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ITEM 6. [RESERVED]</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3c42d5ac_fd53_48cb_a0ed_407d86a8be84"></a><a id="ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following discussion of our financial condition, changes in financial condition, plan of operations and results of operations should be read in conjunction with (i) our audited consolidated financial statements as of December 31, 2025 and December 31, 2024 and (ii) the section entitled &#8220;Business&#8221;, included in this annual report. The discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Company Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Harnessing millions of years of immunologic evolution, Marker&#8217;s multi antigen recognizing (&#8220;MAR&#8221;)-T cell technology is designed to recognize and kill highly heterogeneous tumors without the need for genetic modifications. This approach selectively expands natural tumor-specific T cells from a patient&#8217;s/donor&#8217;s blood that are capable of recognizing a broad range of tumor associated antigens, or TAAs. Unlike other T cell therapies, MAR-T cells are able to recognize hundreds of different epitopes within up to six tumor-specific antigens to produce broad spectrum anti-tumor activity. Targeting multiple antigens simultaneously exploits the natural capacity of T cells to recognize and kill tumor targets via native T cell receptors (&#8220;TCR&#8221;), while limiting tumor adaptation/escape by antigen-negative selection or antigen down-regulation. When infused into a patient with cancer, the MAR-T cells are designed to kill cancer cells expressing the TAA and potentially recruit the patient&#8217;s immune system to participate in the cancer killing process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We licensed the underlying technology for MAR-T cell therapy from Baylor College of Medicine, or BCM, in March 2018. BCM had utilized the therapy in seven exploratory clinical trials. In these studies, BCM treated over 150 patients suffering from a variety of cancers including lymphoma, multiple myeloma, acute myeloid leukemia, or AML, acute lymphoblastic leukemia, or ALL, pancreatic cancer, breast cancer and various sarcomas. In those studies, BCM saw evidence of clinical benefit, expansion of infused cells, and decreased toxicity compared to other cellular therapies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:120.73pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We anticipate to continue to advance two product candidates for 3 clinical indications as part of our MAR-T cell program for:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Off-the-Shelf (&#8220;OTS&#8221;) product in various indications (e.g., MT-401-OTS in AML or MDS)</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not genetically engineer our MAR-T cell therapies and we believe that our product candidates are superior to T cells engineered with chimeric antigen receptors, or CAR-T, for several reasons including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Multiple targets &#8594; enhanced tumoricidal effect&#8594; minimized tumor immune escape </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical safety &#8594; no treatment-related side effects, including immune effector cell-associated neurotoxicity syndrome (ICANS) or other severe adverse effects (SAEs), were attributed to the use of MAR-T cell therapies to date</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-genetically engineered T cell products &#8594; selective expansion of tumor-specific T cells from a patient&#8217;s or donor&#8217;s blood capable of recognizing a broad range of tumor antigens&#8594; no risk of mutagenesis and reduced manufacturing complexity &#8594; lower cost</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="mrkr-20251231x10k008.jpg" alt="Graphic" style="display:inline-block;height:120.73pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:494.91pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For these reasons, we believe our endogenous T cell receptor-based therapies may provide meaningful clinical benefit and safety to patients with both hematological and solid tumors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that the simplicity of our manufacturing process allows additional modifications to expand MAR-T cell recognition of cancer targets. For example, we are assessing the potential of combining MAR-T cell products with other products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2025, we issued a press release providing an update on the progress and clinical observations from the Phase 1 APOLLO study, with a data cutoff date of June 2025. Our Phase 1 APOLLO study is investigating MT-601, a MAR-T cell product, in patients with lymphoma who have relapsed after anti-CD19 chimeric antigen receptor (CAR) T cell therapy or for whom anti-CD19 CAR-T cells are not an option. In this update, clinical data was available for a total of 24 B-cell lymphoma patients from 7 clinical sites across the United States, including 15 patients with Non-Hodgkin Lymphoma (&#8220;NHL&#8221;) and 9 patients with Hodgkin Lymphoma (&#8220;HL&#8221;). At the time of the data cutoff, 12 NHL and 9 HL patients have been assessed. Study participants showed objective responses and a favorable safety profile with and without lymphodepletion.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:236.04pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our clinical-stage pipeline is set forth below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="mrkr-20251231x10k009.jpg" alt="Graphic" style="display:inline-block;height:236.04pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:475.44pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacturing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our manufacturing process was originally developed at Baylor College of Medicine, where we initially conducted our clinical trials. We continue to contract and collaborate with BCM and others to perform a wide variety of services to ensure the continuation of our research and development efforts, with the goal of optimizing our manufacturing process, product quality and commercial scalability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 22, 2024, we entered into a Master Services Agreement for Product Supply (the &#8220;MSA&#8221;) with Cell Ready for the provision of various products and services by Cell Ready pursuant to work orders that may be entered into from time to time. Cell Ready, which is owned by one of our former directors, Mr. John Wilson, is a contract development and manufacturing organization (CDMO). The MSA contains customary representations, warranties and indemnification provision. The initial term of the MSA is three years and may be extended upon the mutual written agreement of the parties. On March 27, 2025, we mutually agreed with Cell Ready to terminate the MSA. In connection therewith, we and Cell Ready entered into a settlement and release agreement pursuant to which we paid Cell Ready approximately $453,000 and we and Cell Ready provided one another mutual releases of all claims associated with any and all agreements between Marker and Cell Ready.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, BCM continues to supply us with products, as we continue our clinical trials. Furthermore, in anticipation of the commencement of our larger pivotal trial for Lymphoma in 2026, as well as the eventual need for commercial scale production, we intend to evaluate and qualify additional potential third-party manufacturing partners to provide potential multiple sources of clinical and commercial supply. We currently are in discussions with a number of CDMO candidates and anticipate that we will select a partner organization and commence the qualification and technology transfer process later this year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">However, there is no guarantee that we will or have properly estimated our required manufacturing capacities or that the third parties on which we rely to manufacture our products will be able or willing to perform on our proposed timelines or to meet our manufacturing demands, if at all. If any of our third-party vendors experience disruptions, or otherwise cease or substantially reduce the amount of products they are willing to supply us, our business and operations could be adversely affected. See &#8220;Risk Factors&#8221;.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recent Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 16, 2025, Company entered into a Statement of Work (the &#8220;SOW&#8221;) with Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (&#8220;CDMO&#8221;), for the manufacturing of MT-601, the Company&#8217;s lead MAR-T cell product candidate. Pursuant to the SOW, Cellipont will provide technology transfer and cGMP manufacturing services to support the scale-up and production of MT-601 for the Company&#8217;s APOLLO study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Between July 17 and 21, 2025, the Company sold 1,624,075 shares of common stock pursuant to our ATM Agreement, with H.C. Wainwright &amp; Co. LLC, for net proceeds of $4.5 million, after deducting agent commissions, at an average price per share of $2.87 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 26, 2025, the Company sold 3,734,217 shares of common stock pursuant to the ATM Agreement with H.C. Wainwright &amp; Co., LLC for net proceeds of $5.4 million, after deducting agent commissions, at an average price of $1.48 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 6, 2025, the Company announced that the first patient has been treated in the Off-the-Shelf (&#8220;OTS&#8221;) program, with encouraging preliminary safety data. The OTS program has the potential to provide a fast treatment option for patients with rapidly progressing diseases. The OTS product will be initially investigated in patients with acute myeloid leukemia (&#8220;AML&#8221;) or myelodysplastic syndromes (&#8220;MDS&#8221;), with the potential to be expanded to other indications. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective November 1, 2025, Kathryn Penkus Corzo joined the Company&#8217;s Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our research and development expenses are primarily costs associated with our clinical trials, including compensation, share-based compensation expense and benefits for employees and selected consultants, manufacturing expenses and fees paid to third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical costs are expensed as incurred. Costs and timing of clinical trials and development of our product candidates will depend on a variety of factors that include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">per patient clinical trial costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients that participate in the clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of sites included in the clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the length of time required to enroll eligible patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of doses that patients receive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the drop-out or discontinuation rates of patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential additional safety monitoring or other studies requested by regulatory agencies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration of patient follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and safety profile of the product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to successfully manufacture patient doses.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the potential for success of each product candidate will depend on numerous factors, including clinical trial outcomes, acceptance by regulatory authorities, competition, manufacturing capability and commercial viability. We determine which programs to pursue and how much to fund each program in response to ongoing scientific assessments, competitive developments, clinical trial results, as well as an assessment of each product candidate&#8217;s commercial potential. We anticipate our clinical trial costs will continue to increase over the next several years due to increased spending on the clinical development and manufacturing of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of personnel costs, including share-based compensation, legal fees relating to patent and corporate matters, insurance costs, consulting and professional fees, audit and investor relations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We recognized ($15,156) and $49,953 in state tax (benefit) expense for the years ended December 31, 2025 and 2024, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other income (expense), net consists of interest income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations for the Years Ended December 31, 2025 and 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the results of our continuing operations (rounded to the thousands except for per share amounts) for the years ended December 31, 2025 and 2024, together with the changes to those items:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Revenues:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,546,669</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,591,080</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,044,411)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (46)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,546,669</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,591,080</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,044,411)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (46)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,799,154</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,467,845</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,668,691)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,184,806</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,241,607</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (56,801)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Loss on early termination of vendor agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 453,135</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 453,135</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">NM</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,437,095</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,709,452</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,272,357)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12,890,426)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,118,372)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,772,054)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Other income (expenses):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 594,206</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 437,010</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 157,196</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 117,444</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 117,444</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">NM</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Loss from operations before income taxes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (12,178,776)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (10,681,362)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (1,497,414)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 14</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 12pt 0pt;">We did not generate any revenue during the years ended December 31, 2025 and 2024, respectively, from the sales or licensing of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 12pt 0pt;">In August 2021, we received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas (&#8220;CPRIT&#8221;), to support the clinical investigation of MT-401 as an Off-the-Shelf (&#8220;OTS&#8221;) product in patients with Acute Myeloid Leukemia (&#8220;AML&#8221;) (the &#8220;CPRIT AML Grant&#8221;).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In September 2022, we received notice from the FDA that we had been awarded a $2.0 million grant from the FDA&#8217;s Orphan Products Grant program to support the clinical investigation of MT-401 for the treatment of AML (the &#8220;FDA Grant&#8221;). </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In May 2023, we received notice of a $2.0 million grant from the National Institutes of Health (&#8220;NIH&#8221;) Small Business Innovation Research (&#8220;SBIR&#8221;) program to support the development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents (the &#8220;SBIR AML Grant&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The above funding agencies have agreed to continue their financial support and to shift funds to the MT-401-OTS program.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2024, we received notice of a $2.0 million grant over a 2-year period from the National Institutes of Health SBIR program to support control over tumor immune escape in pancreatic cancer using a dual T cell product strategy (the &#8220;Decoy Grant&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2024, we received notice of an additional $2.0 million grant from the NIH SBIR program to support the clinical investigation of MT-601 in patients with non-Hodgkin&#8217;s lymphoma (&#8220;NHL&#8221;) who have relapsed following anti-CD19 chimeric antigen receptor (&#8220;CAR&#8221;) T cell therapy (the &#8220;SBIR NHL Grant&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2024, we received another $2.0 million grant from the National Institutes of Health SBIR Program to support the advancement of MT-601 in patients with pancreatic cancer (the &#8220;PANACEA Grant&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December 2024, we received notice an additional $9.5 million grant from CPRIT to support the clinical investigation of MT-601 in patients with metastatic pancreatic cancer (the &#8220;CPRIT Pancreatic Grant&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes grant income recorded for the years ended December 31, 2025 and 2024, by grant:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Grant income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">CPRIT AML Grant<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 900,014</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,411,149</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">FDA Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 118,478</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 519,750</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">SBIR AML Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 472,208</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 982,182</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Decoy Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 391,305</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,822</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">SBIR NHL Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 665,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 665,000</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">PANACEA Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 425,670</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,177</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">CPRIT Pancreatic Grant<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 573,994</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,546,669</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,591,080</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(1) Both CPRIT grants are subject to certain revenue - sharing arrangements, as per the grant agreements (see Note 10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Operating expenses incurred during the fiscal year ended December 31, 2025 were $16.4 million compared to $17.7 million in the prior year. Significant changes in operating expenses are outlined as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Research and Development Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses or clinical trial costs decreased by 12% to $11.8 million for the year ended December 31, 2025, compared to $13.5 million for the year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The decrease of $1.7 million in 2025 was primarily attributable to the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Net decrease of $3.2 million in clinical trial expenses, primarily related to the AML study, offset by</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase of $1.4 million in clinical consulting expenses, process development costs, and other clinical expenses, and </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase of $0.1 million in headcount-related expenses, including stock-based compensation expense</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses decreased by 1% to $4.2 million for the year ended December 31, 2025 from $4.2 million during the prior period, and therefore remained consistent overall year over year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interest Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interest income was $0.6 million and $0.4 million for the years ended December 31, 2025 and 2024, respectively, and was attributable to interest income relating to funds that are held in U.S. Treasury notes and U.S. government agency-backed securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other income was $0.1 million and nil for the years ended December 31, 2025 and 2024, respectively, and was attributable to a state sales tax rebate from 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The increase in our net loss during the year ended December 31, 2025 compared to the year ended December 31, 2024 was due to lower grant income. We anticipate that we will continue to incur net losses in the future as we continue to invest in research and development activities, including clinical development of our MAR-T cell product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not generated any revenues from the sales or licensing of our product candidates since inception and only have limited revenue associated with grants to fund research. We have financed our operations primarily through public and private offerings of our stock and debt including warrants and the exercise thereof, as well as grants. Based on our lack of recurring revenues, anticipated uses of cash and historical recurring cash losses from operating activities, and cash, cash equivalents, and restricted cash as of December 31, 2025, and taking into consideration the net proceeds received in July and August of 2025 through the sale of Common Stock pursuant to its ATM Agreement with H.C. Wainwright &amp; Co., LLC, we anticipate that we will be able to fund our operating expenses and capital expenditure requirements through the fourth quarter of 2026, assuming no additional grant funds are received, either from new grants or from existing awarded grants. We are considering raising additional capital through the issuance of common shares or preferred shares and intend to apply for additional grant funds, which could enable us to fund our operating expenses and capital expenditure requirements beyond the fourth quarter of 2026, although no assurance can be given that such capital or existing awarded grants will be earned or future grants will be awarded. This estimate is subject to our ability to effectively manage our costs, raise additional capital, and receive additional grant funds, of which there can be no assurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Working Capital</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth our cash, cash equivalents, and restricted cash as well as working capital as of December 31, 2025 and 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents, and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,042,847</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 19,192,440</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Working capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16,796,814</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18,558,406</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"><span style="font-style:normal;font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes our cash flows for the years ended December 31, 2025 and 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net cash provided by (used in):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12,014,081)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,910,324)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,864,488</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,991,314</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net (decrease) increase in cash, cash equivalents, and restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,149,593)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,080,990</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:none;">Continuing Operations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:none;">Net cash used in operating activities during the year ended December 31, 2025 was $12.0 million. The use of cash primarily related to our net loss of $12.2 million and a $0.3 million decrease from changes in assets and liabilities, offset by $0.5 million of stock-based compensation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:none;">Net cash used in operating activities during the year ended December 31, 2024 was $10.9 million. The use of cash primarily related to our net loss of $10.7 million and a $0.4 million decrease from changes in assets and liabilities, offset by $0.2 million of stock-based compensation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:none;">Net cash provided by financing activities was $9.9 million and $15.0 million during the years ended December 31, 2025 and 2024, respectively, primarily due to the net proceeds received from sale of common stock through the ATM Agreement in 2025 and Private Placement in 2024, as well as the exercise of stock options.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Future Capital Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, we have not generated any revenues from the commercial sale of approved drug products, and we do not expect to generate substantial revenue for at least the next several years. If we fail to complete the development of our product candidates in a timely manner or fail to obtain their regulatory approval, our ability to generate future revenue will be compromised. We do not know when, or if, we will generate any revenue from our product candidates, and we do not expect to generate significant revenue unless and until we obtain regulatory approval of, and commercialize, our product candidates. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, continue or initiate clinical trials of and seek marketing approval for our product candidates. In addition, if we obtain approval for any of our product candidates, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing and distribution. We anticipate that we will need substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Other receivable mainly consists of grant income receivable. Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. The following table summarizes the Company&#8217;s other receivable balance as of December 31, 2025 and 2024, respectively:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Grant income receivable:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">CPRIT AML Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 815,436</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,059,457</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">FDA Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,678</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">SBIR AML Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 162,897</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 244,810</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Decoy Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 59,501</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,822</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">SBIR NHL Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 87,417</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">PANACEA Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 190,052</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,502</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total grant income receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,318,981</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,316,591</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Interest receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 50,419</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 28,112</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,000</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total other receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,369,400</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,346,703</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, we had working capital of $16.8 million, compared to working capital of $18.6 million as of December 31, 2024. Operating expenses incurred during the fiscal year ended December 31, 2025 were $16.5 million compared to $17.7 million in the prior year. Based on our lack of recurring revenues, anticipated uses of cash and historical recurring cash losses from operating activities, and cash and cash equivalents as of December 31, 2025, we anticipate that we will be able to fund our operating expenses and capital expenditure requirements through the fourth quarter of 2026, assuming no additional grant funds are received. We currently plan to raise additional capital through the issuance of common shares and receive additional grant funds, which could enable us to fund our operating expenses and capital expenditure requirements beyond the fourth quarter of 2026, although no assurance can be given that such capital or existing awarded grants will be earned or future grants will be awarded. This estimate is subject to our ability to effectively manage our costs, raise additional capital, and receive additional grant funds. Our assumptions may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Furthermore, our operating plan may change, and we may need additional funds sooner than planned in order to meet operational needs and capital requirements for product development and commercialization. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates and the extent to which we may enter into additional collaborations with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials. Our future funding requirements will depend on many factors, as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate or continue clinical trials of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue the research and development of our product candidates and seek to discover additional product candidates; seek regulatory approvals for our product candidates if they successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue development of our manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates that may receive regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluate strategic transactions we may undertake; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enhance operational, financial and information management systems and hire additional personnel, including personnel to support development of our product candidates and, if a product candidate is approved, our commercialization efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because all of our product candidates are in the early stages of clinical and preclinical development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of product candidates or whether, or when, we may achieve profitability. Until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to continue to fund our operations and capital funding needs through equity and/or debt financing. We may also consider new collaborations or selectively partner our technology. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our existing stockholders&#8217; common stock. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates or grant licenses on terms unfavorable to us. We may also be required to pay damages or have liabilities associated with litigation or other legal proceedings involving our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to the foregoing, high inflation and concerns about an economic recession in the United States or other major markets have resulted in, among other things, volatility in the capital markets that may have the effect of reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction due to these factors could materially affect our business and the value of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">ATM Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2021, we entered into a Controlled Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald &amp; Co. and RBC Capital Markets, LLC, or the Sales Agents, pursuant to which we can offer and sell, from time to time at our sole discretion through the Sales Agents, shares of our common stock having an aggregate offering price of up to $75.0 million. Any shares of our common stock sold will be issued pursuant to our shelf registration statement on Form S-3 (File No. 333-258687), which the SEC declared effective on August 19, 2021. However, our use of the shelf registration statement on Form S-3 will be limited for so long as we are subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement and in accordance with the ATM agreement. The Sales Agents will be entitled to compensation under the Sales Agreement at a commission rate equal to 3.0% of the gross sales price per share sold under the ATM Agreement, and we have provided each of the Sales Agents with indemnification and contribution rights. During the year ended December 31, 2024, the Company sold 8,178 shares of its common stock under the ATM Agreement resulting in net proceeds of approximately $37,000, after deducting agent commissions. On June 10, 2024, the Company provided notice of its termination of the ATM Agreement with Cantor Fitzgerald &amp; Co. and RBC Capital Markets, LLC. The Company is not subject to any termination penalties related to the termination of the ATM Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2024, we entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;), with H.C. Wainwright &amp; Co. LLC, relating to the sale of shares of our common stock having an agreement offering price of up to $11,431,713 from time to time through H.C. Wainwright &amp; Co. LLC. Any shares of our common stock sold will be issued pursuant to our shelf registration statement on Form S-3 (File No. 333-283512), which the SEC declared effective on December 6, 2024. However, our use of the shelf registration statement on Form S-3 will be limited for so long as we are subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement and in accordance with the ATM agreement. H.C. Wainwright &amp; Co. LLC will be entitled to compensation under the Sales Agreement at a commission rate equal to 3.0% of the gross sales price per share sold under the ATM Agreement, and we have provided H.C. Wainwright &amp; Co. LLC with indemnification and contribution rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Between July 17 and 21, 2025, the Company sold 1,624,075 shares of common stock pursuant to our ATM Agreement with H.C. Wainwright &amp; Co., LLC for net proceeds of $4.5 million, after deducting agent commissions, at an average price of $2.87 per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 26, 2025, the Company sold 3,734,217 shares of common stock pursuant to the ATM Agreement with H.C. Wainwright &amp; Co., LLC for net proceeds of $5.4 million, after deducting agent commissions, at an average price of $1.48 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Private Placement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On December 19, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;), pursuant to which the Company issued and sold in a private Placement the following securities: (i) 1,783,805 shares of common stock, (ii) Series B Warrants, or Pre-Funded Warrants, to purchase an aggregate of 3,247,445 shares of common stock in lieu of shares of common stock and (iii) Series A Warrants, or Private Placement Warrants, to purchase an aggregate of 5,031,250 shares of common stock. The purchase price per share of common stock and accompanying Private Placement Warrant to purchase a share of common stock was $3.20, and the purchase price per Pre-Funded Warrant and accompanying Private Placement Warrant to purchase a share of common stock was $3.199. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Total gross proceeds from the sale of securities in the Private Placement, before deducting commissions to the placement agent and estimated offering expenses, was approximately $16.1 million, which does not include any proceeds that may be received upon exercise of any warrants issued in the Private Placement. Both the Pre-Funded Warrants and the Private Placement Warrants are not exercisable until the Company obtains shareholder approval. On March 21, 2025, the Company obtained shareholder approval for the exercise of such warrants. The transaction closed on December 23, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have no sources of revenue, other than grant income, to provide incoming cash flows to sustain our future operations. As outlined above, our ability to pursue our long-term planned business activities is dependent upon our successful efforts to raise additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These factors raise substantial doubt regarding our ability to continue as a going concern. Our consolidated financial statements have been prepared on a going concern basis, which implies that we will continue to realize our assets and discharge our liabilities in the normal course of business. Our financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Critical Accounting Policies and Estimates</span>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements are prepared in conformity with U.S. GAAP, which require the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses in the periods presented. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s critical accounting policies include grant income, which is discussed further below. The Company does not have any critical accounting estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, due to inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Grant Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Grant Income represents funding under cost reimbursement programs from government agencies and non-profit foundations for qualified research and development activities performed by the Company. In applying the provisions of ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), we determined that grants and awards are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#8220;customer&#8221;, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to each grant or award, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;). For grant and awards outside the scope of ASC 808, the Company applies either ASC 606 or IAS 20 by analogy depending on if the arrangement is considered an exchange or non-exchange transaction, respectively. Under both accounting frameworks, revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract. During the two years ended December 31, 2025, the Company did not participate in any collaboration agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 12pt 0pt;">The Company recognizes grant income when amounts eligible for reimbursement are determinable and have been incurred, the applicable conditions under the grant arrangements have been met, and collectability of amounts due is reasonably assured or already received. The classification of costs incurred related to grants is based on the nature of the activities performed by the Company. Grant Income is recognized when the related costs are incurred. Restricted cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently Issued Accounting Standards Not Yet Adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December 2025, the FASB issued ASU 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities. The new standard is intended to establish authoritative guidance on the accounting for government grants received by business entities and reduce diversity in practice. The amendments establish the timing and methods of recognition of both (1) a grant related to an asset and (2) a grant related to income. The amendments also require certain disclosures including the nature of the grant received, the accounting policies used to account for the grant, and significant terms and conditions for the grant. The new guidance is effective for annual reporting periods beginning after December 15, 2028, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The new guidance may be applied on a modified prospective basis, modified retrospective basis, or full retrospective basis. The Company is currently evaluating the impact of ASU 2025-10 on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures, to improve transparency in financial reporting by requiring entities to present more detailed information about the nature of expenses included within the Income Statement. The guidance will be effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. The Company is in the process of assessing the impact of ASU 2024-03 on its disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off-Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues, expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Tax Loss and Credit Carryforwards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, we have approximately $186.8 million of federal and $38.6 million of state net operating loss carryforwards that may be available to offset future taxable income, if any. The federal net operating loss carryforwards of $38.4 million, if not utilized, will expire between 2030 and 2037. The federal net operating loss carryforwards of $148.4 million generated in 2018 and thereafter are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely. The state net operating loss carryforwards of $21.9 million, if not utilized, will begin to expire in 2035. The state net operating loss carryforwards of $16.7 million generated in 2018 and thereafter are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely. Any change in ownership greater than 50% under Section 382 of the Internal Revenue Code places significant annual limitations on the use of such net operating loss carryforwards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At December 31, 2025 and 2024, we recorded a 100% valuation allowance against our deferred tax assets of approximately $43.3 million and $41.0 million, respectively, as our management believes it is uncertain that they will be fully realized. If we determine in the future that we will be able to realize all or a portion of our net operating loss carryforwards, an adjustment to valuation allowance against our deferred tax assets would increase net income in the period in which we make such a determination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Inflation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inflation affects the cost of raw materials, goods and services that we use. In recent years, inflation has been modest. However, fluctuations in energy costs and commodity prices can affect the cost of all raw materials and components. The competitive environment somewhat limits our ability to recover higher costs resulting from inflation by raising prices. Although we cannot precisely determine the effects of inflation on our business, it is management&#8217;s belief that the effects on future revenues and operating results will not be significant. We do not believe that inflation has had a material impact on our results of operations for the periods presented, except with respect to payroll-related costs and other costs arising from or related to government-imposed regulations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d795ec84_6523_4c0e_8ff3_eacd3d97e041"></a><a id="ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</p><a id="_47d26880_04b2_4578_abd7_1ccbc696ace6"></a><a id="ITEM8FINANCIALSTATEMENTS_684464"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 8. FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Financial Statements are incorporated herein by reference to pages beginning on page F-1 at the end of this report and the supplementary data is not applicable.</p><a id="_af77395b_31ad_41c7_bb4f_311cd7385ddf"></a><a id="ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have had no changes in, or disagreements with our principal independent accountants.</p><a id="_add12e85_92c4_425d_b021_d243f092d736"></a><a id="ITEM9ACONTROLSANDPROCEDURES_136839"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 9A. CONTROLS AND PROCEDURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Evaluation of Disclosure Controls and Procedures</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have established disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. Under the supervision and with the participation of our management, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2025 to ensure that the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure. Our management, with participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2025. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2025 to provide reasonable assurance that the information required to be disclosed by us in this Annual Report was (a) reported within the time periods specified by SEC rules and regulations and (b) communicated to our management, including our Chief Executive Officer and Principal Financial Officer, to allow timely decisions regarding any required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Management&#8217;s Report on Internal Control Over Financial Reporting </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2025 based on the framework in Internal Control&#8212;Integrated Framework 2013 issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Cybersecurity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We utilize information technology for internal and external communications with vendors, clinical sites, banks, investors and shareholders. Loss, disruption or compromise of these systems could significantly impact operations and results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are not aware of any material cybersecurity violation or occurrence. We believe our efforts toward prevention of such violation or occurrence, including system design and controls, processes and procedures, training and monitoring of system access, limit, but may not prevent unauthorized access to our systems.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other than temporary disruption to operations that may be caused by a cybersecurity breach, we consider cash transactions to be the primary risk for potential loss. We and our financial institution take steps to minimize the risk by requiring multiple levels of authorization and other controls.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Changes in Internal Control Over Financial Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no changes in our internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the fiscal quarter ended December 31, 2025 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Inherent Limitations on Effectiveness of Internal Controls</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In designing and evaluating the disclosure controls and procedures, management does not expect that our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Our management, including our Chief Executive Officer and Principal Financial and Accounting Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_05a09906_f396_4c7b_997b_36fb96872821"></a><a id="ITEM9BOTHERINFORMATION_833436"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 9B. OTHER INFORMATION</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-style:italic;font-weight:bold;">Rule 10b5&#8211;1 trading arrangement.</span> During the fourth quarter of 2025, <ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_Ivl427bMU0uiB1nIEy7zew" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_PkZCWaIiakmv_lgry3zSUA">n</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_Ivl427bMU0uiB1nIEy7zew" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_ZF7VZrFKgUe7dafG_MK6HQ">o</ix:nonNumeric> <ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_Ivl427bMU0uiB1nIEy7zew" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_iDv5JAQC10mOpy1k9xjvdg">director</ix:nonNumeric> or Section 16 officer <ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_Ivl427bMU0uiB1nIEy7zew" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_3yt9t5-xhkalWUs5unbIrQ">adopted</ix:nonNumeric> or terminated any Rule 10b5-1 plan or non-Rule 10b5-1 trading arrangements.</p></td></tr></table><a id="_98699061_4c52_4250_b385_26c2795345a4"></a><a id="ITEM9CDISCLOSUREREGARDINGFOREIGNJURISD_4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM 9C. </b><b style="font-weight:bold;text-transform:uppercase;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0f885c5a_9fc9_44c5_b11d_f6ab6e6db0d1"></a><a id="PARTIII_534190"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PART III</b></p><a id="ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item and not set forth below will be set forth in the sections headed &#8220;Election of Directors,&#8221; &#8220;Executive Officers&#8221; and &#8220;Delinquent Section 16(a) Reports&#8221; in our definitive proxy statement for our 2024 Annual Meeting of Stockholders, or our Proxy Statement, to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2025 and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial and accounting officer or controller, or persons performing similar functions, known as the Code of Ethics and Business Conduct. The Code of Ethics and Business Conduct is available on our website at www.markertherapeutics.com under the Corporate Governance section of our Investors page. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form 8-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="Narr_iYvuBwbgGUOCqR7Vp6rM7g">The Company&#8217;s insider trading policy</ix:nonNumeric>&#160;prohibits all employees, including our executive officers, and non-employee directors from engaging in short sales, transactions in put or call options, hedging transactions, using margin accounts, pledges, or other inherently speculative transactions involving the Company&#8217;s securities.</p><a id="_592df86e_5d81_492b_9ee3_965f7ceb27f1"></a><a id="ITEM11EXECUTIVECOMPENSATION_899018"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 11. EXECUTIVE COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item will be set forth in the section headed &#8220;Executive Compensation&#8221; in our Proxy Statement and is incorporated herein by reference.</p><a id="_85c6d332_462a_4555_8baf_d34c3cbc6c02"></a><a id="ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item will be set forth in the section headed &#8220;Securities Authorized for Issuance Under Equity Compensation Plans&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; in our Proxy Statement and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by Item 201(d) of Regulation S-K will be set forth in the section headed &#8220;Executive Compensation&#8221; and &#8220;Information Regarding the Board of Directors and Corporate Governance&#8221; in our Proxy Statement and is incorporated herein by reference.</p><a id="_2d4cc44b_8593_4a1d_a658_d788fb82492e"></a><a id="ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item will be set forth in the section headed &#8220;Transactions with Related Persons and Indemnification&#8221; and &#8220;Information Regarding the Board of Directors and Corporate Governance&#8221; in our Proxy Statement and is incorporated herein by reference.</p><a id="_35984241_bccb_4dc7_9046_785123e54ade"></a><a id="ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item will be set forth in the section headed &#8220;Principal Accountant Fees and Services&#8221; in our Proxy Statement and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2231bafb_807b_4ca1_b1a7_1912cb7ed0d3"></a><a id="PARTIV_855523"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PART IV</b></p><a id="ITEM15EXHIBITSFINANCIALSTATEMENTSCHEDULE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:30.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The documents filed as part of this report are as follows:</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:30.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The financial statements and accompanying report of independent registered public accounting firm are set forth immediately following the signature page of this report beginning on page F-1.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:30.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">All financial statement schedules are omitted because they are inapplicable, not required or the information is included elsewhere in the financial statements or the notes thereto.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:30.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">EXHIBIT INDEX</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style=""><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:34.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated&#160;by&#160;Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></th><th colspan="2" style="border-bottom-color:transparent;border-bottom-style:solid;border-bottom-width:1px;color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:bottom;white-space:normal;width:6.24%;"></th></tr><tr style=""><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.99%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:45.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.63%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.79%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;no.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.98%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.08%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">herewith</b></p></th></tr><tr style=""><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:45.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:6.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418054209/tv504951_ex3-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.4</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/17/18</p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312522162322/d480537dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to Certificate of Incorporation of Marker Therapeutics, Inc.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5/27/22</p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.3</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465923007019/tm234466d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to Certificate of Incorporation of Marker Therapeutics, Inc.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1/26/23</p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.4</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418054209/tv504951_ex3-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of Marker Therapeutics, Inc.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.6</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/17/18</p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.0</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000141057824000297/mrkr-20231231xex4d0.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Certificate of Marker Therapeutics, Inc.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.0</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/25/24</p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000141057824000297/mrkr-20231231xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Securities of Marker Therapeutics, Inc.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/25/24</p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465924131322/tm2431905d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Pre-Funded Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/23/24</p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465924131322/tm2431905d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Series A Warrant (Private Placement Warrant)</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/23/24</p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420419014350/tv514406_ex10-21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive License Agreement between Baylor College of Medicine and Marker Therapeutics, Inc. dated March 16, 2018***</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.21</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/15/19</p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420419014350/tv514406_ex10-22.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Sponsored Research Contract between Baylor College of Medicine and Marker Therapeutics, Inc. dated November 16, 2018***</span></a> </p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/15/19</p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420419014350/tv514406_ex10-39.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Director and Officer Indemnification Agreement*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.39</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/15/19</p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465920072918/tm2022347d1_ex99-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Marker Therapeutics, Inc. 2020 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-8</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-239136</p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6/12/20</p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.5</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465922089426/tm2223091d1_ex4-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Marker Therapeutics, Inc. 2020 Equity Incentive Plan, as amended on May 24, 2022</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-8</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-266797</p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/11/22</p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.6</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465920123055/mrkr-20200930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Grant Notice and Stock Option Agreement under the Marker Therapeutics, Inc. 2020 Equity Incentive Plan.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/9/20</p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.7</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465924130002/tm2431560d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Securities Purchase Agreement dated December 19, 2024</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/19/24</p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.8</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465924131322/tm2431905d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights dated December 19, 2024</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/23/24</p></td><td style="vertical-align:top;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465924123679/tm2429546d2_ex1-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">At The Market Offering Agreement, dated as of November 27, 2024, between the Company and H.C. Wainwright &amp; Co., LLC</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-3</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-283515</p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/27/24</p></td><td style="vertical-align:top;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mrkr-20251231xex14d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Code of Ethics</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style=""><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:34.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated&#160;by&#160;Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:6.24%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></th></tr><tr style=""><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.99%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:45.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.63%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.79%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;no.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.98%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.08%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">herewith</b></p></th></tr><tr style=""><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:45.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:6.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465925076834/tm2421372d1_ex16-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter from Marcum LLP dated August 12, 2025</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/12/25</p></td><td style="vertical-align:top;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">19.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000141057825000549/mrkr-20241231xex19d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Insider Trading Policy</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">19.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/31/25</p></td><td style="vertical-align:top;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mrkr-20251231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of Subsidiaries</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mrkr-20251231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Marcum LLP, an independent public accounting firm.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23.2</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mrkr-20251231xex23d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of CBIZ CPAs, an independent public accounting firm.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">24.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_412578"><span style="font-style:normal;font-weight:normal;">Powers of Attorney (included on signature page)</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mrkr-20251231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14a</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.2</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mrkr-20251231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14a</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mrkr-20251231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to 18 U. S. C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002#</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.2</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mrkr-20251231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to 18 U. S. C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002#</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">97</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000141057824000297/mrkr-20231231xex97.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Incentive Compensation Recoupment Policy</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">97</p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/25/24</p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.INS</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Instance Document</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.SCH</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Schema Document</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.CAL</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.DEF</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Definition Linkbase Document</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.LAB</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Label Linkbase Document</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.PRE</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;white-space:normal;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101 filed herewith)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Executive management contract or compensatory plan or arrangement.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">**</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Confidential treatment has been granted as to certain portions of this exhibit pursuant to Rule 406 of the Securities Act of 1933, as amended, or Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">***</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for conditional treatment and this exhibit has been submitted separately with the SEC.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">#</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">These certifications are being furnished solely to accompany this annual report pursuant to 18 U.S.C. Section 1350 and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p></td></tr></table><a id="_4d5bcd66_00fe_4f67_94ee_5c070c32d0d9"></a><a id="ITEM16FORM10KSUMMARY_680075"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 16. FORM 10-K SUMMARY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_74eb54c2_1733_4e5e_b926_3aa6c4b7174b"></a><a id="SIGNATURES_412578"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section 13 and 15 (d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dated: March 18, 2026</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marker Therapeutics, Inc.</p></td></tr><tr style=""><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Juan Vera</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Juan Vera</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Treasurer (Principal Executive Officer and Principal Financial and Accounting Officer)&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">POWER OF ATTORNEY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each of the undersigned officers and directors of Marker Therapeutics, Inc., hereby constitutes and appoints Juan Vera their true and lawful attorney-in-fact and agent, for them and in their name, place and stead, in any and all capacities, to sign their name to any and all amendments to this Report on Form 10-K, and other related documents, and to cause the same to be filed with the Securities and Exchange Commission, granting unto said attorneys, full power and authority to do and perform any act and thing necessary and proper to be done in the premises, as fully to all intents and purposes as the undersigned could do if personally present, and the undersigned for himself hereby ratifies and confirms all that said attorney shall lawfully do or cause to be done by virtue hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on March 28, 2026 on behalf of the registrant and in the capacities indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:34.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:31.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:29.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:34.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:31.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:29.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ Juan Vera</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Treasurer, Director (Principal Executive Officer and Principal Financial and Accounting Officer)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 18, 2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:29.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Juan Vera</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:29.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:29.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ N. David Eansor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.32%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 18, 2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:29.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">N. David Eansor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:29.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:29.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ Katharine Knobil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.32%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 18, 2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:29.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Katharine Knobil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:29.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:29.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ Steve Elms</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.32%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 18, 2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:29.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Steve Elms</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:29.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:29.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Kathryn Penkus Corzo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.32%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 18, 2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:29.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Kathryn Penkus Corzo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0622b7b8_7a63_4147_ab62_a6d1ecc7da7c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MARKER THERAPEUTICS, INC.</p><a id="CONSOLIDATEDFINANCIALSTATEMENTS_582912"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">DECEMBER 31, 2025 AND DECEMBER 31, 2024</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#REPORTOFINDEPENDENT_817318"><b style="font-style:normal;font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></a><b style="font-weight:bold;"> (PCAOB ID Number </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:AuditorFirmId" id="Narr_Mgw10Jdqa0ywQboxWkRqow"><b style="font-weight:bold;">688</b></ix:nonNumeric><b style="font-weight:bold;">) </b></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-2</p></td></tr><tr style=""><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"><b style="font-style:normal;font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></a><b style="font-weight:bold;"> (PCAOB ID Number 199)</b></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-4</p></td></tr><tr style=""><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDBALANCESHEETS_711572"><b style="font-style:normal;font-weight:bold;">Consolidated Balance Sheets</b></a></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr style=""><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFOPERATIONS_85122"><b style="font-style:normal;font-weight:bold;">Consolidated Statements of Operations</b></a></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr><tr style=""><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUI"><b style="font-style:normal;font-weight:bold;">Consolidated Statements of Stockholders&#8217; Equity </b></a></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-8</p></td></tr><tr style=""><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_67365"><b style="font-style:normal;font-weight:bold;">Consolidated Statements of Cash Flows</b></a></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-9</p></td></tr><tr style=""><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_5"><b style="font-style:normal;font-weight:bold;">Notes to the Consolidated Financial Statements</b></a></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-10</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e23c8ab9_5775_4893_9520_d570de4ff803"></a><a id="REPORTOFINDEPENDENT_817318"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Shareholders and Board of Directors of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marker Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have audited, before the effects of the retrospective adjustments to the disclosures for the adoption of ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;) as discussed in Notes 3 and 12 to the consolidated financial statements, the accompanying consolidated balance sheet of Marker Therapeutics, Inc. (the &#8220;Company&#8221;) as of December 31, 2024, the related consolidated statements of operations, stockholders&#8217; equity and cash flows for the year ended December 31, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;) (the 2024 financial statements before the effects of the adjustments discussed in Notes 3 and 12 to the financial statements are not presented herein). In our opinion the financial statements, before the effects of the retrospective adjustments to the disclosures for the adoption of ASU 2023-09 as discussed in Notes 3 and 12 to the financial statements, present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations and its cash flows for the year ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We were not engaged to audit, review, or apply any procedures to the retrospective adjustments to the disclosures for the adoption of ASU 2023-09 as discussed in Notes 3 and 12 to the financial statements and, accordingly, we do not express an opinion or any other form of assurance about whether such adjustments are appropriate and have been properly applied. Those retrospective adjustments were audited by CBIZ CPAs P.C.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Explanatory Paragraph &#8211; Going Concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:AuditorName" id="Narr_WHCzMS8Lgka1O8ZPZRHwOA">Marcum LLP</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Marcum LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">We served as the Company&#8217;s auditor from 2014 to 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="dei:AuditorLocation" id="Narr_zM0XibSmyUaZ03RooY-7KQ">Houston, TX</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">March 31, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Stockholders and Board of Directors of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Marker Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We have audited the accompanying consolidated balance sheet of Marker Therapeutics, Inc. (the &#8220;Company&#8221;) as of December 31, 2025, the related consolidated statements of operations, stockholders&#8217; equity and cash flows for the year ended Decemebr 31, 2025, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and the results of its operations and its cash flows for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As discussed in Notes 3 and 12 to the financial statements, the Company adopted ASU 2023-09, Income Taxes (Topic 740):&#160;<i style="font-style:italic;">Improvements to Income Tax Disclosures</i>&#160;(&#8220;ASU 2023-09&#8221;). We have also audited the adjustments to the 2024 financial statements to retrospectively adjust the disclosures for the adoption of ASU 2023-09 in 2025. In our opinion, such retrospective adjustments are appropriate and have been properly applied. We were not engaged to audit, review, or apply any procedures to the 2024 financial statements of the Company other than with respect to these retrospective adjustments, and accordingly, we do not express an opinion or any other form of assurance on the 2024 financial statements taken as a whole.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Explanatory Paragraph &#8211; Going Concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Audit Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">/s/ CBIZ CPAs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">CBIZ CPAs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">We have served as the Company&#8217;s auditor since 2014 (such date takes into account the acquisition of the attest business of Marcum llp by CBIZ CPAs P.C. effective November 1, 2024).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Houston, TX</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">March 18, 2026</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_2f166a95_0ea0_4cd1_a511_a16c04f1ac92"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MARKER THERAPEUTICS,&#160;INC.</b></p><a id="CONSOLIDATEDBALANCESHEETS_711572"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_85c3d5ca_44ab_45ce_957c_3ef7769313c5"></a><a id="Tc_B6I-1PSMDE6LBx-HRNPuBw_1_2"></a><a id="Tc_Nj3xKtzz5UOKO1rv7kSP0w_1_5"></a><a id="Tc_t7lrOOSNB0y7w0Ul24yRUw_2_2"></a><a id="Tc_jI9Ot117V0ae7cDFlZFENQ_2_5"></a><a id="Tc_Liw9yLTQR0W4KC9W5xiieg_3_0"></a><a id="Tc_Wo2wCkgSske8L5UzzTwBZA_4_0"></a><a id="Tc_-g5NGR0qYECh45rj8E294Q_5_0"></a><a id="Tc_2YaFf9Vnb0q8boCVFfzDaw_5_2"></a><a id="Tc__yCR5XP2T0STiZdqnQC4Tw_5_5"></a><a id="Tc_HTcu9mbHMUiN5siB3zCpQQ_6_0"></a><a id="Tc_MsDJtK6mZ0emDBeHc9qOvg_6_6"></a><a id="Tc_8DKWvRz69UqdiqJR_LMrIA_7_0"></a><a id="Tc_j2Ckro5IL0O-y69j3K9yxg_8_0"></a><a id="Tc_6vcv1mHtckSzmGpVGLGapg_9_0"></a><a id="Tc_QhbPethwY0KZHkPTEVmufA_10_0"></a><a id="Tc_ulrcgZeEOU6Rc5VIuQRQzQ_10_2"></a><a id="Tc_plTinRU6K0yC_KT9jip9uA_10_5"></a><a id="Tc_ZYc1qjnpHEuxwfJY4Mc8Vw_12_0"></a><a id="Tc_DWfJk_ViwUOMos8_nNhpqg_13_0"></a><a id="Tc_F4rT88TlWE6B1-t63m3FGg_14_0"></a><a id="Tc_XPMuvyas5k65svT2KMSZww_14_2"></a><a id="Tc_7LYRi9mHZkGBwGbWfdsEDw_14_5"></a><a id="Tc_b0cEDVJrHUqD3IUnMwrUiw_15_3"></a><a id="Tc_w1dOCa0ZXk-VeRPIwNepnA_16_0"></a><a id="Tc_iLCd2l48XUS-z9MkhNSakw_16_6"></a><a id="Tc_ONZv1VsMIkWUsqT5njijng_17_0"></a><a id="Tc_xVX7-v7IZUuCoeMf68D9-g_18_0"></a><a id="Tc_8rjSYEbNik-nb_hAOJvdnw_20_0"></a><a id="Tc_s4zOVFISJ0CUtjat-zlx0A_21_0"></a><a id="Tc_lmo01QCZ6UqgKK6wGattGQ_22_0"></a><a id="Tc_OyUciNq9_0Cwzfl43zV36A_23_0"></a><a id="Tc_OKFZjNkT1U6UDfAa_prPAg_24_0"></a><a id="Tc_H_AipER710GFEGZIxvxI7A_25_0"></a><a id="Tc_P6b-K8KEaEixajHD4g_xSA_26_0"></a><a id="Tc_4zaEsn9UBECd0EGlXFQWTg_26_2"></a><a id="Tc_1LYr7959Ek6zb5pMoD5NHw_26_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_ecJ6Gf0NKUmpb4PFjSqSjw_5_3">16,068,048</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_NeHvui_X6kGpGzx_FhE3TQ_5_6">19,192,440</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="0" id="Tc_pW0jHLGRjUOFAYSdDjOZsA_6_3">974,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="mrkr:PrepaidExpenseAndDepositsCurrent" scale="0" id="Tc_MDpaBJ7b506Lg7y-_bYoXw_7_3">658,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="mrkr:PrepaidExpenseAndDepositsCurrent" scale="0" id="Tc_d6Pa2lzgj0iLHY89vWZitA_7_6">483,717</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" id="Tc_SJZeJFkKqUSyfQrDXTDFmg_8_3">1,369,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" id="Tc_xlk7_Vj2mkOU4ke8NmWL5w_8_6">2,346,703</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_GDnHTmWAokaHsZfbntmQHQ_9_3">19,070,997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_Z9QFL934nEal0v0PwxiuDg_9_6">22,022,860</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" id="Tc_RUvsOR9xmEWAS1QDf-MqhQ_10_3">19,070,997</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" id="Tc_bfzsCoyXtU28rL0eN7hr1A_10_6">22,022,860</ix:nonFraction></b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_pTxqtAjOEUaH2RUrFrIHtA_14_3">1,299,384</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_aQ9TrJWsVkqWzCy_16YNTQ_14_6">1,753,954</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_rTRE-7XNW0K4cyqC2oQcTw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Related party payable</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_V_cYeq-DOkGjD3cg9zabDw_15_6">1,710,500</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="0" id="Tc_pIGHiEwE50WbLUR___T8sw_16_3">974,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_-IoLOEtBKUSiZBgIb2URYg_17_3">2,274,183</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_mqy6yiSB50Oo7ER3NZz6Uw_17_6">3,464,454</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" id="Tc_39W2qFHZO0ORio4-qx2zXQ_18_3">2,274,183</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" id="Tc_OMogS1metESy2lPSN-L-NA_18_6">3,464,454</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_gtY4G74am0GjCBp-AVkBPw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_6CeaBFH7UE2k9LUX-p2scw">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_zTogDxxK-ESHIaN41LgRfQ"><ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_d_Avsni2VEiw4VVXgnIZeA">5</ix:nonFraction></ix:nonFraction> million shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="Narr_F6FIorjHFk6CQs6gvY0ShA"><ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="Narr_uj5yAzXR9EWzO4J-jUIRIA"><ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="6" id="Narr_5ZTA8xPLXkOOii54CHkW9Q"><ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="6" id="Narr_WxXC4T3v5k6gEcYu_9cr4w">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2025 and 2024, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_88CJo7lppUKf_UurEb1KRQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_WjgPJmQyyEWPfo3nuOI25g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_8u_X-lPoVEyY-2ImB9uF0A"><ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_4hLj0xE_YUWIRLK_0KeOIA">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="Narr_ShF1VlBtykizk1mZYHx1Yw"><ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="Narr_2ZJU4iAs50K7rFinFVTgzA">30</ix:nonFraction></ix:nonFraction> million shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="Narr_9WucUPsjsE-hGSQu2xwBzg"><ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="Narr_LoGvmiCZ50K1LOWL1H50rQ">16.7</ix:nonFraction></ix:nonFraction> million and <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="Narr_Hwbf6_NMvkuxCMLvqUM3hA"><ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="Narr_JrvyoQtw_kurFPNEYtRYNQ">10.7</ix:nonFraction></ix:nonFraction> million shares issued and outstanding as of December 31, 2025 and 2024, respectively (see Note 7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_UtBgvpX9tE6v2QkqDqKGng_22_3">16,672</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_s2w0bb1W4EuNNbXsCPxoKQ_22_6">10,708</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_jjPolNdKQkKm-0p7o8F6KQ_23_3">475,960,940</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc__8D-GtvxpU6GxTzfjxXHoA_23_6">465,564,876</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_zAr_S9IcPEGzrk--tW-saQ_24_3">459,180,798</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_OoZoXM9Aak-j8G8jrBNAYw_24_6">447,017,178</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_I6LClqHHWEqHPU-C0nFm_w_25_3">16,796,814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_S1Ab77yjq02d-fJ4HedVVA_25_6">18,558,406</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities and stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_y9RxYmgvBUC_4DqpYt-kBg_26_3">19,070,997</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_7IHY8BYAyku8vTk9KBoX_A_26_6">22,022,860</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0d7c6033_5562_426a_9aa8_5ea4d1b280da"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MARKER THERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFOPERATIONS_85122"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_53f51e77_fa60_4752_a10e_bb1f0acdfeb6"></a><a id="_46f8db94_14a3_4e2e_b350_f7c72443ecca"></a><a id="Tc_iR9A-qYBUEGcP6sS9AU-Jg_1_2"></a><a id="Tc_lZhfRVcMQkGocfdJrwi3wQ_2_2"></a><a id="Tc_Ock7vgsPJEqAJ7cc2xAgsA_3_2"></a><a id="Tc_rd856LHgPEmN5f6Rw2ydPg_3_5"></a><a id="Tc_TPngx74kj0-RTs7d1r3P3w_4_0"></a><a id="Tc_qGfgn6qr7EC3mJb9Nmfhxg_5_0"></a><a id="Tc_ufbOyXqaz0qEBnr8Roz0LQ_5_2"></a><a id="Tc_dG2FKdWOjEeZk7xoWHDboQ_5_5"></a><a id="Tc_zpHnpulzjUqfM_bagRND4Q_6_0"></a><a id="Tc_ScMKJe8fKE2TFHfaxn1r-w_7_0"></a><a id="Tc_c4VQvlQ8kkaZxsA2k3wocg_8_0"></a><a id="Tc_uv8rcnH1gk6vQyRNtQeynA_9_0"></a><a id="Tc_avxKhBoI3UmzkgInp5pcAg_10_0"></a><a id="Tc_FAo-wiCi2UmYmZiuUdGafQ_10_6"></a><a id="Tc_eTO6p-Qw3EGC97QsNtvSBA_11_0"></a><a id="Tc_4xvcT3d-WUqMd8agpU05eA_12_0"></a><a id="Tc_2EkjtSKFi0CsToq0ZUwLNw_13_0"></a><a id="Tc_c2FtK6qI2EKmjd_uQ31QXg_14_0"></a><a id="Tc_Bjmwxp99b02fNtmXI-VTvA_15_0"></a><a id="Tc_8URjZuNHRUK1rUE13qtWYQ_15_6"></a><a id="Tc_7ERLjrjlH06kRJ11qYUvtA_16_0"></a><a id="Tc_CNieTHzM-kaA_hVf9W7uKw_17_0"></a><a id="Tc_zanm5v-AjUOxERGoObuMIQ_18_0"></a><a id="Tc_3UGu7JRpn0OAB7V4-9Gf3Q_20_0"></a><a id="Tc_6VfT69DxN0WO-6DXYG3Rsw_20_2"></a><a id="Tc_GKYh7BV9L0-SjfI9QCPoKQ_20_5"></a><a id="Tc_EC9T-QUwAkSMQQza8CoXZA_22_0"></a><a id="Tc_W8U1UcHig0u8YIvARqN26A_23_0"></a><a id="Tc_PS4a45BUskqu1ywuC4bLNQ_24_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenues:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_us-gaap_GrantMember_6LnqjjsZJEiYA6ZxeN_-8Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_RvBDLkxY9E-4qmIKYKD3gQ_5_3">3,546,669</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_GrantMember_UiYnDW3Fo0WMqnl0BxBg_w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_GsWmZESBCEixQqEkTy2h6Q_5_6">6,591,080</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_8YsX6fCEzE6jwiDhs_ynuA_6_3">3,546,669</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_sXWKaFlxCECcKyBEoq8Emg_6_6">6,591,080</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_grQpKZAm7kCon9Y0GNtIWQ_8_3">11,799,154</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_54n0yvjXTkO8MVCQZ7Vrwg_8_6">13,467,845</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_SbjyK_6ASEmg9dd1ShEFvA_9_3">4,184,806</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_sTcLrvosUkGg_NYgE8i9Fw_9_6">4,241,607</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Loss on early termination of vendor agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="mrkr:GainLossOnEarlyTerminationOfVendorAgreement" sign="-" scale="0" id="Tc_brLzJKPcdUmGmU808-7Dxw_10_3">453,135</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_aaL8irJ-ok2nhin2B5iu3A_11_3">16,437,095</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_6jaAvPmpR0WMU8yHb_U62w_11_6">17,709,452</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_8qVAxceYUk-kjC67mSmZTw_12_3">12,890,426</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_pH7PwNCuwEuDAtRPNa-ICw_12_6">11,118,372</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other income:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_qKVBnZhxJkW_Fz2SyN56rA_14_3">594,206</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_9PJPjW485E-bVV0PeX44tQ_14_6">437,010</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="0" id="Tc_uy1A9YIoDkC8DZg1S5Y5_Q_15_3">117,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss from operations before income taxes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_SdH9W6uSJ0WxAIQLCLJLmg_16_3">12,178,776</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_xT88g5WZkkOBAEk3nsPMeg_16_6">10,681,362</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Income tax (benefit) expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_qajmBkwVKEueZ6_a__gviA_17_3">15,156</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_rIz2NtmnQkyPdCkBAef_Sw_17_6">49,953</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_qGYfW9g3PEe8EcL_h0hyuw_18_3">12,163,620</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_5TxrBhuop0K6btObzJfXzg_18_6">10,731,315</ix:nonFraction>)</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_ALr4EYNwbk-3InkqLhmkCw_20_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_ALr4EYNwbk-3InkqLhmkCw_20_3_2">0.79</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_w7G9UutHb0Gi564kFykLyw_20_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_w7G9UutHb0Gi564kFykLyw_20_6_2">1.19</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average number of common shares outstanding:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_NmBRhDCOyEeNsKdN9ZbZkA_23_3">15,310,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_d4eU-_hXw0m4ulDkYbT37w_23_6">8,980,207</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_ENrzgHso5kGPU_3khRzmQQ_24_3">15,310,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_CZ_6diWb3U2GTvQQmnYu7g_24_6">8,980,207</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d9e5af4f_2714_44a3_81d5_60ce3688ae13"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MARKER THERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_133b3394_3b56_4c08_abef_35b282544f78"></a><a id="Tc_LUeark00hEObDyNsBcX7Jw_1_7"></a><a id="Tc_Oah0FLCAWEGDIm5u1F867w_1_13"></a><a id="Tc_PhZRRJ551kCZAxo6x-0vGg_2_2"></a><a id="Tc_u_Ku-I6jHEm5fWhj3DzKTg_2_7"></a><a id="Tc_wKaRThwMwE6N1LB_veHOgQ_2_10"></a><a id="Tc_T3A6KfnucEu9e4JGqj_nxw_2_13"></a><a id="Tc_jCT7kU26_kyj0kEwuH_nIg_3_2"></a><a id="Tc_ekYlHYU6kkqgA-R85zH7qA_3_4"></a><a id="Tc_R4T5AFmcz06dgBI7HAQjow_3_7"></a><a id="Tc_r2mq2Mh5uU6JCZ96_tahlg_3_10"></a><a id="Tc_fE5VLgcJuE6ycL7Eq2VM_g_3_13"></a><a id="Tc_vbGNoQKARkS-7jwF2KrNbg_4_0"></a><a id="Tc_8smH2OOOxES4m0KdGEF8lw_5_0"></a><a id="Tc_dEf_jqhYaEGDlDU5xueYpQ_5_11"></a><a id="Tc_LyJ42SSwXUqGPzpn3gyzDg_6_0"></a><a id="Tc_vZ39azoqjkmpa4-6SyF0PQ_6_11"></a><a id="Tc_iXrq5KHIUEmomAF3F59wnQ_7_0"></a><a id="Tc_y8PX77CrQE2apalyKi6Xqg_7_11"></a><a id="Tc_W_VCUXq8DEGRq06CvmD9Jw_8_0"></a><a id="Tc_hE9Cj-aY90CrzqfS3YIrkg_8_2"></a><a id="Tc_i4kh549i70aO2wMxSgtwmQ_8_5"></a><a id="Tc_RTiQrA6ZBEK4LjuVcHI0ng_8_11"></a><a id="Tc_hRoNWzz3zkq3sPXnJ0fZog_9_0"></a><a id="Tc_2h2EeFGs7k-RC567vM3YAg_9_2"></a><a id="Tc_D4b1q4u6mU-PDZmK8x7w3w_9_5"></a><a id="Tc_-52w9XarxEi7lTHyub8q5A_9_8"></a><a id="Tc_mYdRWi5-D0q7xZ_pj4k3Ug_10_0"></a><a id="Tc_BbMmCrCAuEWxa-uK-3gkTw_11_0"></a><a id="Tc_CGnvZwGX0E6t1XM7Lin_kw_11_11"></a><a id="Tc_TSIxcUngDkGPR920IcelRA_12_0"></a><a id="Tc_dBUO5GvkSUmwESesw5e9NA_12_8"></a><a id="Tc_kfDC5CNWVEifpYvuVp91ww_12_11"></a><a id="Tc_0sqbZPFQLUGw2XF5waC7Hg_13_0"></a><a id="Tc_PlSTbsqzFkyYzqU8fPIYxg_13_2"></a><a id="Tc_0K26Gw1jW0GQRmCVeApDvQ_13_5"></a><a id="Tc_WO205PdpjkWjpcNrUmvgFg_13_11"></a><a id="Tc_3BXWH6_WsEeyo2PBST7U6w_14_0"></a><a id="Tc_SNbhSki9DU6qLKpwTNqWhQ_14_2"></a><a id="Tc_KVqk62OtLEyg9IpmUrcIeA_14_5"></a><a id="Tc_wydkph6vykq_dNYo3OLo2Q_14_8"></a><a id="Tc_Gt40f7YIt0ytDRX9v0aFow_15_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Paid-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Par&#160;value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">in&#160;Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:45.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tksY2KuphU-6mtLP78kkWg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="Tc_MMATFSdJ006I8BVyPWnPsw_4_2">8,891,420</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tksY2KuphU-6mtLP78kkWg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_pC1fyMTYg0ylNcNaXdWtWw_4_5">8,891</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oPOrqZBAU0ezQq1EPL4X1A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_JphcB_G0ukqVfL7BiyLQJg_4_8">450,329,515</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_84AY7Y29u0Wa9RpjQCDF4A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_d6QgzlS9t06nADqy85JXGQ_4_11">436,285,863</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2023_jtXp7bckLE2CuJhkJ9PNfg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_BP2MXr2G5kWh38eeGzXdMQ_4_14">14,052,543</ix:nonFraction></b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Shares purchased pursuant to ATM agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C8n1YFIWQkCqU7lJuKSmFQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_JDzWCjLM0EiTTKQkmj01UA_5_2">8,178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C8n1YFIWQkCqU7lJuKSmFQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_GdqifS6S_UGgczpKK6Oyrg_5_5">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xtMtVYunjEei0jSpfl8XCA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_41nJxvqdrkOCUX2d0Asiqw_5_8">36,894</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_nGTBz3NQwEuF59vXKpIBBw_5_14">36,902</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:45.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of common stock from exercise of stock options </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C8n1YFIWQkCqU7lJuKSmFQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_GKnimRz_b0ehGEfZ7ag-Lw_6_2">25,602</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C8n1YFIWQkCqU7lJuKSmFQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_A-T2cdfKLU-aQh8Sk1BXng_6_5">25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xtMtVYunjEei0jSpfl8XCA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_oLU-XqiRj0W8H4_9ro7lEQ_6_8">62,134</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_Ugdi7UJf4UKII8elAVMtiA_6_14">62,159</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of common stock, prefunded warrants and warrants for cash, net of offering costs of $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="Narr_kFmCkVW0L0u1ga0gHNBLbQ">1.2</ix:nonFraction> million</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C8n1YFIWQkCqU7lJuKSmFQ" decimals="INF" format="ixt:num-dot-decimal" name="mrkr:StockAndWarrantsIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_qOzPbs1dLEuPzx2cmi8eEA_7_2">1,783,805</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C8n1YFIWQkCqU7lJuKSmFQ" decimals="0" format="ixt:num-dot-decimal" name="mrkr:StockAndWarrantsIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_J1perH4Vk0mEH_r9vYM8Kg_7_5">1,784</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xtMtVYunjEei0jSpfl8XCA" decimals="0" format="ixt:num-dot-decimal" name="mrkr:StockAndWarrantsIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_m-pdauX2zEK-Ysi31SYGOw_7_8">14,890,469</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="mrkr:StockAndWarrantsIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_q_JsCuDj4kies63ljImM9A_7_14">14,892,253</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:45.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xtMtVYunjEei0jSpfl8XCA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_qAU4psrSwEeEvpql1kbGSA_8_8">245,864</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_8rrvZ9j9F0y-P9RhypBaTg_8_14">245,864</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Odf2gYh8fUCDHWMqpklBpg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_LdaxXnTHT0WbTZe7zyWWJA_9_11">10,731,315</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_BCV_arOBgUm6j17scszj4A_9_14">10,731,315</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:45.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IyxgTtJMsUeI7g0JQzRu5w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="Tc_GVL9a_OYzUmuP4SGpcPCsg_10_2">10,709,005</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IyxgTtJMsUeI7g0JQzRu5w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_xhgjdkR3Z0SIMQk2-ZBBzw_10_5">10,708</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ewnb_9qGskmiSR_2gvsz1A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_g7Yz1DmjEE-JgXbjts0maw_10_8">465,564,876</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E0qy7Vq1QkiOgpqHJZmV-A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_jcSxRedNMEKgkdB4M-lFug_10_11">447,017,178</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_iFDplPxI60iNwy8vq4pugw_10_14">18,558,406</ix:nonFraction></b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Shares purchased pursuant to ATM agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pYHphuyyu066BcjVFoJ8QA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_RB-gOypkYESzPJlBLUhY7Q_11_2">5,358,292</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pYHphuyyu066BcjVFoJ8QA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_aYPFkkaN3EOA0DjV4e35CQ_11_5">5,359</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XT2HAsu1XEKincjWBVb39A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_0D1sBBcWJUOTdea38SKemw_11_8">9,858,524</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc__LrFyXTmA024OPhs0fVoLg_11_14">9,863,883</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:45.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock from exercise of prefunded warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pYHphuyyu066BcjVFoJ8QA" decimals="INF" format="ixt:num-dot-decimal" name="mrkr:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_fYmjNV3UF0yfb6jgGdcofA_12_2">605,830</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pYHphuyyu066BcjVFoJ8QA" decimals="0" format="ixt:num-dot-decimal" name="mrkr:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_M5Q3RwaqxUe8VDJbnAztBA_12_5">605</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="mrkr:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_LHGrURqmz0OU61e-zHkY-A_12_14">605</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XT2HAsu1XEKincjWBVb39A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_HsoeN6Y3FE2-iakctE8sgA_13_8">537,540</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_hIlJl5WUYEemK9hVaOyp-A_13_14">537,540</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:45.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Sob6q5KlDEqJgHe6539l1A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_sfRWjHB45kOHfyMcXEM9_g_14_11">12,163,620</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_1gwrRS-MHUiAseZ02y9scA_14_14">12,163,620</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:45.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_H1iRzvGfK0C3IBU4YuN-sg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="Tc_keeaFMMADE6FGGMpja1EKg_15_2">16,673,127</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_H1iRzvGfK0C3IBU4YuN-sg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_-d-ZIvtQaEy0kZTXuHqdYg_15_5">16,672</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HXX7qp5MoUuH8nof-BnwCA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_flRbrhCapUijuuA3L6AF4g_15_8">475,960,940</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gV71OOam90epk_Du2IQJ0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_IhlqStQ4g0au-nJKjPO6Hg_15_11">459,180,798</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_mMSOoeexRESxRLsRPpHZVQ_15_14">16,796,814</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a5c74bc0_9bd3_423a_be39_f05da6f3c865"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MARKER THERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS_67365"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_0a2f81dd_7746_4e72_8b1e_c682bb5dcfcd"></a><a id="Tc_n8fa2UpydUGtcB72CgFQZQ_1_2"></a><a id="Tc_jm9ZxvTPBEObIiMTEqFA6A_2_2"></a><a id="Tc_BtNoNuq9WUuW4UmvCwfycw_3_2"></a><a id="Tc__RvIbpc2PUu98h-PzpJgGA_3_5"></a><a id="Tc_zRwqYYHOMkm8o_-6eh1QGw_4_0"></a><a id="Tc_GPNexK7dP0WiSflTcJiLDQ_5_0"></a><a id="Tc_abiKOQgEa0-V0x9lzV0zEQ_5_2"></a><a id="Tc_20fGJcKa-kWvT7kZ4k3wVA_5_5"></a><a id="Tc_mKkYsExfDEyDtx1zwR7kjg_6_0"></a><a id="Tc_GgroW8I360SXcTmVpNA8Rg_7_0"></a><a id="Tc_2nobABbh4E-Iq4D8JxdLOw_8_0"></a><a id="Tc_ySklyao3O0uPJbGG41pB9Q_9_0"></a><a id="Tc_zqgPJ4njLkekZlWMkyGMjw_10_0"></a><a id="Tc_e_lQLWfA9kOduwKJw2ORPA_11_0"></a><a id="Tc_mN2s0jj9f0-ErHhbcpCNoA_12_0"></a><a id="Tc_iR5rZKOVa0q7UEUxta9-2w_13_0"></a><a id="Tc_uoacQSa830qUHYMn8a7rhw_13_6"></a><a id="Tc_iMRTmg4dA024vHBdC6e9-Q_14_0"></a><a id="Tc_6CjhEDTezE-n5L0pNgeCKg_15_0"></a><a id="Tc_Z81dJseucEyn83OVft00oA_16_0"></a><a id="Tc_bDV3FlNHAUe0E33ZN8vo9Q_17_0"></a><a id="Tc_HSXdcEgNM0ugObt8iXr7Ig_18_0"></a><a id="Tc_AElFpBjNNEm-XmmtJ1zsLA_19_0"></a><a id="Tc_glyMTPsEfEOLeO473pb3kg_20_0"></a><a id="Tc_bMZ29yt-fEyW3GqQyIq-5w_21_0"></a><a id="Tc_aQIPNhRWXEeh5lf47AAfLA_21_2"></a><a id="Tc_vaRJH-gfMEGqdaGRqHfVQA_21_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Operating Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_9QxzdRkuGkqpm8xTTVrxsg_5_3">12,163,620</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_kUTSH1cx906e4hupFEpE-A_5_6">10,731,315</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Reconciliation of net loss to net cash used in operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_vvm4YQwJtUWYF7t3nomy2w_7_3">537,540</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_a-MqfkfkOU66K35-gMr07w_7_6">245,864</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Changes in operating assets and liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses and deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="mrkr:IncreaseDecreaseInPrepaidExpenseAndDeposits" scale="0" id="Tc_-kmPZvwYN0qta8eHpDWwdA_9_3">175,033</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="mrkr:IncreaseDecreaseInPrepaidExpenseAndDeposits" sign="-" scale="0" id="Tc_XttCq-E810SpT2qzdHYDmA_9_6">504,409</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" sign="-" scale="0" id="Tc_fta45bhhLEGiRYr74shQzA_10_3">977,303</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" id="Tc_rE3PVitleU6HN8r6_hHAeQ_10_6">1,318,888</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Related party payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" sign="-" scale="0" id="Tc_juhykJpTkEGUT5YMU1-dyA_11_3">1,710,500</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" scale="0" id="Tc_0ipcakS_W0GOSt6vm8jX1g_11_6">380,845</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="0" id="Tc_sJ76207CcEq_PDv5ldsRKw_12_3">454,570</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_zkv0yNcFPUyIG3Q1zFzhpg_12_6">8,761</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="0" id="Tc_GXmJsXHbUke1dLNDJmi-0Q_13_3">974,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_0ip_XSWStkef3Z7uutnY7w_14_3">12,014,081</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_6vvhndHvVkG8TsSUc4Fpwg_14_6">10,910,324</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Financing Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Proceeds from issuance of common stock, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_UuzZPDiZxEKU8a7apK-lpQ_16_3">9,863,883</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_A641OrpkkESTMaucWh7Cig_16_6">14,929,155</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Proceeds from exercise of warrants and stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="mrkr:ProceedsFromWarrantsAndStockOptionsExercised" scale="0" id="Tc_FC-WNt1-UUaTV_XadijVrQ_17_3">605</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="mrkr:ProceedsFromWarrantsAndStockOptionsExercised" scale="0" id="Tc_6YNFkcGFREe4mMrNuLkP7A_17_6">62,159</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_3BAZeDtFrEKktXU0vXj1ew_18_3">9,864,488</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_kUR934ByaEqlPwNjwR_Szw_18_6">14,991,314</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (decrease) increase in cash, cash equivalents, and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="0" id="Tc_taRqS-nVik-UvJZm3xpFJA_19_3">2,149,593</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" id="Tc_Ps7QaXDfAky88kCY5XSDNw_19_6">4,080,990</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents, and restricted cash at beginning of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_-tfqTbbsHEG6g5ANPCuLIw_20_3">19,192,440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2023_jtXp7bckLE2CuJhkJ9PNfg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_yuw9EofJQ02RvoShQlBMvg_20_6">15,111,450</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash, cash equivalents, and restricted cash at end of the year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_IwTOM66aJUWPgZ49sF-NOg_21_3">17,042,847</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_QHU-qJr_0UWshZpIb-CoIw_21_6">19,192,440</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d7475cbc_d893_4336_bd6d_413993e36aa9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MARKER THERAPEUTICS,&#160;INC.</p><a id="NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FOR THE FISCAL YEARS DECEMBER 31, 2025 AND 2024</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:NatureOfOperations" id="Tb_Ftj2ApYDLE6QfLLEah6SKQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;1:&#160;&#160;&#160;&#160;NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Marker Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221; or &#8220;we&#8221;), is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company&#8217;s multi antigen recognizing (&#8220;MAR&#8221;)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Currently, the Baylor College of Medicine (&#8220;BCM&#8221;) supplies the Company with MT-601, the Company&#8217;s lead Multi-Antigen Recognizing (MAR)-T cell therapy in anticipation of the commencement of the Company&#8217;s larger pivotal trial for Lymphoma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 16, 2025, the Company entered into a Statement of Work (the &#8220;SOW&#8221;) with Cellipont Bioservices (&#8220;Cellipont&#8221;), a leading cell therapy Contract Development and Manufacturing Organization (&#8220;CDMO&#8221;), for the manufacturing of MT-601. Pursuant to the SOW, Cellipont will provide technology transfer and cGMP manufacturing services to support the scale-up and production of MT-601 for the Company&#8217;s APOLLO study.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock" id="Tb_W0euYb2vxEaUbVoZYZ4hlA" continuedAt="Tb_W0euYb2vxEaUbVoZYZ4hlA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;2:&#160;&#160;&#160;&#160;FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As of December 31, 2025, the Company had cash, cash equivalents,</span> <span style="font-style:normal;font-weight:normal;">and restricted cash of approximately </span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="Narr_7zrkNozAC0eajQx6PFRiEg">17.0</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> million. The Company&#8217;s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing; successfully progress its product candidates through preclinical and clinical development; obtain regulatory approval of one or more of its product candidates; maintain and enforce intellectual property rights; develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity, debt financings and grants.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2021, the Company entered into a Controlled Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement (the &#8220;ATM Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and RBC Capital Markets, LLC (the &#8220;Sales Agents&#8221;), pursuant to which the Company could offer and sell, from time to time at its sole discretion through the Sales Agents, shares of its common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_cca_sB7gSU6dxZHLZj013g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesSubscriptions" scale="6" id="Narr_tSPWTDQ32kmJ2tjcjz68GQ">75.0</ix:nonFraction> million. Any shares of its common stock sold were issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-258687), which the SEC declared effective on August 19, 2021. However, our use of the shelf registration statement on Form S-3 was limited for so long as we were subject to General Instruction I.B.6 of Form S-3, which limited the amounts that we could sell under the registration statement and in accordance with the ATM agreement. The Sales Agents were entitled to compensation under the Sales Agreement at a commission rate equal to <ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_8_1_2021_To_8_31_2021_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCoAndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_Rn5SiIOVNEaGW-wHHWjNLA" decimals="3" format="ixt:num-dot-decimal" name="mrkr:CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" scale="-2" id="Narr_W8s_TIcvgUi18PeKh330jg">3.0</ix:nonFraction>% of the gross sales price per share sold under the ATM Agreement, and we provided each of the Sales Agents with indemnification and contribution rights. During the year ended December 31, 2024, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCoAndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_F38uZMcfxU2b3xquA6y5bA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_k4jX8bBs8kyeMGAAWr1H-A">8,178</ix:nonFraction> shares of its common stock under the ATM Agreement for proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCoAndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_F38uZMcfxU2b3xquA6y5bA" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_kfCNdtqCOkyFhp__dHptew">0.04</ix:nonFraction> million. On June 10, 2024, the Company provided notice of its termination of the ATM Agreement with Cantor Fitzgerald &amp; Co. and RBC Capital Markets, LLC. The Company is not subject to any termination penalties related to the termination of the ATM Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In November 2024, the Company entered into an At The Market Offering Agreement, or the Sales Agreement, with H.C. Wainwright &amp; Co. LLC, relating to the sale of shares of its common stock having an agreement offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_11_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_X_oxJZvmIEKv7qs6HvnyNQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesSubscriptions" scale="0" id="Narr_aNqxrkEwBUGgzd6dpwwe_w">11,431,713</ix:nonFraction> from time to time through H.C. Wainwright &amp; Co. LLC. Any shares of common stock sold will be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-283512), which the SEC declared effective on December 6, 2024. However, the Company&#8217;s use of the shelf registration statement on Form S-3 will be limited for so long as it is subject to General Instruction I.B.6 of Form S-3, which limits the amounts that the Company may sell under the registration statement and in accordance with the ATM agreement. H.C. Wainwright &amp; Co. LLC will be entitled to compensation under the Sales Agreement at a commission rate equal to <ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_11_1_2024_To_11_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_nPc36OB43EulxDCPK9rlUA" decimals="3" format="ixt:num-dot-decimal" name="mrkr:CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" scale="-2" id="Narr_lGcEotf7LkqRTVyoQVO0nw">3.0</ix:nonFraction>% of the gross sales price per share sold under the ATM Agreement, and the Company&#8217; has provided H.C. Wainwright &amp; Co. LLC with indemnification and contribution rights. Between July 17 and 21, 2025, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_7_17_2025_To_7_21_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_bAz_p3gArkWolV47xKRr_g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_YAAOTN9ETE24FoiveVE9Ow">1,624,075</ix:nonFraction> shares of common stock pursuant to the ATM </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_W0euYb2vxEaUbVoZYZ4hlA_cont1" continuedAt="Tb_W0euYb2vxEaUbVoZYZ4hlA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Agreement for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_7_17_2025_To_7_21_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_bAz_p3gArkWolV47xKRr_g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_ntVdPANX2Ua5qHDiqrgUPw">4.5</ix:nonFraction> million, after deducting agent commissions, at an average price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_QeGMQYKwNUKt8wiYv26-mg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_V6I2fYV7pkyzuSBePLCFDA">2.87</ix:nonFraction> per share. On August 26, 2025, the Company sold an additional <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_8_26_2025_To_8_26_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_dZBSMZhgiU-56Poy6Ff-Yw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_F8p3jjXA0U-mthd3VLZ1lw">3,734,217</ix:nonFraction> shares of common stock pursuant to the ATM Agreement with H.C. Wainwright &amp; Co., LLC for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_8_26_2025_To_8_26_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_dZBSMZhgiU-56Poy6Ff-Yw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_mGRrtzwIpkGMhxlfDpZ0kA">5.4</ix:nonFraction> million, after deducting agent commissions, at an average price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="As_Of_8_26_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_pn_qg4MJb0i_SQXgwMffCA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_0lOtD7xOfEybXeJHw5dFLw">1.48</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2021, the Company received notice of a Product Development Research award totaling approximately $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_8_1_2021_To_8_31_2021_L0Z_1a2Gv0qiuiDAeZfKZw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="Narr_8n71SqIZCkW8e1W2wi1Z2w">13.1</ix:nonFraction> million from the CPRIT to support the Company&#8217;s clinical investigation of MT-401 (the &#8220;CPRIT AML Grant&#8221;). Through the date of this filing, the Company has received $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:FundsReceivedFromCpritGrant" scale="6" id="Narr_MpyXEealt0iv1L58c3icWg">11.8</ix:nonFraction> million in funds from the CPRIT AML Grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2022, the Company received notice from the FDA that it had awarded the Company a $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_9_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_MnQUj6Ma20ugl93GMps1dw" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:GrantReceived" scale="6" id="Narr_22uVIIc29UemfZcUfiOLqQ">2.0</ix:nonFraction> million grant from the FDA&#8217;s Orphan Products Grant program to support the clinical investigation of MT-401 for the treatment of post-transplant AML (the &#8220;FDA Grant&#8221;). Through the date of this filing, the Company has received $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_ZoSbOHwhNE-hXUpvIJbwbg" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:FundsReceivedFromGrant" scale="6" id="Narr_i3wNx8BeLkq9RqJXJ-ZNYA">1.2</ix:nonFraction> million in funds from the FDA Grant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2023, the Company announced that it had received a $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_5_1_2023_To_5_31_2023_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_WnNM8CWplk24UBwBqIF4_g" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:GrantReceived" scale="6" id="Narr_8QzEfmbEZUmrMSEuv5Pi_w">2.0</ix:nonFraction> million grant from the National Institutes of Health (&#8220;NIH&#8221;) Small Business Innovation Research (&#8220;SBIR&#8221;) program to support the development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents (the &#8220;SBIR AML Grant&#8221;). Through the date of this filing, the Company has received $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_ziCCxC0XiEqj3xjfTYljxg" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:FundsReceivedFromGrant" scale="6" id="Narr_Ozveb9iL0Eao0POHN5n3vg">1.7</ix:nonFraction> million in funds from the SBIR AML Grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The above funding agencies have agreed to continue their financial support and to shift funds to the MT-401-OTS program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2024, the Company received notice of a $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_6_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_mjoYIWkR20GbZX_dLT8n1g" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:GrantReceived" scale="6" id="Narr_nDUL4GG00UKafv57MAB9kQ">2.0</ix:nonFraction> million grant over a <ix:nonNumeric contextRef="Duration_6_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_mjoYIWkR20GbZX_dLT8n1g" format="ixt-sec:duryear" name="mrkr:GrantAssistanceTerm" id="Narr_-Kf8Ay-H7060eYwnfhIWdA">2</ix:nonNumeric>-year period from the National Institutes of Health SBIR program to support control over tumor immune escape in pancreatic cancer using a dual T cell product strategy (the &#8220;Decoy Grant&#8221;). Through the date of this filing, the Company has received approximately $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_qnTBapqjVEaOu5WEAR6N1A" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:FundsReceivedFromGrant" scale="6" id="Narr__Avyc6b830KhC99kJHdkGw">0.5</ix:nonFraction> million in funds from the Decoy Grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2024, the Company received notice of a $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_8_1_2024_To_8_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember__Ch-QALgtkqd7AZY24MzHg" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:GrantReceived" scale="6" id="Narr_h0beQeSdzUGgPomApJa9oQ">2.0</ix:nonFraction> million grant from the NIH SBIR program to support the clinical investigation of MT-601 in patients with non-Hodgkin&#8217;s lymphoma (&#8220;NHL&#8221;) who have relapsed following anti-CD19 chimeric antigen receptor (CAR) T cell therapy (the &#8220;SBIR NHL Grant&#8221;). Through the date of this filing, the Company has received $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_v3gveAJvr0u79DQtC91MKA" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:FundsReceivedFromGrant" scale="6" id="Narr_AZUS0-O_mEmSPyzmJ14JLA">1.3</ix:nonFraction> million in funds from the SBIR NHL Grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2024, the Company received another $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_8_1_2024_To_8_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_he6YWLaAFUG7GJ38OI7D1Q" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:GrantReceived" scale="6" id="Narr_gckctDhVuUCkOqmmzcS2uQ">2.0</ix:nonFraction> million grant from the NIH SBIR program to support the advancement of MT-601 in patients with pancreatic cancer (the &#8220;PANACEA Grant&#8221;). Through the date of this filing, the Company has received approximately $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_670n_eqWFEyvZOe0MstmvA" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:FundsReceivedFromGrant" scale="6" id="Narr_JdM3AfTjgkqAGY6eSzGbEg">0.4</ix:nonFraction> million in funds from the PANACEA Grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December 2024, the Company received notice of an additional $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivable" scale="6" id="Narr_kVqatp8M1kKHkvKm7KG-zA">9.5</ix:nonFraction> million grant from CPRIT to support the clinical investigation of MT-601 in patients with metastatic pancreatic cancer (the &#8220;CPRIT Pancreatic Grant&#8221;). Through the date of this filing, the Company has received $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_AdditionalCpritGrantMember_nxUvKve8xkGalcxFRXPFew" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:FundsReceivedFromGrant" scale="6" id="Narr_GbuSZiUJ30-15E2cfpZuOQ">1.5</ix:nonFraction> million in funds from this grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Refer to Note 5 and Note 9 for grant income receivable and grant income recorded for each grant, respectively, for the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">On December 19, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;), pursuant to which the Company issued and sold in a private Placement the following securities: (i)</span><span style="font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_12_19_2024_To_12_19_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8VZRCOP4d0-aokYe1ivjTA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Kxfc4M30UUmOfYSSfs9EOg">1,783,805</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> shares of common stock, (ii) Series B Warrants, or Pre-Funded Warrants, to purchase an aggregate of </span><span style="font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_19_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8uiS2_V-yU681VJlw1Q9uw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_cRQS0twFoku5WBOPuVhQTA">3,247,445</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> shares of common stock in lieu of shares of common stock and (iii) Series A Warrants, or Private Placement Warrants, to purchase an aggregate of </span><span style="font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_19_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PrivatePlacementWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_On3uaIjHpUqZni5K7dWfLQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_umDqUJBWaUS8Q97wi4snrw">5,031,250</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> shares of common stock. The purchase price per share of common stock and accompanying Private Placement Warrant to purchase a share of common stock was </span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="As_Of_12_19_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_NdnoCXF10U2RaVtcYYPkIQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_Ne6PagSoPEqsguywpJjAKg">3.20</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;">, and the purchase price per Pre-Funded Warrant and accompanying Private Placement Warrant to purchase a share of common stock was </span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="As_Of_12_19_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8uiS2_V-yU681VJlw1Q9uw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_6U-rpc_W9kSWHbTFH02jcA">3.199</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;">. The transaction closed on December 23, 2024, with net proceeds from the sale of securities in the Private Placement of approximately </span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_12_23_2024_To_12_23_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_uXfGzxM0uEOSkZZ_6NldVg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_ZYC-XtA_20O_PXz3Qnpx1A">14.9</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> million, which does not include any proceeds that may be received upon exercise of any warrants issued in the Private Placement. Both the Pre-Funded Warrants and the Private Placement Warrants were not exercisable until the Company obtained shareholder approval, which was received on March 21, 2025.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Company expects to continue to incur substantial losses over the next several years during its development phase.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on the Company&#8217;s lack of recurring revenues, anticipated uses of cash and historical recurring cash losses from operating activities, and cash, cash equivalents, and restricted cash as of December 31, 2025, and taking into consideration the net proceeds received in July and August of 2025 through the sale of Common Stock pursuant to its ATM Agreement with H.C. Wainwright &amp; Co., </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_W0euYb2vxEaUbVoZYZ4hlA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">LLC (see Note 7), the Company anticipates that it will be able to fund its operating expenses and capital expenditure requirements through the fourth quarter of 2026, assuming no additional grant funds are received, either from new grants or from existing awarded grants. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management is considering raising additional capital through the issuance of securities and intends to apply for additional grant funds, which could enable the Company to fund its operating expenses and capital expenditure requirements beyond the fourth quarter of 2026, although no assurance can be given that such capital or existing awarded grants will be earned or future grants will be awarded. The Company&#8217;s future cash requirements are based on the Company&#8217;s clinical and research and development plans, timing expectations related to the progress of its programs, and is subject to the Company&#8217;s ability to effectively manage its costs, raise additional capital, and receive additional grant funds, of which there can be no assurances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Company&#8217;s assumptions may prove to be wrong, and the Company could utilize its available capital resources sooner than it currently expects. Furthermore, the Company&#8217;s operating plan may change, and it may need additional funds sooner than planned in order to meet operational needs and capital requirements for product development and commercialization. Because of the numerous risks and uncertainties associated with the development and commercialization of the Company&#8217;s product candidates and the extent to which the Company may enter into additional collaborations with third parties to participate in their development and commercialization, the Company is unable to estimate the amounts of increased capital outlays and operating expenditures associated with its current and anticipated clinical trials. The Company&#8217;s future funding requirements will depend on many factors, as it:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Initiates, continues, or accelerates clinical trials of its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continues the research and development of its product candidates and seeks to discover additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeks regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintains and enforces intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enters into contract manufacturing arrangements with contract manufacturing organizations for clinical manufacturing supply;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishes sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates that may receive regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluates strategic transactions the Company may undertake; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enhances operational, financial and information management systems and hires additional personnel, including personnel to support development of product candidates and, if a product candidate is approved, commercialization efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company&#8217;s financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to the foregoing, high inflation and concerns about an economic recession in the United States or other major markets have resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company&#8217;s ability to access capital, which could in the future negatively affect the Company&#8217;s liquidity. In addition, a recession or market correction due to these factors could materially affect the Company&#8217;s business and the value of its common stock.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_l3PloWcpf0Wwvh886VQO6w" continuedAt="Tb_l3PloWcpf0Wwvh886VQO6w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;3:&#160;&#160;&#160;&#160;SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_4ddmGY66IkKi4U_vh3yWJA" continuedAt="Tb_4ddmGY66IkKi4U_vh3yWJA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the Securities Exchange Commission (&#8220;SEC&#8221;). Any reference </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_l3PloWcpf0Wwvh886VQO6w_cont1" continuedAt="Tb_l3PloWcpf0Wwvh886VQO6w_cont2"><ix:continuation id="Tb_4ddmGY66IkKi4U_vh3yWJA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">in these footnotes to applicable guidance is meant to refer to the authoritative U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_irRF92OIR0u6GqNTcmvHVw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy,&#160;Inc. and GeneMax Pharmaceuticals&#160;Inc.&#160;&#8211; a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada,&#160;Inc. All significant intercompany balances and transactions are eliminated upon consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:UseOfEstimates" id="Tb_cWoKlkIvvES69bkIbxsO-w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accordingly, actual results may differ materially from those estimates. Management considers many factors in selecting appropriate financial accounting policies, controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation expense and income taxes.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_9cnjHORe9ESSvft9mQjoUg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash, Cash Equivalents, Restricted Cash, and Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash, cash equivalents, and restricted cash at December 31, 2025 consisted of cash and certificates of deposit in institutions in the United States. The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limits of $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashFDICInsuredAmount" scale="0" id="Narr_DXcM0RwwEUO_k8P8ZXrvEw">250,000</ix:nonFraction>. As of December 31, 2025, the Company had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:CashAtFinancialInstitutions" scale="6" id="Narr_0UbuzpZaukmtD9-QCkQrjQ">1.6</ix:nonFraction> million in cash at financial institutions, including $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="6" id="Narr_w0SW3x9s5kmgHCVHEFlQ5g">1.0</ix:nonFraction> million of restricted cash at financial institutions, and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:USGovernmentAgenciesSecuritiesAtCarryingValue" scale="6" id="Narr_jA0Bu8u86kiseEK1AdKhGQ">15.4</ix:nonFraction> million in U.S. government agency securities, for aggregate cash, cash equivalents, and restricted cash of $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="Narr_KzDkVdZ1NkaUtxJSH0Jm3w">17.0</ix:nonFraction> million. As of December 31, 2024, the Company had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:CashAtFinancialInstitutions" scale="6" id="Narr_DCWr5MEEEEGd1q7cvVCDuQ">1.1</ix:nonFraction> million in cash at financial institutions and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:USGovernmentAgenciesSecuritiesAtCarryingValue" scale="6" id="Narr_SKyub4Rw6kueiQN69QV3MQ">18.1</ix:nonFraction> million in U.S. government agency securities, for aggregate cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_tJJOC8HM0k6d-67Qrswg7Q">19.2</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event cash is received from grants in advance of incurring qualifying costs, it is recorded as restricted cash until it is earned and recorded to grant income.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="Tb_dcKNYSeP9kKE-yCmkd1qUA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Modification of Stock Options </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2025, the Company recorded incremental stock-based compensation expense of $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="6" id="Narr_8LUDRupSyEWznFZ7QwedQg">0.3</ix:nonFraction> million pertaining to the modification of stock options in connection with certain consultants. The modification provided for an acceleration of unvested options, resulting in $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="6" id="Narr_O-013-t2bEWsqddPRTpfgw">0.3</ix:nonFraction> million in compensation expense that was immediately recognized, and is reflected in operating expenses.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="Tb_TpbBq8AkYk6Nb6ai-c0x1g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patents and Patent Application Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_l3PloWcpf0Wwvh886VQO6w_cont2" continuedAt="Tb_l3PloWcpf0Wwvh886VQO6w_cont3"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" id="Tb_tGQRacG07Eu0BkbDKyiIFA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company incurs stock-based compensation expense related to the issuance of common stock and stock options. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Term</i> &#8212; The expected life of stock options was estimated using the &#8220;simplified method,&#8221; as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Volatility</i> &#8212; The Company computes stock price volatility over expected terms based on its historical common stock trading prices. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i> &#8212; The Company bases the risk-free interest rate on the implied yield available on U.S. Treasury zero-coupon issues with an equivalent remaining term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Dividend</i> &#8212; The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company amortizes the fair value of the awards expected to vest on a straight-line basis over the requisite service period of the awards. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received as if the Company had paid cash for those services. Forfeitures are accounted for as incurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_yZN38wyKL0qmnh--bhuzSw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of costs associated with clinical trial programs. Costs incurred by third parties are expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the clinical trial or project and the invoices received from its external service providers. The Company estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each project and total project spending. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone events are achieved.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_rwQg16a7skCliOGR7xSaxQ" continuedAt="Tb_rwQg16a7skCliOGR7xSaxQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable income in the years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the date of allowances against deferred tax assets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for &#8220;unrecognized tax benefits&#8221; is recorded for any tax benefits claimed in the Company&#8217;s tax returns that do not meet these recognition and measurement standards. As of December 31, 2025 and 2024, <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_3g1Vv1SHRkG7qavki1vpFg"><ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_RW28YNm1zkKSIf2yKr9XPg">no</ix:nonFraction></ix:nonFraction> liability for unrecognized tax benefits was required to be reported. The guidance also discusses the classification of related interest and penalties on income taxes. The Company&#8217;s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="Narr_bdZUdpLvK0G2A53e1XYrPQ"><ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="Narr_5XSP6Gu6YUGhiJPzUultjA">No</ix:nonFraction></ix:nonFraction> interest or penalties were recorded during the years ended December 31, 2025 and 2024.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_l3PloWcpf0Wwvh886VQO6w_cont3" continuedAt="Tb_l3PloWcpf0Wwvh886VQO6w_cont4"><ix:continuation id="Tb_rwQg16a7skCliOGR7xSaxQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="mrkr:GrantIncomePolicyPolicyTextBlock" id="Tb_55mza7XzS0WfLYqkxDkL4A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Grant Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Grant Income represents funding under cost reimbursement programs from government agencies and non-profit foundations for qualified research and development activities performed by the Company. In applying the provisions of ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company determined that grants and awards are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#8220;customer&#8221;, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to each grant or award, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;). For grant and awards outside the scope of ASC 808, the Company applies either ASC 606 or IAS 20 by analogy depending on if the arrangement is considered an exchange or non-exchange transaction, respectively. Under both accounting frameworks, revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract. During the two years ended December 31, 2025, the Company did not participate in any collaboration agreements.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_cgi2zQeZn065USZK_SGcNQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Loss per Common Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per share includes only the weighted average common shares outstanding, without consideration of potentially dilutive securities. Diluted loss per share includes the weighted average common shares outstanding and any potentially dilutive common stock equivalent shares in the calculation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_aYzM62BFmUiSbpSJ-ryQrg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an entity for which separate discrete financial information is made available and that is regularly evaluated by the chief operating decision maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The Company is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company&#8217;s operations are organized and reported as a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its products. The Company&#8217;s CODM, its chief executive officer, reviews operating results on an aggregate basis and manages the operations as a single operating segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accounting policies of the Company&#8217;s single operating and reportable segment are the same as those described in the summary of significant accounting policies. The measure of segment assets is reported on the consolidated balance sheets as total assets. The CODM evaluates performance and allocates resources based on consolidated net income (loss) that also is reported on the consolidated statements of operations as net loss, and consolidated cash used in operations. The CODM makes operating decisions based on the availability of cash and the allocation of cash to the required expenditures. The significant expenses regularly reviewed by the CODM are consistent with those reported on the Company&#8217;s consolidated statements of operations, and expenses are not regularly reviewed on a more disaggregated basis for purposes of assessing segment performance and deciding how to allocate resources.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_B2O5C0UWCESk34m_y7NFBg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">New Accounting Standards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_l3PloWcpf0Wwvh886VQO6w_cont4"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="mrkr:RecentlyIssuedAccountingStandardsAdoptedPolicyTextBlock" id="Tb_fs28hrD8WUij9O1kBsFRzw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently Adopted Accounting Standards</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Improvements to Income Tax Disclosures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. Effective January 1, 2025, the Company adopted the new standard and applied it retrospectively to prior periods presented. The Company does not believe the new disclosure requirements had a material impact to its financial positions, results of operations and cash flows.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="mrkr:RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" id="Tb_H0s0YInT9kOSrbKpJ4hLqw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently Issued Accounting Standards Not Yet Adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In December 2025, the FASB issued ASU 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities. The new standard is intended to establish authoritative guidance on the accounting for government grants received by business entities and reduce diversity in practice. The amendments establish the timing and methods of recognition of both (1) a grant related to an asset and (2) a grant related to income. The amendments also require certain disclosures including the nature of the grant received, the accounting policies used to account for the grant, and significant terms and conditions for the grant. The new guidance is effective for annual reporting periods beginning after December 15, 2028, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The new guidance may be applied on a modified prospective basis, modified retrospective basis, or full retrospective basis. The Company is currently evaluating the impact of ASU 2025-10 on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures, to improve transparency in financial reporting by requiring entities to present more detailed information about the nature of expenses included within the Income Statement. The guidance will be effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. The Company is in the process of assessing the impact of ASU 2024-03 on its disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">U.S Tax Law Changes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was enacted, introducing significant changes to U.S. tax law, including provisions related to bonus depreciation, interest expense limitations, and the treatment of domestic research and development expenditures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company evaluated the legislation in accordance with ASC 740 and determined that the enactment did not have a material impact on its financial statements for the year ended December 31, 2025.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_aae58ab4_2eb7_4103_ae48_0e324c647bbe"></a><a id="_e42134e0_4d91_4ecd_af85_d93b96c7c4bd"></a><a id="Tc_V4bsW2XA0kW9kU650tg0ww_1_2"></a><a id="Tc_rubszJIbbEaBTv-I_V1zyw_2_2"></a><a id="Tc_KMSoXbkWWkG6LbZO-l1xiA_3_2"></a><a id="Tc_Z_aA0Ss87E6c4p-FyvMLyQ_3_5"></a><a id="Tc_DHc_R1XW_062cUQvYLGTuw_4_0"></a><a id="Tc_e8frZp9iSUyw1lj3utqYIw_5_0"></a><a id="Tc_Bc9kSqzRxUG4FPHW5IpjzA_5_2"></a><a id="Tc_MYh-CNXRPUqLjg50fFvCEA_5_5"></a><a id="Tc_avp4d7lN9UKQZfyRFFI7kA_7_0"></a><a id="Tc_LnWUZylX4kKsiMOdedWMQw_8_0"></a><a id="Tc_hublzYK8N0eG58TAdBHBQw_9_0"></a><a id="Tc_B2zEz27pvkiXflfaqn7L6g_11_0"></a><a id="Tc_6d4yrx0aa0iMH8hnPh9n5g_12_0"></a><a id="Tc_5qTd8xsyaUmSalzBxO6qDQ_12_2"></a><a id="Tc_Iu0ziUAB0U-Z3-Gxo_OBjA_12_5"></a><a id="Tc_JEV5fbLFt0um6ADaIzIFkA_1_2"></a><a id="Tc_qXvuIsIVykqJ9O9A2B8pBg_2_2"></a><a id="Tc_0e5k98NLqU6cbKxP4AIltA_3_2"></a><a id="Tc_7GohSSugBkuWGM9pat0gzg_3_4"></a><a id="Tc_JqrYHEc4lUOzCVTc1KExuw_4_0"></a><a id="Tc_oT5SMgBJVUKSWOXt8o-B3g_5_0"></a><a id="Tc_iw27VrObl0ei7Y7EAZ4Rvw_6_0"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:MinorityInterestDisclosureTextBlock" id="Tb_uiDElW5QZ0aqZobQJXvVAw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;4:&#160;&#160;&#160;&#160;NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth the computation of net loss per share for the years ended December 31, 2025 and 2024, respectively:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_7ZzGIoFH20qqmMWTHPpcLQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_Ken_dK3nzEyD-72w7HxzSA_5_3">12,163,620</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_HP_Ggt4M0Uy0e06ZpXb9nQ_5_6">10,731,315</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc__H2cqDZU5ku1DRZBBWPkVA_8_3">15,310,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_mcGWLCmd9kaqnQte5ZBggg_8_6">8,980,207</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_IGEjDXFB5U-Dz-MRtzRWgA_9_3">15,310,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_XgvVJgIe90SJ7pf2CDUAMA_9_6">8,980,207</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net earnings (loss) per share:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_cLpkEFg1H0Cl1CgQL7uPvQ_12_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_cLpkEFg1H0Cl1CgQL7uPvQ_12_3_2">0.79</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_ZZLW814dd0ezkVBd936qOQ_12_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_ZZLW814dd0ezkVBd936qOQ_12_6_2">1.19</ix:nonFraction></ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_-nqNax1nMEWQ_8jFxyAU7A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aSuKfM4-akyKvKZsn6tCGA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_oG5wFeCIb0Olxzrb28R3Hg_4_2">1,762,878</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_B2nRyEV--0GS0eskNh548A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_llG9TFW2IEOycnriagLRgg_4_4">587,704</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_MqvvcKTOj0eV0u3Nau83Wg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_8L0QiT6aR0OfZ8kLgpOx2w_5_2">5,031,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_aIjiS1PliUO1FmEZTPTlFQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_UvYBun7DUEmOeT3WKmQHiw_5_4">8,278,695</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Potentially dilutive securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Q3J1i2neiEWsSxj0f-PMLg_6_2">6,794,128</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_rUaZs8qkaUGM2Q85Wip48g_6_4">8,866,399</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_LcDaYSLGi0OzvvBM4wF-7w_1_2"></a><a id="Tc_HMNaidsBuk64B0ae0ToJ5Q_1_5"></a><a id="Tc_vwaynzZc-k-cH4PK1Ei2oA_2_2"></a><a id="Tc_aRYA3_A8Vkm97qA2ZhbG7Q_2_5"></a><a id="Tc_iOpuV4ramUid4AS2UA2Oxg_3_0"></a><a id="Tc_rSDcQkOlBUefzbvnUVDGTQ_4_0"></a><a id="Tc_zLhAgv_-XUKI6NwH-bl1tg_4_2"></a><a id="Tc_sR-2gcbCEku40_KZxgiqjQ_4_5"></a><a id="Tc_GyVT3wJT1EKJbw18q5u4mA_5_0"></a><a id="Tc_QA3wwnBcjUyr1_9dEJS4qg_5_6"></a><a id="Tc_PJhIq5cKn0qnxI6BtmmCgA_6_0"></a><a id="Tc_8Uqzvc4D9kuDrvLPk4C9BQ_7_0"></a><a id="Tc_5HIlIjpH_ku6ONyfOvLZAA_8_0"></a><a id="Tc_kEHtq6WdD0yUW7reQZcaQg_8_6"></a><a id="Tc_EARJH-NmVEuLItg6qTGPPg_9_0"></a><a id="Tc_FEIe0mzbQEWdl2jsxzKHSw_10_0"></a><a id="Tc_Rw5YiMqmv0e9aNXnMTflDw_11_0"></a><a id="Tc_Kgc4bngM70aA_wrOykb58g_12_0"></a><a id="Tc_4jevWgOO9kOfmpyg63bvuQ_12_3"></a><a id="Tc_CrZuSunjOU6yjUbeiaX0bw_13_0"></a><a id="Tc_8X_qxZq4KU2r47Yo8f8f5A_13_2"></a><a id="Tc_nLU_NPJM0k2Y-bDaElhaVg_13_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="Tb_IhoOTUvo6EOlIAcx9iglGg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 5:&#160;&#160;&#160;&#160;&#160;OTHER RECEIVABLE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other receivable mainly consists of grant income receivable. Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. The following table summarizes the Company&#8217;s other receivable balance as of December 31, 2025 and 2024, respectively:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="mrkr:ScheduleOfOtherReceivablesCurrentTableTextBlock" id="Tb_0y2oho4Ur0yulk4GbLZXmw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant income receivable:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">CPRIT AML Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_mrLGat3Upk2fb1jB4KArIQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivableCurrent" scale="0" id="Tc_ySCVtG4zwUy-umvCU8g_oA_4_3">815,436</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_YiV5PV-xXEmJq6NEHauChA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivableCurrent" scale="0" id="Tc_Ceby3NBIkUySHS8QRXUfKg_4_6">2,059,457</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">FDA Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_FdaGrantMember_faf3JBchfUmF26_0A8acNw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivableCurrent" scale="0" id="Tc_7ZKGbqgAB0uwixYSGf7avw_5_3">3,678</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">SBIR AML Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_hpcaPdhzZESFYUuK8cOwRw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivableCurrent" scale="0" id="Tc_WBXzywEiaky3u9FjeRDFBg_6_3">162,897</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_-Zh_8JjoQEG-VAt8uJFkjw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivableCurrent" scale="0" id="Tc_6I9-YqC9W06xmL5qPiIDAg_6_6">244,810</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Decoy Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_irhoM80iL0yHiHWgBsAv_Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivableCurrent" scale="0" id="Tc_P8qwqyPDNkKYrqJtNYr0Sg_7_3">59,501</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_WeW3pJ_MmkC27F7VxYyoRA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivableCurrent" scale="0" id="Tc_FVN-Id22lUu7tKQ2QzJEkw_7_6">5,822</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">SBIR NHL Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_ka9khI5BP0KG3WlDMZO44g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivableCurrent" scale="0" id="Tc_scDkXw6A_UOFSRv2CV6A5Q_8_3">87,417</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">PANACEA Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_XnQVMZBaJUW4WC5UTNTybw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivableCurrent" scale="0" id="Tc_urPBM7Adp0ebNR1-IPetew_9_3">190,052</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_mMsw9pTVxUmPUqQGanMoDw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivableCurrent" scale="0" id="Tc_B7725zI5yEmJa_toYJ1hlw_9_6">6,502</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total grant income receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivableCurrent" scale="0" id="Tc_Y08aQd6GVUqs0NnxUXiWqw_10_3">1,318,981</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivableCurrent" scale="0" id="Tc_lgFfX9n_aUyf6SP5tDS4eQ_10_6">2,316,591</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivableCurrent" scale="0" id="Tc_5Rgt1e0SsUCw-cnIx8hblQ_11_3">50,419</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivableCurrent" scale="0" id="Tc_hYchkyZ9nE6A5M6F6nppiw_11_6">28,112</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="Tc_SykhWgcKi0qB7vfFQepOUA_12_6">2,000</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" id="Tc_HN6P9lA2tEqqCqcaPI8IXw_13_3">1,369,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" id="Tc_WJbmJX1zHEu-N6-AF0kOew_13_6">2,346,703</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Refer to Note 2 for details related to awarded grants and Note 9 for more information on grant income.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_fX6R433qlUiD8YNZTcLpZw_1_2"></a><a id="Tc_LhHw_7UUVUqCF1Vg0DDj-Q_1_5"></a><a id="Tc_nfAiBpgbZUup_ytAol-XxA_2_2"></a><a id="Tc_AWh-FZr92Eappl28qJyvbw_2_5"></a><a id="Tc_XCLyYAwP6k2QWMFGv7Y4LQ_3_0"></a><a id="Tc_P6c6LA08dUG2U2zEta-sPA_3_2"></a><a id="Tc_otGXOoC5vk6-eRR4UbXENw_3_5"></a><a id="Tc_W-DxakT3QUSy4oYKmT9tKw_4_0"></a><a id="Tc_5BaddQrpxU-uhGO0sYoayA_5_0"></a><a id="Tc_es9n1esBi0mwZ-EFbgdhCQ_6_3"></a><a id="Tc_Qhsyws9WT0SE8XtTD-vR8g_7_0"></a><a id="Tc_Mykzlm1SS0Wc0XG2iZbcPg_8_0"></a><a id="Tc__ExqfaHyqUuWd_K4vPiqDw_9_0"></a><a id="Tc_QvCPNlgruEeqFa7HtoGI5g_9_2"></a><a id="Tc_QkMOIpYRy0WGRFOLessd1g_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_LDXzrlUy5kKHpNC9jYLcyg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 6:&#160;&#160;&#160;&#160;ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Accounts payable, accrued liabilities, and related party payable consist of the following as of December 31, 2025 and 2024, respectively:</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="Tb_j6Bwm-MrSk-dmgcK6uxNtQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_4n_qvoZYMUuCY2kgdBpWTQ_3_3">793,727</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_rKsQsnCOMkKRKxftJWgFyg_3_6">1,066,395</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_If-k0cyw10O2xc0WGfd6Vw_4_3">87,083</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_SFGVjvmaeUOMHFO40GSmeg_4_6">86,350</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_JFLQmNe-dUCtjGbk3s801A_5_3">160,008</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_kiw4xTwIfEibyjZKOrA5nA_5_6">293,189</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_dTBoH9MfTE64AKs-oLTQIA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Related party payable</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_8MvKOFd8IE6N2METRILIdQ_6_6">1,710,500</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Tax fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="mrkr:TaxFeesPayable" scale="0" id="Tc_mWLmZYqasEGlIhw4hcE_Dg_7_3">54,638</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="mrkr:TaxFeesPayable" scale="0" id="Tc_iKV6STwixEuxxR-37RmfZQ_7_6">104,591</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_stEyeq1sqUi5VigA-u8fbw_8_3">203,928</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_K4dq6Yd62EGXKMVdRjiuLg_8_6">203,429</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="mrkr:AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" scale="0" id="Tc_OeBCYqvjJEqjyo9E26NrzA_9_3">1,299,384</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="mrkr:AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" scale="0" id="Tc_RZHrXshV9ESDd6T2Cq8B-Q_9_6">3,464,454</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_SpvmUFoDl0q5J75fLE_V5A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="Narr_PrDyfw8y4kii8_1ICOIl7w">1.7</ix:nonFraction> million related-party payable as of December 31, 2024 reflects amounts for outsourced product development and manufacturing services. See Note 11: Related Party Transactions.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_sIUG6n1DO0GZ5lQ2-DzjaQ" continuedAt="Tb_sIUG6n1DO0GZ5lQ2-DzjaQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;7:&#160;&#160;&#160;&#160;STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has authorized up to <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_nQgYxKNeA0CyH0vpgi_Gpw">30,000,000</ix:nonFraction> shares of common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_VP5fNUS1FkKn0ijWgVtAtA">0.001</ix:nonFraction> par value per share, for issuance. Significant 2025 and 2024 common stock transactions were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Issuance of Common Stock Pursuant to ATM Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2025, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_7bCo5DiTM02jrNls_29_eA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_-IwYwNL6D0S078SlimIslg">5,358,292</ix:nonFraction> shares of its common stock under the ATM Agreement for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_7bCo5DiTM02jrNls_29_eA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_9gqN5vv6mkaujJzeUD2Fig">9.9</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2024, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_Wv20gcHvB0KjVifO_1x-LQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_1--iqg9o-U6FvTW57n0j-A">8,178</ix:nonFraction> shares of its common stock under the ATM Agreement for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_Wv20gcHvB0KjVifO_1x-LQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_I7Rvdk0Mq0Sjdv8pNAp8uQ">37,000</ix:nonFraction>. On June 10, 2024, the Company provided notice of its termination of the ATM Agreement with Cantor Fitzgerald &amp; Co. and RBC Capital Markets, LLC. In November 2024, the Company entered into an ATM Agreement with H.C. Wainwright &amp; Co., LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Private Placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 19, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;), pursuant to which the Company issued and sold in a private Placement the following securities: (i) <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_12_19_2024_To_12_19_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8VZRCOP4d0-aokYe1ivjTA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_RyxkOlCioEKrs88BO-4ZKg">1,783,805</ix:nonFraction> shares of common stock, (ii) Series B Warrants, or Pre-Funded Warrants, to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_19_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8uiS2_V-yU681VJlw1Q9uw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_dwtFobvq-0u-rGsbc2c8AA">3,247,445</ix:nonFraction> shares of common stock in lieu of shares of common stock and (iii) Series A Warrants, or Private Placement Warrants, to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_19_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PrivatePlacementWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_On3uaIjHpUqZni5K7dWfLQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_xUP0gE4YAkevAvIknbAm7w">5,031,250</ix:nonFraction> shares of common stock. The purchase price per share of common stock and accompanying Private Placement Warrant to purchase a share of common stock was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="As_Of_12_19_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_NdnoCXF10U2RaVtcYYPkIQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_y9H5If8i8kipkTX9qPPOVg">3.20</ix:nonFraction>, and the purchase price per Pre-Funded Warrant and accompanying <span style="-sec-ix-hidden:Hidden_vlSFv0gqUE-B3bsGUvHgiw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Private Placement</span></span> Warrant to purchase a share of common stock was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="As_Of_12_19_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8uiS2_V-yU681VJlw1Q9uw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_gXHaHKbSuE6npwEtoiLtIQ">3.199</ix:nonFraction>. Net proceeds from the sale of securities in the Private Placement was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_12_19_2024_To_12_19_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_O2p_zKEtQUqaRKBbLOCA1g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_0dU_riRlQEqv9DEuzXOm_A">14.9</ix:nonFraction> million, which does not include any proceeds that may be received upon the exercise of any warrants issued in the Private Placement. Both the Pre-Funded Warrants and the Private Placement Warrants are not exercisable until the Company obtains shareholder approval. On March 21, 2025, the Company obtained shareholder approval for the exercise of such warrants. The transaction closed on December 23, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise of Stock Options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2024, certain outstanding options were exercised for <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_o-1rcVEOt0WJi5wmjqb2Ew">25,602</ix:nonFraction> shares of common stock providing aggregate proceeds to the Company of approximately <span style="-sec-ix-hidden:Hidden_8t_mC5yobUSo0_SotysiiQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$62,000</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise of Pre-funded Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2025, certain outstanding pre-funded warrants were exercised for <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_U2becBy6kUyXW95FuWcLrQ" decimals="INF" format="ixt:num-dot-decimal" name="mrkr:ClassOfWarrantOrRightExercised" scale="0" id="Narr_Sx2eO7z4QkyR2yvf9MFidQ">605,830</ix:nonFraction> shares of common stock providing aggregate proceeds to the Company of $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_U2becBy6kUyXW95FuWcLrQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Narr_DjQKJsq6gEemKgfDMHrRyg">605</ix:nonFraction>.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_nwO5Ou0vm0KqENBhWamJVQ_1_9"></a><a id="Tc_bjhUnIEnKUuksOTWk2yL2A_1_15"></a><a id="Tc_ApChC4tDkkGB6KcQIp6Efg_2_4"></a><a id="Tc_o2nz9iuM1kKMo-N4zaOJ1Q_2_9"></a><a id="Tc_hIQ_BQTSFEab7cTPwOVBPg_2_15"></a><a id="Tc_gRz-5PPg30694Umb24me9w_3_4"></a><a id="Tc_FWdUKjPTH0mEABQCAMHYSw_3_7"></a><a id="Tc_JlAMl6Qt00SBLEk_rUvwAQ_3_9"></a><a id="Tc_sRnwcx7ud0CRju3kuDWV9g_3_11"></a><a id="Tc_UQgC4Bcz7U6rlJXtYQV5MQ_3_15"></a><a id="Tc_uhsmQXYyokGd41eSbW2Gng_4_2"></a><a id="Tc_2eDNcNCH6UWq1Irs_tRP0g_4_4"></a><a id="Tc_7lSAeid6t0KXqu-AzzisLA_4_7"></a><a id="Tc_LjebGS26zE21Jl9QGJwAdA_4_9"></a><a id="Tc_5mCXN4moNEGx9J6KjZMh1w_4_11"></a><a id="Tc_D66i6pbN4keVYuzBAIslqA_4_13"></a><a id="Tc_Q5vDpIcnRUunUp6n8BTsbQ_4_15"></a><a id="Tc_7uFkiEI7xU2Z0V6lOVItXQ_5_0"></a><a id="Tc_SkSLEmAQskyAix6ckaU2IA_5_2"></a><a id="Tc_wUf1NbLgd0aC_Ss4FZqcWA_5_4"></a><a id="Tc_Q7KuR5aofEeiGpRcgCCrGg_5_7"></a><a id="Tc_nRGVuGa8hkOBiAvn5mFfgQ_5_11"></a><a id="Tc_vSkjnA8xr0Kv0UE3Oa5T9A_5_13"></a><a id="Tc_FImCVRc_2EiObJeYPZoWaQ_6_0"></a><a id="Tc_UNOAH0381UCWUsP_9xiR7A_6_2"></a><a id="Tc_SNMH7DxfXEmt5B2d6BpTtQ_6_4"></a><a id="Tc_R39_fz4x7kasCWaFWMf_nQ_6_7"></a><a id="Tc_irXPsgTjHE-lRteIEjUJBA_6_11"></a><a id="Tc_zz-TzDq2aUa13n03nk3n8w_7_11"></a><ix:continuation id="Tb_sIUG6n1DO0GZ5lQ2-DzjaQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has authorized up to <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_tPEvDDGLnkqh8FdDPdawxA">5,000,000</ix:nonFraction> shares of preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_75XLY8u260q1ZgZiXfyrcw">0.001</ix:nonFraction> par value per share, for issuance. The preferred stock will have such rights, privileges and restrictions, including voting rights, dividend conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company&#8217;s board of directors upon its issuance. To date, the Company has not issued any preferred shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrant Summary</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the total warrants outstanding at December 31, 2025:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_L2qk2PI_d0GIDLesvhY3hw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> as of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> as of</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price Per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">New</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issue Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td></tr><tr style=""><td style="vertical-align:top;width:34.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Private placement warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PrivatePlacementWarrantMember_A7nPIRhbOkCSTYcVdsqkJQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_qjeQZiyDz0SoYoCb-x_2Vg_5_5">4.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PrivatePlacementWarrantMember_A7nPIRhbOkCSTYcVdsqkJQ" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_FHzcfSMAfkGdFy7HIwPHIQ"><span style="font-size:8pt;">5 years</span></ix:nonNumeric><span style="font-size:8pt;"> from shareholder approval</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PrivatePlacementWarrantMember_cafAhZMIDkSljx-lvFkWag" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_1ZNEGNpo3UCdZSucx2wT_w_5_9">5,031,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PrivatePlacementWarrantMember_A7nPIRhbOkCSTYcVdsqkJQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_JThG7gzDeECYO9gSIhohCA_5_15">5,031,250</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:top;width:34.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Pre-funded warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_jieysXAEz0G_tGMRFzVAhw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_3D5rLukktU6VJCIJayBpag_6_5">0.001</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_jieysXAEz0G_tGMRFzVAhw" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_Xq_jKj9LeUu5Z4KqBPi93Q"><span style="font-size:8pt;">5 years</span></ix:nonNumeric><span style="font-size:8pt;"> from shareholder approval</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_Nng2hqeyCUeMaAu9fclCqA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_3f3LdvZQvkSdLqqBMO-WGA_6_9">3,247,445</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_U2becBy6kUyXW95FuWcLrQ" decimals="INF" format="ixt:num-dot-decimal" name="mrkr:ClassOfWarrantOrRightExercised" scale="0" id="Tc_CDz1ymQxC0irdKHNqgAZeA_6_13">605,830</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_jieysXAEz0G_tGMRFzVAhw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_I3NXJYs19UWInIl5_aDKfQ_6_15">2,641,615</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:34.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_6f2XQzgA_EKoT_H5FDOGgA_7_9">8,278,695</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="INF" format="ixt:num-dot-decimal" name="mrkr:ClassOfWarrantOrRightExercised" scale="0" id="Tc_Kd3OizEM_EGmKooXMmYL3w_7_13">605,830</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_VHMFqwxbNUit821WkvnWNA_7_15">7,672,865</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_tb-C8hXda06dFlIWgW5yoQ" continuedAt="Tb_tb-C8hXda06dFlIWgW5yoQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;8:&#160;&#160;&#160;&#160;STOCK BASED COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 19, 2020, the Board adopted the 2020 Equity Incentive Plan (&#8220;2020 Equity Incentive Plan&#8221;) which replaced the 2014 Omnibus Stock Option Plan. The 2020 Plan was further amended effective May 2022 to increase the number of shares of common stock authorized for issuance under the plan by <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_5_19_2020_To_5_19_2020_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_-5xby4R-iU6ab24NiQ858Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_G7dHydvS8EqokcjtibbOwQ">850,000</ix:nonFraction> shares. The 2020 Equity Incentive Plan allows for grants of stock options, restricted shares, stock bonuses and other equity-based awards to employees and non-employee directors of the Company. Awards under the 2020 Equity Incentive Plan may be at prices and for terms as determined by the Company&#8217;s board of directors and may have vesting requirements as determined by the Board, provided that the exercise price for any stock option must be at least equal to the fair market value (as defined in the 2020 Plan) of a share of the stock on the grant date. Once granted, the exercise price of an option may not be reduced without the approval of the Company&#8217;s stockholders, other than under certain limited circumstances such as a stock split or take any other action with respect to a stock option that would be treated as a repricing under the rules and regulations of the Nasdaq Stock Exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Options granted under the 2020 Equity Incentive Plan have a maximum term of <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_Y5VZDx-btUSB5iQ3XO7H4w" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_5lM0HN6z-kurPmbgWLjwnQ">ten years</ix:nonNumeric> from the date of grant and generally vest over <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_Y5VZDx-btUSB5iQ3XO7H4w" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_YMWVL0xVy0aH4gxXGao1hw">four years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2025 Equity Incentive Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 12, 2025, pursuant to the Company&#8217;s 2020 Equity Incentive Plan, as amended, the compensation committee of the Company&#8217;s board of directors approved <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_2_12_2025_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_-zpixAd6L0ukz7Q5PRFHjw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_rUQ11NnKKkK5gWtXd5TLVg">50,000</ix:nonFraction> options to purchase the Company&#8217;s common stock as equity-based incentive awards to the Company&#8217;s Chief Executive Officer and President, Dr. Juan Vera, and <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_2_12_2025_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_br-AgiIl10O-PTuaEnCrgA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_UKcbdkycjESUGCA_vawrVA">30,000</ix:nonFraction> options to purchase the Company&#8217;s common stock as equity-based incentive awards to each Non-Employee Director. Each option award was granted with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="Duration_2_12_2025_To_2_12_2025_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_RyHxP5Ri-UCIy9cqONYc_Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_HiOR67TLzkW0yyL16peS1w">1.59</ix:nonFraction> per share, the closing price of the Company&#8217;s common stock on the Nasdaq Capital Market on February 12, 2025, with the option award vesting in <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_2_12_2025_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_K5BoRY6DdkuHU8WoQnkViA" decimals="INF" format="ixt-sec:numwordsen" name="mrkr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments" scale="0" id="Narr_PfATHC2PQkuiUcRLy5g6rw">three</ix:nonFraction> annual installments, subject to such Optionee&#8217;s continued service on the applicable vesting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 31, 2025, the board of directors (the &#8220;Board&#8221;) of the Company appointed Ms. Kathryn Penkus Corzo to the Company&#8217;s Board, effective November 1, 2025. In connection with the appointment of Kathryn Penkus Corzo to the Company&#8217;s Board and pursuant to the Company&#8217;s 2020 Equity Incentive Plan, the Company granted Ms. Corzo <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_11_1_2025_To_11_1_2025_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_m9FesoReQ0m7x7fy6w2Hag" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_SPs0ZYLRREuKHoOqdz6YjA">147,611</ix:nonFraction> stock options to purchase shares of the Company&#8217;s common stock at an exercise price per share equal to the fair market value per share on the date she was appointed to the Board. The options will vest evenly over thirty-six (<ix:nonNumeric contextRef="Duration_11_1_2025_To_11_1_2025_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_m9FesoReQ0m7x7fy6w2Hag" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Cr8w0wnTlky9XEUDhTitTQ">36</ix:nonNumeric>) months and are subject to her continued service as a director.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_XNeRhZW-vU66alHSqydIRw_1_10"></a><a id="Tc_h9QOZKFfCUKEqCyFb593aw_2_10"></a><a id="Tc_GD0VjWEWAEuizkjh8yEGVQ_3_4"></a><a id="Tc_jLoKAmMxqker9gACdGpjlA_3_10"></a><a id="Tc_uCsY4oiajUSoGAfIjQSagg_4_2"></a><a id="Tc_0jJ4_AAtRkSAWi_iIQwQDQ_4_4"></a><a id="Tc_yGFWBAWMR06Q4KUPv0Vf0A_4_7"></a><a id="Tc_bDt9eBuvfEGdD-RuyUMSBg_4_10"></a><a id="Tc_4k8_dQc1QkqqKrG8WvErnQ_5_0"></a><a id="Tc_VKch4iawikWQPCf0ixc9gg_5_4"></a><a id="Tc_bnr4DlLVJk65pkRaJMEKtA_5_7"></a><a id="Tc_CFRtFt4IR0-1vOCDDa8xDA_6_0"></a><a id="Tc_9mCjFIoej0e4wnm94JgzEQ_6_2"></a><a id="Tc_rfx4BJg0Kk-x6W15PznBUw_6_5"></a><a id="Tc_zLvPPZJcsUSgwXW-daOVmA_6_8"></a><a id="Tc_ZQ_lCfopn0yrgI9LmxdNYg_6_10"></a><a id="Tc_Psu8aKu0UU-83uDpldmtTQ_7_0"></a><a id="Tc_2t5xDexF0kKw1AlX5H995A_7_8"></a><a id="Tc_ecB9xoR-e0mQPMTCnGaBKw_7_10"></a><a id="Tc_jNFnzaonok2UW6LitayUWQ_8_0"></a><a id="Tc_ppL_PzxSFkmlfWte9piNlQ_8_8"></a><a id="Tc_eMZcJs3Mck-WgOz_yg8n0A_8_10"></a><a id="Tc_kD2g_DGT3E-BtqI_kPMMSg_9_0"></a><a id="Tc_5ST8ArKYzkac217k77m1EQ_9_7"></a><a id="Tc_8t2GmtiMgkWeSlyFgGV0xA_10_0"></a><a id="Tc_yzr4GaHq1U-Up_YAU2svsg_10_8"></a><a id="Tc_sXuPVllxMEC3ndJ5LfTQiw_10_10"></a><a id="Tc_x_Zsg3-UBkSV-PZWqcP1Cg_11_0"></a><a id="Tc_euxDsQ_JgUq-P4K0Pfud2A_11_2"></a><a id="Tc_fCjXYcX6kE2vnpOSDomyQw_11_5"></a><a id="Tc_LxGA2yJ7mkmtcYNCUg6ttg_11_8"></a><a id="Tc_OqcMsMzJ-UurhDwfx2SLUw_11_10"></a><a id="Tc_Ie1xFClo7UiDsFCRbtmsNQ_12_0"></a><a id="Tc_wnCA_CWz2kGtFW0VR4CqIg_12_8"></a><a id="Tc__J1xgWgXvUqeMwxiN450Hg_12_10"></a><a id="Tc_m2wAezdNPk2Ju5x8-7aHzA_13_0"></a><a id="Tc_7ETY98ImwEWSCoSaDY57gw_13_4"></a><a id="Tc_4T4FhPCI9U2Wp7J5a8y83w_13_7"></a><a id="Tc_oUccwkrDX0uglsmqu70-WQ_14_0"></a><a id="Tc_JLu70HMI_0CmCmhoxd2Syg_14_4"></a><a id="Tc_e0xoo_pQIkKDEzX0WK_okQ_14_7"></a><a id="Tc_d8GOSXYff0SUlhV2kp7h9Q_1_2"></a><a id="Tc_5ccnK47y2E-pBhZz_QgACg_2_2"></a><a id="Tc_Pw6yRd5qZkuhE8u5NkWNRg_3_2"></a><a id="Tc_wuulxiisy0Si8NW6nkCtRw_3_5"></a><a id="Tc_1U5veD67MkSi6c5oaKZGFA_4_0"></a><a id="Tc_oncVg4oqZ0eUqHyQyEV6Tg_4_2"></a><a id="Tc_7n8-im3rYU-B04b6tBnsPg_4_5"></a><a id="Tc_8iShr2gvD0ONCEqHKtfS0w_4_6"></a><a id="Tc_RrklPQFTWUiYplf0nA7OKg_5_0"></a><a id="Tc_cCqFQTjgckWQVJ5CfzqeJw_5_6"></a><a id="Tc_9pQOcbrmmECDUguQ1iPy4Q_6_0"></a><a id="Tc_wkeEowu9YEuWD1M3HuRLKQ_6_4"></a><a id="Tc_FNHwn3Mdo0KxlT08gG-ZnQ_6_6"></a><a id="Tc_NcbL00q97kyTI1u3ju2efw_6_7"></a><a id="Tc_vbFPykpOD0ydmNJm5ldF6A_7_0"></a><a id="Tc_nm-VkJM6TE2wf988yBxnbA_7_4"></a><a id="Tc_Dkf3S4-YjES6WKdKyMPKJg_7_6"></a><a id="Tc_w5-crh0OLEOCyWtCvUL2iQ_7_7"></a><a id="Tc_kPRbRpFaV0KXUXES_vVIzw_8_0"></a><a id="Tc_ksw6Ddz1HUKw4LIh8x1_Ug_8_4"></a><a id="Tc_q_RGShl4ekW3vziyV7vFsA_8_6"></a><a id="Tc_xpund2Vi20i8NnvFm7QdpQ_8_7"></a><ix:continuation id="Tb_tb-C8hXda06dFlIWgW5yoQ_cont1" continuedAt="Tb_tb-C8hXda06dFlIWgW5yoQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 31, 2025, the Compensation Committee and Board approved a discretionary award of <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_10_31_2025_To_10_31_2025_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_qkF9ZLP_WkaIr8Qab56IzA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_iGnkLDMFG0aydbodJuckeg">250,000</ix:nonFraction> stock options at an exercise price per share equal to the fair market value per share on the date of the grant (the &#8220;CEO Options&#8221;) to Dr. Juan Vera under the Company&#8217;s 2020 Plan. The CEO Options vest annually over <ix:nonNumeric contextRef="Duration_10_31_2025_To_10_31_2025_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_qkF9ZLP_WkaIr8Qab56IzA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_R3yGpcO_R02KR-w1SD0U2w">four years</ix:nonNumeric> beginning on the anniversary of the grant date of the CEO Options and are subject to the terms and conditions of the 2020 Plan and the Company&#8217;s form of option award agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 17, 2025, the Compensation Committee of the Board approved additional grant awards to each Non-Employee Director apart from Ms. Corzo. The Company granted each Non-Employee Director a total of <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_11_17_2025_To_11_17_2025_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_0n8Ce_-UXUS8UIExWuVJBg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_HzViOKsBOkGY0FeXzkjd5g">221,741</ix:nonFraction> stock options to purchase shares of the Company&#8217;s common stock at an exercise price per share equal to the fair market value per share on the grant date, or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="Duration_11_17_2025_To_11_17_2025_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_0n8Ce_-UXUS8UIExWuVJBg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_ZoL7TWujc0yGQKwZq01cig">0.9548</ix:nonFraction>. The options vest fully in <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_11_17_2025_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_XfMX7dcV3UWRP3Ne6O4l6Q" decimals="INF" format="ixt-sec:numwordsen" name="mrkr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments" scale="0" id="Narr_2wcZaf5vv0uRyI4PubZROA">one</ix:nonFraction> annual installment, subject to such Optionee&#8217;s continued service through the vesting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, approximately <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_oLyCD0BiIEeiK_BggHiIyw" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" scale="6" id="Narr_AyZXNtCaYku15ctuJJZsww">0.1</ix:nonFraction> million shares of common stock are available to be issued under the 2020 Equity Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Options </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of the Company&#8217;s stock option activity for the years ended December 31, 2025 and December 31, 2024, is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="Tb_-bVEXW-w_EGwpCQOIUK8cg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Intrinsic Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2023_jtXp7bckLE2CuJhkJ9PNfg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_Yyw3E7xtOE6LS0_FlelPqg_5_2">737,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="As_Of_12_31_2023_jtXp7bckLE2CuJhkJ9PNfg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_9I1lO55SfkiuCDoDtOnk9A_5_5">25.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2023_jtXp7bckLE2CuJhkJ9PNfg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_0x-P4YvqMkueaO6Mk9qFgQ_5_8">1,317,234</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_M_rPwQol10ywKLcDBKqTtw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_t8s0KTS7z02L0vR7CEoftw_5_10"> 7.6</ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_pT-Ovwjx9k25wZgP3boquA_7_2">25,602</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_UID0De8rnUmuEpZUKmESow_7_5">2.43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Canceled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_IqQjN7bHnEuX58NQ9hdH-w_8_2">124,589</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_Blx4wbvgPkKUiaIy99pVCg_8_5">42.24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_CVuoYcFRgUG8YYGubJnG3A_9_2">587,704</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_OgrKgrPsSUKNLaxbNH--MA_9_5">22.85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_bzR54-rgXk6iMSqbtiP5JA_9_8">377,767</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_YYcDztqRv0a7hAfLMAzPIw_9_10"> 6.8</ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_EBBBwThXzEOuYqufw5w_yw_10_2">1,202,834</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_qW1g1qByc0a8Auo7qkYkzg_10_5">1.04</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Canceled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_l7HV6_z6hke_x53wk1DenQ_12_2">27,660</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_0Q3XHRjqZk6ApvWmWcURVQ_12_5">35.66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_4C11Rtt3R0qdEEmc3wkbBw_13_2">1,762,878</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_CFpU3a0-90-SjE7B1xnfiQ_13_5">7.77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_9q1st-XWZEanAOJQTHSFiA_13_8">563,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_eaGs3H7FF06u3IUxVZTjmA_13_10"> 8.5</ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_4TL2L3B1Hk6LPl73--VljA_14_2">461,202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_4zmv2mqBpU2tybaS2JPf4Q_14_5">26.57</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="Tc_WueNICkGu0OWbojy3_RsQw_14_8">7,619</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Tc_dBdIwfLxaEmHzYC0_HM1Jw_14_10"> 5.6</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Black-Scholes option pricing model is used to estimate the fair value of stock options granted under the Company&#8217;s share-based compensation plans. The weighted average assumptions used in calculating the fair values of stock options that were granted during the years ended December 31, 2025 and 2024, respectively, were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_z4h7oCPcUkKXLP9An3jeOA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Tc_G4XyQ5fib06bgS8qOnI-Sg_4_3">1.04</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_woNECRzzm0iVBSvXWLQhFw_5_3"> 5.7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected stock price volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_soFZ-AF3ck2CvnwXEobz_g_6_3">104.82</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_m4Go3y9hUkqOq1iBNKiggw_7_3">3.88</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_3GLAvOT7lUuzqbETBNOk0A_8_3">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="Tc_08KxJe05-0-ftWqBQsE-ug_1_2"></a><a id="Tc_WPzkvTGVwU68AVFeexrgDQ_2_2"></a><a id="Tc_t332es9fuUWPwbddIxCx8Q_3_2"></a><a id="Tc_1-yBBqxP60Sd3VfYoitCXA_3_5"></a><a id="Tc_T-G7Fp6g9kOpWDG_LwxFOQ_4_0"></a><a id="Tc_Dmt77xeCAUiAJ3JtCSKlCg_5_0"></a><a id="Tc_e9Krbi9i40Ck7Je--mmcfQ_5_2"></a><a id="Tc_3FmG79elvUuMrH3eY7u4vQ_5_5"></a><a id="Tc_PV_Nn6-W2k63mNlTOVaI0w_6_0"></a><a id="Tc_STvHO0aNb066fqu0e47gAQ_7_0"></a><a id="Tc__W64xaoliUeCj0rJLh4UPg_7_2"></a><a id="Tc_Ak2CqCS670WbC6C10iFAOw_7_5"></a><ix:continuation id="Tb_tb-C8hXda06dFlIWgW5yoQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth stock-based compensation expenses recorded during the respective periods:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="mrkr:StockBasedCompensationExpensesTableTextBlock" id="Tb_SiaGONfMokyFbOmDDsKpzg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock Compensation expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Ey1Xk4v6f0yORZDZoGT7FA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_GAEaOs_zq0S4h18XcWGPYQ_5_3">308,068</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_j5D-je0g6E6fJSRo58Oxow" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_0xXHs0-21kmZtyOEUU47oQ_5_6">15,247</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1iM8joIEOEKotgV079FgPg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_CNa1Uw8R1EqlwznCQ9Qb-Q_6_3">229,472</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Cf4uLI9Y-kqC1zLcm3sQTg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_ZTabiZjBO0qJD8ZtZo0fkQ_6_6">230,617</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_UtOzJxUfJkCT1wurwuETNw_7_3">537,540</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_tltEeNH2bU2YWzm0USLjjA_7_6">245,864</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the year ended December 31, 2025, the Company recorded incremental stock-based compensation expense of $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="6" id="Narr_4J_LuPtGL0GCvt44jwhNew">0.3</ix:nonFraction> million pertaining to the modification of stock options in connection with certain consultants. The modification resulted in an acceleration of $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" scale="6" id="Narr_niKREVLXQ06FAZlB27W0QQ">0.3</ix:nonFraction> million in compensation expense that was immediately recognized, and is reflected in operating expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At December 31, 2025, the total stock-based compensation cost related to unvested awards not yet recognized was $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_TseiLtlB6Uex5ek5UtlWfA">0.9</ix:nonFraction> million. The expected weighted average period for compensation costs to be recognized was <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_-on7TYrgzUSy3es3psK7Sw">1.8</ix:nonNumeric> years. Future option grants will impact the compensation expense recognized.</p></ix:continuation><a id="_f83e616c_8d66_4c7c_98a3_a369d767f8f4"></a><a id="Tc_25rbeJ2-R0yB2FwmPu7BjQ_1_2"></a><a id="Tc_oS5lkrQbP0KCwCtZ1fpAzg_2_2"></a><a id="Tc_LZtnx0DdgEC73jZ0octiEg_3_2"></a><a id="Tc_Nvtd5sop9ku-VXRMZNyEsg_3_5"></a><a id="Tc_7zIIv_xks0muv7j1a4pdNQ_4_0"></a><a id="Tc_OZi7_Qs9UEihP9s9KfkLZA_5_0"></a><a id="Tc_FrBYZdAIQkm3FZ28VHJKcw_5_2"></a><a id="Tc_spbTnh73kkqkwV8PPc-L4w_5_5"></a><a id="Tc_bnnxaZZdBEGcw0haZUV67Q_6_0"></a><a id="Tc_1zZsBFuG1k-dqmVU7mF3qQ_7_0"></a><a id="Tc_c2Q_b6KBcEmKMzStgKh9Cg_8_0"></a><a id="Tc_LuCU-yRQI0SjYwh7jixXdQ_9_0"></a><a id="Tc_dd1aI4krJ0KIozB1r3Dm_A_10_0"></a><a id="Tc_HcDy83gXcEi5qY2Ny35y_g_11_0"></a><a id="Tc_pzmQlFZYqEihIhNzWrs5Xw_11_6"></a><a id="Tc_v2iP25QHj0GvOtfM1ghi4Q_12_0"></a><a id="Tc_uvw-QooaekmECp10BbftEA_12_2"></a><a id="Tc_V5Yu5ebKkEeL_tm_clVY1Q_12_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="Tb_2sWgtwp-002F-4IEh8EOkw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 9: GRANT INCOME</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Grant Income represents funding under cost reimbursement programs from government agencies and non-profit foundations for qualified research and development activities performed by the Company. Revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract (see Note 3). If restricted cash is received from grants in advance of incurring qualifying costs, it is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. The Company had $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="6" id="Narr_dHomlHE6gkORZiEQiJO-VQ">1.0</ix:nonFraction> million of restricted cash recorded as of December 31, 2025, and <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RestrictedCashCurrent" scale="6" id="Narr_2rxkV7zfqEiI1g4Yo2sGwg">no</ix:nonFraction>ne recorded as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes grant income recorded for the years ended December 31, 2025 and 2024, by grant:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_d8id3eAPmk-qpKuyOO-Vrw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">CPRIT AML Grant<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_tIJI_NC6ykGWgCWOPj17jw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_yMPtymiv7Eux2UgikIAOSg_5_3">900,014</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_bMeEXnqqVEGomKtJCoNZAA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_T3O_SE5mzECZaj57eCNIww_5_6">4,411,149</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">FDA Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_ZoSbOHwhNE-hXUpvIJbwbg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_W3CFakxwXEeW9oMznZ2Htw_6_3">118,478</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_AKZHg4JWuUyRUOYrneJE0A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_NsI_u1J_fkKByFidUBIYFQ_6_6">519,750</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">SBIR AML Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_ziCCxC0XiEqj3xjfTYljxg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc__60z81sln0KnioTX0kwSFA_7_3">472,208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_RRTLLDVCo0iNI2tLPudd5w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_1ejyCffK00CtT7UlOA1DQQ_7_6">982,182</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Decoy Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_qnTBapqjVEaOu5WEAR6N1A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_HTGNQ3k8nki3Kw_U0t3yLA_8_3">391,305</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_qobRXgqC6kWkIYzc8lU_ag" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_sP5-Gn6hkUC7nONzwyJdrA_8_6">5,822</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">SBIR NHL Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_v3gveAJvr0u79DQtC91MKA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_ZDMg7ietCke0C4YVOLer8w_9_3">665,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_dJoyNhvuRUeMzzqqNeKOvQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_u1bJ4sSrU0aGN1PKLKrBOA_9_6">665,000</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">PANACEA Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_670n_eqWFEyvZOe0MstmvA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_Pd-VVFCJck2oDpQq7Rmofg_10_3">425,670</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_CkarEX95-0qd9acV3OWC_Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_y10XtJyvAE6sek46jxqnTQ_10_6">7,177</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">CPRIT Pancreatic Grant<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_CpritPancreaticGrantMember_YmkzplPQXEqeidRVY8TO_g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_D677NjDBA0aYRXrbE2BR-w_11_3">573,994</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_us-gaap_GrantMember_6LnqjjsZJEiYA6ZxeN_-8Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_oMIlyEWjZEm8sgiZo9KPQQ_12_3">3,546,669</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_GrantMember_UiYnDW3Fo0WMqnl0BxBg_w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_n6CewRpxm0KwntaOYK0Nuw_12_6">6,591,080</ix:nonFraction></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>Both CPRIT grants are subject to certain revenue-sharing arrangements, as per the grant agreements (see Note 10).</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If qualifying grant income is earned in advance of cash received from grants, it is recognized as revenue and recorded as other receivable (see Note 5).</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_10R4yNOTBUWrvqfiEKgGVw" continuedAt="Tb_10R4yNOTBUWrvqfiEKgGVw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;10:&#160;&#160;&#160;&#160;COMMITMENTS AND CONTINGENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cancer Prevention and Research Institute of Texas</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In August 2021, the Company received notice of a Product Development Research award totaling approximately $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_RelatedPartyTransactionAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_AFB5466R20GWPhFeBp81GQ" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:GrantReceived" scale="6" id="Narr_daOWZMHXz029-oWjnqnRRQ">13.1</ix:nonFraction> million from CPRIT to support the Company&#8217;s clinical investigation of MT-401 (the &#8220;CPRIT AML Grant&#8221;). In December 2024, the Company received notice of an additional $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_12_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_K0kZGOM0S0iI7apUnHkXog" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:GrantReceived" scale="6" id="Narr_4QMteHQU1EC0JVi3ajplTA">9.5</ix:nonFraction> million grant from CPRIT to support the clinical investigation of MT-601 in patients with pancreatic </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_10R4yNOTBUWrvqfiEKgGVw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">cancer (&#8220;the CPRIT Pancreatic Grant&#8221;). Both CPRIT grants contain identical terms surrounding intellectual property and revenue sharing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Per the CPRIT grant agreements, the Company will retain ownership over any intellectual property developed under the contracts (the &#8220;Project Results&#8221;). With respect to non-commercial use of any Project Results, the Company agreed to grant to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with the right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, solely for academic, research, and other non-commercial purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the Company&#8217;s products become commercially saleable, the Company is obligated to make payments to CPRIT, with respect to net sales of any product covered in the contract, equal to a percentage of revenue ranging from the low-to-mid single digits. These payments will continue up to and until CPRIT receives an aggregate amount of <ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_J7SfSASjZE-svWLtQE3gbg" decimals="2" format="ixt:num-dot-decimal" name="mrkr:GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived" scale="-2" id="Narr_EvEBdAU1qUSKNUFcBoIpNw">400</ix:nonFraction>% of the sum of all monies paid to the Company by CPRIT under the grant agreements. If the Company is required to obtain a license from a third party to sell any such product, the revenue sharing percentages may be reduced. In addition, once the Company has paid CPRIT <ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_J7SfSASjZE-svWLtQE3gbg" decimals="2" format="ixt:num-dot-decimal" name="mrkr:GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived" scale="-2" id="Narr_Ez7DVfHIK0q_wNcDlzsaLA">400</ix:nonFraction>% of the monies received under the grant agreements, the Company will continue to pay CPRIT a revenue-sharing percentage of <ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_J7SfSASjZE-svWLtQE3gbg" decimals="3" format="ixt:num-dot-decimal" name="mrkr:GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm" scale="-2" id="Narr_80LID4UOCEua73lKlhJ2rQ">0.5</ix:nonFraction>% for the remainder of the Revenue Term as specified in the grant agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">License Agreement with the Baylor College of Medicine</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In March 2018, the Company entered into an exclusive license agreement with BCM under which the Company acquired a worldwide, exclusive license to BCM&#8217;s rights in and to certain intellectual property rights, including a European patent to develop and commercialize MAR-T cell product candidates (the &#8220;BCM License Agreement&#8221;). In exchange for the license, the Company issued shares of its common stock to BCM valued at approximately $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineLicenseAgreementMember_mKK3QAV17UG31xtSaZ_jxQ" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:SaleOfStockValueOfSharesIssuedInTransaction" scale="6" id="Narr_ObvtPPNRGku-BuXIVxLL3A">5.0</ix:nonFraction> million at the time of issuance, agreed to make royalty payments to BCM upon commercial sales according to the royalty schedule in the BCM License Agreement, under which the royalty percentages increase in proportion to the aggregate net sales, and agreed to pay BCM certain milestone payments up to an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineLicenseAgreementMember_Eej9dmqQ10SaSsQkQOu8NQ" decimals="-4" format="ixt:num-dot-decimal" name="mrkr:LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid" scale="6" id="Narr_ZNta5IsqfUqMVRVDocJw-g">64.85</ix:nonFraction> million. The milestone payments are based upon the occurrence of nine particular milestones relating to completion of the first dosing in clinical trials for a first and second distinct product, FDA approval, and achievement of certain net sales goals. The Company is also responsible for sublicensing fees and for reimbursing BCM for related-party expenses. In addition, upon a liquidity event (as defined in the BCM License Agreement) of the Company, BCM will receive a one-time liquidity incentive payment of <ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineLicenseAgreementMember_mKK3QAV17UG31xtSaZ_jxQ" decimals="3" format="ixt:num-dot-decimal" name="mrkr:LicenseAgreementLiquidityIncentivePaymentPercentage" scale="-2" id="Narr_95e8PFNEvUa655Z206E37w">0.5</ix:nonFraction>% of the liquidity event proceeds (as defined in the BCM License Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Legal Proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, we may become involved in legal proceedings, including those arising in the ordinary course of our business. We are not currently a party to any material legal proceedings that we believe could have an adverse effect on our business, operating results or financial condition.</p></ix:continuation><a id="Tc_jfItlkAkTUCcujzmldKqUg_1_2"></a><a id="Tc_OlKwSMBa3EeEOcwTgyFDDw_2_2"></a><a id="Tc_kUKBSilkpk-tLSJqFoaMsg_3_2"></a><a id="Tc_0ofUOYhoI0mX5a5tgYIR3A_3_5"></a><a id="Tc_cgGj3_z7d0--mYyvy_qB_A_4_0"></a><a id="Tc_jOAIizNoRUOv3SafxnvscA_4_2"></a><a id="Tc_6emlGKChLkayYfjg7nJypQ_4_5"></a><a id="Tc_FqeEXcX5kEqbJqr4l14q5g_5_0"></a><a id="Tc_ya9Kx1g500qGdI_X71fobQ_6_0"></a><a id="Tc_r2eNMdLUsEKN1rdtMCUnyQ_6_6"></a><a id="Tc_VmF1rBFLN0Schk6ICfl-bg_7_0"></a><a id="Tc_OlGI3IdzukKC4Fjfo4n89g_7_2"></a><a id="Tc_ljbxhsdHGU-LQnojbi_Onw_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_glWwU1366U69zDcrYjWj8Q" continuedAt="Tb_glWwU1366U69zDcrYjWj8Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;11:&#160;&#160;&#160;&#160;RELATED PARTY TRANSACTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth related party transaction expenses recorded for the years ended December 31, 2025 and 2024, respectively.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="Tb_c2QgrlEFNkO2Ek7C015O_g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baylor College of Medicine</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_Ek7VnObDF0qwBQZljA5lrg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" id="Tc_HnqVc_nqNEyi-7byVsCK7A_4_3">3,218,138</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_y1zLnl6EqUepjN6-dcbOxA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" id="Tc_LRmXRn9Ot0eDmn9SWEP00A_4_6">6,723</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cell Ready</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_CellReadyMember_EXj1TZHoG0iefhOIN4rydg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" id="Tc_ZKCw8hn8nkSgUX44w_-tPQ_5_3">1,266,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_CellReadyMember_4FOpwyVQrECS-MHeaC1tvw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" id="Tc_UX1M1pIJ8keM4y7AOCqwMQ_5_6">5,846,456</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Wilson Wolf Manufacturing Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_1TeDARXsOkC9hEbasgXmxA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" id="Tc_o5tH_5JUGkW07kt8zPAkAw_6_3">83,543</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" id="Tc_UKMKS0Yvc02qtM-M8XGg3g_7_3">4,568,485</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" id="Tc_96y7kUIxgkOv4kKf7QMkXw_7_6">5,853,179</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_mrkr_CellReadyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_AVpatNJHyUqIpBAODzA4gA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="Narr_HE_5v1gfQ0-4Sy3GiZ7Qow">nil</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_mrkr_CellReadyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__-jgDBmfiUmEu0GZmK8-5g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="Narr_fPhcHiHneE-qQzlzCEKlhw">1.7</ix:nonFraction> million, respectively, of related party transactions are included in accounts payable and accrued liabilities. See Note 6 for additional information.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_glWwU1366U69zDcrYjWj8Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreements with The Baylor College of Medicine (&#8220;BCM&#8221;)</i><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November&#160; 2018, January 2020 and February 2020, the Company entered in Sponsored Research Agreements with BCM, which provided for the conduct of research for the Company by credentialed personnel at BCM&#8217;s Center for Cell and Gene Therapy. On April 1, 2025, the Company sighed Amendment #1 to the Sponsored Research and Product Development Agreement with BCM to perform research on &#8220;Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T-Cell Product Strategy.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2019, May 2020 and July 2021, the Company entered into Clinical Supply Agreements with BCM, which provided for BCM to provide to the Company multi tumor antigen specific products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2019, the Company entered in a Workforce Grant Agreement with BCM, which provided for BCM to provide to the Company manpower costs of projects for manufacturing, quality control testing and validation run activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2020, the Company entered in a Clinical Trial Agreement with BCM, which provided for BCM to provide to the Company investigator-initiated research studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has also entered into a Clinical Site Agreement and Laboratory Service Agreement with BCM, pursuant to which BCM conducts clinical trials for the Company and testing of Marker&#8217;s product candidates to develop an optimized potency assay.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">BCM is also a shareholder of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the years ended December 31, 2025 and 2024, the Company incurred $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineMember_ip2nTF_Fk0CYXX-yEMZW9Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="6" id="Narr_YM0F_sNkiUqhR9fFseD2Yw">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineMember_-usF9LGyt0GIxeKFzPNwug" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="0" id="Narr_6Z035kpvtEGOAvT76251Ow">7,000</ix:nonFraction> in expenses related to services and manufacturing costs and paid BCM approximately $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineMember_ip2nTF_Fk0CYXX-yEMZW9Q" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:InvoicesReceivedForServicesAndManufacturingCosts" scale="6" id="Narr_az-t6fEtVUGb7vIc7nTMGQ">3.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineMember_-usF9LGyt0GIxeKFzPNwug" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:InvoicesReceivedForServicesAndManufacturingCosts" scale="6" id="Narr_qXupcb4gj0KFWgS59XBJEA">0.1</ix:nonFraction> million for invoices received, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchases from Wilson Wolf</i><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In 2025, the Company utilized Wilson Wolf for the purchases of cell culture devices. Mr. John Wilson is a former director of the Company and is serving as the CEO of Wilson Wolf Manufacturing Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the years ended December 31, 2025 and 2024, the Company incurred approximately $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_WilsonWolfManufacturingCorporationMember_SnKdFpBTG0ewLmW3QKOiwA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="6" id="Narr_4QC5R65SWkmDJrZGyYSGjQ">0.1</ix:nonFraction> million and <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mrkr_WilsonWolfManufacturingCorporationMember_88XPTdVeZEeIbHu_8g-p9A" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="6" id="Narr_g2dY_kuybEKii6dHHRl8ew">nil</ix:nonFraction>, respectively, in expenses related to cell culture devices and paid Wilson Wolf approximately $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_WilsonWolfManufacturingCorporationMember_SnKdFpBTG0ewLmW3QKOiwA" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:InvoicesReceivedForServicesAndManufacturingCosts" scale="6" id="Narr_Lff3FCrPAEedL0Xgal8xNQ">0.1</ix:nonFraction> million and <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mrkr_WilsonWolfManufacturingCorporationMember_88XPTdVeZEeIbHu_8g-p9A" decimals="-5" format="ixt-sec:numwordsen" name="mrkr:InvoicesReceivedForServicesAndManufacturingCosts" scale="6" id="Narr_-LAVEXBfQ0KN0OnK9Z4eqQ">nil</ix:nonFraction> respectively, for invoices received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchases from Cell Ready, LLC.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has utilized Cell Ready, LLC for clinical manufacturing supply and product development. Cell Ready, which is owned by a former director, Mr. John Wilson, is a contract development and manufacturing organization (&#8220;CDMO&#8221;). On February 22, 2024, the Company entered into a <ix:nonNumeric contextRef="Duration_2_22_2024_To_2_22_2024_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_66lUgXxPyUi3q214hjo-SQ" format="ixt-sec:durwordsen" name="mrkr:MasterServicesAgreementTerm" id="Narr_bMbIwE3oEUyiyz1wthRLiw">3-year</ix:nonNumeric> Master Services Agreement for Product Supply (the &#8220;MSA&#8221;) with Cell Ready. During the years ended December 31, 2025 and 2024, the Company incurred $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_zGmyKdpTO0WFcYUPxTzPtA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="6" id="Narr_yAFXd2PtQ0q744Cj3JIYfQ">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_c3M_pD1k30WAzZa10zvfBQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="6" id="Narr_83_qcav76keDMivcT9FL6w">5.8</ix:nonFraction> million in expenses related to services and manufacturing costs, respectively, and paid $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_zGmyKdpTO0WFcYUPxTzPtA" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:InvoicesReceivedForServicesAndManufacturingCosts" scale="6" id="Narr_-9zKnJZzxUOGelbTSbwgvw">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_c3M_pD1k30WAzZa10zvfBQ" decimals="-5" format="ixt:num-dot-decimal" name="mrkr:InvoicesReceivedForServicesAndManufacturingCosts" scale="6" id="Narr_RwG-wgYVsECANdZjVp6Baw">5.5</ix:nonFraction> million for invoices received, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On March 27, 2025, the Company mutually agreed with Cell Ready to terminate the MSA. In connection therewith, the Company entered into a settlement and release agreement with Cell Ready pursuant to which the Company paid Cell Ready approximately $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_3_27_2025_To_3_27_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_CellReadyAgreementMember_JD_kClq_cE2FGVMW6U031Q" decimals="0" format="ixt:num-dot-decimal" name="mrkr:GainLossOnEarlyTerminationOfVendorAgreement" scale="0" id="Narr_X6PlNOYbjku3iaP5r2ghcw">453,000</ix:nonFraction> and the parties provided one another with mutual releases of all claims associated with any and all agreements between the Company and Cell Ready.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_wmeUJiu0O0uzhUECRFjxtg" continuedAt="Tb_wmeUJiu0O0uzhUECRFjxtg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;12:&#160;&#160;&#160;&#160;INCOME TAXES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="0" id="Narr_AxfM-SKCGESuBcrI89d3uA"><ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="0" id="Narr_zXg6vz7PAUiqqbI2Gc4cDw">no</ix:nonFraction></ix:nonFraction> federal income tax expense due to operating losses incurred for the years ended December 31, 2025, and 2024, respectively. The Company recognized ($<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" sign="-" scale="0" id="Narr_CPAw3LC7mEWWGEJ541xKww">15,156</ix:nonFraction>) and $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" id="Narr_2TYrSoMybUiArZKBTUCzTg">49,953</ix:nonFraction> in state tax (benefit) expense for the years ended December 31, 2025 and 2024, respectively.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_E11xjLMw-kCN2DUqrNX-WA_1_2"></a><a id="Tc_BbfZkdXJd0qdlFa1A5XE6Q_2_2"></a><a id="Tc_ejYDTGhzSUKSFfoeFGTdnw_3_2"></a><a id="Tc_Y1Vt_zs-dEODdz6DOG5DTQ_3_5"></a><a id="Tc__dDr0vraaECwmHuUGlXGjA_4_0"></a><a id="Tc_fY_JZX5wjUiR0eIyrRMd8w_5_0"></a><a id="Tc_KIuwiVdHDEaO24NlUyd3xA_5_2"></a><a id="Tc_UvqFuAUJ7EKdo6IvHId4zw_5_5"></a><a id="Tc_65Vd_Yw61E29N6Gfm07xhQ_6_0"></a><a id="Tc_OENQz4YKekC2YcbuYTt43w_7_0"></a><a id="Tc_L2MbiPA0P0eKqDZrox-Ysw_8_0"></a><a id="Tc_1Mre-vwr30m3PAAYmqgEOw_8_6"></a><a id="Tc_I9X8-k4_Ak69psX5hVWQaA_9_0"></a><a id="Tc_pq-4teqt-Uq0WGwfGbJPxw_9_6"></a><a id="Tc_9_o84VdEx06xkphPTlvTWg_10_0"></a><a id="Tc_VYJ0lsK9iE6hrholNulKrQ_12_0"></a><a id="Tc_UkYbeWbt4kyiMa6_JdhkAQ_13_0"></a><a id="Tc_9f5JCAlrkUSSEI2iLWFFzg_13_2"></a><a id="Tc_6Z2ASaFCkEGlh0Cullc-tA_13_3"></a><a id="Tc_5q0xumbLmkuEKF5tY7f6hw_13_5"></a><a id="Tc_xP7iUtYr90G5AoKMTbnkZA_13_6"></a><a id="Tc_9fn4TIRhZUencSy6bHatMw_15_0"></a><a id="Tc_bO7EnqUC-0uuIMhkTAoOjw_15_2"></a><a id="Tc_Vms90S7LEU68W5yht7qqPQ_15_3"></a><a id="Tc_OdTPkVOIUUW95_8PSKDBHw_15_5"></a><a id="Tc_5QsL-JxAtEy23t2X3UOA9g_15_6"></a><a id="Tc_LQVIRNLHFUy5KtJS-uJdHw_17_0"></a><a id="Tc_c9aUR7SBhkux6vZJug-FDA_17_2"></a><a id="Tc_86-0Cb-hpUmN5sgMc7sQrg_17_3"></a><a id="Tc_Im1hKJEcnkSPTN-w6UN7vA_17_5"></a><a id="Tc_1vChfyxcGEGvt0AmMAi1Zw_17_6"></a><ix:continuation id="Tb_wmeUJiu0O0uzhUECRFjxtg_cont1" continuedAt="Tb_wmeUJiu0O0uzhUECRFjxtg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The effects of temporary differences that give rise to significant portions of the deferred tax assets as of December 31, 2025 and 2024 are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_tX6gvHw7s0WjMSuTFXzNmg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended </b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred Tax Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net Operating Loss Carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_yQPQ5yTROEWEcSY2q-4ryw_5_3">40,896,185</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_hrQ-8x1Cu0eLsPfuZlhtUA_5_6">30,724,771</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock Compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="mrkr:DeferredTaxStockBasedCompensation" scale="0" id="Tc_vX2wr9O1g0CMJfqYb_OQFg_6_3">1,548,803</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="mrkr:DeferredTaxStockBasedCompensation" scale="0" id="Tc_KwzotfrTb0i3pkJDMB6K_Q_6_6">1,670,477</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized R&amp;E</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="0" id="Tc_au2XIrkIrECuYwlJysakcg_7_3">29,777</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="0" id="Tc_xGPFqoAhDU6qHElTB7TNUg_7_6">7,868,640</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" scale="0" id="Tc_LmY2x5fVdUGbJW_A7z4e1Q_8_3">18,072</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="0" id="Tc_3JXnmvl16ESZwWHevWgCKQ_9_3">21,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_EwKAxqToF0OnH1tMUMVhKw_10_3">811,961</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_aL4w5-NAMUuYOlOh6eTpNw_10_6">733,328</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_23PAEXaYJkupbbMgUXD6gQ_11_3">43,325,798</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_qW7KQSkeikCfa-MdpW_sRA_11_6">40,997,216</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Valuation Allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_oSRz5vcgOUWvwI9e__LefA_12_3">43,325,798</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_oO2mRTCrSUWOPM18u8c--w_12_6">40,997,216</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Deferred Tax Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Deferred Tax Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Deferred Tax Assets/(Liabilities)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the history of losses, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized and has established a full valuation allowance for the years ended December 31, 2025 and 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Company has approximately $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="6" id="Narr_BPX9IOX_NkGYtVJgrgVi_w">186.8</ix:nonFraction> million of federal and $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="Narr_mPc0xG4F4EWBY9o-ohSPgg">38.6</ix:nonFraction> million of state Net Operating Losses (&#8220;NOL&#8221;s) that may be available to offset future taxable income, if any. The federal net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="6" id="Narr_TMOSOvMCLUG_j7NW3admQg">38.4</ix:nonFraction> million, if not utilized, will expire between <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="mrkr:TaxCreditCarryforwardsExpirationPeriod" id="Narr_C8Y2A7owIk2faRvV8W-FhA">2030</ix:nonNumeric> and <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="mrkr:TaxCreditCarryForwardExpirationYearRangeEnd" id="Narr_t2k6JS1EZEaW0Br8gmFAnQ">2037</ix:nonNumeric>. The federal net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_18qBhBV9dU2bbek_wtQbrg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_h_OckOZ5VUC0GBe07cupiw">148.4</ix:nonFraction> million generated in 2018 and thereafter are subject to an <ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_at2LqTEclEeq_pEAvIINhA" decimals="2" format="ixt:num-dot-decimal" name="mrkr:OperatingLossCarryforwardsLimitationPercentage" scale="-2" id="Narr_fOFlYKK9EkWjqHjraFYWLQ">80</ix:nonFraction>% limitation on taxable income, do not expire and will carry forward indefinitely. The state net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="Narr_wbZRJ19bski-mmaf_s1MFg">21.9</ix:nonFraction> million, if not utilized, will begin to expire in 2035. The state net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ESA9zEAYIUOC4PrJsuQIKw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_Qhp-9FylO0mK4JvtR-9utg">16.7</ix:nonFraction> million generated in 2018 and thereafter are subject to an <ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_FwxvILLeMU2KaVIewcISUw" decimals="2" format="ixt:num-dot-decimal" name="mrkr:OperatingLossCarryforwardsLimitationPercentage" scale="-2" id="Narr_JyQwVY8mQECpLphNpzZeDg">80</ix:nonFraction>% limitation on taxable income, do not expire and will carry forward indefinitely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has federal and state research and development tax credit carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember__a5PjJFdNkGHBThsnBK4rA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_Q_qESbvC20S1CGR0dW8aCg">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_jAeiudl5qEe8J-4VzRHRzg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_w_nawXy6Z0mB9d3dPmh6hw">0.1</ix:nonFraction> million, respectively, available to offset future federal income taxes. The research and development tax credit carryforwards begin to expire in 2030.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">In accordance with Section&#160;382 of the Internal Revenue code, the usage of the Company&#8217;s net operating loss carryforwards may be limited in the event of a change in ownership. A full Section&#160;382 analysis has not been prepared and NOLs could be subject to limitation under Section&#160;382.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was signed into law. Key corporate tax provisions include the restoration of 100% bonus depreciation, immediate expensing for domestic research and experimental expenditures, changes to Section 163(j) interest limitations, updates to Global Intangible Low-Taxed Income and Foreign-Derived Intangible Income rules, amendments to energy credits, and expanded Section 162(m) aggregation requirements. In accordance with Accounting Standards Codification 740, Income Taxes (&#8220;ASC 740&#8221;), the effects of the new tax law were recognized in the period of enactment. Due to the Company&#8217;s valuation allowance position, the provisions of the OBBBA did not have an impact on the Company&#8217;s income tax provision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Company&#8217;s income tax returns for 2022 to 2024 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_wblpzNmgf0asgGdZ2FF20A_1_2"></a><a id="Tc_BzuQDIy3NU-hKNE9Ni0uBw_2_2"></a><a id="Tc_tKdC4I-epEOTe7njfeljWQ_2_7"></a><a id="Tc_kSs1TfAk9UerfwHWjeC3xQ_3_5"></a><a id="Tc_b-YkCjfPRk6H5x5sFqn40g_3_10"></a><a id="Tc_v8MaWMXwTkGRPuR1UFyZ1g_4_2"></a><a id="Tc_I_M88b4hJkKxKmoifHEeAg_4_5"></a><a id="Tc_y3sJZ84RiEe5zAX36IuFAA_4_7"></a><a id="Tc_wzHayc1gxUux54QQT0z29Q_4_10"></a><a id="Tc_wXAa3AG0M0uG4TLoX5WUQw_5_0"></a><a id="Tc_eH8jCZLYsku96-FfDCZ67w_5_2"></a><a id="Tc_hcELOIYhLkmyi_kiKmjpYQ_5_6"></a><a id="Tc_bsCqcEl3S0mcCb7-gFPwIQ_5_7"></a><a id="Tc_QY-gUHEfak-0e5UqNe2u8A_5_11"></a><a id="Tc_095V363qwUufspI54aQ6mg_6_0"></a><a id="Tc_S0XChSvv8UGd85AOcxyeVw_6_6"></a><a id="Tc_pl4hDe-gaEqLFyzOwsXNPw_6_11"></a><a id="Tc_FmJPZ6QNoUuEMd0P_Fanig_7_0"></a><a id="Tc_GH-ZtzA6206HBRBRjxTS3A_7_6"></a><a id="Tc_B04nbDoTpk-2jjXJwXvwWA_7_11"></a><a id="Tc_0UlTTAgWJkyO6oI1UJ4mjQ_8_0"></a><a id="Tc_YJ08xZBYO0WcP8lmRP9ozA_8_6"></a><a id="Tc_CCdywKfdu0qUU89EJjNDDw_8_11"></a><a id="Tc_R_HeWghMhUK7uilzu2OigA_9_0"></a><a id="Tc_c_88XX3UUkW01IDneVQA5w_10_0"></a><a id="Tc_MjvMXRAWakGkbV-NfMYMCg_10_6"></a><a id="Tc_4KIQ08x5SU20M6W9D3U-iw_10_11"></a><a id="Tc_rPlPJqBCCkexhKeAhScNsA_11_0"></a><a id="Tc_0OsFuN6hO0uoqdJRAJ-f7w_11_2"></a><a id="Tc_Jsh_n54eEEOzu__CLssPPg_11_6"></a><a id="Tc_lHwUjYs6nU6WHBml8FFTtA_11_7"></a><a id="Tc_yEKoLa2bSku_b2F9JVYX7w_11_11"></a><a id="Tc_zQ0pd92EBU-xOi0dwtl2SA_1_2"></a><a id="Tc_DtiFxqAgCkaL2HOmcRnZsA_2_2"></a><a id="Tc_S2m67AG1oEWCbyyQ2Vx9_A_3_2"></a><a id="Tc_k9B9nBrwy0uZfd-ot_rttQ_3_5"></a><a id="Tc__yUXaGUIWESXFQW2ddDtuQ_4_2"></a><a id="Tc_13c6OrBoJky9i5IzMh8gVA_4_5"></a><a id="Tc_jZC6VoLS7km6XTbPQbOjgA_5_2"></a><a id="Tc_DIJzjMPFfUeCIkWPOxb0yQ_5_5"></a><a id="Tc_rl8xP2nFRkGVpdafN_jrJg_6_0"></a><a id="Tc_sn8N2k8PUUqfg6ZPJ4zNKQ_7_0"></a><a id="Tc_jdiKTGKRkk6Y5tyztla0Iw_7_2"></a><a id="Tc_RC50-I8pFkakPKIYrpGnaw_7_3"></a><a id="Tc_SZqveP0RlEO0Yztms3WRZw_7_5"></a><a id="Tc_8p_YDI2Ab0SYpyzdZGpvCw_7_6"></a><a id="Tc_uF9vzxOeRkiU2jda-hwcRQ_8_0"></a><a id="Tc_SI3jVIyhVE6utwBZLfgZLA_9_0"></a><a id="Tc_2E-YV3bfxEanubipdPKVfA_10_0"></a><a id="Tc_n92RcAfHy0uAMnhzQD8c3Q_10_2"></a><a id="Tc_4oiI9u9z50yf4BoielJFaA_10_5"></a><ix:continuation id="Tb_wmeUJiu0O0uzhUECRFjxtg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the years ended December 31, 2025, and 2024, the expected tax (benefit) expense based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_3epxXl08pE2GjPeG6cNeQQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:43.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pretax Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pretax Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_jVqAs_8wWU2rKECzfRfrog_5_3">2,557,543</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_rjvCUaRBVkCr-oYRaDukZw_5_5">21.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_XdFCwprrH0iFSitUCqvI4w_5_8">2,243,086</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_IpsPGI_wu0-oA1B5C2hchA_5_10">21.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" sign="-" scale="0" id="Tc_4I1XiwFDfkCGWjGzQ9O3hQ_6_3">15,156</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_W6Zb36M_MEesUcVHWcsUfQ_6_5">0.10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" id="Tc_ESYHQBbuOEKyZkvoDPD8Lw_6_8">49,953</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" sign="-" scale="-2" id="Tc_RzLcm1miNkGBI8dtcqqiBw_6_10">0.50</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="Tc_xqQxiitbE0KmloMdz0aXLg_7_3">2,336,604</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_5GigfI-FUUCkPehh7xQ0-g_7_5">19.30</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="Tc_xiouXU5E7EKVRJuyanWY5A_7_8">1,271,570</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_WqNXy38dckevoh1F8xbo5w_7_10">11.90</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nontaxable or nondeductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" scale="0" id="Tc_pLX2jGp2FEi73L4nN8bdTA_8_3">90,207</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" sign="-" scale="-2" id="Tc_OxVDNzUzhkWKxVx18QpcoQ_8_5">0.70</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" scale="0" id="Tc_P3PY2d9HhkqMVsocV9V_fw_8_8">27,712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" sign="-" scale="-2" id="Tc_4n_ZTpw9YUqbZgPdfm3HrA_8_10">0.30</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">SBC cancellations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="0" id="Tc_kuwGx6MhTU2CZomSJ9EP6A_10_3">130,732</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" sign="-" scale="-2" id="Tc_Avo_OOunyUGxNUcMQfdMgQ_10_5">1.10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="0" id="Tc_YMsqNcF3vEOSlIDayq6qNQ_10_8">943,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" sign="-" scale="-2" id="Tc_YaetVGJTkkSmRmQ92WRRfQ_10_10">8.77</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision/(benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_KbJiq_X3XUCK22tfxDcLwg_11_3">15,156</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_7ICJ-t6tFUKTE5rYDf3CLw_11_5">0.00</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_NxBZQqcNbUeMS2w4zHW-Ag_11_8">49,953</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Tc_rI_MMROxGE2XoSzSsymgyQ_11_10">0.47</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognized approximately $<ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" sign="-" scale="0" id="Narr_xvVtk5BsqECWotnKZGPPEA">15,156</ix:nonFraction> in state tax benefit for the year ended December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, the Company updated the presentation of its effective tax rate reconciliation to reflect the standardized categories required by the new guidance. The effective tax rate reconciliation for the year ended December 31, 2024 has been recast for comparative purposes to conform to the current-year presentation. The recast was solely for presentation purposes and did not result in any changes to the Company&#8217;s previously reported income tax expense, effective tax rate, or other financial statement amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. As of December 31, 2025, and 2024, there were <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_bjA_Hq3sA0awSDBePBYiiQ"><ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_skacmqmp4EKiN3Ca5EE49g">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits. The Company recognizes accrued interest and penalties as income tax expense. <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" id="Narr_KufL0WNZY0q4SqAxlWTyAg"><ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" id="Narr_cM6H-WcG9UGMB1hiFR8JwQ">No</ix:nonFraction></ix:nonFraction> amounts were accrued for the payment of interest and penalties at December 31, 2025 and 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position in the next year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth a summary of income tax payments made and income tax refunds received during the year ended December 31, 2025, and 2024 as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="mrkr:IncomeTaxPaymentsByJurisdictionTableTextBlock" id="Tb_IbgbJtLgSkCHlERBkyDvvA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.12%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payment (Refund)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payment (Refund)</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Amount</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Jurisdiction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Texas</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_stpr_TX_Rjqllw7i7k-FAGtEiFvgPQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="0" id="Tc_U2VzoHSKeEmWogR3_FO6Uw_8_3">37,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_stpr_TX_B-Dm5j-e00KX7oWR9bXJxw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="0" id="Tc_yqUfMWmTtEG0dxHL6OHlHg_8_6">64,000</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other US States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalTaxJurisdictionOtherMember_X-zB0CIm-UCdX3pra_QnCw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="0" id="Tc_pnYjz01yoEym0IrlYLA06A_9_3">5,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalTaxJurisdictionOtherMember_RP8A9ma7LU69CXCfisa1tw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="0" id="Tc_KN-akuz9cUKJOKqBDFHkRg_9_6">8,150</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Income Taxes Paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" id="Tc_9HU9Wo2oaEylFzWbeqXrJw_10_3">42,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A" contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" id="Tc_Y05CidBVLkqEPYLVaPrrNQ_10_6">72,150</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="endoffinancial"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw" name="us-gaap:SubsequentEventsTextBlock" id="Tb_RgSF50x5kkmFYJl-ntxc8A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">NOTE 13:&#160;&#160;&#160;&#160;SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has evaluated subsequent events and transactions that occurred up to the date these consolidated financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment to or disclosure in the unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-14.1
<SEQUENCE>2
<FILENAME>mrkr-20251231xex14d1.htm
<DESCRIPTION>EX-14.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/18/2026 08:29:20 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 14.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Marker Therapeutics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Code of Ethics and Business Conduct</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">1.&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Introduction</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">1.1&#160;&#160;The Board of Directors of Marker Therapeutics, Inc. (together with its subsidiaries, the &#8220;<b style="font-weight:bold;">Company</b>&#8221;) has adopted this Code of Ethics and Business Conduct (the &#8220;<b style="font-weight:bold;">Code</b>&#8221;) in order to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>promote full, fair, accurate, timely and understandable disclosure in reports and documents that the Company files with, or submits to, the Securities and Exchange Commission (the &#8220;<b style="font-weight:bold;">SEC</b>&#8221;) and in other public communications made by the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>promote compliance with applicable governmental laws, rules and regulations;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>promote the protection of Company assets, including corporate opportunities and confidential information;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>promote fair dealing practices;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>deter wrongdoing; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font>ensure accountability for adherence to the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">1.2&#160;&#160;All directors, officers and employees, are required to be familiar with the Code, comply with its provisions and report any suspected violations as described below in <b style="font-weight:bold;">Section 10</b>., Reporting and Enforcement. This Code should also be provided to and followed by the Company&#8217;s other agents and representatives, including consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2.&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Honest and Ethical Conduct</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2.1&#160;&#160;The Company&#8217;s policy is to promote high standards of integrity by conducting its affairs honestly and ethically.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">2.2&#160;&#160;Each director, officer and employee must act with integrity and observe the highest ethical standards of business conduct in his or her dealings with the Company&#8217;s customers, suppliers, partners, service providers, competitors, employees and anyone else with whom he or she has contact in the course of performing his or her job.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">3.&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conflicts of Interest</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.1&#160;&#160;A conflict of interest occurs when an individual&#8217;s private interest (or the interest of a member of his or her family) interferes, or even appears to interfere, with the interests of the Company as a whole. A conflict of interest can arise when an employee, officer or director (or a member of his or her family) takes actions or has interests that may make it difficult to perform his or her work for the Company objectively and effectively. Conflicts of interest also arise when an employee, officer or director (or a member of his or her family) receives improper personal benefits as a result of his or her position in the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.2&#160;&#160;Loans by the Company to, or guarantees by the Company of obligations of, employees or their family members are of special concern and could constitute improper personal benefits to the recipients of such loans or guarantees, depending on the facts and circumstances. Loans by the Company to, or guarantees by the Company of obligations of, any director or executive officer or their family members are expressly prohibited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.3&#160;&#160;Whether or not a conflict of interest exists or will exist can be unclear. Conflicts of interest should be avoided unless specifically authorized as described in <b style="font-weight:bold;">Section 3.4</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">3.4&#160;&#160;Persons other than directors and executive officers who have questions about a potential conflict of interest or who become aware of an actual or potential conflict should discuss the matter with, and seek a determination and prior authorization or approval from, their supervisor or the Chief Executive Officer. A supervisor may not authorize or approve conflict of interest matters or make determinations as to whether a problematic conflict of interest exists without first providing the Chief Executive Officer with a written description of the activity and seeking the Chief Executive Officer&#8217;s written approval. If the Chief Executive Officer is himself involved in the potential or actual conflict, the matter should instead be discussed directly with the Chairman of the Audit Committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Directors and executive officers must seek determinations and prior authorizations or approvals of potential conflicts of interest exclusively from the Audit Committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">4.&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">4.1&#160;&#160;Employees, officers and directors should comply, both in letter and spirit, with all applicable laws, rules and regulations in the cities, states and countries in which the Company operates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">4.2&#160;&#160;Although not all employees, officers or directors are expected to know the details of all applicable laws, rules and regulations, it is important to know enough to determine when to seek advice from appropriate personnel. Questions about compliance should be addressed to the Chief Executive Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">4.3&#160;&#160;No director, officer or employee may purchase or sell any Company securities while in possession of material non-public information regarding the Company, nor may any director, officer or employee purchase or sell another company&#8217;s securities while in possession of material non-public information regarding that company. It is against Company policies and illegal for any director, officer or employee to use material non-public information regarding the Company or any other company to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:43.2pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:25.2pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>obtain profit for himself or herself; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:43.2pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:25.2pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>directly or indirectly &#8220;tip&#8221; others who might make an investment decision on the basis of that information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">5.&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5.1&#160;&#160;The Company&#8217;s periodic reports and other documents filed with the SEC, including all financial statements and other financial information, must comply with applicable federal securities laws and SEC rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5.2&#160;&#160;Each director, officer and employee who contributes in any way to the preparation or verification of the Company&#8217;s financial statements and other financial information must ensure that the Company&#8217;s books, records and accounts are accurately maintained. Each director, officer and employee must cooperate fully with the Company&#8217;s accounting and internal audit departments, as well as the Company&#8217;s independent public accountants and counsel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5.3&#160;&#160;Each director, officer and employee who is involved in the Company&#8217;s disclosure process must:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:43.2pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:25.2pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>be familiar with and comply with the Company&#8217;s disclosure controls and procedures and its internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:43.2pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:25.2pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>take all necessary steps to ensure that all filings with the SEC and all other public communications about the financial and business condition of the Company provide full, fair, accurate, timely and understandable disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">6.&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protection and Proper Use of Company Assets</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6.1&#160;&#160;All directors, officers and employees should protect the Company&#8217;s assets and ensure their efficient use. Theft, carelessness and waste have a direct impact on the Company&#8217;s profitability and are prohibited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6.2&#160;&#160;All Company assets should be used only for legitimate business purposes. Any suspected incident of fraud or theft should be reported for investigation immediately.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:14.4pt;margin:0pt 0pt 12pt 0pt;">6.3&#160;&#160;The obligation to protect Company assets includes the Company&#8217;s proprietary information. Proprietary information includes intellectual property such as trade secrets, patents, trademarks, and copyrights, as well as business and marketing plans, engineering and manufacturing ideas, designs, databases, records and any non-public financial data or reports. Unauthorized use or distribution of this information is prohibited and could also be illegal and result in civil or criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">7.&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Corporate Opportunities</u>. All directors, officers and employees owe a duty to the Company to advance its interests when the opportunity arises. Directors, officers and employees are prohibited from taking for themselves personally (or for the benefit of friends or family members) opportunities that are discovered through the use of Company assets, property, information or position. Directors, officers and employees may not use Company assets, property, information or position for personal gain (including gain of friends or family members). In addition, no director, officer or employee may compete with the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">8.&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</u>. Directors, officers and employees should maintain the confidentiality of information entrusted to them by the Company or by its customers, suppliers or partners, except when disclosure is expressly authorized or is required or permitted by law. Confidential information includes all non-public information (regardless of its source) that might be of use to the Company&#8217;s competitors or harmful to the Company or its customers, suppliers or partners if disclosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">9.&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fair Dealing</u>. Each director, officer and employee must deal fairly with the Company&#8217;s customers, suppliers, partners, service providers, competitors, employees and anyone else with whom he or she has contact in the course of performing his or her job. No director, officer or employee may take unfair advantage of anyone through manipulation, concealment, abuse or privileged information, misrepresentation of facts or any other unfair dealing practice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">10.&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reporting and Enforcement</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">10.1&#160;&#160;Reporting and Investigation of Violations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Actions prohibited by this code involving directors or executive officers must be reported to the Audit Committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Actions prohibited by this code involving anyone other than a director or executive officer must be reported to person&#8217;s supervisor or the Chief Executive Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>After receiving a report of an alleged prohibited action, Chief Executive Officer (or the Audit Committee if the Chief Executive Officer is involved in the conflict) must promptly take all appropriate actions necessary to investigate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>All directors, officers and employees are expected to cooperate in any internal investigation of misconduct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">10.2&#160;Enforcement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>The Company must ensure prompt and consistent action against violations of this Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>If, after investigating a report of an alleged prohibited action by a director or executive officer, the Audit Committee determines that a violation of this Code has occurred, the Audit Committee will report such determination to the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>If, after investigating a report of an alleged prohibited action by any other person, the relevant supervisor or the Chief Executive Officer determines that a violation of this Code has occurred, the supervisor or the Chief Executive Officer will report such determination to the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>Upon receipt of a determination that there has been a violation of this Code, the Board of Directors will take such preventative or disciplinary action as it deems appropriate, including, but not limited to, reassignment, demotion, dismissal and, in the event of criminal conduct or other serious violations of the law, notification of appropriate governmental authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">10.3&#160;Waivers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Each of the Chief Executive Officer or Audit Committee (in the case of a violation by a director or executive officer) may, in its discretion, waive any violation of this Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:32.4pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Any waiver for a director or an executive officer shall be disclosed as required by the applicable rules of the SEC and any exchange on which the Company&#8217;s stock is listed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">10.4&#160;Prohibition on Retaliation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company does not tolerate acts of retaliation against any director, officer or employee who makes a good faith report of known or suspected acts of misconduct or other violations of this Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ACKNOWLEDGMENT OF RECEIPT AND REVIEW</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">[To be signed and returned to the Chief Executive Officer.]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">I,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, acknowledge that I have received and read a copy of the Marker Therapeutics, Inc. Code of Ethics and Business Conduct. I understand the contents of the Code and I agree to comply with the policies and procedures set out in the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">I understand that I should approach the Chief Executive Officer if I have any questions about the Code generally or any questions about reporting a suspected conflict of interest or other violation of the Code.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[NAME]</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[PRINTED NAME]</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[DATE]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>mrkr-20251231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/18/2026 08:29:20 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SUBSIDIARIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Marker Cell Therapy, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">GeneMax Pharmaceuticals, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GeneMax Pharmaceuticals Canada, Inc.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>mrkr-20251231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/18/2026 08:29:20 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">We consent to the incorporation by reference in the Registration Statements on Form S-3 (File No. 333-228059, No. 333-283512, and No. 333-284233) and on Form S-8 (No. 333-239136 and No. 333-266797) of our report dated March 31, 2025, with respect to the consolidated financial statements of Marker Therapeutics, Inc. as of December 31, 2024 and for the year then ended included in this Annual Report on Form 10-K for the year ended December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">/s/ MARCUM LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Houston, TX</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 18, 2026</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>mrkr-20251231xex23d2.htm
<DESCRIPTION>EX-23.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/18/2026 08:29:20 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Exhibit 23.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">We consent to the incorporation by reference in the Registration Statements on Form S-3 (File No. 333-228059, No. 333-283512, and No. 333-284233) and on Form S-8 (No. 333-239136 and No. 333-266797) of our report dated March 18, 2026, with respect to the consolidated financial statements of Marker Therapeutics, Inc. as of December 31, 2025 and for the year then ended included in this Annual Report on Form 10-K for the year ended December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">/s/ CBIZ CPAs P.C.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Houston, TX</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 18, 2026</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>mrkr-20251231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/18/2026 08:29:28 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">I, Juan Vera, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>I have reviewed this Annual Report on Form 10-K of Marker Therapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a.</font></font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b.</font></font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">c.</font></font>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">d.</font></font>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font>The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the Audit Committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a.</font></font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b.</font></font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;">Date: March 18, 2026</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style=""><td colspan="2" style="vertical-align:bottom;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/ Juan Vera</i></p></td><td style="vertical-align:bottom;width:55.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:39.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Juan Vera</b></p></td><td style="vertical-align:bottom;width:55.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:39.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Treasurer</p></td><td style="vertical-align:bottom;width:55.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:39.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td><td style="vertical-align:bottom;width:55.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>mrkr-20251231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/18/2026 08:29:28 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">I, Juan Vera, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>I have reviewed this Annual Report on Form 10-K of Marker Therapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a.</font></font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b.</font></font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">c.</font></font>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">d.</font></font>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font>The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the Audit Committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a.</font></font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b.</font></font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 18, 2026</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style=""><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/ Juan Vera</i></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Juan Vera</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Treasurer</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>mrkr-20251231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/18/2026 08:29:28 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">18 U.S.C. Section 1350,</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report of Marker Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Juan Vera, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 18, 2026</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style=""><td style="vertical-align:bottom;width:47.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/ Juan Vera</i></p></td><td style="vertical-align:top;width:52.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Juan Vera</b></p></td><td style="vertical-align:top;width:52.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Chief Executive Officer</p></td><td style="vertical-align:top;width:52.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>mrkr-20251231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/18/2026 08:29:28 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">18 U.S.C. Section 1350,</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report of Marker Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Juan Vera, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 18, 2026</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style=""><td style="vertical-align:bottom;width:47.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/ Juan Vera</i></p></td><td style="vertical-align:top;width:52.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Juan Vera</b></p></td><td style="vertical-align:top;width:52.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:bottom;width:47.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Principal Financial Officer</p></td><td style="vertical-align:top;width:52.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>mrkr-20251231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20251231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !? 60# 2(  A$! Q$!_\0
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MI+V/3X3-<.HX51_6JG@OQIJ_PZ\4VFN:1.]K?V4N2HXW 'E37W1_P34MXI?
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MK7@O6;3Q/X2\*^&WT.*57#28SOSD<FOST^*W@R_^'OQ#UO1=1@:"6.Y=D+#
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MNH:K=Q6-E%]^:9MJK]37D5\=B<5BGBYR_>-WNNYZ%+"TZ=)8>$?=VL?#<O\
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.5PGF!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>mrkr-20251231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20251231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "F JH# 2(  A$! Q$!_\0
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M1V;_  /4)?\ @I#\++>V@N)=.\4Q6\^3#,^FH$EQUVDRX./:H?\ AY?\(O\
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MPWG]X?V!@_/[_P#@'Z;_ /#Q7X5?\^_B#_P"C_\ CM'_  \5^%7_ #[^(/\
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M,NG33))# \KAHS& ,*#@$.>3Z"OF31;W5/#T[Z_%"PU224-;!\*#\X,C'<.
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M7[UB_;/<4?;/<5/*3<VOM?O1]K]ZQ?MGN*/MGN*.4+GB7[>UQYG[.&HKG/\
MQ-+'_P!&&OS/K]'OVZ+CS/V>+]<_\Q.R_P#0S7YPU]GE"MAWZO\ 0\7&?Q/D
M%%%%>T<1J^%_"^I^,]=M=&T>V%WJ5T2(83(J;B 2?F8@#@'J:Z3X@_!#QO\
M"NP@O?%>AMH]O.XCC:2>)RS$9'RJQ."!UQBN&;.#@D'U!P:^L[SQAX4\2?M%
MP:NGBG3K:UM?!=I#:75R$:&2^CM54P;Y598GSN_>%3@C@'-<E:I4IR7*KJS>
MSZ6Z_/L:PC&2UW/DO>O'(YHW G&1FOL7XP?%;P5HOA[QW?>#KGP]+K&K-HZQ
MM;6T4S[?LS)?&(M& I+<%@JGG.!7<>*M/\,:?X5\5ZEK-II)\"6K>'VL-*71
MS;WNGVIDC\^.1FC4DOAB0&8L,D<5S?76DFX-7_X'EY_@S7V";:4OZU_R/A#1
MM&O_ !'?K9:79S:A>,K.(+==S;5!9CCT !)/M4FK>'[_ $.RTF[OH!!;ZK;?
M:[-]ZMYL6XKNP#QRI&#@\5]S)\7?!6A?%?0)=/UGPO9/=)J\$6L6KQND-I+"
M1:13[856- X7"G++R&.#7F\/Q"\)^'?A\9H;_0+KQ9:> I+='-M',#JHU)WR
MJLNTOL.X<?=Q]*(XNI)K]WO;]?\ ('1BOM?UH?)^]< Y&#6GX;\.ZEXOUVPT
M71K5[_5+^406UM&1NE<]%&>*^UK&]\-^,-6\6ZAX-DT*VU:ZD\//=ZK+I'VB
MSDC:%1>6ZA8F5)'DSE<#=V/%>3ZOJ6B^#/V\;F\FEM='T/3O$Y9Y$4)#;HO!
MX'W0#V[5<<6Y\R4;-*_X+_,ETE&SOI<\H/P/\="3Q:A\-W0;PFN_6\E?]"&T
MMEN>?E!/&>*X>)3-(D:?,[L$4#N2< 5]W^)_C]X'U/X;>+4L]<M4USQAX7U"
M36$9CN>^BA2VMDSC[TBAGQ[UPFHZI\/&\+:OK\&N>'0^H>!+#3;32U7%Y%J,
M4L7G,4VX1L*WS9RV?K6=/%U7_$AY=?G^-_D7*C'[,CYVO_A1XNTO6'TN[T&Z
MMKQ+Z/3&$@ 1;IU#)$7SMW$$'KTKF=1LY=)O[FRNU$5S;2M#+'N!VNIP1D<'
MD=J^Y_$/QD\+>(I]5M$\5:(VD0?$*QU2XAN@O^DV!BB5VCRN6PZG/< 'M3[#
M4/".C>%/"^M7]_X5L_!U]=^(7U6VO;-'N=5M//D$"VYV$MABF I4C@]*F.-J
M))SA^?:_]+\1NA%_#(^)?$7A75O"8TTZO9/8C4K1+^T\PC]] ^=KC'8X-9-?
M;/A+XB_#R[73(_[4TA?$,/A'2;*QN=2E1(K<QSN;J R21NJOL*YRO(R 037R
MC\6+_1]4^)GB:[\/V]K::--?2/:PV);R%3/_ "SW '83DC('6NNA7E5DXRC:
MW]?U\S&=-15TSE****[#$[_X"_\ )7_"/_84M?\ T<E?N/7X<? 7_DK_ (1_
M["EK_P"CDK]QZ^*S[^+#T/K\/_N%+UE^:/BG]B^7;^SQX?'_ $UN/_1AKV_S
MO>O!OV-I-O[/N@#_ *:W'_HPU[7YOO7LSA>39\HI%[SO>CSO>J/F^]'F^]1[
M,.8O>=[U%)J4$-S#;R3QI<3 F.)F 9P!DD#J0*P?%?BJR\'^'-0UG4)?*M+.
M(R,1U)[*/4DX ^M>8?!WX<ZQ'K\?Q \2:O<7FK:E9N%L+D9-HCL&50>@^0 $
M #DUT0P\94Y5)NR6WF^W^9R5,3*-6-*$;MZOR7?_ "._^*'A/PGXGT3[5XJ@
M"Q6(+PWT3M%<0,>/W;K\V2<#:,Y]*^<M-N%\/P1O+IZKJH5T$VK7TM[)#G(5
MXH@5$;;2#EB6!]*]?^,FLR1ZE86HYAM+.;40IZ-+N$:'_@.XFOE7XI:U>:3X
M8FNK:5TG:0!I >3G.>:X?;U_;PP.'=G-K>]M?(^FP&6TL;5I\T(N;:LVKV]'
M^)Z;JGCWQ'J?A2WT"YU;[99V\:HC36^UW*C"L[!MS'N<GFKG@OQ-9ZK96/A]
M_#DEQKUI:@/<F:6;S40<RD#''08'(],<U\=:;\0=;TO4(KL7LDH1LO$YRKCN
M#7T?HNNS[=*\1:++Y-]!MNK5_7CF-O\ 9894BNG'X3$Y9.%/&R4Z<[V:TM+^
MOP]#Z#-\CJ8&TGRIR^TEVZ/;^M4>Y>$[VRU8>+[2Y\.:1-J.K::=UQ]GW&8P
MX;8P)QDJI]#D U!K'C_3K#P)HNDZ/HMMH+QS2-%Y)W$ X#&)?X69@>>3@<&H
M4^,%KX\\.WE[8:#!IVM>1(_VTD2/9X=4#9&/WARW!SM&.N:M_#WP"?$6@1:-
MJ5HEMJ^F6I>Q\031$,BJI=HYV&=H(R03R/<&N3$1=-N%:HVDU[N^RMWMHK+T
MZ'PM)N3O1A&]G[VEM[].^KWMYF/\+-&NM4\1VVJKJ=I:#4K>1([2ZMS-)<VT
M<@,\F[/[I@P4#=SUXKLOBOKVB>%;5;72H+5=6GC,C7  9;>$C_6$],_W?SZ5
MQ>E3:)X7MH-3LXM/\2&<2)#<VQ(M%.<R*<89SD@E3@<@\YKEOB%\,[;2M$A2
M+5)TU+6+269=&SA;6'*[0Q]^BJ?NJ165?!9=C*R5>E:2LO>CV=]>NF[OH]4]
M-#TLHJ2HRBZM7XY+5?"E*R<G=].B2=^NSOYQ%\=+=]8CLI8)FT9&*)>RR%GR
M3RY!_A/YU['X6\4OX7U&TUVW5KD6@"RQ0D$W%LY 9!DX."59<]"#ZU\Q:7\/
M-4U2_:%(ML"MM:0D9^F.Q^M?1WPU\%-<16WAK^T$M[DVS;7E&2(P>2H/WR.F
M!T[XKZC'97@\NE2C@VO[R79[O3:^M_6Y^R<5Y/E.5UJ%3 U.:3TJ1NY7A;6<
MGJU=:>=URK0^I-)U&XO]-M[BZLWTZXD7<]K*ZNT1]"5R#^%3SE;B"2)^4D0H
MV..",&L?1$OK32K:'4KJ*\O47;)/#%Y:/Z87)QQCO5WS?>O&E37,['X;5DE4
MDHVM=[7M\KZV]=>Y@W_PWT;48]-C>2^BBL;>&U2."Y*K+'$P:-9./FPPSVZF
MG_\ "NM"^PK9F*=K=8H8=C3$Y2*1I$!_X$[9]1Q6WYOO1YOO2Y69<QBZ-\/=
M'T2\MKJ%[R>>U*BW:YN#)Y**I58EXX0!C@?K74>=[U1\WWH\WWH<+[AS%[SO
M>NVMGS\/96_V6_\ 0Z\[\WWKO;9_^+:2M_L-_P"AUYV,A94_\2.S#2NY^C.0
M\[WH\[WJCYOO1YOO7H>S./F+WG>]'G>]4?-]ZQ_&'B5?"OAG4=5*>:UM$6CC
M_ON2%1?Q8@4*G?0J+<FHK=C];^)GAOPWJ<NG:GJ\-G?1Q+.;>0'>R,2%*C'S
M=#P*XE/VC=-BU74HKC2M1.GQN@L[F&V8&92OS%E?&W#9 ]J\;\5:O<Q:G<--
M<&?4]N;R_/\ K'?&2B'^%!T"C%>&:E\=;>"\D2+3GG56(+M)R?TK##^WQLY0
MP-'GY=VW9?IV/JL%E$\6FJ,')I*^MO\ (^L?$7Q)_P"%HW5^=,NS8Z?X=DAO
M'TRZ@ N+U<'?,I/*K&&;(&<XKR#Q'I6\:CI[_==7C![$$<'\B*R?#OB%-?L+
M'7-'F-O=1-NAD(YC<<,C#NIZ$="#7<:'HE_\0---U80V*7?FR)#I(O5^U1QI
M@-N#8RH8_+W ('-<%:%3%KFIQY:E-V<?Z\_ZV&X?57_+R_>G_P /_6Q\K#X1
M>)I;UXELD2,,0)I)5"X]?6O8?A_X2D\&Z +&:X%Q*TAE<J,*I/85TMS!?6M]
M=V3V02[M)G@N(I)U'DLH!);V.1@]ZR;"YU#Q%8W<^F3VK?9[H0%8"'+J"-S!
MVXZ$XX[5ZF88O,\TIJCB>6$59_Y7U?Z'N8[-<9CZ7+524%;IIKM=ZVOT+TWB
M74O <-[?Z?>R6UEJ02WU*T0\W"9X9/1QTR.HR*\C\1>--4U?73>0W<]A% V+
M6"%MJQ(.F1W)[YKV63PIIEOJ,EMJ$KSS[TNK2\GFP[QYX [ @Y4@=>/6LS_A
M4.G:IXB!),HE;,5M$V&?U!4#) ]0>G6O<RBI@L-[F,O)I:.VZ_K:_IT/I>$\
MPRK+*]7^U(\TN7W7R\R::U26MVU;5]$T[;&]\-/$;>--'B:[AVRR9M;E0,*X
M(QN7ZYS[&OIWX/71G\#65Q)KD^N74RAYY9YED,3[0#&-H^4#'0\\UYMX8^$&
MI:3%ITL=C:K;"91<6,LABD,)X+ C."/[O4CCBO9]/TRPT<3+86=O9+*^^06\
M80.V,9('? %>;*,%S^S5HR=TM&U;O_70_.\UQ6$?MHX1<M.<^:,;I\J5]'U5
M[IZ=DKNVFQYWO6%X]FSX$\2C/_,,NO\ T4U7_-]ZP_'<O_%#>(_^P9<_^BFK
MG4-3Y7F/&M(;9\-/V36]!+_Z)->Z?:_>O!K-MGPL_91;T$O_ *)->O\ VSWK
MPZRO;_M[_P!*9]=B/]WP_P#A_P#;I&U]K]Z/M?O6+]L]Z/MGO7/RGGW-K[7[
MT?:_>L7[9[T?;/>CE"YM?:_>JNJ:];Z-IUQ>W4@CMX$+NW]![UG_ &SWKCM=
MF/BWQ3;Z/DMIEABYO?1W_@0_SKMPF&C7J?O':$5>3\E^KV7FT<&-Q$L/2_=J
M\Y.T5YOOY+5OR3+6@>%(O%&H1^*M:C>._EF6>UMPV!#&OW P[D]37,_&.XU#
M5;NVFO\ 2[Z"RL9V-@JQR1-,VW:TK..0A!("@C/4UW^MZ_%HNDW5[*LSQPIG
M;;1&1\]!M4<GDBO-[34+KQS8Z=-=^,;O1O*TY[BX@N3(QD$98N8U'&_@_*V*
M,;C*]5>VV2]V*_E79?(Z<OP<,%!NG\3?O2ZR?5OS?X+1%"S\-S:7\(=9U^[;
M3O#^FW-U"7NYP(PL*$GHH+L6<H .2<5'_P *YU3Q)+H6H)?6,-WHEJ)X=7N+
MI1:-8R_/')N/+#EEVCG#=.*](N_B-KOCWP;/\/\ 1OAQ+X@M9_#C7MMK.I(L
MMO+=(/E61=H4N" .N=P'&.:\_P# ^N^,+;X5:K;?$O0H;V[MQ]EM(+LB"ZMK
M1=I VQ_= DX3(R #Q@USQHU*=!XI3M/_ !)W37;[[WZ=#W*F$A6H-S]=R#2]
M:\/37^IKHRS:Y-89@ODFB:.S*NI# ?Q,A!(RQ7CM7>S7NAVWAGP#)IW@W1'T
MJVD>(V\MOYQMKE9-\A5B<X92& .>]><Z/X8T'0?$VFZOJEQKWA_S-K-HUL%F
MFU*/.44HK*S -@\K^!S797\>I>)O$NGQ^$"EKI5N[W-W=RV@-NK(IRY3&5=5
MWJ00 =Q Z5WTJBJ0C*E-P6[NW:]FNGSMOH[=SYG$T8TDI.*FWI:RNM4[:W\F
M]CE?$_Q%U37;_5M0D,FJVQF:>6WY>W@4M@$GI&H&.1SQ7HELNL?!_3HD\/Z?
MJVK6>HAF\HE'M[6Z8 YRRAMAYYSP!ZFN=_X68+1WATZRLH--4_NH#;E,CU;!
M(R?I5?Q'H_C/7_!^G>,?$>HK=VP22V.9O+0HK%A,$;&<@[20.-H]:+04%&*5
MNSZ]M--O7[R:;M5=2KK9771)^M^M^NFATVB^!OBB3H/B"RT^WUJ:XOI9=6_M
M27=.EKM!4P*6&W>0Z@IR/EQ7(?"CXRWWQ3\2^*M5\:^&CI-KHFGR6NV$2*\D
M;$H+5R^<R+D-NZ_+S72>&_&<DGP9NIY=9FTC2[BWETJ74K.=#/INY<Q2E0WW
M<<8R#E1CK56Q\&ZSJW@C0+--1OK^QM[,,FKZE"R->9)8LZ'DE20.O*@9-80K
MT94Y4Y\KETMNE=W?9]CZ966#?/#7NTUKO=O;];"^ +*&U\8O=IJUXNGS0K+:
MVQFV133$%'\Q/XI-JJ>O\.17J_VOWKB?!]E-I/AZVM[^"V2^#^9,8#O1I!D*
MX)&0=IZ=LD5N?;/>L*WO2]-#SYRO9=M#:^U^]'VOWK%^V>]'VSWK'E,[FU]K
M]Z/M?O6+]L]Z/MGO1RA<\B_;9N/,^ %^N?\ F)6?_H9K\\J^^_VR[CS?@3?+
MG_F(VG_H9KX$KZS*U:@_5_H>3BOXGR"O5_@K^SSK'QLT?Q/J&GZA;:<NCP@P
M1W*DF_N2K.MM'R/G*HQ[]N.:\HKW[X=?M2I\(_ GA'0O#OA;3[R\TW4Y-8U"
M]U>'S&DNB0J- 58;-L64R?6N[$.JH6HKWOZ_X8PI\G-[^QYEX<^#?CGQ=HHU
M;1O"FIZCIQ$I%Q!#N4F/_6 >I7N!S75R?LU>(]/T70M5U5C:66M:#=:]:M;V
MSW!"0C/ER!?NDJ0V[HH(S7?K^U+X6TGQ=X)OM$\/:K9:+X?\0:EK36)F3++=
MQE?+3!Q\K,W)[5DV'[1_AZS\,^'8WTC57UG3/"FJ>&)=KQFW=;AV>*51G=D%
MB&![ 8KE=3%-Z1LO^'\_)?>:J-);O^M/^">67?P8\=6/AM?$%SX3U.'1F@2Y
M^V-!\@C<@(Q[@,2,9'.>*Z7Q'X,^,^HQ:+X6UNP\4WL4ZL^G:3=222HWEIE@
MJ9(W(O.T\@=J^BO$_P 2_#&@> _$'CI+_3[KQ'KFEZ)$MC;:PEQ!//:R1'RT
MMPH>(!8SN+_=/"YS7(:O^V5H<WB^QU>PTG5X[4WFH:G=6K+;1>7<W-NT(\MH
MU#-M+9+N<D <9K*.(Q%354T[7^^W^>G^13ITXZ.1X*WP,\?QZ['HK^$M134I
M;7[<L+Q@ P9QYF[.W;GC.>O%<Y?>$]7TOQ*WAZ\TV>TUQ9UMFL9UV2+*2 %(
M/U%>Z> ?VF=+\,:9X-L+NUU=(]&T"ZT:[DMU@N$N3+>&X!:&8%9$ .,,00>1
M7E?Q;\:Z3X\^)NJ>(M#T<Z#I=S+&\5B7W,NT*"Q[ L03@<#.!7;3G7<W&<;+
MO\_4QE&"C>+/4-9^!'Q2^#OCRX\,^!-0UW4M6&GPW6J/H<<EK'%YF=L9;?B3
MG(!X).<"O*Y/A7XXU#1-8\23>'=4ETRPGECU'4;B,[89D($BR,W.\%AD'GFO
M8]5_:7\)^,-6\9V^OZ/KUMH.N:CIVK02:1<QI>136L80(^[Y2C<G@Y4\BN6^
M-7[1(^+OA2335TZ?2KB;Q->:[,B2YA:*6&.*.,XY9QY>22,$G-<]*6)NE.*Z
M7?R]?EY&DU3LVG\CF=!^!VN^*_AUIGB?0DDU>\U#5I]*AT:T@+3DQ0^:T@.>
M1MSQCM575_@/\0M TJ^U/4?!VJ6FGV4 NKBYDA^1(C_RTR#RHSR1T[UZ#\%/
MVD-,^%?A30M*N=*OKNXT[5-0U!IK9T4,+BR:W4#)SE6;<?85%8_M'6%EX2TK
M29--OYGLO MYX49O-4J\\TI<3 $_=P0#WXJW/$J;2C=7_#7S]/O)Y:;6KU.
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MM;RP*59(@.=ISP3ST':OGFM\/*K*+=56=_T7ZW(J*":4#O\ X"_\E?\ "/\
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M4YK++E*4(\RDE_P/SV.'^"VAZMHVFWQOX'MK>=U>&.3ALXY..U>H>'/%&J>
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MFWOIHDDKZ*UC-\:PZ7=2^&XM01IITN97CA2/>QC*@?,!_#NQS[5G>+]7\/\
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M?M?O1]K]Z]7E/#N;7VKWH^U>]8OVOWH^U^]'*%SS+]KV?S/@C>K_ -1"T_\
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M-0D46"1+(;8+\H4-(#@$ -@#'S5R:Z%BZU.Y;4M0:?4KE+V\?S@OG3(VY'(
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M#SC56\OX)?LO-Z1R_P#HNM[[;[FN;\0OY?P)_9B;TBE_]%U8^VU\E:Z^<O\
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M6+^LM:?I_F4O97U,?3_@AK6L37,.GZMH.H7$1F$4-K?AVN3$F^3RP!V&1EL
MD'&:U-#_ &>]5N/%?AS2-8U73-+75KB."0"Y#36V^(R*60@9!4=5R,\9I?AY
M^T#<_#SPYI^EV^BI</9R7+K*E[)!'/YZD$SQJ,2L@/R$GCC@U8A_:,NK.S\/
M6UIH,*1:3?07PBN;Z6>,&-"IC@#<P(X)+!2>?I1)XF[26GR!>ST;.1^'GP_B
M\<?$JU\*R:M;644TTT1U#=F,A%8Y4]\[>/K4MQ\']=M]#DU+S]-D=+(ZG_9\
M=V#=M9AB/M(CQRG&[UV\XQ6=X6\;)X0\?VWB:RTV-H+>Z>=-.FF8KY;;@8S)
MU^ZQ&[KWKI;OXTQW.F3^3X=MXM;?26T%-6-T[E+$Y4)Y>,&01GR_,[CG&:VE
M[92]W;0E<EM=S'\#?"C6?B!827MA<Z;:6RWT.FJ^HW8A\RYF#&*) 0<EMI'\
MZTKCX$>(K5D>2[T?[$$N6NM06^!M[(P,JS),^/E96=!@9R6&,UB^%?B-/X3T
MRQL8K2"=;37K37U:1R"TENK!8S_LG><GKQ6_I?QKFMM&N]%OM$M]1T6_GOIK
MVU\]HFE%R\;X5P,H4:)2K8/?(I3]OS/EV!<EM=R2#]G?Q3,82]SHUO'=7*VE
MC+-J"JE_(\0EC$!Q\X96&#P,\'%91^#?B-=$:_(LOM*V1U,Z1]H!OOL@.#/Y
M6/N\9ZYQSC%;&K?'F]U*Y\,&+1K2TLO#E_'>:?:+*S!8TB2-(68\G[A8MU)8
MT]/CY=PQMJ%MHT%MXN&F-H\7B"*Y</%:DD#$73S AV!\].V:A/$]4OZ^8[4S
MGO#GPFUWQ+H%WK,;6>G6,$QM@VI3>09)1&9-BY& =HXW8!.!FK-U\%O$5KH,
M>I>9ITTDFFIJZZ;#=AKS[&S;1+Y>.F2,C.>^,5M>#?VA=9\,RWMYJ$$_B'5[
MAPYO;O4)1YRA"@BN(^5GB'7:V/KS5[Q5\9=*@TW2U\/Z3"=<_P"$:MM'N=9:
M1QY0#%I8UA(VYX"[\]">*'+$<UK:?U_7Z!:G;<R9OV=/&44R1"*Q>1)?)O=M
MS@:<WEM(?M!( 0!$8DC(&TCK6EX ^ H\3Z[9V-]JUB=/N+ZTA_M?3[Y'@\J5
M9&( (SO/ED#(&".1TJ[JO[4>JZM=/<3Z4TYO7<ZI!=:I/-!=(\31R1QQDXA5
M@[-QD@XQ@#%86A_&V/PI-"F@^%K+3K""ZM;M+<W#R.SP+*,R2$ NS>:<G QM
M %1?$N+35G_7F5^Z3\B36O@PUXZWVBO!I?A[R7N'U/5]21H GVEX(\2*@Y9D
M( VY.">!7F^LZ5/H6K7>G71B:XM9#$[02K)&2.ZLO# ]B*[ZP^-!_P"$9M_#
M>KZ!!JV@):BWEM1<O"\CK<R3QR!P#M(,K+C!!%<)KNIIK.LWE]%96^FQ3R%T
ML[12(H5[(H/. /SKHI>T3:GL9RY;>Z=A\!?^2O\ A'_L*6O_ *.2OW'K\./@
M+_R5_P (_P#84M?_ $<E?N/7R6??Q8>A]7A_]PI>LOS1^=G[+4FWX*:*/^FD
MW_H9KUCS:\=_9@DQ\&-&'_32;_T,UZMYOO7Z#"%XH_-JDK39<\VL_P 0>(;7
MP[I%QJ%Z6^SQ  J@R6+$*J@>I) _&J>LZPVG1VT<$8GOKR=+6UA)P'E8\9]@
M,D^PKCO&NLZ--)?:)>K<:RL;^1<2F9D1I%(SM1&4*%8<9W'C)-;4Z,JL^2"N
M_(\W%8VEA8WJ.QUL?CK3O['U&]998!IK^1<6\B8=)<#$8[$G<H&..:QO&>NV
M]JDVD:S+<274L %Y9VDFR. 2+GRB1AG;:1DD@<\"N(U":2Z\!WFD:3 )9;1X
M[^V5.9)_)D1Y$8]Y,8(/?(K'\5Z3JOQ%U&+Q?X/UZS-Q=P)%=V^H*SQ2%1A2
M=O*NHX/KBNBC0A[6U:]ENEO_ %O<\3,<SE"E3G2E92O[SVNNC\[;=&:F@>$-
M.US7;*QNKNXF\/=1:.WS3S*"429LY*A<[5Z<8[YKW*'9;Q)%$BQ1( J(@ 50
M.@ [5XI\-?"EUINJ01WFIKJ^J)<B]U"Y@39!!M1DB@0?\#8G//>O3M2\4Z9I
M%TEO>7L=O*R>9A^@7IN8]%&>.>M&(2<[1VZ';E-1SH.I+=O?OMM?I?8W_-K#
M\;:%_P )7X7OM-5@DSJ'@<_P2J=R'\QCZ$U?$P(!!!!I?-]ZXIT54BX26C/=
MC4<6I+='S'K.FR>)])DA4_8]0MW*2)*I/E2#[R,/\]C7-:+X#UE-8M'N6M#%
M'(&58&9FD?\ A&"/7%?25Y\,- O]7U'4YTN?M]_*LDEQ'<,C+A0H5=N,# Z5
MR%IX5O?".L9O=2FOE<3RVHDEW*HR @P0/F4-G.37YEF65XG!4G9^[)\MUTN[
M)OMN?61S.C67+9J3_K\!EY;Z3X>TV==16*X\R/RKN:1B$(/)10.P(Z]ZK:/X
MA\#1PW]Q/!97:W#[V)(WJV,!4Q@CZ5S?Q>M+BZ\*?N$:0),K2*@R=OK7F/PX
MTN74_&%BL8^6%O.D;'11_P#7Q7C?6WEN,C3HQ[?XG??75:^:9\WC,PQ-/&K"
MTX_%;76^N[T?3]#ZD\(^$M<A\$Z2)3IVD:=)&D[1W-U' UQGD-)SN<XXR?P
MKTN?X7^!/%>A^(_$&IW<]]J.KV)@33+&^4JTD #J(N.&!51SQSP.:^?;&&Y\
M/0XF8ZG;RRDLB*$>)F/6/MC_ &3^!KOO"^G_ /"6Z3JVEZ?<)<W^G@WT5KG9
M.I7 E0H>0=N&_P" 5]DZM:A5G6H5-+J[5UI>ZOU6J_#0]=>RQ,51Q,??ML[.
M[M:_9]?U+NCW_AO1?AYX7L?^$,OK:^*S2-::G?,,$R<NP4 G=M![8VUI^'-,
MLEEDUJ/3X;"\O%.4M]PC6//R@*2<9 !)Z\U@:OI5_>>&](N;!(M2O,2I.);C
M@JL@S'OYPQ#=^@S77I* B\!>!\H[>U?08&E*K.IC):<[>EV]+^?]:'E8F48*
M&&CJH):V2UM_7WEWS:/-JGYOO1YOO7K\AR<Q<\VCS:I^;[T>;[T<@<Q<\VO8
MK!_^+#W#?],W_P#1M>(^;[U[1I[_ /&/]RW_ $S?_P!&UX6:PM&C_P!?(_J>
MIE\M:G^!_H>1^;1YM4_-]Z/-]Z]WD/+YBYYM'FU3\WWH\WWHY YC(^('AQO%
MOAFXLX2JWT3+<6CMT$J\@?0\J?8U\^7=G;>,[&2S+R6UY!*4EA4CSH)5X92O
M?!_"OIKSL=ZP)_ WANYBD231;)O,D:5F\H!B['+-NZY)KP,RRAXV4:E.7+)'
MK8+,?JL7":NF?/WA_P"%=QINKQ7\DUS=F 'RUEB$:(2,%B?I73^#?AW=WNK7
M%MI6K12Z<)))KF8P;[:%SC9!"006(Y+$' S7=V/P7\+P:!_9EW:OJ):)HGNI
MY&\QMV>>N 1G@CT%=KIEG!I&G6MC;+LM[:-8HU]@,<^]>9A>'Y<ZGB7==CMK
MYNN7EH*S/)K?P=XBMO#T^H7L>E6-XA=8[66&25F;<5C_ .6F/FX/MFLW4&N-
M"TF75]5E^UZS!;!)7!'E1'^)(@  J9]!SWKTWQA9?:9]/GMK1[F_64%2IPNQ
M<DACT[\9[UP'B/31J&E75A>B2S,Z%,S+MP?Y&O$QV'^K5:M.G'E459/75M7W
M:2OMHMM^IA'&UL12J+F7-K;[M/Q/()?BWJ5]=VYN0?L:2*[6R'Y7P>_O_A7J
M,FLZ3KUC/97F8Q-'LEMKA"K ,/\ .*\VTOX1W\.O6PN)H)-/20.\J/RRCG&/
M4UZO>VUK;6U]+A8VG7,C9Y) P/RKYO 0Q:C5G-^Z]U.^NC[]-EVW^?7DV-Q7
MU5PS%/FIO]VU:+W7Q.SNNJ=N:^E[6MS'P]^ F@MJ<]S;^9J[6TNW-R0(H6QD
M#W(!'K7N>@^&9M)U*9IGMKFQ:)1$OEX>-^C#T*D=SS^%.\*6MO9:):O%:QVD
MD\:2S!%VEWVC+'WK8\WWK]&RC)*%"A3JN/O.STO;RWU>CZWUVL:9KQ+C,TJ.
M52;::M[VK6U[;):K[*5UH[EM&6)%1%5$4855& !Z 5E>,)?^*0UW_KPN/_1;
M5:\WWK(\7R_\4EKG_7A/_P"BVKZET[(^54[O4X;Q<^S]G[]F=O2"7_T76?\
M;/>K7CI]G[.O[-C>EO+_ .@5S'VSWKXBFKQ^<O\ TIGZ-C7:CAO\'_MTC=^V
M>]'VSWK"^V>]'VSWK3E/(N;<E^L2,[N%51DDG@4WQ)H'B:;0XY[/3+E$:1'>
M,R+#-+#U.Q2=PR.AQ5#PKJMHOQ(\,0:@GFV1DDN&BQD2.BY0$'J 3NQ[5SOB
M;XO0:;XGUBV\1ZA-I>IQ74C8F#G[2A8E)$('S C  [8Q7T.699'%-3J245Y^
M70^.SG.YX.H\-1AS2MKWL^I>;4+J'1+&WO[IB]YJ$=M,X/S11O)@QD\<A?ES
M[US/[0VM7L'Q&N+61Y+32X88TTZ-24C6$*!M7''!SGWK<U2-==T6U;4;>737
MU"T:YDC?Y9(@)#Y,I'\+;<'\!6?%\<-EA'8^)]!M-=%O&LBWSX4!&;9&\JD'
M9N([=:ZJ$H996E4=FD[=M]K?=]Q^U>'N?4,/A7C:L;6=FWM?56OWT;7S16\
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MO1]L]ZTY3IN;OVSWH^V>]87VSWH^V>]'*%SE_C[<>9\-KA<_\O4'_H1KSO\
M9NU*)OB5I>B7>D:3JVGZE*_GIJ5DL[#;$[ (QY7D#..M=A\;;CS? $ZY_P"7
MF'_T(UX-HVMWWAS4X-1TVZDLKZ DQ3Q'#(2"#C\"1^->I0AST)0[W.6<K33.
ML\+Z=)\9/B38V=[]CT9+E6,[:79K$B111L[%(AP7*J?J:ZSPA\(_"OC32]2\
M1VFJ:A8>&[*WA+1:K-!:2O/)*T859WQ$R@*6R!G/R]>:\ETG5KS0=3MM1TZZ
MELK^UD$L-Q"VUXV'0@UTJ_&#Q@-2:^&N3>:\ M3&40PF(-O">5C9C=\W3KS7
M14A4>E-V7]?UY&<91^TCVW6O@]X;T+PJ=+\^TO-MI.O]O00%W*G4($6;:.2R
MQN1@>X&:\F^+_P -[#P%)I4^DSW%[IE\)0EX\\-Q#*R-C,<L1P<@@E& 9<X.
M:Q+CXI^+KJ4R3>(K^24LS>8TOS9,BRDY_P!]5;Z@5<3XG>*]?U/;-.VL7,]M
M<6,5MY (_?J5D98U !<]<XSD ]JRITZU-W<K[W+E*$M$CL_V>O#F@^)=%\=6
M6M6$%S+=VMO86-W*/FL[B:7;'(A['=M'XUV-C\%-,U/P+\._#,UA#9>(G\0?
M\5#J+?))#"ULT\D3L>%$<2KUZ,37SKIOB#4='M[BWL;V6UBN'BDE2-L;VB</
M&3[JP!'O6U<_%+Q;>#5O/\07DIU:26:^+/DSO(NV1F/JRC!]J*E&I*;E&5O^
M&M_7R",XI6:/H2]^'&CP?%/3O$BZ5H6FZ#JV@:E/]FB9;_3["\MH7'(C+!OE
M$4NT9.6/%<=\0_!-OXD\,>"+?36\.7NNZM)<W,6OZ7$-+TZ2U55'D2-+M'G(
MX8D$ @,!SFO'=(\:ZYH&D2Z5I^ISVFG2M([VT9PA:2/RW..VY#M/J*J'7]0;
MP\-!:\D;1UN?MBV3',:S;=I<#L2, ^N!2CAZD6GS;?\ !_X'76P.I%IJQ[!X
M6\0R:)\(/&C3Z!X8O-2\/WEA96]W+IL5PVV1W60E\XDSM&&_*N%\$>$])UG0
M_$WB/7[B[BTK1OLZO;Z8J>=+)/(54 MD*HVL2<'L!7,V^K:C9:+>:?#/+%I=
M](C3PCB.9X^4SZE=V?QJSX9\8:QX-NIKC1[][)YX_+F  9)%!R RL"#@@$9'
M!K94FE+E>K?^7_!^\CF3M?H>N6?[/6AW7AJ._N?$YTY]5:^_LPWSQ6LD<<'"
M&6!SYCLQX(3[O7GI74^,OA1X3U+4+:VE^S^'8%O+UA)$RP"<I8V#QPF9\I$"
M\KD,W&6/K7CUYXZ^(OA_3Y!?7VKV5MK!EN1->Q,IF,HQ*\;N,C<#@E3R*SX?
MBOXNM[K[0NO7+2?O-PDPZN'1$<,I&&!6*,$'^X*P]E7D^;G[_P!;&G/!*UBM
M\1/"G_"$>,M2T8)=)';LIC^V*HD9&4,K'82I!!!#*<$8(ZUSE:&L:SJ7BG5I
MK_4+B74+^;!>1N6(5<  #H HP . !56ZLY[&18[F&2W=D615E4J2K#*L,]B.
M0>]=T;J*4MS!VOH0T49HS5""BBB@#O\ X"_\E?\ "/\ V%+7_P!')7[CU^''
MP%_Y*_X1_P"PI:_^CDK]QZ^*S[^+#T/K\/\ [A2]9?FC\V/V9Y=OP=T<?]-)
MO_0S7J/G5Y+^S:Q'P@TC_KI+_P"AFO3]YK].I1O3CZ'Y96E:I+U.6^)YO;6R
MTC7+&.6>31;T7<L,&=[1%2CE?4J&SCVKSW7?!UUXIUBZ\2>$O&-I96VJ$374
M-U$)X_,Q@R*,@JQ[@]Z]KWFO-/'5OX8T>YL;M-)TLS7-P4GO&AWI$ "265>"
M6/R\]S6\.:D[Q_X)X6/P:Q;C44^5I6U2::WU3:U3OJ4-)TX^&="CCTF\GU&X
M)>T34Y!EKN\N&4/(H'9%7@#TQVI?&_P]M/#TVD+9>'KZUMQ Z274*/"TUQP(
MQ,<@;222Q//'6M7P_P"+[U[3Q5JQL9++7-&T\0Z=I\/ A+IN=U']\KPO''2N
M%A^,.F7ELDUIJD=_<W>(HM.4[II)&X$93KG/7/OFM(4Y8B^J27?=_P!=^YYZ
MQ"P+=&"<WL]-GOJO/MM9'MF@A--L&T^);73DTZU2XU*X@BS%"S<!47^)W;.
M3[DUQ_B6+1]=U?[=%>WL\IB2"YLYBB17<2MD(2HXY-8^D7#W<GC[P2;^2SDU
M&59K2=SEBJ!0I0_Q>6R[2*YZR\)>.IYXX-?DTG2-'MV#W>JVTY>2:-3DA$_@
M+8ZGIFE1ITWS2JM^5OU\S'$YI/VG)3:BE9N^ET]4UW7]6/?M.U./4+*&XA!6
M-Q]UA@J1P5(]001^%6/.KG/"D<L6D&25#$US/+<K&W5%=B5'Y8K2NKZ&QA,U
MS/';Q#J\K!1^9J'#6Q]13JN5.,Y*S:-'SJS[W1K'4K@S74 GD*; 6)^4?[/H
M?<5REW\7/#5N[)#>OJ$@_AL8'E_4#%5E^*DEPNZU\*Z[.IZ-]G"@_F:SJX.%
M>/+5@I+S7^9'UNDGI+[M?R-B;P<7O7$5R\-GY8P&Q(2V>1SVQBLVX\#RZ3'/
M<V"VTLS 95(=KOSZ@U1U7XLW.CV/VR[\*:M;6Z.HEDF5555)QG.>OM76Z#XE
MM?$NE+?V!=HF!P)8RC XZ8->)6X=PDXM\K3UL[[7[=%;IH==/,I2ERQGJN__
M  3";PGJ%U<@1RVUS':2QO<_-Y448)R \C' )[* 2?2L[PYHE]X7\?O>-<1Z
M<DM]-=17MO<,SW"R*5%NV0,#YB>0,\#FLC5_&-\OP=\/7NGV,]Z8KR>XUA+?
MYY69R0T@7KN0C&/3I7-^%O%__"63W(TRTNVT:VMY9KR]NH'AC1MIV(FX ERV
MWITQ7?@,JH8:%2K&5G*RL];I;?GMM\[GS^*SBK4K7Y>91;N^S73;3]7M<]YT
M+3ET'2;>P29YT@!"O( &())YQ]<5?\ZLS3I9GT^U:?\ UQB0R9_O;1G]:L;S
M7H.-V>W&5DDBWYU'G54WFC>:7(5S%OSJ/.JIO-&\T<@<Q;\ZO;].?/[.MRW_
M $R?_P!'5X+O->ZZ:Q_X9MNC_P!,I/\ T=7S^<1M&A_U\C^I[&6RO*K_ ()?
MH>*^=1YU4PYI=YKZ#D/'YBWYU'G5S_B+Q F@Z1?77R2SV\#2I;[P&<@<#'6L
M[P3XINO$MO/+(D<EM&$$=Y"K*DK$$NH4\_*<#O1R"Y];'5SZI;6S!9KB&%CR
M%D<*3^=3"?/3FN6\0Z''JVJZ%</907*VUV7F>6-6(C\J0=QR-Q'%<_':>*;V
MXM+:8WEI;1-''//'.@,J^:2S+CD#9@=C6;5GL:JS6YZ3YQH,^T$D@ =S7F$>
ME>*[:W@$EQJ%W"T<37:1W*B8N"P81L<!?X<^N*V-$TW6_P"S-4_M6>6:ZFMQ
M%%$TH*#Y.< <;L]3WH2OT!Z=3MQ/N (((/(([U7N;:"\F@EFC$CP$F//0$C!
MX[\5YRGA[Q&((PM]?0;8Y4$,5R B[8U\D =OF!S^M/FT7Q/-NF-_?),T=PQB
M2X 02#!A '89SG]:B=.-1<LXW6GX:K[GJ.R[G>SZ387 ;?9P%B"-WEC(_2J=
MMX5TN"Q2V>TBGVIL,DB LWO]:X^XM_%=[/';'[7;0HY$MS'.@\Q6N$;Y<<C$
M>X<BHX-/\8QZUIP:[G-C$X!8NK902-GS/F&24VX.#^=<D\#A:DN:5%-VMLNM
MK_D/6WQ'I-JBV=M% A9DC4*I<[FP/4]ZE\ZJF\T;S7H1I1A%1BK)&/,6_.K*
M\639\*:W_P!>,_\ Z+:K6\UE>*W/_"*ZU_UXS_\ HMJ)0T949:HY+XC/Y?[-
MG[.#>EM+_P"@"N ^V>XKN?BDVS]F']G1O2UE_P#0!7E'VWW%? 4%>#]9?^E,
M_3<>[4<-_@_]ND;WVSW%'VSW%8/VWW%'VWW%='*>/<TM31[T02P7!M+VUD$U
MM<H,F-Q[=P>A%;G_  LZ_,4 U30=+N+]#MBNGF&S/J%*[AZX!K$\-Z3>^*M6
M73[#R_,$;32S3-MB@B7[TCMV4?K6=K^E:+>ZC]GL?$J75PJM#\]IY<4H/4*Q
M8D$] 2H_"O5P7UE7C1O;=Z7-EP@^(U[=X=S4$_>5T[=M'=J_Z^9VGAW1T^(?
M_"1ZOK]_/'H^G-%%?SV8 EN9Y/\ 5VL)/"C!!9CG /<FJ'B/P1X4U>[%YID%
MQ;:E$J(HN;EI()E0Y17! R 23^N.,5B?"K7+5HO&7PWU6^?2)=5O!J6GO*VW
MS&"J/ESP7C9!D=2#6]?>'G\,7-L?%_B'3;73U/FF&UW?:+L(<A " !N( /7K
MBOSW,,;B)5Y>UFU9[/;MM]QZ^#PBHT(X.A#W8WM%+;OIWTU]#W;]F[4Y+_X2
M^,8-,18/$,EW+ ?..&C=%79&WMG<,_6LCPKJOB+4?%-G96?AS5['54F7[3+>
MP%(+=0?G9I,X88SC'7BO#O!GQ&UWP5KMUKFDSK;7-[(\ES9SC?#*K.6"N!W7
M.-PYKO\ Q+^USXEO;)+&TTZTT^XEC;,L4C.>!SMW<*3GC.:X(/-,I6*5.E&<
M*^\G;3F<GK[R:LYM;25DFNL3YC'X:6)Q$*L9KEBTUJTU916RB^9/E35FGJT^
MC(/C%=6B_$O7A8[?(\[)V]-V!N_7-<;]L]Q6 NK27RBYE+^;-^\?S3ELGDY]
MZD^TD#+,%'O7TV!I0P.!HT7*_+&*OKK9+9;_ *G37Q,%)U)/?[W\EN_0V_MG
MN*/MGN*PS>J.G/UI#?>XKIYZTOX=/[W;\KO[TCC=>M+^'2_\"=ORN_O2-TW8
M88.#2G4&,*0ER8D)*QD_*I/4@5@?;/<4OVWW%93IXF7O<D&_-O;UM^AG*6,M
M>,87]7^=OT.Z\%Z%JOB;6672&\F2V0337;R^7';)TW,W;/0 <GL*I'X6'1+N
M6>UUFRUVYMWE(2VR)0KDDCG[V!@<X/'2K7PR\4"[^&7C/0[4M%KDFJEQ*3@,
MB!3&A] 5S@].:QO".D:RGB.SE^Q7&F16LRR3W,_R@*IR0/[Q.,5^99ACJGUM
M^QC&*I2;2LMTW>_5W\O(^)S+B26%Q<J-**M3?O7Z>?HT].XTW0+!L#<. 2.1
M2_;/<5G:S?QR:O>O$0(VF=EQZ$U2^V^XK]6PU1XBA3K-6YDG;M=7/T&C5]K3
MC4M;F2=O5&]]L]Q1]L]Q6#]M]Q1]M]Q73RFUS>^V>XH^V>XK!^V^XH^V^XHY
M0N9?Q<N/-\$S+_T\1?SKD_AU/HNE^ /&>IZCI6G:GJ$<^GVEHVH M]G29Y1-
M(BAAE@JCGD#@UK_$NY\WPG*N<_OH_P"=<3X3^'NI>+]&\1:O;O%:Z9H-L+B[
MNK@/MRQPD:[5.78@XZ =20*[*:7LK2=M?\OSV,9-\VA]*:S\/OAY;WZQ1Z%;
M&WBN&7P_-,4@@U0BVD:..1Q*6F5W$9+87!.TXS@<99>$YVM+^Y7P/X:N/'O^
MA"3P]O)CAM6\WS9C!O 20E8@P#'8K;N,\>"GP]JBR6\;:3?+)<IO@0VKAI5]
M4&/F'N*BATF]N;_[##8W,U\&*_98X6:4$=1L SD?2E'#M+X[_P!>OW@ZB?V3
MZMG^'/@L:Q?V/A?0M%UWPBNCZO=7.KSW&^ZM[Z)9BD<;;P2J!8]HVD,"3DXJ
MAIFD^"-1\<ZEIHT71M,LM#UK1DM+JTE9)9HYXG^T;Y-_S#<H/&-M>$VOQ!\6
M:-HDGA6)S:Q['L_*-DHO$C<Y> /M\P*QZK[^]<]+X9U:WCD>71[^*.*,2NSV
MDBA(ST<DCA3ZGBH6'EKS3]-?/?\ 0IU%TB?0,/@>RT_P;X/M?%'AC2([?5+R
MSGU+7K%!&=-L2XPC2"0[I9,@N<813CKG'.?M#>'- T/3=*>PT4:+J;7UQ$%C
MCCA6:T4#RV\M9'+8/27C<">N*\=_L+41%;3?V9>"*Z.+>3[,^V8^B''S?AFG
M/X?U2".YD?2[Z..U(6X=K9P(2>@<X^7\<5M&BXS4G/\ K[R'.ZM8]C^'GPZT
MOQ'X;\&:PUA9SV$$.LIKEQ+.J!)5C+6HD!8'/3;CK[UN?%3P/I&B>$]:,_AK
M3-$TZ'1=*N=&U.W<_:;N^D2$S(?G.X%6E9EP-NT'OS\[VVFW&J2F"UM)KR5A
M_JX(FD8CIT )[C\ZVM:D\1^,-;N;B^L[V^U.VACBG5+5M\,<:!%WJ!\N%4#)
M]*3I2]IS<^G_  ;]_EZ IKEM8]M^'-K8>)?A!X5M+G2M)U%]/OM9:W@N2$-Q
M?&&%K6&5MP)5_GP. QC SZ\7XZTS1M \<^!9M1T^TT>\EAMKCQ%I=G_J;63[
M0P(VY;86B"L4SP3[XKA+_P !Z_IZ:,\VCW;'6;7[98K%"SM/%N*[@ ,]5/'I
M@]ZSX]#U*6&>6/3+V2*#<9G2V<K'M^]N('&.^>E.-)*3DI:._P"-_,'+2UCW
MC]HQ$GT34[R=9M.>7Q+-)IT!U/[7'JEJR$B[5?X, (H*X4A@,?+70_#[X:>&
M;SP#I_\ ;&FZ3,D^D0ZA'?11[2]Q]H3<C7#29:0*6#1*@ &?K7S?XC\):KX1
MEL8]6L9+)[ZTCOK<2+C?"^2K#\NG:J%GIEUJ<K1V=G/>RJID:.VB:1@HZL0H
M/ ]:GV%Z:C&>W7^F/VGO-M'U1X3N/#J^*+FYTCPYX>LK^#6=9T&Q@C!*SVYL
MI6A#AG^9BZA0_&=Q'<4W2O!.@WFI^'8=.\/:-K^I7-QI%KK%IJ5P<6MH]I&7
M:/,@VDR%P2"2N ,"OFWQ3X,U/PEXDO=#O;<R7MK,UNWD*71V4 L$./FQD9QT
MK=\%>)_&_@N 0:#97*K>2^?;[]+\]A,J_P"M@+(2'"D<KVQ64L.[<T)[HI5%
M>TD>ZR?#_P  P>'I!'H\=U8_Z6;V_54'V2[6Z=$B\YI 5VJ$ CV'<#WZUF6V
MF>#-;\4742^$='\G2O%+Z;:VEA,(WN;8VLSC<9'Q,RR1H0,C<?E[UX5?> O$
M \.Q^(YK*XGM[B[N()2(G:6*2+:9&E&/E'[P<GWJ#5/ FL:9/90"RDOI+K38
M-55;*-IMEO,@="VT<<$9]*I4=_WG?^MQ.?\ =.D^.>@6GA[QRL-FEG"D]E#<
M/;VEN;<PN<@K+$7?RY/ER5#$?,,8SBO/: ,45W0BXQ46[F#=W<[_ . O_)7_
M  C_ -A2U_\ 1R5^X]?AQ\!?^2O^$?\ L*6O_HY*_<>OC<^_BP]#Z[#_ .X4
MO67YH_,[]F[_ ))#I'_727_T,UZ=7FO[-<6_X/Z0?^FDW_H9KT_R#[U^HT6O
M9Q]#\KK)^UEZF0ES;ZCXTT_1+IPMD+66_N8]Q4SA" D(/HS'GV&.]<(/BO+X
MALGO5GMUL!N5X@BHD(4D,F/X0,8Q[<YKH?'&@:I'J6F^(M$@%Y>V"O#/8[@I
MN8&P2%)XW@@$9]Z\^NO!'@3Q1KKZC-X3U>35I7WS6/D30I(_K(G"'ZDXK:C*
ME&HY5(J71)]/-?J?+9G'%>T2@I<CMK%7UZJ2Z=T]B]H]OJ4U\?$GAZ6&X\ZS
MADFL[QS&MQ =VS#G[K+@X)X(.*CO-<M]%U!+VV\&6NB:M=JX35G@20[\=%,8
M)8L3@5UN@7JZ7K'BV\U&&*2]T;34NX-,1-T1EV$QH!T;RT7@="Q)["N;N_BU
M_:FCOJEUJL5WITL>\M+(&W9'3KUS_#Z\ "JHTYUY25.UEKJ_RT_$X:_U>/*\
M3!^TT3LW\E*SULK>?JCJ7\*:;J_A71[;6M.<7WR>4D+G[2MP_)".N#N)SG]:
MR?$?PYN+86KP:K%=WME.7;3]3U!KA#@$;&P-I(.#QG!&,U;\+^+)=+^(^@QW
MB-)%#:W44!E/S>:5C8<]Y%C<C\#7F-WXC\0:%J,FDZCX:U;4=61REM/8P>9#
M=KGY7WY^7/&<].:5*"J5&YRY5WWNSMQ6-4>2G1@I-)-7MHGU3?Z;'J.@7&I7
M&B0:;H4N4@RD^JZ@"Q5R<LJ1YRV,\9.,8ZU>@^&^ERS"YU=Y]>N^OF7[[D!]
MHQ\H'X4WX?V=_ TT5^4-U%:6ZW0A.46X^8LH/?:I09]J[+R#[U7/RZ(]3#I8
MFG&K)7O]W]>94MK.WLD"V]O%;J.@B0+_ "J<L3W-2>0?>CR#[U%T=ZC;8KS0
M1W,9CFC66,\E'&0?PIX 4    = .@J7R#[T>0?>BZ#E9PEQX)U31-6NK[PQ?
MV]O!>2&:XTV^1FA\P_>>-EY0GN.F:T;/0=4OY8WURYMF@B8.EC9*PC+#H79N
M6QZ8 KJO(/O1Y!]ZE-1V9R3P.'J5?;RIIS[_ *]K^=KD5%2^0?>CR#[T[HZ[
M,BHJ7R#[T>0?>G=!RLBHJ7R#[T>0?>BZ#E9%7NVF_P#)MEU_URD_]'5X=Y!]
MZ]TTV/\ XQPNE_Z9/_Z.KY[.6N6A_P!?(_J>QEJM*K_@E^AX,.E8WBW67T/1
M_-A*K<3S16L3/]U&D<*&/TSG\*WO(/O6'XV\*OXJ\-W-A#-]FN\K-;3'D)*C
M!D)]LCGVKWY2TT/'Y6U9;F/XM\<0Z#XGO/"VCR1(NGQQ.SL TEUO0$S,QY;)
M)'H,#I6=X2\4)?ZS+Y,P<&Y6TN8DY02F,N"/1L*<_49KF/$VEZ!XT>VC\;^'
M=3T[7;5?+$UHDHW^HCEC!W*>N#ZUVW@3P=;:7;V:6&E-HFC6>Y[:UE'[Z:1A
MAI9,\YQP,\_2M(.E&DH1BKK>75^I\IAXXV6)3J1DG?5->ZN]I7L_*QV-%2^0
M?>CR#[U-T?5\K.$\<V$EWKFF2&!9K5+>4-YMJ]P@8LN/E5A@XSS5>[U+Q';:
MA>16<-Q)9>2ODF.W"B!1LR0K#YFP6P,GD8(KT3R2/6CR#[UG97O<U4G9*QYK
MJ&M^)8+C3_LL=]);J%,LEQ;HOF(6;<S  X(4 ]OI52+7/%EUI-M-:M<2PS"-
MI;F6V571BK$JBJIRN0G.#UZUZH8,@@\@]0:1+81J%4;5 P . !2MYCYO[I2T
MQ[B33;5KL 71B4RA5P-^.<#MS5FI?(/O1Y!]ZTNC*S(J*E\@^]'D'WIW0N5D
M59?BO_D5=:_Z\I__ $6U;/D'WK+\60'_ (176O\ KQG_ /1;5,FK,J*=T<%\
M7G\O]EC]GAO2TE_]!%>(_;?>O:/C4^S]D[]GUO2SE_\ 05KYZ^V5\'A%>F_6
M7YL_3,Q=J6&_P?\ MTC=^V^]'VWWK"^V4?;*[.4\7F/6_@S=1ZH_C70?.2WO
M=5TY8X)&Z[!G./H2"1Z5QEK\'?&ESJBZ<VCO;G?M:^>11"H[ONS^-<NE])#<
M0W,$TEM=0MNBGA;:Z'V-=%??%3Q7J=@;.[UZ>2W8;6"(L;./0L!FO7PV,EAH
MOV;M??Y=4?J60<84\HP;H.+4K6T2=][=='J=-J?@C3OB9XMUNW>2V.AZ<4:X
MU&9"P0JH3>@')=F4XP16==_#+PLC,NC:[=:A?1](-0^?..RL6;'X=*E^&%\N
MJ^'/$_AM)UMKN[*S(W?  VD>H!'/UJ#3O OB)KZ-+Z*#3K.)MTU\)@1L'7:!
MSDCUK^;^(,]Q-7,*M*7NJ$FDK=N_>^^NFO8_;N%>%LHQ&!>8UY6J58J5T_YE
M>R_PO32SNK[G1_!;PK9^.O'CV&J%DT[3[9KR[B#;'DVG B'?)(.?85U6J_%7
M3;W=90>%='31/NB%;5-RCU#8SD>I.3CJ*\>T_P"(<?A7XDWFO8D;2+UFBG>%
M26A^?<DN!R1U!],YKMI1X"O6.J'6T-I*?-:VM[M1'(3R< ?,,^@KMS>MB\35
MA+%)Q4HQ:5M-8JZ7G>_GWZ'\!<:5L9EV<5<'AW+V49-0E%.2E9M-/E3UZ]FC
M'\;:;;^']4@-E)OL;NW2ZM\]45AG:?I7/&^R<DYIWC;QA'XEUHSV\8AM(D$4
M* 8 0=..U<_]LK]5RF%=8*D\5\=M;[[Z7\[6OYGUV!E5EAJ<\1&TVM>_H_/O
MYF[]M]Z/MOO6%]LH^V5Z_*=_,;OVWWH^V^]87VRC[91RAS&K'=7FFZK_ &II
M%\;"_*".7<GF13H.@D3(SCL0016]<_$+7]2@$-S<6T$>W:PM4;+?BQX^@_.N
M,^V4?;*\BMD^!Q%;V]6DG+\_5;/YH\K$97@,57CB:]",IQV;2;\ONZ=C=^V^
M]'VWWK"^V4?;*]?E/5YC=^V^]'VWWK"^V4?;*.4.8W?MOO1]M]ZPOME'VRCE
M#F&>.[GS?#LBY_Y:I_.J_P -O'UIX0\+>*;&[>>3^T)].E2R0D1W"PSEY5?'
M RG'/7I5/Q7<^;HSK_TT7^=9?A#P1?>-);A;2XLK5("@>6^N!$NYVVHHZEB3
MZ XZG%;*,?9VGM?_ "(N^;0]V7XX:%X>7Q3=6OBV_P!;U#6);^\TR4VLD;:1
MYMK-''$"QX8M*BG9\H$0->6_!_Q/I.DZ_KMYXAU2XM+B[T^2*WN7:8QRS,RD
MB=HB)=I4-]T@DXR<4MY\ ?%]A:32W,%C;SHEVZ64M[&+B86S$3E$SE@NTG/<
M=,U)\2?@[)\/[:X:*Z.LB*:RB^TVK*T8,]LT^PH/FW#;P>F!SU%8QC05X1EO
MZ="VY[M;&YXD^)GAZ]_:*\,^,+2XDET6PFTJ2XG^SLKDVZ1+*P1B6/*$C))/
M&36IH?QYA&G^&K?6-9U&\6W_ +>&I12[G69;E6%NC<_,N2..BUPNJ?""]M/
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M_K^D@4Y1T3/=KKXX>'_%GASQ9'XDT>6\>YM-.L[>!KLK=WGE7#2--+<*@!D
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M]G>PGU+XT>$(+:-I96U2VPJC)XE4_P @:_;^OBL^_BP]#[##_P"XT?67YH^
M?VL/V;];^$?B36/BO\.O$2:';7KF;4=-<L/WC$EB@"E65CD[6Q@DX/I\K_\
M#6'Q-_Z#L7_@)'_A117LY75G5PR<W>Q\UC*<(U79!_PU?\3?^@[%_P" D?\
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%EY)'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>mrkr-20251231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20251231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &I U # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAFQ^R6S/YDLDC;Y9G_O.QZG]*G,<UP6*P4J:;G-\O+S12E&V]YIWFNBNAX+
M8JABE.RC%7O:3:E?:T7\/GJ=C1117PI]4%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6C.,$GI?K+EM9K1I_@=\,:W.%.I3<92;6MNBO>ZW7ZGO5%?/_P 8?%^M:/\
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M>O\ >'YT;U_O#\Z '5YY^T%X9U+QE\&O%.BZ/;&\U*\M1'! &"EVWJ<9) Z
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MTW_GF_\ W\-'_"(:;_SS?_OX:VJ* ,7_ (1#3?\ GF__ '\-'_"(:;_SS?\
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M_A$--_YYO_W\-'_"(:;_ ,\W_P"_AK:HH Q?^$0TW_GF_P#W\-'_  B&F_\
M/-_^_AK:HH Q?^$0TW_GF_\ W\-'_"(:;_SS?_OX:VJ* ,7_ (1#3?\ GF__
M '\-'_"(:;_SS?\ [^&MJB@#%_X1#3?^>;_]_#1_PB&F_P#/-_\ OX:VJ* ,
M7_A$--_YYO\ ]_#1_P (AIO_ #S?_OX:VJ* ,7_A$--_YYO_ -_#1_PB&F_\
M\W_[^&MJB@#%_P"$0TW_ )YO_P!_#1_PB&F_\\W_ ._AK:HH Q?^$0TW_GF_
M_?PT?\(AIO\ SS?_ +^&MJB@#%_X1#3?^>;_ /?PT?\ "(:;_P \W_[^&MJB
M@#%_X1#3?^>;_P#?PT?\(AIO_/-_^_AK:HH Q?\ A$--_P">;_\ ?PT?\(AI
MO_/-_P#OX:VJ* ,7_A$--_YYO_W\-'_"(:;_ ,\W_P"_AK:HH Q?^$0TW_GF
M_P#W\-'_  B&F_\ /-_^_AK:HH Q?^$0TW_GF_\ W\-'_"(:;_SS?_OX:VJ*
M ,7_ (1#3?\ GF__ '\-'_"(:;_SS?\ [^&MJB@#%_X1#3?^>;_]_#1_PB&F
M_P#/-_\ OX:VJ* ,7_A$--_YYO\ ]_#1_P (AIO_ #S?_OX:VJ* ,7_A$--_
MYYO_ -_#1_PB&F_\\W_[^&MJB@#%_P"$0TW_ )YO_P!_#1_PB&F_\\W_ ._A
MK:HH Q?^$0TW_GF__?PT?\(AIO\ SS?_ +^&MJB@#%_X1#3?^>;_ /?PT?\
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M\-G?#'_H)7G_ (!O1[&I_*P_M_*O^@F'_@2/<Z*\,_X;.^&/_02O/_ -Z/\
MAL[X8_\ 02O/_ -Z/85?Y6']O95_T$P_\"1[G17AG_#9WPQ_Z"5Y_P" ;T?\
M-G?#'_H)7G_@&]/V%7^5A_;V5?\ 03#_ ,"1[G17A?\ PV?\,/\ H)WG_@&]
M'_#:'PP_Z"=Y_P" ;T_J];^1_<']O95_T$P_\"1[I17A?_#:'PP_Z"=Y_P"
M;_X4G_#:/PP_Z"=Y_P" ;T_JU?\ D?W!_;V5?]!,/_ D>ZT5X5_PVE\+_P#H
M)WG_ (!O1_PVE\+_ /H)WG_@&]5]4KO[#^X?]O95_P!!,/\ P)'NM%>$_P##
M:?PO_P"@G>?^ ;T?\-I_"_\ Z"=Y_P" ;T_J>(_Y]O[@_MW*O^@F'_@2/=J*
M\)_X;4^%W_03O/\ P#>D_P"&U?A=_P!!.\_\ WI_4L2_^7;^X/[=RO\ Z"8?
M^!(]WHKPC_AM;X7?]!.\_P# )Z3_ (;7^%O_ $$[S_P">J^H8O\ Y]/[F/\
MMW*_^@F'_@2/>**\&_X;9^%O_03O/_ )Z/\ AMGX6_\ 03O/_ )ZK^SL8_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1/%%EHDGA7QA;I96MO9!OM%IMC7:S.?O$Y7/;DUTX_8EU#4_AU\1K'7O&O\
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M &*]HH **** "BBB@ HHHH \T_:2&?@?XN]K,G]17Y?GK7Z@_M(?\D/\8?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ"]O;?3K:2YN[B*U
MMXQEYIG"(H]23P*Q/^%B^$_^AGT;_P &$7_Q5.S>QE.K3INTY)>K.BHKG?\
MA8OA/_H9]&_\&$7_ ,51_P +%\)_]#/HW_@PB_\ BJ?*^QG]9H?SK[T=%17.
M_P#"QO"?_0SZ-_X,(O\ XJC_ (6-X3_Z&C1O_!A%_P#%4<K[!]9H?SK[T=%1
M7._\+&\)_P#0SZ-_X,(O_BJ/^%C>$_\ H:-&_P#!A%_\51RR[!]9H?SK[T=%
M17._\+&\)_\ 0T:-_P"#"+_XJC_A8WA/_H:-&_\ !A%_\51RR[#^LT/YU]Z.
MBHKG?^%C^$_^AHT;_P &$/\ \51_PL;PG_T-&C?^#"+_ .*I\DNP?6:'\Z^]
M'145SO\ PL?PG_T-&B_^#"'_ .*H_P"%C^$O^AHT7_P80_\ Q5')+L'UFA_.
MOO1T5%<Y_P +'\)?]#1HO_@PA_\ BJ/^%D>$O^AHT7_P80__ !5/V<^S#ZS1
M_G7WHZ.BN<_X61X2_P"AIT7_ ,&$/_Q5'_"R?"/_ $-.B_\ @PA_^*H]G/\
ME8?6*/\ .OO1T=%<Y_PLGPC_ -#3HO\ X,8?_BJ/^%D^$?\ H:=%_P#!C#_\
M53]E4_E?W!]8H_SK[T='17-_\+*\(_\ 0U:)_P"#&'_XJC_A97A#_H:M$_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /G/]MSXDZSX5^'ND>$_"=]-8>,?&
M6IPZ3I\]M(4EA4NOF2*PY&!@9'0,:Y/]E;XH^(]0^#WQ'\#>+=5N;SQWX"N+
MRQN+Z>9FGFB^=HIMY.X\A@#Z*OK4WQ>_9E\1_M!_M(PZKXDN;O0_ V@:=Y>E
M7.F7>RXDN6(+.,<KU;GV%<]I?[(WBCX,?'&76/!-W>>(/"_B/0[G3]<DU:\W
MW"SE3Y;Y/WAD1_3#>M 'C?[*/[1_B[P;\.?B'+XR\2ZIK4DWATZUI%SJ=W).
MRL&:(JA<DC#8/'I78_L=>,O'LOPX^.H\4>*=7U35],TI[BVEO+V25K5S;2N#
M&6)VD'!X]!6-JG[#/Q!U7X?_  =T\6T%K?Z49;+7XTN0 ;5KCS.O\7';WKWS
MP+\!?$_AK5/V@MUE#%9^*K>2'1=LH_>#[.\:AA_#R10!UW[$'B;5O&'[+W@G
M5]<U*ZU?5+E+HS7EY*999,74RC<QY.  /H!7NM?$WP+M?VC_ ((_##0O!-I\
M.-!O[/2Q*JW4VJ%7</,\A) &.-Y'X5]H:9+<S:;:27D2P7CQ(TT2'(1R!N /
M< Y% %FBBB@ HHHH **** "BBB@ HHHH \S_ &D_^2'^+?\ KT_]F%?F&97S
M]]OSK]/OVD/^2'^+_P#KQ;^8K\OCUKU<'\+]3\$\05_PH4O\'_MS'>:_]]OS
MH\U_[[?G3:]X^$_[-UK\3/A'JOBH:K-;ZG;S7$%M9*@*RO'$' SUYR?RKOE-
M05Y'Y]@L!7S"HZ6'C>23?;1'A)E?'WV_.FB5\_?;\Z]T^%_[.5MXY^$NK^,+
M_5)K&6V$QMK9$!$HC7))S[G%+\&/@UX!^*J66G-XIU"V\1O;M//:):@QH%ZX
M8]>HH]M%7?8]"ED6,JNDDDG45XW:5U\WOY'A9E?/WV_.D\U_[[?G7:?$W0_!
MNAW%E'X1UR\UH-Y@NOM=OY7E$$;<>N?F_*CX/_"V^^+?C*VT6T8P6_\ K+J[
M(^6",=2??L*Z%-*/.]$><L#5EB5A()2FVDK--._FM#BC*^/OM^= E?'WV_.O
M9[+]GR"[^)OC'0YM8:S\/>&%::\U-X]S[ .,*.YYK*^('P-FT2]\*R>%;Q_$
MFD^*$)TN81^7(S@C<C#H",C]?2M(UX-I7.R63XR%.55PT3MNKZ/EVW:YM+[7
M/*_-?^^WYTUI7S]]OSKUKXQ_ EOA%X4\,7USJ*WFI:GY@N882&BA9?X58=2.
MA]ZX#P1X,U'X@^+-.T#2D#WM[)L4M]U!U+'V R:ZZ=6,H\Z>ASULOQ&'Q"PM
M2'[QVTZZVM^9B&5\_?;\Z:TKX^^WYU]$K\ OAO=>(CX/MOB'(WB[S# NZV_T
M5IQ_RS#>N>*QO OP0\*W_BB7P?XL\07VC^+UOVLDL[>V#Q., JVX]CG-5'%4
M[-ZZ:[/;N>G_ &%BU*,/=U=K\T;<W\K=]'Y=3P[S7_OM^=-:5\_?;\Z]F\??
M"+P=IGB:T\+>%_$EWJ?B634DT^6"\MQ'%'DX+;AUP<5TNJ_LZ^ [+7;OPDWC
MJXLO%]M$S'^T+40V<CA<[5<UUQQE))-WU\GMW]!QR/%RE**Y?==OBC:[Z)WW
M\CYR\Q\CYV_.FF5\??;\ZDNK=K2ZE@<J7B=D8J<@D''![BH#TKV8,\2UM&!E
M?'WV_.FM*_\ ?;\Z#TIK=:[8E)(0ROS\[?G3#(^/O-^=*>],/2NV#-$D!D?C
MYF_.F&1\_>;\Z4]J8>M=D&6DA/-?^^WYTPROC[[?G2TP]*[(-FJ2$,K_ -]O
MSI#(^?O'\Z0]J0]:ZXMEI(3S'_O-^=,,CY^\WYTM,/6NB+9HD@,K_P!]OSIK
M2/\ WV_.@]::W6NJ+9:2 R/C[S?G3?-?^^WYT'I3:U39:2%,KY^^WYTWS'_O
M-^=(W6DK9-E60K2/G[S?G09&Q]X_G36ZT'[M7=E60OFO_>;\Z_2_]AKXUCXB
M_#G_ (1W4;C?KF@*L1WGYI;<\1O[X^Z?H/6OS.KT#X$?%:[^#?Q,TGQ%;EFM
MD?RKR 'B6!N'7ZXY'N!7SG$.5+-\#*E'XXZQ]5T^>Q]#D>8_V9C(U'\#TEZ=
M_EN?L115/1]7M-?TJSU*PF6YLKN)9X94.0Z,,@_D:N5_,K3B[/<_?TU)7044
M44AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 07=[;V$7FW
M5Q%;19QOF<*,^F34HD0Q[PP*8W;L\8]<U\R>&_A?X<_:$^+'Q&U/XAV?_"1C
MP_JIT?2]%O96-K9P+&K>8(@0"[DD[B#QTKS7XFZ;J'PPT7XX?#CP;J;0^$K+
M0K+5K>UO'DN5TPSM*D]K$V_<JN$5U4DA<GCF@#[;AUBPN6A6*^MI6F!,8292
M7 Z[<'G'M5SI7QS\$?#]M\-OC#XPU7Q5)X-T_3-#L+""&>ST@VHM!)&Q @+2
M,(@3G=C[Q]*[GQ%XLU+Q?^T9\/KOPQXDT^[\*W&BZC(\:))(LVR2)9,%7"[^
M0%8@[<-US0!]$PSQW,2RPR++&PRKHP(/T(J2OCS]GSXA^-/A[\&_@Y/?6^BR
M^#]9N(M&2TA67[=")&D\N<R$[#DKDH%X!^\:MV?[8NM:I?'5;*WTZYT<ZDUF
MFA1V-TU^\*RF,RB<?NMW!;9MQC^+- 'UQ5>&_M;BXE@BN899XO\ 61(X+)]1
MU%>;>,OB/X<\;>%O%/AK0?&]AH_B*339XUN!.!)8N5VB1NZ[69<GJ*^>_#/P
MZ\+_  GUCP?<>(?AKJ7PXUBTOK>)?&F@:BMW;7DK,$V7,FXN8YF.#YB=6'(/
M- 'VC%/'.&,4B2!6*ML8'!'4'WJ2OCWP=XZ\;?#;0OB#XBTVWT2;PQ9>,[A+
MFUN5E^UW DDC1V1P0J;=PP"K9YZ5K>,?VMM9@\3>*K?0AI4-OX>N&METZ^LK
MJ>XU.1%#.J2Q?)#DG:N0_/7 H ^J!<1&5XO-3S$4,R;AE0>A([#@_E3;6\M[
M^$2VT\=Q$3@/$X9?S%?%WQ;U[4O$G_"ZM<T9O[&N+_X?:+=LE[$WF1Q.;MGC
M(5E*OAL9['L:^@--?_A37[.LEY!9:5;3Z7H[7(BT>S^RVQDV94B/)QVR23DY
M- 'JB3QR;]LBML.&P0=I]#Z5%:7]K?HSVUS#<HIVLT3A@#Z'%?*OB+PRVHZ/
M\&OAYJ-]<V^B>+WN=0\0W%M.T,FI2K")O):12&P[.20#R$Q5WXF_";PI^SOJ
MW@?Q3\.=.3PMJ=SK]EH]WIUA(ZPZK;3OL>*2(DJS*#O#XR-O6@#Z3?Q+I$;L
MCZK9*ZG!5KA 0?3K5F34K2*T%T]U"EL<$3-( A]/FSBOEGXF_LV?"YOCU\/[
M<^!M',.L/?S7Z>3Q<.(]P9N>3N)-:'QD^"-G>>*_#<&F^#M.\<^$=!TLVP\"
MB_6U%FS.2MS'&Q".2HVX8C&.* /IK[3"(XW\U-DA 1MPPV>F#WS4M?,7PU\)
M>%-=^$_Q%\(^'K;7?#$MC=?:#X<UA_WGA^Z,2RP_9CD[8RRB5<,PR3C'2O:O
M@UXRG^(7PJ\*^([I=EWJ&GQ33@# \S&'(]MP- '9T444 %%%% 'FG[2)Q\#_
M !?[V3#]17Y?GK7Z?_M)_P#)#_%W_7F?_0A7Y@'K7JX3X'ZGX+X@?\C"E_@_
M]N85]:? ?Q-_PB7P(\,Z@SE+?_A.1!.?^F<D(C;]&KY+J=;ZY6V%L+B86X?S
M!")#LW?WMN<9]Z[9P]HK'P^5YB\LK2K)7=K+UNG?\#[RURVLO"6I:[X(TLYL
M]*\+W=VP[[YI2PS]!D5\]?L8 GXS<#/_ !++G_V6O%GUC4'EDF:_NFED78\A
MF8LZ^A.>1[5!:7MQ83>;:W$MM+C&^%RC8],BIA0:A*-]SVJ_$$*V,H8E4K*D
MVTK]-++;HE8[3P%<^!K7Q#JI\=V>J7ED01;KI; .)-_);+#C%>]_"WQ)\*8;
M&PT7P_K^I:#>:AJR3RP2V;233(K?NX&D&0%[G![U\EL<G)Y-+%*\,BR1NT;J
M<JRG!!]0:Z)T?:=6>9@,WE@6K4HRWU:]ZSWU33\C[:U&STK4/'_QJ\+Z'J#7
M^OZWI_F"TE41'SU)W1(3C=QMY]Z\J^.LEYX ^$/PE\+W,C:?XITZ*XO+B".0
M>;:JY^7)!X)R?^^37S\=0NQ>?;!=3B[#;A<>8WF9]=V<YIMW>7&H3O<74\MS
M</RTLSEW;ZD\FG3PSC)-O1?Y6/3Q6?QQ%&I"-+EE*Z33T47/GVM>]^M_D>\?
M%UD;X!?!Y[G>\1^T-*0?F8>8V>?7K6S\)O'7PB\)_%/PK>^'K;6-+D=I+:\N
MM7=?*0.F%((8X^88SQUKYMEO;B>"*"6XEDAB_P!7&[DJGT!X'X57:NI8=2@X
M-]_Q.19U*GB8XFG35TH;J[]Q):/I>VI]+:5^RUXWL?C5#?3V\<?ANWU(:BVO
M&X3R3 )-^X<YW$=L=?;FJS>+;#QQ^VI8ZKI3K-8OJD444R=)-B;2P]B0<&O
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M;[O_ ,!E_P :^P:*M9SCE_R\_!?Y#_U5R;_GQ^,O\SX]/_!.W2S_ ,S?=_\
M@,O^-)_P[KTO_H;[O_P&7_&OL.BK6=Y@O^7OX+_(?^JV3_\ /C\9?YGQV?\
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M44 %%%% !1110 4444 %%%% !14<\OD0O)M9]H)VJ,D_2LD^)0"1]ANO^^*
M-JBL7_A)1_SX77_?%'_"2C_GPNO^^* -JBL7_A)1_P ^%U_WQ1_PDH_Y\+K_
M +XH VJ*Q?\ A)1_SX77_?%'_"2C_GPNO^^* -JBL7_A)1_SX77_ 'Q1_P )
M*/\ GPNO^^* -JBL7_A)1_SX77_?%'_"2C_GPNO^^* -JBL7_A)1_P ^%U_W
MQ1_PDH_Y\+K_ +XH VJ*Q?\ A)1_SX77_?%'_"2C_GPNO^^* -JBL7_A)1_S
MX77_ 'Q1_P )*/\ GPNO^^* -JBL7_A)1_SX77_?%'_"2C_GPNO^^* -JBL7
M_A)1_P ^%U_WQ1_PDH_Y\+K_ +XH VJ*Q?\ A)1_SX77_?%'_"2C_GPNO^^*
M -JBL7_A)1_SX77_ 'Q1_P )*/\ GPNO^^* -JBL7_A)1_SX77_?%'_"2C_G
MPNO^^* -JBL7_A)1_P ^%U_WQ1_PDH_Y\+K_ +XH VJ*Q?\ A)1_SX77_?%'
M_"2C_GPNO^^* -JBL7_A)1_SX77_ 'Q1_P )*/\ GPNO^^* -JBL7_A)1_SX
M77_?%'_"2C_GPNO^^* -JBL7_A)1_P ^%U_WQ1_PDH_Y\+K_ +XH VJ*Q?\
MA)1_SX77_?%'_"2C_GPNO^^* -JBL7_A)1_SX77_ 'Q1_P )*/\ GPNO^^*
M-JBL7_A)1_SX77_?%'_"2C_GPNO^^* -JBL7_A)1_P ^%U_WQ1_PDH_Y\+K_
M +XH VJ*Q?\ A)1_SX77_?%'_"2C_GPNO^^* -JBL7_A)1_SX77_ 'Q1_P )
M*/\ GPNO^^* -JBL7_A)1_SX77_?%'_"2C_GPNO^^* -JBL7_A)1_P ^%U_W
MQ1_PDH_Y\+K_ +XH VJ*Q?\ A)1_SX77_?%'_"2C_GPNO^^* -JBL7_A)1_S
MX77_ 'Q1_P )*/\ GPNO^^* -JBL7_A)1_SX77_?%'_"2C_GPNO^^* -JBL7
M_A)1_P ^%U_WQ1_PDH_Y\+K_ +XH VJ*Q?\ A)1_SX77_?%'_"2C_GPNO^^*
M -JBL7_A)1_SX77_ 'Q1_P )*/\ GPNO^^* -JBL7_A)1_SX77_?%'_"2C_G
MPNO^^* -JBL7_A)1_P ^%U_WQ1_PDH_Y\+K_ +XH VJ*Q?\ A)1_SX77_?%'
M_"2C_GPNO^^* -JBL7_A)1_SX77_ 'Q1_P )*/\ GPNO^^* -JBL7_A)1_SX
M77_?%'_"2C_GPNO^^* -JBL7_A)1_P ^%U_WQ1_PDH_Y\+K_ +XH VJ*Q?\
MA)1_SX77_?%'_"2C_GPNO^^* -JBL7_A)1_SX77_ 'Q1_P )*/\ GPNO^^*
M-JBL7_A)1_SX77_?%'_"2C_GPNO^^* -JBL7_A)1_P ^%U_WQ1_PDH_Y\+K_
M +XH VJ*Q?\ A)1_SX77_?%:%A??;XB_DR0X.,2#!- %JBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZSKFG^(/$-IXT\(H VEZ]%,C2NW!VL%]B>O0K[UG/"N%-5');7MK^>WR,JF
ME3HJK*2U2=M=GV=K-^5SWFBBBN$\L**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSGZBNG_:D^(VD?%SP7\.];\._:9K$>)4A)FA*,&4KGCTYK[&_LBQ)_X\X/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?E[4ZF&HJK[./2_5WT5[:JWYCJX+#*O[*"VOLW=V3=M5;7RN>G_#?]J3PO\
M$+Q5%X9GT[6?"OB">,RVUCK]IY#7*C)S&02#P"<'&><9Q77_  _^+.C?$C5O
M$NG:5%>1S^'[S[%=FZC55:3+<H0QR/E/7%8GB#X@_#R7XL>%=$NXK35O%MQ'
M(^G7$,"W#VJ\$G>,^7G!Y]C7F/[+FM:?I?C_ .,ZWE];6C-XA)43RJA/,G3)
MKDE1A*$IQBUHG^-ON."6'ISI3J1@XV2:3\Y6T\CV3Q7\7M(\'_$'PQX/O+:\
MDU+Q!O\ LTL**8DV@D[R6!'W3T!K,^%O[0?A?XM:YXCT;2?M5MJ>A2F.XMKQ
M%5I%#%3(F&.5R,'H1D9'(KR_XT7D%_\ M3?!::VFCN(6^T8DB8,I^23N*\#\
M%^'=5\()XJ^,'AI99]2\.>*[NUU2R0\7.GL$+C'JI8G\<_PUT4\)3G23>DFE
M;UNU^ECJI8"C4H)MVDTK=KN37XVL?5LW[6'A2'PI)KYT_53:)K;:"4$4>_SP
M0-V-^-G/7.?:M;XH_M'>&_A=J5GI$MGJFO\ B"ZB\Z/2-%MO/G"?WF&0 /U]
MJ^+;;4XM:_9Y&H0*RP7?Q",Z!NH5F1AGWP:^@/AEJ5EX=_:Y\?IK\T5G>WUC
M;MILMTP4/"!R%)_#\JTJ82E3O*S=KZ=[6_S-JN7T*7-*S?+S:7WLXK]=3V;X
M1_'/PS\9K:__ +%:ZM-1TYQ'>Z7J,/DW-L3G&Y<D8.#R">F#@UFW'[2'A*U^
M,T?PT=KK^W'4?OPJ_9PY7<(RV[.[&.W>J.E_%OX;P:]\1-2T>"V75-"M_/UG
M5(+8 3A4R!YP'SD8QC/4&OB.75]1U'P==^-F\*:X?%\VN_V_'K2VW^CK #PF
M_KMP2.G85G1PD:LI-II:6OW?Z&.&R^%><W*+BM$DWU:O]WZ6/T)\1_%K1?"_
MQ"\.^#;R*\;5M=1WM7BC4PJ%#$[V+ C[IZ UVM?(GBGQUI_C+X^_ CQ.EQ%%
M:7NG33-([A51BDF02>G/%?5UAK>G:H[)97]M=NHRRP2JY ]3@UPUZ/LHPTU:
MU];M'F8G#^QC3TU:U];M?H7:***Y#@"BBB@ HHHH *Y[X@>-K+X<^#M4\2:C
M%/-9:?%YLL=LH,C#(' ) [^M=#7E'[5/_)OGC7_KS'_HQ*UHQ4ZD8O9M'1AX
M*I6A"6S:7XE74_VI?!^BZSX&T_4$OK/_ (2^TBN[*YEC010K)P@E.[*G.!P"
M!GKBNHUWXO:1X?\ B)9>#KBVNWU*[L9=026-%,0CC!)!.[.>..*^/_%WPYM?
MBQXJ^!7A>ZD: 7O@E_*F4\Q2I;R/&WN RKD>E/\ AAXYUGQ/\>]#T;Q-!+#X
ME\-Z#?Z5?/)_RV*(VR0'OE<<]^O>O8>#I<O-'HFW][L_PU/?>747#GCNHR;7
MS:3_  L_D>SVO[<_@Z>":\E\,^+8=*BD,;ZG_9RO;J0<$EED/ _.O?/#7B33
M?%^@V.LZ1=I>Z;>Q":">/HZGI]/H:^8_V8?$WA_2/V:-=CUN_LXK<7&H>;!<
M2KEE);C:>N:Z[]AJUO+7X Z>;I72&6]N9;4.,?N3(<$>Q.XCZUS8FA3A&;@F
MN5V]=_\ (Y,;A:-.-25.+7)*V][[_P"1] T445Y9X84444 %%%% !7 _&7XR
MZ1\$O#EMK&L6=_?0W%RMK'#I\:O(7;IPS+Z5WU?,W[>/VC_A7?AG[&4%W_;U
MMY)D^[OS\N?;.*Z<-3C5K1A+9G;@J4:^(A3GLV=9X(_:T\(^,?%MCX9N=,U[
MPQK%^#]DAUVQ$"SGGY5(8\G'? /3KQ78?#+XQZ/\5-+UV^TJVO+>+1[V6QG6
MZ159GC&25PQX^N*\CT_X*?$KXA?$?P=XF^(>J:)'IWAAS=6=KI$3!Y9/E(W%
MNV57OVZ<UYA^SUX6^(NN:1\0;CPGXPL]!TU->O!-:W%F)6=NI(;''&!7?+#T
M)1DX2LU;JVE=OR/5GA,+.$I4Y)-6OJVDVWUMVL?5WPQ^,&B_%/PS?Z[IT5S9
M6-E<2VTQO552#']YOE8C'%9/P8_:(\+?'.XUNW\/B[BGTF15FCO$5"ZMD*ZX
M8Y4E3UQ^M?)/A3Q_>>!/V0_$5A;NUQK^N:[<Z7;B%?FD9FQ(5 ]1Q_P*G?#S
MQ9;_  >^,WP_U*U\-:QX9T*]L(O#NKR:G;B))YC]V;(."=P1CGLK5K+ 1M4M
MOKR_+?[]C:65P:J\M[IOE^6K];[+S/ICQU^U;X;\&^*[_P /VFA^(?%-[IN#
MJ+Z'8B>.SR,_.Q8<@?\ ZZNZY^U%X-TGX56GC^W%]JNC7%PMJ(K2$?:$E.?E
M9&88(QSS7C>J^&EU7XI^/-8^%GQ#3PMKT-P5UO1M8B"V\\B@C<-PY4X/.._7
M!K@O'?CV;Q]^RN[OI>FZ'?V7B>*UFFTN%8[:>0%OWR@<<]31'"4I\EEU5^^O
ME;[K"A@*$_9I)[QOK9ZKJK?<TV?1_AC]JFS\4:_INEQ_#_QQ8F^G2!;N\TD)
M!'N( 9VWG"C.2?2O<:\!^'FC^/;+7=&GU;XNZ7K&EJ5\W38[:%7F4K@("!D'
M.*]]90ZE3T(QQ7F8B,(R2A^OZI'CXN%*$TJ5K>3;_-(\]U+X[>%M/^*.E^ $
MN'O?$%\K,4MMKI;X!.)#G@G'3!KT.OE#Q#\.?#_P[_:I^&D.A:>EF;R.[N;F
M7):2:1MQ+,QY/7\*^KZ=>G""@X=5?7U88JE3IJFZ5[25]?5K] HHHKD. ***
M* "BBB@ KY]U3]M'PMI>N:WIQ\+^*[U=(F:"ZN['3TEA1EZY;S!@=^<5]!5\
M._"NP^)^I^-/BW:^ [C0[>SFUB2.Z;549G#$$ KCCIZBN_"TJ=13E4Z6ZVZG
MK8&A2JQJ2J_9MUMN^^I]"_\ #4'@RXTWP3J%@UYJ-IXLOO[.LW@B ,,VY5(E
M#,"N"XSC/0UTOCGXMZ3X!\5>%= O[>[EN_$=PUM:O;HI1&&WER6! ^8= :^2
M?BE\&-1^$6@?!7PS8:Q'_P )!/XF><Z@8\Q1W,CPX8*>JJ<<=\5N?$7PUX\\
M/_'+X/'QIXJM/$:R:JWV<6UJ(?*P4W9X&<\?E77]5H2:<9:/F]7:]NAW?4<-
M)QE"6C4^]W:]NENGD?0/QB_:)\*_!'4-$L]?^U23ZK)MC%JBMY2Y +ON887)
M[9KH_B'\4_#WPP\&/XGURZ>/3!L$?D)YDDS/]U$7N3^7!)(%?%'Q)\20?%[X
MK_$&]NO#&L>)-+MK)]%TF;3K<2I!,IR7))X^8=JZJP\>>%?B;^R?I6C?$'4+
MW1[O3M3BTAKZ&(O):72 ^5(X[ IG.<=^<TW@HQC3;3W7-;S[#>60C"DY)[KF
MMYZZ+RV9[EX#_:I\-^,O%=GX<O=$\0>$]5OP38QZ]8^0MT!_<8,>3[_G67K/
M[8>@Z9XKUG0+3P?XNUNZTF<V]S)I6GI/&&^H?/Y@5YA_PDOC/X3_ !+\!Z9X
MIUW0OB=I&I78@L;MH$>_M"2/WBL!D=N><XZUD> -,\57_P :OBR?#GCVS\&J
MNJCS4NH8Y/..."-X[>U-86C=R:TM=:NV]NU_P+6!P]W-KW>6ZU=M[=K_ (;G
MUM\,_B'%\3/#S:M%HNK:$HE:+[+K-MY$W&.=N3QSUJA\5OC1X>^#]I8/K(O;
MN\U"0Q6>G:;;^?<W##KL3(Z9'4CJ/6K_ ,,(-6M?"L4.M^)+?Q5J22/YFHVJ
M*BL"<JN%XR 0*Y/]H'XC^%/A1I%CXBUG3;74_$,;M%HT+QJ9C,V/N,>5'3)K
MSHPC*MR)779?\$\:%.$\3[.,;J^B3_5K;Y;'0?"OXR>'OB_I]Y<:*;NWN;&7
MR;O3]0@\FYMW]'3)Q^!-=S7AG[,7@RXTFW\0^)M;U&RO?%7B.Y%Y?06,JNEJ
MN/DCX/4#K7N=9UXPA4<8;&6*A3IUI1I[+^G^(4445@<H4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !14=QYH@D\@(9MIV"3.W/;..U<\9?%V3BW
MT;'O++_\30!TM%<UYOB__GWT;_O[+_\ $T>;XO\ ^??1O^_LO_Q- %"Z^#_A
M2\U?Q!J<VF*][KUN+;4)-Y_?1C''MT%2:A\)?"NJ^ 8O!=WI4<_AR%$CCM')
M(0*<K@]01ZU;\WQ?_P ^^C?]_9?_ (FCS?%__/OHW_?V7_XFM/:ST]YZ&WMJ
MFGO/3S[;'+>)/V;_ (?^+;71+?4]#6>+1K-;&Q'F,OE0KT48-:W@GX*^#/AW
M9WMOH&AV]@+U#'<2+DR2*1@@L><5I^;XO_Y]]&_[^R__ !-'F^+_ /GWT;_O
M[+_\35.M4<>5R=O4IXBM*/(YNW:Y2TOX0^$M)\%3^$H=&@?P_.SO)93#>K%C
MDGGOFL3P/^S?\/OAYKBZQHV@QQ:C&"L4TSF0PCT3/W:ZCS?%_P#S[Z-_W]E_
M^)H\WQ?_ ,^^C?\ ?V7_ .)H]M4LUS/7?7</K%:TESNSWUW]1/"'PXT#P+=Z
MM=:-8BVN=5G-S>2EBS2OSR2?J:9:_#/P[9>-K[Q9!8"+7+Z#[/<W",1YJ<<$
M=.PYJ3S?%_\ S[Z-_P!_9?\ XFCS?%__ #[Z-_W]E_\ B:CVD[MWW(=6HVWS
M/71B^!OA[H7PWT-]'\/V0L=/>9YVB#$Y=L;CS]!570/A1X6\-Z1J^EV6DPC3
M]6F>XO+>7YUF=_O$@^M6?-\7_P#/OHW_ ']E_P#B:/-\7_\ /OHW_?V7_P")
MINI-W;>X.K4;;<GKN</HW[*7PQT+6X=4MO#433P/YD,<SL\4;>JH3BNZF^'V
MA3^.;;Q>]DIU^WM#8Q763E8<L=N.G5F_.F^;XO\ ^??1O^_LO_Q-'F^+_P#G
MWT;_ +^R_P#Q-5*M4F[RDV7/$5JCO.;?3?H067PL\,Z;X[NO&-KI<<'B&ZC\
MJ:[3@NN,<CIGCK765S7F^+_^??1O^_LO_P 31YOB_P#Y]]&_[^R__$UFY.6[
M,I3E.W,[G2T5S7F^+_\ GWT;_O[+_P#$T>;XO_Y]]&_[^R__ !-20=+17->;
MXO\ ^??1O^_LO_Q-'F^+_P#GWT;_ +^R_P#Q- '2T5S7F^+_ /GWT;_O[+_\
M31YOB_\ Y]]&_P"_LO\ \30!O7MG%J%G/:SKO@F0QNOJI&"*R/!/@C1OAYX>
M@T30;066FP%F2$$G!)R>M0>;XO\ ^??1O^_LO_Q-'F^+_P#GWT;_ +^R_P#Q
M-5S.W+?0KFDH\M]!9OAYH,_CB'Q>]D#K\-N;5+K<<B,]1BJM_P#"GPQJ/CN#
MQC+IJKXBAA-N+R-BK-'@C:P'#<,1S[>E6?-\7_\ /OHW_?V7_P")H\WQ?_S[
MZ-_W]E_^)JO:377R^78M5:BVD]K?+MZ'GA_8^^%6YF'AL*6)8[9W')_&NTNO
M@[X0O_ L'@^ZT:&ZT"!<16LV6V>A!Z@^]7_-\7_\^^C?]_9?_B:/-\7_ //O
MHW_?V7_XFKE7JRMS2>GF:RQ5>=N:;=O-F%\._@)X(^%NH3:AX?T9+?4)4\MK
MN5C)*%_NACT'TK$UC]E/X::]K%]JEYX?$E[>S-//()G&]V.2>#ZFNX\WQ?\
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M[^R__$T>;XO_ .??1O\ O[+_ /$U#DW:[V,W*4DDWL=+17->;XO_ .??1O\
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M]&_[^R__ !-'F^+_ /GWT;_O[+_\33]I.[=W=E*M43<E)W>^IRW@K]FWX?>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** (KJ<6MK-,1N$:%\#O@9KY
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M _#K7OB5-H1*ZM>:41'!;,.J!BK;V&#QQR#C.*^DYT,MO(JG#,I /OBOB/\
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MO#_:,S>;'<@G#3HO0$_4#\ZS1\5;L^(;R^N+*&>QN[<6LEADA?* P #ZCUK
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MJ>:\0D\*:L<_Z%+^5?0M%=^'Q;P\7%*YZN$Q\L)%P4;W=SYQD\)ZO_SXS?\
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@>ZANTWP31S)TW1L&'Z5\^5ZQ\,?^0'-_UU_]E6@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>mrkr-20251231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20251231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %7 ID# 2(  A$! Q$!_\0
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M &@+_3O[0MO!J3V.,_:(]+D*8]<TGE&)CO;[QK&4GM?[C]*:*_+5_P#@I/\
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MC_C0/^"EOQ3)P+31B?06Q/\ 6C^QL5Y?>'UVB?J;17Y9?\/+OBE_SZZ-_P"
MQ_QH_P"'EWQ2_P"?31O_  &/^-']C8KR^\/KM$_4VBORR_X>7?%+_GTT;_P&
M/^-7-+_X*)_&/7)FBT[1M.OY4&YDMK)W('J0#0\GQ2WM]X?7:7F?J#17Y:2_
M\%*?BK!*\<EEH\<B$JR-;$%2.H(S31_P4M^*9SBST<XY.+8\?K1_8V*\OO#Z
M[1/U-HK\P;'_ (*'_&;4[6:YL]#L+NWAYEFAL794^I!XJA_P\N^*7_/IHW_@
M,?\ &C^Q\4^WWA]=I>9^IM%?EE_P\N^*7_/IHW_@,?\ &C_AY=\4O^?31O\
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MTT;_ ,!C_C1_P\N^*7_/IHW_ (#'_&C^QL5Y?>'UVB?J;17Y9?\ #R[XI?\
M/IHW_@,?\:/^'EWQ2_Y]-&_\!C_C1_8V*\OO#Z[1/U-HK\LO^'EWQ2_Y]-&_
M\!C_ (T?\/+OBE_SZ:-_X#'_ !H_L;%>7WA]=HGZFT5^67_#R[XI?\^FC?\
M@,?\:/\ AY=\4O\ GTT;_P !C_C1_8V*\OO#Z[1/U-HK\LO^'EWQ2_Y]-&_\
M!C_C1_P\N^*7_/IHW_@,?\:/[&Q7E]X?7:)^IM%?EYI__!3;XD6\H:ZTK1[J
M/NHB9/U!KZ.^"'_!0WPA\1[RVTKQ+;'POJTQ"+([[K=V/HW;\:QJY7BJ,>9Q
MNO(N&+I3=DSZUHID4J3QK)&ZO&XW*RG((]13Z\D[#\N_^"@W[0M_XT^(=UX$
MTRZ>+P_HCB.Y2,X%Q<C[Q;U"] /7-?(%:7B76YO$GB+5-6N'9Y[ZZEN9&8Y)
M9V+'/YUFU^GX:C'#THTX]#Y2K4=2;DPHHHKI,@HHHH **** "BBB@ HHHH *
M*** /<?V+O#7A[Q7^T-X=L/$B0SV7SR103XV2S*,HI!Z\]J^P_CK\7_C[\*_
MB#='1/ UO??#^VE7R?L-EYXDA&,[MO*G&>W%?"_[/GPAUGXS_$&'1?#^LV^A
MZM ANX;J9V4@J1RA7G<.M?13?M??'3X!^.+CP9XHLX?%SV$P@#7-LZRW"= R
M2+UR.A(->!C*3JXB\;2:7PO\T>C0GRT];K7='GO[5OQ/^'WQ:\<^&]:\#:9<
M:7X@\U(]2CNK;R49]PVY'<AN"<=*T_VT[+XBSW_@.W\<KH223V_EV!T?<!M8
MJ/WF0.>17KG[>'@[0;_0OAUX_CTA-"\2:G>VZW,&T+(ZMM;#@=64]ZRO^"BW
M_(R_"/\ ZY1_^C$K/#U8MT%!?S;ZM6\RZD&E4<GV/,_^'>'Q)AUFVM;N^T6T
MT^6W6X?59+@B"/<<",Y )<XS@5YW\>_V8/%_[/4MD^O_ &:\TZ])6"_LF+1L
MP_A((R#7TG_P5 UR]CM?AMI*7$B6#6\UR\*L0KR (H)'? SCZFM+]IJY^W_L
M?_"&>_D:;=-9^;)(<DKC!R3[55'%XAJE4FTU-M6M^I,Z--<\8K5'A7PY_83\
M>^/O!L'B:XOM*\-:==)OM1JLQ1I@?N]N >V:QOB5^QKX]^%/PXN_&/B Z?;V
M-O.+=K>.8M*<MM5AQ@J>HYZ5] _\%&;75KKP5\-3I23S>&1:\BV!,?F;5V$X
MXZ=*VOB]%KD/_!-W14\1"8:FJV@87&?,">8=F[/.=N*4,97DJ=1R5IRM:VR&
MZ--.4;.Z5[F!^TM$B?L)_#5@BJQ%OE@.3\K5X=\)OV*O'/Q4\*Q^)3=:;X;T
M2;_476K3;/.]"H]">YKWC]HX*?V&OA<'^YOMMV?3G->B_M))\+D^"/P\@\<O
MXB7P[]GC-L/#YVQE_+'^LXQZXK&EB*E*FH4]Y2ETOMY%RIQG)RET2\CX-^-G
M[/?C#X":K;6OB6TC-K=@FUU"T??!/CJ W8CT-<!HVCWOB'5K33-.MWN[Z[E6
M&&",99W)P *^T?VI/B7X6UW]F3PUX9TC1O%*6]G/ ^F:KKUH0)(P""#+W)4_
MI7RY\$/!>N_$#XI:!H?AN_;2M8N)P8;Y'*&#')<$<Y S7L8>O.=!U*NC5_PZ
MG%4IQC448:W/>K'_ ()O>/9[6!;OQ%X>T[5ITWII<T[&4\=.!V]@:\<MOV<_
M%LGQMC^%MU';6'B61RBM.Y\DC9O#!@#D%>1Q7U]IWA[X8> OVD_#NCZWJOB_
MX@_%*.YB3^T;B7$$#;3\QQ_"!GBI?'G_ "DX\*_]><?_ *(:O,AC:]Y)N_NN
M2TMMV[KU.J5"G9675+>YXIH__!.CXD7^IWEG?:CHND>5(8[>2XG)^UD#),:X
MSCW(KGO /[)/B6+]HFP\ ^)8+.%K8I>W EE(BNK8,,^6V.<^E=3^U?XHU6;]
MN"V_T^X4:=>6,5H%D($*G:3M],DDGZUZK^V2RI^UU\(Y&X)>WRW_ &UJUB,0
M^52DO?BWMMIZB=.DKM+X7;U.8_X*!?L[OX5O-,\8Z%%I>F^%["TM=,73X3LE
M\PR/A@H&".1DYKCOVS(OB/'X,\ ?\)NF@K8M%_H']CAO,(\M?]9D#MCIWJ]_
MP4LBD_X:!TA]C^7_ &-;?-@[?];)7H_[>/D?V!\$?M) M]\/F9Z;=D>:RP\Y
M1CAN;6]_78JHDW5MIL>'^!/V"_'_ (S\'6_B*ZOM(\.6MV@>UAU2<I)-G[OL
MN>V:YOXI_L@^.?@[\/!XO\1FP@L_M*VQMHYBTP9B0#TQ@XSUZ&O?_P#@I1::
MW=P?#XZ<ES-X=^R?NQ;!C'YN!MSCC.,8KHOVBXM7C_8(\$IXD\T:D+BP%P)\
M[P,G&[/?;BM*>+KR]E4<E:;M:VQ,J--<\4G>*W/G3X5_L1>._B;X1M_$TEWI
MGAG1[H VLVKS%#.#T('8'MFN#^,/[/WC#X'^(;72_$EI&JWA M;VW??!/SCA
MOZ&OOG]K)?A6GPZ\ 0>.Y/$D>A"!#8#P\=L6X1KC?QC..GXUXY^U)\2_#?B3
MX+>!M TO1?$\"6-U ;'4M>M"OFQ<#_6]SC%/#XVO5G&37NR;Z;?.^OF%2A3A
M%J^J\_T//HO^">WQ(:YTXS7NBV^F7=N+E]3DN2L-N#C"L2!ECGH*X;X^?LJ^
M,/V?(;&\UM[34-*O&\N&_L6)3=C.U@1D$CI7TA_P4@UF\B^'?PQTM)Y$L9X3
M-+"K$*[+&H4D=\9I_P"T)<RZA_P3V^&UQ<R-/.4L\R2'+' 8=?I11Q6(E[*I
M-JTG:UOU%.C37/%+5*Y\B? SX97/Q=^)NC^&[:2VC,TGF2_:G*(T:D%AD=R*
M^N/V]_V:H_#WA31?$GAJWTK2/#OAZP^SW%I&=DTCO( &4 ?-UZDYKXG\!,$\
M<^'F)P!J$'/_  ,5]>?\%-;::Y\=^ 1&CMOTHJ" =N3( .:Z,1[3ZY22E9:_
MU_6QG3Y?83;6NAYW\//V#/'7C?PA8^(]0U/2/"FGWR"2U75I2LDBG[IQVSV!
MYK@_C3^S-XO^!>N:78:\+6>'4W"6M]:.6B<D@8.1D=:^D?'_ ,+/"/PD\#^#
M?^%X^+_%GC+4KB,26&AZ?*?(MVP/D4GDX! R3]*Z3]NY[:7X>?"%[.VFL[1K
MF$PP7!S)&F%PK'UQ7/3QE5UHJ]XR;Z66G9[LUE0@H/2S5NIX]I__  3A^)=Y
M?P12W^C6]G+;"X%Z97,8)Z)C:#NKSSX6?LF>-/B]XIU_2=#>R^QZ'<O:WFKS
M2$6P=21A3C+9P3TKZ._X*2>*]5TS2?AQIEEJ%S:6SVIN'CMY63<X"@$X/..U
M3_!P7]W_ ,$Y_%@\*/-)K[S7379MB3.6++OY'.3'C]:F.*Q/U>-:4E[S26FV
MN[&Z-+VC@ELK^IY))_P3O^(SWUTMGJ6AWVG00M,-2AN28G(ZIP"0WL:\K^$'
M[.7C#XV>)M0T?P];P[=/8K=WUP^R"'!(Y.,G..@%?5W_  39M/$%KX6\?_:8
M[F+06A/E+,&"&;:<[<]\=:Z7]DW^PX/V8OBA-?M?+$VHWPU%M(XO!%G'R$<Y
MVY_6B>-KT?:1;3:<4G;N$:%.?*TK7O\ @?+WQ7_8G\=_"[PM/XDCN-.\3Z);
M9^TW.CRF0P8ZEE]!WQTKZ2_9?_91M[G]G+7=1NK72;GQ+XCLF.G7\C;OL\;K
MP&./E.>N*I?!+XD?"/P#X \9VG@32/'NMZ-?PLE\MW;&XAA8H1GC[I(/)JA^
MROLE_8R^+B6X8KON=BX.0NSCCZ5E7K8B=)QD[6DM;6O?ROT_$NG"G&::ZIGS
M!X;_ &8O&OBWXK:IX T>"VOM4TI]EY=QR_Z-$/[Q?'3\,UW'Q#_8.^('@?PS
M>:Y97FE>*;6Q!-Y%I$Q>6# RV5/7'Y^U>X_\$XX].M_A'\29;@7"78)$_P!D
M&+D1>4?N=]W7'O4W[/'Q#^#WPZN?%4_@/3/B#KINH-FIV]Q ;F->3\[*.C=1
MFMJN,Q$:DXPUY+=-_5WT\C.%&FXIRZWZ[?YGR'\#_P!GKQ=\?M9N++PW;Q)!
M:@-<WMVQ2&'/0$]2?85]O?L:?LN^)/@=\3==O-6NM+UK2KFP\A+S3IA(JRA\
ME&!Y!K"_9JN!+^RY\8IO"BR0:H]Y=O&BKMF1"#M&!R"!FN9_X)>MKB^,/&22
M?:?[)-JAE\S.SS]Q]?XL9S66,K5:U.M9I1C96Z_>71IPA*&EV^I\?_$Q-WQ,
M\4HN!G5;D#T_UK5]^>%/V-0/V2;W1[6#1D\:ZS&L[:L\A*>62&5=^,CCL.]?
M 7Q0_P"2E>*_^PI<_P#HUJ^S=)#7'_!,G45C#2,)W!"Y)_UJUUXWG]G1Y)6U
M1C0Y>:?,KZ,U/V*/!]Y_PI+XN^'HX([W5$FGLT6+#!Y/+*_*3ZFO&;S_ ()Z
M?$BW\)W6KPWVBWU[:H9)])MKG?/'@9*D@8W>U>M?L':A<Z/^SI\5+RVD:&ZM
MUE>-QPRL(3@_6N>_X)AZA=7'Q%\?K+<2RK-I<<T@=R0[^8WS'WYZUR2J5J,L
M15IM>ZUTW_R-E&%14X26]SYE^$'P+\6_&WQ/+H?ANR5I[<9NI[AMD5N,XRY^
MO:O3/B3^PKX_^'WA>[U^VNM+\3Z?9 F[_LB8O)!C[Q*GKCOCGVKZ9_8V31[?
MP+\:9)_M"2#5+D7/]G\7(A^;[G?/7%8OP ^(WPA^'EIXL;P/I7Q UVWO(BFI
M0W-N;F.,X.6('0\G)K6KC:_M)>S6D;:6WOYWT\B(X>GRKF>Y\L_!S]E3QG\<
MO!VK>(?#+6,D&G3?9WMII&6:1\ X48QW[FM/XE?L<>-/AOXA\+:"]SI^LZUX
MA<QV]E8.2\;#[V[(Z#UKZ4_8RUIM%_9H^,>IZ8[VQ@O+N6W8_*T?[DE?H1Q7
MRM^S=X1\9?&;XPZ7INC^)[[2M13?<R:K]H9I+>/^-ER>I_6NB.(K2J56Y)1A
MY>1FZ<%&"2NY'J@_X)M>/6B\I?$OAPZN(_,.F?:&\P#\OUQBO'/ '[-WB[X@
M?%G4_AU"MMIGB/3HY9+A+YRJ+Y94$ @'.=P(K[)^$EC\*/#/[4MOI-E<>+/&
M7Q)BDE2[US4)#Y$;!#N+ 8R,<>E)\+O^4E_CK_L&S?\ H,-<BQM>*FI.]H\R
MTM_2-G0IOEMWMO<\)\/_ /!.OXE:U:W;7%[I&E7D<DB065U,?-N I(W@ <*<
M<$UQ?P7\">//AW^TUI/AVSL;.S\96DLB1PZKDVY^0\D@'((Z$5VOQ+N/&J_M
MWRR;[_\ M1=;B6S*EN+;Y<!?]C;G/;K7T9\5%M!_P4 ^&QCV_;CI[?:-N.NU
ML9JY8FLERU&I*4&]MM/Q1*I0;O%-6:1\<_M!>%_&_B[]I34]"U6SL[SQG?30
MP_9M'!\EV*#:%R!VZYKO;O\ X)R_$BWTMI(]4T&YU=(O.;1X[D^>%Q],9[>G
MO7O'@2'39?\ @IAXN:^V?:8]*=K+>!_KMD8.,]_+,E9VH>(_A%X:_:DU+5U3
MX@WGQ%@OGWVUN"\4F!]Q5QS'MZ#I4/%UDHTZ2M:*>U_UT12HP=Y3ZNVY\7?#
M[X%>,?B3\0IO!>E:6T>MVS,+M+D[%M@IP2Y["O9KW_@GMXT;3;Z;0_$WAKQ+
MJ%BI:XTW3[O=,A'\/U]CBO2]"^-M]IG[7?B?Q-X9\!:WJFE:C:1P:MIYLC'=
M0''^LVGZ=#UKL_!/@SX%_&SQ'J\'PVUS7OA]XWNX9#<1:9/+;2<'+AT/! ;J
M 15UL97BU+963VOZWUNB84*;TW=^]ON/S@NK:6RNIK:XC:&>%VCDC<8*,#@@
M^X(J*ND^)?A6]\#?$+Q%X?U&[^WW^FWTEO-=;BWG,#G?D\DG.>:YNO?BU)*2
MZGG-6=@HHHJA!1110 4444 %%%% !1110 4H)4@@X(Z$4E% 'Z6?\$Z?VA+K
MQIH=YX"UV[:XU'2XQ-82RG+26_0KGN5)'X&OM>OQ]_80U&;3_P!IKPKY3%1/
MYT#X/53&QQ^@K]@J^!S:C&CB?=V:N?18.;G2UZ'\_E%>F_ SX Z_\?M4U6PT
M"[LK2;38$N)3>LR@JS;0!@'G->P?\.X_B+_T&-!_[_2?_$5]M/$4J<N64K,\
M%4YR5TCY2HKZM_X=Q_$7_H,:#_W^D_\ B*/^'<?Q%_Z#&@_]_I/_ (BH^MT/
MYT/V4^Q\I45]6_\ #N/XB_\ 08T'_O\ 2?\ Q%'_  [C^(O_ $&-!_[_ $G_
M ,11];H?SH/93['RE17U;_P[C^(O_08T'_O])_\ $4?\.X_B+_T&-!_[_2?_
M !%'UNA_.@]E/L?*5%?5O_#N/XB_]!C0?^_TG_Q%'_#N/XB_]!C0?^_TG_Q%
M'UNA_.@]E/L?*5%?5O\ P[C^(O\ T&-!_P"_TG_Q%'_#N/XB_P#08T'_ +_2
M?_$4?6Z'\Z#V4^Q\I45]6_\ #N/XB_\ 08T'_O\ 2?\ Q%'_  [C^(O_ $&-
M!_[_ $G_ ,11];H?SH/93['S7X.\8:OX!\26.O:%>/8:I9OYD4R=O8CN#Z5]
M56?_  4J\5_9[=M3\&Z#JFHPJ%6^D!5\^O0XK)_X=Q_$7_H,:#_W^D_^(H_X
M=Q_$7_H,:#_W^D_^(KEK2P5=IU&G8VA[>GI'0\D^,?[1GBWXX>*;#6/$,T?E
MV$@>UL8!MABP0>G<G'6M#XY?M+ZU\=K_ ,,W6J:9:6#Z$JK"MLS$28(/S9_W
M:]+_ .'<?Q%_Z#&@_P#?Z3_XBC_AW'\1?^@QH/\ W^D_^(JE/!QY;->[MY7$
MU6=[]3R_]H3]H_6/VB)]!EU?3;733I$#P1"U8G>&QDG/TJQ\0OVF=:^)'PF\
M.?#^]TRTM-.T;RQ%=Q,QD?:,9(Z=Z](_X=Q_$7_H,:#_ -_I/_B*/^'<7Q%_
MZ#&@_P#?Z3_XBDIX.*BDU[NWD#59MM]3W_P5'\;_  ?\%]"'A6;P]\3=)EA3
M[+YR?O;92,@')P=O2LW]KSQ+K'A[]CO2=!\=WL#^.=6NXGFMHF&1AR[8 Z*H
MP*\X\-_L8?'+P?;FWT7QW9Z9;DY\JWOIE3/TVXK-\1?L%_%WQ;?_ &W6O%>F
M:I=8V^;=7<LC >@RO%>9&E1]JIRJ1LG?16;_ $.MU)\CBHO:QY%X^_::UKX@
M?!W0/AY=Z79V^G:/L\JZB9C(^T$#(Z=ZZ;X9_MK^)O O@F#PGK&@Z5XRT2VQ
M]GAU9-QB Z#.#G%='_P[C^(O_08T'_O])_\ $4?\.X_B+_T&-!_[_2?_ !%>
MBW@I1Y&U:]_F<J]NGS'F'QX_:;\4_'PV%MJD=MI>BV'-MI5B-L*'&,GU..*\
M_P# OC;5?AUXLT[Q%HL_V?4K"42Q.1D>X(]#7T?_ ,.X_B+_ -!C0?\ O])_
M\11_P[C^(O\ T&-!_P"_TG_Q%:PK82$/9Q:MV(<:LI<SW(=<_P""@/B?4[Z#
M5;/PCX?TSQ$H19=9CAWW$B@C*Y(X!Z?C7)^(?VN];\0?'/0?BB^@V$&M:5;_
M &?R$=O+G&& +=P<-^E=E_P[C^(O_08T'_O])_\ $4?\.X_B+_T&-!_[_2?_
M !%816 A\-MK?)FC>(>YXE\1?C'J/Q'^+DGC^\LH+;4'GAG-M$28\QXP,GGG
M%=!\:?VF-?\ C1XXT'Q3=V-MI.HZ,J"W%JQ9<JVX$Y]Q7IO_  [C^(O_ $&-
M!_[_ $G_ ,11_P .X_B+_P!!C0?^_P!)_P#$5LJF$3B[K167H1RUM?,YOXU?
MMGZW\</ D?AW6/#.DVUP'A9M4AR9SY;;L#(X!/49KF_C;^TMK/Q[TGPOI.K:
M=::9!HH$44UNS$L-H7+9]AFO2/\ AW'\1?\ H,:#_P!_I/\ XBC_ (=Q?$7_
M *#&@_\ ?Z3_ .(K.#P5.W*TK;?,J7MY7OU/H;0T^.WA#X2:%#X8D\._$S39
M84%I<R)^]MU*_*3G@[>GX5S/[;GB/4M&_97\*>&O&%[#/XVOKJ*>Z@C8$C;E
MF.!T R!7#^'/V-/CIX1M?LNC>/+33;;M#!?3*@^@VUDZ_P#L#_%OQ5?M>ZQX
MITO4[LC!FNKJ5VQZ<K7G0I4554Y3CH[Z*S?Z'5*I-P<5%ZJQR'PZ_;?\3>#O
M!%IX4UOP_I/C/2;(!;5=63<T0'W1G!SCM7%_&_\ :9\5?'34M.EU9+>PTS3F
M#6NF68VPQD?S/%>H_P##N/XB_P#08T'_ +_2?_$4?\.X_B+_ -!C0?\ O])_
M\17HQ>!A/VD;7.5^W<>5WL>8_'C]I/6?CWIOAVSU73+33TT2(Q1-;,27! '.
M?I4OC']IK6O&?P/T'X97.EVD.EZ0(A%=QLWFOLSC(Z=Z])_X=Q_$7_H,:#_W
M^D_^(H_X=Q_$7_H,:#_W^D_^(JE/!Q48IJT7=>HFJS;?<^5[2ZDL;N"YA;9-
M"ZR(WHP.17T9\3/VW?$/Q5^&4GA+6/#>D_:'A2$:P@)G0*RG*Y'RD[1T-;G_
M  [C^(O_ $&-!_[_ $G_ ,11_P .X_B+_P!!C0?^_P!)_P#$552KA*LHRFTV
MMA1C6@FHK<I1_M[>);OPEIFDZYX4T'Q%?Z:@6TU/4(M\D9 P&VD8STKE?BY^
MUUXD^-'A?0=*U_2['[1I%PMS'?0Y5W8=BO0#Z5V__#N/XB_]!C0?^_TG_P 1
M1_P[C^(O_08T'_O])_\ $5E%8&$N:-KEMXB2LSRWX^_M&ZQ^T"^@MJVFVNG'
M2+<V\7V9B=X..3GZ5[Q^PEI7Q!A\(^(=7\!>(M(GD6=DN_"^I*29,*"DBD=-
MV2,^U<S_ ,.X_B+_ -!C0?\ O])_\16GH'[!7Q=\*7OVO1O%>F:7<XP9;2[E
MC)'H<+S4U98:5#V-.22^]#A[15.>2;/J;X;>*_B1HV@>-O$OQ6LM.\)Z)!9.
MMGI]L51 V#EN.I/%?GU\'OVFO$WP-\4:S?Z"(+S3=3F9[G3KP$Q2@DX/L<&O
M<_$O[&/QR\8VBVNM^.[/4[93D0W%],R9]<;:YC_AW%\1?^@QH/\ W^D_^(K#
M#PPU-35247S6T6VAI4E4DX\J>AB^/OVY/$WBCP9?>&?#_AW2/!.GW^[[6=(3
M:\H/WN<#&?6N<_9[_:O\0?L^:;JFEV.EV6MZ5J+!Y;2]) #8QG(]1VKO?^'<
M?Q%_Z#&@_P#?Z3_XBEC_ ."<'Q&D=5&L:#DG'^ND_P#B*Z?]A4'3TLS*]=R4
MM;GG?A;]JSQ3X(^+>M>.=!M;+3CJ[YNM(1?]%9>R@=OK7<>*/V^/$VH^'-3T
MOPYX6T3P=)J>?M=[ID>)9,]3T'/O6Z?^"8OQ- S_ &UX?_[_ $G_ ,16:?\
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M0A5O3<*\.IG.74<1/"U:\8S@DVF[;WMOOMTVZG;'!XB=.-6,&T[VMKL=#O\
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M&$5^8Z\0[6)=_O1O]ZA\SWH\SWKT>4X[DV_WHW^]0^9[T>9[T<H7)M_O1O\
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M/+-[XDU*Y:/[-;_/Y#, "F1QD#KZ5G?%K6KKPG\4;J\M'N%BN#'>Q&*ZD1)
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MX%FBA.'F89#'T%<U+@^IF="C2S&O*5:+C*7*TH*46G914;R6FO-S>5K7/O\
M 8/$8^O/"9123DK\TFWHFK)7N]5U:W>VBU]B'RXQQBGZE976K?9]8TJ7[)XK
MTH^;:W*<&=!UC;U!%<-X ^)5KXQ0V\J_9M20?-"W\7N*[NTN7L[F.9#AD.:^
MU7M<%54EHU]S\O1[,^/G3QW#N/Y*L>6<=T]FGNNSBUH?2'PV\=V_Q"\(V>KP
MCRI6'EW$!ZQ2CAE/XUU&_P!Z^8/#/CRQ^#WC.]GO&E&@:[#]H2*)"Y6Y'4 #
MUKV[X<?$"#XC>'CJT%A=:='YS1"*[3:QQW'M7H5L.^7ZQ37[N6WSZ?)Z$YIE
M=2BGCL/!_5Y6<7VO]GS<6FOEYG8[_>C?[U!O%&\5Q6/FKD^^O&_@2CR?!;58
MU4L[7NI@*!R3YTE>N[Q4-K;6]C%Y5M!';QY+;(D"KDG).!W-4M%85SY5UOQ]
MH=W\"_!_AZ"_276H-5M8Y[)03+"5F.=X_A_&NW\,>%-&UOQY\9;O4=+M;^=6
MCB1[F$2;5^S9^7(..>XKV@^']',LDITJR\V5@\C_ &9-SL.A)QR1ZU:CM+6%
MYWCMXD>?F5EC ,G&/F]>..:U<]+)?UH(^6)/#&DZ7^S-X U2UTVWBU7^T;&8
MWPC'V@LTV"2_WNG&,]*Z*PU#P?HGBSXD+\18[+^UKJ<M;/J<0=IK4I\BPEAZ
M]EYS7T"=,L&LX[0V5N;6,@I 8E\M".A"XP,4E[I.G:E)%)>6-M=R1',;SPJY
M0^Q(XHY[WN!\[^ O#BZIKWPFMO$%B+M8=.OYH;>]3>%3</*W*W4A2,9KZ90+
M$BH@"(HPJJ, #T%56M[=[B.=H8VGC!5)2@W*#U /4"I=XK.;YG<:T)]_O1O]
MZ@WBC>*BP[D^_P!ZL:<W^GV_^^/YU0WBK.F./[1MO^N@_G4S7NLJ+U1ZU+_J
M'_W3_*O)9'_>/]37K4O^H?\ W3_*O'I7'FO_ +QKQ<L5^?Y'HXU_"2[_ 'HW
M^]0;Q1O%>Y8\RY/O]Z-_O4&\4;Q18+D^_P!Z-_O4&\4;Q18+D^_WHW^]0;Q1
MO%%@N3[_ 'HW^]53<Q"41F11(1D(2-Q'TJ.[U"VL(S)<SQVZ#^*5PH_6CE#4
MO;_>C?[UX(/VB8=/^,>IZ+J>I:9#X6BM!+!=(^YB_'&1WZ\5UZ?M#_#Z1PH\
M1VV3ZYQ71+#U(V]T[9X3$0M[C=U?1=STMI5099@H]2<5\O[V%[\05))D&H2$
MDGG&!BMGQWX_TOXT^*[7X=:1=W2VES&+MM9TR;&PKSM8>G_UJQ4\"P?#;QMJ
M/AZ.[NKRVU2T$\4]XY=W<###)K+$4''#R3^)J]O([J-'V,&INTFKVMT3W_X!
MYW7#?%VU,_AQ6 SM?G\17?7,#6UQ+$PPR,5(K#\5Z6VL:%<VR#,A&Y1[BOF<
MJQ"PF.HUI;*2OZ=3V\!66'Q5.J]DT?+F,45>U+2KFSO9(C;RYST"&K>F>#=;
MUB15MM.FP?XY%VJ*_H2IBJ%*//.:2[W/V:6)H0CSRFDO4Z?X*:P]CXEFL\GR
M;E.5]_6O>Z\W^'7PM;PQ<_;[^42W9'")T6O1Z_#>(L5A\7CG5PSNK*[[L_)L
MYKT<3BY5*.J.1\56":/KNF^)UL(M1CM)5-W:3+N65 >X^E?8E[\4O#%U\,['
MQ-9RJMJX46UK  ',F.(L=L5\U!%E!C=0R.-K*>A%<3*LGP[\16DF]YM"FD.V
M%V)6%CU('0&M*5'#9Y@OJ>.ASI75NZWM?=>J/.H5;U(1;?-"[C;JOY?ZZ'IN
MO:^\]W>^)_$4Z+=2\GGY84'1$'^<UP%G\>](N-3\B2VEAM6;:MT3Q^(Q7&_%
M#Q:WBO6#:0R'^S+8\*.DC>IKD3&K)L*@KC&,<5]W@LBJ8RFZU>R;VO?\+-62
MVUOZ=_V3(^ Z&.P?UK-TW4J+1)M<BZ))=ET=TMK'U7;7,5Y DT$BRQ.,JZG(
M(J\VGKXDT6[T=WV2L/-M9>\<J\J1^->!?"CQK)H6HIH]W(SV$YQ"S'/EMZ?2
MO>]/G-O>P2 ]&%?*XO#5LNK\KT:=U\C\ASK*,5PMF2A?9\T)=U?\UU1ZIX'_
M &@_#\7@72)O$^JP6.L[_L-Q;DYD,JG:6VCD ]<^]>PK*'56!RK $'U%?.GP
MN\"^'M2^)GBU=3T>UO9=MO?023)DH3G=C\0#7T+O%=6*5%N,J*:YE=]M4G9>
MFQYN>PP-.O%X-23DE)WMRKF2DE&VME=K4GW^]&_WJ#>*-XKAL?,W)]_O0'YZ
MU!O% <9HL%SXX\)G/_!1R _]/9_])S7Z75^:'A Y_P""C4'_ %]G_P!)S7Z7
MUXV<?Q8?X5^IZV!^!^I^5_\ P3R./&'C+_L'0_\ HVON+=]:^&_^">QQXO\
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MZ8U^9O@LY_X*+6W_ %]G_P!)S7Z95\]G/\6'^%?J>Y@/X;]3\J?^"?9QXO\
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M'':NTW5T+$TL55J>S:O%ZI;)M7_(^<S"%=S6*K4U!5;R26BM=IV71731/O\
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MC=46^C?1RL+DNZC=46^C?1RL+DNZKNC-_P 3:T_ZZK_.LW?5W17_ .)O9_\
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MC?5W1'_XG%E_UV7^=96^KVA/G6K'_KLO\ZSJ1]R7H7!^\CZ*G_X])/\ </\
M*OG.=_W\G^\?YU]&3_\ 'I)_N'^5?-=P_P#I$O\ OG^=?,9$K^T^7ZGN9K]C
MY_H2;Z-]5]]&^OJ^4\"Y8WT;ZK[Z-]'*%RQOHWU7WT;Z.4+EC?1OJOOK,\3^
M);;PEX>U#6;P.;6RA::0(,L0.PJ6E%78U=NR."U_X)Z5XY^(6I:[J6KG4(/L
M_P!F33XV!-I)Q\V0?E/&<>]<UJGP(\66X,6F>)8;JV0_NUOHLNH]-U>0^"]8
M\;Z;KGB;6O"XMO#VG^(;C[4JZ@3<3(IZ8[=\\UO3S^.M1).I?$'4"#U6SB6$
M?UKQWF<9P7M(7];6_&Q]-&IBHVASII)*S5_PM^IRWA#Q!J_B_P"(4WA1]1BT
MZ9)FMQ<&#<&=>P%=SX6\ R>(?BSK?@S4M5U*5=*MEGFO+<*D3%L87U&<G'T-
M<=9?"[3+"Z-U'J6J_:BQ<SK<;7+'J<@=35N'P!IL%U<7,=[JJ7-QCSIA>N'D
MQTW'/->>LRC!1M&*:WVUW\O0]"I4G+^$N73^5;]_N,'3_A;8ZGXK\0'6&GG?
M3[Z2VBMY'/RQ@_*3ZY%=7:^#= T_ @TJW!'<H#6!+8KX!\00:A!)<3V%^P@N
MS<2F1E8_=?)_*NUZ^]>-6Q&G-'=MW>Y"C.I)NHV1QVEM" ([6&,#^[&*E&!T
M50/914%[>0:=:2W-S(L,$2EG=CP!7/#QN)[=;BWT^46SC,<UTXA#CU /)'X5
MQJK5F[)LU]G3CNCJ#ANJJ?JHJI=:187P(N+*WF!&/FC%<T?'K(>;2%O9+G)_
ME6MX=\56GB03K"KQ3P$"6&3&5ST/'44.56.[8*-.6Q)8^%)?#DZZ[X/8VNL6
M ,IL&^:*ZC'+* >C?2NV^'O[0_B#4O"?B?Q3XA6TAL(Y!;Z;91$><)>A1AUZ
MUD:;>/87T,Z'!1@?PKA/'GA>'P[\9+-UW+H^LK]L2 ?<$P')QTKU<!C?933J
M-\JZ?D9SH4ZLTJNJ_&RUM\S:T6UN[FXN=8U5S-JU\WF2NW)4'HH^E<[\2/'=
MEH%N=/W.]Y,N<1'!0>IKM+RZ2RM)KA_N1(7(]@,U\JZOJTVO:I=:A<.7DGD9
MOH,\#\J]K)\MCQ#BJM7&:P6ZVO?9>22/M<AP;QF*]O+10L_GT7HCT[PC\8X_
M#DR"&U&QB!,KL<2CW]_>O;[0Z%\3]&)AA2[C(S):3 >;'ZX]1[BOC8U[]X$%
MS8^!FNK8[+V(%XI 2"I ]:]#B+)<#DN ]OA(6BG9PW35GWO9Z?/J?0YY@*52
M5.NI.-64DE.^J;[^2_#IV+.J?L\Z?-=[["^EM8B<F)AN ^E;7B.TL_"'A2/2
M]/O&BO596"Q<R28ZY JUX2\:Z]XNTE[>6.&2<MAM2*[6C'I@<,??M[UU&E:#
M::22\:>9<-RUQ+\SL?K7Y?AL/0Q^'=3 PY%45N9WT_PJ^_G=+UU1Y.89GC\K
MQ4,/G-?VSHRNH1MJUUG)K;R:;>^FC&^'/''AY=&GU6ZOD86* M:L<2N_88^M
M=O\ L]R6_BF#5?%]PWFZM=S& J5PMO&/NHOZ9KB/$_@2R\=6#/;P16_B&W'F
M02A0%N,<[''0YKUCX,>)(_$7@:UD,$%I?V[-!>6]O$(PDJG!^4=,C%>IEL,5
M4S:%+&M6A%N-D[2>U]7HTGMKNV>)F,LNIY#5Q&61ES5)J,[M7A'=1T6L9-;Z
M:I)KOZ%OHWU7WT;Z_3.4_);EC?2B3FJV^@/S1RA<^9/AZ<_\%"K,_P#3VW_H
M@U^G-?F)\.CG_@H19?\ 7VW_ *(-?IW7Q6=_QX^GZL^KR[^$?DO^PL<>*O%?
M_7A%_P"C*^Q-]?'/[#1QXI\5?]>,7_HROL#>*^ZBKH^5JNTR;?1OJ'>*-XJN
M4QN3;Z-]0[Q1O%'*%R;?5'7;@P:)J$G]VWD/_CIJQO%4=<3[1HNH1#J]O(/_
M !TU2CJB9-\K/.OV:+46_P /7F_CN+N5R?QQ7K.^O-/@%%]G^&E@#U,DA/\
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M=]7KJ]==MB??2A^:K[Z _-=7*<-SYW^&!S_P4"L/^OIO_1!K]0*_+[X6G/\
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M\U7\SWH\SWHL%RQO-+O-5O,]Z42<]:+!<\,^$IS^WSIO_7TW_H@U^HU?EO\
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M$_G6/NK4\+M_Q4FF?]?"?SK*LOW<O1FE-^_'U1]AW?\ QX3?]<F_E7QE=O\
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M^GQ3WK@ R2#=TZ<&MA(UB4*BA%'0*,"BI4C-;:BPV&K4).\[Q['/_$2TEO\
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M:P/^%J^"O^AKTC_P*6C_ (6KX*_Z&O2/_ I:/:!R/L;_ )-'DU@?\+5\%?\
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M7P5_T->D?^!2T?\ "U?!7_0UZ1_X%+1[0.1]C?\ )H\FL#_A:O@K_H:](_\
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M !@>@HP/0444 &!Z"C ]!110 8'H*,#T%%% !@>@HP/0444 &!Z"C ]!110
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H=X.TCP%X<LM"T.SCL=,LXQ'%#&. /4^I]ZVJ**^&;<G=GO)6T1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>mrkr-20251231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20251231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $Q I$# 2(  A$! Q$!_\0
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M\ _7:BOS!\;_ !,_:0^'.B66K^(M4U33=.O"!!._ED,2,@<#CCUK-^'WQO\
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M_P"&NOBU_P!#E>_DG_Q-'_#77Q:_Z'*]_)/_ (FG_8U;^9?B'^KF(_GC^/\
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M $.5[^2?_$T?V-6_F7XA_JYB/YX_C_D?KO17Y$?\-=?%K_H<KW\D_P#B:/\
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M!]"%%%% !1110 4444 %%%% !1110 4444 %%%% !7V+_P $\=3?11\3=1C
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M"G_0N:7_ . B?X4?\*]\*?\ 0N:7_P" B?X4?VQ'^3\0_P!9J?\ SZ?W_P#
M/QWVG^ZWY4;3_=;\J_8C_A7OA3_H7-+_ / 1/\*/^%>^%/\ H7-+_P# 1/\
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M7B\ZQFD((G3U&#[]ZYNOL?QG\&]+U=?V<]+U'5M:U"Q\21!+F"YO-ZP*0,B
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M?L=?#_7?AWK^I^+/$VF3:1I\EE)%:VNHQF)KEU^?>8VP0BE1R0.2 *VOC_\
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MW$WW+>,_+%GT''ZUZQXYUO7_ (=>!?'^JW.K?#C1;'4();:U71K0/<ZG&X8
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M<=S)E5/J!TS5QP,X58SBTDK=^BML[_>)UXR@TUO<Y.BBBO9.(**** "BBB@
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MO&UY&);/2VDM=-B;E4"#YY /[Q]:^=?&OQ$U/Q?K=U?SW+&29R<Y^XN>%'H
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MI7TWX3\8:';_  DT;0?''_"3>#]-75;RZTCQ+X><B.X<OAQ*JD;BI'&:\_\
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MOP_K B-U %=)K=]\4T;#*R(>ZD<US'4X[T0I47&\(JS!RG?5ZGH7@SX\>,?
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M0DDIVLN5?-]QUY*[5[N[/K_Q%K=W\1_A+\ ?"E]!IL-CK]P]M=20V:)(J)*
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M.]CD:>[U2X$\L?.QA(X.1UKR;SSZU@>&?%8^$_C2]:\5AX8UV43-.!E;6Y(
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MM_\ T%J_-U?O#ZU^D7_!,C_D$^,_^NEO_P"@M7B9Q_NLOE^:/LLE_P!QQ?\
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M.K)V^7X'V9X6^-_@'P?\3;[Q-JGQ(\0^,(KZ&YAM[4VK1PV*RH0"RDX8C(
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M;2X/"GB2P\8VFO>#=2U--/N+Z.VD1K>7(.QXSS@CI7JOQ#^'-OI/[1/C?3_
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M1110 J_>'UK](O\ @F1_R"?&?_72W_\ 06K\W5^\/K7Z1?\ !,C_ )!/C/\
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M[1XBTT?$_P"']QX-T*5?LL/C;3]"LVW#"Q1VK*\GTX=LU>C^('PO\;_$'7O
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MZ!>H_P#@(_\ A1[6GW#_ %;S/_GVO_ H_P"9R_G^]'G^]=1_PJ_7?^@7J/\
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M^@7J/_@(_P#A1[6GW#_5O,_^?:_\"C_F<OY_O1Y_O74?\*OUW_H%ZC_X"/\
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M_@(_^%'M:?</]6\S_P"?:_\  H_YG+^?[T>?[UU'_"K]=_Z!>H_^ C_X4?\
M"K]=_P"@7J/_ ("/_A1[6GW#_5O,_P#GVO\ P*/^9RDLF]0,U%78?\*OUW_H
M%ZC_ . C_P"%'_"K]=_Z!>H_^ C_ .%'M8=P_P!6\S_Y]K_P*/\ F<?178?\
M*OUW_H%ZC_X"/_A1_P *OUW_ *!>H_\ @(_^%/VL.X?ZMYG_ ,^U_P"!1_S.
M/HKL/^%7Z[_T"]1_\!'_ ,*/^%7Z[_T"]1_\!'_PH]K#N'^K>9_\^U_X%'_,
MX^BNP_X5?KO_ $"]1_\  1_\*/\ A5^N_P#0+U'_ ,!'_P */:P[A_JWF?\
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M[_T"]1_\!'_PH]K#N'^K>9_\^U_X%'_,X^BNP_X5?KO_ $"]1_\  1_\*/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2
0BBB@"8=*6BB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>mrkr-20251231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20251231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (Q _ # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MOBW]N3XM>-O GCGPOI7A357L?M\14QK_ !N6P*\Q\3:U^TU\-](_X2'5KMWT
M^W D<AMP ]Q7VN$X7JXK#TJ_MX1]I\*;LWK8^<KYU"A5J4_9R?)NUL?I!17R
M!J?[2.N>-OV2KWQAI\W]G:_:L(99(^FX=Q]:[+]F3XYV=W\&]'U'QOXGLXM5
MN68;KJ4*S<\<5YM;(<70H3K25W&?(TKMWM>_H==/-,/5JQIIZ./-=[6/HVBJ
MMCJ=IJ=C'>6ES'<6DB[EFC8%2/7-<K=_&?P-8:B;"X\4Z9%=@[3$TXR#Z5X<
M*%6HVH0;:[)GIRJTX).4DK^9VE%54U.TDL!>I<Q-:%=_GAALV^N:Y/\ X75X
M$%Y]E_X2O2_M&=OE_:!G/I1"A5J7Y(-VWLFPE5IPMS22OYG;45!%>V\UJ+F.
M:-[<KN$JL"N/7-<O'\7?!<NJ?V<GB;36OMVWR!.-V?2E"C4J7Y(MVWLARJ0A
M;FDE<Z^BD5@ZAE((/(([UX!^VSX\UWX>?!N35?#]ZUA?BZC3S5ZX)Y%=&!PD
M\=B:>%@[.;MJ98FO'#495I;15SZ HKS?]GCQ#J'BKX0>'=4U6X-S?7$ :64_
MQ&O2*QQ%%X>M.C)ZQ;7W&E*HJU.-1;-7"BBH[F=+6WEFD.U(U+L3V &:Y]S4
MDHK\SO''[67Q!D^+&J:SI&H2KX.LM1$!11E-@;!!/YU^C/A'Q#!XL\,Z;J]L
MP>&\@652#ZBOH\UR+$Y33I5:S34^W1V3L_/4\? YG1Q\YPIWO'\?-&Q17.^)
M/B'X9\'R*FM:Y9:8[=%N)0I/X5+I_CG0-6T>;5;+5[2ZT^%2TEQ%*"BCW->'
M["KRJ?([/K9V/3]K3YG'F5_4W:*^1/A)^UA+XU^._B#2=7U>RL?#ML[0V&7
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M_:!UKQ'X6TNVU#2=7NR\L\C#"QL>>/6MV/X%^.'_ &P;+QO+I6-!&UI;H.,
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M3C1O+D MRQ(Z<5Q6J>*M#^*'[0?B>Z^(J:MJNBV4CQ6UCIZLP!!P,@=!7O\
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MV^._^@=8_F:[O[)Q/E]YP?VQA>[^X_06BOSZ_P"&[?'?_0.L?S-'_#=OCO\
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MOO#^V,+Y_<?2GPW_ &7-+^'/Q5U?QO;:E-/=:B6+0,/E7->XU^?7_#=OCO\
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M[?'?_0.L?S-']DXGR^\/[8PO=_<?H+17Y]?\-V^._P#H'6/YFC_ANWQW_P!
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MNWQW_P! ZQ_,T?V3B?+[P_MC"]W]Q^@M%?GU_P -V^._^@=8_F:/^&[?'?\
MT#K'\S1_9.)\OO#^V,+W?W'Z"T5^?7_#=OCO_H'6/YFC_ANWQW_T#K'\S1_9
M.)\OO#^V,+W?W'Z"T5^?7_#=OCO_ *!UC^9H_P"&[?'?_0.L?S-']DXGR^\/
M[8PO=_<?H+17Y]?\-V^._P#H'6/YFC_ANWQW_P! ZQ_,T?V3B?+[P_MC"]W]
MQ^@M%?GU_P -V^._^@=8_F:/^&[?'?\ T#K'\S1_9.)\OO#^V,+W?W'Z!O\
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M=T7&/LEKU(J***ZCD"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /V.
M?[C?2ORH^.7_ "5[Q+_U\M_.OU7?[C?2ORH^.7_)7O$O_7RW\Z^4R?\ B3]#
MZ_._X4/4XBBCD]%+'T49-*L4T@)2VF<#J5C)Q7U9\@)12 Y_PI: "BBD^8]$
M9@.I49 ^M "T4A('>C(]: %HI"<?PL1TR!3GCDBQYL,L0/0R(5S^= "4444
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M%-$ 9()H@>ADC*@TT'/W06/HHR: %HI"<'!^4^AX-&X9ZB@!:*3(SC/-&<G
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MI,.F:I>^;:1D,0HP9#C&6/>O*CAJO.IMVU_JWZGKRQ5+V;@E?2W_  YR:$E
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M_/I!_P!^Q1_95E_SZ0?]^Q7J_P!LO^3\3R?[#7_/S\#\C?\ A$?$'_0#OO\
MORW^%'_"(^(/^@'??]^6_P *_7+^RK+_ )](/^_8H_LJR_Y](?\ OV*/[9?\
MGXA_8:_Y^?@?D;_PB/B#_H!WW_?EO\*/^$1\0?\ 0#OO^_+?X5^N7]E67_/I
M!_W[%']E67_/I!_W[%']LO\ D_$/[#7_ #\_ _(W_A$?$'_0#OO^_+?X4?\
M"(^(/^@'??\ ?EO\*_7'^R[+_GU@_P"_8I?[*LO^?2#_ +]BC^V7_)^(?V&O
M^?GX'Y&_\(CX@_Z =]_WY;_"C_A$?$'_ $ [[_ORW^%?KB=,L0<?98,_[@I?
M[*LO^?2#_OV*/[9?\GXA_8:_Y^?@?D;_ ,(CX@_Z =]_WY;_  H_X1'Q!_T
M[[_ORW^%?KE_95E_SZ0?]^Q1_95E_P ^D'_?L4?VR_Y/Q#^PU_S\_ _*+PVG
MC?P?=S76BV&HV-Q-&8I'2%LLAZCI4VF7'CW1=.DL+&TU*WLY+C[4T2PG!ESG
M=TZYK]5_[*LO^?2#_OV*/[*LO^?2#_OV*AYNGO312R9K:JS\O+7QA\4;.ZO+
MF,:F9KSF8O 6!/K@CK6?+J/Q#F@LH7AU0I8S&XML0L/+D/)8<5^J?]E67_/I
M!_W[%']E67_/I!_W[%+^U8K_ )=(K^R)/>JS\WO#_P 7_B?IOB"PU'5K#4-8
MMK,LZV;6Y"ER,;CQUK&UKQ[\4=;UP:FT6I0/%*TEO&D! BW=L 5^G(TNR/\
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MXA_8:_Y^?@?D;_PB6OGIHE\?^V+?X4?\(CX@_P"@'??]^6_PK]<1I-DHP+2
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M'Q!_T [[_ORW^%?KE_95E_SZ0?\ ?L4?V59?\^D'_?L4?VR_Y/Q#^PU_S\_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0?3- #Z*:)$)P'4GV-)YT?\ ?7\Z 'T4T2*02&! ZG-)YT?]]?SH ?133(@
M)90#WS2>='_?7\Z 'T4UI$4X+*#Z$T@E0G =2?K0 ^BF>:F?OK^=*)%()# @
M=3F@!U%,\Z/^^OYTID50"6 !Z$F@!U%,\U"<;US]:4R(IP64'T)H =135D5C
M@,"?8TAE0'&]<^F: 'T4T2*V<,#CK@TGG1_WU_.@!]%-,B!=VY<>N:3SH_[Z
M_G0 ^BFM(BG!=0?<T@E1C@.I/H#0 ^BF&:,'!=0?K2B1&!(8$#K@T .HIGG1
M_P#/1?S%+O7;NW#;ZYXH =13/.C_ .>B_F*4R(H!+*,],F@5QU%,$J$X#J3]
M:#*BG!=0?0F@+CZ*:LB-T93]#2>='_ST7\Q0%Q]%-\Q-N[<NWUSQ2>='_P ]
M%_,4#'T4UI$7&6 STR:02HQP'4GT!H ?13#*BG!=0?0FE617^ZP/T- #J*9Y
MT?\ ?7\Z42*02&! ZG- #J*9Y\?_ #T7\Q2F1% )90#T)- KCJ*9YT9_C7\Z
M5I44X9U!]": N.HIJR(QPK*3[&D\Z/\ OK^= 7'T4T2(03N&!WS2>='_ ,]%
M_,4!<?132ZA<E@!ZYI/.C_YZ+^= Q]%-:1$QN91GU-()48X#J3Z T /HIAFC
M!P74'TS2JZO]U@WT- #J*** /&/&?P;\4)XUO_$?@;Q)#HLVJQ>5J%O>1ET8
M] Z8Z,!6+/\ L@>'M<U=[GQ+._B2.32_L+->LWF+)G)D!!'K7T#10!Y#I_P>
MU/2/@U=^#9-0COVMT*:>X7;M0<HK>IKF/$?P<\9?%#0],TZ]UB/2= D2-+_3
M9H]TR&,CF%P/ESC-?0M% 'B_Q6^$WC;QGIFF:9HGB2RT[3K-UWV]Q$["XC4
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M/Q/9>,_#MAK6GL6LKV(2Q%A@[36O532M*M-$L(;*Q@2VM(5VQQ(,*H]!5N@
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MNNO9=&4->^('Q.^&WBLV>IZWJ$%]92A@LDA*2 '@CU!KUS5?&VN_'WPN^O\
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MO-KN(7U()_H\<Q /E,?[W->#^*/A)X@\81Z3KNA://J-P=-338BLODMIURC
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M6%S/M"[Y(@2!Z5U=%-U)MIML/94_Y5]QRFG_  J\(:5<BXM/#NGV\X! D2$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW+<C3Y#++:_8V)D/^K_Q]Z]1TK38='TVUL;8%8+:-8HP3DA0,"K5% !1110
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ME=8 >8UST%>TT4 4M%TN+1-)M+"'_56\2QK] ,5=HHH **** "BBB@ HHHH
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M0;^\UZY3_B::ZD!.,CE(SZ5=6=^5*2Y^_P"=_+R)HP:YVXOV?;KY6\_,\/\
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MF)P%'N30!TE%<)\+/BWI_P 4;.Z:"TN-+O[5L36%W_K$!Y!^A!KNZ "BBB@
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M"V>ZM'$B1.3@;L=.:[)'61%=2&5AD$=Z '4444 %%%% !1110 4444 %%%%
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MJY7XJ6=_J'PY\16VEAFU"6SD6 +U+8XH @M?B]X/O+/5+N+7K0V^F$BZD,@
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M*& P\XRBX[=?Z_$<\PQ,)1DI;]/Z_ ^P_$O[<OB3P?K5QI.K>##;7D)Q@O\
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M,'R\GLE8/['R_D]G[%6W/"?!G[('@SP-'?-IPF%Y<QF-;ECEX@?[OH:YN?\
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M=5U%-)?GY_()X6NJ*IN#;_+R^?X$7P/U2;XIZ5<^ /$=JVH:-%$TEOJC#YK
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_9X("TL*@X+2+_"*Z/PI\55U[QK-HSQK]GGMEN[&X3I+&: /1:*** "BBB@
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M.2DM]WU/:XFXLS'BK$JOCI64?ABOA7HN[[BT4F1ZT9'K7HGQ@M%)D>M&0>]
M"T4F1ZBC(]: %HI,CU%&<4 +129'K1D>M "T4F0>]&1ZT +129'K1D>HH 6B
MDR/6C(]: %HI,CUHR#WH 6BDR/6C(]: %HI,CU%&1ZT +129'K1D>M "T4F1
MZT9'K0 M%)D>M&1ZB@!:*3(]:,CU% "T4F0*,CUH 6BDR/6C(]: %HI,CU%&
M1ZT +129'J*,@=Z %HI,CUHR/6@!:*3(-&1ZT +129'K1D>HH 6BDR/6C(]:
M %HI,CUHR#WH 6BDR/449'K0 M%)D>HHR/6@!:*3(]:,@=Z %HI,CUHR/6@!
M:*3(]:,CU% "T4F1ZT9'J* %HI,CUHR/6@!:*3(]:,YH 6BBB@ HHHH ****
M "BBB@ HHHH *Q/&6D7^N^&[ZRTN_P#[-OY4Q%<[0P0^X/6MNB@#Y9G_ &3]
M>\1PZW>:OK-M9ZO=VR6R?V?'LA<JV0[J.,FNT^&GP4\2V/B?2M:\9ZS%J<NC
M6YM].A@7"H",%C[U[E10!XO?>!/$]AXX\6RZ+<?8_P"VXUN(+[:&6*11C8P]
M#3_@[\&M8^&SZCJ%QJ,5QJ>KWAN;Y(EVQ*,=$7M7LM% 'GO@[X7R>&/B1XK\
M3M>F==;6-1!C_5[:X+4?V86OM3N[O^TU!GUQ=7P4[!"NS]:]_HH ^76_9(U?
M0W^UZ!K\=O?70:WO6EC!5H&)R%'8\UWG@'X;W^C>/X)FC>+2=&L5LK:23K,>
M[5[-10 4444 %%%% !1110 4444 %%%% !1110!3U?5K70M,N=0O91#:VT;2
MR.>R@9->4?\ #4?A&Z^':>+[#[3>V<UPUK;0)'B6=U/(5:]8U:RCU'3+JVEB
M69)8F0QN,ALCH:^/=3_9\\2Q?"O3HI=)-Q+I&LSWO]EVK^6TT;\*%(Z8SF@#
MZP\%>+(/&OAZVU6"WFM4F&3#<+M=3Z$5NUYI^S[X;UWPO\.K6U\0.WVII&DC
MAD.YH(S]U">Y%>ET %(3@9-+69XETRXUG0+^QM;IK&YN(6CCN4&3&2/O"@#S
M>^_::\'VE[XNM8Y9[F;PT +SRH\AF/15/<U#;?M.^&)/AOJ/C":&[@MK"7R9
M[5H_WP?&< =^*\!M_P!F?XF>%;SQH8-1AU6RN0DB[D >\'5A]>O-:_A?X)^-
MM9ANK6]TT:=X;FDEN[6QE;=+$YCP%<]^: /66_:[\#+\(8_B*9+G^Q'N1:;!
M%^]$A.,%:]CT;5(=<TFSU"WSY%U$LR;A@[6&17PV?V7O'4VAS^'#9PIH*P?;
M$AW<&Z)R>*^U_!MC-IGA/1[2Y4)<06L<<BCLP4 T ;-%%% !1110 4R:9+>%
MY9&"1H"S,>@ I]<K\3_"=]XX\$:GHFG:I)HUU=Q[%O(AEDYH SOA7\9?#WQB
MBUR7P[+)/!I%\VGSR.FT-(O7;ZCWKNZ^>_V3/@_XJ^$/_":VGB&YBGM;O5#-
M9F) N]<#YSCN:^A* "BBB@ KF/B+X/F\;^&+G3;;4[G2+IAF*ZM7VLC=OPKI
MZS/$?B/3_">CW.IZI<I:V<"EWD<U<')23CN1-1<6I;'YL?$C6/BQ\*_$LVD:
MQXFU53&V8;CSCLE7/!!KT/0OBMK?QR\*1Z1#XENM \<Z?'^X:.;9'?*.Q_VJ
MX']I']H'_A='B14M(/)T6Q<K;L4^>3W)J;X7^!['P5IL/Q#\92265G;'?IMB
MN5ENI!T_"OM903HQG4BE/I9=?ZW/A8S:KRA2DW#K=].]_P C"MOC-\3/ GB=
M&O-=U WMA+^\L[MR4?!Y!![5[QXJ\3:S\?/!P\6> ?$E[I?B*RCQJ&A1SD;L
M#ED%?,OCGQOJ'Q7\;3ZJ]J3>WCA(;:&/G'11]:]]\&Z9IO[)WA5O$_B"5I_&
MVIP[;72HR<1J>A<5.(A%*,E%*IT2Z]UZ>96'J2DYQ<FZ?5M[=GZ^1Y;X/_:%
M\?>!?$\5W?:Q?7\<3>7<V-VY.5Z'@]#7<?$W6/%E]I2^-_ WB_5+SP]<_-=6
M2SDR6+GJ"/2O$Y;C5_B?XSEDM[4W&K:E,6\J%,*"3_*O7=;\0Z9^SSX+O?"6
MDW U3Q7J\>-4EQNAM@1]T#IFM:E.*G%QBN9].EO^!W,J524H24Y/D77K?R]>
MQ7^$W[2>N:7+<Z'XJUJ]NM%U/Y#>^8?.M6/1@?2J7Q/U'XD_#O4E*>,M2U#0
MKH>99:C%.2CJ>@)]:X7X:_#C4/B7K'V2V!M].B_>7M_(,)"G4DFNO^,'Q2TJ
M70+/P#X8W3>'=*;YKV527FD[D'L*;IP59*G%:[Z?CZB52<J%ZDFK;.^K\O3\
MCN_ ?QHU7XL>&4\&ZMXGNM"\3P G3=6278LY[))]:\TUCXC_ !2^'_B5K+5/
M$.I17]G+GRYI24D /7W!JS\*?AE:75H?&GB^=]*\*:<PDC/*R74@Y"I6%\6_
MBK<?%[Q<-1-J8+>)1;V4"(=Y0<+D]S2A3A[5QA%./739^7ZKH$ZL_9*4Y-2Z
M:[KS_1]3VG5O'?B'XW>%SKGA/Q)?:7XJL8_]/T:.8JLR@??C%>:^!?VC/'7@
M/Q1'>7^K7NIVZ'RKJQNW)^7H<>AKI/!>F67[/.BIXQ\0NS>*KN(C3M)0G**1
M]Z05Y%!'K'Q.\8.MG:M=:OJ4Q8QQ)A5)/7V I4J=-J4;)P[_ )_)=RJM6HG"
M7,U/M^6G=]CVKXGZIXN.FIXS\$>,-5U#PO>'=-;K.3)8N>JL/2J'PG_:/UFV
M6Y\.>+-<O9=)U'Y4U)9#YUJYZ-GTH\1^)M*^ 7@J]\$:)<C5O$FJ+_Q-[C&Z
M&#U11TS7F_PR^&=[\2]4:%&^R:/;_O+W4)1A(DZG\:F-.G*D_:+W5L[:^O\
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M/$?BGQKX=;Q[X \6ZHUFW.I:,EP3)9OW(']VN/\ A'^U'XE\,:M-9>)=8O\
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MUV5KV[5(PF"20%QVX%>NTU45%"J JCH!3J "BBB@ IDTR6\322.L<:C+,QP
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MBOLC^:PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR.77H(FN-5MY9=J0Q*3DH>YXKT+P#\2;_6?'T$#R-+I.L6*WMLC_ 'H3_$M
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MLX.+2[;'5B>&JN5ODQ5.=.4OYDT[>5T?GWX%_8?\9WWB*W3Q((;/2$.^9HY
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MJ1Q6*LK2@U[K6\FU>R?\O4](HHHK[X_D<**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF/B
M7XMN/ O@?5M<M;"34Y[.$R):Q#+.:Z>L/QKH^H:_X9OK'2[_ /LR_E3$-SMW
M!&]QW% 'S[I_[3/BA? .M^(I[+2;X6L2-"EI*04D9L;)%/((KJ/ 'QG\6?\
M"7:'HGC72[*U&O6QN;"XT]RR\#)5L]ZY74/V4/$'BC^V[_6==TZVUJ]M4ME?
M2X&C@<JV0\B=S]*[+X=_!/Q-9>*-)UKQIKEGJTFBVWV;3H;&(QH@(P6;/4T
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MW/<Q^:01R4/IV%?5E% '#_!S15T'P/9VO]BS:%*,M+;7#AY"YZL2.YKN***
M"N=^(GAV?Q=X&UO1K:40SWMJ\*2'^$D5T5% 'P[HOP%^(]CHNJVNFZ5+IEC;
MVXAGT^ZG63^TW!'SQG^#(SUK;\-? WQUJT-U8WNC#2?#,DDEU:Z=-,KRQ.8\
M!7(Z\U]CT4 ?"!_98\?R:#-X:.G0)X?6#[7'")%^:[)R017VMX-L)]*\)Z19
MW*".X@M8XY$!Z,% (K9HH **** "BBB@ K"\:W&IV?AR[GT?3X]4OXUW1VDA
M $OJ,FMVB@#PK]F_P-X@\-ZOXNU74M);PWINJW?GP:3+())%;NY8>M>ZT44
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M[PY+>7UPEY\0-8@*+IJMF.TB8=9!Z\U]RZ9\(?!>C7\5[9>&=.MKN([HY4A
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"VGPWN?M*QX;<<D>@K9,*-C**<=,CI3Z "BBB@ HHHH **** "BBB@ HHHH
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M_P"%?6GEI_=7\J/+3^ZOY4O[1R__ * E_P"!2_S'[&M_S]?W(^3/^&Q_'/\
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MD[_AL;QQ_P!$CU;]:3_AL;QS_P!$CU;]?\*^LO+3^ZOY4>6G]U?RI?VA@/\
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M[/DO_ALCQU_T2+5OU_PI/^&R/'7_ $2'5OUKZU\M/[J_E1Y:?W5_*CZWA?\
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MQ7JFMV=W*]I]FCCMV8-W+>U ':T5YG)\3+K3M.TY([8WUS<1XYX(<=012/\
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M6EN8BQMR.5/O0!Z117DVA:UXIBNKZ^,3S6OVEHECE/49X(':IS\3]5$Q@:P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
H@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>mrkr-20251231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20251231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %T J # 2(  A$! Q$!_\0
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M?)CI\B\5[11653-<7/%5<73GR2J7ORW6CU:]#6&!H1H0P\H\T86M?RZGSO\
MM9_##Q;\:[OP1X/TFTFB\*2ZA]KUS58Y8U^SHHP@"L<L?F<C (SMS7 _%/\
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M / HT?\ "_?B5_T/.M_^!1K@J*/8T_Y5]R#V]7^=_>SO?^%^_$K_ *'G6_\
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M$UYY2A+F5[6*G'E=D[A1115F84F0>]7] NK6RUW3KB^MHKRRBN(WGMYMVR1
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M'QY.*DY4/A=I:[?Y@\SPD8R<J<ER.TE=:=+[69H?\,H?%?\ Z%*7_P "8O\
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M"Y/:2IR23M+5:/[M=NG9^5]3_AE#XK_]"E+_ .!,7_Q5'_#*'Q7_ .A2E_\
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M9>(-8\.79NQ8:CIXU&:*VOIR,F>S&[_OY&.$)R.#@#XZJ)RC[!7BK[[KNO\
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M-#\0ZYX7M]=F:*?P]<:I.N)QRTUIELO 3_WR3BM'QS52J?N%S0W5^G=/^O\
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M$Q?_ !5 _9/^*P)/_"(RY/7_ $F'_P"*K]-Z*/[8K_RK\?\ ,/[%H?S/\/\
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MQFL[#1;SR/!\UK_:"BV@MTD$"7/V=G<S LRNT4I 3# ,.XH ^EU4(H50%4#
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MV\9*L/A31(V.E:_(/W]G>,,K:0CK,DG5H^B??RO>O\!_M'B/^U/#.L6L=YX
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MB7#2$-D]0<YJQXG_ &4_ACXSURYU?6?#TE]J%P1OE?4+D  # 55$@"J   H
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M*B*,*B(L@5% X"J !3_$/[+GPT\46NEVNH^'3)9Z7!]FLK6.]GBB@3.3M17
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M_P"(NE>+["3QA#K-O97VC3R%[O4;R_2XN?M.1YR3#;9R)'C:B?+()#@_N\4
M?1,^D65U?6M[+;1R75JKI#,5^9%8 , ?0X&1["K7EIN#;5W#H<<U\3>,?$'Q
MV^(>GWDEL_BSPO#87TMW:"QT=H;F2/[.Q$,H  DV2*5 7<K%AR_!KT#P;XY^
M-^O^)5LM4L1I-C)K<<,LBZ-,6M;0?:21OD54<.L<!WJ7"F3KDA0 ?3=4WTBR
MDU.'4&MHVO88WABG*_,B,06 ],E5S]*\;^)/_"0Z3X^\1WMQ)XLU3PH_AV$Q
MZ?H"R*1="ZP8XFA7S [*?G8$L$R1C%9&LZE\3/#GPE\'0>$[N_U356@O9;R\
MU'2I[F<>7!++!"ZS;).9%CAWN-[#G[QS0!]#T5\S:;X\^,*Z]I.FZU97*V/V
MYK>:Z316BCO;8W&V:668-BT\FW/F(V1YC# R1BO:/A!JFHZU\-M"O-4=Y;N6
M#B>7[\T88B.5O=T",?=J .QHHHH **** "BBB@ HHI&!92 2I(X([4 +17RO
M?^&?$UMIFF:+J<?C>[U-O%6HRVWB*&6XF^QV:WH>.6186"L9(\)&K+Y:H6)
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MFJMK^U_\)KK5H]-_X2H6]X\WV?9=65Q"$?.,.SQ@)@\$L1CO7YY?$5]-\?\
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MN_$5OXB-QI-G,L%S-%93LT#-]TN@3<JGH&(VD\9S5CP?^TK\.O'S:A'H&O\
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MLR?F28G DW+\NSJQ],9"I\0XN<J?N+WNEG?UWVZZVV>O45+BG&U)4E[./O\
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M33Y-S'B2O5J0Y:<;36JY=8^;=[./76SM\F_M[0/C[\%/%/AO5UTO3K>]L-+
MOKG3(]#RX7[IG6'9\P4?>8 E0>>*;X(_:"^"'BZ\N]$T"RM#<W<#,U@NBB(W
MH3YO*52@$C]PG4XXYKX0^&VF7^N?$&YU_P ,70\%Z1I4S7TNJ33%XM*MRQPK
M,?\ 6$@[ G60\8P32ZU;Q?%?XPW3?#W2FTF"XF\^ >8(5@" %[IR#M@3(+D
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MW""&2RB9(MQRVU2N%R>N.M/B\%>'H=-FTZ/0=,CT^9@\MHMG&(I&'0LFW!/
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MR)UW'G@>_2I)-1M(8(IY+J%(92JQR-( KEON@'H<]O6OEK6/@G?^-9[BXC\
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M,HZ8YZ<<1\%[75G\=7&M:!>Q>']$TX/+J.H:EB6UM[)C@Q3C $V\?((\9<]
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MXX^1UY\M1ACR20O!B^#WA_4?AK92>/\ 7+:_CTR2.6RM-#2W8OKK$8>*12I
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M71N5B;R,G[Y"N2RX.<KG(Y&:L>./VY-!\ :W_9^I>$]9D22,3VM[;2026]Y
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M.X'GWQ _9L^*FLZ?IW@_PSX,DTWP7IDYD@-WJ%L9KNX8!7NYR)#AF X1>%4
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MN%%%%66%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0\-P0:Y_Q?\ LI?$K1_##>"O!6BVW]B2E)=5U:6_BCGUB9>5RN<I"A)V1_\
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MC*5D3D,,<,.,BL'2/V-_B7XQ\:ZCXD^(=LE]NW7<UO!J$7G:C+_# '!VQ*>
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M 3&-H&PG;CC&* .BMYEN8(Y5!"R*& (P<$9J2D P*6@ HHHH **** "BBB@
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MYDXVCA>3FK7]K\ZYN>UO>MW_ +OG^%[_ &31?V[[1<_/;E]ZU]_[OGMY7O\
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M)/W4R]&7\1D$4_Q7^R/\7/B_X^M=0\6W>C:5I *P)#I]P7CT^U7I%!%M X'
MZ9/)J/Q]^R+\4?%S6&B:59Z+X?\ !FFOML=.&H%R">&N)B$_>3-U)[?=& *)
M_P!K6J<G/:_N]_GY6[];6ZA4_MRU7V?M+7]S^;Y_W;=];VM]HM^-?VPOB(^@
MQ^+_  >^D7OA>1EBNK:>R+W6DSD?ZJ?#C*$YV2@ ,..""*?+^V)\0?%W@O\
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MH*\N>^GO;+^]KKY:;?)$+"Y_[""O/GYM/>VC_?UL]=M+VO?HCA/&?[2WQ=\
M:EHVMV?C!/$W@[5";G3;F?3H(UNHU;$D,H5 R2*?E8 ]>0<&I_'G[2OQ0;0H
M?&WA#QA++X3NIQ;SV=Q8VS3Z5=$;OL\A\OYU(R4D'WAUP0:[3Q5^P]XX^(7B
MFUO=>\5Z)::5#LMX;'3()1'96JGB*!" !@=R>3R234_Q!_8F\9>+19:3I>OZ
M%HGA+3,KI^E1B9MN?O32G;^\F?JS'Z# %*6'S:U3EY[=/>=[]]](^3OTZZBG
MA,\M5Y?:6TY?>=[]_BTCOH[]%OJN,U;]I[XF>./!]QXI\'^)C876E0H==T#[
M';N(%X474#.A+1,<;E)+(Q[@@UZ_^R9^UJ?BH8_"GBR1$\6HI:WNT0(E^@&3
MP!A9 .H& 0,CN*YOQ5^Q+XG;PO;>$_"OB#2-*\.KLFO9)TE^U:G<@<O.5&-B
MG(2,' Z\DYKUO]F_]F72?@1I+W$SQ:KXINEVW.I!,*B_\\X@>57U/4GKV ]'
M!4,UCC(2J-\MO>N[I^BOOY][]-#ULNP^=PQ\)59/DM[_ #.\6_[JOH_-65[]
M-#VRBBBOMS]%"O*?C!X[U/P_XDT'1;3Q'I?@RTO+2\O9=;U> 31LT/E[;=0S
MHH+"1G.3G;&=HZD>K53U31M/URW6WU*QMM0@5Q((KJ%95##HV&!&1ZT ?/<_
MQWUN7_A(-5_X2G0=.&G;[:T\.S64AFOL60N$N5+,)%5R2R@IM"(<G.2'?!?X
MZ^)M9\,^,-0\1A[R71M"MM8CBO;!-.N)'>"25U2-9) \&%CVS9Y8R+R4->_S
M:#IESJ OYM.M);X1&#[4\"F7RSU3<1G:<GCIS4C:38ONW65N=T/V8YB7F+_G
MGT^[S]WI0!\S>+OVB?&>G>+9?#=C#;V\D'A]+R2_NM.D19Y_.MA--;O(R0NB
M1SL$0R?.XP6'&=?5OCMX@D_9XT[QG;:KI>E:ZB37$EM?Q1JU]'$\@&V-I0%W
MHGF$(S-C(3=P:]YM_#&E6VDPZ8+"&6PAM_LB0SKYH\G@>62^25X'!]!3IO#>
MD7,,<4VEV4L49C*(]NA52GW" 1QMR<>G:@#R7XF?M#W_ ()\16FEZ5X7AUE9
MK*RNFGN]2^Q%#=//'$NSRG/!@)8G& > 2,'FM/\ VL;CQ9:WYTO1(-->WTY]
M1C-U>B64F&*WN)4DA"C9&Z3E(Y=QR1G:.,_1,VG6ES+YDMK#+)A1O>,$\$D<
MGT)./J:S=1\&:%JT,L5UI5JZ3+$DNV,(9$C8,B,5P60$#Y3P1P1@D4 :UO,+
MBWBE"E0ZAL,,$9'>I*.E% !1110 4444 %%%% !535KA;32KR=YWM4BA=VGC
M3>T8"D[@N#N(ZXP<^AJW10!\7W'CKQX=.TC5/"GBK7-;TZZU1X=-TS4$87P<
MM:A?M3?9MKJ5-PYA)3:LH^;,9"_:%%% !1110!\52?$/XD3>'-6EU#4]9L[N
MTU-+B[MXQ<*;EREV/[-AD2U)@DW+;MP'C(\L!\NV>Y\/W/Q&^(7QJM+IK_5]
M(\*/:?;_ .S9IWM!"B71@"Y6)O,=EA+E'8?ZSC@YKZ<HH **** "BBB@#QSP
M)XAEU;X[^*K2T\3ZK?:=9V\L=UI>IQ;8A<B5-IM1Y2[8XUW(6W-YADSSLW'T
MGQAH=YXC\.7NGZ?K%UH-]*G[G4+,*9(7'0X8$$9Z@]1Z5M5C^+;;6[SP]>P>
M';RUT_6)$V07=Y$98XB?XM@(W$=AG&>M9U$G!IJ_H954G"2:;TZ;_+8_/W6_
MV@_B_P# KXI7>@^--?GUVWMP8KB"-HE\V!Q\LT+A<H^,,NX<'@C%1>,OC[\5
M_AGKNA:U:>.+GQ)X5U1/M^ER7UO$@NX V&BFC"AE93E6P<9Y4D5ZKH7[ =]/
MXRDU_P 8>+X?$Y=GN98)+>1#=S]5$K[R=F?O 8)' (HUO]A'Q#XZ\:)K7BSQ
MW:W=N[HLMO8V#0^7 O"PP L5C4#Y0,8'N:_.G@\WY9<G,O>]WWM4O-WU7EWU
MTZ_E$LOSUPDH<Z][W;SUBO[SOJO+OKI]KR[Q_P#'CXEQZ#9>.O"GCC5#X4U"
MY-LUG=I"9M.NP-S6S$H/-3'*N.J\-@BNEU+X[_$#XN?#Z]\7>#/%-YH>N>'[
M=3X@T%%C^SO&!@75NS*<9P=T9.?3W[+X@?L.^)/'E_:1_P#"8:9I.@:<OD:9
MH]I82>39PY[9?YG;JSGECU[ ;GC?]C;5=0\'6/@OPGXGL_#OA. +-=1/:.]S
MJ5SWEN'##<!_"H&!^6-EA,TYJC?-RM;<VKEW6ONJ^OII;MT+ YUS56^?E:VY
MM7+O'WO=5]=>FENB\5\!?M%_$7XKZ/%X6M/%U[IGCJ 22:;=(D?DZJ@!9H)O
MD(20 $I)PI'#8X-9_P //VJ/'.NFY\(^(O&-_IM]>SA=.U^&&-GM;G[HBF0(
M=\+'@D#<IY&1D5[3I?[$&K>%/ \^D>'O%=E8ZSJ:M'JNMO9N9G@SQ;P8?]W&
M?XSRS=,@<4SP'^PUJ7P\TZ^O=-\46$GC"4^59ZK/8LT>G1$89XDW?ZX] Y^Z
M.@SS6<<'FZ=/F<KI>][VC7:U]_/37KI<RA@,]4J7,Y72]Y\VC716YM9=+Z:V
MUTYCQG2?VH/B5\/?&FL^%_'_ (AU"6 .UC>3V@A:YT^0'B> A=K8ZE3PR\<'
M!#]8_:)^+?P9^(<%KX@\3R^)])DA2X1,)&E[9RKE)4(0-$Y4Y&X95AR".OK/
M@3]@:X\+:Q=:WJGB.P\0:I$IDL(KNS=K87).?-G4OF0+U"Y )QG(X,>G_L#:
MGJ_CAO$'C7QI'XE$LK7%U$+=XWNI/X59]QVIG (49P,#':5@LXY$ES)WT][9
M?WM=?N_R(67Y][.*3DI<VEY[+^]K[WW=^]CRKQQ\>?BKX"O-!\1Z3X[O==\(
MZOFZTQ]0MXE:14;$D$Z!0=RGY25X;JIYXG\>?'OXD7OAB'Q[X1\:ZG!X<N+D
M6EYIEPL32:9>%=WE!BG[V(C)1AR!PV",GT_Q/^PIXD\?^+(=5\1^.;(VBE(1
M9Z?I[1);6R](8%+E44#@<'U.3FK'Q"_8?\0^-9K.RM/%NF:+X9TQ3%IFC6]C
M(8[=#U=CO^>5NK.>2?0 "G+!YJU4Y>:SV7-K?OOHO+7HO-.> SMJKRJ=G;E7
M/K?O?FT6^C;Z+=<R\PU+]H;XC_$7P3>^*?#'BV]TG5=#@1M>T9$C\CR\A%N[
M=F4X!. T1.03E<@X&S\-?V@?'7QP\,KX2L?%5WH?Q'L8Y)M/NXD3[/K$:C+1
M3 H1'* /E?A3WKOO%W[$&K7_ (:LO"OASQ79:+X8MRLT\3V;O/J%SCF>X<,-
MV.0J#Y5'3G)K4TC]CC5/!7PWG\/^$O$UII>N:JI36?$$MH[7$L/:"###RHS_
M !=2?6MX83-55O/F<;>][V[_ +NNC\].KM;1]-/ YTJUZG,X\OO>]\3_ +NN
MCVUT6C=K:/P#P'^U9XZGN;_PGXL\77^GRW<WE6VNP0QO-IUR"5 =54B2%CPP
M W#[RGC!=;?M,_%#X7>/M5\-^/=?OKZWCW65X;0P^?:YP5N+=PN"PX8*PPP.
M" >GLGP^_86U#X>07VIV?B;3[GQ;PFFW]Q8LT.G@CYIECW?--V4GA>N"<8J^
M#/V [G1/$-QKFO>);+Q+>(K36T%W:2&&2Z)R)+CY\R*#\Q7(W'J<9SSQP6<<
ML%>7-??FT2[/75_IIKTY89?G_)35Y<R>_-HH]I:^\_EMI=Z*/E'B+]H7XM_!
MWQUIQU+Q=)XJT.YA2^M?,C2./4+*0':^ H>)L9Z\JP[CJOCSX\?%'PDNA^*_
M#_CS4-4\'ZN[26 U"&'S4>-AYEM.H0;BIX++\K Y!'0>J#]@G6/$WCK^W_&W
MCB/7DFF\Z[CAM6BDGP/EC#;B$3@#"CA>!CBG>,/V&/$OQ!\26]]K/C;3[?3H
M EO;Z=IVG.D5E:J>(8%+X4 9Y.<GDY)HE@\VY9\O-J_=][5>KOMY:_YDLOSQ
MPJ<G/J_=7/JO-OFVMTUUZZ:^9>-OC]\1]=\)-X_\(^,M2LM&%PEKJND2B(G3
M+IP2HC8I^\A?!*GEEZ-V)FD_:'^(_P 3?!=WK?AOQ9>:3XAT"T$NLZ3&D8M[
MBW7"_:X69?E89&^,GDG*]P/4/B#^P_KOBY++2M,\6:=HGA32P5T[2([*1@I/
MWII6WCS)GZLY^@P!BIO$G[#^JR^$;3PGX;\5V>CZ"-D]^7LW:XU.Y _UDSAQ
M\B]$C'"]>2<UI+!YKS2?O6M_-O+O'717_P"&ULM98#.^>;]YQMK:6\N\=?=5
M_P .FO*O)_ O[1/Q%^+.B1^&K'Q=>Z9X[M$DEL)T2/R=6C +M#+E"(Y5 )5^
M%8##8.#3/A-^U?XNUY[KP9XM\5W]C<:G,L>G^([:%&GL;G.U4D0+B2)C@' R
M,Y!]/6]/_8@U;PQX%ET3P[XKLK#5=35DU?6GLW,\T.>+>'#_ +N(]6ZESU..
M*N?"_P#8GNOA98ZCJ=CX@L+SQLX\K3M3NK)FM].0C#2)%N^:7KAB<#TZTZ>#
MS=3I\S>B][WM&NUKZOI?37KI<=+ 9ZITG)RT7O/FT:[6YM96TNK:VUTYGX;/
M^T?\5_@[\2=1\.^.]>O-5MX,VMY%;-")41@"L]NX7 < A@&&#T(]#Q1^T'\6
MOA+XOT:^D\9R^*O#E]"NHZ>US"D:7]HV1AT"AXVZ@^C#(R,5ZKX5_8"NK/Q3
M-KOB?Q1:^)YAON%MKBVD$=Q<DY5ISOW,F>2HP6Z9 S2W?[!FM^,?'2Z]XT\=
M1:M#-*'NHK2S:%VC ^6*,[B(U  4 #@=*R^I9OR-1YD^;W?>V7F[Z^EO/39X
M_P!GY[R-1YT^;W;SUBO[SOJO*W=Z;/ROQ_\ '?XG:'I^D>,_#/CO4[SP?JL[
M);Q7\4)FM;A,&2UE&P;PN>'7AE/8Y%6O%O[0/Q'\6>#Y_'GA+QAJ&G6=K)'!
MK>B,L973YGX1X'9/GA<@X7)9#D'(P:],\<?L->)?B!K=M/?>,]-L-)M%6VLM
M+L-/=8;&V!_U<0+]>Y8\L>35KQ]^Q!K7B6RL="T;Q78:'X1TTYM-,6S=V>0C
M#7$[[QYDK>N, 8"@"JE@\U;J6YK/;WNO=:Z+RUTT\U<\!G;=6W/RM*RY]>;N
MO>TC>^COII;JO+++]H;XC_%+P=<7?A_Q;>Z5XL\/V1GU'3T2/[/J%JGWKF,E
M/DE7(WH3ANJ\Y%1_#W]H[XA_%32XO",/B^]TSQLK.^DWT<<?E:EP6-M.-A"/
MP=D@P.S=C7K>K_L0:M#X(M_"?AOQ79:1IDP675KA[-VN=3G'(\Q@XQ$O\,8X
MSR<FC1/V(-6\'^"[G3?#_BNRL]?U,/#J6N26;F46YZ06X#_NU;^-L[FZ9 XJ
ME@\VYXN7,U;WO>W]-=_/377UI8#//:1<^9KE][WM_)>]H_[VBOKZ^*^ ?VJO
M'6H2WGA+Q1XOO].N+R<)9Z]##&\MC<CY0DB*A$D+'A@!N'W@3R#9T/\ :E^)
M7PG^(VI^'_B)J]YJUE$S6-_' T7GVV>DUNZKC<,A@#D$<$ ]/7? '[#&H?#R
MTOM1L?$]A/XN;]WI^HSV+-#IZ$?-*D>[F;LK'A>H&<89\.OV!QX;\4R:[XF\
M06OBF:(--;VDULZPRW)Y5YR6)=0>2O?N:B&#SE*GK+F3W<M$NSUU_P M->D4
M\OS]*DKR4D]W*Z4>TM?>?RVTUVCY9\2/C3\7_@GXRT>[/C>7Q-X;OXTU'2Y;
MJ&-4OK4]%E0*&1L'!Z<\@U7\?_'CXEVVB6'CCPIXYU-_">HW)M_LEXD)FT^Z
M W-;.2@\Q<<JXZKP<&O5->_86\2?$'QW_P )!XS\?PZDL\RM<QVMDT;"(=(H
MLN0B@<#CCW-.\??L.^)/'FI6H?QAIFE:%IZ?9]-TBSL)/)LH,]%R_P SGJSG
MECR:=3!YJU4Y%*S?NKFU7G>^WEK^%PJX#.FJOLU-1;]U<^J\[\VB\KOIVN>9
M^(?VA/B/XX\%W?C7PIXNOM+?3!%'KVB;8S';,_RI<6[,G,;D<H260^JX(70O
MVAOB/\5_"<D.B>+;W2_&VAV;W$]K&D8M]5M8QEY02F(YT'W@2%<=,$8/JOC?
M]B#6-;T>Q\-Z#XKL=#\)V)$B67V-WENI\8:XN'##?(>0.,*. .N77?[#^K:=
MX#C\+>&_%=EI<-XJOK5_)9NUQJ,@.1'N#C9 O:,=3RQ/&*>#S;G;?,U;7WMW
M_=UT]?737E+> SOVC<N9KEUM+>7]W7W?7;?2SY3R'X<?M*_$#XEZ?'X-D\87
MFE^+I)6;1M6CBC*7DC?\NMR-AP#CY) /E/#<'(H^"_VJ_'EOJ&I^%/&7BS4+
M$W$WD1ZU;Q1//IERI*@E54B6(GAU'..5.1@^V>&?V(-5\#^$KRVT'Q79VWBC
M4=\%UKDEFY>"V(QY5L _[LMSN?.<<# SF#X??L)WWP_%[JL'B33K[Q2H"Z7=
MW-BS06!/WIO++?/*/X<\*><$XQ,<'G"]G=RNM_>TMVM?5^>G37J1# 9\O9<S
ME=7YGS:6[6YM9>:MTUTNO'A^TK\5/A-\0]1\/>.M?O=4M8P;6\6U:$2Q*P!6
M>W<+@. 0P##!!P0.S_$G[0OQ;^#_ (UTB[N/&#^*_#]W$FHV/VF%$BU"S?.-
MZA0\;=01V89&1U]5\)?L!W6G>)I]=\2>)[3Q/<J'GBM[JUD\J>Y)RK7!W[G3
M/)4$;NA.,T2_L%ZSXM\=KKWC;QU'K,$TPDO(K6T:*21!TB0EB(U  4 #@=*G
MZEG'):/,GS:>]LO-WU]+?Y./[/S[DM'G3YO=O/X5_>=]5Y6[O39\#\5OC%\2
M+;PUI_Q$\%^.]4?P5JTYA^RW:0^?IUT.6MVRG[Q1SM<9XZ^];5/VAOB/\0_!
M-[XK\+^+;W2=2T2&,Z]HRI'Y 0D(MU;LRGY6. T9.03D9!X]8^*G[&/BGXG:
MI;*?&&EZ/X>TY/L^E:):6$@@LH1T &_YG/5F/)--\7_L0:MJ/ARR\+>'?%=E
MHOA>V*S2PM9N\]_<X^:>X<.-Q'(51\JCISDUK4P>:.=1QYN6W\V\NZUT5];=
MM+=NBK@,Y=2HX\_*UMS;R[Q][W5?6SZ:6[>5>%?VA_B/\6_#0TG2?%EYI?CO
M2K:2:-(TC$&L6Z L^XE<1SH,G/"N!C@]:?PW_:=\>^/+4>#K_P 97NE^(KJ?
M.CZW'$C!YFX%M<*$.48XVN!E#URIX]B_X8?U71? /_"-^'/%=GILVHI_Q/-4
MDLW:XO><K A#CRX!P2HY8\L<8%)X/_8?U7P#X=O3HGBJRB\6WA: ZW)9.39V
MQ&&6W7?\LC=#(3D#A<9)I1P>;<T.;FT7O>]H_)*^_GIKZ7<1P&>*=-S<M%[W
MO:/R2YOBZ7TU]+OQ'PW^U-\0M"US6/"OCCQ3J5JLDAM'U.U2)[G2[A&(WJ%7
M;(F>'3J1RI!',4/[5/Q=^ GQ=.F^-]9;Q5I]L5%S9MY>R>!P&66)@H*L5(8;
MO7!%>T> _P!@R^\$3WFKGQ)INJ>(HU']ERW=BS6UK*3S.\9?]XZ]5!X!Y(.*
MI^"_^">!'Q!3Q#X^\6CQ9;&5KFXM5@='NY2<CS'9B2N>2!R>G%71PF;J,4W+
MFOI>6R_O:Z_=_DOZ1\)<3@\JRW&PXOG"=*2?)3E#GK7ZN-1+W4]DN;?7W>OU
MKX)\9:7\0O"FF>(M&E>;3-1A$\#R(4;![%3T(.1^%;E16UM#9V\5O;Q)!!$H
M2.*-0JHH&  !P !VJ6OT"-TES;GQE9TY5).BFHW=DW=I=$W97=NMEZ!1115&
M(4444 %%%% !1110 5A>.[O5[#P3K]SX?@%SKL-A/)80E0V^<1DQC!(SEL<9
M&?6MVB@#Y<3QG<?V-I\=IXS\;7/A:6\A_P"$AU^XT\K<6#F"4^5$_DAT#2K"
M) $81[P R[SC"OO%WQ$;QK%J&FWGBN?PM9#1574[\+ B0232">:XLUAW3[XU
M4$J5*;T8JN&K[ HH ^=?C)K_ (UU+QI+I'A^75G$&IV5L-/TF[6R>:W>SN9G
MD:=HW" RHB9P!\@7()S577/C/XV\!_LU^'==@LKC6_&DBO;RVMYILTS>?&LC
M&"?9L(?]WY?FA2'<#:N'!'T<+.W%X;OR(_M101&?8-Y0$D+NZXR2<>]34 ?$
MD?QA^,?A+Q5XGU:6Y?6-.OIY?L=EJ.DSQ6>FQ"Z6,2[E)9E5-HQW+[NQKW+P
MAX^\5^+_  3XRU+Q4C>%+:T$,$(TFQN#=0J;6&6:96D4LXW2LHQ$"H0D@D$#
MVFB@#YQ^'/BWQQ<3?"ZZU/5-0DT64:O#J7FV1(NTA#_9[EY2@<(RJI3*HS9R
MP).!W?ANSU?_ (6=XQUF+5M;FT.UM(X[;3KV7?:SSR()FDB7:&544H@ /4OG
MD#'J=% 'RC#^T)\7[.U6ZO?"^G7,<MDD^RVTB\0VS26<-SN;,C%UA,DBL@ 9
M]F 5/%>E_"7X@Z_XK\46BZG,DD-YI,]PR16LEO$?*NVBAN8XY"7C6>,[]C$G
MY1@XZ^QU#'96\5U+<I!$ES,JK),J .X7.T$]2!DXSTR: )J*** "BBB@ HHH
MH *@OU9[&X5%D=S&P"Q/L<G'16XP?0]JGHH ^-1X \?EX$TK0/$EKI UB670
MDFNS#-I\KR63":X3SVQ$B1WB9R^\LS;1Y@K[*HHH *JZFC2:;=JB2RNT+A4@
MD\N1CM/"L2-I]#D8/>K5% 'QS#X%\:6?]DWNF^&?$$]MI^O3W&C:-J@'D-!(
MULS&Z'VDM T9281OF0-\S%07VG(\3_"KXP36GCVWLHM=D'C*S26XDCU+8;&>
M.%KK$'[S,;.[_9ODP,H#T.:^W:* (K4,+:(.,/L&X'UQS4M%% !1110!XUX7
MT'X@0_M*^(=9UR*-O"%QHHMM/DMM0=X8BMQE%,!10LS*69VRW\(!P,5ZOKFE
M_P!MZ1=V'VNZL#<1F,7-E*8YHB?XD;L15ZJ>L0WUQI5W%IMS%97[QE8+B>(R
MI$Y'#%,C=CTR*F6L7I<F:O%IJY^>/Q-^)?Q?_9K^+D5A?^-[KQ+:0D74$5Y<
M>9%=V[$C;+'U1L CV/(/2K'Q>^)'CR'POI/Q)\'>//$-KX2UN=H3I=]=D36%
MT,EXES_K8N#M<9XX->KP_L!_VUXX'B#QCX\N?$PFN/M%[$;+R9+D_P!TOYC;
M5Z# ' X&*O\ Q/\ V)]5^*6OQWE]X]CL=-M$%OIVDVFD;;>QMQTCC'G>@Y;&
M2?RK\\E@,S<*JC&5F_=7.KKSO?:VEM;_ "N?E4\LSATZRC&23?N1YU>/GS<V
MUM+:W^5SPW5OC=\0/B5X$U#QAH/C#6-$U70HXEUW38[@QVDJL=J7%N>BL3PT
M.<Y^9>,@+X2^-_Q ^,'AE]'L?&&KZ3XTT6SDN8;B&X,=KJ=K&"SB<](YE'20
MX5QPV#@GW+QI^PX_B#1=.\.Z1XR&@^%M/Q)'IR:;YCSW!&'N)Y/-7S)#T' "
MC  '<N/V'&L_ 4?A70?&0T>WNL2:S>?V;YD^I2 Y56;S1LA7M&,@GDDG%']G
MYISW=VK:^\O>?EKIZ^5[:V#^R\Z]HW)2:Y;2]Y>\_P"[[WN]-=-F[:\K\"^%
M_P"T'XX^($,?@;4/&.M66LWL^=&URUD9I%N&&!!<!02\+?WAS&>>5R!2\)?M
M*>.O#NO:MX5\9^*M:N+.XF-G+?V%T);O3YT8J)8&7(D4'[R=''3!P:^B_#/[
M#C>"O"E_9Z'XR%GXBU'=#<Z\VF[I8K4C!A@7S1Y>[^)\DD<# SF'X?\ ["$7
MP^DO=3MO%D5YXC"!--O[C2PT6GL?O3+$9"'D ^Z2<*><$XQ$,NS=>SO>ZW?,
MMNUKZOSTWM?JHAE6>+V5V[J]WS*UOY6N;5^>F]KZ77@-[\>/BA\$_B9?Z)XG
M\4W_ (DLH1Y%U"MX09()%!$D3XW0RA2",C*GAAU%.\9?&7XH?"3Q9H6JVGCS
M5/$&@:A"FIZ:FJ.<W%LQ(V7$)Y5NJDC@XW*>E>Y^$_V +32/%#ZYKWBW_A*)
MUWSI!>6!$<MR>5>?]Z3(H/)7(W=SC.6W/[ TOBCQL-?\7_$"XU\33B6\ACT_
MR&F4=(U;S"(UP   .!P,4O[.S;D:BI)\WN^\O=7F[Z^GSTV<?V5GG(U%23YK
MQ]]>ZO-WU7E9[7TV?B'Q#^+GQ"L=$T?QWX8\>>((O#.KSO$EA?W>Z:RNDP9(
M>1^^B&?ED (QPV&!ST^N_%_QU\7/AIJ'CSPMXLU?PYJOA^../7](CN6CLI01
MA;BV8\!CCYHLY].V?3/''["FH?$#78;S4?'T=M86R+;V>F66D>7!96RGB*(>
M<0..Y!).2<DUN_$3]C27Q9X?TKPMH?BY/#'@[35#1:5#IWFM//CYIYY/-7S'
M/;(P.U;?4,SO4;3Y6M%S+5]UK[JOK;Y6[="RS.+U6U+E:T7,KN7\R][W5?6U
MWII;M\]^ _CA\0/B_H2^%[;QAJ^E^--/@EN+"_AG*P:C"H+O%<GHCJ 2LQP#
M]UNQJA\,?VB_&WB[/@C6O&.MVU[J-P!I>NVDK/-;7)^58Y54$RP,< XY4_,,
MC(KZ"3]AQM)\ GPSH/C(:4U_SK6I?V;OGOP#E80?-'EPCKL&=QY8G@4>$/V&
MV\">']131O&(M_$]]F#^WGTW+VML1AD@3S?D=NADR3C@8R341R_-5*'-?1>]
M[RU7:U]^E]-?2[B&5YVI4^:[LO>?,K-=(VYM^G-IKZ<S^=M _:0\?^!O%>M>
M%_&WBC6+ZQ>5K"\N;&\$EU92(Q FMI!PV#U7HXX.#@B?5_CG\4_@?\2Y-.UW
MQ;?>)[%(P7@EN647%M*N5=<_-#+M((R R-U!'7WKX?\ [!D'@.^NM6'BJ+4]
M=C3_ (EEQ=:6&ALYL\SF(RGS' ^[D@ \D'BJ_A[_ ()_VT'BYM>\3>,7\5.7
M>X>WNK$HMS.>5:9O-)9-W+*,%NF14++LWY(I73OH^9:+L]=?N_.QE'*L]]G!
M+F4N;1\Z]U=GK[W?;\[+PWQS\8/B;\--9\/:_I/C_6-8\-ZM$-1TN/5I,R/$
M&PT5Q"?0Y7</E8?,I])OB#\7_B!-X8L/B#X7\<Z_9>']1NFM9M+NKPE[&\4;
MFCC+#]]#CE6&2!\K<]?;-7_8*NO&7C,:]XK^(4VKB653<00:8(,Q+P(HSYI$
M:@ * %P!T%3>/OV%[[Q_JT$L_CJ+3])LD%OIVD6>D8@L;<'A$!FY)ZLYY8DD
MTY9?FC53E4K/9<RNGWOS:+RU_"Y4\JSIQJ\L96?PKG5T^]^;1>5W^%SP_P 2
M?'KQQXY\#7'C+1O&VJZ!J>FM#;:QI*W12VF9^$GM>P)Q\\/4<L/ESCK_ (,?
M&CQI\>/"]UX&E\3ZOHWB[3H9+W3_ !):2%8Y449,5[CC'H_]>OK&O?L%^%M;
ML[&P3Q+K-CI=BF(+*W6'8'(&^5B4RSL1RQ[8 P !736W[(N@:/\ #&7P7H>N
M:IHEM>OOU34+41_:M0'9)'*\(/[JX'YG/72R[,U5YZCO&VJYOB?EKIZ^5_([
MJ&59Q&OSU9-QY;27-\3\M?=]?*]KNQ\:>$?VF/'^F:W>Z%X@\6ZWJ=C>2?9'
MN-/NO,N;:0-A9;=A]_G^'HX..#@B;4/C]\3_ (3?$2^TK6/&=]XCMK1FM[F$
M7AVRQL.2K=8I "/=&&"."*^I?"'["GA;P3+=W>G>(=7_ +7DB\JUU"186DLL
M_>>(;,!R. QR5ZC!YJOX8_8#\&^'=<359=;U75IXMSQ1WRPO&)3]V1EV?/M/
M.UN">N:Y(Y5FZC%<SO??FV7;S_KOIQ1R7/5""YWS)[\^R[/77O\ \/I\S>-/
MC5\3_AIXHTJZL_'^L:GIUW!%J=G;ZG+F7R6.1'<P]FX(]&&&7@BG^/OC/\0[
M71]'\7:)X[U^RTC6GD":9=WA,MM*A'F!,C][!D_+)]5/(.?I-_V O"FI>)#K
M.M^*=?UR:6?S[I;EXA]H.<D,P3(!Z<8XZ8J3Q5^P;X>\9ZR^HZEXNUMGVK%%
M!#' D5O$O"11J$PB*. !]>22:<LKS5J?*WKLN;;SO?\ #_()Y+G3C446[-^Z
MN?;SO?Y6U_!'A^M_&GQY\3/A=>^.M'\7:OX:U30?*M=8LDN#%8WF[A);8]!*
M<?/%^(K!\$_'7XA_$K1)M 'C/6--\0Z;;S7EKJJ7!2">%07>.[/1<8^24]R%
M;J"/J7QQ^Q;X<\9:;I.CQ>(-6T7P[I486TTBQ$7DJY'SS.64EY&/)9B3V&!5
M _L+>&(/!X\.6/B/6-/M)Y/-OYH1#YM\P.4$C%/N)V08&>3DUO/+<T=3FNVK
M:^]\3\M=/7RO;6QTSRC.75YN9M<MI>];F?DKZ>OE>UW8^7OAI^T1X_\ %=P/
M"&H^+]>^T:G,HL-5M)6>XM;C&%#@<R0G^)>J_>'0@U-!_:4^(7A;Q-J6B>(O
M%NKZS822-87$MA>B2:)@^!-:R#@L",@=''!ZY'U;H'["_ACPQHFI6>F>(]8M
M;[4!Y,VJ*(?M"VY'S0QG9A W\1')'&<9!9X._80\*>"KR>_LM?U:35?*V6=Y
M.D+&S<]98UV8W@9 )SM)R.0*QCE>;)03F[K=\W3M:^O]+8YX9+GB5-.;NMWS
M=.UKZ_\ !M>VWR[K7QX^*7PB^(LVGZAXVOO$=O:X$L$URVV:&1,X8?>BE"MT
M^\C#VIWCCXT?$OP%K&B:IIGQ UN[TK4H$U*QM=4FS.D>['EW$7?D'!Z.N&'7
MCZ7T#]@#P9I&OQZK>:[J^M2QNTODWXB>.24Y(:0;<OAN2"<''.1FFW_[ ?AC
M7?$;ZQKGBWQ!K%Q-,);GSC"OG#/W<JGRC P N,#IC%2\JS9QDDVM=/?V^?7T
M^?JGDN=N$E&35W[OO_"O6^OI\_7YO\=_&KXA3>'-,\::)XXU[3-,U6>2W?2I
M[P[K>X0 OY)/,D'/#?PGY3R,F]>_&?XE_$'P#J/C#1_%NM:3=Z$(HM9MX[@Q
MVDP;Y4F@/17/\47_  )>,@?1/B[]A#P[XSU87M]XKUJ..-!!:V=O' D%K"OW
M8HEV?*H_,G).22:K_$#]B:7Q9I>F>'])\8)X=\):8N;;28=-\PO*1\\\\GFC
MS96_O$# X %7++<T3F]6FME+=]]].]OEZ5/*,Y3J2NVFM$I[R_FWM%7UM\K6
M>GC_ ,/OCCXR^-W@V;PTOB_4_#OCC1;66\M-7AG,=KJ%N@RZ79Z(X XE. >A
MYZ\/\.OVC_'VM7C>%M6\7:_*-5F2.UU*QE,EU9W'1" .9(CG#)Z<KR.?JJR_
M8BT*P^'2>%+;Q+J5@ERPEU:\LHHTDU)A]Q7+!BL:]HP<9Y.3S3/#7["_ACPC
MINI1Z9XCUBWU.]3R?[5Q"9X(2"'2+Y,(6S@L/FQP",FK_LW-9.FW+5+WGS;^
M5K[]+Z?A=Z_V3G4G2<I.Z7O/FW\K7WMIS:?A=_*=A^T?\1_ 7C'5-&\0^+]3
MUVQ1WL+PV5]O=<-CS;:7LX(R.QZ$<U8\2?'/XI?"/X@I;3^.=0\06L2I.+>\
MF($L$BY"31_>BDVGE?O*W3M7T]X/_8,\(^#=2?4K;7M5N=12,BSGN8X7%K*>
MDRILPSKSMW9 /.,@5!I7_!/[P;:^(H]6U+Q!K6NN)3/+#?F-EGD.3F0A<L-W
M)&>>AZUBLJS;E24FG?3WME^O]=SG62YYR)*;3O=>_P#"O/O]VEO-GS3X\^,_
MQ(\(W&@ZYI'C_7GT?6(OM]E9ZE<;KB!5;!CF0C#KD?*^,.O/J*L>-OC;\0M3
M\*6?CC1O&VN:397MTUG=:3)=L!%<A=S-;$\O"1VZQD[3G(-?1^L_L#^&_$_B
M&36-;\7Z_J5S-(KS!O)0,HQA%PGR* -H"X '2K'C#]A/PYXSU&.>Y\4:Q:VE
MM&(+*PMDA6"TA'2.-=G3N2>6))))-5+*\T?/9NSV7-U[[Z>FN_E<N639T_:6
M;L[67/U[[Z>FN]NESYS3XT?$OXD^!-3\1:3XNUK2]5\.6\9U:..X\NSNH<A5
MFC/1)NFZ/^/[R\Y%6? WQP^('Q?T#_A&[;QAJ^E>--,MY;BRO89REOJ," N\
M=R>B2* 2LIP#]UN<&O>O''[$\GB'P_IOAC1/& \.^$K#$BZ<FG>;)<W&/FN+
MB3S5\QSVX 4< 5!_PPXVE^ ?^$8T'QE_9/V[G6M1_L[?/J&#E8L^:/+A7KL&
M=QY8G@4_[/S13UNU;7WE[S\M=/7RO;HW_96<QJ:\S7+:7OKWGY>]IT]YVVO;
M6S\,^#?[2WBOQ2TG@+Q/XIUN.35YU33?$-BY>\L;D\*K!>9(6/5>HZCVS&^/
MWQ-^#GQ&U?P[XP\3ZEKUI 6L;^."^RZJ<$2V\O\ !(.",^ZL.M?2OPY_8N7X
M7:'JDFB>*4'C*\4P0>(9M.#&PA(PP@B\SY9#TWEB1V K"\$_L!6GACQ!)K6I
M^*4\1WL:M):Q7NG?N1<DY669?-)E /.W(!/4D<%++\V]G35WS)[\RLEV>OO/
M]-+OHEE>>>RHQN^=/5\RLH]FK^\_EMI=]/"_%?QI^*7P8\=Z7<'QQJ'B71KJ
MWCU&RCU"0@75I(#A9HC\T3XR/4$94D8-'Q!^+OQ%\-VN@^,_#?C[7I/"VM2-
M)9VFIW.Z:VEC(\R"12,2H#P) -K#@X.17N,/[ ?]L^-?^$@\7^/+CQ-YTYGO
M(C8^2]R>RE_-.U>@P!T&!CL[Q?\ L(W_ (_\3)JFM_$ &W39#%8V6D"&*UME
M/RPPCS2$4#@<'GDY.:B67YJXSY5)7?NKF5UYWOMY:_AKG+*LZ<*BC&2N_=7.
MKKS;YMK:6U]=-?%O&?QG\?>+/!4GQ"\->,];TBUCN4L]8T=KMEBMKEQE6M6/
MWXFP3LR63OE<&I8/C?\ $#XK^![_ %32/&&KZ+XG\-60FU*WBN#'9W]JIV^>
MI^['.,@,F0'ZKSD5[=\0/V&[CQH;&PM/&L>B>&=,4QZ;HT&EED@!^\[MYP,D
MK'EG(R?8 "I?$G[#C7WA*P\*Z'XR_L/P_#MFNXAIWF2ZA= <S3OYJ[L=%3&%
M'J>:TEE^:<\G9M6U]Y:ONM?=[_IK9:RRO.N>;:DU;7WDN:7=>][NNOZ:\J\*
M^'?QS\??%O28_!Z>,-8TSQA;I+/I>J0SE8KU0"[P76!\I !*S'@=&XP1G?#?
M]I'QKKDDW@SQ#XPUN&74;@)8:W9RF2YLKK[JJP7)EA8\,HY'WE]#]"V?[#C:
M#X#F\/:#XR&F7>HY&KZO_9N^>[CS\L"?O1Y47=E!)8]3CBD\$_L-'X?Z3J,F
MD>,%C\4W0\F'7)--W&R@(PX@C\WY9&Z>9DD#. #S2CE^;)T^:^B]Y\RU7:U]
M7TOIZZ7)AE>=J5/FO=+WGS*S72-N;5]+Z:]=.9^%>"/VI?B'\$OBE>Z7XWU>
MY\4Z?;3FSU"UDN!/LVG'F0OZCT[]#@]/T5T?58-<TJSU&UWFVNX4GB\V,HVU
M@",JP!!P>AKYG^$'["&A_#[QA%K^OZV?%KVQ\RVM9;/R8EESGS'!=MY'4 \9
MY.:^I*^CR7#XW#TY+%O1O1-W:^9];P_A<PPM*:QLM&_=BWS->LOT_(****^C
M/K HHHH **** "O'?CIH5WJ>N:!<7N@ZUXI\*PVUTD^EZ%<F*87K>7]GF<"1
M"RA1,H.[",X)'<>Q44 ?,%[X3\5?VCX@-]X7\2WOBZZBD_LS6+?6";6TLS9;
M5@:0, SK('!4QY=V#[N<B;X,^!?'WPX\,^,K:[L6M=2G\.6TNF+ISRRVS7:P
M2;V?SI7871D8*P'R,J1D$DMCZ9HH ^1/%GA/Q'K-Z;GPEHOB&YTF[\/16^I7
M373 7"[K=A)!^^S*_EB1?((C^ZXW R5N>+/#/Q2U']F:P\,^'M/O+;7;>'-T
MEWJ;V]Y- '=H8XI@),.0L>]"PVJ2@<]:^GZ* /#?BS!\5[[Q9 GA74+[2=(2
MSL5<6$-I,K2R27"W)W3(6RB+ 1P!E@<'D5PQU?XP2Z?JO_"7)J5LBZ8K1BW@
MMT@%WLMC9F!H_P!X;AKGS1(A)3& !C&?JNB@".V,AMXC, )=HWA>F['.*DHH
MH **** "BBB@ HHHH *@OT:2QN$5&E9HV 19/++''0-_#]>U3TA(4$DX ZDT
M ?)%K\)M:\F'3)/A]J]II-QXA-_8WD5Q:_:]$MA]G9U2-+D(C/)&RK(FYO+#
MNP+OM;ZXKG;;XB^%+R&PFM_$^C3Q7\YM;22/4(F6YF'!CC(;YW']T9-=%0 5
M7U'[4=/N?L)A%[Y3>0;C/E^9@[=V.=N<9QSBK%-DD6*-G=@B*"S,QP !U)-
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MC4H4(4JL^:26Y^F8&A5PV&A1K3YY):OO_7W]PHHHKL.\**** "BBB@ HHHH
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M^*GP'\0?$+Q-:7_]ME;6"RL;7RTO[FT#,DEP;IMD1"_O$DB7U^4CC -<?;?
M;X@:+9ZL^J:DOB.6YTHZ>KIJ-Q(\\DD5O%$K1. B);R1R2^<"78.20#G/U+1
M0!%;1O%;Q)(_F.J@,^,;CCDU+110 4444 %%%% !1110 45Y7\3?&OQ2\/>(
M8[;P9\.+/Q9I)@5VOI];BLV63)RFQAG  !S[UR7_  M+X_\ _1$M-_\ "I@_
MPKUZ665JT%4C."3[U()_-.2:^9P3QM.G)Q<9:=H2:^]*Q] T5\_?\+2^/_\
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ME_9U7^:'_@</_DAV/=:*\)_X67\=/^B.:=_X4T/_ ,31_P ++^.G_1'-._\
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MO_HBNF_^%1!_\31_PM#X^?\ 1%=-_P#"I@_^)H^J3_FC_P"!1_S#ZI/^:/\
MX%'_ #/?:*\!_P"%H?'S_HBFF_\ A4P?_$T?\+0^/O\ T133?_"I@_\ B:7U
M2?\ -'_P*/\ F/ZI/^:/_@4?\SWZBO /^%H_'[_HBFF?^%3!_P#$TG_"T?C]
M_P!$3TS_ ,*F#_XFCZK/^:/_ (%'_,?U.I_-'_P*/^9] 45\_P#_  M'X_\
M_1$],_\ "J@_^)I#\4OC_P#]$2TS_P *J#_XFCZK/O'_ ,"C_F'U.I_-'_P.
M/^9] T5\^_\ "TOV@/\ HB.F?^%5!_\ $TA^*?[0./\ DB.F'_N:H/\ XFE]
M5GWC_P"!1_S']2J?S1_\#C_F?0=%97A6]U34O#FG76MZ:FD:O- KW5A'.)E@
MD(^9 XX;![BM6N5JSL<+5G8****0CE/&7BZ_\*_/'I?VZ!P@A\J0F1WR3("@
M!P%C!;/KQ61?_%Z&T6&9=+G:TD;*3;U)DC\PHK*H.>2K<'& ,FM?Q!?:[8ZZ
M'L8);NS^SC]VL8V(^\98_P 3G:> ",8[YXSCKOBN^@G@N/#<,:"W9I [;UD.
M<!%PW.5.?P(H I0_&RTN-RQ:-?2NN02CQE"1DMAMW( '!Z'D5-K'Q6&C:Y?P
M26GFV5M!%,H0XFDWJ#G!(  SSUZ5?T*77C9ZG8QZ5#HL5LA33F1<B3 R"P)P
MN3VY/)YXJF_B3QC&A(\/>:3")<,5W*S./W8PV"54]3CE3[4 5[_XV6%K%$8[
M"=Y)V*QJS+D#L7 )*Y/;&>_>HQ\;K26_$4.FSF'S6A\QW50S9P#G. O0EB<#
M-7I-;\96\_DIH@N(43S//,BAW8NWR8'& ,>A-:&G^(/$4_F)<:%L8)*Z/G:K
M@*-@(R2I9LC;S@<YH JQ?$Z.^T[4;BWTZ>(VZHT;71"HZLX0L<9("DY/L,U5
MG^*XMRD*6*ZA<B0(SV<H,3@8+,A;!P 1@D8)# $XJQ:>(?& \.7]W=:%$VJ!
MHOLUE$?EVLHW;F+<X.[Z>]:=PVMW&B6/E^=!?B[C6XVK'DQ%_FZ@C 4]1SQ0
M!E6GQ7AU*2);/2[B17*,SRR(BQQL\: MSPW[P?)U&.:[RN*UK4_$]E-?S6FF
MO=SHB"UM(V7[-("1N9W(#[ASP,# [U90^(KFSE\UI;:;[9#M\H1\0EP),9!X
M"D\]>* .LHKA8-<\:0W4%I)HMO/%Y(9[TOC+;%(&T'J"2#V..,56N/''B>T:
M<SZ"D:0^9*=^1NB7H<@D!CR .<G% %_Q)X\NO#VM7L1TV2YTZSMHYI)8E)9G
M=BJKDD*O(')[9J@WQDM(H#-+I%]#$0?+9RGS-D@*>>,E6'X#UK2U'4_$\$]G
M<06"2PRVJ^;:A=VR4DD@G(/0*N>@R3@T[5_$.MZ-9Q7DNGB51:RO)#$,J) Z
M;$)SG)7>!VSB@#*T+XP0Z\E_Y.E7,;P6TUU&TF C!5W*IYSD@CD C.1FJ\?Q
M>N;2VMDU#1G2^N8?M$2(^Q#'M!RV[E>CCG^[[UHW?B7Q;8VQN9M%MMA*J$CW
M,ZY8@'KSVXX^][4@U[QE!$C2:)%.9MSA0>8N>$;YN_\ >[=\T 5K?XR07)V1
MZ-?.Z@%F.U5_A!."<CYF P1G'-0:_P#%ZZTJ_M;6#0Y+CSK"*\:?S!Y<1<XP
MS=,#(R<CK6C<>(O&5J(6'AZ"X,LB K$Y'EK\N[<2WH2..Z^]7-8UCQ%9W5VM
MEICW:1N=@*J%=#Y>-ISR1^\ZX'Z4 5+WXJ6]E>Z58#3KBYOM0MXIHXXB  SD
M *2V,=3R?2J,_P 8T;2=8U&TTF>:&Q@AE2)V ED9Y"A!49VXQGGDCGO4]UXQ
M\2:0EM]MTB)!-*D49R7=B21M(!Z\ Y P,]*L7>I^+['5;G99+=6#32F)@BDQ
MQ@QJH(!!;^-@0?4'H,@$*_$B\$MM%/I\%E--/;1)#/.0\GFH&.!C *Y/4]O4
M@4:G\7[+3]7U#3DTR]NI;(MYCQ;-I X)R3_>X_7I3[OQ)XTBNHDB\-6\T3G)
M<S8V#!X//)R.O2FCQ=XA.K)IDNEQK=%#+MA/WE5L;LDG (P,'GDX- $FJ?$X
MZ?/I3+I,TMK>6RW<A\Q?-B0AB1L_B(VCH>^/2E/Q8L4T2'5)-/O(K>6]-GAP
MF5XSO.&Z8(XZ@\54G\4^/(IC''X6MI%7:OF^<0&R>2!GH!CCKWJ2[\1>-5DF
MB30(8XS#N6>,[V60AL#;D9P0!GWSTXH KP?&RQN()9TTB_>")BLCH%)!R>@S
MEN!GCZ5V'A7Q''XJT:/4([::T5V9?*GV[A@XSP2*YC7]2\;VVJ7":781W-H'
M@>)WV#@*/-3KGYF/7L V.U2KK?BN2=Y_[)>.TV,5M@JB0LKK@9W8&Y=QY]N1
M0!W5%>?/XA\;S06K#0H8-[8EVG<R $YP"W<8QZ<]:9;^-O$]WJ36=IH<5PL$
MOEW,K.1Y7#<9SACPO(QC=C% 'HE%<I]H\27NGP--;BQN$NT5Q:NK>9%OPQVN
M#@;>1SFL:Y\;^*+#3(;N\T*&V>280K 26=B68*,!NX"^N,GK0!Z)17G7_"3^
M/0D<O_"-VS-)@?9_,(\OYV!);/IM[=\^U:L-QXDU#38)9$EL[DZDBO'&B#%M
MD;N&SQUYZT =A17&:IJ?B:QNKM[&PEOY3=I%'#+M2W2 _P#+16'S%O7)[].*
M=9ZCXH%O=P3V9,HLI)8;C"Y\\<*A&<<\$<>N<4 =C17%7>K^)7M+.Y_L^9)8
M[N19K.V5<S1 X1MS$X'?'!/J.]?3-:\:2ZE8276CQ):W,BQSQ[L"V09R_J2>
M.O3&/>@#O:*X>3Q+XN+7+Q>'4\J.X*1I(^'>/( ;[V,C))]<<427/B^>+298
M(T1A%/-=I*BJ&8./+CQR02N>XQU)[$ [BBN%NM?\8&5X8]&1 )0HG09!PX!'
M+="N3N[=,9YI+OQ7XM\J9K7PUEU""-)CC>2%WDD-P%.[ [C!XH [NBN%OM5\
M5W6DVDB6,ME>&>9)4MD1Q@*?*;YS]TMMST.,]*8_B?QFMI=./#<7GP1*!'OR
M)I2<$*=WW1US^E '>T5Y_-KOC2WMI'AT=;J:)RBQR80."XY)!YVKGIC.>G%:
M.IW'B :E<>0EUA601Q1K'Y#1[/F.XC=NWY'T XH Z^BN,DUOQ3!=(7TA7B.,
MM#\P52 <;<@ELY7.<=\57&K>+KWP_=7+::;"_P!\*QVZ;2=GG,';G//E[3WQ
MVH [NBO/7U+QSIMS'(EA'JD5QN+1N1'Y !<@<<DD!!_DUJZ5K?B-]:6&]TT'
M3I"2)XXBC1CRT(R"Q_B+@]QC\: .MHKAKZ^\3R7VI-##=1PKG[ J11E7& &\
MS)SD$$KTSD9]*M"^UI/#5X/)OY+T2[;:4QQB8H3\K./N\<Y &2,<9- '7T5P
M=A>>*9=6ABG2ZCA:7+3&&/RE'S K@'<01Y9!SP=V2< 5-JFJ^*M.TK3'M-/;
M4;X6[M=1LJJK2?*%!P1CDD\=J .VHKC&U?Q-<Z%=M/ICV=\6C%N+0JY7=U+!
ML@A>^.HZ5>\&W&N7!U/^VHFC N#]F+*JYCQVQ_7UZT =+1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>mrkr-20251231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20251231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #R ]X# 2(  A$! Q$!_\0
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M\#4_QK\,MQ]31N/J:/["I_SO[@_M"7\I^YO_  NOP#_T..B_^!J?XT?\+K\
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M<Y 7:0>020.*N.4X=V7M;-]-+Z_,EXRJK^YL?L)_PNOP#_T..B_^!J?XT?\
M"Z_ /_0XZ+_X&I_C7Y$V_P"RS\5+KP8/%$7A*\;23#]H!W#S3%C.\1YW8Q6+
MX+^!7C[XB:/!JOAWPY=ZIITUV;%;B$C:)@"2K9/  !R3Q3_LG#6;]MMZ!]<J
M[<A^R'_"Z_ /_0XZ+_X&I_C1_P +K\ _]#CHO_@:G^-?C'\3?A)XN^#VKP:;
MXMTF72[FXC\V LP9)5'!*L.#BO4OV>_V4]3^-?@#Q=XG07+#3K=DTRV@*C[9
M<@?=))X I3RG#0A[1U?=[Z#CC*LI<BAJ?J5_PNOP#_T..B_^!J?XT?\ "Z_
M/_0XZ+_X&I_C7Y"^ _V8?B;\2+6[N=#\-S36UK.]M)/-(L:&5#AD4D_,0<CC
MCBLBU^!?C^]\6ZOX8@\-7LFO:3'YUY8C&^-./FZ\@Y&,4_[(PUVO;;;["^N5
M='R'[(_\+K\ _P#0XZ+_ .!J?XT?\+K\ _\ 0XZ+_P"!J?XU^0S?LP?$]?&-
MIX6_X1BX;6[FV%XMNLBG9"?XG.<+SZU2\<?L\?$7X<:1?ZKXA\-7.GZ78S)!
M->,ZF/<^-NT@_,#D<BA93AFTE6U?H#QE5*_(?L-_PNOP#_T..B_^!J?XT?\
M"Z_ /_0XZ+_X&I_C7Y%']E?XJCP:/%'_  B-Y_91A^T=1YOE8SO\O.[&*ZSP
ME^R/X@\4_L[:E\1;>"ZN-1\Y39:>A55:V7)EF8D]@.GM42RO"Q5W6ZVZ;E+%
MU7IR'ZD_\+K\ _\ 0XZ+_P"!J?XT?\+K\ _]#CHO_@:G^-?D+X+_ &8OB?\
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MCHO_ (&I_C7X9;CZFC<?4T?V%3_G?W!_:$OY3]S?^%U^ ?\ H<=%_P# U/\
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M_P#X&)_C7Y%^,/@_XV\ ZQINEZ_H-WIMYJ3!+19,%9F) PK XSDCC/>MB\^
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ME6'=K5=_0E9'A':U??;;7\3]8_\ A</@?_H;-'_\#$_QH_X7#X'_ .ALT?\
M\#$_QK\F?!'P$^(?Q'T<ZKX=\-7FI:=O,8N%*JK,.H7<1G\*QM*^&?B[6_&$
MOA6RT.^G\01,4DL A#QD==V> /<\4_[)H7:]KMOMH5_8.%NU[?;?;3UU/U__
M .%P^!_^ALT?_P #$_QH_P"%P^!_^ALT?_P,3_&ORKL_@3XG\,_$KPAH/C?1
M+W2+/6M0AMMY(Q(C. P5P2,X-=;\9OV4_%GASQKXF/A+PWJ=[X3TQAY=VY#,
M5" L1SE@"3T%9?V;AE)1]KOKTL8O)\&IJ'M]U=/2V]M[GZ3_ /"X? __ $-F
MC_\ @8G^-'_"X? __0V:/_X&)_C7XLEW!()8$<$$TF]O[Q_.NG^Q:?\ ._N.
MS_5NE_S\?W(_:?\ X7#X'_Z&S1__  ,3_&C_ (7#X'_Z&S1__ Q/\:_%C>W]
MX_G1O;^\?SI_V+3_ )W]P?ZMTO\ GX_N1^T__"X? _\ T-FC_P#@8G^-'_"X
M? __ $-FC_\ @8G^-?BQO;^\?SHWM_>/YT?V+3_G?W!_JW2_Y^/[D?M/_P +
MA\#_ /0V:/\ ^!B?XT?\+A\#_P#0V:/_ .!B?XU^+&]O[Q_.C>W]X_G1_8M/
M^=_<'^K=+_GX_N1^T_\ PN'P/_T-FC_^!B?XT?\ "X? _P#T-FC_ /@8G^-?
MBQO;^\?SHWM_>/YT?V+3_G?W!_JW2_Y^/[D?M/\ \+A\#_\ 0V:/_P"!B?XT
M?\+A\#_]#9H__@8G^-?BQO;^\?SHWM_>/YT?V+3_ )W]P?ZMTO\ GX_N1^T_
M_"X? _\ T-FC_P#@8G^- ^,/@<G \6:1_P"!B?XU^+&]O[Q_.C>W]X_G1_8M
M/^=_<'^K=+_GX_N1^Z%E?VVI6Z3VEQ'<P.,K)$X93^(J>OR(_9__ &DO$GP2
M\26SQ7DUYH$DBB[TZ1RR,G<H#]UA[5^LOAS7[/Q3H-AJ^GRB:RO84GA<=U89
M%>'C,%/"25W=/9GS.8Y;4R^2N[Q>S/P6U"_N-5O[F]NY6N+JYD::65SEG=CE
MF)]2235>MC1/!NO^)8))](T34-4AC;8\EG;/*JMC."0.#BM'_A57C7_H4M;_
M / "3_"OT3FBM+GYS9LY:BNI_P"%5>-?^A2UO_P D_PH_P"%5>-?^A2UO_P
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ML?=O[)_B"XN?V'?'5ON938-=)&P/0,BG_&OA=OO'ZU]I?LB?\F6?$[_?G_\
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M@O=2NM:U&\@ $5S=R32R1X.1M9B2.>>*KZH->UV]:\U+^T]1NV #7%YYDLC
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M^UR?\]'_ .^J/M<G_/1_^^JI^9[T>9[U7(A<S+GVN3_GH_\ WU1]KD_YZ/\
M]]53\SWH\SWHY$',RY]KD_YZ/_WU1]KD_P">C_\ ?54_,]Z/,]Z.1!S,N?:Y
M/^>C_P#?5'VN3_GH_P#WU5/S/>CS/>CD0<S+GVN3_GH__?57-(N'?48078CG
M@GVK'\SWJ]H;YU6 >Y_E45()0?H7"7O(V_$<K110;6*Y8]#CM6%]KD_YZ/\
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M?>'_ +]K_A1LM_\ GWA_[]K_ (54\_WH\_WHL%RWLM_^?>'_ +]K_A1LM_\
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M(Y KIJX^,/A5_P#]GF,H4'+=_P!7L?GM%H6I36EW=1Z?=26MF0MS,L3%(">
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MXG]/I7LWQ;\$7^L7T=_86[W)90&5!D@CC]1C\JXW3/A%XEU)UWVJV49ZR7#
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M?"#QOXPL+2]T3PKJNJV=W(T,$]K;,Z2.OWE! ZBA4,+%:6MZ^5N_8'4JM_\
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M_1GV.6_\BNI_U\7_ *2SYC_X)]-M^&WBC_L+K_Z)6OJ3S*^5?V &V_#CQ/\
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MZQ"VN5W1S+G.&'<+UKW?P-\.M7\:>&-7N;61+F^2ZCDN[J[F$:8VG)+'@ =
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M=M7(FOY 92/X8P>_\_PKKK""'3+&"TMUV00H$0#T%>_#_8<#S+^)6T](+?\
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M.Q2.X5F6<QC;O5!@'<<L>H&:V-1\<^$K33([Z33H;QM)!NK*SN;9T43*,IC
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M#<[ ?KTS3X+^ZM;E+F&YFBN$.5F20AU^AZUU2R].]GO?IW:??I8R6(:MIV_
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MHY YK'B/Q9D?XH_%[P_X%@8G3=/Q?ZECIGJ ?P_]"KWJ/9#&D<:A(T4*JCH
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M<-I>N:=>^-O$ M()'>YNF87:IF-PH ^]]:O>*O%-EX0TB2_OF^0'"1C[SMV
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M)+C/AS5A_P!.<W_H!IQ6J!['YJM]]OJ?YTE*WWF^I_G25]R>$%%%% !1110
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M8MA>@R<\4RO?. **** "BBB@ HHHH GLO^/R'_?%?L-^P[_R;5X7_P!^Z_\
M2B2OQYLO^/R'_?%?L-^P[_R;5X7_ -^Z_P#2B2OFL]_@1]?T9]EEO_(KJ?\
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M]%>T>"OA#X%\3O9QOXKU^[EU*[-O:QZ-HGV@VB%]L<EV2PV9R#M7) K3TO\
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M&B5C(),E_-?/+9^7MFHEBDFDE^:M^!2I75VSXXHKVV+X&^$-&?1M!\4^.I-
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M#$5IX=U"Z2W=C*S7A4/A6+'C_@.*[#XEZ1KOBWQ'#HKOI_AW0[:8P:?ISW
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MW48//EB,BL+,*=X="!\X!Z$]1QUKSOX'>&/!<>@^)KSPQ/J/B.^DB:TN'U&
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M02..C.54%C]<THX2<91=UI;]/+R\OF-U4TT<71117J'*%%%% !1110 4444
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M[J*20.M==IOQ\CU[0/!=W9?%'3_!%AH^F6VGZOHUYHL%W?AX!M\RS9X'\S>
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M:*WL87';Z-]-HIV%<=OK/\0-_P 2'4O^O:7_ - -7JH>(/\ D ZE_P!>TO\
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MW'+'C<2 !_\ 7KJ)/&W@7QW8K;>((+594^_9ZK$4>)NX&<&KOA^72_LLNC>
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M'U+P]9Q6MMK!U^5H-.GTJY6XAGD7[Z;QP"O?/2G?#W3NK[_K_P $5JEMC#\
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M^2?2CR3Z4<X<A0\BCR*O^2?2CR3Z4<X<A0\BCR*O^2?2CR3Z4<X<A0\BNO\
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M[5+D?8I_-\H-_!)P-KCNO:LNC&**]%>9SA1110 4444 %%%% $]E_P ?D/\
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MQ-J]A;VVI7.FJMJ+>.+[-&<R"-U)<D\KD+]P<5Y'_P -UV__ $)[_P#@:/\
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M/?\ \#1_\11_PW7;_P#0GO\ ^!H_^(H]H+V,NQ].^1]:/(^M?,7_  W7;_\
M0GO_ .!H_P#B*/\ ANNW_P"A/?\ \#1_\11[0/8R['T[Y'UH\CZU\Q?\-UV_
M_0GO_P"!H_\ B*/^&Z[?_H3W_P# T?\ Q%'M ]C+L?3OD?6CR/K7S%_PW7;_
M /0GO_X&C_XBC_ANNW_Z$]__  -'_P 11[0/8R['T[Y'UH\CZU\Q?\-UV_\
MT)[_ /@:/_B*/^&Z[?\ Z$]__ T?_$4>T#V,NQ].^1]:/(^M?,7_  W7;_\
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MAJ,KM]3197FBM:A+[F>P:]\9= U?X5IH4EK>W^K?V=;6,)O8XC]A:+;NDCG
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M /$T?\*O\&_]"EH7_@MA_P#B:** #_A5_@W_ *%+0O\ P6P__$T?\*O\&_\
M0I:%_P""V'_XFBB@ _X5?X-_Z%+0O_!;#_\ $T?\*O\ !O\ T*6A?^"V'_XF
MBB@ _P"%7^#?^A2T+_P6P_\ Q-'_  J_P;_T*6A?^"V'_P")HHH /^%7^#?^
MA2T+_P %L/\ \31_PJ_P;_T*6A?^"V'_ .)HHH /^%7^#?\ H4M"_P#!;#_\
M31_PJ_P;_P!"EH7_ (+8?_B:** #_A5_@W_H4M"_\%L/_P 31_PJ_P &_P#0
MI:%_X+8?_B:** #_ (5?X-_Z%+0O_!;#_P#$T?\ "K_!O_0I:%_X+8?_ (FB
MB@ _X5?X-_Z%+0O_  6P_P#Q-'_"K_!O_0I:%_X+8?\ XFBB@ _X5?X-_P"A
M2T+_ ,%L/_Q-2VWPW\)6LR2P^%M%AE4Y5X]/A5@?8A:**3V)ELSJ(T6- J*%
.4= !@4ZBBO%/G7N?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>mrkr-20251231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20251231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '9 [<# 2(  A$! Q$!_\0
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MC795R+,:$%.I2:3:6ZT;VNKW5_.QST\UP=63C"I=I-]=4M[=[>1[117S[?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M==58^9Q.!JXC,744I1C[.UXNUWS/3J?%7PH+G]B/XJF4 2?:?F Z9W+FN[^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%6<5?51VNNJ=^G0Z#X-^(]-NM;U*XM/@Q=^ KFTL)9DU*ZMMBO@?ZL'8.O\
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MA:XB5R=S!@Q&1DX^4U]"_L__  =M_@;\-[/PW'=?;KLR/=7MWC FG?&X@=@
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M^"J>UIQ45)T(QY^9ZNT%RVO:Z^_0PCA,5'DFV^556^6VRO+6^_\ PYX%^T9
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M_P#&C_A6VE_\]K[_ ,"G_P : .KS1FN4_P"%;:7_ ,]K[_P*?_&C_A6VE_\
M/:^_\"G_ ,: .KS1FN4_X5MI?_/:^_\  I_\:/\ A6VE_P#/:^_\"G_QH ZO
M-&:Y3_A6VE_\]K[_ ,"G_P :/^%;:7_SVOO_  *?_&@#J\T9KE/^%;:7_P ]
MK[_P*?\ QH_X5MI?_/:^_P# I_\ &@#J\T9KE/\ A6VE_P#/:^_\"G_QH_X5
MMI?_ #VOO_ I_P#&@#J\T9KE/^%;:7_SVOO_  *?_&C_ (5MI?\ SVOO_ I_
M\: .KS1FN4_X5MI?_/:^_P# I_\ &C_A6VE_\]K[_P "G_QH ZO-&:Y3_A6V
ME_\ /:^_\"G_ ,:/^%;:7_SVOO\ P*?_ !H ZO-&:Y3_ (5MI?\ SVOO_ I_
M\:/^%;:7_P ]K[_P*?\ QH ZO-&:Y3_A6VE_\]K[_P "G_QH_P"%;:7_ ,]K
M[_P*?_&@#J\T9KE/^%;:7_SVOO\ P*?_ !H_X5MI?_/:^_\  I_\: .KS1FN
M4_X5MI?_ #VOO_ I_P#&C_A6VE_\]K[_ ,"G_P : .KS1FN4_P"%;:7_ ,]K
M[_P*?_&C_A6VE_\ /:^_\"G_ ,: .KS1FN4_X5MI?_/:^_\  I_\:/\ A6VE
M_P#/:^_\"G_QH ZO-&:Y3_A6VE_\]K[_ ,"G_P :/^%;:7_SVOO_  *?_&@#
MJ\T9KE/^%;:7_P ]K[_P*?\ QH_X5MI?_/:^_P# I_\ &@#J\T9KE/\ A6VE
M_P#/:^_\"G_QH_X5MI?_ #VOO_ I_P#&@#J\T9KE/^%;:7_SVOO_  *?_&C_
M (5MI?\ SVOO_ I_\: .KS1FN4_X5MI?_/:^_P# I_\ &C_A6VE_\]K[_P "
MG_QH ZO-&:Y3_A6VE_\ /:^_\"G_ ,:/^%;:7_SVOO\ P*?_ !H ZO-&:Y3_
M (5MI?\ SVOO_ I_\:/^%;:7_P ]K[_P*?\ QH ZO-&:Y3_A6VE_\]K[_P "
MG_QH_P"%;:7_ ,]K[_P*?_&@#J\T9KE/^%;:7_SVOO\ P*?_ !H_X5MI?_/:
M^_\  I_\: .KS1FN4_X5MI?_ #VOO_ I_P#&C_A6VE_\]K[_ ,"G_P : .KS
M1FN4_P"%;:7_ ,]K[_P*?_&C_A6VE_\ /:^_\"G_ ,: .KS1FN4_X5MI?_/:
M^_\  I_\:/\ A6VE_P#/:^_\"G_QH ZO-&:Y3_A6VE_\]K[_ ,"G_P :/^%;
M:7_SVOO_  *?_&@#J\T9KE/^%;:7_P ]K[_P*?\ QH_X5MI?_/:^_P# I_\
M&@#J\T9KE/\ A6VE_P#/:^_\"G_QH_X5MI?_ #VOO_ I_P#&@#J\T9KE/^%;
M:7_SVOO_  *?_&C_ (5MI?\ SVOO_ I_\: .KS1FN4_X5MI?_/:^_P# I_\
M&C_A6VE_\]K[_P "G_QH ZO-&:Y3_A6VE_\ /:^_\"G_ ,:/^%;:7_SVOO\
MP*?_ !H ZO-&:Y3_ (5MI?\ SVOO_ I_\:/^%;:7_P ]K[_P*?\ QH ZO-&:
MY3_A6VE_\]K[_P "G_QH_P"%;:7_ ,]K[_P*?_&@#J\T9KE/^%;:7_SVOO\
MP*?_ !H_X5MI?_/:^_\  I_\: .KS1FN4_X5MI?_ #VOO_ I_P#&C_A6VE_\
M]K[_ ,"G_P : .KS1FN4_P"%;:7_ ,]K[_P*?_&C_A6VE_\ /:^_\"G_ ,:
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M_#2WQ+_Z&V__ .^Z[E@IOJC\X_XB%@/^?,__ "7_ #/T[HK\Q/\ AI;XE_\
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M17YA?\-+_$S_ *&Z_P#^^Z0_M,?$S/\ R-VH?]]U:X;Q#^W'\?\ (?\ Q$'
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MF_B<!_R-^H?]]TW_ (:<^)W_ $-^H?\ ?=5_JCBO^?D?Q_R#_7_ _P#/F?\
MY+_F?J117Y;']IWXGY_Y'#4/^^Z0_M/?$_'_ ".&H?\ ?=5_JAB_^?D?Q_R'
M_K]@?^?,_P#R7_,_4JBORS_X:>^)_P#T.&H?]_*0_M/_ !0S_P CAJ'_ 'W5
M_P"IV+_Y^1_'_(K_ %]P/_/F?_DO^9^IM%?E@?VG_BAC_D<=1_[^4A_:@^*'
M_0XZC_W\JO\ 4S&?\_8_C_D'^OF!_P"?4_P_S/U0HK\K?^&H?BC_ -#CJ/\
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MT\W=+0]C+.),+F=;V$(N,K75[:_<SW6BBBOC#ZP**** "BBB@ HHHH ****
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M)<')6VV_KYGWF#X:ABZ&%K*K95+\VGPKWK/SORL^*;?P?KMW<SV\&CWTL\!
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M^:^[*_F+.LLEE.-GA6[I:I^3V^9_0V58^.982.(2LWH_5;A1117AGKA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 >??&7XS:?\ !?1]*O;W
M1]5UV74[]-.M;+1XXWFDF<$J,2.B]O6N<T+]I:SNO%FE>'_$G@GQ9X$N-6<P
MZ?<^(+6!;>YE SY0DAFD ;'(#8S7&_MO1ZG+H_PU31IK:WU5O%MH+:6\0O$D
MF&P74$$CV!K9'P=^(?C+Q3X<U;XD^*M#N])\.W1U&"PT'3Y(3+,%(4N[NQP,
MDX% 'O9D0-M+J&],\URE_P#$W2+3Q5JGAJ%+J^U[3],&K26-M#EGA9BJA"2%
M+$J1C-?!?Q6U*VU?X9>+OB)X>TS5KRY@O)KBT\=ZKXA-K=12+<;0D%JK_P"K
M&-H3:,CM7J7BGPMH?_"]_B!XA^S+%K4OP]BU".Z6=U9IWWHSJ-V/N # &!C/
M7F@#Z_T35_[7T6RU"6TN-,:YB60VMZ DT)(SM< D!AWP35[>H .1@]#FO@![
MOQ#XZ\0^ O#-WI4?B;0K?P=:WL.EZAKCZ;!<3-P\K,"#*R\#&>,YK5@TSQ%J
M'P[\'>&M=UHKIY^*5M869TC6FNI[2T,,Y-JUR.6*'<N3SC'H* /M?Q)XFT[P
MGX>U#6]2N!#IUA"UQ<2J"VU%&2<#D_2G^'-?L_%6@Z?K&GNSV-] EQ"SKM8H
MPR,@].#TKXX^)/P]T;P=K?QE\%Z5'<Q^%9?!,>LC29+N66**[$KKYB;F++D*
M,C.#7>_#CQ7XA^&'PJ\!Z7X#^&MQXGTBXTJ"YGNK2_55CF=07!WDG.>?2@#Z
M:,BA@I8!CT&>:&D1>K*/J:^#OB=ISZ7XG\=>--8MY?%^F6NI/<?\)#X>\2M;
M:KX=2, FV6V9@A\O:<X!W;CG.:[2Q\+^#/C#\=_'\WBK5;M]/&AZ5>V-C-J,
MEHN)(G8W!167YU^7Z;NE 'U\S!1DD >I- 8,,@@CU%?GA%XM\:>.;#X9>%M0
MB;Q)X?E_M,I#J&K/IZ:JD,VR RW .7PG.W//6M>^U3QIX#^&7C_1HM0AT/P]
M)XBT:Q%MI6MM?SZ!:W#A;L"<_,BD;-O/R^8U 'W-X@ULZ'H5]J,-C=:N]K&9
M!9:>JO/,1_"@) )/N17F_BC]H*/0_&^E>%-.\'Z_K^L7-@NI7<-DD*_8(2./
M,WN,OD$;5SSWKQ_XL>"O ?PJ\)^,K+P;XAOK"_O?"]S(^B0:A)<0RA-O^DL6
M9BD@SC((SFN7B\ Z"_Q>U;638DZI%\-8]12Z\^7<+@V[*9/O8SC\._6@#[.\
M-:Z?$'AZPU2;3[O1FNHEE:QU%52> D?<D"L0&'?!-:@(89!R/45\,?">UM?B
M?J7PA\'^-]0NF\()\/(]8ALGOY+>/4+_ ,]8V,C*RES&F"%)X+9KZ<^ EMX?
MTKPQJND>&O$-[XBTO3=5N+9)+V4RFU(()MTD/+HF< DGKC/% 'IE%%% !111
M0 4444 %>'_MFMM^ FK^]S;#_P BK7N%>&?MH'_BPVJ#UNK;_P!&"M:7\2/J
M>#GSME6*_P $OR9^<]/IE/KZ.)_*!ZU\./B/HOAGX*_$3PY>3RQZOK+6[62)
M$S*VPY.6'"_C7KGB[]J/PSXAL/AS"EQ<++87=O=ZTPMF 4QI@X_O_-TQ7R31
M2>'A.7,_ZTL?2X?B#&86BJ%.W*DH[=%)R[]VUZ'?_&GQCIGC;XM:QK^E2R2Z
M;<W"R1O)&48@8S\IY[5TW[2WQ1T7XC>-] U;PU=32Q6.EQ6[22PM$5E21VX#
M=?O#FO&J*ZHTHIQ?;0X)YG7J1KQ=OWLE)^J;>FOF>N^'/VEO&$'B_0=5\0:I
M-K5EIUR)S;.J+D$%6Q@#G!->K7WQ6^%_@R3QEXO\.:YJ&K^(/$]H\*:3- 56
MV=P<ER0!@$YZGIBODX=*:>M6\+3F[[>G4[L-Q!C:$7&34W>Z<KMQ=K73OV[W
M1]->$_B3\._B%\-_!^C^/=8N]#U+PA/YD1A@+I>PC&$!53@X"CL?ESSFO)?C
MI\1XOBK\2M4U^VB>"R?;#;)+][RUX!([$\G%<".E!Z5T4L/"G/G7_#7W.?%Y
MSB,9AXX::2MRW:6LN56C?7HNR7F>N?M _$;0_B$/!_\ 8L\L_P#9FDI:7/FP
MM'MD!Y SU'N*\C/2@=*#TKLI4U2BH1V1YV,Q53&UWB*EKNVWDDOT$6AJ%H:N
MV)QB4445LAA2'I2TAZ5N@ =*:>M.'2FGK6Z *0]12TAZBMXE U-IS4VMD-"-
M24K4E;1*$[TC=:7O2-UK>(T)3*?3*UB4!Z4VG'I3:V10T]::>E./6FGI6J+&
MTT]:=33UK=%(0]*;3CTIM:HI#*1J6D:M4:#6Z4T]*<W2FGI6J+0RFTZFUHC1
M#&[TRGMWIE:HM#:8>M/IAZUHC08_>F'I3W[TP]*UB:(:>E.M;2:_N8K:WC::
M>9A''&@RS,3@ #UIIZ5]@?L'_  ^(M:_X3W6K;.G6#;;".0<2S=W^B_SKSLS
MS"EE>$GBJO39=WT1ZN78&IF.)CAZ?7=]EU9]+_LI? J'X*_#N%;J)?\ A(=2
M"W%_)W4X^6('T4'\\U[9117\PXO%5<=7GB:SO*3N_P"O(_H?"X:GA*,:%)6C
M%6"BBBN,Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,7Q+
MX-T;Q?\ V?\ VQ817W]GW2WEKYG_ "RF7[KCW&:V>M+10!YE>?LU?#+4+B_F
MN/!^GRF^+M/&RMY;,_WF"9V@GU K:U;X/>#]<U6QU.]T.WGO[*S.GPSG(9;<
MKM,9P>5P3P:[.B@#AO$7P1\#^+-$TS2=5\.VEW9:9&(K-""K0(!C:K @@>V:
MNV7PI\):;HVBZ3::#:6VG:->)J%A;Q)A8+A0P64>K?.W)]:ZRB@#"NO ^A7V
MM7VK7&F03W]]9#3KF9UR9;?);RS[9)-'@SP1HGP]T./1O#UA'IFF1LSI;1$E
M5).3C)-;M% 'GFO_ +/OP\\3^(Y-=U/PK8W6IRR+++*RD"9QT9U!VL?J*X^?
M]FG1?%GQ=\9>(_%NBV&JZ7J$%A'IP+,)(O*602 @8PIW+QT.*]SHH Y+Q'\)
M_"'BSPW::!JGA^RN=(L\?9K;R]H@P, H1@K^%&A_";P?X;\*7GAK3O#UE!H=
M[N^U6?E[EG+=2^<EB?4UUM% 'GVA? 'X?^&M,U73].\,6=O;:I#]GO%PS&6+
M^X6))V^PK;'PW\-K>RW8TF 7$NG#27DP<M:@8$7TP:Z:B@#@]:^!?@3Q#X;T
MC0=0\-V=QIFD)Y=A%@J;9<8PC @@8XQFNG\,>%M)\&:);:1H=A!IFFVXQ';V
MZ[57N3[D^IK5HH **** "BBB@ HHHH *YCXB_#W2OB?X8FT'6?--C+(DC>2^
MQLJ<CFNGHIIM.Z,JM*%>G*E55XM6:?5'S]_PQ%\.?[FH_P#@4:/^&(OAS_<U
M'_P*-?0-%;>WJ_S,\+_5W*/^@:'W'S]_PQ'\.?[FH_\ @4:7_AB/X<_W-1_\
M"C7T!13^L5?YF'^KN4?] T/N/G[_ (8C^'/]S4?_  *-+_PQ'\.?[FH_^!1K
MZ HI_6:W\[#_ %=RC_H&A]Q\_P#_  Q'\.?[FH_^!1H_X8C^'/\ <U'_ ,"C
M7T!13^M5_P"=A_J[E'_0-#[CY_\ ^&(_AS_<U'_P*-'_  Q'\.O[FH_^!1_P
MKZ HJOKF(_G8?ZNY1_T#0^X^?O\ AB/X=?W-1_\  H_X4O\ PQ'\.O[FH_\
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M\Y?\,&_#+^YJ?_@6?\*3_A@SX9?W-3_\"S_A7T=11_;N9_\ 01+[Q_V%E?\
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MJ+?9!1117FG>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5RWQ1^(>F_"?X>Z_XOU<G[!I%
MH]RZ*<-(1]U%_P!IF(4>Y%=37PI_P4X^*""S\%_#"!+JZ&L7J:GJT%A'YD_V
M2)OE55[DD,P![Q"@#Z'_ &8_VFM"_:>\(ZAK6D6,^E36%U]FN+&YD5W3*Y5L
MCLW/;^$UQ;_MR^'K?]I-OA!=:!>6UZ+TV(U5[A/)+[-P.W&>>G7J:^:/V=?C
M;X?\)?MGW9T+1-4\*>#/&UO':I8:K;^0(KE% 4J,D$$J.<_QFN8^-6D2P_&K
MXY>,;3<M[X0U_3-55T.#L#@.,]<?=H ^O_C!^W)X=^$GQQTSX9RZ#=ZMJ-X]
MK$]W;W**D#SL JLI!.0&5NW!KL[O]I33K3]I.T^#QT6Y;4;BP^WC4Q*OE*NU
MCMVXSGY/7O7YW^(=03XH>(=+^+;JV[Q%\4K*SLVD W"U@B&T XSCYP,?[(KZ
M0UR1(O\ @J7I#R.J*/#G+,<#_5S4 ?<E%0PWD%PQ6*>.5AR0C@FIJ "BBB@
MHHHH **** "BBB@ HHHH *\P_:.^(&K?#+X7W>NZ*\:7T4\4:F5 XPS8/!KT
M^O"_VT?^2$ZC_P!?5O\ ^A5K22<XI]SQ,[JSH99B*M)VDH2::W3L?-'_  VW
M\2#_ ,O%C_X")_A1_P -L_$C_GYL?_ 1/\*\ '6G5[T:-/\ E1_-G^L&;?\
M05/_ ,"9[]_PVS\1_P#GYLO_  $3_"C_ (;9^(__ #\V7_@(G^%>!QQ22D[$
M9\==H)H$;L^P(Q?^Z!S71'#T?Y4/^W\W_P"@F?\ X$SWS_AMGXC_ //S9?\
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M/\*3_AM[XD_\_-C_ . B?X5\_GK2'I6RRS!?\^8_<BO[?S7_ *"9_P#@3/H
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M "]6'_@&G^%-/[=/Q-'_ "]6'_@&G^%?/;4UJU639=_SXC]R+6>YI_T$S_\
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ML(DVPY<!1GIQ'_X\:I_'#P#X+M?C)I5_K$S>'_#NKZ8-2G2T49\T#)11VW9
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#[X;Q1:LBKK^K7<^LZKMZ"ZN',CK_P !R%_X#0!Z;1110 4444 %>%_MH_\
M)"=1_P"OJW_]"KW2N,^+?PTMOBUX+N/#MU>26,,TJ2F:)0S J<XP:TIM1FFS
MR,WP]3%Y?7P])7E*+2]6C\J!UIU?;?\ PP#H7_0TW_\ X#I_C2_\,!:%_P!#
M1?\ _@.G^->TL7274_ O]2LZ_P"?2_\  H_YGQ'17VY_PP%H7_0T7W_@.G^-
M'_# 6@_]#1?_ /@.G^-;1QM!=?P#_4K.O^?2_P# H_YGQ'3J^VO^& M"_P"A
MHO\ _P !T_QI?^& ]"_Z&B__ / =/\:W688==?P%_J5G?_/I?^!1_P SXB'6
MG5]M_P## 6@_]#1?_P#@.G^-'_# >@_]#1?_ /@.G^-;K,L-_-^#!\%9W_SZ
M7_@4?\SXC R*&Z5]N?\ # >@_P#0T7__ (#I_C1_PP'H/_0T7_\ X#I_C6JS
M3"_S?@P_U*SK_GTO_ H_YGQ(.E-/6OMW_A@/0?\ H:+_ /\  =/\:3_A@+0O
M^AHOO_ =/\:W6;81?:_!C_U*SK_GTO\ P*/^9\1$ ]12U]N?\,!:%_T-%]_X
M#I_C1_PP%H7_ $-%_P#^ Z?XULLXP:^U^##_ %*SK_GTO_ H_P"9\1&@]#7V
M[_PP#H7_ $-%_P#^ Z?XTG_# .A?]#3?_P#@.G^-;+.L$OM?@P_U*SK_ )]+
M_P "C_F?$(&.E(>E?;__  P!H/\ T-%__P" Z?XTA_8 T'_H:;__ ,!T_P :
MU6>8%?;_  8_]2\Z_P"?2_\  H_YGQ">@IM?<'_#O_0?^AIO_P#P'3_&C_AW
M]H/_ $--_P#^ Z?XULL^P'\[^YC7!>=?\^E_X%'_ #/AT]:0]*^XO^'?V@_]
M#3?_ /@.G^-)_P ._-!_Z&F__P# =/\ &M5Q!E_\[^YE?ZF9U_SZ7_@4?\SX
M>;I3:^XS_P $_-!/_,TW_P#X#I_C2?\ #OO0?^AJO_\ P'3_ !K9<19=_._N
M?^0UP9G/_/I?^!1_S/AL]::W6ON7_AWUH/\ T-5__P" Z?XTA_X)\:"?^9JO
M_P#P'3_&M5Q)EO\ ._N?^12X-SG_ )]+_P "C_F?#)Z4VONC_AWOH'_0U7__
M (#I_C2'_@GMH'_0U7__ (#I_C6JXERQ?\O']S_R*7!N<_\ /I?^!1_S/A6F
MGK7W7_P[TT#_ *&J_P#_  '3_&D_X=YZ ?\ F:[_ /\  =/\:U7$^5K_ )>/
M[G_D4N#LX_Y]K_P)?YGPFU-:ONW_ (=X^'S_ ,S7J'_@.G^-)_P[P\/_ /0U
MZA_X#I_C6BXIRO\ Y^/_ ,!?^12X/SC_ )]K_P "7^9\(GI3#TK[P_X=W>'_
M /H;-0_\!D_QI#_P3L\/G_F;-0_\!T_QK5<5Y5_S\?\ X"_\BUPAG'_/M?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\
MC6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M
M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C
M^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_M
MO_W]7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_
M &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_
M /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0
M?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] R
MW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\ C6=_
MP@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#O
MZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#
M_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]
M7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8
M?\_MO_W]7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_ /?-
M &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^
M@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[Y
MH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\ C6=_P@^A
M?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\
MC6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M
M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C
M^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_M
MO_W]7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_
M &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_
M /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0
M?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] R
MW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\ C6=_
MP@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#O
MZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#
M_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]
M7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8
M?\_MO_W]7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_ /?-
M &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^
M@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[Y
MH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\ C6=_P@^A
M?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\
MC6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M
M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C
M^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_M
MO_W]7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_
M &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_
M /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0
M?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] R
MW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#OZO\ C6=_
MP@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#_G]M_P#O
MZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]7_&C^V+#
M_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8?\_MO_W]
M7_&C^V+#_G]M_P#OZO\ C6=_P@^A?] RW_[YH_X0?0O^@9;_ /?- &C_ &Q8
M?\_MO_W]7_&IX+N"Z!,,T<P'4HP;'Y5C_P#"#Z%_T#+?_OFM#3=&LM'5UL[9
M+</RP08S0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BO OVT/BWK_P (_A1%>^'6-O?W]XMG]M"Y^SJ59B1Z$[< _6O'K+P/\2[+
M1=,\5_#CXKM\0M6+))>:6MPFQU8\_*S< 8QAL&N^EA/:4U4E))/17_K0]6A@
M'5I*K*:BF[*]^G=[+YGV]17S5^TC\>O%/@?P?X3T31+'[!X[\3;(O*;#_9&.
M V",C.XX![5R>L_L_P#QE\)^%YO%6G_%&^U'Q1:PM=S:<X)AEP-QC7)Y/!'(
MP?:B&%O%2G-1OMY_=T"G@;PC.K44>;17OK;TZ>9]@T5\;^(OVE]9\?\ [(&I
M>*]/NVT;Q387<-G>/:';A]Z_,OH&4_GFOH_X'ZO>:]\(_"NH:A</=7MQ8I)+
M-(<L['N:SJX:=&'-/O8RKX*IAZ;G4Z2<;>:U.YHKYB_:(\?^(?#?[1WPAT;3
M-6N+/2]3NX$O+6)L),#<!2&'?(XKB_B!>?$#X@_M:Z]X%\/^.KSPQ816D<\8
MC!=%Q C$!01U)/YUK#!N:4G))--_).QM2RZ52*DYI)Q<NNB3L?:-%?&;>./B
M3^S+\6/#6C^,_%/_  F'A77I! MQ*FUXF)"Y&<XP2._(K["U&"2^TNZAMIS;
MS30LD4X&=C%2 WX$YK"M0='E=[I[-'-B,*\/ROF3C+9HM45\ _M"Z-\6?@19
MZ#<2?%;4-5&JWGV0*B&/R^,YY8YKU/7/!OQ%^$/P<\<>(M4^)%YX@G?2XVM
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MW\M=DV?:U%?&'[1/CWQ9XD^.OPZ\.^$O%MUX;T[Q)ID,HEA.44O))\Y&1G@
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M"X9''VH<@C@BH[37=.\/?\% _$=UJE_;:=;?V:B^==2K&N3;1X&2:^B#\!/
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M^U_&OB.[EL+6:=<@-YT@WD#KA0H ]2*?U*HVDK=%]ZO^0_[-K-I1:;;2_P#
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M[OK@<U=K&M-5*CFKZ]]3GQ%2-:K*I&^O=W?WZ!1116)S!1110 4444 %%%%
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M>UC_ -\FCRO%/_/:Q_[Y-=+10!S7E>*?^>UC_P!\FCRO%/\ SVL?^^372T4
M<UY7BG_GM8_]\FCRO%/_ #VL?^^372T4 <UY7BG_ )[6/_?)H\KQ3_SVL?\
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M@TW3K9"\US<N$1![DUY/X0_;&^#_ (Y\4)X>TCQI93:G))Y4*2!HUF;L$9@
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M^&QX-U2&8:9H=D8#<PI)&SR22(#OD;R^ < 9SW- &_J_Q*^-_P 4OV@?BO\
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MA_X6?%'Q%XKTJYT/Q3=6MI/X9M]/")%'(GF;B_4LRJQ)&-I.!D5Z=\5_BO\
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M6/$FI>%?#VG^&]-N=ITW4=<$6LW$ D">;'"%*9;.Y5W9(]ZSO$7CCQ2OQ_\
M'@N(;.]\(6_@F.^6Q:ZE5FB9G.[;C"R,PVG!^Z!SF@#ZG!!&1R*6OE:X_:MM
MO#6F>"O#>A0>&M&U"\T.'4Y7\5:U]BLK6)AA(E<AGD<_3@#DU?M/VPKC7O &
MDZGX?T'3];\1S>+8O"-UI]KJ8>U\]T=A+#<!2'C(56!QT)[B@#Z:HKY?\?\
MQH\?Q>%?B;X5U;1]*T7Q=I/AX:O:WNE7\LEL]NY9"0Q17612#@8P?6O3O@?X
MQE3X1>$)?%NJ:7::O<Z?#)C[9S*A4;6)DP2Q[^] 'J5%?-=Y^U!XFU/Q]XIT
M/POH/AW4G\/:A]A?0[[6_LNM7ZJ5W2V\++L*G=\A+?-CZ5OZW\9OB!J7Q1\3
M>$/!W@_2KZ/0[.VO)K_5M0>!3YJL1%M1&.\[>.W!S0![K17S%K'[:>GMX>\)
M#38-'TSQ%KAN%GC\3:F+*QL&@;9,))L'<=XPH49/6GZ5^VE82>"/%MU<66F:
MMXIT"_L],2S\/:FMU9:A->'%J8;C PI(;=D97RVH ^F20!DG J"XO[6S>%)[
MF&!YFVQK)(%+GT7/4_2O!/&OQ%\?:+X%\8)\0/ >FO80Z-)>QW6BZE)):R%?
MO6\K,J.C'.05!%>3:Z-2\6?'F.]U;0M)U#P_HW@A-6L[&:]GS;IY3,"@QCS"
M0%)].<YH ^VP01D'(I:^9? ?QWUC5_#GPZ\*?#WPII\FN:GX:37YH-4U"2.S
MTZRW"-07"L[LSG &.Q)KV[X:>)/$/B;PXTWBGPXWAG6H+B2VFM5G$T,FT\2P
MN.3&PY&X ]<B@#K**** "BBB@ HHHH *Y;XE?\BI<?[P_K74URWQ*_Y%2X_W
MA_6NG#?QH>J.S!_[S3]4>&O562K3U5DK[%'Z&CMOA>_EVGBA\XVV0.1V^_76
M7UY!%X>M-;B.+K4UMK=B/8\_U_*O'8-0NK%9EM[B2%9EV2!&QO'H:AEU>]-M
M#;FZE,$#;HH]YVH?4#M7!4PKJ5'._8\JM@G5JNI?=K[DMOO2.A^,G_([W7_7
M-/Y5+\5/^0#X+S_SX'^25QNH7UQJ5P9[J9[B8C!>1LDU!?ZE=W\<$=S<23I
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M%0M^S+XL;HUF/^VW_P!:OJ^BC^TZ_E]P_P"VL5Y?<?)C?LP>+F_CL1_VV_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "LM_%.C1L5;5;-6'4&=?\ &M,]#7S1J'_'[+]?Z4 ?07_"
M6:+_ -!:R_[_ *_XT?\ "6:+_P!!:R_[_K_C7SK10!]%?\)9HO\ T%K+_O\
MK_C1_P )9HO_ $%K+_O^O^-?.M% 'T5_PEFB_P#06LO^_P"O^-'_  EFB_\
M06LO^_Z_XU\ZT4 ?17_"6:+_ -!:R_[_ *_XT?\ "6:+_P!!:R_[_K_C7SK1
M0!]%?\)9HO\ T%K+_O\ K_C1_P )9HO_ $%K+_O^O^-?.M% 'T5_PEFB_P#0
M6LO^_P"O^-'_  EFB_\ 06LO^_Z_XU\ZT4 ?17_"6:+_ -!:R_[_ *_XT?\
M"6:+_P!!:R_[_K_C7SK10!]%?\)9HO\ T%K+_O\ K_C1_P )9HO_ $%K+_O^
MO^-?.M% 'T5_PEFB_P#06LO^_P"O^-'_  EFB_\ 06LO^_Z_XU\ZT4 ?17_"
M6:+_ -!:R_[_ *_XT?\ "6:+_P!!:R_[_K_C7SK10!]%?\)9HO\ T%K+_O\
MK_C1_P )9HO_ $%K+_O^O^-?.M% 'T5_PEFB_P#06LO^_P"O^-'_  EFB_\
M06LO^_Z_XU\ZT4 ?17_"6:+_ -!:R_[_ *_XT?\ "6:+_P!!:R_[_K_C7SK1
M0!]%?\)9HO\ T%K+_O\ K_C1_P )9HO_ $%K+_O^O^-?.M% 'T5_PEFB_P#0
M6LO^_P"O^-'_  EFB_\ 06LO^_Z_XU\ZT4 ?17_"6:+_ -!:R_[_ *_XT?\
M"6:+_P!!:R_[_K_C7SK10!]%?\)9HO\ T%K+_O\ K_C1_P )9HO_ $%K+_O^
MO^-?.M% 'T5_PEFB_P#06LO^_P"O^-'_  EFB_\ 06LO^_Z_XU\ZT4 ?17_"
M6:+_ -!:R_[_ *_XT?\ "6:+_P!!:R_[_K_C7SK10!]%?\)9HO\ T%K+_O\
MK_C1_P )9HO_ $%K+_O^O^-?.M% 'T5_PEFB_P#06LO^_P"O^-'_  EFB_\
M06LO^_Z_XU\ZT4 ?17_"6:+_ -!:R_[_ *_XT?\ "6:+_P!!:R_[_K_C7SK1
M0!]%?\)9HO\ T%K+_O\ K_C1_P )9HO_ $%K+_O^O^-?.M% 'T5_PEFB_P#0
M6LO^_P"O^-'_  EFB_\ 06LO^_Z_XU\ZT4 ?17_"6:+_ -!:R_[_ *_XT?\
M"6:+_P!!:R_[_K_C7SK10!]%?\)9HO\ T%K+_O\ K_C1_P )9HO_ $%K+_O^
MO^-?.M% 'T5_PEFB_P#06LO^_P"O^-'_  EFB_\ 06LO^_Z_XU\ZT4 ?17_"
M6:+_ -!:R_[_ *_XT?\ "6:+_P!!:R_[_K_C7SK10!]%?\)9HO\ T%K+_O\
MK_C1_P )9HO_ $%K+_O^O^-?.M% 'T5_PEFB_P#06LO^_P"O^-'_  EFB_\
M06LO^_Z_XU\ZT4 ?17_"6:+_ -!:R_[_ *_XT?\ "6:+_P!!:R_[_K_C7SK1
M0!]%?\)9HO\ T%K+_O\ K_C1_P )9HO_ $%K+_O^O^-?.M% 'T5_PEFB_P#0
M6LO^_P"O^-'_  EFB_\ 06LO^_Z_XU\ZT4 ?17_"6:+_ -!:R_[_ *_XT?\
M"6:+_P!!:R_[_K_C7SK10!]%?\)9HO\ T%K+_O\ K_C1_P )9HO_ $%K+_O^
MO^-?.M% 'T5_PEFB_P#06LO^_P"O^-'_  EFB_\ 06LO^_Z_XU\ZT4 ?17_"
M6:+_ -!:R_[_ *_XT?\ "6:+_P!!:R_[_K_C7SK10!]%?\)9HO\ T%K+_O\
MK_C1_P )9HO_ $%K+_O^O^-?.M% 'T5_PEFB_P#06LO^_P"O^-'_  EFB_\
M06LO^_Z_XU\ZT4 ?17_"6:+_ -!:R_[_ *_XT?\ "6:+_P!!:R_[_K_C7SK1
M0!]%?\)9HO\ T%K+_O\ K_C1_P )9HO_ $%K+_O^O^-?.M% 'T5_PEFB_P#0
M6LO^_P"O^-'_  EFB_\ 06LO^_Z_XU\ZT4 ?17_"6:+_ -!:R_[_ *_XT?\
M"6:+_P!!:R_[_K_C7SK10!]%?\)9HO\ T%K+_O\ K_C1_P )9HO_ $%K+_O^
MO^-?.M% 'T5_PEFB_P#06LO^_P"O^-'_  EFB_\ 06LO^_Z_XU\ZT4 ?17_"
M6:+_ -!:R_[_ *_XT?\ "6:+_P!!:R_[_K_C7SK10!]%?\)9HO\ T%K+_O\
MK_C1_P )9HO_ $%K+_O^O^-?.M% 'T5_PEFB_P#06LO^_P"O^-7++4[/4E9K
@2ZAN57J8G#8_*OFFO5_@S_QYZA_OK_*@#TFBBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>mrkr-20251231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/18/2026 8:29:31 PM-->
<!--Modified on: 3/18/2026 8:29:31 PM-->
<xsd:schema targetNamespace="http://www.tapimmune.com/20251231" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:mrkr="http://www.tapimmune.com/20251231" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:cef="http://xbrl.sec.gov/cef/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt="http://fasb.org/srt/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:attributeFormDefault="unqualified" xmlns:srt-roles="http://fasb.org/srt-roles/2025" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:snj="http://xbrl.sec.gov/snj/2025" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2025" xmlns:rxp="http://xbrl.sec.gov/rxp/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:cyd-8k-sub="http://xbrl.sec.gov/cyd-8k-sub/2025" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:spac-lab="http://xbrl.sec.gov/spac-lab/2025q3" xmlns:spac-despac="http://xbrl.sec.gov/spac-despac/2025q3" xmlns:spac-reg="http://xbrl.sec.gov/spac-reg/2025q3" xmlns:spac="http://xbrl.sec.gov/spac/2025q3">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivableDetails" id="DisclosureOtherReceivableDetails">
        <link:definition>40501 - Disclosure - OTHER RECEIVABLE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" id="DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails">
        <link:definition>40601 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails">
        <link:definition>41201 - Disclosure - INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails" id="DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails">
        <link:definition>41203 - Disclosure - INCOME TAXES - Schedule of expected tax expense (benefit) from continuing operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>30803 - Disclosure - STOCK BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails" id="DisclosureFinancialConditionGoingConcernAndManagementPlansDetails">
        <link:definition>40201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails" id="DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails">
        <link:definition>40401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Computation of loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersAntiDilutiveSecuritiesDetails" id="DisclosureNetLossPerShareApplicableToCommonShareholdersAntiDilutiveSecuritiesDetails">
        <link:definition>40402 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Anti-dilutive securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>40701 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityWarrantSummaryDetails" id="DisclosureStockholdersEquityWarrantSummaryDetails">
        <link:definition>40702 - Disclosure - STOCKHOLDERS' EQUITY - Warrant Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" id="DisclosureStockBasedCompensationStockOptionActivityDetails">
        <link:definition>40801 - Disclosure - STOCK BASED COMPENSATION - Stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" id="DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails">
        <link:definition>40802 - Disclosure - STOCK BASED COMPENSATION - Weighted average assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails" id="DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails">
        <link:definition>40803 - Disclosure - STOCK BASED COMPENSATION - Stock-based compensation expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" id="DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>40804 - Disclosure - STOCK BASED COMPENSATION - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureGrantIncomeDetails" id="DisclosureGrantIncomeDetails">
        <link:definition>40901 - Disclosure - GRANT INCOME (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail" id="DisclosureCommitmentsAndContingenciesDetail">
        <link:definition>41001 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>41101 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails" id="DisclosureIncomeTaxesAdditionalInformationSDetails">
        <link:definition>41202 - Disclosure - INCOME TAXES - Additional Information's (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxPaymentsMadeAndIncomeTaxRefundsDetails" id="DisclosureIncomeTaxesSummaryOfIncomeTaxPaymentsMadeAndIncomeTaxRefundsDetails">
        <link:definition>41204 - Disclosure - INCOME TAXES - Summary of income tax payments made and income tax refunds (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>00305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNatureOfOperations" id="DisclosureNatureOfOperations">
        <link:definition>10101 - Disclosure - NATURE OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans" id="DisclosureFinancialConditionGoingConcernAndManagementPlans">
        <link:definition>10201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders" id="DisclosureNetLossPerShareApplicableToCommonShareholders">
        <link:definition>10401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivable" id="DisclosureOtherReceivable">
        <link:definition>10501 - Disclosure - OTHER RECEIVABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable" id="DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable">
        <link:definition>10601 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10701 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>10801 - Disclosure - STOCK BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureGrantIncome" id="DisclosureGrantIncome">
        <link:definition>10901 - Disclosure - GRANT INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11001 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>11101 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11201 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11301 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables" id="DisclosureNetLossPerShareApplicableToCommonShareholdersTables">
        <link:definition>30403 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivableTables" id="DisclosureOtherReceivableTables">
        <link:definition>30503 - Disclosure - OTHER RECEIVABLE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTables" id="DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTables">
        <link:definition>30603 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>30703 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureGrantIncomeTables" id="DisclosureGrantIncomeTables">
        <link:definition>30903 - Disclosure - GRANT INCOME (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables" id="DisclosureRelatedPartyTransactionsTables">
        <link:definition>31103 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31203 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="mrkr-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mrkr-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mrkr-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mrkr-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/cyd/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" />
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" />
  <xsd:element name="StockBasedCompensationExpensesTableTextBlock" id="mrkr_StockBasedCompensationExpensesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccountsPayableAndAccruedLiabilitiesTable" id="mrkr_AccountsPayableAndAccruedLiabilitiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccountsPayableAndAccruedLiabilitiesLineItems" id="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommitmentsAndContingenciesTable" id="mrkr_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommitmentsAndContingenciesLineItems" id="mrkr_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightExerciseAxis" id="mrkr_ClassOfWarrantOrRightExerciseAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightExerciseDomain" id="mrkr_ClassOfWarrantOrRightExerciseDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OperatingLossCarryforwardsLimitationPercentage" id="mrkr_OperatingLossCarryforwardsLimitationPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" id="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LiquidityFinancialConditionAndGoingConcernAbstract" id="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LiquidityFinancialConditionAndGoingConcernTextBlock" id="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EquityIncentivePlan2020Member" id="mrkr_EquityIncentivePlan2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ControlledEquityOfferingSalesAgreementMember" id="mrkr_ControlledEquityOfferingSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" id="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" id="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FundsReceivedFromCpritGrant" id="mrkr_FundsReceivedFromCpritGrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="FundsReceivedFromGrant" id="mrkr_FundsReceivedFromGrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="WilsonWolfManufacturingCorporationMember" id="mrkr_WilsonWolfManufacturingCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" id="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="GrantReceived" id="mrkr_GrantReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="GrantIncomePolicyPolicyTextBlock" id="mrkr_GrantIncomePolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FinancialConditionGoingConcernAndManagementPlansTable" id="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FinancialConditionGoingConcernAndManagementPlansLineItems" id="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CellReadyAgreementMember" id="mrkr_CellReadyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FdaGrantMember" id="mrkr_FdaGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IndaptaMember" id="mrkr_IndaptaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CellReadyMember" id="mrkr_CellReadyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" id="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" id="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="TaxFeesPayable" id="mrkr_TaxFeesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CashAtFinancialInstitutions" id="mrkr_CashAtFinancialInstitutions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" id="mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="InvoicesReceivedForServicesAndManufacturingCosts" id="mrkr_InvoicesReceivedForServicesAndManufacturingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="GrantAssistanceTerm" id="mrkr_GrantAssistanceTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NationalInstitutesOfHealthNationalCancerInstituteGrantMember" id="mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember" id="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember" id="mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived" id="mrkr_GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm" id="mrkr_GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BaylorCollegeOfMedicineLicenseAgreementMember" id="mrkr_BaylorCollegeOfMedicineLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SaleOfStockValueOfSharesIssuedInTransaction" id="mrkr_SaleOfStockValueOfSharesIssuedInTransaction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid" id="mrkr_LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LicenseAgreementLiquidityIncentivePaymentPercentage" id="mrkr_LicenseAgreementLiquidityIncentivePaymentPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockAndWarrantsIssuedDuringPeriodSharesNewIssues" id="mrkr_StockAndWarrantsIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockAndWarrantsIssuedDuringPeriodValueNewIssues" id="mrkr_StockAndWarrantsIssuedDuringPeriodValueNewIssues" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MasterServicesAgreementTerm" id="mrkr_MasterServicesAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PreFundedWarrantMember" id="mrkr_PreFundedWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PrivatePlacementWarrantMember" id="mrkr_PrivatePlacementWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember" id="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AdditionalCpritGrantMember" id="mrkr_AdditionalCpritGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClassOfWarrantOrRightExercised" id="mrkr_ClassOfWarrantOrRightExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AtMarketOfferingMember" id="mrkr_AtMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RecentlyIssuedAccountingStandardsAdoptedPolicyTextBlock" id="mrkr_RecentlyIssuedAccountingStandardsAdoptedPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GainLossOnEarlyTerminationOfVendorAgreement" id="mrkr_GainLossOnEarlyTerminationOfVendorAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodValueWarrantsExercised" id="mrkr_StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesWarrantsExercised" id="mrkr_StockIssuedDuringPeriodSharesWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ProceedsFromWarrantsAndStockOptionsExercised" id="mrkr_ProceedsFromWarrantsAndStockOptionsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember" id="mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EquityIncentiveAward2025Member" id="mrkr_EquityIncentiveAward2025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BaylorCollegeOfMedicineMember" id="mrkr_BaylorCollegeOfMedicineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PrepaidExpenseAndDepositsCurrent" id="mrkr_PrepaidExpenseAndDepositsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IncreaseDecreaseInPrepaidExpenseAndDeposits" id="mrkr_IncreaseDecreaseInPrepaidExpenseAndDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ClassOfWarrantOrRightRollForward" id="mrkr_ClassOfWarrantOrRightRollForward" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScheduleOfOtherReceivablesCurrentTableTextBlock" id="mrkr_ScheduleOfOtherReceivablesCurrentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CpritPancreaticGrantMember" id="mrkr_CpritPancreaticGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredTaxStockBasedCompensation" id="mrkr_DeferredTaxStockBasedCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TaxCreditCarryforwardsExpirationPeriod" id="mrkr_TaxCreditCarryforwardsExpirationPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TaxCreditCarryForwardExpirationYearRangeEnd" id="mrkr_TaxCreditCarryForwardExpirationYearRangeEnd" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments" id="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="IncomeTaxPaymentsByJurisdictionTableTextBlock" id="mrkr_IncomeTaxPaymentsByJurisdictionTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>mrkr-20251231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/18/2026 8:29:31 PM-->
<!--Modified on: 3/18/2026 8:29:31 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureOtherReceivableDetails" roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <calculationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_639094625705510181" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639094625705510181" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_639094625705510181" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_PrepaidExpenseAndDepositsCurrent" xlink:label="mrkr_PrepaidExpenseAndDepositsCurrent_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639094625705510181" xlink:to="mrkr_PrepaidExpenseAndDepositsCurrent_639094625705510181" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639094625705510181" xlink:to="us-gaap_RestrictedCashCurrent_639094625705510181" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639094625705510181" xlink:to="us-gaap_OtherReceivablesNetCurrent_639094625705510181" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_639094625705510181" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639094625705510181" xlink:to="us-gaap_PreferredStockValue_639094625705510181" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639094625705510181" xlink:to="us-gaap_CommonStockValue_639094625705510181" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639094625705510181" xlink:to="us-gaap_AdditionalPaidInCapital_639094625705510181" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639094625705510181" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_639094625705510181" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_639094625705510181" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_639094625705510181" xlink:to="us-gaap_LiabilitiesCurrent_639094625705510181" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639094625705510181" xlink:to="us-gaap_DeferredRevenueCurrent_639094625705510181" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639094625705510181" xlink:to="us-gaap_OtherLiabilitiesCurrent_639094625705510181" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639094625705510181" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_639094625705510181" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit_639094625705510181" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639094625705510181" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639094625705510181" xlink:to="us-gaap_OtherNonoperatingIncome_639094625705510181" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639094625705510181" xlink:to="us-gaap_InvestmentIncomeInterest_639094625705510181" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639094625705510181" xlink:to="us-gaap_OperatingIncomeLoss_639094625705510181" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_639094625705510181" xlink:to="us-gaap_OperatingExpenses_639094625705510181" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_639094625705510181" xlink:to="us-gaap_ResearchAndDevelopmentExpense_639094625705510181" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_639094625705510181" xlink:to="us-gaap_GeneralAndAdministrativeExpense_639094625705510181" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GainLossOnEarlyTerminationOfVendorAgreement" xlink:label="mrkr_GainLossOnEarlyTerminationOfVendorAgreement_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_639094625705510181" xlink:to="mrkr_GainLossOnEarlyTerminationOfVendorAgreement_639094625705510181" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_639094625705510181" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_639094625705510181" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_639094625705510181" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639094625705510181" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639094625705510181" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ProceedsFromWarrantsAndStockOptionsExercised" xlink:label="mrkr_ProceedsFromWarrantsAndStockOptionsExercised_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639094625705510181" xlink:to="mrkr_ProceedsFromWarrantsAndStockOptionsExercised_639094625705510181" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_639094625705510181" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639094625705510181" xlink:to="us-gaap_ProfitLoss_639094625705510181" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639094625705510181" xlink:to="us-gaap_ShareBasedCompensation_639094625705510181" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_IncreaseDecreaseInPrepaidExpenseAndDeposits" xlink:label="mrkr_IncreaseDecreaseInPrepaidExpenseAndDeposits_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639094625705510181" xlink:to="mrkr_IncreaseDecreaseInPrepaidExpenseAndDeposits_639094625705510181" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639094625705510181" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_639094625705510181" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639094625705510181" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_639094625705510181" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639094625705510181" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_639094625705510181" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639094625705510181" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_639094625705510181" order="7" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosureOtherReceivableDetails" xlink:type="extended" xlink:title="40501 - Disclosure - OTHER RECEIVABLE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_639094625705510181" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_InterestReceivableCurrent_639094625705510181" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherAssetsCurrent_639094625705510181" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" xlink:type="extended" xlink:title="40601 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_639094625705510181" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_639094625705510181" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_639094625705510181" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_639094625705510181" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_TaxFeesPayable" xlink:label="mrkr_TaxFeesPayable_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:to="mrkr_TaxFeesPayable_639094625705510181" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_639094625705510181" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_639094625705510181" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_639094625705510181" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_639094625705510181" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_639094625705510181" xlink:to="us-gaap_DeferredTaxAssetsGross_639094625705510181" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639094625705510181" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639094625705510181" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_DeferredTaxStockBasedCompensation" xlink:label="mrkr_DeferredTaxStockBasedCompensation_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639094625705510181" xlink:to="mrkr_DeferredTaxStockBasedCompensation_639094625705510181" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639094625705510181" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_639094625705510181" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639094625705510181" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_639094625705510181" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639094625705510181" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_639094625705510181" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639094625705510181" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_639094625705510181" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails" xlink:type="extended" xlink:title="41203 - Disclosure - INCOME TAXES - Schedule of expected tax expense (benefit) from continuing operations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639094625705510181" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_639094625705510181" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639094625705510181" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_639094625705510181" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_639094625705510181" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639094625705510181" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_639094625705510181" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639094625705510181" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_639094625705510181" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_639094625705510181" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_639094625705510181" order="5" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>mrkr-20251231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/18/2026 8:29:31 PM-->
<!--Modified on: 3/18/2026 8:29:31 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureFinancialConditionGoingConcernAndManagementPlansDetails" roleURI="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureNetLossPerShareApplicableToCommonShareholdersAntiDilutiveSecuritiesDetails" roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersAntiDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureOtherReceivableDetails" roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureStockholdersEquityWarrantSummaryDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityWarrantSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureStockBasedCompensationStockOptionActivityDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureStockBasedCompensationAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureGrantIncomeDetails" roleURI="http://www.tapimmune.com/role/DisclosureGrantIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureCommitmentsAndContingenciesDetail" roleURI="http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureIncomeTaxesAdditionalInformationSDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureIncomeTaxesSummaryOfIncomeTaxPaymentsMadeAndIncomeTaxRefundsDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxPaymentsMadeAndIncomeTaxRefundsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" xlink:type="simple" />
  <link:roleRef roleURI="http://www.tapimmune.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_1" xlink:title="us-gaap_RelatedPartyMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyDomain_1" xlink:to="us-gaap_RelatedPartyMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_RelatedPartyDomain_1 To us-gaap_RelatedPartyMember_1" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_IndaptaMember" xlink:label="mrkr_IndaptaMember_1" xlink:title="mrkr_IndaptaMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyMember_1" xlink:to="mrkr_IndaptaMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_RelatedPartyMember_1 To mrkr_IndaptaMember_1" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_WilsonWolfManufacturingCorporationMember" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember_1" xlink:title="mrkr_WilsonWolfManufacturingCorporationMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyMember_1" xlink:to="mrkr_WilsonWolfManufacturingCorporationMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_RelatedPartyMember_1 To mrkr_WilsonWolfManufacturingCorporationMember_1" order="2" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:label="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_1" xlink:title="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_IncomeStatementAbstract To us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_1" order="1" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tapimmune.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="OptionIndexedToIssuersEquityTypeAxis" xlink:title="OptionIndexedToIssuersEquityTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="OptionIndexedToIssuersEquityTypeDomain" xlink:title="OptionIndexedToIssuersEquityTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OptionIndexedToIssuersEquityTypeAxis" xlink:to="OptionIndexedToIssuersEquityTypeDomain" xlink:title="definition: OptionIndexedToIssuersEquityTypeAxis to OptionIndexedToIssuersEquityTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="AssetAcquisitionAxis" xlink:title="AssetAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="AssetAcquisitionDomain" xlink:title="AssetAcquisitionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AssetAcquisitionAxis" xlink:to="AssetAcquisitionDomain" xlink:title="definition: AssetAcquisitionAxis to AssetAcquisitionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:title="CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProjectMember" xlink:label="ProjectMember" xlink:title="ProjectMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="ProjectMember" xlink:title="definition: CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis to ProjectMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis" xlink:label="RestatementAxis" xlink:title="RestatementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain" xlink:label="RestatementDomain" xlink:title="RestatementDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestatementAxis" xlink:to="RestatementDomain" xlink:title="definition: RestatementAxis to RestatementDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:title="DerivativeInstrumentsGainLossByHedgingRelationshipAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="HedgingRelationshipDomain" xlink:title="HedgingRelationshipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="HedgingRelationshipDomain" xlink:title="definition: DerivativeInstrumentsGainLossByHedgingRelationshipAxis to HedgingRelationshipDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="definition: ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis to ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="BalanceSheetLocationAxis" xlink:title="BalanceSheetLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="BalanceSheetLocationDomain" xlink:title="BalanceSheetLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BalanceSheetLocationAxis" xlink:to="BalanceSheetLocationDomain" xlink:title="definition: BalanceSheetLocationAxis to BalanceSheetLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis" xlink:label="RestructuringPlanAxis" xlink:title="RestructuringPlanAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain" xlink:label="RestructuringPlanDomain" xlink:title="RestructuringPlanDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestructuringPlanAxis" xlink:to="RestructuringPlanDomain" xlink:title="definition: RestructuringPlanAxis to RestructuringPlanDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="GranteeStatusAxis" xlink:title="GranteeStatusAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="GranteeStatusDomain" xlink:title="GranteeStatusDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="GranteeStatusAxis" xlink:to="GranteeStatusDomain" xlink:title="definition: GranteeStatusAxis to GranteeStatusDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VestingAxis" xlink:to="VestingDomain" xlink:title="definition: VestingAxis to VestingDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ClassOfWarrantOrRightExerciseAxis" xlink:label="ClassOfWarrantOrRightExerciseAxis" xlink:title="ClassOfWarrantOrRightExerciseAxis" />
    <link:loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ClassOfWarrantOrRightExerciseDomain" xlink:label="ClassOfWarrantOrRightExerciseDomain" xlink:title="ClassOfWarrantOrRightExerciseDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightExerciseAxis" xlink:to="ClassOfWarrantOrRightExerciseDomain" xlink:title="definition: ClassOfWarrantOrRightExerciseAxis to ClassOfWarrantOrRightExerciseDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis_1" xlink:title="us-gaap_DisposalGroupClassificationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_1" xlink:title="us-gaap_DisposalGroupClassificationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DisposalGroupClassificationAxis_1" xlink:to="us-gaap_DisposalGroupClassificationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DisposalGroupClassificationAxis_1 To us-gaap_DisposalGroupClassificationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_1" xlink:title="dei_EntityAddressesAddressTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_1" xlink:title="dei_AddressTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_EntityAddressesAddressTypeAxis_1" xlink:to="dei_AddressTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_EntityAddressesAddressTypeAxis_1 To dei_AddressTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis_1" xlink:title="us-gaap_GovernmentAssistanceTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain_1" xlink:title="us-gaap_GovernmentAssistanceTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GovernmentAssistanceTypeAxis_1" xlink:to="us-gaap_GovernmentAssistanceTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GovernmentAssistanceTypeAxis_1 To us-gaap_GovernmentAssistanceTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GainLossOnEarlyTerminationOfVendorAgreement" xlink:label="mrkr_GainLossOnEarlyTerminationOfVendorAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="mrkr_GainLossOnEarlyTerminationOfVendorAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="mrkr_StockAndWarrantsIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_StockAndWarrantsIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_StockAndWarrantsIssuedDuringPeriodSharesNewIssues" xlink:label="mrkr_StockAndWarrantsIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_StockAndWarrantsIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="mrkr_StockIssuedDuringPeriodValueWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_StockIssuedDuringPeriodValueWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="mrkr_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails" xlink:type="extended" xlink:title="40201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" xlink:label="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_FdaGrantMember" xlink:label="mrkr_FdaGrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GrantMember" xlink:to="mrkr_FdaGrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember" xlink:label="mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_AdditionalCpritGrantMember" xlink:label="mrkr_AdditionalCpritGrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrkr_AdditionalCpritGrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_AtMarketOfferingMember" xlink:label="mrkr_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mrkr_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_PreFundedWarrantMember" xlink:label="mrkr_PreFundedWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mrkr_PreFundedWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_PrivatePlacementWarrantMember" xlink:label="mrkr_PrivatePlacementWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mrkr_PrivatePlacementWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ControlledEquityOfferingSalesAgreementMember" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrkr_ControlledEquityOfferingSalesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_CommonStockSharesSubscriptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" xlink:label="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_FundsReceivedFromCpritGrant" xlink:label="mrkr_FundsReceivedFromCpritGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_FundsReceivedFromCpritGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GrantReceived" xlink:label="mrkr_GrantReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_GrantReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_FundsReceivedFromGrant" xlink:label="mrkr_FundsReceivedFromGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_FundsReceivedFromGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GrantAssistanceTerm" xlink:label="mrkr_GrantAssistanceTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_GrantAssistanceTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_GrantsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersAntiDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="40402 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Anti-dilutive securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureOtherReceivableDetails" xlink:type="extended" xlink:title="40501 - Disclosure - OTHER RECEIVABLE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfReceivablesWithImputedInterestTable" xlink:label="us-gaap_ScheduleOfReceivablesWithImputedInterestTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfReceivablesWithImputedInterestTable" xlink:to="us-gaap_GovernmentAssistanceTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_FdaGrantMember" xlink:label="mrkr_FdaGrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="mrkr_FdaGrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember" xlink:label="mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesWithImputedInterestLineItems" xlink:label="us-gaap_ReceivablesWithImputedInterestLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems" xlink:to="us-gaap_ScheduleOfReceivablesWithImputedInterestTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems" xlink:to="us-gaap_GrantsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems" xlink:to="us-gaap_InterestReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems" xlink:to="us-gaap_OtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" xlink:type="extended" xlink:title="40601 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesTable" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_TaxFeesPayable" xlink:label="mrkr_TaxFeesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mrkr_TaxFeesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="extended" xlink:title="40701 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_AtMarketOfferingMember" xlink:label="mrkr_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mrkr_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_PreFundedWarrantMember" xlink:label="mrkr_PreFundedWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mrkr_PreFundedWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_PrivatePlacementWarrantMember" xlink:label="mrkr_PrivatePlacementWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mrkr_PrivatePlacementWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ClassOfWarrantOrRightExercised" xlink:label="mrkr_ClassOfWarrantOrRightExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="mrkr_ClassOfWarrantOrRightExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquityWarrantSummaryDetails" xlink:type="extended" xlink:title="40702 - Disclosure - STOCKHOLDERS' EQUITY - Warrant Summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_PrivatePlacementWarrantMember" xlink:label="mrkr_PrivatePlacementWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mrkr_PrivatePlacementWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_PreFundedWarrantMember" xlink:label="mrkr_PreFundedWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mrkr_PreFundedWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ClassOfWarrantOrRightRollForward" xlink:label="mrkr_ClassOfWarrantOrRightRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mrkr_ClassOfWarrantOrRightRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="mrkr_ClassOfWarrantOrRightRollForward" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ClassOfWarrantOrRightExercised" xlink:label="mrkr_ClassOfWarrantOrRightExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_ClassOfWarrantOrRightRollForward" xlink:to="mrkr_ClassOfWarrantOrRightExercised" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="40801 - Disclosure - STOCK BASED COMPENSATION - Stock option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_EquityIncentivePlan2020Member" xlink:label="mrkr_EquityIncentivePlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="mrkr_EquityIncentivePlan2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="40803 - Disclosure - STOCK BASED COMPENSATION - Stock-based compensation expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="extended" xlink:title="40804 - Disclosure - STOCK BASED COMPENSATION - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_EquityIncentiveAward2025Member" xlink:label="mrkr_EquityIncentiveAward2025Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="mrkr_EquityIncentiveAward2025Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_EquityIncentivePlan2020Member" xlink:label="mrkr_EquityIncentivePlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="mrkr_EquityIncentivePlan2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureGrantIncomeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - GRANT INCOME (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember" xlink:label="mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_FdaGrantMember" xlink:label="mrkr_FdaGrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrkr_FdaGrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CpritPancreaticGrantMember" xlink:label="mrkr_CpritPancreaticGrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrkr_CpritPancreaticGrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RestrictedCashCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail" xlink:type="extended" xlink:title="41001 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CommitmentsAndContingenciesTable" xlink:label="mrkr_CommitmentsAndContingenciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="mrkr_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_BaylorCollegeOfMedicineLicenseAgreementMember" xlink:label="mrkr_BaylorCollegeOfMedicineLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mrkr_BaylorCollegeOfMedicineLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="mrkr_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CommitmentsAndContingenciesLineItems" xlink:label="mrkr_CommitmentsAndContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_CommitmentsAndContingenciesLineItems" xlink:to="mrkr_CommitmentsAndContingenciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GrantReceived" xlink:label="mrkr_GrantReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_CommitmentsAndContingenciesLineItems" xlink:to="mrkr_GrantReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived" xlink:label="mrkr_GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_CommitmentsAndContingenciesLineItems" xlink:to="mrkr_GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm" xlink:label="mrkr_GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_CommitmentsAndContingenciesLineItems" xlink:to="mrkr_GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_SaleOfStockValueOfSharesIssuedInTransaction" xlink:label="mrkr_SaleOfStockValueOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mrkr_CommitmentsAndContingenciesLineItems" xlink:to="mrkr_SaleOfStockValueOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid" xlink:label="mrkr_LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="mrkr_CommitmentsAndContingenciesLineItems" xlink:to="mrkr_LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_LicenseAgreementLiquidityIncentivePaymentPercentage" xlink:label="mrkr_LicenseAgreementLiquidityIncentivePaymentPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="mrkr_CommitmentsAndContingenciesLineItems" xlink:to="mrkr_LicenseAgreementLiquidityIncentivePaymentPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - RELATED PARTY TRANSACTIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CellReadyMember" xlink:label="mrkr_CellReadyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mrkr_CellReadyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CellReadyAgreementMember" xlink:label="mrkr_CellReadyAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mrkr_CellReadyAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_WilsonWolfManufacturingCorporationMember" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mrkr_WilsonWolfManufacturingCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_BaylorCollegeOfMedicineMember" xlink:label="mrkr_BaylorCollegeOfMedicineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mrkr_BaylorCollegeOfMedicineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrkr_CellReadyMember" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrkr_WilsonWolfManufacturingCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrkr_CellReadyAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_MasterServicesAgreementTerm" xlink:label="mrkr_MasterServicesAgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mrkr_MasterServicesAgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_InvoicesReceivedForServicesAndManufacturingCosts" xlink:label="mrkr_InvoicesReceivedForServicesAndManufacturingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mrkr_InvoicesReceivedForServicesAndManufacturingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GainLossOnEarlyTerminationOfVendorAgreement" xlink:label="mrkr_GainLossOnEarlyTerminationOfVendorAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mrkr_GainLossOnEarlyTerminationOfVendorAgreement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails" xlink:type="extended" xlink:title="41202 - Disclosure - INCOME TAXES - Additional Information's (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_TaxCreditCarryforwardsExpirationPeriod" xlink:label="mrkr_TaxCreditCarryforwardsExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="mrkr_TaxCreditCarryforwardsExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_TaxCreditCarryForwardExpirationYearRangeEnd" xlink:label="mrkr_TaxCreditCarryForwardExpirationYearRangeEnd" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="mrkr_TaxCreditCarryForwardExpirationYearRangeEnd" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_OperatingLossCarryforwardsLimitationPercentage" xlink:label="mrkr_OperatingLossCarryforwardsLimitationPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="mrkr_OperatingLossCarryforwardsLimitationPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxPaymentsMadeAndIncomeTaxRefundsDetails" xlink:type="extended" xlink:title="41204 - Disclosure - INCOME TAXES - Summary of income tax payments made and income tax refunds (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_TX" xlink:label="stpr_TX" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="stpr_TX" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalTaxJurisdictionOtherMember" xlink:label="us-gaap_StateAndLocalTaxJurisdictionOtherMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalTaxJurisdictionOtherMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_IncomeTaxesPaidNet" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>22
<FILENAME>mrkr-20251231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/18/2026 8:29:31 PM-->
<!--Modified on: 3/18/2026 8:29:31 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Documents Incorporated by Reference [Text Block]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_PrepaidExpenseAndDepositsCurrent" xlink:label="mrkr_PrepaidExpenseAndDepositsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_PrepaidExpenseAndDepositsCurrent" xlink:to="mrkr_PrepaidExpenseAndDepositsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_PrepaidExpenseAndDepositsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and deposits that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_PrepaidExpenseAndDepositsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense And Deposits, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_PrepaidExpenseAndDepositsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xlink:to="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liability, Current, Related Party, Type [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at December 31, 2025 and 2024, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value, 30 million shares authorized, 16.7 million and 10.7 million shares issued and outstanding as of December 31, 2025 and 2024, respectively (see Note 7)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Including Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GainLossOnEarlyTerminationOfVendorAgreement" xlink:label="mrkr_GainLossOnEarlyTerminationOfVendorAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_GainLossOnEarlyTerminationOfVendorAgreement" xlink:to="mrkr_GainLossOnEarlyTerminationOfVendorAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_GainLossOnEarlyTerminationOfVendorAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of gain (loss) on early termination of vendor agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_GainLossOnEarlyTerminationOfVendorAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Early Termination of Vendor Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrkr_GainLossOnEarlyTerminationOfVendorAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on early termination of vendor agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_GainLossOnEarlyTerminationOfVendorAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (loss) on early termination of vendor agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax (benefit) expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax provision/(benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net earnings (loss) per share:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic, Other Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of common shares outstanding:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares purchased pursuant to ATM agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares purchased pursuant to ATM agreement (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options exercised for cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock from exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="mrkr_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:to="mrkr_StockAndWarrantsIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_StockAndWarrantsIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of new stock and warrants to purchase common stock issued during the reporting period. Includes shares issued in an initial public offering or a secondary public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_StockAndWarrantsIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock And Warrants Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_StockAndWarrantsIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, prefunded warrants and warrants for cash, net of offering costs</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_StockAndWarrantsIssuedDuringPeriodSharesNewIssues" xlink:label="mrkr_StockAndWarrantsIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_StockAndWarrantsIssuedDuringPeriodSharesNewIssues" xlink:to="mrkr_StockAndWarrantsIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_StockAndWarrantsIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock and warrants to purchase common stock issued during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_StockAndWarrantsIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock And Warrants Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_StockAndWarrantsIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, prefunded warrants and warrants for cash, net of offering costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="mrkr_StockIssuedDuringPeriodValueWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="mrkr_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock from exercise of prefunded warrants</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="mrkr_StockIssuedDuringPeriodSharesWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="mrkr_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants exercised during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock from exercise of prefunded warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net of offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flows from Operating Activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_IncreaseDecreaseInPrepaidExpenseAndDeposits" xlink:label="mrkr_IncreaseDecreaseInPrepaidExpenseAndDeposits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_IncreaseDecreaseInPrepaidExpenseAndDeposits" xlink:to="mrkr_IncreaseDecreaseInPrepaidExpenseAndDeposits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_IncreaseDecreaseInPrepaidExpenseAndDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in prepaid expenses and deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_IncreaseDecreaseInPrepaidExpenseAndDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Prepaid Expense And Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrkr_IncreaseDecreaseInPrepaidExpenseAndDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flows from Financing Activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock, net</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ProceedsFromWarrantsAndStockOptionsExercised" xlink:label="mrkr_ProceedsFromWarrantsAndStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ProceedsFromWarrantsAndStockOptionsExercised" xlink:to="mrkr_ProceedsFromWarrantsAndStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ProceedsFromWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash inflow from exercise of options and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ProceedsFromWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Warrants and Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ProceedsFromWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of warrants and stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (decrease) increase in cash, cash equivalents, and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents, and restricted cash at end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents, and restricted cash at beginning of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATURE OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATURE OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xlink:to="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock" xlink:to="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity Financial Condition And Going Concern Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity Financial Condition And Going Concern [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="us-gaap_NoncontrollingInterestAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_NoncontrollingInterestAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncontrolling Interest Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OTHER RECEIVABLE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OTHER RECEIVABLE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GRANT INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GRANT INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principles of Consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Modification of Stock Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patents and Patent Application Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Director [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GrantIncomePolicyPolicyTextBlock" xlink:label="mrkr_GrantIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_GrantIncomePolicyPolicyTextBlock" xlink:to="mrkr_GrantIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_GrantIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for grant income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_GrantIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_GrantIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per Common Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Standards</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_RecentlyIssuedAccountingStandardsAdoptedPolicyTextBlock" xlink:label="mrkr_RecentlyIssuedAccountingStandardsAdoptedPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_RecentlyIssuedAccountingStandardsAdoptedPolicyTextBlock" xlink:to="mrkr_RecentlyIssuedAccountingStandardsAdoptedPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_RecentlyIssuedAccountingStandardsAdoptedPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for recently issued accounting standards adopted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_RecentlyIssuedAccountingStandardsAdoptedPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Issued Accounting Standards Adopted [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_RecentlyIssuedAccountingStandardsAdoptedPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Adopted Accounting Standards</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xlink:label="mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xlink:to="mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for recently issued accounting standards not yet adopted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Issued Accounting Standards Not yet Adopted [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Issued Accounting Standards Not Yet Adopted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of computation of net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of anti-dilutive securities</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ScheduleOfOtherReceivablesCurrentTableTextBlock" xlink:label="mrkr_ScheduleOfOtherReceivablesCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ScheduleOfOtherReceivablesCurrentTableTextBlock" xlink:to="mrkr_ScheduleOfOtherReceivablesCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ScheduleOfOtherReceivablesCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of other receivables classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ScheduleOfOtherReceivablesCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Other Receivables Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ScheduleOfOtherReceivablesCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of company's other receivable balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accounts payable, accrued liabilities, and related party payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of the company's stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule or Description of Weighted Average Discount Rate [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of weighted average assumptions used in calculating the fair values of stock options that were granted</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_StockBasedCompensationExpensesTableTextBlock" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_StockBasedCompensationExpensesTableTextBlock" xlink:to="mrkr_StockBasedCompensationExpensesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of stock based compensation expenses recorded.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based Compensation Expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summarizes grant income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of related party transaction expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of expected tax (benefit) expense based on the U. S. federal statutory rate reconciled with the actual tax provision (benefit)</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_IncomeTaxPaymentsByJurisdictionTableTextBlock" xlink:label="mrkr_IncomeTaxPaymentsByJurisdictionTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_IncomeTaxPaymentsByJurisdictionTableTextBlock" xlink:to="mrkr_IncomeTaxPaymentsByJurisdictionTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_IncomeTaxPaymentsByJurisdictionTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of income tax payments by jurisdiction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_IncomeTaxPaymentsByJurisdictionTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Payments by Jurisdiction [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_IncomeTaxPaymentsByJurisdictionTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of income tax payments made and income tax refunds received by jurisdiction</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Condition Going Concern And Management Plans [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" xlink:label="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" xlink:to="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Cantor Fitzgerald &amp; Co and RBC Capital Markets, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cantor Fitzgerald Co. And Rbc Capital Markets Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Agents</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_FdaGrantMember" xlink:label="mrkr_FdaGrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FdaGrantMember" xlink:to="mrkr_FdaGrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FdaGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award of money not required to be repaid for FDA grant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FdaGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FDA Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_FdaGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FDA Grant</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to National Institutes of Health Small Business Innovation Research.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">National Institutes of Health Small Business Innovation Research [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SBIR AML</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SBIR AML Grant</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember" xlink:label="mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember" xlink:to="mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to grants from National Institutes of Health-National Cancer Institute.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">National Institutes of Health National Cancer Institute Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">National Institutes of Health National - Cancer Institute Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decoy Grant</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to grant from National Institutes of Health and Business Innovation research for Lymphoma.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">National Institutes of Health Small Business Innovation Research For Lymphoma Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SBIR lymphoma grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SBIR NHL Grant</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to grant from National Institutes of Health and Business Innovation research for pancreatic cancer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">National Institutes of Health Small Business Innovation Research For Pancreatic Cancer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SBIR pancreatic cancer grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PANACEA Grant</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_AdditionalCpritGrantMember" xlink:label="mrkr_AdditionalCpritGrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AdditionalCpritGrantMember" xlink:to="mrkr_AdditionalCpritGrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AdditionalCpritGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award of money not required to be repaid for additional CPRIT grant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AdditionalCpritGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional CPRIT Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_AdditionalCpritGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional CPRIT grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_AtMarketOfferingMember" xlink:label="mrkr_AtMarketOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AtMarketOfferingMember" xlink:to="mrkr_AtMarketOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to At The Market Offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At The Market Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Market Offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_PreFundedWarrantMember" xlink:label="mrkr_PreFundedWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_PreFundedWarrantMember" xlink:to="mrkr_PreFundedWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_PreFundedWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to pre-funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_PreFundedWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre Funded Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_PreFundedWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre Funded Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_PreFundedWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded warrants</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_PrivatePlacementWarrantMember" xlink:label="mrkr_PrivatePlacementWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_PrivatePlacementWarrantMember" xlink:to="mrkr_PrivatePlacementWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_PrivatePlacementWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to private placement warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_PrivatePlacementWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_PrivatePlacementWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_PrivatePlacementWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private placement warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ControlledEquityOfferingSalesAgreementMember" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ControlledEquityOfferingSalesAgreementMember" xlink:to="mrkr_ControlledEquityOfferingSalesAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to controlled equity offering sales agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Controlled Equity Offering Sales Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ATM Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscriptions" xlink:to="us-gaap_CommonStockSharesSubscriptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Subscriptions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate offering price</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" xlink:label="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" xlink:to="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percent of calculation of compensation rate by using gross sales price per share sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Commission Rate Calculation on Gross Sales Price per Share, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commission rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product development research award</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_FundsReceivedFromCpritGrant" xlink:label="mrkr_FundsReceivedFromCpritGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FundsReceivedFromCpritGrant" xlink:to="mrkr_FundsReceivedFromCpritGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FundsReceivedFromCpritGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funds received from grant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FundsReceivedFromCpritGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funds Received From CPRIT Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_FundsReceivedFromCpritGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funds received from CPRIT grant</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GrantReceived" xlink:label="mrkr_GrantReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_GrantReceived" xlink:to="mrkr_GrantReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_GrantReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of grant income transfer product and service to customer for which consideration has been received or is receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_GrantReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_GrantReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income received</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_FundsReceivedFromGrant" xlink:label="mrkr_FundsReceivedFromGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FundsReceivedFromGrant" xlink:to="mrkr_FundsReceivedFromGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FundsReceivedFromGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funds received from grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FundsReceivedFromGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funds Received From Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_FundsReceivedFromGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funds received from grant</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GrantAssistanceTerm" xlink:label="mrkr_GrantAssistanceTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_GrantAssistanceTerm" xlink:to="mrkr_GrantAssistanceTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_GrantAssistanceTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Duration of grant assistance transaction, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_GrantAssistanceTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Assistance Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_GrantAssistanceTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant assistance term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares of common stock, warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from the sale of securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, FDIC Insured Amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, FDIC insured amount</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CashAtFinancialInstitutions" xlink:label="mrkr_CashAtFinancialInstitutions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CashAtFinancialInstitutions" xlink:to="mrkr_CashAtFinancialInstitutions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CashAtFinancialInstitutions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash held at financial institutions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CashAtFinancialInstitutions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash at Financial Institutions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CashAtFinancialInstitutions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash at financial institutions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue" xlink:label="us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue" xlink:to="us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US Government Agencies Securities, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government agency securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental stock-based compensation expense in connection with the termination of certain employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock purchase warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potentially dilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfReceivablesWithImputedInterestTable" xlink:label="us-gaap_ScheduleOfReceivablesWithImputedInterestTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfReceivablesWithImputedInterestTable" xlink:to="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Receivables with Imputed Interest [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="us-gaap_GovernmentAssistanceTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistanceTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Assistance, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember" xlink:to="mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to  Cancer Prevention And Research Institute Of Texas grant for Acute Myeloid Leukemia.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancer Prevention And Research Institute Of Texas, Acute Myeloid Leukemia [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CPRIT AML</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesWithImputedInterestLineItems" xlink:label="us-gaap_ReceivablesWithImputedInterestLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems" xlink:to="us-gaap_ReceivablesWithImputedInterestLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesWithImputedInterestLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables with Imputed Interest [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesWithImputedInterestLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OTHER RECEIVABLE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total grant income receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesTable" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesTable" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This table lists the accounts payable and accrued liabilities. The line items identify information about the accounts payable and accrued liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable And Accrued Liabilities [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable And Accrued Liabilities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation and benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_TaxFeesPayable" xlink:label="mrkr_TaxFeesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_TaxFeesPayable" xlink:to="mrkr_TaxFeesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_TaxFeesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of tax fees payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_TaxFeesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Fees Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_TaxFeesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Including Related party payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accounts payable, accrued liabilities and related party payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ClassOfWarrantOrRightExercised" xlink:label="mrkr_ClassOfWarrantOrRightExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ClassOfWarrantOrRightExercised" xlink:to="mrkr_ClassOfWarrantOrRightExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants or rights exercised by the holders of the instruments during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrkr_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Per Share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Term</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ClassOfWarrantOrRightRollForward" xlink:label="mrkr_ClassOfWarrantOrRightRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ClassOfWarrantOrRightRollForward" xlink:to="mrkr_ClassOfWarrantOrRightRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ClassOfWarrantOrRightRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ClassOfWarrantOrRightRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_EquityIncentivePlan2020Member" xlink:label="mrkr_EquityIncentivePlan2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_EquityIncentivePlan2020Member" xlink:to="mrkr_EquityIncentivePlan2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_EquityIncentivePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents member information pertaining to 2020 equity incentive plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_EquityIncentivePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan 2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_EquityIncentivePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Executive Officer, President and Chairman [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Executive Officer, President and Chairman</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Director</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non employee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares Outstanding, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options granted to director amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares, Canceled/Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares, Options vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per Share, Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per Share, Outstanding, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per Share, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per Share, Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per Share, Canceled/Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Options vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Intrinsic Value Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Intrinsic Value, Options vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Life, Outstanding (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Life, Options vested and exercisable (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected stock price volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free rate of interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stock compensation expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_EquityIncentiveAward2025Member" xlink:label="mrkr_EquityIncentiveAward2025Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_EquityIncentiveAward2025Member" xlink:to="mrkr_EquityIncentiveAward2025Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_EquityIncentiveAward2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2025 equity incentive awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_EquityIncentiveAward2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Award 2025 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_EquityIncentiveAward2025Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025 Equity Incentive Awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional shares authorized</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" xlink:to="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based compensation arrangement number of share options available for issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Options Available for Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares options available to be issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments" xlink:to="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of annual vesting installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Annual Vesting Installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of annual vesting periods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options to purchase shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Accelerated Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acceleration of compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stock-based compensation cost related to unvested awards not yet recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected weighted average period of recognition of unrecognized compensation costs (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Table]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CpritPancreaticGrantMember" xlink:label="mrkr_CpritPancreaticGrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CpritPancreaticGrantMember" xlink:to="mrkr_CpritPancreaticGrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CpritPancreaticGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to CPRIT Pancreatic Grant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CpritPancreaticGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CPRIT Pancreatic Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CpritPancreaticGrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CPRIT Pancreatic Grant1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Line Items]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CommitmentsAndContingenciesTable" xlink:label="mrkr_CommitmentsAndContingenciesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CommitmentsAndContingenciesTable" xlink:to="mrkr_CommitmentsAndContingenciesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember" xlink:to="mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the grant agreement with Cancer Prevention and Research Institute Of Texas ("CPRIT").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancer Prevention And Research Institute Of Texas Grant Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancer Prevention and Research Institute of Texas</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_BaylorCollegeOfMedicineLicenseAgreementMember" xlink:label="mrkr_BaylorCollegeOfMedicineLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_BaylorCollegeOfMedicineLicenseAgreementMember" xlink:to="mrkr_BaylorCollegeOfMedicineLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_BaylorCollegeOfMedicineLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the exclusive license agreement with Baylor College of Medicine ("BCM").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_BaylorCollegeOfMedicineLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Baylor College Of Medicine License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_BaylorCollegeOfMedicineLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement with Baylor College of Medicine</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CommitmentsAndContingenciesLineItems" xlink:label="mrkr_CommitmentsAndContingenciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CommitmentsAndContingenciesLineItems" xlink:to="mrkr_CommitmentsAndContingenciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived" xlink:label="mrkr_GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived" xlink:to="mrkr_GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of net sales of any product to the grants received by the entity for which payments have to be made as per the terms of the grant agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Agreement, Payments Required, Percentage Of Net Sales To Grants Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate amount (in Percentage)</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm" xlink:label="mrkr_GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm" xlink:to="mrkr_GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of revenue sharing by the entity with the counter party for the remainder revenue term as per the terms of the grant agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Agreement, Revenue Sharing Percentage, Remainder of Revenue Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue sharing percentage</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_SaleOfStockValueOfSharesIssuedInTransaction" xlink:label="mrkr_SaleOfStockValueOfSharesIssuedInTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_SaleOfStockValueOfSharesIssuedInTransaction" xlink:to="mrkr_SaleOfStockValueOfSharesIssuedInTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_SaleOfStockValueOfSharesIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The value of shares issued or sold by the entity for the stock transaction during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_SaleOfStockValueOfSharesIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Value of Shares Issued in Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_SaleOfStockValueOfSharesIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued in common stock value</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid" xlink:label="mrkr_LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid" xlink:to="mrkr_LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate amount of the milestone payments agreed to be paid by the entity as per the terms of the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Maximum Milestone Payments Agreed To Be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments agreed</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_LicenseAgreementLiquidityIncentivePaymentPercentage" xlink:label="mrkr_LicenseAgreementLiquidityIncentivePaymentPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_LicenseAgreementLiquidityIncentivePaymentPercentage" xlink:to="mrkr_LicenseAgreementLiquidityIncentivePaymentPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_LicenseAgreementLiquidityIncentivePaymentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of the liquidity event proceeds that will be paid as a one-time liquidity incentive payment by the entity as per the terms of the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_LicenseAgreementLiquidityIncentivePaymentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Liquidity Incentive Payment Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_LicenseAgreementLiquidityIncentivePaymentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity incentive payment in percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CellReadyMember" xlink:label="mrkr_CellReadyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CellReadyMember" xlink:to="mrkr_CellReadyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CellReadyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Cell Ready.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CellReadyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cell Ready [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CellReadyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cell Ready</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CellReadyAgreementMember" xlink:label="mrkr_CellReadyAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CellReadyAgreementMember" xlink:to="mrkr_CellReadyAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CellReadyAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Cell Ready Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CellReadyAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cell Ready Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CellReadyAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cell Ready Purchase Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_CellReadyAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cell Ready</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_WilsonWolfManufacturingCorporationMember" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_WilsonWolfManufacturingCorporationMember" xlink:to="mrkr_WilsonWolfManufacturingCorporationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Clinical Trial Agreement with Wilson Wolf Manufacturing Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Wilson Wolf Manufacturing Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Wilson Wolf Manufacturing Corporation</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_BaylorCollegeOfMedicineMember" xlink:label="mrkr_BaylorCollegeOfMedicineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_BaylorCollegeOfMedicineMember" xlink:to="mrkr_BaylorCollegeOfMedicineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_BaylorCollegeOfMedicineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents of baylor college of medicine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_BaylorCollegeOfMedicineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Baylor College of Medicine [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_BaylorCollegeOfMedicineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BCM</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" xlink:to="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Clinical Trial Agreement with Baylor College of Medicine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical Trial Agreement with Baylor College of Medicine [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Baylor College of Medicine</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total related party expenses</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_MasterServicesAgreementTerm" xlink:label="mrkr_MasterServicesAgreementTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_MasterServicesAgreementTerm" xlink:to="mrkr_MasterServicesAgreementTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_MasterServicesAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The term of the master services agreement entered into by the entity, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_MasterServicesAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Master Services Agreement, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_MasterServicesAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Master Services Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service and manufacturing costs</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_InvoicesReceivedForServicesAndManufacturingCosts" xlink:label="mrkr_InvoicesReceivedForServicesAndManufacturingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_InvoicesReceivedForServicesAndManufacturingCosts" xlink:to="mrkr_InvoicesReceivedForServicesAndManufacturingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_InvoicesReceivedForServicesAndManufacturingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Invoices for the cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_InvoicesReceivedForServicesAndManufacturingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Invoices Received for Services and Manufacturing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_InvoicesReceivedForServicesAndManufacturingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid invoices</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Purchases from Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party transaction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxesAbstract" xlink:label="us-gaap_DeferredIncomeTaxesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAbstract" xlink:to="us-gaap_DeferredIncomeTaxesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Taxes and Other Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Operating Loss Carryforward</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_DeferredTaxStockBasedCompensation" xlink:label="mrkr_DeferredTaxStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_DeferredTaxStockBasedCompensation" xlink:to="mrkr_DeferredTaxStockBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_DeferredTaxStockBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax stock-based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_DeferredTaxStockBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Stock Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_DeferredTaxStockBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized R&amp;E</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserves</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accruals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Valuation Allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Deferred Tax Assets/(Liabilities)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Paid, by Individual Jurisdiction [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Tax Credit Carryforward [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign tax authority</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and local jurisdiction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Paid, by Individual Jurisdiction [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Federal Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current State and Local Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State tax (benefit) expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets, operating loss carryforwards, foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets, operating loss carryforwards, state and local</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_TaxCreditCarryforwardsExpirationPeriod" xlink:label="mrkr_TaxCreditCarryforwardsExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_TaxCreditCarryforwardsExpirationPeriod" xlink:to="mrkr_TaxCreditCarryforwardsExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_TaxCreditCarryforwardsExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carry forward expiration year range start.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_TaxCreditCarryforwardsExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforwards Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_TaxCreditCarryforwardsExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforwards expiration period</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_TaxCreditCarryForwardExpirationYearRangeEnd" xlink:label="mrkr_TaxCreditCarryForwardExpirationYearRangeEnd" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_TaxCreditCarryForwardExpirationYearRangeEnd" xlink:to="mrkr_TaxCreditCarryForwardExpirationYearRangeEnd_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_TaxCreditCarryForwardExpirationYearRangeEnd_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforward expiration year range end.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_TaxCreditCarryForwardExpirationYearRangeEnd_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carry Forward Expiration Year Range End</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_TaxCreditCarryForwardExpirationYearRangeEnd_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforward expiration year range end</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_OperatingLossCarryforwardsLimitationPercentage" xlink:label="mrkr_OperatingLossCarryforwardsLimitationPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_OperatingLossCarryforwardsLimitationPercentage" xlink:to="mrkr_OperatingLossCarryforwardsLimitationPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_OperatingLossCarryforwardsLimitationPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of limitation for operating loss carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_OperatingLossCarryforwardsLimitationPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards Limitation Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_OperatingLossCarryforwardsLimitationPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards limitation percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. federal statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. federal statutory rate, Percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State taxes, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State taxes, net of federal benefit, Percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance, Percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nontaxable or nondeductible items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nontaxable or nondeductible items, percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SBC cancellations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SBC cancellations, percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax provision (benefit), Percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Amount [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent Differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits income tax penalties and interest accrued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_TX" xlink:label="stpr_TX" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_TX" xlink:to="stpr_TX_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_TX_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TEXAS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="stpr_TX_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Texas</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalTaxJurisdictionOtherMember" xlink:label="us-gaap_StateAndLocalTaxJurisdictionOtherMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalTaxJurisdictionOtherMember" xlink:to="us-gaap_StateAndLocalTaxJurisdictionOtherMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalTaxJurisdictionOtherMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Tax Jurisdiction, Other [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalTaxJurisdictionOtherMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other US States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:to="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Paid, State and Local, after Refund Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Income Taxes Paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insider Trading Arrangements [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rule 10b5-1 Arrangement Adopted [Flag]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rule 10b5-1 Arrangement Adopted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Rule 10b5-1 Arrangement Adopted [Flag]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Rule 10b5-1 Arrangement Adopted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rule 10b5-1 Arrangement Terminated [Flag]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rule 10b5-1 Arrangement Terminated</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Rule 10b5-1 Arrangement Terminated [Flag]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Rule 10b5-1 Arrangement Terminated</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insider Trading Policies and Procedures [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insider Trading Policies and Procedures Adopted [Flag]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insider Trading Policies and Procedures Adopted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cybersecurity Risk Management Processes Integrated [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cybersecurity Risk Management Processes Integrated [Text Block]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cybersecurity Risk Management Third Party Engaged [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cybersecurity Risk Role of Management [Text Block]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>23
<FILENAME>mrkr-20251231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/18/2026 8:29:31 PM-->
<!--Modified on: 3/18/2026 8:29:31 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureNatureOfOperations" roleURI="http://www.tapimmune.com/role/DisclosureNatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureFinancialConditionGoingConcernAndManagementPlans" roleURI="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureNetLossPerShareApplicableToCommonShareholders" roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureOtherReceivable" roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable" roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureStockholdersEquity" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureStockBasedCompensation" roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureGrantIncome" roleURI="http://www.tapimmune.com/role/DisclosureGrantIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.tapimmune.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureIncomeTaxes" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureSubsequentEvents" roleURI="http://www.tapimmune.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureNetLossPerShareApplicableToCommonShareholdersTables" roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureOtherReceivableTables" roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivableTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTables" roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureGrantIncomeTables" roleURI="http://www.tapimmune.com/role/DisclosureGrantIncomeTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureRelatedPartyTransactionsTables" roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureFinancialConditionGoingConcernAndManagementPlansDetails" roleURI="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails" roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureNetLossPerShareApplicableToCommonShareholdersAntiDilutiveSecuritiesDetails" roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersAntiDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureOtherReceivableDetails" roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureStockholdersEquityWarrantSummaryDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityWarrantSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureStockBasedCompensationStockOptionActivityDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureStockBasedCompensationAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureGrantIncomeDetails" roleURI="http://www.tapimmune.com/role/DisclosureGrantIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureCommitmentsAndContingenciesDetail" roleURI="http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureIncomeTaxesAdditionalInformationSDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20251231.xsd#DisclosureIncomeTaxesSummaryOfIncomeTaxPaymentsMadeAndIncomeTaxRefundsDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxPaymentsMadeAndIncomeTaxRefundsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <presentationLink xlink:role="http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_639094625706138346" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentAnnualReport_639094625706138346" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_639094625706138346" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_639094625706138346" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_639094625706138346" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_639094625706138346" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_639094625706138346" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_639094625706138346" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_639094625706138346" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_639094625706138346" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_639094625706138346" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_639094625706138346" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_639094625706138346" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_639094625706138346" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_639094625706138346" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_639094625706138346" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_639094625706138346" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_639094625706138346" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_639094625706138346" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_639094625706138346" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_639094625706138346" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_639094625706138346" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_639094625706138346" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_639094625706138346" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_639094625706138346" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_639094625706138346" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_639094625706138346" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityPublicFloat_639094625706138346" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_639094625706138346" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_639094625706138346" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_639094625706138346" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_639094625706138346" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_639094625706138346" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_639094625706138346" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_639094625706138346" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorName_639094625706138346" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorFirmId_639094625706138346" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorLocation_639094625706138346" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639094625706138346" xlink:to="us-gaap_AssetsCurrentAbstract_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639094625706138346" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639094625706138346" xlink:to="us-gaap_RestrictedCashCurrent_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_PrepaidExpenseAndDepositsCurrent" xlink:label="mrkr_PrepaidExpenseAndDepositsCurrent_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639094625706138346" xlink:to="mrkr_PrepaidExpenseAndDepositsCurrent_639094625706138346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639094625706138346" xlink:to="us-gaap_OtherReceivablesNetCurrent_639094625706138346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639094625706138346" xlink:to="us-gaap_AssetsCurrent_639094625706138346" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639094625706138346" xlink:to="us-gaap_Assets_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639094625706138346" xlink:to="us-gaap_LiabilitiesCurrentAbstract_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639094625706138346" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639094625706138346" xlink:to="us-gaap_OtherLiabilitiesCurrent_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrent_639094625706138346" xlink:to="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639094625706138346" xlink:to="us-gaap_DeferredRevenueCurrent_639094625706138346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639094625706138346" xlink:to="us-gaap_LiabilitiesCurrent_639094625706138346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639094625706138346" xlink:to="us-gaap_Liabilities_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639094625706138346" xlink:to="us-gaap_StockholdersEquityAbstract_639094625706138346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639094625706138346" xlink:to="us-gaap_PreferredStockValue_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639094625706138346" xlink:to="us-gaap_CommonStockValue_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639094625706138346" xlink:to="us-gaap_AdditionalPaidInCapital_639094625706138346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639094625706138346" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_639094625706138346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639094625706138346" xlink:to="us-gaap_StockholdersEquity_639094625706138346" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639094625706138346" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_639094625706138346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_639094625706138346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_639094625706138346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_639094625706138346" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_639094625706138346" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_639094625706138346" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_639094625706138346" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_StatementTable_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639094625706138346" xlink:to="srt_ProductOrServiceAxis_639094625706138346" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_639094625706138346" xlink:to="srt_ProductsAndServicesDomain_639094625706138346" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639094625706138346" xlink:to="us-gaap_GrantMember_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639094625706138346" xlink:to="us-gaap_StatementLineItems_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="us-gaap_RevenuesAbstract_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_639094625706138346" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="us-gaap_CostsAndExpensesAbstract_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639094625706138346" xlink:to="us-gaap_ResearchAndDevelopmentExpense_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639094625706138346" xlink:to="us-gaap_GeneralAndAdministrativeExpense_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GainLossOnEarlyTerminationOfVendorAgreement" xlink:label="mrkr_GainLossOnEarlyTerminationOfVendorAgreement_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639094625706138346" xlink:to="mrkr_GainLossOnEarlyTerminationOfVendorAgreement_639094625706138346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_639094625706138346" xlink:to="us-gaap_OperatingExpenses_639094625706138346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="us-gaap_OperatingIncomeLoss_639094625706138346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_639094625706138346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639094625706138346" xlink:to="us-gaap_InvestmentIncomeInterest_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_639094625706138346" xlink:to="us-gaap_OtherNonoperatingIncome_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639094625706138346" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="us-gaap_IncomeTaxExpenseBenefit_639094625706138346" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="us-gaap_NetIncomeLoss_639094625706138346" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="us-gaap_EarningsPerShareAbstract_639094625706138346" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_639094625706138346" xlink:to="us-gaap_EarningsPerShareBasic_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_639094625706138346" xlink:to="us-gaap_EarningsPerShareDiluted_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_639094625706138346" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_639094625706138346" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_639094625706138346" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639094625706138346" xlink:to="us-gaap_StatementEquityComponentsAxis_639094625706138346" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639094625706138346" xlink:to="us-gaap_CommonStockMember_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639094625706138346" xlink:to="us-gaap_AdditionalPaidInCapitalMember_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639094625706138346" xlink:to="us-gaap_RetainedEarningsMember_639094625706138346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639094625706138346" xlink:to="us-gaap_EquityComponentDomain_639094625706138346" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639094625706138346" xlink:to="us-gaap_StatementLineItems_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="us-gaap_StockholdersEquity_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="us-gaap_SharesIssued_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_639094625706138346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639094625706138346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_639094625706138346" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_639094625706138346" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_StockAndWarrantsIssuedDuringPeriodValueNewIssues" xlink:label="mrkr_StockAndWarrantsIssuedDuringPeriodValueNewIssues_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="mrkr_StockAndWarrantsIssuedDuringPeriodValueNewIssues_639094625706138346" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_StockAndWarrantsIssuedDuringPeriodSharesNewIssues" xlink:label="mrkr_StockAndWarrantsIssuedDuringPeriodSharesNewIssues_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="mrkr_StockAndWarrantsIssuedDuringPeriodSharesNewIssues_639094625706138346" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="mrkr_StockIssuedDuringPeriodValueWarrantsExercised_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="mrkr_StockIssuedDuringPeriodValueWarrantsExercised_639094625706138346" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="mrkr_StockIssuedDuringPeriodSharesWarrantsExercised_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="mrkr_StockIssuedDuringPeriodSharesWarrantsExercised_639094625706138346" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_639094625706138346" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="us-gaap_NetIncomeLoss_639094625706138346" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6390946257061383461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="us-gaap_StockholdersEquity_6390946257061383461" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_6390946257061383461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639094625706138346" xlink:to="us-gaap_SharesIssued_6390946257061383461" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639094625706138346" xlink:to="us-gaap_ProfitLoss_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639094625706138346" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639094625706138346" xlink:to="us-gaap_ShareBasedCompensation_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639094625706138346" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639094625706138346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_IncreaseDecreaseInPrepaidExpenseAndDeposits" xlink:label="mrkr_IncreaseDecreaseInPrepaidExpenseAndDeposits_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639094625706138346" xlink:to="mrkr_IncreaseDecreaseInPrepaidExpenseAndDeposits_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639094625706138346" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639094625706138346" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_639094625706138346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639094625706138346" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_639094625706138346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639094625706138346" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_639094625706138346" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_639094625706138346" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_639094625706138346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639094625706138346" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ProceedsFromWarrantsAndStockOptionsExercised" xlink:label="mrkr_ProceedsFromWarrantsAndStockOptionsExercised_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639094625706138346" xlink:to="mrkr_ProceedsFromWarrantsAndStockOptionsExercised_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_639094625706138346" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_639094625706138346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_639094625706138346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639094625706138346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6390946257061383461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6390946257061383461" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNatureOfOperations" xlink:type="extended" xlink:title="10101 - Disclosure - NATURE OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans" xlink:type="extended" xlink:title="10201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xlink:label="LiquidityFinancialConditionAndGoingConcernAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityFinancialConditionAndGoingConcernAbstract" xlink:to="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders" xlink:type="extended" xlink:title="10401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="NoncontrollingInterestAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncontrollingInterestAbstract" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureOtherReceivable" xlink:type="extended" xlink:title="10501 - Disclosure - OTHER RECEIVABLE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract" xlink:label="ReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable" xlink:type="extended" xlink:title="10601 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10701 - Disclosure - STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="10801 - Disclosure - STOCK BASED COMPENSATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureGrantIncome" xlink:type="extended" xlink:title="10901 - Disclosure - GRANT INCOME" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11001 - Disclosure - COMMITMENTS AND CONTINGENCIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="11101 - Disclosure - RELATED PARTY TRANSACTIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11201 - Disclosure - INCOME TAXES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11301 - Disclosure - SUBSEQUENT EVENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_639094625706138346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_639094625706138346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_639094625706138346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_639094625706138346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_639094625706293963" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_639094625706293963" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_639094625706293963" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_639094625706293963" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_639094625706293963" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_639094625706293963" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GrantIncomePolicyPolicyTextBlock" xlink:label="mrkr_GrantIncomePolicyPolicyTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="mrkr_GrantIncomePolicyPolicyTextBlock_639094625706293963" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_639094625706293963" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_639094625706293963" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_639094625706293963" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_RecentlyIssuedAccountingStandardsAdoptedPolicyTextBlock" xlink:label="mrkr_RecentlyIssuedAccountingStandardsAdoptedPolicyTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="mrkr_RecentlyIssuedAccountingStandardsAdoptedPolicyTextBlock_639094625706293963" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock" xlink:label="mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock_639094625706293963" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables" xlink:type="extended" xlink:title="30403 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="NoncontrollingInterestAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncontrollingInterestAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncontrollingInterestAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureOtherReceivableTables" xlink:type="extended" xlink:title="30503 - Disclosure - OTHER RECEIVABLE (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ScheduleOfOtherReceivablesCurrentTableTextBlock" xlink:label="mrkr_ScheduleOfOtherReceivablesCurrentTableTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="mrkr_ScheduleOfOtherReceivablesCurrentTableTextBlock_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTables" xlink:type="extended" xlink:title="30603 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30703 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30803 - Disclosure - STOCK BASED COMPENSATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_StockBasedCompensationExpensesTableTextBlock" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="mrkr_StockBasedCompensationExpensesTableTextBlock_639094625706293963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureGrantIncomeTables" xlink:type="extended" xlink:title="30903 - Disclosure - GRANT INCOME (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables" xlink:type="extended" xlink:title="31103 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_1" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31203 - Disclosure - INCOME TAXES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_IncomeTaxPaymentsByJurisdictionTableTextBlock" xlink:label="mrkr_IncomeTaxPaymentsByJurisdictionTableTextBlock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="mrkr_IncomeTaxPaymentsByJurisdictionTableTextBlock_639094625706293963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails" xlink:type="extended" xlink:title="40201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xlink:label="LiquidityFinancialConditionAndGoingConcernAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityFinancialConditionAndGoingConcernAbstract" xlink:to="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_639094625706293963" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_639094625706293963" xlink:to="srt_CounterpartyNameAxis_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639094625706293963" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" xlink:label="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639094625706293963" xlink:to="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_639094625706293963" xlink:to="srt_ProductOrServiceAxis_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_639094625706293963" xlink:to="srt_ProductsAndServicesDomain_639094625706293963" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639094625706293963" xlink:to="us-gaap_GrantMember_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_FdaGrantMember" xlink:label="mrkr_FdaGrantMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GrantMember_639094625706293963" xlink:to="mrkr_FdaGrantMember_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639094625706293963" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember" xlink:label="mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639094625706293963" xlink:to="mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_639094625706293963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639094625706293963" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_639094625706293963" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639094625706293963" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_639094625706293963" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_AdditionalCpritGrantMember" xlink:label="mrkr_AdditionalCpritGrantMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639094625706293963" xlink:to="mrkr_AdditionalCpritGrantMember_639094625706293963" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_639094625706293963" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639094625706293963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639094625706293963" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_AtMarketOfferingMember" xlink:label="mrkr_AtMarketOfferingMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639094625706293963" xlink:to="mrkr_AtMarketOfferingMember_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639094625706293963" xlink:to="us-gaap_PrivatePlacementMember_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_639094625706293963" xlink:to="us-gaap_StatementEquityComponentsAxis_639094625706293963" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639094625706293963" xlink:to="us-gaap_EquityComponentDomain_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_639094625706293963" xlink:to="us-gaap_CommonStockMember_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_639094625706293963" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639094625706293963" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639094625706293963" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_PreFundedWarrantMember" xlink:label="mrkr_PreFundedWarrantMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639094625706293963" xlink:to="mrkr_PreFundedWarrantMember_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_PrivatePlacementWarrantMember" xlink:label="mrkr_PrivatePlacementWarrantMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639094625706293963" xlink:to="mrkr_PrivatePlacementWarrantMember_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_639094625706293963" xlink:to="us-gaap_TypeOfArrangementAxis_639094625706293963" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_639094625706293963" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ControlledEquityOfferingSalesAgreementMember" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639094625706293963" xlink:to="mrkr_ControlledEquityOfferingSalesAgreementMember_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_639094625706293963" xlink:to="srt_RangeAxis_639094625706293963" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639094625706293963" xlink:to="srt_RangeMember_639094625706293963" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639094625706293963" xlink:to="srt_MaximumMember_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_639094625706293963" xlink:to="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_639094625706293963" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_639094625706293963" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_639094625706293963" xlink:to="us-gaap_CommonStockSharesSubscriptions_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" xlink:label="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_639094625706293963" xlink:to="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent_639094625706293963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_639094625706293963" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639094625706293963" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_639094625706293963" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639094625706293963" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_639094625706293963" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_639094625706293963" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_FundsReceivedFromCpritGrant" xlink:label="mrkr_FundsReceivedFromCpritGrant_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_639094625706293963" xlink:to="mrkr_FundsReceivedFromCpritGrant_639094625706293963" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GrantReceived" xlink:label="mrkr_GrantReceived_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_639094625706293963" xlink:to="mrkr_GrantReceived_639094625706293963" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_FundsReceivedFromGrant" xlink:label="mrkr_FundsReceivedFromGrant_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_639094625706293963" xlink:to="mrkr_FundsReceivedFromGrant_639094625706293963" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GrantAssistanceTerm" xlink:label="mrkr_GrantAssistanceTerm_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_639094625706293963" xlink:to="mrkr_GrantAssistanceTerm_639094625706293963" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_639094625706293963" xlink:to="us-gaap_GrantsReceivable_639094625706293963" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_639094625706293963" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639094625706293963" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_639094625706293963" xlink:to="us-gaap_SharesIssuedPricePerShare_639094625706293963" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_639094625706293963" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639094625706293963" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashFDICInsuredAmount_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CashAtFinancialInstitutions" xlink:label="mrkr_CashAtFinancialInstitutions_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mrkr_CashAtFinancialInstitutions_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashCurrent_639094625706293963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue" xlink:label="us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue_639094625706293963" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639094625706293963" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_639094625706293963" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_639094625706293963" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_639094625706293963" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_639094625706293963" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails" xlink:type="extended" xlink:title="40401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Computation of loss per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="NoncontrollingInterestAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncontrollingInterestAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_639094625706293963" xlink:to="us-gaap_NetIncomeLoss_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncontrollingInterestAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_639094625706293963" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_639094625706293963" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncontrollingInterestAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_639094625706293963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_639094625706293963" xlink:to="us-gaap_EarningsPerShareBasic_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_639094625706293963" xlink:to="us-gaap_EarningsPerShareDiluted_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersAntiDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="40402 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Anti-dilutive securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="NoncontrollingInterestAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncontrollingInterestAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639094625706293963" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639094625706293963" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_639094625706293963" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_639094625706293963" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_639094625706293963" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_639094625706293963" xlink:to="us-gaap_EmployeeStockOptionMember_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_639094625706293963" xlink:to="us-gaap_WarrantMember_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639094625706293963" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_639094625706293963" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureOtherReceivableDetails" xlink:type="extended" xlink:title="40501 - Disclosure - OTHER RECEIVABLE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesAbstract" xlink:label="ReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfReceivablesWithImputedInterestTable" xlink:label="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReceivablesAbstract" xlink:to="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_639094625706293963" xlink:to="us-gaap_GovernmentAssistanceTypeAxis_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeAxis_639094625706293963" xlink:to="us-gaap_GovernmentAssistanceTypeDomain_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeDomain_639094625706293963" xlink:to="mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_FdaGrantMember" xlink:label="mrkr_FdaGrantMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeDomain_639094625706293963" xlink:to="mrkr_FdaGrantMember_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeDomain_639094625706293963" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_639094625706293963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember" xlink:label="mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeDomain_639094625706293963" xlink:to="mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_639094625706293963" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeDomain_639094625706293963" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_639094625706293963" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeDomain_639094625706293963" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_639094625706293963" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesWithImputedInterestLineItems" xlink:label="us-gaap_ReceivablesWithImputedInterestLineItems_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_639094625706293963" xlink:to="us-gaap_ReceivablesWithImputedInterestLineItems_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems_639094625706293963" xlink:to="us-gaap_GrantsReceivableCurrent_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems_639094625706293963" xlink:to="us-gaap_InterestReceivableCurrent_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems_639094625706293963" xlink:to="us-gaap_OtherAssetsCurrent_639094625706293963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems_639094625706293963" xlink:to="us-gaap_OtherReceivablesNetCurrent_639094625706293963" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails" xlink:type="extended" xlink:title="40601 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesTable" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesTable_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesTable_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesTable_639094625706293963" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639094625706293963" xlink:to="us-gaap_RelatedPartyDomain_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639094625706293963" xlink:to="us-gaap_RelatedPartyMember_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesTable_639094625706293963" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_639094625706293963" xlink:to="us-gaap_AccountsPayableCurrent_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_639094625706293963" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_639094625706293963" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_639094625706293963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_639094625706293963" xlink:to="us-gaap_OtherLiabilitiesCurrent_639094625706293963" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrent_639094625706293963" xlink:to="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_TaxFeesPayable" xlink:label="mrkr_TaxFeesPayable_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_639094625706293963" xlink:to="mrkr_TaxFeesPayable_639094625706293963" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_639094625706293963" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_639094625706293963" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_639094625706293963" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent_639094625706293963" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="extended" xlink:title="40701 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639094625706293963" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639094625706293963" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_AtMarketOfferingMember" xlink:label="mrkr_AtMarketOfferingMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639094625706293963" xlink:to="mrkr_AtMarketOfferingMember_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639094625706293963" xlink:to="us-gaap_PrivatePlacementMember_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639094625706293963" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639094625706293963" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_PreFundedWarrantMember" xlink:label="mrkr_PreFundedWarrantMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639094625706293963" xlink:to="mrkr_PreFundedWarrantMember_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_PrivatePlacementWarrantMember" xlink:label="mrkr_PrivatePlacementWarrantMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639094625706293963" xlink:to="mrkr_PrivatePlacementWarrantMember_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639094625706293963" xlink:to="us-gaap_StatementEquityComponentsAxis_639094625706293963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639094625706293963" xlink:to="us-gaap_EquityComponentDomain_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_639094625706293963" xlink:to="us-gaap_CommonStockMember_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639094625706293963" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_639094625706293963" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639094625706293963" xlink:to="us-gaap_CommonStockSharesAuthorized_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639094625706293963" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639094625706293963" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639094625706293963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639094625706293963" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639094625706293963" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639094625706293963" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639094625706293963" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639094625706293963" xlink:to="us-gaap_SharesIssuedPricePerShare_639094625706293963" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639094625706293963" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639094625706293963" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639094625706293963" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_639094625706293963" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639094625706293963" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_639094625706293963" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ClassOfWarrantOrRightExercised" xlink:label="mrkr_ClassOfWarrantOrRightExercised_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639094625706293963" xlink:to="mrkr_ClassOfWarrantOrRightExercised_639094625706293963" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639094625706293963" xlink:to="us-gaap_ProceedsFromWarrantExercises_639094625706293963" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639094625706293963" xlink:to="us-gaap_PreferredStockSharesAuthorized_639094625706293963" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639094625706293963" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_639094625706293963" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquityWarrantSummaryDetails" xlink:type="extended" xlink:title="40702 - Disclosure - STOCKHOLDERS' EQUITY - Warrant Summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639094625706293963" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639094625706293963" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_PrivatePlacementWarrantMember" xlink:label="mrkr_PrivatePlacementWarrantMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639094625706293963" xlink:to="mrkr_PrivatePlacementWarrantMember_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_PreFundedWarrantMember" xlink:label="mrkr_PreFundedWarrantMember_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639094625706293963" xlink:to="mrkr_PreFundedWarrantMember_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639094625706293963" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639094625706293963" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639094625706293963" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ClassOfWarrantOrRightRollForward" xlink:label="mrkr_ClassOfWarrantOrRightRollForward_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639094625706293963" xlink:to="mrkr_ClassOfWarrantOrRightRollForward_639094625706293963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_ClassOfWarrantOrRightRollForward_639094625706293963" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_639094625706293963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ClassOfWarrantOrRightExercised" xlink:label="mrkr_ClassOfWarrantOrRightExercised_639094625706293963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_ClassOfWarrantOrRightRollForward_639094625706293963" xlink:to="mrkr_ClassOfWarrantOrRightExercised_639094625706293963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_6390946257062939631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_ClassOfWarrantOrRightRollForward_639094625706293963" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_6390946257062939631" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="40801 - Disclosure - STOCK BASED COMPENSATION - Stock option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639094625706450280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639094625706450280" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_639094625706450280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639094625706450280" xlink:to="us-gaap_PlanNameAxis_639094625706450280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639094625706450280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_639094625706450280" xlink:to="us-gaap_PlanNameDomain_639094625706450280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_EquityIncentivePlan2020Member" xlink:label="mrkr_EquityIncentivePlan2020Member_639094625706453629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639094625706450280" xlink:to="mrkr_EquityIncentivePlan2020Member_639094625706453629" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_639094625706453629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639094625706450280" xlink:to="srt_TitleOfIndividualAxis_639094625706453629" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_639094625706453629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_639094625706453629" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_639094625706453629" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_639094625706453629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_639094625706453629" xlink:to="srt_ChiefExecutiveOfficerMember_639094625706453629" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_639094625706453629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_639094625706453629" xlink:to="srt_DirectorMember_639094625706453629" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_639094625706453629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639094625706450280" xlink:to="us-gaap_GranteeStatusAxis_639094625706453629" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_639094625706453629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_639094625706453629" xlink:to="us-gaap_GranteeStatusDomain_639094625706453629" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_639094625706453629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_639094625706453629" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_639094625706453629" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_639094625706453629" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639094625706450280" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_639094625706458849" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_639094625706458849" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6390946257064588491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6390946257064588491" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_639094625706458849" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_639094625706458849" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_639094625706458849" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_639094625706458849" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_639094625706458849" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6390946257064588491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6390946257064588491" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_639094625706458849" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_639094625706458849" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_639094625706458849" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_639094625706458849" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_639094625706458849" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended" xlink:title="40802 - Disclosure - STOCK BASED COMPENSATION - Weighted average assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_639094625706458849" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_639094625706458849" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_639094625706458849" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="40803 - Disclosure - STOCK BASED COMPENSATION - Stock-based compensation expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639094625706458849" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639094625706458849" xlink:to="us-gaap_IncomeStatementLocationAxis_639094625706458849" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_639094625706458849" xlink:to="us-gaap_IncomeStatementLocationDomain_639094625706458849" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_639094625706458849" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_639094625706458849" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="extended" xlink:title="40804 - Disclosure - STOCK BASED COMPENSATION - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639094625706458849" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639094625706458849" xlink:to="us-gaap_AwardTypeAxis_639094625706458849" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639094625706458849" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_EquityIncentiveAward2025Member" xlink:label="mrkr_EquityIncentiveAward2025Member_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639094625706458849" xlink:to="mrkr_EquityIncentiveAward2025Member_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639094625706458849" xlink:to="us-gaap_PlanNameAxis_639094625706458849" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_639094625706458849" xlink:to="us-gaap_PlanNameDomain_639094625706458849" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_EquityIncentivePlan2020Member" xlink:label="mrkr_EquityIncentivePlan2020Member_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639094625706458849" xlink:to="mrkr_EquityIncentivePlan2020Member_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639094625706458849" xlink:to="us-gaap_GranteeStatusAxis_639094625706458849" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_639094625706458849" xlink:to="us-gaap_GranteeStatusDomain_639094625706458849" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_639094625706458849" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_639094625706458849" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639094625706458849" xlink:to="srt_TitleOfIndividualAxis_639094625706458849" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_639094625706458849" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_639094625706458849" xlink:to="srt_DirectorMember_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_639094625706458849" xlink:to="srt_ChiefExecutiveOfficerMember_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_639094625706458849" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments_639094625706458849" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_639094625706458849" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_639094625706458849" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_639094625706458849" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_639094625706458849" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_639094625706458849" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_639094625706458849" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_639094625706458849" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639094625706458849" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_639094625706458849" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureGrantIncomeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - GRANT INCOME (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable_639094625706458849" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_639094625706458849" xlink:to="srt_ProductOrServiceAxis_639094625706458849" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_639094625706458849" xlink:to="srt_ProductsAndServicesDomain_639094625706458849" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639094625706458849" xlink:to="mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_FdaGrantMember" xlink:label="mrkr_FdaGrantMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639094625706458849" xlink:to="mrkr_FdaGrantMember_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639094625706458849" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_639094625706458849" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember" xlink:label="mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639094625706458849" xlink:to="mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_639094625706458849" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639094625706458849" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_639094625706458849" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember" xlink:label="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639094625706458849" xlink:to="mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_639094625706458849" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CpritPancreaticGrantMember" xlink:label="mrkr_CpritPancreaticGrantMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639094625706458849" xlink:to="mrkr_CpritPancreaticGrantMember_639094625706458849" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_639094625706458849" xlink:to="us-gaap_GrantMember_639094625706458849" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_639094625706458849" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_639094625706458849" order="2" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_639094625706458849" xlink:to="us-gaap_RestrictedCashCurrent_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_639094625706458849" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail" xlink:type="extended" xlink:title="41001 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CommitmentsAndContingenciesTable" xlink:label="mrkr_CommitmentsAndContingenciesTable_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="mrkr_CommitmentsAndContingenciesTable_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommitmentsAndContingenciesTable_639094625706458849" xlink:to="us-gaap_RelatedPartyTransactionAxis_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_639094625706458849" xlink:to="us-gaap_RelatedPartyTransactionDomain_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_639094625706458849" xlink:to="mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_BaylorCollegeOfMedicineLicenseAgreementMember" xlink:label="mrkr_BaylorCollegeOfMedicineLicenseAgreementMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_639094625706458849" xlink:to="mrkr_BaylorCollegeOfMedicineLicenseAgreementMember_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommitmentsAndContingenciesTable_639094625706458849" xlink:to="srt_RangeAxis_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639094625706458849" xlink:to="srt_RangeMember_639094625706458849" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639094625706458849" xlink:to="srt_MaximumMember_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CommitmentsAndContingenciesLineItems" xlink:label="mrkr_CommitmentsAndContingenciesLineItems_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommitmentsAndContingenciesTable_639094625706458849" xlink:to="mrkr_CommitmentsAndContingenciesLineItems_639094625706458849" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GrantReceived" xlink:label="mrkr_GrantReceived_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommitmentsAndContingenciesLineItems_639094625706458849" xlink:to="mrkr_GrantReceived_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived" xlink:label="mrkr_GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommitmentsAndContingenciesLineItems_639094625706458849" xlink:to="mrkr_GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm" xlink:label="mrkr_GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommitmentsAndContingenciesLineItems_639094625706458849" xlink:to="mrkr_GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm_639094625706458849" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_SaleOfStockValueOfSharesIssuedInTransaction" xlink:label="mrkr_SaleOfStockValueOfSharesIssuedInTransaction_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommitmentsAndContingenciesLineItems_639094625706458849" xlink:to="mrkr_SaleOfStockValueOfSharesIssuedInTransaction_639094625706458849" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid" xlink:label="mrkr_LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommitmentsAndContingenciesLineItems_639094625706458849" xlink:to="mrkr_LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid_639094625706458849" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_LicenseAgreementLiquidityIncentivePaymentPercentage" xlink:label="mrkr_LicenseAgreementLiquidityIncentivePaymentPercentage_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommitmentsAndContingenciesLineItems_639094625706458849" xlink:to="mrkr_LicenseAgreementLiquidityIncentivePaymentPercentage_639094625706458849" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - RELATED PARTY TRANSACTIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_2" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639094625706458849" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639094625706458849" xlink:to="srt_CounterpartyNameAxis_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639094625706458849" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CellReadyMember" xlink:label="mrkr_CellReadyMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639094625706458849" xlink:to="mrkr_CellReadyMember_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639094625706458849" xlink:to="us-gaap_RelatedPartyTransactionAxis_639094625706458849" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_639094625706458849" xlink:to="us-gaap_RelatedPartyTransactionDomain_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CellReadyAgreementMember" xlink:label="mrkr_CellReadyAgreementMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_639094625706458849" xlink:to="mrkr_CellReadyAgreementMember_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_WilsonWolfManufacturingCorporationMember" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_639094625706458849" xlink:to="mrkr_WilsonWolfManufacturingCorporationMember_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_BaylorCollegeOfMedicineMember" xlink:label="mrkr_BaylorCollegeOfMedicineMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_639094625706458849" xlink:to="mrkr_BaylorCollegeOfMedicineMember_639094625706458849" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639094625706458849" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639094625706458849" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639094625706458849" xlink:to="us-gaap_RelatedPartyDomain_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639094625706458849" xlink:to="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CellReadyMember" xlink:label="mrkr_CellReadyMember_6390946257064588491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639094625706458849" xlink:to="mrkr_CellReadyMember_6390946257064588491" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_WilsonWolfManufacturingCorporationMember" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember_6390946257064588491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639094625706458849" xlink:to="mrkr_WilsonWolfManufacturingCorporationMember_6390946257064588491" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639094625706458849" xlink:to="us-gaap_RelatedPartyMember_639094625706458849" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639094625706458849" xlink:to="us-gaap_TypeOfArrangementAxis_639094625706458849" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_639094625706458849" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_CellReadyAgreementMember" xlink:label="mrkr_CellReadyAgreementMember_6390946257064588491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639094625706458849" xlink:to="mrkr_CellReadyAgreementMember_6390946257064588491" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639094625706458849" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639094625706458849" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639094625706458849" xlink:to="us-gaap_OperatingCostsAndExpenses_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639094625706458849" xlink:to="us-gaap_OtherLiabilitiesCurrent_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_MasterServicesAgreementTerm" xlink:label="mrkr_MasterServicesAgreementTerm_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639094625706458849" xlink:to="mrkr_MasterServicesAgreementTerm_639094625706458849" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639094625706458849" xlink:to="us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_639094625706458849" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_InvoicesReceivedForServicesAndManufacturingCosts" xlink:label="mrkr_InvoicesReceivedForServicesAndManufacturingCosts_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639094625706458849" xlink:to="mrkr_InvoicesReceivedForServicesAndManufacturingCosts_639094625706458849" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639094625706458849" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_639094625706458849" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_GainLossOnEarlyTerminationOfVendorAgreement" xlink:label="mrkr_GainLossOnEarlyTerminationOfVendorAgreement_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639094625706458849" xlink:to="mrkr_GainLossOnEarlyTerminationOfVendorAgreement_639094625706458849" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxesAbstract" xlink:label="us-gaap_DeferredIncomeTaxesAbstract_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxesAbstract_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_639094625706458849" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_DeferredTaxStockBasedCompensation" xlink:label="mrkr_DeferredTaxStockBasedCompensation_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_639094625706458849" xlink:to="mrkr_DeferredTaxStockBasedCompensation_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_639094625706458849" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_639094625706458849" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_639094625706458849" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_639094625706458849" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_639094625706458849" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_639094625706458849" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_639094625706458849" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_639094625706458849" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_639094625706458849" xlink:to="us-gaap_DeferredTaxAssetsGross_639094625706458849" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_639094625706458849" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_639094625706458849" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_639094625706458849" xlink:to="us-gaap_DeferredTaxAssetsNet_639094625706458849" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails" xlink:type="extended" xlink:title="41202 - Disclosure - INCOME TAXES - Additional Information's (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_639094625706458849" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_639094625706458849" xlink:to="us-gaap_TaxCreditCarryforwardAxis_639094625706458849" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_639094625706458849" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_639094625706458849" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_639094625706458849" xlink:to="us-gaap_ResearchMember_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_639094625706458849" xlink:to="us-gaap_IncomeTaxAuthorityAxis_639094625706458849" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_639094625706458849" xlink:to="us-gaap_IncomeTaxAuthorityDomain_639094625706458849" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_639094625706458849" xlink:to="us-gaap_ForeignCountryMember_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_639094625706458849" xlink:to="us-gaap_StateAndLocalJurisdictionMember_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_639094625706458849" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_639094625706458849" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_639094625706458849" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_639094625706458849" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_639094625706458849" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_639094625706458849" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_639094625706458849" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_639094625706458849" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_TaxCreditCarryforwardsExpirationPeriod" xlink:label="mrkr_TaxCreditCarryforwardsExpirationPeriod_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_639094625706458849" xlink:to="mrkr_TaxCreditCarryforwardsExpirationPeriod_639094625706458849" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_TaxCreditCarryForwardExpirationYearRangeEnd" xlink:label="mrkr_TaxCreditCarryForwardExpirationYearRangeEnd_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_639094625706458849" xlink:to="mrkr_TaxCreditCarryForwardExpirationYearRangeEnd_639094625706458849" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_639094625706458849" xlink:to="us-gaap_OperatingLossCarryforwards_639094625706458849" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20251231.xsd#mrkr_OperatingLossCarryforwardsLimitationPercentage" xlink:label="mrkr_OperatingLossCarryforwardsLimitationPercentage_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_639094625706458849" xlink:to="mrkr_OperatingLossCarryforwardsLimitationPercentage_639094625706458849" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_639094625706458849" xlink:to="us-gaap_TaxCreditCarryforwardAmount_639094625706458849" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails" xlink:type="extended" xlink:title="41203 - Disclosure - INCOME TAXES - Schedule of expected tax expense (benefit) from continuing operations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_639094625706458849" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_639094625706458849" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639094625706458849" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639094625706458849" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_639094625706458849" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_639094625706458849" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_639094625706458849" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_639094625706458849" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_639094625706458849" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_639094625706458849" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639094625706458849" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639094625706458849" xlink:to="us-gaap_UnrecognizedTaxBenefits_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639094625706458849" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxPaymentsMadeAndIncomeTaxRefundsDetails" xlink:type="extended" xlink:title="41204 - Disclosure - INCOME TAXES - Summary of income tax payments made and income tax refunds (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_639094625706458849" xlink:to="us-gaap_IncomeTaxAuthorityAxis_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_639094625706458849" xlink:to="us-gaap_IncomeTaxAuthorityDomain_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_639094625706458849" xlink:to="us-gaap_StateAndLocalJurisdictionMember_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_TX" xlink:label="stpr_TX_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StateAndLocalJurisdictionMember_639094625706458849" xlink:to="stpr_TX_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalTaxJurisdictionOtherMember" xlink:label="us-gaap_StateAndLocalTaxJurisdictionOtherMember_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StateAndLocalJurisdictionMember_639094625706458849" xlink:to="us-gaap_StateAndLocalTaxJurisdictionOtherMember_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_639094625706458849" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_639094625706458849" xlink:to="us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_639094625706458849" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet_639094625706458849" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_639094625706458849" xlink:to="us-gaap_IncomeTaxesPaidNet_639094625706458849" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="InsiderTradingArrLineItems" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag_639094625706609560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrAdoptedFlag_639094625706609560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_639094625706612711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_639094625706612711" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag_639094625706613700" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrTrmntdFlag_639094625706613700" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_639094625706614121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_639094625706614121" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="InsiderTradingPoliciesProcLineItems" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_639094625706614121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_639094625706614121" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended" xlink:title="995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_639094625706614121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_639094625706614121" order="1" use="optional" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_639094625706614121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_639094625706614121" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_639094625706614121" order="1" use="optional" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_639094625706619443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_639094625706614121" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_639094625706619443" order="1" use="optional" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_639094625706620259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_639094625706614121" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_639094625706620259" order="2" use="optional" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_639094625706621157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_639094625706614121" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_639094625706621157" order="3" use="optional" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_639094625706621547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_639094625706614121" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_639094625706621547" order="4" use="optional" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_639094625706621547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_639094625706614121" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_639094625706621547" order="5" use="optional" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_639094625706621547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_639094625706614121" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_639094625706621547" order="2" use="optional" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_639094625706621547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_639094625706621547" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_639094625706621547" order="1" use="optional" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_639094625706621547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_639094625706621547" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_639094625706621547" order="2" use="optional" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_639094625706621547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_639094625706621547" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_639094625706621547" order="3" use="optional" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_639094625706621547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_639094625706621547" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_639094625706621547" order="4" use="optional" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_639094625706627106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_639094625706621547" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_639094625706627106" order="5" use="optional" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_639094625706627445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_639094625706621547" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_639094625706627445" order="6" use="optional" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_639094625706627445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_639094625706621547" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_639094625706627445" order="7" use="optional" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_639094625706627445" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_639094625706621547" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_639094625706627445" order="8" use="optional" priority="9" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 16, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MARKER THERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-4497941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2450 Holcombe Blvd, TMC Partners Office 1.311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400-6400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRKR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,312,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,673,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text"><span style="font-size:7pt;">Portions of the registrant&#8217;s proxy statement relating to registrant&#8217;s 2025 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;) to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than 120&#160;days after the close of the registrant&#8217;s fiscal&#160;year, are incorporated by reference in Part&#160;III of this Annual Report on Form&#160;10-K. Except with respect to information specifically incorporated by reference in this Annual Report on Form&#160;10-K, the Proxy Statement is not deemed to be filed as part of this Annual Report on Form&#160;10-K</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001094038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Marcum LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Houston, TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 16,068,048<span></span>
</td>
<td class="nump">$ 19,192,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">974,799<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_PrepaidExpenseAndDepositsCurrent', window );">Prepaid expenses and deposits</a></td>
<td class="nump">658,750<span></span>
</td>
<td class="nump">483,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">1,369,400<span></span>
</td>
<td class="nump">2,346,703<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">19,070,997<span></span>
</td>
<td class="nump">22,022,860<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">19,070,997<span></span>
</td>
<td class="nump">22,022,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 1,299,384<span></span>
</td>
<td class="nump">1,753,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,710,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration', window );">Other Liability, Current, Related Party, Type [Extensible Enumeration]</a></td>
<td class="text">Related Party [Member]<span></span>
</td>
<td class="text">Related Party [Member]<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 974,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,274,183<span></span>
</td>
<td class="nump">$ 3,464,454<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,274,183<span></span>
</td>
<td class="nump">3,464,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at December 31, 2025 and 2024, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 30 million shares authorized, 16.7 million and 10.7 million shares issued and outstanding as of December 31, 2025 and 2024, respectively (see Note 7)</a></td>
<td class="nump">16,672<span></span>
</td>
<td class="nump">10,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">475,960,940<span></span>
</td>
<td class="nump">465,564,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(459,180,798)<span></span>
</td>
<td class="num">(447,017,178)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">16,796,814<span></span>
</td>
<td class="nump">18,558,406<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 19,070,997<span></span>
</td>
<td class="nump">$ 22,022,860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_PrepaidExpenseAndDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and deposits that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_PrepaidExpenseAndDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates status and type of related party for liability classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">16,700,000<span></span>
</td>
<td class="nump">10,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">16,700,000<span></span>
</td>
<td class="nump">10,700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3,546,669<span></span>
</td>
<td class="nump">$ 6,591,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">11,799,154<span></span>
</td>
<td class="nump">13,467,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,184,806<span></span>
</td>
<td class="nump">4,241,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GainLossOnEarlyTerminationOfVendorAgreement', window );">Loss on early termination of vendor agreement</a></td>
<td class="nump">453,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">16,437,095<span></span>
</td>
<td class="nump">17,709,452<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(12,890,426)<span></span>
</td>
<td class="num">(11,118,372)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">594,206<span></span>
</td>
<td class="nump">437,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="nump">117,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from operations before income taxes</a></td>
<td class="num">(12,178,776)<span></span>
</td>
<td class="num">(10,681,362)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">(15,156)<span></span>
</td>
<td class="nump">49,953<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,163,620)<span></span>
</td>
<td class="num">$ (10,731,315)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net earnings (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (1.19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (1.19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">15,310,308<span></span>
</td>
<td class="nump">8,980,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">15,310,308<span></span>
</td>
<td class="nump">8,980,207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3,546,669<span></span>
</td>
<td class="nump">$ 6,591,080<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GainLossOnEarlyTerminationOfVendorAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gain (loss) on early termination of vendor agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GainLossOnEarlyTerminationOfVendorAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 8,891<span></span>
</td>
<td class="nump">$ 450,329,515<span></span>
</td>
<td class="num">$ (436,285,863)<span></span>
</td>
<td class="nump">$ 14,052,543<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">8,891,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares purchased pursuant to ATM agreement</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">36,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares purchased pursuant to ATM agreement (in shares)</a></td>
<td class="nump">8,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">62,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options (in shares)</a></td>
<td class="nump">25,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockAndWarrantsIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, prefunded warrants and warrants for cash, net of offering costs</a></td>
<td class="nump">$ 1,784<span></span>
</td>
<td class="nump">14,890,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,892,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockAndWarrantsIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, prefunded warrants and warrants for cash, net of offering costs (in shares)</a></td>
<td class="nump">1,783,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,731,315)<span></span>
</td>
<td class="num">(10,731,315)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 10,708<span></span>
</td>
<td class="nump">465,564,876<span></span>
</td>
<td class="num">(447,017,178)<span></span>
</td>
<td class="nump">18,558,406<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">10,709,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares purchased pursuant to ATM agreement</a></td>
<td class="nump">$ 5,359<span></span>
</td>
<td class="nump">9,858,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,863,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares purchased pursuant to ATM agreement (in shares)</a></td>
<td class="nump">5,358,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock from exercise of prefunded warrants</a></td>
<td class="nump">$ 605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock from exercise of prefunded warrants (in shares)</a></td>
<td class="nump">605,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">537,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">537,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,163,620)<span></span>
</td>
<td class="num">(12,163,620)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2025</a></td>
<td class="nump">$ 16,672<span></span>
</td>
<td class="nump">$ 475,960,940<span></span>
</td>
<td class="num">$ (459,180,798)<span></span>
</td>
<td class="nump">$ 16,796,814<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance (in shares) at Dec. 31, 2025</a></td>
<td class="nump">16,673,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_StockAndWarrantsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock and warrants to purchase common stock issued during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_StockAndWarrantsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_StockAndWarrantsIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock and warrants to purchase common stock issued during the reporting period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_StockAndWarrantsIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Net of offering costs</a></td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (12,163,620)<span></span>
</td>
<td class="num">$ (10,731,315)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Reconciliation of net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">537,540<span></span>
</td>
<td class="nump">245,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_IncreaseDecreaseInPrepaidExpenseAndDeposits', window );">Prepaid expenses and deposits</a></td>
<td class="num">(175,033)<span></span>
</td>
<td class="nump">504,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">977,303<span></span>
</td>
<td class="num">(1,318,888)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent', window );">Related party payable</a></td>
<td class="num">(1,710,500)<span></span>
</td>
<td class="nump">380,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(454,570)<span></span>
</td>
<td class="nump">8,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">974,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,014,081)<span></span>
</td>
<td class="num">(10,910,324)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">9,863,883<span></span>
</td>
<td class="nump">14,929,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ProceedsFromWarrantsAndStockOptionsExercised', window );">Proceeds from exercise of warrants and stock options</a></td>
<td class="nump">605<span></span>
</td>
<td class="nump">62,159<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">9,864,488<span></span>
</td>
<td class="nump">14,991,314<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(2,149,593)<span></span>
</td>
<td class="nump">4,080,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of the year</a></td>
<td class="nump">19,192,440<span></span>
</td>
<td class="nump">15,111,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of the year</a></td>
<td class="nump">$ 17,042,847<span></span>
</td>
<td class="nump">$ 19,192,440<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_IncreaseDecreaseInPrepaidExpenseAndDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses and deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_IncreaseDecreaseInPrepaidExpenseAndDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ProceedsFromWarrantsAndStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of options and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ProceedsFromWarrantsAndStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;1:&#160;&#160;&#160;&#160;NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Marker Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221; or &#8220;we&#8221;), is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company&#8217;s multi antigen recognizing (&#8220;MAR&#8221;)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Currently, the Baylor College of Medicine (&#8220;BCM&#8221;) supplies the Company with MT-601, the Company&#8217;s lead Multi-Antigen Recognizing (MAR)-T cell therapy in anticipation of the commencement of the Company&#8217;s larger pivotal trial for Lymphoma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 16, 2025, the Company entered into a Statement of Work (the &#8220;SOW&#8221;) with Cellipont Bioservices (&#8220;Cellipont&#8221;), a leading cell therapy Contract Development and Manufacturing Organization (&#8220;CDMO&#8221;), for the manufacturing of MT-601. Pursuant to the SOW, Cellipont will provide technology transfer and cGMP manufacturing services to support the scale-up and production of MT-601 for the Company&#8217;s APOLLO study.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_LiquidityFinancialConditionAndGoingConcernAbstract', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock', window );">FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;2:&#160;&#160;&#160;&#160;FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As of December 31, 2025, the Company had cash, cash equivalents,</span> <span style="font-style:normal;font-weight:normal;">and restricted cash of approximately </span><span style="font-style:normal;font-weight:normal;">$17.0</span><span style="font-style:normal;font-weight:normal;"> million. The Company&#8217;s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing; successfully progress its product candidates through preclinical and clinical development; obtain regulatory approval of one or more of its product candidates; maintain and enforce intellectual property rights; develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity, debt financings and grants.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2021, the Company entered into a Controlled Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement (the &#8220;ATM Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and RBC Capital Markets, LLC (the &#8220;Sales Agents&#8221;), pursuant to which the Company could offer and sell, from time to time at its sole discretion through the Sales Agents, shares of its common stock having an aggregate offering price of up to $75.0 million. Any shares of its common stock sold were issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-258687), which the SEC declared effective on August 19, 2021. However, our use of the shelf registration statement on Form S-3 was limited for so long as we were subject to General Instruction I.B.6 of Form S-3, which limited the amounts that we could sell under the registration statement and in accordance with the ATM agreement. The Sales Agents were entitled to compensation under the Sales Agreement at a commission rate equal to 3.0% of the gross sales price per share sold under the ATM Agreement, and we provided each of the Sales Agents with indemnification and contribution rights. During the year ended December 31, 2024, the Company sold 8,178 shares of its common stock under the ATM Agreement for proceeds of $0.04 million. On June 10, 2024, the Company provided notice of its termination of the ATM Agreement with Cantor Fitzgerald &amp; Co. and RBC Capital Markets, LLC. The Company is not subject to any termination penalties related to the termination of the ATM Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In November 2024, the Company entered into an At The Market Offering Agreement, or the Sales Agreement, with H.C. Wainwright &amp; Co. LLC, relating to the sale of shares of its common stock having an agreement offering price of up to $11,431,713 from time to time through H.C. Wainwright &amp; Co. LLC. Any shares of common stock sold will be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-283512), which the SEC declared effective on December 6, 2024. However, the Company&#8217;s use of the shelf registration statement on Form S-3 will be limited for so long as it is subject to General Instruction I.B.6 of Form S-3, which limits the amounts that the Company may sell under the registration statement and in accordance with the ATM agreement. H.C. Wainwright &amp; Co. LLC will be entitled to compensation under the Sales Agreement at a commission rate equal to 3.0% of the gross sales price per share sold under the ATM Agreement, and the Company&#8217; has provided H.C. Wainwright &amp; Co. LLC with indemnification and contribution rights. Between July 17 and 21, 2025, the Company sold 1,624,075 shares of common stock pursuant to the ATM </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Agreement for net proceeds of $4.5 million, after deducting agent commissions, at an average price of $2.87 per share. On August 26, 2025, the Company sold an additional 3,734,217 shares of common stock pursuant to the ATM Agreement with H.C. Wainwright &amp; Co., LLC for net proceeds of $5.4 million, after deducting agent commissions, at an average price of $1.48 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from the CPRIT to support the Company&#8217;s clinical investigation of MT-401 (the &#8220;CPRIT AML Grant&#8221;). Through the date of this filing, the Company has received $11.8 million in funds from the CPRIT AML Grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2022, the Company received notice from the FDA that it had awarded the Company a $2.0 million grant from the FDA&#8217;s Orphan Products Grant program to support the clinical investigation of MT-401 for the treatment of post-transplant AML (the &#8220;FDA Grant&#8221;). Through the date of this filing, the Company has received $1.2 million in funds from the FDA Grant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2023, the Company announced that it had received a $2.0 million grant from the National Institutes of Health (&#8220;NIH&#8221;) Small Business Innovation Research (&#8220;SBIR&#8221;) program to support the development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents (the &#8220;SBIR AML Grant&#8221;). Through the date of this filing, the Company has received $1.7 million in funds from the SBIR AML Grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The above funding agencies have agreed to continue their financial support and to shift funds to the MT-401-OTS program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2024, the Company received notice of a $2.0 million grant over a 2-year period from the National Institutes of Health SBIR program to support control over tumor immune escape in pancreatic cancer using a dual T cell product strategy (the &#8220;Decoy Grant&#8221;). Through the date of this filing, the Company has received approximately $0.5 million in funds from the Decoy Grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2024, the Company received notice of a $2.0 million grant from the NIH SBIR program to support the clinical investigation of MT-601 in patients with non-Hodgkin&#8217;s lymphoma (&#8220;NHL&#8221;) who have relapsed following anti-CD19 chimeric antigen receptor (CAR) T cell therapy (the &#8220;SBIR NHL Grant&#8221;). Through the date of this filing, the Company has received $1.3 million in funds from the SBIR NHL Grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2024, the Company received another $2.0 million grant from the NIH SBIR program to support the advancement of MT-601 in patients with pancreatic cancer (the &#8220;PANACEA Grant&#8221;). Through the date of this filing, the Company has received approximately $0.4 million in funds from the PANACEA Grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December 2024, the Company received notice of an additional $9.5 million grant from CPRIT to support the clinical investigation of MT-601 in patients with metastatic pancreatic cancer (the &#8220;CPRIT Pancreatic Grant&#8221;). Through the date of this filing, the Company has received $1.5 million in funds from this grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Refer to Note 5 and Note 9 for grant income receivable and grant income recorded for each grant, respectively, for the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">On December 19, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;), pursuant to which the Company issued and sold in a private Placement the following securities: (i)</span><span style="font-style:normal;font-weight:normal;">1,783,805</span><span style="font-style:normal;font-weight:normal;"> shares of common stock, (ii) Series B Warrants, or Pre-Funded Warrants, to purchase an aggregate of </span><span style="font-style:normal;font-weight:normal;">3,247,445</span><span style="font-style:normal;font-weight:normal;"> shares of common stock in lieu of shares of common stock and (iii) Series A Warrants, or Private Placement Warrants, to purchase an aggregate of </span><span style="font-style:normal;font-weight:normal;">5,031,250</span><span style="font-style:normal;font-weight:normal;"> shares of common stock. The purchase price per share of common stock and accompanying Private Placement Warrant to purchase a share of common stock was </span><span style="font-style:normal;font-weight:normal;">$3.20</span><span style="font-style:normal;font-weight:normal;">, and the purchase price per Pre-Funded Warrant and accompanying Private Placement Warrant to purchase a share of common stock was </span><span style="font-style:normal;font-weight:normal;">$3.199</span><span style="font-style:normal;font-weight:normal;">. The transaction closed on December 23, 2024, with net proceeds from the sale of securities in the Private Placement of approximately </span><span style="font-style:normal;font-weight:normal;">$14.9</span><span style="font-style:normal;font-weight:normal;"> million, which does not include any proceeds that may be received upon exercise of any warrants issued in the Private Placement. Both the Pre-Funded Warrants and the Private Placement Warrants were not exercisable until the Company obtained shareholder approval, which was received on March 21, 2025.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Company expects to continue to incur substantial losses over the next several years during its development phase.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on the Company&#8217;s lack of recurring revenues, anticipated uses of cash and historical recurring cash losses from operating activities, and cash, cash equivalents, and restricted cash as of December 31, 2025, and taking into consideration the net proceeds received in July and August of 2025 through the sale of Common Stock pursuant to its ATM Agreement with H.C. Wainwright &amp; Co., </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">LLC (see Note 7), the Company anticipates that it will be able to fund its operating expenses and capital expenditure requirements through the fourth quarter of 2026, assuming no additional grant funds are received, either from new grants or from existing awarded grants. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management is considering raising additional capital through the issuance of securities and intends to apply for additional grant funds, which could enable the Company to fund its operating expenses and capital expenditure requirements beyond the fourth quarter of 2026, although no assurance can be given that such capital or existing awarded grants will be earned or future grants will be awarded. The Company&#8217;s future cash requirements are based on the Company&#8217;s clinical and research and development plans, timing expectations related to the progress of its programs, and is subject to the Company&#8217;s ability to effectively manage its costs, raise additional capital, and receive additional grant funds, of which there can be no assurances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Company&#8217;s assumptions may prove to be wrong, and the Company could utilize its available capital resources sooner than it currently expects. Furthermore, the Company&#8217;s operating plan may change, and it may need additional funds sooner than planned in order to meet operational needs and capital requirements for product development and commercialization. Because of the numerous risks and uncertainties associated with the development and commercialization of the Company&#8217;s product candidates and the extent to which the Company may enter into additional collaborations with third parties to participate in their development and commercialization, the Company is unable to estimate the amounts of increased capital outlays and operating expenditures associated with its current and anticipated clinical trials. The Company&#8217;s future funding requirements will depend on many factors, as it:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Initiates, continues, or accelerates clinical trials of its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continues the research and development of its product candidates and seeks to discover additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeks regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintains and enforces intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enters into contract manufacturing arrangements with contract manufacturing organizations for clinical manufacturing supply;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishes sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates that may receive regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluates strategic transactions the Company may undertake; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enhances operational, financial and information management systems and hires additional personnel, including personnel to support development of product candidates and, if a product candidate is approved, commercialization efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company&#8217;s financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to the foregoing, high inflation and concerns about an economic recession in the United States or other major markets have resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company&#8217;s ability to access capital, which could in the future negatively affect the Company&#8217;s liquidity. In addition, a recession or market correction due to these factors could materially affect the Company&#8217;s business and the value of its common stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_LiquidityFinancialConditionAndGoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_LiquidityFinancialConditionAndGoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity Financial Condition And Going Concern Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;3:&#160;&#160;&#160;&#160;SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the Securities Exchange Commission (&#8220;SEC&#8221;). Any reference </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">in these footnotes to applicable guidance is meant to refer to the authoritative U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy,&#160;Inc. and GeneMax Pharmaceuticals&#160;Inc.&#160;&#8211; a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada,&#160;Inc. All significant intercompany balances and transactions are eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accordingly, actual results may differ materially from those estimates. Management considers many factors in selecting appropriate financial accounting policies, controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation expense and income taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash, Cash Equivalents, Restricted Cash, and Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash, cash equivalents, and restricted cash at December 31, 2025 consisted of cash and certificates of deposit in institutions in the United States. The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limits of $250,000. As of December 31, 2025, the Company had approximately $1.6 million in cash at financial institutions, including $1.0 million of restricted cash at financial institutions, and approximately $15.4 million in U.S. government agency securities, for aggregate cash, cash equivalents, and restricted cash of $17.0 million. As of December 31, 2024, the Company had approximately $1.1 million in cash at financial institutions and approximately $18.1 million in U.S. government agency securities, for aggregate cash and cash equivalents of $19.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event cash is received from grants in advance of incurring qualifying costs, it is recorded as restricted cash until it is earned and recorded to grant income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Modification of Stock Options </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2025, the Company recorded incremental stock-based compensation expense of $0.3 million pertaining to the modification of stock options in connection with certain consultants. The modification provided for an acceleration of unvested options, resulting in $0.3 million in compensation expense that was immediately recognized, and is reflected in operating expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patents and Patent Application Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company incurs stock-based compensation expense related to the issuance of common stock and stock options. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Term</i> &#8212; The expected life of stock options was estimated using the &#8220;simplified method,&#8221; as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Volatility</i> &#8212; The Company computes stock price volatility over expected terms based on its historical common stock trading prices. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i> &#8212; The Company bases the risk-free interest rate on the implied yield available on U.S. Treasury zero-coupon issues with an equivalent remaining term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Dividend</i> &#8212; The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company amortizes the fair value of the awards expected to vest on a straight-line basis over the requisite service period of the awards. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received as if the Company had paid cash for those services. Forfeitures are accounted for as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of costs associated with clinical trial programs. Costs incurred by third parties are expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the clinical trial or project and the invoices received from its external service providers. The Company estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each project and total project spending. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone events are achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable income in the years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the date of allowances against deferred tax assets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for &#8220;unrecognized tax benefits&#8221; is recorded for any tax benefits claimed in the Company&#8217;s tax returns that do not meet these recognition and measurement standards. As of December 31, 2025 and 2024, no liability for unrecognized tax benefits was required to be reported. The guidance also discusses the classification of related interest and penalties on income taxes. The Company&#8217;s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the years ended December 31, 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Grant Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Grant Income represents funding under cost reimbursement programs from government agencies and non-profit foundations for qualified research and development activities performed by the Company. In applying the provisions of ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company determined that grants and awards are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#8220;customer&#8221;, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to each grant or award, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;). For grant and awards outside the scope of ASC 808, the Company applies either ASC 606 or IAS 20 by analogy depending on if the arrangement is considered an exchange or non-exchange transaction, respectively. Under both accounting frameworks, revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract. During the two years ended December 31, 2025, the Company did not participate in any collaboration agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Loss per Common Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per share includes only the weighted average common shares outstanding, without consideration of potentially dilutive securities. Diluted loss per share includes the weighted average common shares outstanding and any potentially dilutive common stock equivalent shares in the calculation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an entity for which separate discrete financial information is made available and that is regularly evaluated by the chief operating decision maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The Company is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company&#8217;s operations are organized and reported as a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its products. The Company&#8217;s CODM, its chief executive officer, reviews operating results on an aggregate basis and manages the operations as a single operating segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accounting policies of the Company&#8217;s single operating and reportable segment are the same as those described in the summary of significant accounting policies. The measure of segment assets is reported on the consolidated balance sheets as total assets. The CODM evaluates performance and allocates resources based on consolidated net income (loss) that also is reported on the consolidated statements of operations as net loss, and consolidated cash used in operations. The CODM makes operating decisions based on the availability of cash and the allocation of cash to the required expenditures. The significant expenses regularly reviewed by the CODM are consistent with those reported on the Company&#8217;s consolidated statements of operations, and expenses are not regularly reviewed on a more disaggregated basis for purposes of assessing segment performance and deciding how to allocate resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">New Accounting Standards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently Adopted Accounting Standards</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Improvements to Income Tax Disclosures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. Effective January 1, 2025, the Company adopted the new standard and applied it retrospectively to prior periods presented. The Company does not believe the new disclosure requirements had a material impact to its financial positions, results of operations and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently Issued Accounting Standards Not Yet Adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In December 2025, the FASB issued ASU 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities. The new standard is intended to establish authoritative guidance on the accounting for government grants received by business entities and reduce diversity in practice. The amendments establish the timing and methods of recognition of both (1) a grant related to an asset and (2) a grant related to income. The amendments also require certain disclosures including the nature of the grant received, the accounting policies used to account for the grant, and significant terms and conditions for the grant. The new guidance is effective for annual reporting periods beginning after December 15, 2028, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The new guidance may be applied on a modified prospective basis, modified retrospective basis, or full retrospective basis. The Company is currently evaluating the impact of ASU 2025-10 on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures, to improve transparency in financial reporting by requiring entities to present more detailed information about the nature of expenses included within the Income Statement. The guidance will be effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. The Company is in the process of assessing the impact of ASU 2024-03 on its disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">U.S Tax Law Changes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was enacted, introducing significant changes to U.S. tax law, including provisions related to bonus depreciation, interest expense limitations, and the treatment of domestic research and development expenditures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company evaluated the legislation in accordance with ASC 740 and determined that the enactment did not have a material impact on its financial statements for the year ended December 31, 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;4:&#160;&#160;&#160;&#160;NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth the computation of net loss per share for the years ended December 31, 2025 and 2024, respectively:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,163,620)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,731,315)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,310,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8,980,207</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,310,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8,980,207</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net earnings (loss) per share:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.79)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.19)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,762,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 587,704</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,031,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,278,695</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Potentially dilutive securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,794,128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,866,399</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER RECEIVABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">OTHER RECEIVABLE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 5:&#160;&#160;&#160;&#160;&#160;OTHER RECEIVABLE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other receivable mainly consists of grant income receivable. Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. The following table summarizes the Company&#8217;s other receivable balance as of December 31, 2025 and 2024, respectively:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant income receivable:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">CPRIT AML Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 815,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,059,457</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">FDA Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">SBIR AML Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 162,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 244,810</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Decoy Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59,501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,822</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">SBIR NHL Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87,417</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">PANACEA Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 190,052</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,502</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total grant income receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,318,981</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,316,591</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,112</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,369,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,346,703</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Refer to Note 2 for details related to awarded grants and Note 9 for more information on grant income.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/310-10/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 6:&#160;&#160;&#160;&#160;ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Accounts payable, accrued liabilities, and related party payable consist of the following as of December 31, 2025 and 2024, respectively:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 793,727</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,066,395</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 86,350</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 160,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 293,189</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_dTBoH9MfTE64AKs-oLTQIA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Related party payable</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,710,500</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Tax fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,638</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 104,591</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 203,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 203,429</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,299,384</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,464,454</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The $1.7 million related-party payable as of December 31, 2024 reflects amounts for outsourced product development and manufacturing services. See Note 11: Related Party Transactions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;7:&#160;&#160;&#160;&#160;STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has authorized up to 30,000,000 shares of common stock, $0.001 par value per share, for issuance. Significant 2025 and 2024 common stock transactions were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Issuance of Common Stock Pursuant to ATM Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2025, the Company sold 5,358,292 shares of its common stock under the ATM Agreement for gross proceeds of $9.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2024, the Company sold 8,178 shares of its common stock under the ATM Agreement for gross proceeds of $37,000. On June 10, 2024, the Company provided notice of its termination of the ATM Agreement with Cantor Fitzgerald &amp; Co. and RBC Capital Markets, LLC. In November 2024, the Company entered into an ATM Agreement with H.C. Wainwright &amp; Co., LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Private Placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 19, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;), pursuant to which the Company issued and sold in a private Placement the following securities: (i) 1,783,805 shares of common stock, (ii) Series B Warrants, or Pre-Funded Warrants, to purchase an aggregate of 3,247,445 shares of common stock in lieu of shares of common stock and (iii) Series A Warrants, or Private Placement Warrants, to purchase an aggregate of 5,031,250 shares of common stock. The purchase price per share of common stock and accompanying Private Placement Warrant to purchase a share of common stock was $3.20, and the purchase price per Pre-Funded Warrant and accompanying <span style="-sec-ix-hidden:Hidden_vlSFv0gqUE-B3bsGUvHgiw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Private Placement</span></span> Warrant to purchase a share of common stock was $3.199. Net proceeds from the sale of securities in the Private Placement was approximately $14.9 million, which does not include any proceeds that may be received upon the exercise of any warrants issued in the Private Placement. Both the Pre-Funded Warrants and the Private Placement Warrants are not exercisable until the Company obtains shareholder approval. On March 21, 2025, the Company obtained shareholder approval for the exercise of such warrants. The transaction closed on December 23, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise of Stock Options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2024, certain outstanding options were exercised for 25,602 shares of common stock providing aggregate proceeds to the Company of approximately <span style="-sec-ix-hidden:Hidden_8t_mC5yobUSo0_SotysiiQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$62,000</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise of Pre-funded Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2025, certain outstanding pre-funded warrants were exercised for 605,830 shares of common stock providing aggregate proceeds to the Company of $605.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has authorized up to 5,000,000 shares of preferred stock, $0.001 par value per share, for issuance. The preferred stock will have such rights, privileges and restrictions, including voting rights, dividend conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company&#8217;s board of directors upon its issuance. To date, the Company has not issued any preferred shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrant Summary</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the total warrants outstanding at December 31, 2025:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> as of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> as of</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price Per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">New</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issue Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td></tr><tr style=""><td style="vertical-align:top;width:34.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Private placement warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">5 years</span><span style="font-size:8pt;"> from shareholder approval</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,031,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,031,250</p></td></tr><tr style=""><td style="vertical-align:top;width:34.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Pre-funded warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">5 years</span><span style="font-size:8pt;"> from shareholder approval</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,247,445</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (605,830)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,641,615</p></td></tr><tr style=""><td style="vertical-align:bottom;width:34.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,278,695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (605,830)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,672,865</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK BASED COMPENSATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;8:&#160;&#160;&#160;&#160;STOCK BASED COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 19, 2020, the Board adopted the 2020 Equity Incentive Plan (&#8220;2020 Equity Incentive Plan&#8221;) which replaced the 2014 Omnibus Stock Option Plan. The 2020 Plan was further amended effective May 2022 to increase the number of shares of common stock authorized for issuance under the plan by 850,000 shares. The 2020 Equity Incentive Plan allows for grants of stock options, restricted shares, stock bonuses and other equity-based awards to employees and non-employee directors of the Company. Awards under the 2020 Equity Incentive Plan may be at prices and for terms as determined by the Company&#8217;s board of directors and may have vesting requirements as determined by the Board, provided that the exercise price for any stock option must be at least equal to the fair market value (as defined in the 2020 Plan) of a share of the stock on the grant date. Once granted, the exercise price of an option may not be reduced without the approval of the Company&#8217;s stockholders, other than under certain limited circumstances such as a stock split or take any other action with respect to a stock option that would be treated as a repricing under the rules and regulations of the Nasdaq Stock Exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Options granted under the 2020 Equity Incentive Plan have a maximum term of ten years from the date of grant and generally vest over four years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2025 Equity Incentive Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 12, 2025, pursuant to the Company&#8217;s 2020 Equity Incentive Plan, as amended, the compensation committee of the Company&#8217;s board of directors approved 50,000 options to purchase the Company&#8217;s common stock as equity-based incentive awards to the Company&#8217;s Chief Executive Officer and President, Dr. Juan Vera, and 30,000 options to purchase the Company&#8217;s common stock as equity-based incentive awards to each Non-Employee Director. Each option award was granted with an exercise price of $1.59 per share, the closing price of the Company&#8217;s common stock on the Nasdaq Capital Market on February 12, 2025, with the option award vesting in three annual installments, subject to such Optionee&#8217;s continued service on the applicable vesting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 31, 2025, the board of directors (the &#8220;Board&#8221;) of the Company appointed Ms. Kathryn Penkus Corzo to the Company&#8217;s Board, effective November 1, 2025. In connection with the appointment of Kathryn Penkus Corzo to the Company&#8217;s Board and pursuant to the Company&#8217;s 2020 Equity Incentive Plan, the Company granted Ms. Corzo 147,611 stock options to purchase shares of the Company&#8217;s common stock at an exercise price per share equal to the fair market value per share on the date she was appointed to the Board. The options will vest evenly over thirty-six (36) months and are subject to her continued service as a director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 31, 2025, the Compensation Committee and Board approved a discretionary award of 250,000 stock options at an exercise price per share equal to the fair market value per share on the date of the grant (the &#8220;CEO Options&#8221;) to Dr. Juan Vera under the Company&#8217;s 2020 Plan. The CEO Options vest annually over four years beginning on the anniversary of the grant date of the CEO Options and are subject to the terms and conditions of the 2020 Plan and the Company&#8217;s form of option award agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 17, 2025, the Compensation Committee of the Board approved additional grant awards to each Non-Employee Director apart from Ms. Corzo. The Company granted each Non-Employee Director a total of 221,741 stock options to purchase shares of the Company&#8217;s common stock at an exercise price per share equal to the fair market value per share on the grant date, or $0.9548. The options vest fully in one annual installment, subject to such Optionee&#8217;s continued service through the vesting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2025, approximately 0.1 million shares of common stock are available to be issued under the 2020 Equity Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Options </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of the Company&#8217;s stock option activity for the years ended December 31, 2025 and December 31, 2024, is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Intrinsic Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 737,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,317,234</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.6</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,602)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Canceled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (124,589)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 587,704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 377,767</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.8</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,202,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Canceled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27,660)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,762,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 563,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.5</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 461,202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.6</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Black-Scholes option pricing model is used to estimate the fair value of stock options granted under the Company&#8217;s share-based compensation plans. The weighted average assumptions used in calculating the fair values of stock options that were granted during the years ended December 31, 2025 and 2024, respectively, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected stock price volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 104.82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth stock-based compensation expenses recorded during the respective periods:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock Compensation expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 308,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,247</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 229,472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230,617</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 537,540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 245,864</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the year ended December 31, 2025, the Company recorded incremental stock-based compensation expense of $0.3 million pertaining to the modification of stock options in connection with certain consultants. The modification resulted in an acceleration of $0.3 million in compensation expense that was immediately recognized, and is reflected in operating expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At December 31, 2025, the total stock-based compensation cost related to unvested awards not yet recognized was $0.9 million. The expected weighted average period for compensation costs to be recognized was 1.8 years. Future option grants will impact the compensation expense recognized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GRANT INCOME<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>GRANT INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">GRANT INCOME</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 9: GRANT INCOME</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Grant Income represents funding under cost reimbursement programs from government agencies and non-profit foundations for qualified research and development activities performed by the Company. Revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract (see Note 3). If restricted cash is received from grants in advance of incurring qualifying costs, it is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. The Company had $1.0 million of restricted cash recorded as of December 31, 2025, and none recorded as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes grant income recorded for the years ended December 31, 2025 and 2024, by grant:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">CPRIT AML Grant<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 900,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,411,149</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">FDA Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 118,478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 519,750</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">SBIR AML Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 472,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 982,182</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Decoy Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 391,305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,822</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">SBIR NHL Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 665,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 665,000</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">PANACEA Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 425,670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,177</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">CPRIT Pancreatic Grant<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 573,994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,546,669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,591,080</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>Both CPRIT grants are subject to certain revenue-sharing arrangements, as per the grant agreements (see Note 10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If qualifying grant income is earned in advance of cash received from grants, it is recognized as revenue and recorded as other receivable (see Note 5).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;10:&#160;&#160;&#160;&#160;COMMITMENTS AND CONTINGENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cancer Prevention and Research Institute of Texas</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from CPRIT to support the Company&#8217;s clinical investigation of MT-401 (the &#8220;CPRIT AML Grant&#8221;). In December 2024, the Company received notice of an additional $9.5 million grant from CPRIT to support the clinical investigation of MT-601 in patients with pancreatic </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">cancer (&#8220;the CPRIT Pancreatic Grant&#8221;). Both CPRIT grants contain identical terms surrounding intellectual property and revenue sharing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Per the CPRIT grant agreements, the Company will retain ownership over any intellectual property developed under the contracts (the &#8220;Project Results&#8221;). With respect to non-commercial use of any Project Results, the Company agreed to grant to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with the right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, solely for academic, research, and other non-commercial purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the Company&#8217;s products become commercially saleable, the Company is obligated to make payments to CPRIT, with respect to net sales of any product covered in the contract, equal to a percentage of revenue ranging from the low-to-mid single digits. These payments will continue up to and until CPRIT receives an aggregate amount of 400% of the sum of all monies paid to the Company by CPRIT under the grant agreements. If the Company is required to obtain a license from a third party to sell any such product, the revenue sharing percentages may be reduced. In addition, once the Company has paid CPRIT 400% of the monies received under the grant agreements, the Company will continue to pay CPRIT a revenue-sharing percentage of 0.5% for the remainder of the Revenue Term as specified in the grant agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">License Agreement with the Baylor College of Medicine</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In March 2018, the Company entered into an exclusive license agreement with BCM under which the Company acquired a worldwide, exclusive license to BCM&#8217;s rights in and to certain intellectual property rights, including a European patent to develop and commercialize MAR-T cell product candidates (the &#8220;BCM License Agreement&#8221;). In exchange for the license, the Company issued shares of its common stock to BCM valued at approximately $5.0 million at the time of issuance, agreed to make royalty payments to BCM upon commercial sales according to the royalty schedule in the BCM License Agreement, under which the royalty percentages increase in proportion to the aggregate net sales, and agreed to pay BCM certain milestone payments up to an aggregate of $64.85 million. The milestone payments are based upon the occurrence of nine particular milestones relating to completion of the first dosing in clinical trials for a first and second distinct product, FDA approval, and achievement of certain net sales goals. The Company is also responsible for sublicensing fees and for reimbursing BCM for related-party expenses. In addition, upon a liquidity event (as defined in the BCM License Agreement) of the Company, BCM will receive a one-time liquidity incentive payment of 0.5% of the liquidity event proceeds (as defined in the BCM License Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Legal Proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, we may become involved in legal proceedings, including those arising in the ordinary course of our business. We are not currently a party to any material legal proceedings that we believe could have an adverse effect on our business, operating results or financial condition.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;11:&#160;&#160;&#160;&#160;RELATED PARTY TRANSACTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth related party transaction expenses recorded for the years ended December 31, 2025 and 2024, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baylor College of Medicine</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,218,138</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,723</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cell Ready</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,266,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,846,456</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Wilson Wolf Manufacturing Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,543</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,568,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,853,179</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;">As of December 31, 2025 and 2024, nil and $1.7 million, respectively, of related party transactions are included in accounts payable and accrued liabilities. See Note 6 for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreements with The Baylor College of Medicine (&#8220;BCM&#8221;)</i><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November&#160; 2018, January 2020 and February 2020, the Company entered in Sponsored Research Agreements with BCM, which provided for the conduct of research for the Company by credentialed personnel at BCM&#8217;s Center for Cell and Gene Therapy. On April 1, 2025, the Company sighed Amendment #1 to the Sponsored Research and Product Development Agreement with BCM to perform research on &#8220;Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T-Cell Product Strategy.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2019, May 2020 and July 2021, the Company entered into Clinical Supply Agreements with BCM, which provided for BCM to provide to the Company multi tumor antigen specific products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2019, the Company entered in a Workforce Grant Agreement with BCM, which provided for BCM to provide to the Company manpower costs of projects for manufacturing, quality control testing and validation run activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2020, the Company entered in a Clinical Trial Agreement with BCM, which provided for BCM to provide to the Company investigator-initiated research studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has also entered into a Clinical Site Agreement and Laboratory Service Agreement with BCM, pursuant to which BCM conducts clinical trials for the Company and testing of Marker&#8217;s product candidates to develop an optimized potency assay.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">BCM is also a shareholder of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the years ended December 31, 2025 and 2024, the Company incurred $3.2 million and $7,000 in expenses related to services and manufacturing costs and paid BCM approximately $3.0 million and $0.1 million for invoices received, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchases from Wilson Wolf</i><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In 2025, the Company utilized Wilson Wolf for the purchases of cell culture devices. Mr. John Wilson is a former director of the Company and is serving as the CEO of Wilson Wolf Manufacturing Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the years ended December 31, 2025 and 2024, the Company incurred approximately $0.1 million and nil, respectively, in expenses related to cell culture devices and paid Wilson Wolf approximately $0.1 million and nil respectively, for invoices received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchases from Cell Ready, LLC.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has utilized Cell Ready, LLC for clinical manufacturing supply and product development. Cell Ready, which is owned by a former director, Mr. John Wilson, is a contract development and manufacturing organization (&#8220;CDMO&#8221;). On February 22, 2024, the Company entered into a 3-year Master Services Agreement for Product Supply (the &#8220;MSA&#8221;) with Cell Ready. During the years ended December 31, 2025 and 2024, the Company incurred $0.8 million and $5.8 million in expenses related to services and manufacturing costs, respectively, and paid $2.6 million and $5.5 million for invoices received, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On March 27, 2025, the Company mutually agreed with Cell Ready to terminate the MSA. In connection therewith, the Company entered into a settlement and release agreement with Cell Ready pursuant to which the Company paid Cell Ready approximately $453,000 and the parties provided one another with mutual releases of all claims associated with any and all agreements between the Company and Cell Ready.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;12:&#160;&#160;&#160;&#160;INCOME TAXES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has no federal income tax expense due to operating losses incurred for the years ended December 31, 2025, and 2024, respectively. The Company recognized ($15,156) and $49,953 in state tax (benefit) expense for the years ended December 31, 2025 and 2024, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The effects of temporary differences that give rise to significant portions of the deferred tax assets as of December 31, 2025 and 2024 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended </b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred Tax Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net Operating Loss Carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,896,185</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,724,771</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock Compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,548,803</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,670,477</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized R&amp;E</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,868,640</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 811,961</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 733,328</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,325,798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,997,216</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Valuation Allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43,325,798)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(40,997,216)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Deferred Tax Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Deferred Tax Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Deferred Tax Assets/(Liabilities)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the history of losses, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized and has established a full valuation allowance for the years ended December 31, 2025 and 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Company has approximately $186.8 million of federal and $38.6 million of state Net Operating Losses (&#8220;NOL&#8221;s) that may be available to offset future taxable income, if any. The federal net operating loss carryforwards of $38.4 million, if not utilized, will expire between 2030 and 2037. The federal net operating loss carryforwards of $148.4 million generated in 2018 and thereafter are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely. The state net operating loss carryforwards of $21.9 million, if not utilized, will begin to expire in 2035. The state net operating loss carryforwards of $16.7 million generated in 2018 and thereafter are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has federal and state research and development tax credit carryforwards of $0.7 million and $0.1 million, respectively, available to offset future federal income taxes. The research and development tax credit carryforwards begin to expire in 2030.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">In accordance with Section&#160;382 of the Internal Revenue code, the usage of the Company&#8217;s net operating loss carryforwards may be limited in the event of a change in ownership. A full Section&#160;382 analysis has not been prepared and NOLs could be subject to limitation under Section&#160;382.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">On July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was signed into law. Key corporate tax provisions include the restoration of 100% bonus depreciation, immediate expensing for domestic research and experimental expenditures, changes to Section 163(j) interest limitations, updates to Global Intangible Low-Taxed Income and Foreign-Derived Intangible Income rules, amendments to energy credits, and expanded Section 162(m) aggregation requirements. In accordance with Accounting Standards Codification 740, Income Taxes (&#8220;ASC 740&#8221;), the effects of the new tax law were recognized in the period of enactment. Due to the Company&#8217;s valuation allowance position, the provisions of the OBBBA did not have an impact on the Company&#8217;s income tax provision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Company&#8217;s income tax returns for 2022 to 2024 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the years ended December 31, 2025, and 2024, the expected tax (benefit) expense based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:43.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pretax Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pretax Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,557,543)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,243,086)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15,156)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,336,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19.30)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,271,570</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11.90)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nontaxable or nondeductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 90,207</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.70)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.30)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">SBC cancellations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 130,732</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 943,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8.77)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision/(benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15,156)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.00)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.47)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognized approximately $15,156 in state tax benefit for the year ended December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, the Company updated the presentation of its effective tax rate reconciliation to reflect the standardized categories required by the new guidance. The effective tax rate reconciliation for the year ended December 31, 2024 has been recast for comparative purposes to conform to the current-year presentation. The recast was solely for presentation purposes and did not result in any changes to the Company&#8217;s previously reported income tax expense, effective tax rate, or other financial statement amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. As of December 31, 2025, and 2024, there were no unrecognized tax benefits. The Company recognizes accrued interest and penalties as income tax expense. No amounts were accrued for the payment of interest and penalties at December 31, 2025 and 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position in the next year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth a summary of income tax payments made and income tax refunds received during the year ended December 31, 2025, and 2024 as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.12%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payment (Refund)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payment (Refund)</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Amount</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Jurisdiction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Texas</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other US States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,150</p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Income Taxes Paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72,150</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">NOTE 13:&#160;&#160;&#160;&#160;SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has evaluated subsequent events and transactions that occurred up to the date these consolidated financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment to or disclosure in the unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the Securities Exchange Commission (&#8220;SEC&#8221;). Any reference </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">in these footnotes to applicable guidance is meant to refer to the authoritative U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy,&#160;Inc. and GeneMax Pharmaceuticals&#160;Inc.&#160;&#8211; a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada,&#160;Inc. All significant intercompany balances and transactions are eliminated upon consolidation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accordingly, actual results may differ materially from those estimates. Management considers many factors in selecting appropriate financial accounting policies, controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation expense and income taxes.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents, Restricted Cash, and Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash, Cash Equivalents, Restricted Cash, and Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash, cash equivalents, and restricted cash at December 31, 2025 consisted of cash and certificates of deposit in institutions in the United States. The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limits of $250,000. As of December 31, 2025, the Company had approximately $1.6 million in cash at financial institutions, including $1.0 million of restricted cash at financial institutions, and approximately $15.4 million in U.S. government agency securities, for aggregate cash, cash equivalents, and restricted cash of $17.0 million. As of December 31, 2024, the Company had approximately $1.1 million in cash at financial institutions and approximately $18.1 million in U.S. government agency securities, for aggregate cash and cash equivalents of $19.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event cash is received from grants in advance of incurring qualifying costs, it is recorded as restricted cash until it is earned and recorded to grant income.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Modification of Stock Options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Modification of Stock Options </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2025, the Company recorded incremental stock-based compensation expense of $0.3 million pertaining to the modification of stock options in connection with certain consultants. The modification provided for an acceleration of unvested options, resulting in $0.3 million in compensation expense that was immediately recognized, and is reflected in operating expenses.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patents and Patent Application Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patents and Patent Application Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company incurs stock-based compensation expense related to the issuance of common stock and stock options. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Term</i> &#8212; The expected life of stock options was estimated using the &#8220;simplified method,&#8221; as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Volatility</i> &#8212; The Company computes stock price volatility over expected terms based on its historical common stock trading prices. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i> &#8212; The Company bases the risk-free interest rate on the implied yield available on U.S. Treasury zero-coupon issues with an equivalent remaining term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Dividend</i> &#8212; The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company amortizes the fair value of the awards expected to vest on a straight-line basis over the requisite service period of the awards. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received as if the Company had paid cash for those services. Forfeitures are accounted for as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of costs associated with clinical trial programs. Costs incurred by third parties are expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the clinical trial or project and the invoices received from its external service providers. The Company estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each project and total project spending. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone events are achieved.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable income in the years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the date of allowances against deferred tax assets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for &#8220;unrecognized tax benefits&#8221; is recorded for any tax benefits claimed in the Company&#8217;s tax returns that do not meet these recognition and measurement standards. As of December 31, 2025 and 2024, no liability for unrecognized tax benefits was required to be reported. The guidance also discusses the classification of related interest and penalties on income taxes. The Company&#8217;s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the years ended December 31, 2025 and 2024.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantIncomePolicyPolicyTextBlock', window );">Grant Income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Grant Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Grant Income represents funding under cost reimbursement programs from government agencies and non-profit foundations for qualified research and development activities performed by the Company. In applying the provisions of ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company determined that grants and awards are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#8220;customer&#8221;, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to each grant or award, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;). For grant and awards outside the scope of ASC 808, the Company applies either ASC 606 or IAS 20 by analogy depending on if the arrangement is considered an exchange or non-exchange transaction, respectively. Under both accounting frameworks, revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract. During the two years ended December 31, 2025, the Company did not participate in any collaboration agreements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per Common Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Loss per Common Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per share includes only the weighted average common shares outstanding, without consideration of potentially dilutive securities. Diluted loss per share includes the weighted average common shares outstanding and any potentially dilutive common stock equivalent shares in the calculation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an entity for which separate discrete financial information is made available and that is regularly evaluated by the chief operating decision maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The Company is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company&#8217;s operations are organized and reported as a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its products. The Company&#8217;s CODM, its chief executive officer, reviews operating results on an aggregate basis and manages the operations as a single operating segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accounting policies of the Company&#8217;s single operating and reportable segment are the same as those described in the summary of significant accounting policies. The measure of segment assets is reported on the consolidated balance sheets as total assets. The CODM evaluates performance and allocates resources based on consolidated net income (loss) that also is reported on the consolidated statements of operations as net loss, and consolidated cash used in operations. The CODM makes operating decisions based on the availability of cash and the allocation of cash to the required expenditures. The significant expenses regularly reviewed by the CODM are consistent with those reported on the Company&#8217;s consolidated statements of operations, and expenses are not regularly reviewed on a more disaggregated basis for purposes of assessing segment performance and deciding how to allocate resources.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Standards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">New Accounting Standards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_RecentlyIssuedAccountingStandardsAdoptedPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently Adopted Accounting Standards</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Improvements to Income Tax Disclosures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. Effective January 1, 2025, the Company adopted the new standard and applied it retrospectively to prior periods presented. The Company does not believe the new disclosure requirements had a material impact to its financial positions, results of operations and cash flows.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock', window );">Recently Issued Accounting Standards Not Yet Adopted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently Issued Accounting Standards Not Yet Adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In December 2025, the FASB issued ASU 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities. The new standard is intended to establish authoritative guidance on the accounting for government grants received by business entities and reduce diversity in practice. The amendments establish the timing and methods of recognition of both (1) a grant related to an asset and (2) a grant related to income. The amendments also require certain disclosures including the nature of the grant received, the accounting policies used to account for the grant, and significant terms and conditions for the grant. The new guidance is effective for annual reporting periods beginning after December 15, 2028, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The new guidance may be applied on a modified prospective basis, modified retrospective basis, or full retrospective basis. The Company is currently evaluating the impact of ASU 2025-10 on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures, to improve transparency in financial reporting by requiring entities to present more detailed information about the nature of expenses included within the Income Statement. The guidance will be effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. The Company is in the process of assessing the impact of ASU 2024-03 on its disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">U.S Tax Law Changes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was enacted, introducing significant changes to U.S. tax law, including provisions related to bonus depreciation, interest expense limitations, and the treatment of domestic research and development expenditures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company evaluated the legislation in accordance with ASC 740 and determined that the enactment did not have a material impact on its financial statements for the year ended December 31, 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GrantIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for grant income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GrantIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RecentlyIssuedAccountingStandardsAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recently issued accounting standards adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RecentlyIssuedAccountingStandardsAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recently issued accounting standards not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award granted to director under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,163,620)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,731,315)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,310,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8,980,207</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average common shares outstanding, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,310,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8,980,207</p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net earnings (loss) per share:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.79)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.19)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,762,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 587,704</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,031,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,278,695</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Potentially dilutive securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,794,128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,866,399</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER RECEIVABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ScheduleOfOtherReceivablesCurrentTableTextBlock', window );">Schedule of company's other receivable balance</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant income receivable:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">CPRIT AML Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 815,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,059,457</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">FDA Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">SBIR AML Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 162,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 244,810</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Decoy Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59,501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,822</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">SBIR NHL Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87,417</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">PANACEA Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 190,052</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,502</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total grant income receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,318,981</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,316,591</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,112</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,369,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,346,703</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ScheduleOfOtherReceivablesCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other receivables classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ScheduleOfOtherReceivablesCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accounts payable, accrued liabilities, and related party payable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 793,727</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,066,395</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 86,350</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 160,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 293,189</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_dTBoH9MfTE64AKs-oLTQIA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Related party payable</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,710,500</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Tax fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,638</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 104,591</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 203,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 203,429</p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,299,384</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,464,454</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of warrants outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> as of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> as of</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price Per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">New</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issue Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td></tr><tr style=""><td style="vertical-align:top;width:34.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Private placement warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">5 years</span><span style="font-size:8pt;"> from shareholder approval</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,031,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,031,250</p></td></tr><tr style=""><td style="vertical-align:top;width:34.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Pre-funded warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">5 years</span><span style="font-size:8pt;"> from shareholder approval</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,247,445</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (605,830)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,641,615</p></td></tr><tr style=""><td style="vertical-align:bottom;width:34.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,278,695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (605,830)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,672,865</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of the company's stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Intrinsic Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 737,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,317,234</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.6</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,602)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Canceled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (124,589)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 587,704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 377,767</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.8</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,202,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Canceled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27,660)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,762,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 563,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.5</p></td></tr><tr style=""><td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 461,202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.6</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions used in calculating the fair values of stock options that were granted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected stock price volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 104.82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationExpensesTableTextBlock', window );">Schedule of stock-based compensation expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock Compensation expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 308,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,247</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 229,472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230,617</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 537,540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 245,864</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_StockBasedCompensationExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of stock based compensation expenses recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_StockBasedCompensationExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GRANT INCOME (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>GRANT INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summarizes grant income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">CPRIT AML Grant<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 900,014</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,411,149</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">FDA Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 118,478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 519,750</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">SBIR AML Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 472,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 982,182</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Decoy Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 391,305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,822</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">SBIR NHL Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 665,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 665,000</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">PANACEA Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 425,670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,177</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">CPRIT Pancreatic Grant<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 573,994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,546,669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,591,080</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>Both CPRIT grants are subject to certain revenue-sharing arrangements, as per the grant agreements (see Note 10).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related party transaction expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baylor College of Medicine</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,218,138</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,723</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cell Ready</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,266,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,846,456</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Wilson Wolf Manufacturing Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,543</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,568,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,853,179</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended </b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred Tax Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net Operating Loss Carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,896,185</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,724,771</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock Compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,548,803</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,670,477</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized R&amp;E</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,868,640</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 811,961</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 733,328</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,325,798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,997,216</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Valuation Allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (43,325,798)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(40,997,216)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Deferred Tax Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Deferred Tax Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Deferred Tax Assets/(Liabilities)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of expected tax (benefit) expense based on the U. S. federal statutory rate reconciled with the actual tax provision (benefit)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:43.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pretax Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pretax Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,557,543)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,243,086)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15,156)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,336,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19.30)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,271,570</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11.90)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nontaxable or nondeductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 90,207</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.70)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.30)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">SBC cancellations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 130,732</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 943,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8.77)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision/(benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15,156)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.00)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.47)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_IncomeTaxPaymentsByJurisdictionTableTextBlock', window );">Summary of income tax payments made and income tax refunds received by jurisdiction</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.12%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payment (Refund)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payment (Refund)</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Amount</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Jurisdiction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Texas</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other US States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,150</p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Income Taxes Paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72,150</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_IncomeTaxPaymentsByJurisdictionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income tax payments by jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_IncomeTaxPaymentsByJurisdictionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 26, 2025</div></th>
<th class="th"><div>Jul. 21, 2025</div></th>
<th class="th"><div>Dec. 23, 2024</div></th>
<th class="th"><div>Dec. 19, 2024</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,042,847<span></span>
</td>
<td class="nump">$ 19,192,440<span></span>
</td>
<td class="nump">$ 15,111,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,863,883<span></span>
</td>
<td class="nump">14,929,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Product development research award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromCpritGrant', window );">Funds received from CPRIT grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrkr_ControlledEquityOfferingSalesAgreementMember', window );">ATM Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,358,292<span></span>
</td>
<td class="nump">8,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrkr_AtMarketOfferingMember', window );">Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,431,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent', window );">Commission rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrkr_AtMarketOfferingMember', window );">Market Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="nump">3,734,217<span></span>
</td>
<td class="nump">1,624,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,358,292<span></span>
</td>
<td class="nump">8,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,900,000<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from the sale of securities</a></td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from the sale of securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,900,000<span></span>
</td>
<td class="nump">$ 14,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Pre Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Issuance of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,247,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Private Placement Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Issuance of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,031,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,783,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_FdaGrantMember', window );">FDA Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantReceived', window );">Grant income received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember', window );">SBIR AML Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantReceived', window );">Grant income received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember', window );">National Institutes of Health National - Cancer Institute Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantReceived', window );">Grant income received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantAssistanceTerm', window );">Grant assistance term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember', window );">SBIR lymphoma grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantReceived', window );">Grant income received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember', window );">SBIR pancreatic cancer grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantReceived', window );">Grant income received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_AdditionalCpritGrantMember', window );">Additional CPRIT grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember', window );">Sales Agents | ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent', window );">Commission rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percent of calculation of compensation rate by using gross sales price per share sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FundsReceivedFromCpritGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds received from grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FundsReceivedFromCpritGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FundsReceivedFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds received from grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FundsReceivedFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GrantAssistanceTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Duration of grant assistance transaction, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GrantAssistanceTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of grant income transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrkr_ControlledEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrkr_ControlledEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrkr_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrkr_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mrkr_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mrkr_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mrkr_PrivatePlacementWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mrkr_PrivatePlacementWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_FdaGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_FdaGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_AdditionalCpritGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_AdditionalCpritGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC insured amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CashAtFinancialInstitutions', window );">Cash at financial institutions</a></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">974,799<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue', window );">Government agency securities</a></td>
<td class="nump">15,400,000<span></span>
</td>
<td class="nump">18,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">17,042,847<span></span>
</td>
<td class="nump">19,192,440<span></span>
</td>
<td class="nump">$ 15,111,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">16,068,048<span></span>
</td>
<td class="nump">19,192,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_CashAtFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash held at financial institutions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_CashAtFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt securities issued by a United States government agency such as Government National Mortgage Association (Ginnie Mae), Federal Home Loan Mortgage Corporation (Freddie Mac), and Federal National Mortgage Association (Fannie Mae), which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Computation of loss per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,163,620)<span></span>
</td>
<td class="num">$ (10,731,315)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">15,310,308<span></span>
</td>
<td class="nump">8,980,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">15,310,308<span></span>
</td>
<td class="nump">8,980,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net earnings (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (1.19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (1.19)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToParentDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Anti-dilutive securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">6,794,128<span></span>
</td>
<td class="nump">8,866,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">1,762,878<span></span>
</td>
<td class="nump">587,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">5,031,250<span></span>
</td>
<td class="nump">8,278,695<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER RECEIVABLE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesWithImputedInterestLineItems', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Total grant income receivable</a></td>
<td class="nump">$ 1,318,981<span></span>
</td>
<td class="nump">$ 2,316,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">50,419<span></span>
</td>
<td class="nump">28,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Total other receivable</a></td>
<td class="nump">1,369,400<span></span>
</td>
<td class="nump">2,346,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember', window );">CPRIT AML</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesWithImputedInterestLineItems', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Total grant income receivable</a></td>
<td class="nump">815,436<span></span>
</td>
<td class="nump">2,059,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=mrkr_FdaGrantMember', window );">FDA Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesWithImputedInterestLineItems', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Total grant income receivable</a></td>
<td class="nump">3,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember', window );">SBIR AML</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesWithImputedInterestLineItems', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Total grant income receivable</a></td>
<td class="nump">162,897<span></span>
</td>
<td class="nump">244,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember', window );">Decoy Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesWithImputedInterestLineItems', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Total grant income receivable</a></td>
<td class="nump">59,501<span></span>
</td>
<td class="nump">5,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember', window );">SBIR NHL Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesWithImputedInterestLineItems', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Total grant income receivable</a></td>
<td class="nump">87,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember', window );">PANACEA Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesWithImputedInterestLineItems', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Total grant income receivable</a></td>
<td class="nump">$ 190,052<span></span>
</td>
<td class="nump">$ 6,502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesWithImputedInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesWithImputedInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=mrkr_FdaGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=mrkr_FdaGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_AccountsPayableAndAccruedLiabilitiesLineItems', window );"><strong>ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 793,727<span></span>
</td>
<td class="nump">$ 1,066,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="nump">87,083<span></span>
</td>
<td class="nump">86,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">$ 160,008<span></span>
</td>
<td class="nump">293,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,710,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration', window );">Other Liability, Current, Related Party, Type [Extensible Enumeration]</a></td>
<td class="text">Related party<span></span>
</td>
<td class="text">Related party<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_TaxFeesPayable', window );">Tax fees</a></td>
<td class="nump">$ 54,638<span></span>
</td>
<td class="nump">$ 104,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">203,928<span></span>
</td>
<td class="nump">203,429<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent', window );">Total accounts payable, accrued liabilities and related party payable</a></td>
<td class="nump">$ 1,299,384<span></span>
</td>
<td class="nump">3,464,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_AccountsPayableAndAccruedLiabilitiesLineItems', window );"><strong>ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_AccountsPayableAndAccruedLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_AccountsPayableAndAccruedLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_TaxFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax fees payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_TaxFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates status and type of related party for liability classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 26, 2025</div></th>
<th class="th"><div>Jul. 21, 2025</div></th>
<th class="th"><div>Dec. 23, 2024</div></th>
<th class="th"><div>Dec. 19, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,863,883<span></span>
</td>
<td class="nump">$ 14,929,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">605,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,358,292<span></span>
</td>
<td class="nump">8,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mrkr_PreFundedWarrantMember', window );">Pre Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">605,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrkr_AtMarketOfferingMember', window );">Market Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="nump">3,734,217<span></span>
</td>
<td class="nump">1,624,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,358,292<span></span>
</td>
<td class="nump">8,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,900,000<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from the sale of securities</a></td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from the sale of securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,900,000<span></span>
</td>
<td class="nump">$ 14,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,783,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Pre Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Issuance of shares of common stock, warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,247,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Private Placement Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Issuance of shares of common stock, warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,031,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercised by the holders of the instruments during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mrkr_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mrkr_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrkr_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrkr_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mrkr_PrivatePlacementWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mrkr_PrivatePlacementWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Warrant Summary (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ClassOfWarrantOrRightRollForward', window );"><strong>Class of Warrant or Right [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at the beginning</a></td>
<td class="nump">8,278,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="num">(605,830)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at the end</a></td>
<td class="nump">7,672,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mrkr_PrivatePlacementWarrantMember', window );">Private placement warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ClassOfWarrantOrRightRollForward', window );"><strong>Class of Warrant or Right [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at the beginning</a></td>
<td class="nump">5,031,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at the end</a></td>
<td class="nump">5,031,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mrkr_PreFundedWarrantMember', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ClassOfWarrantOrRightRollForward', window );"><strong>Class of Warrant or Right [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at the beginning</a></td>
<td class="nump">3,247,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="num">(605,830)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at the end</a></td>
<td class="nump">2,641,615<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercised by the holders of the instruments during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ClassOfWarrantOrRightRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ClassOfWarrantOrRightRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mrkr_PrivatePlacementWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mrkr_PrivatePlacementWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mrkr_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mrkr_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK BASED COMPENSATION - Stock option activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>STOCK BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Beginning Balance</a></td>
<td class="nump">587,704<span></span>
</td>
<td class="nump">737,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="nump">1,202,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,602)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Canceled/Expired</a></td>
<td class="num">(27,660)<span></span>
</td>
<td class="num">(124,589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Ending Balance</a></td>
<td class="nump">1,762,878<span></span>
</td>
<td class="nump">587,704<span></span>
</td>
<td class="nump">737,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Options vested and exercisable</a></td>
<td class="nump">461,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Outstanding, Beginning Balance</a></td>
<td class="nump">$ 22.85<span></span>
</td>
<td class="nump">$ 25.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Granted</a></td>
<td class="nump">1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Canceled/Expired</a></td>
<td class="nump">35.66<span></span>
</td>
<td class="nump">42.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Outstanding, Ending Balance</a></td>
<td class="nump">7.77<span></span>
</td>
<td class="nump">$ 22.85<span></span>
</td>
<td class="nump">$ 25.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options vested and exercisable</a></td>
<td class="nump">$ 26.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Total Intrinsic Value Outstanding</a></td>
<td class="nump">$ 563,368<span></span>
</td>
<td class="nump">$ 377,767<span></span>
</td>
<td class="nump">$ 1,317,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Total Intrinsic Value, Options vested and exercisable</a></td>
<td class="nump">$ 7,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding (in years)</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Options vested and exercisable (in years)</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK BASED COMPENSATION - Weighted average assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 1.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">104.82%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate of interest</a></td>
<td class="nump">3.88%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK BASED COMPENSATION - Stock-based compensation expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>STOCK BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock compensation expenses</a></td>
<td class="nump">$ 537,540<span></span>
</td>
<td class="nump">$ 245,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>STOCK BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock compensation expenses</a></td>
<td class="nump">308,068<span></span>
</td>
<td class="nump">15,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>STOCK BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock compensation expenses</a></td>
<td class="nump">$ 229,472<span></span>
</td>
<td class="nump">$ 230,617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK BASED COMPENSATION - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 17, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 01, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 12, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 19, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>STOCK BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted to director amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,202,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental stock-based compensation expense in connection with the termination of certain employees | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Acceleration of compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total stock-based compensation cost related to unvested awards not yet recognized | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period of recognition of unrecognized compensation costs (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrkr_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>STOCK BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued', window );">Number of shares options available to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrkr_EquityIncentiveAward2025Member', window );">2025 Equity Incentive Awards | 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>STOCK BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments', window );">Number of annual vesting periods | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrkr_EquityIncentiveAward2025Member', window );">2025 Equity Incentive Awards | 2020 Equity Incentive Plan | Employees | Chief Executive Officer, President and Chairman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>STOCK BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of options to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted to director amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrkr_EquityIncentiveAward2025Member', window );">2025 Equity Incentive Awards | 2020 Equity Incentive Plan | Non employee | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>STOCK BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments', window );">Number of annual vesting periods | $</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of options to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted | $ / shares</a></td>
<td class="nump">$ 0.9548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted to director amount</a></td>
<td class="nump">221,741<span></span>
</td>
<td class="nump">147,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of annual vesting installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement number of share options available for issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrkr_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrkr_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mrkr_EquityIncentiveAward2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mrkr_EquityIncentiveAward2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GRANT INCOME (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">$ 974,799<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">3,546,669<span></span>
</td>
<td class="nump">6,591,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember', window );">CPRIT AML</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">900,014<span></span>
</td>
<td class="nump">4,411,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_FdaGrantMember', window );">FDA Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">118,478<span></span>
</td>
<td class="nump">519,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember', window );">SBIR AML Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">472,208<span></span>
</td>
<td class="nump">982,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember', window );">Decoy Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">391,305<span></span>
</td>
<td class="nump">5,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember', window );">SBIR NHL Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">665,000<span></span>
</td>
<td class="nump">665,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember', window );">PANACEA Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">425,670<span></span>
</td>
<td class="nump">7,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrkr_CpritPancreaticGrantMember', window );">CPRIT Pancreatic Grant1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">573,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">$ 3,546,669<span></span>
</td>
<td class="nump">$ 6,591,080<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_FdaGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_FdaGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrkr_CpritPancreaticGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrkr_CpritPancreaticGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember', window );">Cancer Prevention and Research Institute of Texas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommitmentsAndContingenciesLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantReceived', window );">Grant income received</a></td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="nump">$ 13,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived', window );">Aggregate amount (in Percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm', window );">Revenue sharing percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mrkr_BaylorCollegeOfMedicineLicenseAgreementMember', window );">License agreement with Baylor College of Medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommitmentsAndContingenciesLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_SaleOfStockValueOfSharesIssuedInTransaction', window );">Shares issued in common stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_LicenseAgreementLiquidityIncentivePaymentPercentage', window );">Liquidity incentive payment in percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mrkr_BaylorCollegeOfMedicineLicenseAgreementMember', window );">License agreement with Baylor College of Medicine | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommitmentsAndContingenciesLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid', window );">Milestone payments agreed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,850<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of net sales of any product to the grants received by the entity for which payments have to be made as per the terms of the grant agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of revenue sharing by the entity with the counter party for the remainder revenue term as per the terms of the grant agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of grant income transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_LicenseAgreementLiquidityIncentivePaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of the liquidity event proceeds that will be paid as a one-time liquidity incentive payment by the entity as per the terms of the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_LicenseAgreementLiquidityIncentivePaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of the milestone payments agreed to be paid by the entity as per the terms of the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_SaleOfStockValueOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of shares issued or sold by the entity for the stock transaction during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_SaleOfStockValueOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mrkr_BaylorCollegeOfMedicineLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mrkr_BaylorCollegeOfMedicineLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 27, 2025</div></th>
<th class="th"><div>Feb. 22, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total related party expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,568,485<span></span>
</td>
<td class="nump">$ 5,853,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,710,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GainLossOnEarlyTerminationOfVendorAgreement', window );">Gain (loss) on early termination of vendor agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(453,135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrkr_CellReadyAgreementMember', window );">Cell Ready Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_MasterServicesAgreementTerm', window );">Master Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Service and manufacturing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_InvoicesReceivedForServicesAndManufacturingCosts', window );">Paid invoices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember', window );">Baylor College of Medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total related party expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,218,138<span></span>
</td>
<td class="nump">6,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_CellReadyMember', window );">Cell Ready</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total related party expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,266,804<span></span>
</td>
<td class="nump">5,846,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_WilsonWolfManufacturingCorporationMember', window );">Wilson Wolf Manufacturing Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total related party expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mrkr_CellReadyAgreementMember', window );">Cell Ready Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GainLossOnEarlyTerminationOfVendorAgreement', window );">Gain (loss) on early termination of vendor agreement</a></td>
<td class="nump">$ 453,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mrkr_WilsonWolfManufacturingCorporationMember', window );">Wilson Wolf Manufacturing Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_InvoicesReceivedForServicesAndManufacturingCosts', window );">Paid invoices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Related party transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mrkr_BaylorCollegeOfMedicineMember', window );">BCM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Service and manufacturing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_InvoicesReceivedForServicesAndManufacturingCosts', window );">Paid invoices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrkr_CellReadyMember', window );">Cell Ready | Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GainLossOnEarlyTerminationOfVendorAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gain (loss) on early termination of vendor agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GainLossOnEarlyTerminationOfVendorAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_InvoicesReceivedForServicesAndManufacturingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Invoices for the cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_InvoicesReceivedForServicesAndManufacturingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_MasterServicesAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The term of the master services agreement entered into by the entity, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_MasterServicesAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrkr_CellReadyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrkr_CellReadyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_CellReadyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_CellReadyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_WilsonWolfManufacturingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_WilsonWolfManufacturingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mrkr_CellReadyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mrkr_CellReadyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mrkr_WilsonWolfManufacturingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mrkr_WilsonWolfManufacturingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mrkr_BaylorCollegeOfMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mrkr_BaylorCollegeOfMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrkr_CellReadyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrkr_CellReadyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net Operating Loss Carryforward</a></td>
<td class="nump">$ 40,896,185<span></span>
</td>
<td class="nump">$ 30,724,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_DeferredTaxStockBasedCompensation', window );">Stock Compensation</a></td>
<td class="nump">1,548,803<span></span>
</td>
<td class="nump">1,670,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized R&amp;E</a></td>
<td class="nump">29,777<span></span>
</td>
<td class="nump">7,868,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves', window );">Reserves</a></td>
<td class="nump">18,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accruals</a></td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and Development</a></td>
<td class="nump">811,961<span></span>
</td>
<td class="nump">733,328<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets</a></td>
<td class="nump">43,325,798<span></span>
</td>
<td class="nump">40,997,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation Allowance</a></td>
<td class="num">$ (43,325,798)<span></span>
</td>
<td class="num">$ (40,997,216)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_DeferredTaxStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_DeferredTaxStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Additional Information's (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State tax (benefit) expense</a></td>
<td class="num">(15,156)<span></span>
</td>
<td class="nump">49,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Deferred tax assets, operating loss carryforwards, foreign</a></td>
<td class="nump">186,800,000<span></span>
</td>
<td class="nump">38,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred tax assets, operating loss carryforwards, state and local</a></td>
<td class="nump">$ 38,600,000<span></span>
</td>
<td class="nump">21,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_TaxCreditCarryforwardsExpirationPeriod', window );">Tax credit carryforwards expiration period</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_TaxCreditCarryForwardExpirationYearRangeEnd', window );">Tax credit carryforward expiration year range end</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign tax authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 148,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OperatingLossCarryforwardsLimitationPercentage', window );">Operating loss carryforwards limitation percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and local jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 16,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OperatingLossCarryforwardsLimitationPercentage', window );">Operating loss carryforwards limitation percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_OperatingLossCarryforwardsLimitationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of limitation for operating loss carryforwards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_OperatingLossCarryforwardsLimitationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_TaxCreditCarryForwardExpirationYearRangeEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year range end.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_TaxCreditCarryForwardExpirationYearRangeEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_TaxCreditCarryforwardsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carry forward expiration year range start.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_TaxCreditCarryforwardsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of expected tax expense (benefit) from continuing operations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory rate</a></td>
<td class="num">$ (2,557,543)<span></span>
</td>
<td class="num">$ (2,243,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="num">$ (15,156)<span></span>
</td>
<td class="nump">$ 49,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit, Percent</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">$ 2,336,604<span></span>
</td>
<td class="nump">$ 1,271,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance, Percent</a></td>
<td class="num">(19.30%)<span></span>
</td>
<td class="num">(11.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Nontaxable or nondeductible items</a></td>
<td class="nump">$ 90,207<span></span>
</td>
<td class="nump">$ 27,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Nontaxable or nondeductible items, percent</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">SBC cancellations</a></td>
<td class="nump">$ 130,732<span></span>
</td>
<td class="nump">$ 943,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">SBC cancellations, percent</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(8.77%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision/(benefit)</a></td>
<td class="num">$ (15,156)<span></span>
</td>
<td class="nump">$ 49,953<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax provision (benefit), Percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.47%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Permanent Differences</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits income tax penalties and interest accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Summary of income tax payments made and income tax refunds (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Total Income Taxes Paid</a></td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="nump">$ 72,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_TX', window );">Texas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">US States</a></td>
<td class="nump">37,000<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalTaxJurisdictionOtherMember', window );">Other US States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">US States</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 8,150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after income tax refund received, of cash paid to state and local tax jurisdictions for tax on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_TX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_TX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalTaxJurisdictionOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalTaxJurisdictionOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We operate in the biotechnology sector, which is subject to various cybersecurity risks that could adversely affect our business, financial condition, and results of operations, including intellectual property theft&#894; fraud&#894; extortion&#894; harm to employees or customers&#894; violation of privacy laws and other litigation and legal risk&#894; and reputational risk. We have implemented a risk-based approach to identify and assess the cybersecurity threats that could affect our business and information systems. Our cybersecurity program is aligned with industry standards and best practices, such as the National Institute of Standards and Technology (&#8220;NIST&#8221;) Cybersecurity Framework. We expect the third-party vendors that provide our IT services to use various tools and methodologies to manage cybersecurity risk and to monitor and evaluate our cybersecurity posture and performance on an ongoing basis through regular vulnerability scans, penetration tests and threat intelligence feeds. We expect to require third-party service providers with access to personal, confidential or proprietary information to implement and maintain cybersecurity practices consistent with applicable legal standards and industry best practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business depends on the availability, reliability, and security of our information systems, networks, data, and intellectual property. Any disruption, compromise, or breach of our systems or data due to a cybersecurity threat or incident could adversely affect our operations, customer service, product development, and competitive position. They may also result in a breach of our contractual obligations or legal duties to protect the privacy and confidentiality of our stakeholders. Such a breach could expose us to business interruption, lost revenue, ransom payments, remediation costs, liabilities to affected parties, cybersecurity protection costs, lost assets, litigation, regulatory scrutiny and actions, reputational harm, customer dissatisfaction, harm to our vendor relationships, or loss of market share.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our cybersecurity risk assessment and management processes are implemented and maintained by various members of our management team, third party service providers and other employees, who we believe have a combination of relevant expertise, experience, education and training.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our board of directors addresses our cybersecurity risk management as part of its general oversight function.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our cybersecurity risk assessment and management processes are implemented and maintained by various members of our management team, third party service providers and other employees, who we believe have a combination of relevant expertise, experience, education and training.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain members of our management team are responsible for hiring appropriate personnel and third-party IT service providers, helping to integrate cybersecurity risk considerations into our overall risk management strategy, communicating key priorities to relevant personnel, approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including in some cases to our executive team. Our cybersecurity incident management team, and other individuals as needed, work to help us mitigate and remediate cybersecurity incidents of which we are notified. In addition, our incident response processes include a procedure for reporting certain cybersecurity incidents to the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The board of directors receives regular reports from management concerning our cybersecurity risk management program. The board also receives various summaries and/or presentations related to cybersecurity threats, risks and mitigation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">board of directors<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The board of directors receives regular reports from management concerning our cybersecurity risk management program.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our cybersecurity risk assessment and management processes are implemented and maintained by various members of our management team, third party service providers and other employees, who we believe have a combination of relevant expertise, experience, education and training.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain members of our management team are responsible for hiring appropriate personnel and third-party IT service providers, helping to integrate cybersecurity risk considerations into our overall risk management strategy, communicating key priorities to relevant personnel, approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including in some cases to our executive team. Our cybersecurity incident management team, and other individuals as needed, work to help us mitigate and remediate cybersecurity incidents of which we are notified. In addition, our incident response processes include a procedure for reporting certain cybersecurity incidents to the board of directors.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">members of our management team<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our cybersecurity risk assessment and management processes are implemented and maintained by various members of our management team, third party service providers and other employees, who we believe have a combination of relevant expertise, experience, education and training.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including in some cases to our executive team. Our cybersecurity incident management team, and other individuals as needed, work to help us mitigate and remediate cybersecurity incidents of which we are notified. In addition, our incident response processes include a procedure for reporting certain cybersecurity incidents to the board of directors<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>128</ContextCount>
  <ElementCount>265</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNatureOfOperations</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans</Role>
      <ShortName>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders</Role>
      <ShortName>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - OTHER RECEIVABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureOtherReceivable</Role>
      <ShortName>OTHER RECEIVABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable</Role>
      <ShortName>ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - STOCK BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>STOCK BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - GRANT INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureGrantIncome</Role>
      <ShortName>GRANT INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>20302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30403 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables</Role>
      <ShortName>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30503 - Disclosure - OTHER RECEIVABLE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureOtherReceivableTables</Role>
      <ShortName>OTHER RECEIVABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureOtherReceivable</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30603 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTables</Role>
      <ShortName>ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30703 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30803 - Disclosure - STOCK BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>STOCK BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30903 - Disclosure - GRANT INCOME (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureGrantIncomeTables</Role>
      <ShortName>GRANT INCOME (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureGrantIncome</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>31103 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>31203 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails</Role>
      <ShortName>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Computation of loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Computation of loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40402 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Anti-dilutive securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersAntiDilutiveSecuritiesDetails</Role>
      <ShortName>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Anti-dilutive securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40501 - Disclosure - OTHER RECEIVABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureOtherReceivableDetails</Role>
      <ShortName>OTHER RECEIVABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureOtherReceivableTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40601 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails</Role>
      <ShortName>ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40701 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40702 - Disclosure - STOCKHOLDERS' EQUITY - Warrant Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockholdersEquityWarrantSummaryDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Warrant Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40801 - Disclosure - STOCK BASED COMPENSATION - Stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>STOCK BASED COMPENSATION - Stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40802 - Disclosure - STOCK BASED COMPENSATION - Weighted average assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails</Role>
      <ShortName>STOCK BASED COMPENSATION - Weighted average assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40803 - Disclosure - STOCK BASED COMPENSATION - Stock-based compensation expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails</Role>
      <ShortName>STOCK BASED COMPENSATION - Stock-based compensation expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40804 - Disclosure - STOCK BASED COMPENSATION - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>STOCK BASED COMPENSATION - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40901 - Disclosure - GRANT INCOME (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureGrantIncomeDetails</Role>
      <ShortName>GRANT INCOME (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureGrantIncomeTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>41001 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>41101 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>41201 - Disclosure - INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails</Role>
      <ShortName>INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>41202 - Disclosure - INCOME TAXES - Additional Information's (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails</Role>
      <ShortName>INCOME TAXES - Additional Information's (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>41203 - Disclosure - INCOME TAXES - Schedule of expected tax expense (benefit) from continuing operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails</Role>
      <ShortName>INCOME TAXES - Schedule of expected tax expense (benefit) from continuing operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41204 - Disclosure - INCOME TAXES - Summary of income tax payments made and income tax refunds (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxPaymentsMadeAndIncomeTaxRefundsDetails</Role>
      <ShortName>INCOME TAXES - Summary of income tax payments made and income tax refunds (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mrkr-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mrkr-20251231.xsd</File>
    <File>mrkr-20251231_cal.xml</File>
    <File>mrkr-20251231_def.xml</File>
    <File>mrkr-20251231_lab.xml</File>
    <File>mrkr-20251231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="mrkr-20251231x10k.htm">mrkr-20251231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mrkr-20251231x10k001.jpg</File>
    <File>mrkr-20251231x10k002.jpg</File>
    <File>mrkr-20251231x10k003.jpg</File>
    <File>mrkr-20251231x10k004.jpg</File>
    <File>mrkr-20251231x10k005.jpg</File>
    <File>mrkr-20251231x10k006.jpg</File>
    <File>mrkr-20251231x10k007.jpg</File>
    <File>mrkr-20251231x10k008.jpg</File>
    <File>mrkr-20251231x10k009.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="415">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>82
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mrkr-20251231x10k.htm": {
   "nsprefix": "mrkr",
   "nsuri": "http://www.tapimmune.com/20251231",
   "dts": {
    "schema": {
     "local": [
      "mrkr-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "mrkr-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mrkr-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "mrkr-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrkr-20251231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "mrkr-20251231x10k.htm"
     ]
    }
   },
   "keyStandard": 228,
   "keyCustom": 37,
   "axisStandard": 18,
   "axisCustom": 0,
   "memberStandard": 20,
   "memberCustom": 22,
   "hidden": {
    "total": 13,
    "http://xbrl.sec.gov/dei/2025": 5,
    "http://fasb.org/us-gaap/2025": 8
   },
   "contextCount": 128,
   "entityCount": 1,
   "segmentCount": 51,
   "elementCount": 410,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 415,
    "http://xbrl.sec.gov/dei/2025": 38,
    "http://xbrl.sec.gov/cyd/2025": 15,
    "http://xbrl.sec.gov/ecd/2025": 5
   },
   "report": {
    "R1": {
     "role": "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw",
      "name": "mrkr:PrepaidExpenseAndDepositsCurrent",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "us-gaap:PreferredStockSharesOutstanding",
       "us-gaap:PreferredStockSharesOutstanding",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tksY2KuphU-6mtLP78kkWg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tksY2KuphU-6mtLP78kkWg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "longName": "00305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.tapimmune.com/role/DisclosureNatureOfOperations",
     "longName": "10101 - Disclosure - NATURE OF OPERATIONS",
     "shortName": "NATURE OF OPERATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans",
     "longName": "10201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS",
     "shortName": "FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies",
     "longName": "10301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders",
     "longName": "10401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS",
     "shortName": "NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.tapimmune.com/role/DisclosureOtherReceivable",
     "longName": "10501 - Disclosure - OTHER RECEIVABLE",
     "shortName": "OTHER RECEIVABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable",
     "longName": "10601 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE",
     "shortName": "ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.tapimmune.com/role/DisclosureStockholdersEquity",
     "longName": "10701 - Disclosure - STOCKHOLDERS' EQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.tapimmune.com/role/DisclosureStockBasedCompensation",
     "longName": "10801 - Disclosure - STOCK BASED COMPENSATION",
     "shortName": "STOCK BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.tapimmune.com/role/DisclosureGrantIncome",
     "longName": "10901 - Disclosure - GRANT INCOME",
     "shortName": "GRANT INCOME",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "11001 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions",
     "longName": "11101 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.tapimmune.com/role/DisclosureIncomeTaxes",
     "longName": "11201 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.tapimmune.com/role/DisclosureSubsequentEvents",
     "longName": "11301 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "longName": "20302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables",
     "longName": "30403 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)",
     "shortName": "NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.tapimmune.com/role/DisclosureOtherReceivableTables",
     "longName": "30503 - Disclosure - OTHER RECEIVABLE (Tables)",
     "shortName": "OTHER RECEIVABLE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "mrkr:ScheduleOfOtherReceivablesCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "mrkr:ScheduleOfOtherReceivablesCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTables",
     "longName": "30603 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Tables)",
     "shortName": "ACCOUNTS PAYABLE, ACCRUED LIABILITIES AND RELATED PARTY PAYABLE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.tapimmune.com/role/DisclosureStockholdersEquityTables",
     "longName": "30703 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.tapimmune.com/role/DisclosureStockBasedCompensationTables",
     "longName": "30803 - Disclosure - STOCK BASED COMPENSATION (Tables)",
     "shortName": "STOCK BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.tapimmune.com/role/DisclosureGrantIncomeTables",
     "longName": "30903 - Disclosure - GRANT INCOME (Tables)",
     "shortName": "GRANT INCOME (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables",
     "longName": "31103 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)",
     "shortName": "RELATED PARTY TRANSACTIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.tapimmune.com/role/DisclosureIncomeTaxesTables",
     "longName": "31203 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
     "longName": "40201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details)",
     "shortName": "FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_8_1_2021_To_8_31_2021_L0Z_1a2Gv0qiuiDAeZfKZw",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails",
     "longName": "40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails",
     "longName": "40401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Computation of loss per Share (Details)",
     "shortName": "NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Computation of loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersAntiDilutiveSecuritiesDetails",
     "longName": "40402 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Anti-dilutive securities (Details)",
     "shortName": "NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Anti-dilutive securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
     "longName": "40501 - Disclosure - OTHER RECEIVABLE (Details)",
     "shortName": "OTHER RECEIVABLE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw",
      "name": "us-gaap:GrantsReceivableCurrent",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:ScheduleOfOtherReceivablesCurrentTableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw",
      "name": "us-gaap:GrantsReceivableCurrent",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:ScheduleOfOtherReceivablesCurrentTableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails",
     "longName": "40601 - Disclosure - ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE (Details)",
     "shortName": "ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "longName": "40701 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_U2becBy6kUyXW95FuWcLrQ",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.tapimmune.com/role/DisclosureStockholdersEquityWarrantSummaryDetails",
     "longName": "40702 - Disclosure - STOCKHOLDERS' EQUITY - Warrant Summary (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - Warrant Summary (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
     "longName": "40801 - Disclosure - STOCK BASED COMPENSATION - Stock option activity (Details)",
     "shortName": "STOCK BASED COMPENSATION - Stock option activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.tapimmune.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails",
     "longName": "40802 - Disclosure - STOCK BASED COMPENSATION - Weighted average assumptions (Details)",
     "shortName": "STOCK BASED COMPENSATION - Weighted average assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails",
     "longName": "40803 - Disclosure - STOCK BASED COMPENSATION - Stock-based compensation expenses (Details)",
     "shortName": "STOCK BASED COMPENSATION - Stock-based compensation expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:StockBasedCompensationExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:StockBasedCompensationExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
     "longName": "40804 - Disclosure - STOCK BASED COMPENSATION - Additional Information (Details)",
     "shortName": "STOCK BASED COMPENSATION - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "unitRef": "Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
     "longName": "40901 - Disclosure - GRANT INCOME (Details)",
     "shortName": "GRANT INCOME (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw",
      "name": "us-gaap:RestrictedCashCurrent",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_tIJI_NC6ykGWgCWOPj17jw",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail",
     "longName": "41001 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_12_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_K0kZGOM0S0iI7apUnHkXog",
      "name": "mrkr:GrantReceived",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_12_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_K0kZGOM0S0iI7apUnHkXog",
      "name": "mrkr:GrantReceived",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails",
     "longName": "41101 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:OperatingCostsAndExpenses",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:OperatingCostsAndExpenses",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails",
     "longName": "41201 - Disclosure - INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)",
     "shortName": "INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails",
     "longName": "41202 - Disclosure - INCOME TAXES - Additional Information's (Details)",
     "shortName": "INCOME TAXES - Additional Information's (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:CurrentFederalTaxExpenseBenefit",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:CurrentFederalTaxExpenseBenefit",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails",
     "longName": "41203 - Disclosure - INCOME TAXES - Schedule of expected tax expense (benefit) from continuing operations (Details)",
     "shortName": "INCOME TAXES - Schedule of expected tax expense (benefit) from continuing operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxPaymentsMadeAndIncomeTaxRefundsDetails",
     "longName": "41204 - Disclosure - INCOME TAXES - Summary of income tax payments made and income tax refunds (Details)",
     "shortName": "INCOME TAXES - Summary of income tax payments made and income tax refunds (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:IncomeTaxesPaidNet",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:IncomeTaxPaymentsByJurisdictionTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "us-gaap:IncomeTaxesPaidNet",
      "unitRef": "Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:IncomeTaxPaymentsByJurisdictionTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Uncategorized",
     "order": "49",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2025_To_12_31_2025_Ivl427bMU0uiB1nIEy7zew",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2025_To_12_31_2025_Ivl427bMU0uiB1nIEy7zew",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "50",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mrkr-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r18",
      "r21",
      "r720"
     ]
    },
    "mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities Including Related party payable, Current",
        "totalLabel": "Total accounts payable, accrued liabilities and related party payable"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_AccountsPayableAndAccruedLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "AccountsPayableAndAccruedLiabilitiesLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts Payable And Accrued Liabilities [Line Items]",
        "verboseLabel": "ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_AccountsPayableAndAccruedLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "AccountsPayableAndAccruedLiabilitiesTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This table lists the accounts payable and accrued liabilities. The line items identify information about the accounts payable and accrued liabilities.",
        "label": "Accounts Payable And Accrued Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails": {
       "parentTag": "mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r541"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails": {
       "parentTag": "mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "verboseLabel": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "mrkr_AdditionalCpritGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "AdditionalCpritGrantMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid for additional CPRIT grant.",
        "label": "Additional CPRIT Grant [Member]",
        "terseLabel": "Additional CPRIT grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r541",
      "r787"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r665",
      "r666",
      "r667",
      "r668",
      "r735",
      "r789"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Net of offering costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r40"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Reconciliation of net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated Share-based Compensation Expense",
        "verboseLabel": "Total stock compensation expenses",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r251",
      "r252"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "verboseLabel": "NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r54",
      "r68",
      "r85",
      "r86",
      "r87",
      "r120",
      "r127",
      "r140",
      "r141",
      "r147",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r300",
      "r304",
      "r329",
      "r364",
      "r365",
      "r369",
      "r433",
      "r507",
      "r508",
      "r511",
      "r541",
      "r546",
      "r547",
      "r559",
      "r684",
      "r685",
      "r746"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r70",
      "r85",
      "r86",
      "r87",
      "r147",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r300",
      "r304",
      "r329",
      "r541",
      "r684",
      "r685",
      "r746"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_AtMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "AtMarketOfferingMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to At The Market Offering.",
        "label": "At The Market Offering [Member]",
        "terseLabel": "Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r564",
      "r565",
      "r578"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r564",
      "r565",
      "r578"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r564",
      "r565",
      "r578"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "mrkr_BaylorCollegeOfMedicineLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "BaylorCollegeOfMedicineLicenseAgreementMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the exclusive license agreement with Baylor College of Medicine (\"BCM\").",
        "label": "Baylor College Of Medicine License Agreement [Member]",
        "terseLabel": "License agreement with Baylor College of Medicine"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_BaylorCollegeOfMedicineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "BaylorCollegeOfMedicineMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents of baylor college of medicine.",
        "label": "Baylor College of Medicine [Member]",
        "terseLabel": "BCM"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to  Cancer Prevention And Research Institute Of Texas grant for Acute Myeloid Leukemia.",
        "label": "Cancer Prevention And Research Institute Of Texas, Acute Myeloid Leukemia [Member]",
        "terseLabel": "CPRIT AML"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the grant agreement with Cancer Prevention and Research Institute Of Texas (\"CPRIT\").",
        "label": "Cancer Prevention And Research Institute Of Texas Grant Agreement [Member]",
        "terseLabel": "Cancer Prevention and Research Institute of Texas"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Cantor Fitzgerald &amp; Co and RBC Capital Markets, LLC.",
        "label": "Cantor Fitzgerald Co. And Rbc Capital Markets Llc [Member]",
        "terseLabel": "Sales Agents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r67",
      "r488"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash, Cash Equivalents, Restricted Cash, and Credit Risk",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "mrkr_CashAtFinancialInstitutions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "CashAtFinancialInstitutions",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash held at financial institutions.",
        "label": "Cash at Financial Institutions",
        "terseLabel": "Cash at financial institutions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of the year",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of the year",
        "verboseLabel": "Cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r34",
      "r82"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r34"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, FDIC Insured Amount.",
        "terseLabel": "Cash, FDIC insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_CellReadyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "CellReadyAgreementMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Cell Ready Agreement.",
        "label": "Cell Ready Agreement [Member]",
        "terseLabel": "Cell Ready Purchase Agreement",
        "verboseLabel": "Cell Ready"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_CellReadyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "CellReadyMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Cell Ready.",
        "label": "Cell Ready [Member]",
        "terseLabel": "Cell Ready"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer, President and Chairman [Member]",
        "terseLabel": "Chief Executive Officer, President and Chairman"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityWarrantSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityWarrantSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityWarrantSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise Price Per Share (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r89",
      "r195"
     ]
    },
    "mrkr_ClassOfWarrantOrRightExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "ClassOfWarrantOrRightExercised",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityWarrantSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights exercised by the holders of the instruments during the reporting period.",
        "label": "Class of Warrant or Right, Exercised",
        "negatedLabel": "Exercised",
        "terseLabel": "Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityWarrantSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "verboseLabel": "STOCKHOLDERS' EQUITY",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Issuance of shares of common stock",
        "verboseLabel": "Issuance of shares of common stock, warrants (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityWarrantSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Outstanding at the end",
        "periodStartLabel": "Outstanding at the beginning",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_ClassOfWarrantOrRightRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "ClassOfWarrantOrRightRollForward",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityWarrantSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Class of Warrant or Right [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityWarrantSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Clinical Trial Agreement with Baylor College of Medicine.",
        "label": "Clinical Trial Agreement with Baylor College of Medicine [Member]",
        "terseLabel": "Baylor College of Medicine"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r154",
      "r155",
      "r481",
      "r679",
      "r681"
     ]
    },
    "mrkr_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_CommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "CommitmentsAndContingenciesTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r550",
      "r551",
      "r553",
      "r554",
      "r555",
      "r556",
      "r665",
      "r666",
      "r668",
      "r735",
      "r785",
      "r789"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r421"
     ]
    },
    "mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percent of calculation of compensation rate by using gross sales price per share sold.",
        "label": "Common Stock, Shares, Commission Rate Calculation on Gross Sales Price per Share, Percent",
        "terseLabel": "Commission rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r25",
      "r421",
      "r439",
      "r789",
      "r790"
     ]
    },
    "us-gaap_CommonStockSharesSubscriptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesSubscriptions",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Subscriptions",
        "terseLabel": "Aggregate offering price",
        "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r25"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 30 million shares authorized, 16.7 million and 10.7 million shares issued and outstanding as of December 31, 2025 and 2024, respectively (see Note 7)",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r173",
      "r179",
      "r372",
      "r541"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Modification of Stock Options",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r43"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r497"
     ]
    },
    "mrkr_ControlledEquityOfferingSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "ControlledEquityOfferingSalesAgreementMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to controlled equity offering sales agreement.",
        "label": "Controlled Equity Offering Sales Agreement [Member]",
        "terseLabel": "ATM Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "terseLabel": "Service and manufacturing costs",
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r599",
      "r600"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r85",
      "r92",
      "r93",
      "r169",
      "r184",
      "r350",
      "r356",
      "r368",
      "r489",
      "r490",
      "r491",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r731",
      "r732",
      "r733",
      "r734"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_CpritPancreaticGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "CpritPancreaticGrantMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents information pertaining to CPRIT Pancreatic Grant.",
        "label": "CPRIT Pancreatic Grant [Member]",
        "terseLabel": "CPRIT Pancreatic Grant1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal income tax expense",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r660",
      "r663",
      "r728"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current State and Local Tax Expense (Benefit)",
        "verboseLabel": "State tax (benefit) expense",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r660",
      "r663",
      "r728"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r573",
      "r590"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r573",
      "r590"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r575",
      "r592"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r575",
      "r592"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r577",
      "r594"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r575",
      "r592"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r568",
      "r585"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r569",
      "r586"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r569",
      "r586"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r567",
      "r584"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r567",
      "r584"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r570",
      "r587"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r572",
      "r589"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r573",
      "r590"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r576",
      "r593"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r574",
      "r591"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r571",
      "r588"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxesAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Taxes and Other Assets [Abstract]",
        "terseLabel": "Deferred Tax Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred Tax Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized R&amp;E",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net Deferred Tax Assets/(Liabilities)",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total Deferred Tax Assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net Operating Loss Carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "terseLabel": "Deferred tax assets, operating loss carryforwards, foreign",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Deferred tax assets, operating loss carryforwards, state and local",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "verboseLabel": "Research and Development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "verboseLabel": "Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves",
        "terseLabel": "Reserves",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "mrkr_DeferredTaxStockBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "DeferredTaxStockBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax stock-based compensation.",
        "label": "Deferred Tax Stock Based Compensation",
        "terseLabel": "Stock Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r786"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Summarizes grant income",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "STOCK BASED COMPENSATION",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r216",
      "r245",
      "r246",
      "r249",
      "r522"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK BASED COMPENSATION"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r565",
      "r578"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r565",
      "r578",
      "r580"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net earnings (loss) per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "verboseLabel": "Net loss per share, basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r77",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r110",
      "r112",
      "r114",
      "r115",
      "r116",
      "r119",
      "r171",
      "r250",
      "r294",
      "r297",
      "r323",
      "r324",
      "r363",
      "r380",
      "r499"
     ]
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, Other Disclosure [Abstract]",
        "terseLabel": "Weighted average number of common shares outstanding:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "verboseLabel": "Net loss per share, diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r77",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r112",
      "r114",
      "r115",
      "r116",
      "r119",
      "r171",
      "r250",
      "r294",
      "r297",
      "r323",
      "r324",
      "r363",
      "r380",
      "r499"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Loss per Common Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r118"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Income tax provision (benefit), Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r526"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "U.S. federal statutory rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r88",
      "r262",
      "r285",
      "r526"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "verboseLabel": "Change in valuation allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r526",
      "r660",
      "r664",
      "r721"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "Nontaxable or nondeductible items, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r664",
      "r721",
      "r723"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "terseLabel": "SBC cancellations",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r721",
      "r722"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "terseLabel": "SBC cancellations, percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r721",
      "r722"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State taxes, net of federal benefit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r526",
      "r660",
      "r664",
      "r721"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails": {
       "parentTag": "mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Compensation and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total stock-based compensation cost related to unvested awards not yet recognized",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected weighted average period of recognition of unrecognized compensation costs (in years)",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Common stock options",
        "verboseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r61",
      "r62",
      "r63",
      "r74",
      "r75",
      "r76",
      "r94",
      "r95",
      "r96",
      "r98",
      "r105",
      "r107",
      "r109",
      "r121",
      "r148",
      "r149",
      "r150",
      "r170",
      "r196",
      "r250",
      "r283",
      "r284",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r341",
      "r342",
      "r343",
      "r379",
      "r393",
      "r394",
      "r395",
      "r409",
      "r462"
     ]
    },
    "mrkr_EquityIncentiveAward2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "EquityIncentiveAward2025Member",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2025 equity incentive awards.",
        "label": "Equity Incentive Award 2025 [Member]",
        "terseLabel": "2025 Equity Incentive Awards"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_EquityIncentivePlan2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "EquityIncentivePlan2020Member",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member information pertaining to 2020 equity incentive plan.",
        "label": "Equity Incentive Plan 2020 [Member]",
        "terseLabel": "2020 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_FdaGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "FdaGrantMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid for FDA grant.",
        "label": "FDA Grant [Member]",
        "terseLabel": "FDA Grant"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "FinancialConditionGoingConcernAndManagementPlansLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS [Line Items]",
        "terseLabel": "FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_FinancialConditionGoingConcernAndManagementPlansTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "FinancialConditionGoingConcernAndManagementPlansTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Financial Condition Going Concern And Management Plans [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign tax authority",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263"
     ]
    },
    "mrkr_FundsReceivedFromCpritGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "FundsReceivedFromCpritGrant",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funds received from grant.",
        "label": "Funds Received From CPRIT Grant",
        "terseLabel": "Funds received from CPRIT grant"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_FundsReceivedFromGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "FundsReceivedFromGrant",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funds received from grant",
        "label": "Funds Received From Grant",
        "terseLabel": "Funds received from grant"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_GainLossOnEarlyTerminationOfVendorAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "GainLossOnEarlyTerminationOfVendorAgreement",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of gain (loss) on early termination of vendor agreement.",
        "label": "Gain (Loss) on Early Termination of Vendor Agreement",
        "negatedLabel": "Loss on early termination of vendor agreement",
        "verboseLabel": "Gain (loss) on early termination of vendor agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r442"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative [Member]",
        "terseLabel": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_GovernmentAssistanceTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistanceTypeAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Type [Axis]",
        "documentation": "Information by type of government assistance."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_GovernmentAssistanceTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistanceTypeDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Type [Domain]",
        "documentation": "Type of government assistance."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "mrkr_GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of net sales of any product to the grants received by the entity for which payments have to be made as per the terms of the grant agreement.",
        "label": "Grant Agreement, Payments Required, Percentage Of Net Sales To Grants Received",
        "terseLabel": "Aggregate amount (in Percentage)"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of revenue sharing by the entity with the counter party for the remainder revenue term as per the terms of the grant agreement.",
        "label": "Grant Agreement, Revenue Sharing Percentage, Remainder of Revenue Term",
        "terseLabel": "Revenue sharing percentage"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_GrantAssistanceTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "GrantAssistanceTerm",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duration of grant assistance transaction, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Grant Assistance Term",
        "verboseLabel": "Grant assistance term"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_GrantIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "GrantIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for grant income.",
        "label": "Grant Income, Policy [Policy Text Block]",
        "terseLabel": "Grant Income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrantMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant [Member]",
        "terseLabel": "Grant income",
        "documentation": "Award of money not required to be repaid."
       }
      }
     },
     "auth_ref": [
      "r688",
      "r689"
     ]
    },
    "mrkr_GrantReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "GrantReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail",
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of grant income transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Grant Received",
        "terseLabel": "Grant income received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "us-gaap_GrantsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrantsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grants Receivable",
        "terseLabel": "Grant receivable",
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_GrantsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrantsReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails": {
       "parentTag": "us-gaap_OtherReceivablesNetCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grants Receivable, Current",
        "verboseLabel": "Total grant income receivable",
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r564",
      "r565",
      "r578"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss from operations before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r49",
      "r53",
      "r364",
      "r366",
      "r376",
      "r493",
      "r495",
      "r496",
      "r504",
      "r507",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r306",
      "r307",
      "r308",
      "r309",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r390",
      "r392",
      "r447",
      "r484",
      "r486",
      "r527",
      "r528",
      "r533",
      "r534",
      "r535",
      "r540",
      "r729",
      "r730",
      "r756"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r306",
      "r307",
      "r308",
      "r309",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r390",
      "r392",
      "r447",
      "r484",
      "r486",
      "r527",
      "r528",
      "r533",
      "r534",
      "r535",
      "r540",
      "r729",
      "r730",
      "r756"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails",
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxPaymentsMadeAndIncomeTaxRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r262",
      "r263",
      "r271",
      "r280",
      "r526",
      "r726"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails",
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxPaymentsMadeAndIncomeTaxRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r262",
      "r263",
      "r271",
      "r280",
      "r526",
      "r726"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r88",
      "r257",
      "r262",
      "r267",
      "r268",
      "r269",
      "r273",
      "r278",
      "r286",
      "r288",
      "r289",
      "r290",
      "r367",
      "r399",
      "r404",
      "r526"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax (benefit) expense",
        "totalLabel": "Income tax provision/(benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r59",
      "r85",
      "r108",
      "r109",
      "r120",
      "r131",
      "r141",
      "r261",
      "r262",
      "r287",
      "r381",
      "r493",
      "r495",
      "r496",
      "r526"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "verboseLabel": "Permanent Differences"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidByIndividualJurisdictionLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails",
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxPaymentsMadeAndIncomeTaxRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Paid, by Individual Jurisdiction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r280"
     ]
    },
    "us-gaap_IncomeTaxPaidByIndividualJurisdictionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidByIndividualJurisdictionTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails",
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxPaymentsMadeAndIncomeTaxRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Paid, by Individual Jurisdiction [Table]",
        "documentation": "Disclosure of information about income tax paid by jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r280"
     ]
    },
    "us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidStateAndLocalAfterRefundReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxPaymentsMadeAndIncomeTaxRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Paid, State and Local, after Refund Received",
        "terseLabel": "US States",
        "documentation": "Amount, after income tax refund received, of cash paid to state and local tax jurisdictions for tax on income."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r279"
     ]
    },
    "mrkr_IncomeTaxPaymentsByJurisdictionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "IncomeTaxPaymentsByJurisdictionTableTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income tax payments by jurisdiction.",
        "label": "Income Tax Payments by Jurisdiction [Table Text Block]",
        "terseLabel": "Summary of income tax payments made and income tax refunds received by jurisdiction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r259",
      "r260",
      "r273",
      "r274",
      "r277",
      "r282",
      "r401"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r526",
      "r721"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "U.S. federal statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r526"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount",
        "terseLabel": "Nontaxable or nondeductible items",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r723"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "verboseLabel": "State taxes, net of federal benefit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r526",
      "r721"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxPaymentsMadeAndIncomeTaxRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net",
        "totalLabel": "Total Income Taxes Paid",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r81",
      "r279",
      "r280"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Due to Related Parties, Current",
        "terseLabel": "Related party payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "mrkr_IncreaseDecreaseInPrepaidExpenseAndDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "IncreaseDecreaseInPrepaidExpenseAndDeposits",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses and deposits.",
        "label": "Increase (Decrease) In Prepaid Expense And Deposits",
        "negatedLabel": "Prepaid expenses and deposits"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r566",
      "r583"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r566",
      "r583"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "verboseLabel": "Patents and Patent Application Costs",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r362",
      "r498",
      "r678"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails": {
       "parentTag": "us-gaap_OtherReceivablesNetCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Receivable, Current",
        "terseLabel": "Interest receivable",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r130",
      "r141",
      "r507",
      "r614"
     ]
    },
    "mrkr_InvoicesReceivedForServicesAndManufacturingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "InvoicesReceivedForServicesAndManufacturingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Invoices for the cost of product sold and service rendered, excluding depreciation, depletion, and amortization.",
        "label": "Invoices Received for Services and Manufacturing Costs",
        "terseLabel": "Paid invoices"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r85",
      "r86",
      "r87",
      "r147",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r301",
      "r304",
      "r305",
      "r329",
      "r420",
      "r503",
      "r511",
      "r559",
      "r684",
      "r746",
      "r747"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r48",
      "r374",
      "r541",
      "r546",
      "r547",
      "r660",
      "r662",
      "r677",
      "r739"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r66",
      "r85",
      "r86",
      "r87",
      "r147",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r301",
      "r304",
      "r305",
      "r329",
      "r541",
      "r684",
      "r746",
      "r747"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_LicenseAgreementLiquidityIncentivePaymentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "LicenseAgreementLiquidityIncentivePaymentPercentage",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of the liquidity event proceeds that will be paid as a one-time liquidity incentive payment by the entity as per the terms of the license agreement.",
        "label": "License Agreement, Liquidity Incentive Payment Percentage",
        "terseLabel": "Liquidity incentive payment in percentage"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of the milestone payments agreed to be paid by the entity as per the terms of the license agreement.",
        "label": "License Agreement, Maximum Milestone Payments Agreed To Be Paid",
        "terseLabel": "Milestone payments agreed"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_LiquidityFinancialConditionAndGoingConcernAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "LiquidityFinancialConditionAndGoingConcernAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "LiquidityFinancialConditionAndGoingConcernTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity Financial Condition And Going Concern Text Block",
        "label": "Liquidity Financial Condition And Going Concern [Text Block]",
        "terseLabel": "FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "OTHER RECEIVABLE",
        "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r675"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_MasterServicesAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "MasterServicesAgreementTerm",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term of the master services agreement entered into by the entity, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Master Services Agreement, Term",
        "terseLabel": "Master Services Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail",
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r126",
      "r156",
      "r157",
      "r158",
      "r159",
      "r212",
      "r240",
      "r241",
      "r242",
      "r253",
      "r325",
      "r357",
      "r389",
      "r391",
      "r398",
      "r412",
      "r413",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r483",
      "r510",
      "r512",
      "r521",
      "r527",
      "r529",
      "r530",
      "r536",
      "r537",
      "r538",
      "r539",
      "r543",
      "r686",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753"
     ]
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterestDisclosureTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS",
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "NationalInstitutesOfHealthNationalCancerInstituteGrantMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to grants from National Institutes of Health-National Cancer Institute.",
        "label": "National Institutes of Health National Cancer Institute Grant [Member]",
        "terseLabel": "National Institutes of Health National - Cancer Institute Grant",
        "verboseLabel": "Decoy Grant"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to grant from National Institutes of Health and Business Innovation research for Lymphoma.",
        "label": "National Institutes of Health Small Business Innovation Research For Lymphoma Grant [Member]",
        "terseLabel": "SBIR lymphoma grant",
        "verboseLabel": "SBIR NHL Grant"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to grant from National Institutes of Health and Business Innovation research for pancreatic cancer.",
        "label": "National Institutes of Health Small Business Innovation Research For Pancreatic Cancer [Member]",
        "terseLabel": "SBIR pancreatic cancer grant",
        "verboseLabel": "PANACEA Grant"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "NationalInstitutesOfHealthSmallBusinessInnovationResearchMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents information pertaining to National Institutes of Health Small Business Innovation Research.",
        "label": "National Institutes of Health Small Business Innovation Research [Member]",
        "terseLabel": "SBIR AML",
        "verboseLabel": "SBIR AML Grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "verboseLabel": "NATURE OF OPERATIONS",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r123",
      "r500",
      "r501"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r36",
      "r50",
      "r63",
      "r64",
      "r71",
      "r72",
      "r76",
      "r85",
      "r86",
      "r87",
      "r91",
      "r97",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r108",
      "r109",
      "r113",
      "r147",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r171",
      "r174",
      "r176",
      "r180",
      "r250",
      "r294",
      "r297",
      "r324",
      "r329",
      "r378",
      "r440",
      "r460",
      "r461",
      "r493",
      "r495",
      "r496",
      "r557",
      "r684"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToParentDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAttributableToParentDilutedAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent, Diluted [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "New Accounting Standards",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncontrollingInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Total related party expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r493",
      "r496",
      "r504",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "mrkr_OperatingLossCarryforwardsLimitationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "OperatingLossCarryforwardsLimitationPercentage",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of limitation for operating loss carryforwards",
        "label": "Operating Loss Carryforwards Limitation Percentage",
        "terseLabel": "Operating loss carryforwards limitation percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails": {
       "parentTag": "mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails": {
       "parentTag": "us-gaap_OtherReceivablesNetCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r541"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails": {
       "parentTag": "mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to Related Parties, Current",
        "terseLabel": "Related party payable",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r541"
     ]
    },
    "us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liability, Current, Related Party, Type [Extensible Enumeration]",
        "documentation": "Indicates status and type of related party for liability classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income",
        "terseLabel": "Other income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables",
        "totalLabel": "Total other receivable",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ]
    },
    "mrkr_PreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "PreFundedWarrantMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityWarrantSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to pre-funded warrants.",
        "label": "Pre Funded Warrant [Member]",
        "terseLabel": "Pre Funded Warrant",
        "verboseLabel": "Pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r182"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r421"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock issued (in shares)",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r182"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r421",
      "r439",
      "r789",
      "r790"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at December 31, 2025 and 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r173",
      "r178",
      "r371",
      "r541"
     ]
    },
    "mrkr_PrepaidExpenseAndDepositsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "PrepaidExpenseAndDepositsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and deposits that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Deposits, Current",
        "terseLabel": "Prepaid expenses and deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_PrivatePlacementWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "PrivatePlacementWarrantMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityWarrantSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to private placement warrants.",
        "label": "Private Placement Warrant [Member]",
        "terseLabel": "Private Placement Warrant",
        "verboseLabel": "Private placement warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock, net",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "verboseLabel": "Proceeds from exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "mrkr_ProceedsFromWarrantsAndStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "ProceedsFromWarrantsAndStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of options and warrants.",
        "label": "Proceeds from Warrants and Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of warrants and stock options"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r143",
      "r361",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r487",
      "r492",
      "r495",
      "r496",
      "r513",
      "r514",
      "r542",
      "r543",
      "r544",
      "r545",
      "r548",
      "r597",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r682",
      "r683",
      "r755",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r143",
      "r361",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r487",
      "r492",
      "r495",
      "r496",
      "r513",
      "r514",
      "r542",
      "r543",
      "r544",
      "r545",
      "r548",
      "r597",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r682",
      "r683",
      "r755",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r71",
      "r72",
      "r79",
      "r85",
      "r86",
      "r87",
      "r91",
      "r97",
      "r105",
      "r108",
      "r109",
      "r147",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r171",
      "r250",
      "r294",
      "r297",
      "r299",
      "r302",
      "r303",
      "r324",
      "r329",
      "r364",
      "r366",
      "r377",
      "r408",
      "r440",
      "r460",
      "r461",
      "r531",
      "r532",
      "r558",
      "r613",
      "r684"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail",
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r126",
      "r156",
      "r157",
      "r158",
      "r159",
      "r209",
      "r212",
      "r240",
      "r241",
      "r242",
      "r249",
      "r253",
      "r325",
      "r354",
      "r355",
      "r357",
      "r389",
      "r391",
      "r398",
      "r412",
      "r413",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r483",
      "r510",
      "r512",
      "r521",
      "r527",
      "r529",
      "r530",
      "r536",
      "r537",
      "r538",
      "r539",
      "r543",
      "r551",
      "r680",
      "r686",
      "r737",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail",
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r126",
      "r156",
      "r157",
      "r158",
      "r159",
      "r209",
      "r212",
      "r240",
      "r241",
      "r242",
      "r249",
      "r253",
      "r325",
      "r354",
      "r355",
      "r357",
      "r389",
      "r391",
      "r398",
      "r412",
      "r413",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r483",
      "r510",
      "r512",
      "r521",
      "r527",
      "r529",
      "r530",
      "r536",
      "r537",
      "r538",
      "r539",
      "r543",
      "r551",
      "r680",
      "r686",
      "r737",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER RECEIVABLE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesWithImputedInterestLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesWithImputedInterestLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables with Imputed Interest [Line Items]",
        "terseLabel": "OTHER RECEIVABLE",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r741"
     ]
    },
    "mrkr_RecentlyIssuedAccountingStandardsAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "RecentlyIssuedAccountingStandardsAdoptedPolicyTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recently issued accounting standards adopted.",
        "label": "Recently Issued Accounting Standards Adopted [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Standards"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recently issued accounting standards not yet adopted.",
        "label": "Recently Issued Accounting Standards Not yet Adopted [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Standards Not Yet Adopted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r90",
      "r91",
      "r146",
      "r210",
      "r211",
      "r347",
      "r348",
      "r370",
      "r375",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r438",
      "r469",
      "r788"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related party",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r90",
      "r91",
      "r347",
      "r348",
      "r349",
      "r350",
      "r370",
      "r375",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r438",
      "r469"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r90",
      "r91",
      "r347",
      "r348",
      "r745"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r90",
      "r91",
      "r745"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r90",
      "r91",
      "r146",
      "r347",
      "r348",
      "r350",
      "r443",
      "r444",
      "r447"
     ]
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Purchases from Related Party",
        "terseLabel": "Related party transaction",
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r90",
      "r91",
      "r146",
      "r210",
      "r211",
      "r347",
      "r348",
      "r370",
      "r375",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r438",
      "r469",
      "r745",
      "r788"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r348",
      "r351",
      "r405",
      "r406",
      "r407",
      "r445",
      "r446",
      "r447",
      "r466",
      "r468"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r85",
      "r92",
      "r93",
      "r169",
      "r184",
      "r350",
      "r356",
      "r368",
      "r489",
      "r490",
      "r491",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r731",
      "r732",
      "r733",
      "r734"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Product development research award",
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r484",
      "r493",
      "r494",
      "r507",
      "r754"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Member]",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and development",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r658"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r40",
      "r373",
      "r396",
      "r397",
      "r403",
      "r422",
      "r541"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r94",
      "r95",
      "r96",
      "r98",
      "r105",
      "r107",
      "r109",
      "r148",
      "r149",
      "r150",
      "r170",
      "r250",
      "r283",
      "r284",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r311",
      "r313",
      "r314",
      "r316",
      "r322",
      "r341",
      "r342",
      "r393",
      "r395",
      "r409",
      "r789"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "GRANT INCOME"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenue recognized",
        "verboseLabel": "Total revenues",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r120",
      "r128",
      "r129",
      "r139",
      "r141",
      "r143",
      "r144",
      "r145",
      "r205",
      "r206",
      "r207",
      "r361"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "GRANT INCOME",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r207",
      "r208"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from the sale of securities",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_SaleOfStockValueOfSharesIssuedInTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "SaleOfStockValueOfSharesIssuedInTransaction",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureCommitmentsAndContingenciesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of shares issued or sold by the entity for the stock transaction during the reporting period.",
        "label": "Sale of Stock, Value of Shares Issued in Transaction",
        "terseLabel": "Shares issued in common stock value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of accounts payable, accrued liabilities, and related party payable",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of anti-dilutive securities",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of deferred tax assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Schedule of computation of net loss per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of expected tax (benefit) expense based on the U. S. federal statutory rate reconciled with the actual tax provision (benefit)",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r526",
      "r721"
     ]
    },
    "mrkr_ScheduleOfOtherReceivablesCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "ScheduleOfOtherReceivablesCurrentTableTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other receivables classified as current.",
        "label": "Schedule Of Other Receivables Current [Table Text Block]",
        "terseLabel": "Schedule of company's other receivable balance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfReceivablesWithImputedInterestTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfReceivablesWithImputedInterestTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Receivables with Imputed Interest [Table]",
        "documentation": "Disclosure of information about receivable with discount or premium resulting from determination of present value in cash or noncash transaction. Includes, but is not limited to, description of receivable, amortization period and method, effective interest rate, and face amount."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r741"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r90",
      "r91",
      "r347",
      "r348",
      "r350",
      "r443",
      "r444",
      "r447"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of related party transaction expenses",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r743"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Schedule of the company's stock option activity",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r42"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r249"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule or Description of Weighted Average Discount Rate [Table Text Block]",
        "terseLabel": "Schedule of weighted average assumptions used in calculating the fair values of stock options that were granted",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of warrants outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r142",
      "r144",
      "r505",
      "r506",
      "r509"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Accelerated Cost",
        "terseLabel": "Acceleration of compensation expense",
        "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "verboseLabel": "Exercise price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate of interest",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "STOCK BASED COMPENSATION",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r249"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of annual vesting installments",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Annual Vesting Installments",
        "terseLabel": "Number of annual vesting periods"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of options to purchase shares",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement number of share options available for issued.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Options Available for Issued",
        "terseLabel": "Number of shares options available to be issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Number of Shares, Options vested and exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Options vested and exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Shares, Canceled/Expired",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Stock options granted to director amount",
        "verboseLabel": "Number of Shares, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Total Intrinsic Value Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares Outstanding, Ending Balance",
        "periodStartLabel": "Number of Shares Outstanding, Beginning Balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r221"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price per Share, Outstanding, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price per Share, Outstanding, Beginning Balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r221"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "terseLabel": "Incremental stock-based compensation expense in connection with the termination of certain employees",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Award [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price per Share, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price per Share, Canceled/Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercise price of options granted",
        "verboseLabel": "Weighted Average Exercise Price per Share, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Director [Policy Text Block]",
        "verboseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award granted to director under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees [Member]",
        "terseLabel": "Employees",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Employee [Member]",
        "terseLabel": "Non employee",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Total Intrinsic Value, Options vested and exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life, Outstanding (in years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life, Options vested and exercisable (in years)",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Issued",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Purchase price (in dollars per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails",
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxPaymentsMadeAndIncomeTaxRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and local jurisdiction",
        "verboseLabel": "United States",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_StateAndLocalTaxJurisdictionOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalTaxJurisdictionOtherMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxPaymentsMadeAndIncomeTaxRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Tax Jurisdiction, Other [Member]",
        "terseLabel": "Other US States",
        "documentation": "Designated state and local jurisdiction entitled to levy and collect income tax in country of domicile, classified as other."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r725"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r25",
      "r28",
      "r29",
      "r61",
      "r62",
      "r63",
      "r74",
      "r75",
      "r76",
      "r94",
      "r95",
      "r96",
      "r98",
      "r105",
      "r107",
      "r109",
      "r121",
      "r148",
      "r149",
      "r150",
      "r170",
      "r196",
      "r250",
      "r283",
      "r284",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r341",
      "r342",
      "r343",
      "r379",
      "r393",
      "r394",
      "r395",
      "r409",
      "r462"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements",
        "verboseLabel": "Statement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r121",
      "r172",
      "r173",
      "r175",
      "r177",
      "r342",
      "r361",
      "r400",
      "r410",
      "r411",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r441",
      "r442",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462",
      "r495",
      "r496",
      "r552",
      "r788"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "INCOME TAXES",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r121",
      "r146",
      "r172",
      "r173",
      "r175",
      "r177",
      "r342",
      "r361",
      "r400",
      "r410",
      "r411",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r441",
      "r442",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462",
      "r495",
      "r496",
      "r552",
      "r788"
     ]
    },
    "mrkr_StockAndWarrantsIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "StockAndWarrantsIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock and warrants to purchase common stock issued during the reporting period.",
        "label": "Stock And Warrants Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, prefunded warrants and warrants for cash, net of offering costs (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_StockAndWarrantsIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "StockAndWarrantsIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock and warrants to purchase common stock issued during the reporting period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock And Warrants Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, prefunded warrants and warrants for cash, net of offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_StockBasedCompensationExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "StockBasedCompensationExpensesTableTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of stock based compensation expenses recorded.",
        "label": "Stock based Compensation Expenses [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares purchased pursuant to ATM agreement (in shares)",
        "verboseLabel": "Number of shares issued (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r24",
      "r25",
      "r40",
      "r402",
      "r462",
      "r475"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Shares, Exercised",
        "terseLabel": "Issuance of common stock from exercise of stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r24",
      "r25",
      "r40",
      "r225"
     ]
    },
    "mrkr_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised during the period.",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Issuance of common stock from exercise of prefunded warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Shares purchased pursuant to ATM agreement",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r24",
      "r25",
      "r40",
      "r409",
      "r462",
      "r475",
      "r558"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r24",
      "r25",
      "r40"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock options exercised for cash",
        "verboseLabel": "Issuance of common stock from exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r25",
      "r28",
      "r29",
      "r40"
     ]
    },
    "mrkr_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Issuance of common stock from exercise of prefunded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r28",
      "r29",
      "r37",
      "r423",
      "r439",
      "r463",
      "r464",
      "r541",
      "r559",
      "r660",
      "r661",
      "r662",
      "r677",
      "r739",
      "r789"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "STOCKHOLDERS' EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r181",
      "r183",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r310",
      "r321",
      "r465",
      "r467",
      "r476"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r353"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_TX": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "TX",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfIncomeTaxPaymentsMadeAndIncomeTaxRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TEXAS",
        "terseLabel": "Texas"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_TaxCreditCarryForwardExpirationYearRangeEnd": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "TaxCreditCarryForwardExpirationYearRangeEnd",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year range end.",
        "label": "Tax Credit Carry Forward Expiration Year Range End",
        "terseLabel": "Tax credit carryforward expiration year range end"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "mrkr_TaxCreditCarryforwardsExpirationPeriod": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "TaxCreditCarryforwardsExpirationPeriod",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carry forward expiration year range start.",
        "label": "Tax Credit Carryforwards Expiration Period",
        "terseLabel": "Tax credit carryforwards expiration period"
       }
      }
     },
     "auth_ref": []
    },
    "mrkr_TaxFeesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "TaxFeesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails": {
       "parentTag": "mrkr_AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAccruedLiabilitiesAndRelatedPartyPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of tax fees payable.",
        "label": "Tax Fees Payable",
        "terseLabel": "Tax fees"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r744"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relationship to Entity [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentAgenciesSecuritiesAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Securities, at Carrying Value",
        "terseLabel": "Government agency securities",
        "documentation": "Debt securities issued by a United States government agency such as Government National Mortgage Association (Ginnie Mae), Federal Home Loan Mortgage Corporation (Freddie Mac), and Federal National Mortgage Association (Fannie Mae), which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "verboseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r272",
      "r525"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesScheduleOfExpectedTaxExpenseBenefitFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "verboseLabel": "Unrecognized tax benefits income tax penalties and interest accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r525"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r525"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r122",
      "r124",
      "r125",
      "r126",
      "r364",
      "r366",
      "r502"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Common stock purchase warrants",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r550",
      "r553",
      "r554",
      "r555",
      "r556"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityWarrantSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r736",
      "r737",
      "r738"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "verboseLabel": "Weighted average common shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r116"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted average common shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r116"
     ]
    },
    "mrkr_WilsonWolfManufacturingCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.tapimmune.com/20251231",
     "localname": "WilsonWolfManufacturingCorporationMember",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Clinical Trial Agreement with Wilson Wolf Manufacturing Corporation.",
        "label": "Wilson Wolf Manufacturing Corporation [Member]",
        "terseLabel": "Wilson Wolf Manufacturing Corporation"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/310-10/tableOfContent"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0001104659-26-031274-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-26-031274-xbrl.zip
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M#P<"1$4DZ2&9+56I(D\)01EJJP,N^X 4,<,^+K*8VDO%RDVA7*]*^K:)DA3
M %+9Q-^BY)F;A-<)N[I*?Q%H2DP.806G;']Y?8DA 5)3G#OO&)YHF!-10UBU
MU5*2$!$@'1T&Y6S'[?H1>VEM?X)S@U:8H'W2?);>B2*FXJ+K';*+1Q2*D;F^
MJ%B]&&5%;^RPQ5YMY1]-1MQ.Q0#.P"C_:8>YH7N:E2LW#@YUKXK]KKEB.1
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MLZ55@&I89P=VF MEOE)]XT*E()3[.55V6="4 JY.AK(P\4/-5RO$3L<DPYB
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M!N>6IHKHLQ@?/I;^HZY2/H*A[Z2<\*/J*V@!1![*C*@D=1Z"+@[D1I9O(_)
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M8N[XK1Y<[IBG,(.=X E<>I)QAZ@4+8_"3(^?;I!/=24ZX*DL!:K7UM9])4Q
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MJ0RAIM3!<,@YR59KU9IP._GU]^3@"0^HU\<S81)2CQ\6C /"?HS(=:AX](.
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MT=D@'D4T.8'+,H!'E@9H#^B2PV&7&FY">K!<)\'?N>]<TT,0N1?[AQK=D8*
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M*R,A_#FBZ]TRBMV]%4L?J+UHA#Q,JY4J!F:Y!>)0E BJZWZ?Q0O*&4%\@^C
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MA<%["O')[,'SO;;7HG5(3@:+] TFN2#=FMXD4*F#6KU<E4[9D[S^N%CR+HN
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MVKHSTMC2,T*V?JC<$_L:87M%],LYNQ$1UR8]-V(I+!1]LQ+VY"#X\P(MEI"
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M%(-=O3?BN-=00O^:5GH8F[\ QQ_]R/F1(L,NSW]T#I'*]:WYJRM;]JEKCSP
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MTA)7;2@V]T(>E8IJE]X_KN^".%95)=>_F<CH\SR=<SA;N#0:O>.I[G'5_[/
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M)G+:AUSZ0LD,O  W!&P=E%]8.:A45D$"=';,Q<6]'%W"2B2V"%7V9V6VQHI
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M]CFY$R':]]U#WW(\/T2%!_!";2B''6E+BCC9"99N.X*EWP!<K?&\,?#"9Z[
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M*SOE\U\MITS[HL(-3_TGZ$:K13J0@Y2*YCU'364F/9^$LA._+'6U+N@WC:B
MDW!8SDG^^7R23Q:_X-D]&_0'PU_)O%9V F=B?RFS-K=$PU-UY.&-U=@+\,*#
M3)L$]IT&+O-/WE)M*3.=&?+*SF%Y1-8ZJV\;F=6G8:%G,:&1-W,?JKQ+RG'.
M_B_GLS\QVO$2;_Q.9O]?R3>SKX/[WFAHW U'>&L_F/\UVLS/!J,H+<#4F"U^
M3\LKJRT2SOAI9*WIT+0&LV33-WDYPH+Y]4?)UI31(!PR/+I=*Y%</?<%)9]8
MO;[Z,6=KK]=#JJ>$DQ6%FON#7;CU='!D./RSG+N^,O.:3UKL9'$B-.KJSX^H
MIMZ!+YC2/U&F=._.F.-5'&_=IX/Q/#K74W9:9[8[RRP+$A,HRO$4N3K(V+!%
MM&.=YU5MK&&UP#W<N^QPBY1%Q5:542%RD)%5,75P1D\KXI&$TL8I*3AUS>VY
MKGF<D3.!X1CK&74W"<F=*1)!W">>)PR-WV"P[H=^@(E'5#<#9ZW&7W-ECJM(
M-?!65T8'"$KO^('7"K1VX#B0G!+ .!,-WB81%D!W!5S^P\#KJ_,I3TX#AHLX
M82!Q&/0GT6G@8*ST42"#%1F_3+XF$*S;PFOOA:,KT@IBC2BC&TI)]?1Q^(IT
MUWPUJ1E-D?4V+K!AX&-^\0<67N<$%A[[$1?83I@;?;7#"VE,*+@(6ERM<0LA
M?T#\ZD"@!65T@:@4CPV%:O3JZGJ(S?^%^<IM$.1$"<;6?V]A_%/A]7]/:>%J
MSRS9? J-T[$435U6%67F*H<T3M)AB-&DZWR<A\\^^%>(VQF\9"^!%$S*O)"]
MKW?SP7]_)3&Y@U^)K:[LS#REF>;.IQ9KVI%_,I!"QSVMO#*SL4@"1RYZ(6JT
M3<+/&5(K%%I[<_7QZD8PM+;WE[0+=5_UT#'*]L[TH3]9GHQH%_];-*/Y*BLS
MO<6B;"L0UTR\78..E<R=)#YDL*IHB@=ADB3EVZ#Y0YK'P5<?3)8#/X ;O$>D
MW;,[+J2IK#F(J#4O9@MS/+XZ?)HD@6^R\]0]8N+-[<?;+Q]U0$)YVFK)7-GN
M,I!_2LR[(G#5UA4F%:CK6+;*(9:/NX(D(M'W0> _0!<&8 1?@!US@^JO*:BG
M*33*T96 XHLJ>=ZJ>PMR7^2($Y=A!3MT+<QMS)3HIO8]1,#"8V "ID*+FD))
M-L4)R'[L#,AF6'"8Z>OH\847X'A;<J*9O,C !!-'34U!4Y:R!!P_=08<>^<Y
MG\%"*ZXI#(3(261_JXKL*6DC,I%[/&XKKCJ:B;<\3:F3ZJHC=N? 1"YFUOZ6
M.-\L+ZBE&1JJ4)7BH?;XG>9,3K B2]T,;#TDZMKFJJLI.LK3EF*D.SF$OV=8
MASP7?[3BO%HB8!%M1E/<2"$SA5!5QVG=M@6YD.T&SBY^9OU ]QSOYFT3V;YA
MXZ&G>WBFR5&R*<U0(IW4%"F5W]B0HVS*XF3L!;^#0"):6 UV$C/"!*?(J=FE
MJD[.H\71^XK,X(N/5Y^N/LK(?-3[2]RKNO$8.J= FEMK8(<..88\L>5)7()%
MG#G0"?%\B(10:,V6:TT9;2*>*DDFQ34&4;: )P,K5YO0#E_ '%@ABA)%Q(GO
M@1U?$=MLPS3E["G[^*$FJZ-.H+!69C3SLDN3^;V$%K3/YPO::98O]1>KXG1?
MS))2;-D#7$]S4B4OQ#(7FS)-*#.W.<2P-UAET-B!@."2R;N$IO:7\ZG-E<*+
MGL%+?4V@9RJOS%+'D9=*T&H5;U(9Q2*8U$LZS=K> #I+@22D.'X\5QQY&;[4
MUP9"J;[X*OW10O3/'M;Y0TL?-)R@&5RM.>X2E6U/&;W +RJ6DI!!?0=,D?S,
M84(*XR>*PLC)'Z:^TKCD1&*9R9$;+I<\8;D3-$%$&E-&R<A/&R:1(;5E"VL5
M:@D3C>\F.GJ;]U?3"6,.^7ZXB;\K#<'RG5P8-"4SJO6'VVF.F]SU+XGQ9,-,
MN'X'$22'!S7<"&LV^Z&0O71[;B]E<R"J;R.52X8H7+OY-*KF:H7 *CE(2,;)
MM=)PU55F^I>4XTD.U)($=V#/1$OU)*(%KJ_/M0 ]WYD..J&6Q&>M.ER8<N8W
M/OF:45 [%(N&94I6(+L#.B*3%DU(+=R<JX5L<C3U%8&>6=(.L+U/$(;'%=\Z
M-=P*QR]"K2FC @1SJ\DDMUL10X/E$A"WSD$=S+!.G '+<RW,DX.O52 ,3;A)
M_6$EB>9F@GTJ.B0.MPV3;??=[K]"!'T;6H5H$6] -VQ(HK#6%#3-&!BB3[C?
M@\"$#I\9\DGB2^Z]OR0]UV:R=.Y-=U'1+K(O^V550:F&E%$)$MYUE\< JETB
MP[;P49"Q*_!?!YL"__%'GT2S +0E.ZFQN0'&*SS-(48KIHPP)8OC(&<ARB59
MEXX\L[) ]#.P#9&UQCK16"$0<>:4V'MO8T(W!P_<=94!B9 LCR%0C=@V<4%9
M!/JFBXL^P.#/%4"F8_>]'TA4Z+/5QU9!8#I/)OJ&-U@CQWH"FV> \O2_:!M*
M :&:1$\6 BF<4/38O4"%3)%GAU8P07. 7J!%6SWRBBF#AUI7#V[*)>T?FUL]
M$LJ(%R:AS:>N%M2RRH! 2%:Y(N8DKE9;3\"/%!TPYVKWG!(JBHF3W^>NGR*Z
M6M?$M)V;;=*%EE-"&:'Q,OYT?U5,C:JB&IOQ0(:N'\ @#( _6?X"3"=8SS>F
MX]R%/G2![P]=UWM)@F/B;'!TV59L4ADP5)G!M3&BEIS@-2,I_05;G]A$V?]>
MH"*JM'<)&"K)A=J"S-I21 \>&NTVVS5F:6E$E>KB$D FCS&2LIDKA;LIGGH(
MX&^M>!+6 [W\7M[0)\B;&K*D2P&@8<>[>*S)MP@&!3J,7KH[@!"D45*F\S:O
M@83//K2AB79S<W\I+\=!55A>&0S4YJDJQP))1H]$EY4(.@X$$F_O9)D)(\SU
M8_%75 8OY<2: XMR)"MX\&$$L3-^LL0#P+.&L23DEE1/M.5$<[HV\!/;NLNE
M>B(/!+'%0UYCB+.D,IV@^86[!X,2]+9^ZTY"$@=,:O3L0G1'GUPP\]SH-AK#
M2F#54087]5L*PFR0M%5MQUHXH9)I(.265089Y05X#@)^2M6+C1$0?I+8E2A7
MYEIQ5DXYH?,+[%S8?-3I;Q[T'=/W)\LD64N2JX6Q(%#+*R/]VA<#,19(<AFU
MI OR2&4N!XP:RB"DG" Y@:#HLD#9(4X1> A)V'I"!'V'F%]2#YGR;PT%J&Q=
M]U-%>KRGX9 LHT+W!"Q*K/X;OP5N>[(T"*'QDL=8WW/+*@."VM=V?O(EG1BT
MLZYG""3'*V,\\L,WV1OFS!V 8"O*H$A<V.= D4&[@O9 /TDM#^QX\Y2Z2(G'
MS=\'CS/"Y 7J*X<'&3(]66XJ\Z-U*Z/<71O"-4IT_/XW9>1?:T@\FUQ)CQ\W
M>(N*D),[_T]^54:ZQ4+($5B9&=D ]Y_,5[@)-U3^'_VNG@2X]"8?':WK14D7
MCD?0!<, ;$XU9;7&E!%];:JU!OY(>FN\36>NZ:_)_XBM\8(M#&S'S( ?(&B1
M5)3XA^@QC.P7F9(TAUZ5-O7&(1LN.?Y Z:RJ)85/FV_=9HY5HJRH/@G6L1",
MD]\6GS3E5+HPC(GS0HM</6=TD2^@[Y-073, ?=.Q0B?.D.D^(L_WHQW4%$\E
ML']?'"#RAF?^ME16ZY>!MB:8UDSBH&:?2(E?C[T/R18?TPX].^;<&'R/?J*'
MV?!4O@SL2>")I. ;=9;-*?(L &R?Y!<F=)-["E&^\72"4N/Y"NI=%J3*L4/2
M";XZ:$KOOI#W9\$+<+QMY/P^^#K3%-8+#\^YI8<V#QZ*7AGTC[+2F\@]Y#L[
MRT8LL8_+0FG]K*OAMHM\BY"<P_OQLY;)V[3[BSRYOA)Z\<N 3RDN2/(_UXN$
M:/@I47FR/RIP0=(NIKL&GU8#,YU_DE_\_"Z<VK=*BSX:OH'WE'Y C+$%0!OJ
M!#\N=D%"YZ4^]19>=<92C2CW#V];4XS-TV*7@0TAZE-LU/P01+N1R>.0G!=.
MEG-@A2A*D]\W2>S%W>[T,5*1Z&7^5B\+=W4P*X6I(L[JZE[!R%L5>[&./*,T
M1R"M_&5!2XP-*6@ZXTH^7&_%'/4AIB[)61+;?1,W$XQ& Y)(&Q<&KLJL20$G
M,Q%1XZ]5PY4+E] BIJ5ED6S Q,7N.=#".EOLA8./YR\<S(>/X^'#L$_>8C3Z
M_<G7\8*\;C"=C(;]X:"!EPRJATB?,:7@_356A1;B0![N,:==(@[;V)"!,>([
MSLHJHQ#XI7$:B,%'DZIA9%&T2+#7A&E:JYP@B:+BFHJR%%GZ7]4Y#@_JAPB=
M1S0PRVHJ;G&:6L]!65G67^>/W@NV:*+3G15P"6\.VR8CZ.,-TP[SC3P33MLO
M"+6A.3:JT]IZ_LBW"$_%,%5;R*;<:($64(8)/R&73R-QU>T :LK1V($\D\0-
M<X?W8W8VV" 3G7"W.Q1)7A4TOIO()GOU)\^.]IRDRI!D726_DHW^H:6^Y],,
MGB:ZUAR9K;%(4B!!JVKOJXN Y:U<^&?T[.X=<,$24I=-2FG- 21"E:3@ A5E
M?G@7%6"*(OO2M8?DQ2QL# Q>R7R@FN3E6^PF=DI3+BF"X>AR;*T^U3$(1I[O
MIX<5QG:+F18]H>LE0:;DZ[7GV$FL7AAW.%EFJXDY7S^=.U_'@T5O-)G/>]/!
MK#?_Q9@->L9T.AKVC;O1H+>8]/J3IZ?)./[IE\GH?C";XVJ9 ?6\90\WY_>V
M /6B06G@L1U[&&CQ=7L,V!1@%*]M4>&&U1!&3CQ-"!", .\WGK$H(N1,HUEZ
M#YT0[T *?-"BS2BC</ADEU4V4DBMY7Y=F]#AP84R0I<JR@*$M'&]\J9Q+/P&
M2&@%YA0>DKD"^V",Z#A]$@8D@,S&$ZQ C8@VHPRBQ-6(%%(5>%"K,>C@G2.T
M*N(F:D,9T$B%0GF$T9G2A56*PH5$LY\Q0PQ@M%8N'&)";*E%A[49147N/V%B
M#[LQ]II'*ZX,AL37-B&2))VGMJID3@EFK56Y9941=BD1%B.@X35&I>F?*$-.
M-"2ENXX'%IE-+0CJ>.0,-X 11^ +. 06B+KC;B2YX\AHWMO)<'K^?CQOGKAZ
MSS>M-;!#$B%,!&"?P6'P:CFAG5RNS;IP3^?6@G%A26XGRF@I<1.E 48P5K;V
M5J>*U-[M\AM@)/:NL4=E\-<@JLZAW#2#:\U#6AG*Y%TVYD,A1=64 U73\N5%
M6 '+5(')8+-UO!T T;V;230*9G)Y:GE-@%$@EAS;7(C@UB\N5/<(,MXER2W3
M5<%?PA,D%97GB)(E67;SRD%,1TN&S<V:W0K-G[E6Y!;S<IZ4MI4#=:WXD@[G
M-FX/UNH3BU+%'=*%B/FW/I^'FTT6OPQFO=F@/QC^&KFTU'=0':BGW>K-+=&:
M*RHSFM]@L!X2N()]#"6?IXFC#64T!4,^^=ZCLL1I_5)OYCK<(3D4[H_A!6)5
M44;Z\L1[#AEA!G02(4S/#+N2<B@1EB@_*/1ZR[5/AHVF"+Q@0@C_HZN+42K9
M].8\GDH+\&KZAH4_/^V XT%[!,)O8 --QJ-N,AK6!C?\;XG6QY?6O3NT3)VV
M^<A^3/:X1 >%SD%@Z^X:BO3&9CR0/3C]R?(78#K!>KXQ'><N]/'.RO>'KNN]
M)!F18C33Q5VQR0[BHPZ.M)[K0AA0Z2^QBMS_7J \JK1W45 JR8Y:WL5H5S4]
M>&BTVVS7F*FEP56JBXO"FSP.*9 >HP8(3DUR71Y_:\4SLAX4YO?R!L2R3)*4
MC*/5D&>V9Z3HW(RSMG(0J\,S5(47K5O\TC.MLU//44HKAY,J,LUQ$PE0W;EX
M^I1IO!"AEN\X2,3H5NMMSLH@B8X6\:H/ I^-CO."'8<%)\$=>Q3SY*C9'X.
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M!]AWNZ2<GQ04.G?A;[6;B*N#*;4D[FQU*8Q4=ZS2IPA:1<83M7PW,21&KJ0
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M^:BBGN6^W:N.2$JK50[Z]->JLI[A:U_>3>M7/HXPPE#;<V'*?%ZO?<'S":)
M@!H<S)Y#MJF7\A23L=!A6T6B]=?P+ :\O917'CQ:OY0G^I![CF7 ^^1Y^_)O
MRC(0XXBDH/WFGFP7?.B:!RY"3V6W!R0QP18 H@3-ZCWP6^M[[HH)NH3 CB'
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MCY/H#MW,[C4/1@+5NXF:J@Q0*]TE!21G;H?$](98Q0:>"_8/S),"]L*[P]_
MW*6M7$O=A(Y$7JB56Y(312.(%V[[Z.'2F.*#MN6!$$<SEX&?LHRH-6%C,]$(
M%'^K+W2__OKZ/!9A-A@9B\%];VK,%K_W%C-C/#?ZB^%D/-?BMGT^5RC!![S5
M_FCA39/]2S.TP=WMCGYA7,$OU98R&D1$2.=GE?)H;]/#V?="%VN;+1EA^G9Y
MCJ,SKYAR<I0GD6/O*#?QZL4G%)TN@&V(K+696?E.B:7>_>>NJPQ.A&1Y<DA1
MB5@5@Q2 X\R :>\800?'19028S5YG'K%.0AM_?SC+1RM<=U?,4SMW FJAL3?
M(LXZ%W&6*C">4#)*65UD6T*M-QC\5<,=T]_POMAS?_.<Y9/IADO,A9"XT?L>
MVGKQHU9T8?/6[9[P*U'>>KR76"2@<.1?5X4N3F[K<0VU.::.S1UQ*R^G >4
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MJW-)KQEG?R3VO+>M$VV$VD-![:%>PKP4:Y-QD<^4,M>+VZ71BFQ@]W,JJ%%
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M =^!*<4D31WJI] :#EF_^H:%T2-X)@X M0U-59C_L.2/?P?9T1V75YOQ:R?
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MG+8:U3:F'I(:>]9M"6V12Z2SB1=V*Z.\\VA4?P;F^0;;#SV++4.CH6>2'ZV
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MS,6B-W/5YERGT*7U&_D%#]$1L%R&I1.>@?*D0%O$N =A4]LOB8P"#:BVX4+
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MH*@HKS6PH0T34$9X!4C[N*\]ALS<>-[V(+MDOH<0T1#R Z0RA-?"Z0992;+
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M(33V1=5SPDSEM!.6=SL'IJ'A22+'=[!SDN3D?9YO\>.$_%79XD#D2VU/2-:
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MNS*R4U0O9HUDHF!TD,#@V-F04X\/8%?C5,M;U2!U/0^QLZ0U&AV[(Y2KKQ"
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MHN$1J_"3!'>K=NNDR;@*"24093R506*V;3#-])_:9B7_I3?E-6^UFA^7Y-'
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MUU+3Y_><]/C[,-('N:'>G#62H)ZO"=$3Y0Z):)?2 L&UQ('PJ^1&%^1!&=A
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M*UG>?VSQ_1>I-YT[M+[S.R=M8EA-F6T.;_\4O=F2JX5X\P]Q5MXUL4^*+@_
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M"D<P'M+)A=*EF%><F_WV3U\3KZ#B'(@*A8];DHT <W(("L(Z)=^4PYV8"_G
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MV/1(A@,"5B%R^,6(A@<M]M3KR/17,!)+S["C@Z#DMFKLD1*<D\M4ROP3KY&
M)WZL7"O<P5-UV<EK7;GUEANO#9C';2G/XD@-2>K]''95;+V14M7FE+Y<(>VQ
M59!^IZJDD)$ZEP;NJ[ZW I01).6P5O/P,;R'LN^/>VGNN%;.G*-D=K=I(*_5
MT*']*00-4C6;8@ABG[A(X0^\9_0-Y8!?RK0YIQNK%!$IL$""A.O%6]<%+!L'
MNUK6[8'\?+E"/Q)UH?612*X4% %PP7K6TBTQ&]^UU.UU::(:E /Z<D"MLQF$
M1CG4##3-[\N:+!%;H<HT;MZT744!03'F' /3UD"0XV-/T7PM=7OBTV#H<G I
M!V+&C.=9&4[V4U_QSI"2T_LFA LF4AFL4JI%A?S'KUS'>X)PY;A!MQ7V6E+"
MHCY7#[ 35DCP2;9L($[C]1I;G["-C3>@@:;<T)=C*LQR4.8"GQ1S^;&<[2-*
MV"VR27FJOVK+*OJ)F]:Q1M*)N.G*/4.&J"5S5.8A[G>-L=9N',M'C!HI*D#Z
ML2, S"33:4]&$_YOQ.>*7]*G%V0HZ)E6G*#U6_6G5( AX%</DR*?$#><+Q;D
M6/)2-N7)"[!0E)O; U8C1/549FC)\>[)3PQM4W$\$HP[_@LC<RP)'3-'=B,-
M^L-#X=)2B8G'#G=Z;/<(<:*?YJ-NC3NFKA?S2W\X+H,%$Y./FAG]F+55X\MP
MW?[DL:D8M<O](8* #<8;JV6^:^4.08[RI .<&$)Z:0HB,VQ$3!P9SU!WWH%S
MF"!&I<J<2[,LW-BIE>J[Q!=^*<?.SM$@N@,[XLVR5H=$6XH,JM46(00.6!)"
M#H(C]*+ @/I?@E(J9:0B7\JR/HJ;^3#\LQM]$7%.#KHYT8]$Y3;YD<]\K;X2
M!XC*07 /TEE%"G,+JT\''^8%%V1_.-F')W8"3!?6@*P2SBC\RF$/)3J=6<CY
M]JVRX(I)1Z<QOD2FVLA A0A#$&[:0JBZ#(T!ER%E6/>*!"%5^E,[!ZO:MM+@
MTT.+X9#'X)%W@"-S/:Y7>'<*(\O.W]"C$FC P7=R2S;':B\C#]S!W*O.)\/<
M2EI:,O*YR)J]K$ _JJ$6M6^@$Z#.Z/!A^.SIP'!;6Y%(+@U(302Q8_LF"[>G
M0('CV_:0>) 4F28G2HC*RC5],OU<:<7YM )-,KN-38KK\V T,,$9WAG<XX9G
MO:LJ0ORS+PA\^F@N] 939=_1K[9AF794?XJ C<R&2(M'BCXSM%G',^U,3^UC
M@0@XEL?2(MVH6(!*4)Y-5,]V]E3JH-+MQ>>,.W@E4]C938UVBV0?'S0U]!&V
M;Y]?VK>7]NU3;-]^>%[VW;%[<.@-M19!&Z830]6<T/3<^4)A7,5YBU8?SB+5
M)',3B9D:.$2KD#[(T^3]G4[\9M/OK 9'D9F+!:,U!!#J01>D7(:OMXTF.R@F
ME1XX-+KKWGGSIS==^7>/ZSWA.;W1B-L'#.H57G:BGY;RN6I-[YMOCZK@#]MJ
M7!_+;3;9:(2G<OMLR/'SRR^L(S9N.FGX6 ;E0F#4EOUF1YRX5MJ#K+I\E? #
MM(W!%)'(<AX:)6"95F<%F J]T!RS@0'-N:BLTB"<&>*MYD-U]B?S/#5*.R"Q
MY632DGYR]&MWE;3CTX7 +,J(&>&^)S>P9;'XYLTKP6!#06*&0((?AZ$DW(E=
MP=?%V2SOM80RH4ET<XJYS:8B+I*[LS6F38KKQ3=A#02V2)M3,XCINH4K2"(Y
M/DED&174('=R):LC;0.\THXR5WUH"6DU3'?XZH7L']<5-H!)%N=M4"%?!>>'
M K#(P 2*7( >"",P&#,JH/<B#_N<+4<\8#)ZEI9"AUOF%2&8E>)#2"EZAA3(
M+0US,FQI81;.;5?'#30:].PSP8%*3I(9'KJ:QYO"*VQO&HQD(9>B(1?;3H"X
MT9FA@QK!6V\V@ 1(WR@E5,&#)&->3HKC5%@?:C3W*G_WL 6Q2XY$=XZ.@?%*
M0%)@/7=S,\[A$?2N^8Z::L=:3;;*WKYI@0P]X-Z:2D7-B>H5UL?*8 _FE(RB
M027%R$>K5'U[EA1BS):6&%:.)ZWC0L4JK$BY(FQ&^/V51](W6BPNQO-R$A)*
M22KQI!(@)O](*!@*NIJRZX"+J1RA&6)N?Z^QTS6Z,[JI'1T0%/.&: SC(O2_
M,8H8M6U=Z,U[%LBZ*YO"#W8F_/M<D!,ZHG"H$OV:D>_I.+.61<5_%1ZG5,0'
MSAVI5A972J(X$5$8--!57-4Y(&2O]UP]W1[W2(4XQDJ5@SXH68D]D*C\Y(H]
MC;)A!T?UEMSGIL8,IIXJ>G#&,L_,R>MP0W24TKMU=6'^X-]B)W'F9G5A[5%7
M[<'@&S8/YT-8QS 23JNLQJ^8M\S7TRS"MKWC.(.&PL8P#0W&6884,IK 4&RH
M)L(BF,>Q#Q=Y1AS=U7HFW,C'@X_F65Z9W5'],*SC2"IZYA5)U;_/E/T-TZ:[
MN8^JJD3_V=?=-#>.4:(_OLEY^TJUCJGODB81Z5HPP18UO &1B0&1"K5:]X>U
MA"X4R/_326S/B';1(;KNRCM7%1C%E1=R[8ME_1S+TL#"G?8"%]<Y]'#6+*N+
MY-3%P,X86(:5)&H[EI)5(<BZ.=(A&][1CBN>@$B&B#@ZM.04!I<"567JY5&K
M6E8;<'/O;F["C7J4BQ^^>?/V8KD7RSUGN:[6*&68+0FR[VH3<4:>+@&A,\"+
M85T,ZSZ7J!4T*;@:1I,*9W4CY!<CVJA(.L7H &7QJ^K]\MCU\',OZ6]/R/Z>
M7<SO29D?HP$/QR&6-TWL8!%9Q[0^Y50?$EPO(^.?OIK%N(CP#K0Y0@'7M$!_
M=@*B24AA>B'X-8INA[=T51MM<XR[(0),Y]'%,N$AETI>KC-$ Y(G05<Q &]/
MI:\.I2\T87R'(RGSR^^F_?:C-@3@703+I/X%Q7C&NZ<OFT=[E8HQUQ%,:'*Y
M;T\_.^*&^SL&Z#XVB-*+"T3I E'ZOP.B]&.,3V2@-HU)*F53F&K?M-V!N ;1
M.6=NW8CA$4"[.)SJ)Z!S;^OA]-A8FQ_R-1!%[/_U&+)0S&6.-(N&+&TW_>LW
MQRYXM[ 0X<_T]+2<NAR,*] 1 #8-JA%CP'':?F34<%S6_CI<5'DGON-__YJ6
M^Y6.Y=#I0C]X0YA:^VI\&9S^*KA!Z:HC?;,QK9:+3N;O&7W5Q<:C@KMJ@NWG
M/B#].<W5JSNEH22^C^#XT!&YK=='-W:4K&5AA?T/^AJ6U3IV3"G?M()LQ^[F
M;F$9;U+9/AU/<>2)?X__-&AUGJQ]NIB1!O?$W:#L&D4Z!83UR@? :@RS3X>;
M'O_B]>)?N8--G9$H R(3O_W<QN2Q.AO6W9UBLX3)QKJP+F10R1P]P#'R0'&]
M:_XE5&K\3]3$#C+4PT[F8MR=J!.(K,N+3T!<9;[A4[6T?4527/;"U,@QW29D
M!XB&>#;1$QV W  ^QZ#Y,^]+_CH:(:2V;;,X!3\?C#+<6HB36*-+IE7K;G7<
M]XB=W(ALB9Z=S ]%"!K-UT#![.0F%V4B<N0_O8=<O(K^8YU\2A=!1UMFKD !
M6WA!M%^U)\GC'TR^6>)/RZXMU[I1A^UD)>P]RX^M,][ET9J#VB(G&X3K&RV4
M-TEZF'-4@B +I,!+GI3] ?@R""@2#*8?JKW@32+;G;+AATM_\4"6PA+85AH1
M84(G@&]>/'OQJT)O\*X4.-U]#R4PFU0P34X(4%*#.?![S>$DS+>C2CX27M K
M3D(^^>;-JT\?\A!AM6SPJZ^J]V>7G3>H'Y//CM0DN+0[)3K5:&3^\ED%I+M,
M0(-+^ W"9W>91";V-<.H,MG)H/,AN ?6NA7U(IW=@<]78OIXXIN3F1RE5FNT
M#>H0U_Z>X$'6P24DW7 VUS)=';?=8VP@F9IW^M&#3OQG>M?\O#/.LMZXW^ Y
M5.>Q&9>@M\4$%#RG3^B0D,SBL(]@8,2<[W&\[LN_MC(<.2WV$XEO=:V&/CI6
M8L<?F<R<V@IM+^E2["@2J),\W;8(MA:/P'XB'3"67Y"]1(&#2_-GMU:A^$;:
M886N3,5P0[]F0E;*O0YGZ>03'%'-NG*+5ALAMO+Y=+3@D:T7!8]D*EZD4 W8
MC$54AF,,GE75NI]N?-SB7(C(H"5'6"Q;K[QG ^?Q,+*%)3Y3^0D'K7/Y"85'
MHZL.GEX\@G.4:(NWE+V6Y,*9%&CNC%44!P;V1M _LF6_YASD96YE BJG35+N
MN#1#,\7 XR- !.!P[8&%]9"R&0$15$;0B0HW\)2?56 B2P^?85.DX>,Q'RR3
MWTPSU1_0'OPAUN7>^-GGWW^V?+2<\F=EW1T=+VU:]E?F8*ZQ,3WY6 :KNRD;
M@:KUR5[@Z)Y99*9,P[BD2,6H D(LRCUV5AYI1_B>V/KIU"!%YM&CA/^JC:Y9
M)U:3Y4PX^!.:IY+ DBT(+NRL='CMA!CM/)M.GLCY#NE7?2-<:;)5F>'^J_*T
M:TGD=K>K>')%SPH%ID6!Q3:^?WC?KUZ_P3'(ZLQAE]]1>]R-<ZNR (_MPNES
ME#*EI*2Y_+*CS*5)>4'">4S<@45T^$14P>5;&H[]FRH:9I^]L*7R=-I^6BF\
M '&20@0=GY9G(JSG@"B+GIDN0?]7/]LK5]*.5#DDKE8%D4?CG6P6?ZB6'9-P
MOR@HI/^<>4X-=XXRS)NRI\/_K;XJTZ2 G2J'UUM^ND]H_?_EGW_SXL6SEV_>
MOL)_/7_YJ0AKT$[^(=C]R4P<L%9E[%#:$EM0. ?]W9 \N L<CEU/,0&M[%W;
MO>=WX41VEJ,'V8SY/:[=Y5RQ*&S?R80X62^$P3MATO1\3_TVQ!?$[EI1]OTF
MY$?_WFZ;Q8]U"-FHK$CAH6V+L<C@O)M<?/+ZZS???>IK:6%!BV0-HMJ3;+%P
MY\;]HNO&(VN^*CBWE8K,+8$I3=SS#*'&O[5W%7H]X:;?X+HOOH0Y_5IF^8BJ
MA$)X,ISUQ!2@$*A3+/*8R#%7-,.PDBI8>)'TQ9R!]M4P.-W+X%,1Z95FI^-?
M3&Q'D=R'LE[[#\'3_J2J./_/Y[_^%:I[XO,$CKWF*4!.2? S_+1Z$PB?6 *G
MK/?38C0FO:A-3GP24>ME60UWA([&:E!^P(P*\>X>C^-C2[)[#_5M0J89?696
M&0I1@$#FO11RP@W$ML=4=XM#?=L."<W_[K0_;,/CTL6"Y7TQH?%$KY'>#"8O
M-@F7"GR\Q;4\4B#D_<^_4$N6PL6!7MG( )&CZ6W^2,[(N\&WW_TX=8/U(2S)
MXJNZM6WZB7S<_JI?HF(I"0VP])H;'WJM3N7KD5-)0LR0=GJGHK\2?$O\ ?7&
M$^U2+A,E#T_?>O[ERQ[WE%'S^SA[H[^Z]$8OO=&GV!L5Q3.J/!6IK"Y-;@%:
MY=#/47G0)V@CFLOR4)I:EYLLBM^-E*!0,>N3_L X/(;G=T% %8NBA& ATN6N
M^AF7+&8>H>J2Z4YJ4"D5M52/4!.BTX)K0L+MCSIES0+:6DU".<7%_9\)O<Y*
M2T5.Z0R-)^4YJB-@1(>Y>=!/[\$"/J[X^JH*'Y7A^>GVJDCG#,BZF[BCH,BD
MNNY B$OUDBC4S<)I1<JRQ9#CPY&5XT',1F-N+)BC-&N</F_K@WPF6=VSI.,R
MCEMP1+8405&;+$L(^&;&O6=8+?G\01.L)HHY.8I'[;]8E"IMPCRJ*_8\\"K]
M/>+PH-O>M=3:Y4>7">32=(MEWGE3#Y;DR="_-[\E!+AX>2U8[4'B-0HSCR;
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M"BLWG3TN"+U7WK:=+]G2Y"&_CT?3D6D[IT9"XPV)=_(G865'4>&L\DYCB:2
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M,T^GD%R'U$Y Q@*73'/!_'VLT%**3L59*Q<T-'B2F$I4:RH:YN+O^#TRDFR
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M'IQ[._MR.OZPM$@=JNB.N^,P\JTU@J4B7B__=EDLS0YB)=@Y9\A/R<B'P4E
M@4,QB:' ,7Y_OZ._$,*CFJ(0'_P))R&M<Z9#P@0>8AYK>F7H5@.<"GB>PGXA
M;H(D27?+L[0Y, O'P!EM^Q?5]AIF9*S<WE-Q@$GPQ:4 O(AXCNC%>]?CTI2L
MA8YS>2',?B@Y4^ 9,E&33RV/XXRV/%WG;-\<O(:?N9!I#F4,MQK.G%W(D#5F
M>S\9[&QM;Y.W]"Y+KQ8;9S-8< <@PCY*!\<(.J@'!Z,&'='@._ W0.\P5RTR
M;KH9I#I,]$TI5M4!9XUM@!WQ&W07B;:^ +:DWF6H:ZBVX;/P4$%:YG)%S0!:
MT..?=XJ]7 *6/9(8V]N9ANZ":5P$2=XYO:SWV,CE9GN7?!F+[5",L/A"@NT@
M DT?Q'FG*?Y%O_<DT.",Q"0TCA+(:UCBQ.H++S4 7;5#B']\I<:$O+TH:,LE
MJ%/,5)ML$XA+V$?882%2DP/= J8'9D09@+LG #:6) #*:CE,2>HPRAH6^EY]
MV%^C%'!0:/).\$T*(X #'\N>.,UU397; (QB< =2;W2'%+T [NWNJ34E(5MT
MTAUW"+Z-FQJ61IE1WK;*H(1!>_6L!0;:;'"(Z+VJG>+DN7$+\D#@PAB'D;H,
M@X7MT_3E1*U*ED8209<5!QS.H2_X<OY-2-[EIF#HM5S!/5*KO2JA]\@!(X;2
MRNZV$,)@:&&7"FE7B"@Z)"6$Y[:7V5 6 &"JR;)"%97:A,=]M\.&4-FVL;\#
MYGSDA7@V!Z\R"5/* D&A9"5E8\*K.BR+RTJYO2;9&-^/=CDS6IGY0+$EH*>M
MB+D'K%O ,!PTX@-D)S3E<[#+@HK'[]'K6C*)!63E3#W=HX7@^YCELG?V^7\/
MO)\AG)6O%[P,PVL<597I+"D688A?,RMO6?D>"H)(BG$-64BASV3,V%3<]_P2
M+$VMG/S0UL'U@L[+DC?2>7%B=<C,8@A)A8&.!Q* 6;^WZN?^NOJYKGY^H^KG
M[QW%_J1-5R1)H/G\E?2_1IO =&?<BO+PU21LFX!V#?2$@6+EWH+8USEI["J@
M;AFCZH *NW'&B]D8?*S5]W1\EE"?+^KPD2R6]G*PZ--M,Z>]VYY<9"D=#D=D
MR"6"%/#8,V+H0_JAV'%#!X>D$[IQAS-;CB9Y^:M?/-,NIS-EI7<^A9SLF)>#
M42P/;O%L,>3*_80<7M\PZ$T@5+:J/?F.1Z%E#M_CBD(D%,^QFYC[8;628EMB
M"<5)J/&>>Q4<AO;B+2E^#T".\.AAMY)T0P4UZSS&1A(QB%=*;&+6,>O"FL[C
M!NG\074@Z"^;$"J,B,W<\L7R42-L?D:=S!>.RH!&/AQ/9P@$IV,O:I;YCM6
M&YM:8WH7" 7@YB4(GZ DJ#H=<]Y_NT,MV2PWU;>C%C&5N0I6H(N)&;+!+=/W
MQ^XNU(H$),'I=U$DP<#=!(847R4 IW$Y&3;JT"[>9JEZL;J4<J&\&HMN8"I)
MPB7/Q1_D_.1S4Q0V7V4;A%T4N";L^K%!2*BT<1M\P*[*8#1D/RT*M9MC]%V=
M-H2%FBS@>WQ/.6EE!*UC<14ORIX%=8EN*SY,?;=KKXOI4&7 3="CU#Q"%,-T
M.(W[$=@QH-KB/B!#2I/MO*>,R\T9J,,))T;32.^4=A_'!$,"(DH$E=-&_8,-
MU5"!^3XSC0QI(]RFG$EU_TD!_72A9^X23B:Y(#;?,=J9)200%5T"\6ETRC0E
M@T*5NEY+6"L+*M+AZ;DBJ%G%![I2OE([I>(R+$3K^^R-D0HZ>I@O8-).-P<'
MHU&)%'=PCMHW$BV 6X0@N*-1_!RMS*H$CJU3!4E4+\:IT%O?"K&:2,.@VSC2
MO3_WT::L*1J68D'$NH_1>JP1@IX.<X+6FM"AY".GK;#JBWX9_1AZ3R'O -1M
MJ-M)5^($[ TJ1S1H"T3U#.PAUN5WMG9VQ1Z9=S&5P+R.QQ< H<CJ8;(3KFQ2
MK'P_,3C<(T$CVG0'M"2C>X><^)M&0!WGCFG7;SDG.]S.W3THX6H2N@GM>S?W
MN$?1)X ;?>3^&\(5J=A"T+IH#9DD5*+?8[(0W;Y/'P_=UJ&BE_LW@=S@;5 W
ML#R1:2" G>[>!+9-\.DTHLN9[!U-3K!2T"J8#/]'-G1]\P\K#MDU@V=PP^N;
M0])18W4)18GTSH*[ J739E)G<T\4*@QY/]U]68]D/US<LBH#(@MAV=WD%5G,
MY74[A8.*?7LP(LYFX=<W*(-EFG<L>09T=>>3H/@NG5UR,MB<>,?_O[DJJ7KO
M-DK*SJOXZ[ *NN4Q@I;I2\3@R3FL&Y!/9V^QEE=KH)I437K(M>Z?^@3:;?4/
MSX]>83HZ>WV-U^J-X<*\ 9^>F!6DZQLDS: _(M2@"WKF.C"F^ZV!4SOD;P2:
M!BG]:"9OP'9?ILP& U)]I$XY">:8G(Z<@#(\B("$<3GR4!) 8*3RZWC*&0&H
MKF-/VV),Q$:#'QC!/:K]X$/80</^NB'2R@R[-B$?0D\.+J%'$H3MULMP!;9Y
M>\DJ)76>?V.M@EL#'BS5] ,>^Z]=NQ"DAIYC/#2HK&X_?8&PU$S_#J[ .U]M
MXP?V7*.>RL7+7<.]A!CJR/. A-"D 497$MOU_3CI*_,M<_AQZ4!.!F8$9]$L
M<+<+4PYO$+DAC_Q[[N*@?7Q91GB9=82B/15[_GR5C]U+1)KA9SM;NYXR_3NL
M5#Q=5RK6E8KOM%*!#!!*THA1%I>>L1 ZG+)EJHT@H!9@!9,8JKL:VICN%Q*V
MYB1@2N*EW4IW&?U&6[>X-:I XH#KI2U1=\GZWZ?4,0)M/!=&SSSBG+P\?,\Y
MV9E;4EG EHU6B7+=XN@@U%4@_6E5I9SLJJ6O*LBH*(TG7WOL##/(C?DV-SU)
MNB!P9,^&N4X&;L:RNH%.=28)2P95N4B1/,(==MP [I."=DV5!29P3KSL-M.1
M-5>&L;#_+?;0Y3 XU^#4QPIFL9RIS95B8L5I\%._.7C5U=?UR@5E,-;^H>G(
M\6F$<3&@0+$9 $C-0\ CU<*F7"L&KM4.1#%0H5&28.9,A0_[.^8C2L%[J.N&
M=%-@E\):J&:]]E:O/=$X+SG7%['X<AP+H0[62(7F<1G0@5-22HG"5'QH_")3
M;@XR6=7KU;I>K:LM)8H-\;(Q7/F>N!,MZ'H=K=?12LD[]81[XI_EY^T-HD<]
M]VCM?E=/I*K=>\WU2EROQ)46C6#K5_D\X$*E^/:S>ZP- !!3ME YPS 0 CPY
MTZXQ#4?_B8Q 9M"V8J8QQ?+(&5US &C:0]>K=KUJ[Q"Q(#*E#65BA$9\;0/7
MJ^FNIS&'O8A0L"U4BHC0^& M';E>3+_)- 7J%C8]Z3Y*40F)$[78VR_K[>&+
M-/8D^S7U#OU;RS*K4<"D9=Y02,:S7(U[JM96U,*PUP1$.JQ7ABE:)E!;DL#N
MX3-(0G83!K($FA++Y9[NPCNQI"X"H^W&!5T"N)X,1IUTLLU*M<26C>8UR/M9
M(R@QR,P3JA,B32H#V/86S A/0K*$K@)1,SP!DH_15ZSW"S/D]U4Y^:0EJ&X(
MI@43H3=]?W"Z<3X8@6 WK.5TOH@TQ+E6KPPO$4G^@M@+; 6^4^K@OD@L=S"0
M"8:@+8"DX>FV02N=$D 1I6@E)7Q2D'';Y*QI$U1 PH$S=+4VPUC2R8LQ!#;@
MXO:>Y(UE0FD];"J@H^)]A?KJM/C]SD'$I+*A!%LXHNOW\3),2>>%):J'*B(M
M2%BN[;GS;)1/<O>)3CJ2T7@$BD#;F6SQ6KHLOPJH\R#TU="U ;H9M_R0YY8,
MYZ,46#PF>>')'GIG4I?^XS#!FF6WO8/!(TSK)N&/:D#[$?U;AMTQ;H4\3O *
MK Z%F*9@Q'D!, EL%A<7?S+8VGSR)S^D\.&XT;V.GW+I6!][+-60&^=UQ'#$
M--#(4HX^7Y73L5'9BN[K66'&^92ZTO H4 Y%'9=O.P\RTLOOUGF!WROTT%(>
M$ [9Z]<AG,HF)6(>UA6-'_=9<%^-8 NQ8 1?,PD/WQL0>C@$1BC,A(AB: \Y
MRZJ)^4W0,T-(TWUO2]]9X-F$V#3AHQ!86@2A=!L;OC8#5G08E^71@D$C]3:T
MGZ^0[!1Y*R+"+92K?S7O;<:T%"'(XZM!=\'#?07F3IIL KQ=A+5C)M@0<?>]
MX=B>K7%L:QS;=XICXY820O7TMDO9/OI>#M6E?.4B;J-7\^X"X*#N[5R39A"V
MFP(?FN:3#%XYNNH];=;0SN;<.*M(C?RO8$,1UP6=1#DSJ+J0M(4N\NS+//<)
M$ZM[JPV/@YTMYM(D(1,W,O=?TQS.0R0P 2DA]=2!YY3DM&".-P?_2"M JTM/
MO>AX6U9#:F(F7VP2,$_Y=C[3=9TC,9BS,/#,M4R//S8\<8T[9I3?J8>OM_(,
M.TRX8QI<<"C X8,S!-^XZ74W9,4)Q#]8@MK4:D!A><D20^ZD>T/*OE?QTO,A
MJS1!F;#'O<"LU@9C)N\A[2>BO9H0T4XO.S!-C6E2IM/34)=BIH$>6KJFH&'[
MJJP:#$ !GAC_2#2N-)P<8]N7"+=1QR31[2!/8"0:#VWQDW*:EZ;?D\1'3)^X
M!^=A6F^<!6(FL72L1KZ]&K++I88>L&]_R)%Q'_<^$B2K7GI?WJYW*V$0!_Y=
M2(I R!V8K"KC])BD\Z#'H_Q=F49_$P%+2@VT<*AY$9Q(EAG"38Y2K0(]<^6Y
M\%/UF6#DG.99GEHT>:=^7I-&R-GQ#14CIBXV^\##4OV[LH2UZ&KK>.UP,%W-
M#Q.^J\D:4[HN@P2X@@'JO?:QF6/::*IBQ<%"BI7-/5'-''YC4H+5,LGX)<%A
M<->2V$;@$S!*#ZBLMU[0#VQ!@_V&7+5PXE =)4A)(P4*=!V*FG"8*#6UC34<
M8;W2EJXT4Q%$QADLJT@)9MQR3NZ&B$,A\V[().48?^$,XP-:8VN0PH-=8LSO
M$NM' [E%6=@Z. 3T#8FQ&7_1.+>5AD">Y<94]E%G-<PW*UF9A?L',(!T"HSE
M"QM-?)> "+-%TV$)K&.C45NM]K:E0\U&4DLH]IDC93G1L@%$A'%$'+LE/E:%
M.)LY"YCXBQ7ED(ML"1+!K(A$, 86^,(KPHKLV2I;@&(0UBU*U$]!]JR:X8@G
M.624*'5></$ K:*;#Z+UHA#G04?0/R$+V8(*L]9Q[2W(Q\E%JT?S4P]$Y:Z$
MGD&[)U!.YGB%"=(I*"'@<EJG!Z6A%RYSY U4HC]$Z@ [1"TYV#Z4$*<DE#0#
M,Y/]"H,F@Z%?MW07,B-4.;^Y<KM"S%K&M'W86&L$(7D9]X%Z\"T#HZ-[,5 /
M]OL-B76\V$&/FAL)'2Q7%DJ &^@&<@EI'6G)U8%2'!,.0A*'&VI%"T2FEG7M
M>Z8XH"ZW:1\$P"Q5PR#U\I5RPF;P<(V.Q!L_=6X9C^0Z0'4BI%6MT#EY#LH>
MH;?.^)%"!G1$+%T:LNS2FJ(=9G*'$]2RI]1FK*E#LWIG^1@RMF[7M^Z9*TAU
M#L*-"X<(\HC9DK)Y6;8,N?K%V4<B&6JCW)*AT5 MD%<D792)Y"-31KH;C=/*
MW=BR+_JP7866 ]'TKLIU)Z7>8>@)6A@"F!M7L8G>U>#./-5]W\,G_LG-D#R+
M5NT)P#CUP-(T3"@GFDNPE5(RH+^TD#9'4LTCJ\^]>GVO7ML3% #-ZE&5#]&Z
MW'5M<\K\&HV26RXK7R_^'<T83R;:-[.^<;(38=,!\TD;8(Z$L[P!&7HU2CU9
ML5P?\3^2<P^D?J<+EJV3*E14(PN)$0.(&#@MD6F,T_MM]U',W9=;(*M/WO];
MTG!W(X-[I/WTB0(@Z"O9\!VH!?:;G; Q@LPK"URV*?:'&S6#X.4-12"160G@
M<U&,\-K%/<2=5)49+@(=!/2%NQ4U7(+#+%,!4^PLLG=?,63L7U+IQ< &4"G.
M7XLV@]5 F?K/.[KT@&\)R7A58N26%^SYJ&+J3\6[\$R<+V/V#GE=_WUV[Z6G
M\NPK^(B5+I<IKI=R$F,@<"L%\6LBL09%S@2OC3)=AOL/!^,_P'TS=@N. U/5
M'5.3;XFD>2D!M*?GTB3"ZC\99^"?X7OX+K$XS]=8G#46YQMA<;XJF.LQF]QA
MZAT%W*:2:H<C@^)/AAZJ-2*SLL((H>Q89LPOD+Y"29]/+QM!VI_=0>^AUX0E
M(8L4:%<06[;JA!JGG+,>V?UI;)S[PIW*HR-C[VU$F48UT@-.#&.W$5MG?_DN
M[C*::P983_ ,6!4M>'5@YGD%N>* Z=6SW8H6K]#0CH&B"FBZG0=ICO[$LI-C
MCHMDPJYQ25+\IA&*V\S!)7&=&F@8X'Z!2Q.^Z-Y FWE*UD!MNE"/',3?H_$(
MQXDIL;)K4U_)DA*'V7U7&=2!/;.I6ABTS $265._A/$<EKB]^21XCG%VC3QK
MH,&%PNN?>7?=$GO ^P R8Q.U6EDIR'N(*]:7W.IAQ^\&Q;UA,,83[/@(!XW,
M?I@3-7KR*AJ?],=JD++PU'1>K.)K BRV2-;PA$+>72D$R2PA[ /S"Q$5O&3[
M\HG/PM^K30FQ?AZ293U_F9"AR+6">=!^"N?292AW26[D'3IQ&*,&'1[H?F*?
M"6/;J$T**&^M$G.-@;<@L_-A*\33ZK@784!7.].7T7[N2\0'Y(&<I"92[ZQB
MH<"'G;)6U*L7VO3Z!V9G5CU*%)&4I>I#" U$*+<QS*S$$L3WD41O6W@P_GVW
M?;AS2I11V/;2#&%<8WIXF+.8U<V]]4Q(/%6UCB1=+'41?]2:;P:)99]&=K/E
M5E.-TAZBGRY5-3I-O*'% "^_M4>7@\ZO(,<VX;D[_J"G(2-3/%P812O3(.')
M#^_8Z1,4,.)85+BHEU$GZFW=FKTD@0L;EVM:IJO<Y G(;G, <;&7=18O<S>7
MI:32([V8JG-L6:2O;1U%-=[@Q])TPGN(7 _=090*#391I!>&DZ"$^N;"7BXV
MP6D"L004I<Y&I+$%9R8QN\S**O+2:RE.:O7"US,%VZD9%DRD!KX->SS\11G6
M.!"]]4TUH>X"DL!"=J&.U':]"$TXZKMJTB2#*P!6=MVPI4(U?;HW=Y&L :U5
M>@#-4LEKIOV""G'TF=O%(*<-/:\BE8!.M4WQF\FAE4'K0A7NTN#;*/E3"WT!
MMQW!=+N'&(FE"KNE@A4U7=UP%BC5!*G9I%/M[#@\0DR4L':K*!_3\1R& 8FD
MI.&'&B[(,NWZCT9;^2&I_G"C!1,>3/!E:3,:+@NB8#);UP?/:D?(3:3>\^!E
M2Z>=$8VI,G!+Y3%8[JFLBFSA&>XS3JR!CTY=<?[^B8>7^(T6 @4B6#B,RG>Z
MES!EXPRRB6QN.Q)U8N_$+P&>X3KG%"T;S. YL:,!<YC28X@[P2T)D.V]MRX;
M=XG2!:B=AAG8Z$5V XTL&04818NM]1F_D6MN::$51HK)J"=#OT '-:Y]B%E=
M41/6F&O<:G.REUP/B\1NF67%B#,KHL5=-[3VKY7/;I+AW'?[>6$H]M[D;/B[
MR2/*78.'C(<@[SRF8[8U<LD)IU/0GW/!.URJ<MMPDOG><N]^2->&)P  8A<)
M0[J3)[4:JZE19<[Z8Y3G#(<[O:&#S-\!:!.RFCJ6T(]V!\P<B@K$"9)P59'S
M[FE-*\%J6@P0M*<9AY8#3=,HGPZ E1<?T<VW),S0PE S M;._(15+9!(\&.9
M%G6OIA?DM38';\L;>/>BH$3Z.Z)_#G>@G5I -X*^&QBP.<"'[D'+0IPA>J80
M/5[VG9^)X:=C" +L];*2F-&CESJB>!1*3C/P^*(G^A ,E:74T=['[;S+!IZN
M'#;;6NXY0X1<P-"=($P/$@EN[H&[OJ2&D1*+C) B$Z%0:HHQQ5_<:G@EMU2P
M)\ZO!+4=YNH*K<<@!J!A5+0=NBM@ZSH<$;Q5Z)RON;V:*0_BM):2Q,C:P6H$
M(320%":$K7U=6[8-]^^17L.-%2M!HXQ\S2J_-@: W4W6&ASW)*#< Z'><,-:
M[W@1=Y)77OW-ZZ]W^_6MQ^-\&!<TD%MC !"QZD$4C/?68)>&+6>43HRD>?/I
MDEIN9>K FA'5@-3$D9!T% T>_ (]OG%:HN"'3% .%X7-E]_M14@U$V<TF,#>
MR;.XNM_CYI(.Z+J[%$D+D4!P$!Z \AIJHU*5)Z RD*..)$A'(#[HDZT#86$/
M)9@ BM T[E!JK":$39S2:D)?EWP#)(\XL;M/$S14FP OMN]7SF!D%+A1X13!
M#W++&'$<,V]]E^P&3[;6%=5U1?4A5E3/4;FDIN@VS)$P-Q>;J@"<MSS'558J
ML09_9P/25\)$!P%,!"0.)&>,*&XP:^Y4*7U08!V(TN*\H::!N51./:"[,'$N
MZ"748S"TEH^<?U:@T&S)4!6TX,.L@:^I%"7!L1H[*V'UT>-&G!5V)Q0GR#CL
MMP!IS=W9"8%M.[H"/UT>WWW7'0$EGVI,<B6Q2@%R]2R4F<\H"9 W2DLH?C<5
MUH04AM&*$I)SIDDE\3AY-/;5MV8Q)[2*/9G 7:5ZZT@\=:G&FE'9=!&]99%'
M"@L<_I5]'Q#\#G!>^#>PVD^Y%H-DQ I@OP[Y$JW%>U6  L\*FPQ@#07C7E%%
M#6N?Z#O2$7V#<=V-MN,.LVF>77MX0(")QGJ:NR9V20KNBB#./E ,I[+*C+:Z
M'R Z8O@4!EUN%1JQ^!^I6BU7BH1=T]0(UD2@)N#40BJN9 "1EG-Y4:"6BHQ8
ML/$OVX4G.1*7WYJH7+TX(-/1I>I$PH, =M*W$)>*5(K9L^!6RRR#:<B%^,.:
M3PQ*#W>[593PY88'*I.H%B=T7KBK82:H?XZ6SLXA >N[M8LNM=:R[#(5AVVH
M%'">=M._21P:2PZS,FTBYA'LNE_"D!FS 7GP#WL'#]E('BOWF3>2/"6:R@5V
MS7Y^F.7%>*J8X,7IL RZY/R&(/RV5I&BD 4#LKOPW_6FF\/VN_C2TK8(2>4*
M;(>X1%KON+?40\\[L2T*/ZK%_??>D3*)()RE4T-0?I*IVU\%>@/4CW1=YN-N
MG3FH^S=D4JU:^"BEZ)7%U5&'5YGQG%>Z$.@>CC+6#PR5["N!\4DX'' 6&99B
M7(9 F(M^T30MBB5DS=9/U4D5\SI!V KE[>:8RZ]CSF]64R>/SQFC?-;./$>,
MI.0LY^^/:'(65,=MP)B.";2D^H)@#_D%^O9O<*I_RDR#$7+>D@?8>]_H)9?2
M%!,F>OSU4!S.<FAQC0%B">?5VH9.S.7G-0'+@;2R8N%X0=N5 FNR2U6(L,*1
MW9].N$I?0BK>+N2(PT0?(&CNZ@5[(0C (,\L0[;9?[QJ)2&&6UZ)G[N-H@N5
MQ?0+J2S"L7'D 8S>N)8OJY)@J!,(:Y ^&AO=>##$)2TN194IV:^23 =?-V-O
MW7E<%N4,D"&1H]#<O9WX#DW$6&_(Y?3M:QC6 W=IYS#@S_XX#)8]?)>OL].\
M_EP/3B5O5P[>:*'+_169U=SH'K"K\%,6"Z9ZJ$^E#Q!!5*AY,I&XUR*\X!MR
M,4IRNN.ND.RK' H!1ZOP1ALF.D'VK7)%;CS(U(R^+"Y+&(MSFZ>",#87M@3]
M''N#,FS6PX-GR]2&!-:TR1A]78ZUX]9L,S#W.9?(\Z42 L$8\-11\62X@7-Z
M(6,=3JB;&F>;9B:&>D!TY@=3?85B+]!3#Z"VP5L5?C0("V1-^:,?_Z)2:DF\
M=&$NJ^RJLWRE,O/ZU<'R!JDAMT=1\H3C*FD^8$)E:2NB<C</$Y]0>Y3@'CZ(
MU"I$S^(.@!M2*+<?UA$6K)PTP/:8?H;C"FPPL6K*MKN&@"AL1*!SAR1RKBB9
ME$C23'9'X2S6- #7$$Q6\*+1.6 ?1 KX2/.<CC[;5:K+L=.!W[N9=:L!ZMZ-
M0XJ\,3DESWFB'B?>PSJ6D0/*?N4U8<4!<M51K=X<W-?^^ #)JW*.$6:D24%^
MM2<-K)%,%-&9*@\Q4;D.KJ+CR@;J +_@(2)WENF7%L-ZJ?0C.@_][6R,#>XB
M+F+@21UQ;\I"TNH(I"SL*XZ6BZ#<KU)VA,7E-DL%VFZH!H7+HZT02!>6)H-$
M <(_^W>47T@N!,S&V9+6>.:SQ<UJ=IP0YJ WCN,&AW#A?/&:BK[V!TS_NUCZ
M"GFR?#^$4 =P^!?RNG HC19<(JQ^'ZUQ)\>-<,\&0V+B@A(O1LL?C)<8)T8\
M]C3+!\\EY7WVQ" <+^%MAS'T]U;GVU[7^=9UOH=8YZ/,T'5>3BG3V^\#<M,^
M8O3 S&7H7WB"92)6]J>![N:\-BS5WC6=T!\PNAT36&E6(J!';(Y""U01*K#:
MFE5'T,](#ID1.DSBUJ -"IM$5@9[%B0T"(/X&X_K-394[#GVUT-UP]V4VSG\
MD8$8CSJOE">)'9U9&8A0\MFF*!*LQ410$DP?@ L&B>!FP\]W \_D?ON1 %US
MO/*X:B^U39%N* DA&88>YI;[HP?;%WP7'Y6<T-#?5)<LE4*$Y5I%!@(3$>&]
MW"6O\F&N/5KAO$PF&W@S0/M(LQRW;G!^+ >49TLH-SPRW<$KR#3_R'J=;F1D
M0RK@LL+#R92<YE>+&K!SQ/PN0D[8 :,%BP&@M*&=Y>=V?"F]?HRLHUHII/95
MND?=&.07")[1SZI"87BV: Z'F7O(O"10JA^9#FIT5>:C+.@[5'IZO:JDU6Q6
MLV)\-B)(9VWA45E,O\(S%K\5WTO@%W#8)8+VQ9/]455H JP78T'KU6P_C!-R
MBU?#I!M%  ^D\D 8KVF B@1Z26^8SXL"%OJX2F^8@ G;A6<2PT6[-,9YW5^,
M6RQZ?5'M,I#\Q@HZF@!:4+?5=>;^@'L?J@1E ? *SN!-,NF;AK)K.HH#-W]9
MOY+5F,DM4NI<R9"FQ!<@?8$.-&V:['(1=%:R^5F>D3%6'N#9^30\PH@(B'8J
MWN6RS0%)J]LH7/F8VJ?66I-HF?+%L%Z(Q4Z8$^J[(GRKWUZ9:0+%##8U!2?"
MOP3O+>?F-Q.SP]1@UET"GZ8LISV[2K8T/I;)'4@L;U<%IQ-4VZ]>.HNTGZ(=
M1#Q"B9YQ\ BCS^DE_M,^8^)AN-?TA% (PZ_5;B3H/! "/:_I.F+N$RZ:)7#(
M ^T3=]ZZU_\YR^:<I%BY@H=+$HDXMYR86^+?2%D]6#",M29,<UT+CX'9!%RJ
M#X_BN+!.<T -6*C6Q!/E2;I\&C#N01B]>?^14RQO#C_6&O.-W%L@*0@\]W6S
M0XX:I@:')+9@<_ .$4]24R=.-,AHE&T-?)(%]$85=\KEV:11\*IK!@28W" V
M=N0$_9I4Y)XMDD#/'0M&&X3]M(=13<7S)<L0KN>K[7=(829A&C4!&C H,C:L
MGE9<UFL=@C73,81XIN18A_X%DU.$JW)5A8#=":HCV#,R"FUP05^7TQ9[BO@>
M8UK%\A-G"9T3N>:!7R_=Y4L78FI8=VE5$(<F %AKX7_%U1R=&^OEM%Y.*RSA
MI*T!F.RK5\8+[^L^06!,Z_[@G63-&03?@Q:@L6]AJMMZ3L@0ZL&]+D<:="G/
MMP0VZS6[7K-+UZQB4++\5Q:4!RAGP6A36%RTJ+$D7D&K(JQM"CVXT%U6*_!M
M+\ 9?T K<&N] !_4 LR+G]MBI-90%I=H>4X&H_PZIS[C"OH:H<@FT(SO3ZB"
M,SR:.K3(@T[RP3VA<$#,RVFNI?O155I<,G;%I%I\SWZ0+Q9X8Y%B@L7T5G.9
M/:$:+VW]:=J;'5N^OS'[SB2 S #(8+C/V32_*LMQHA3_E4#QW-5Z1TNCP_17
ME8NNG\#5(!D@N47(,4'*A[(#D+(8D<7*<L8G]Z!&X%?(=2\,E@A'F98WS JD
M[2DIM6[2/&.N./N2UZQZ$>)\,,V/F5=:K:#$&7]'7IZ!8TLC>@=9;.;>IS9"
M;6Y(9_34C22CH>AA7T4R(">\Z>@*FTK(D2#- ,0F2B[_OE*SRRJ,RY!S/_SE
M1'$\J2'/C_)6MR_B 1.H6&X"7T\ _@:=7I\XLRKE'D_T]??%!1M2,*M=NR>A
MCV\QJQ%=^$V7@[*G*Z3O_LP6U)U'S' #-DR37VKB;GUE?4/7G95J9YXA3XCP
M3WHE09W)JP:";;2$*<"Z?/.BA P(_:[[=CB17<33G-A4=O\ILI0H=S!S:X%*
M#1*F=-+9B1T*P<%\O;&WD$'6M\0JLP+P#H+Y(+9P1,!19C$<ED#DI$\RK*SC
ML1=8?P&;<5N IP^' X3LGW2Q0N]JPL/K.R7"?*T>KMCJP*F NFG'3"X1IY4A
M-QU_C5/,W)7;MZBD1H[]^13G+7^1??8"2AV(, RG4;KP>AZR9R'18AAF(5[-
MK9K9L*UJ:L%E_$+>"+0X^"[V>.1L*T.>%V S05H%8M9A/HV1W_S(R33F8[>Z
M[)3?4 ,$5ZHI66C"_KM$..VL$4YKA--#1#A9/ WS$P7'T=0"7SI0Z].EIJO?
M.O$Q$OKJ>,YVJ]'F*.PM:B);*[<QHCGC6A?2SY"C'<!OX12(3*EW?OKJPHH6
M$$I46WSL^4'P"#&E5:#A@8T624BC3S>I^>E;^0-<I0\L'37H10 ,:-]A!27S
MMHZ7=C=T -U!I9=8>8J4ST>:5^VID^L)EL)PG'4=&^;K;\#LRTI39Y#:J,;:
M0F3 L,[8(1*7^M>F,@@#Q^7>)SVD5A3"?W\-@-^[]8> *QS67^5S7N]7;A::
MJU%*#1J>XPZ@ LZ5R>>LUU4C6*14@F1IU1^Y&Y? ECQXQ,0:Z.7)'#YFKDU?
M=IZG"VC+)RWF@MNRM4#=TS?B&;FU%00#8 Q+8?JEG \OU6,28"^X]0/=Z0B#
MEO]"ZM))-D8.1,1/@\FP\P"X.1OC^]A>R/Z@Q"-P<5@Z$FTCYI(4JJ##TEW'
M=S#_UW]L[V^]0!IJS4 E 2.)$GP2%2%O#5A9\"SHL5[1*ISDHOM'4Y11"8HW
M> N[="J<)UA@;:/ZZ1_32??5<I#Z:OUXR#_W;YKS3_[M12_3N'/*0GG;R[5.
MNH@;8!*+H2*3*FW)9*1#@-S1;R9N5Z@F%?W)V0#PA/-K &;A[3(W^V!?Z',K
M?.CB,G>R PL9?1KP:2\TV\,-\DU&PE< V<I,(V49;5CX<Z5P&KPN0R\(<8@6
MGA"?SFF_@0.S2I$<>]*WL<S,$.5A3'<H;!M)'.6%J"1PSN7/>%JLB@03[E1%
M2AVT/]ZLP'C DI 4EPMN U9._P05/E6 +=+)R%U\"_:@"T))0IOC5QUNXB4&
M4)0!2-J UU_XLGNL&#ZBF0*/2AN52OV8NJ>'?BYFQ8"S2XGJ\-GO;;>>B4$3
ME-8:O[,NP$  @]X3&]P#MU$W_I://D/PB:XXJ'&01RU6J.[?AZ*'0$WX5F@!
ML'(YZ$7J@4\G;HUI<=I*R%Z(__+:(:5H/E*.;M86F4 !ESD&X).D]17]>? Y
M1QVC$C431DQ7#;3@? :Y_W([&U-C6C@@I]<-IA+W$6_@1M%2!YEJ;L];9SW2
M&MD< '"+5\<6,8 BD0.>H/MY699CH_6=$)DW32K;#3XDC6AJJB\E/"_ BBAP
M]CUB<]F5HO_(Q^MZ_WJWWVFW4V45/4XIK?:X2(:LOO/;U_CU0_KZ 1[1<#7\
M3,G??2<]^].X\K'(F_D[^Q_Z[PNWOM^!U%NOY@6V8Y\Q\B8'NDHR]EX@7\O\
M-Q1H\(<960G[>+XZF<ALH/0O;U?E+:+Y0KBN\SC;*;OLK,R5\N?HP](/F;D'
MA,^D'QI9#4<9SH$A/! % 9C'Q?+QK7?[>K??:;>_Q6-D< Q-&.B@?@3&+<ZF
MP.X#9>=6-<)A.\,!N/W\^3YNG;?''P\.PMU;]VU?;0E;OCVS+R[*HC!B4(^N
MW-8@JBL)VQ;VS!MF10:\.7+V^>T5;:Y0]-Q<898BKG.]4]8[9>E.X=7M?*IT
M1C1@C.+4;>-[5,X]W3<<"D=,P81[X%"J?_P[/!1Q]YP?';YEE0E(H,X8]&D*
MT#F*;](&P]R[[#+#@F//8P]ZMTDHI/9.B,"3U!#EO+2_E4QP7S(BX;]20Q>-
MV7P/ZQ?N&E>E[S&EAD9FP0_X%UU$7(YR3+42] CKL.+G9XFO[9<5Y5B@W.!/
M?. DI0;('#<I#\WV#&&EL((GAF;/Z80*Y<'3+X),#M.*T.<N_I?IP^1HS.</
MW4N 55 7B--%B<\5X0S0T&L1<_J:)UA;IK5ENM,9_E$[+S]*QO&LA6) D9&E
M(>/!I9I:=WG4*3:A1O<$!65'L(>'.=+!C)B&CINS$9K.CG84L$(Q7MNS*6*5
M8#312%1"Y<.K?#JNLD)ACUU?A YW2;X#'S)P!F=? !%!=@\+/MSH6-"V<G\Z
M?'^6!,:@\MQNW:PL;M()SP%E9C'DAB_[WO!'SA-!;D1,'5!+X[AD\X [N4:.
MXSDD.)N*_FM>CIV5P_\@9^@J!]Y;LBJ/F;A7]GZW6O/XD<3TOKM6DHE\Q0)0
M& .\)%:)W6-P<0:H7<$Z797U'$I-82XSG!U)68,4; 5E)&;VA/PHO5FHZV7P
M&"C!!PI'?FJ\K<]GL$I0[@C7OULTH/U$>._! S)H:\#WP[)GJ5ONY264>=!S
M3P;3<B1,2%) [R.^\.WB5!*"QMF-SY*K)$+I3O+"TTM!!7I!Y_DTXVY9+6:8
MX@-MWEA@UK@_7-G1=%[M(5*X6T )*I!/(X[7C8&MGEI7#/T)1,W5:)]?\ /B
M) 24MLODW_LJ]_VRL0LUP;Y]TJ 8L,%_"HZ;['2OVQ5]#?\!%:!V>IDVWE_N
MR5#P\RRW"=\;<&MW#=Q: [=N!6ZM3[IO==+]^(".MZ[5!E\[\L"]+WN;Z^I+
MY3V^:^BV^J_V!?7AB6<$64D3#\;(-?\7>L".Z6SN.8D8&Z;L',2N%)PX=,ZZ
MQZ0D.U'7=Z\-!]+.U@L< /!T@?7$OVV_Z'4#7AA42,=EH$,G"M1#7(<;:$\*
M(1=X<EZ-VAE5\+'83_Q*Y$80K)R*FJBF(%H( 9 /C+>A?Y5.GSFH+0BZF[--
MS97HCR*@$M(R1@L3]).:[[#'[8@&;AA_2+^\70+W$ R8]U\,6C "_K#P25=V
M&U&2FX.?L.%#-+4J*]ZY%"A'2#!D:A6@%6W"R*6J T(VVJKB"24 B<]1;82D
MD?&1 S?0L-,35,1@8P4%1[%F=[HHZ!ME7KO&CJU+[5Y3Y;Y.[,ZA^A<]Q4!U
MU VD%[F0(N24ALY]\+H0B(;]=2'"3XGFAM@70)R);"Z,% E.ZUB%5=-A2=UI
MOJTGF$G[3%2)$]\^U+/TR+*D%R5F=RW6+I*PGA$UF1C0GP+]M,C)5!+CO+XL
M*]$. V:]O"ZYCJAK@XGV(7,)IL2K7;(EZDFD>-N^'!4 4;]O6%$BJ6[S3(F:
M\T"/R]HP&2I>VKX*M[ZJ.6@U46/&914(0&'TPXK-_H\DH(L[,YU.,Z%MAZ9(
M%Q+%6&F_H1X AC(9!(9^A<:0Y>+%G]^?9D9 ;X9<HR(78=OQ2I2 MLS%X[ O
M".BGT?Y@R0';=A>1)("<L;"0G.<AY%7P\XY])NH V<5A_<^>U0\9:7V:C4A4
M2YJFS2JS;<A+N>FCG@A*0- BTLZG6BP5MSFN(&NC#!WC!> "VB2PT!:!+D'U
M ],6.%XV63-OYG7&$F#UBQ(OU CA#^N4<!,$X#(GA.<+]%D,=?DDX>S\P0;*
MT[3AKXB$T$TH=>E9)7OI @<MW]ZT5*K"+=+7,7'&!QY'UPISZME&DE&4CXTV
MDZ^YV4$O:DP^F1[^?M,D[=RPDS$+W"]]X]/Z0ONNLD#=+HU[6SA!MRQ,T\'A
M@?.R:]V=O=L0SE'$]^YL;6\E/B^&D8-SW$H$$TU$'JEOK=$!7E['^B0N>$J9
MRP=[P$.X02+;%7PY,(AIC5&6$@H$10!(MP'#8!)N<+_\+/8)'T*70R+NM1^%
MU'N&J0L*@_M(LI(16F6A-,R\T="&P'RX;R, N\K,7ONY'4.4Z3RD0V?.*_&=
M>3H0S0%?A7%=P6-.018B"\:48D55#P[W$J-&:+FRJJ("<;*QMM0IRBU4<\!+
MX<$^SW@<[I]3:,X @2S$:E5-<#.*#?0NL.<Q,$OK.M-+FALFQ,<(A$XYZ#G0
M5I.]J@5\=6CE09OT2R::>K)<38CA%CVN6;(G1/IZGGX9'+9LK_Y:#FM!W[C%
M^]2OI93"^5IG@P8-^#75LAS\-2U:\$BW$_CU<]HR;DP;) %1.U>*1#=!@#-G
MFZ%EO1E+!RQTZ*5O&PO6XE6I75Y:PL==,EGXS415]I3;>:,WDZ(@BK)2P^F%
M5-N$OZ48C,KUDB4P4%P"/V2<*HC)Q^$W.UL[6^HNUT*_13RL&9(9I04?\U/T
M^IL5$[FSI;9G@V\]EE$=IF.@_QU)VL)--LS:E?,^-G!;L4IJM>%%3^/IL657
MJLKB9=)BQ9#<_Z+/IL.O.V<=+,'TR^;@I!C\M2VRP?93^:7Z?F?M'((#MS'<
MJ04!#( 8,J0-EWT\H 8&;-N'U#XFMU6]\;(E@3!<+3FL?-C 3=ZT[+S#RFEJ
M!&)40 3KXHVT94-WVXM%0R_+'):E[%]G/.B41:C+07L)W9[;^_AX.PG2NB/J
M8O 2_H]L.[CE<3%ABW*:2:^D;C?XK5NBQZ<'B>Y1Q>3T0MF@;1T>[@IL,L))
MW(VE:&YW# /&S>;P)[NN S=7,(UT_*(]@WFN0,T$X3BT9=PXGY#E< /M7022
M5BL+%_1>E5.=3V^7%#S^$?;C*P78#9T)+ IND84[P;2;6!E$8<H;A.LSPSH
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MDQZ&PC2FOF)+;@.&[&[1-)2G1,\6+ZB93]S*GINO_T8^-8I<>P\"*0(S=%+
MF[D<O(1,1PX<UB]A:8"K]HA-_<G+ER\/V((_%G\-DO%1 0LF'H\7>D-/)'1
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M 8DH  V:!Z1J<=#!-GL84T"U&@&;G7-++BL9%?R-^R*ID8XH_D*6XJES2C:
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M[U4><M?<*0Y$^SK"?!TVFN(OC<2?,04H5J !H&T&$()S"0KOS2K_)GDHCE?
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MAU>#X[.S3^Y/'S^='KX].#LZ&YR\YM\.N+OF]XTEON(,?$\HGV,/Y+M/KIQ
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M15DYE!,Q]@4,@I])WB]\5+Y,%U/W\:%SCC+:AN]!0L#Y +CK7AZ^1V)@2E2
M?O F_ TS(EQ"ICO+10']AX*(N(Q9"Z:CJ7(LQW'=.&<'=BY<%$TZ1/4@,[H-
MFJ5"6EZWL%-1-H<,D"&"I5=B*3&GB]G\RDUVXC?;;.$.'_A+.@*F"OS/',@]
MVL_9+$_Q60_>OY//Z0K#:5J#$0V_]<Y]R]E*H*2"#V6Y0@6@;F2!(/FN8)7<
MW+E[RV.7\6/7Z8T[7)C]U8K4,95@0L99_%79.[CF$Q9M$F[#IOR2HYW H[BB
MG<)R"^[[B.12>[GY719OGJR+-^OBS>KBS<S-#K_D[9VMS:>[-.Q[\IP]U6Q$
M]YV.KXD[^J;4EFIG/\88\I&GN^NM@7%<;5,A1(S&N O#C_OQGW$BB<I:=@>N
M9-@9TW1>9W^6?[SX'59*@*8Q2Q3G# :Q,4T7SE$EV&O?-)IW*EN.7EQ3N?\_
MEH?@KSV#SWZT'_Q;#W$-X"@(;6A,.#PW_!?.(6JR#<1'N>5[XRSG"S, WKX\
MT/_ZC^?[3Y^_^.\?F[$=5_BE[G;Y'<A%5^VU@Q9#(SB*PH6""ZXWGI(3E/RG
M^+ ;/'I_OK&_M?U8-RT\[X_PEG[$-WT/JVYKO>@>U*([F4PVW++:.+O*IA,-
M-4[.SY3\2Q:@\QC%4[(FCGG*W4K;V]K><#^$+SH7#7RP]Z_.5JR]_I,2S9*>
MT?>4WJ=:$P?G&)!DA?MZEE6Q'?<)#R8N%X09AM6$JNR<&"B=TZ(Z>P4'C(1.
M<A/5!;O*J:/!Y"PH*$07]Q"&D:!E0#D'3+H!#XEQLM>'RWJ?PSY_KT(HG'%P
M^_L)\C,65RFI9$(*P7E 8P E(Q!2OH*DRA1!4FJ. G!.,3R@PV6]ZA[8JCM4
M^=!T FD 65%%Z?T8;4J%!EW1T@X:%7FYX2<E!<@;)OU89"T(>7) 72^*<06
MY$?'AP<?SAY[9#U+WH1@7W> G1T<U9!1PP^;ILJ'K9&$;@F-W&OR65'D >V
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M6C,6[%V-4ELSF I:%M.%>>/%>:/)O'$/;S2_&P59M5:GU+QQ3!GBV^..<ML
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M-T;E9(%'NP$]&/NHR<9C^A78C"R*L5,>-1F4O1BIEQNH65"=L>*GN]B(!/7
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M@DOK#7+&BNJ*>73UQ3@:A8(4Q([SNX!^1_,17(8I)Y:$#;2'NBH.3_94"$8
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MKWX[2<$T^DG3,T:JZ*6TD\\QO.'*X%TACK$F"0+"S1Z,&F0'/4L&38X0V50
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M(5I-6(Q5=FZ>7YQ^/3X]/_J<UCWX>'*"''UY<O&OT^.3R]VR<[-F)$/,UF;
M01+GZF%6BEG3A*:CI%"#\5&HA*!+5;ZM>%O5WH5A>AR&X3#,8\,PMMVP /6
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MZ[#&][$;9BG.DGQO:*-JZ[#JB6#.N,_%L#_KL.H.8,ZX#][OSSJL0G'FC/L
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M"AEBZ#4LNV7;5MMNV/:AV^S66XV.*^X:UHX"#$=) Y(X,.X+/N 77ZAA"[:
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M/92@2%2;D047B2J^0#$^*"L^X+ "AQ78BN:PPEX9X1Q6J*[USF&%?3+^.:S
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MN:P*,N2 6.4GR9AGGZ;-F*>ZDLR89Y^FS9BGNI)<",S# ;%]04@-FP]_[6]
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MU#Q]JF/2<.2B6 6*5:!8!8I57,PP4:SB,!@_ 81?QSPC&HUH-*+1%S9&%*5
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M89UN3>\:JN$A%PV=:+_Z$^U;@\?^NC8N4]4]Q;!T35(<"\C.W3#51&BI //
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M>A7X.<$^9=>P%$LU@C =^& $NN ^@"D[YA _%OZA**L9T]__!3_6WU.'NN)
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M'4SI.;J.8C)WOY5[0>G[YQ;312'QJ6C4R#&=QY1B6! D2I8$(:+^BA"E[E.
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M?,I%<)J,\#2'<HR0I2-+OVIWJ))N1"=91\8;3;??'F<ZT;@-W:&@'NI![E!
M=/[CP:)E%V.=1U<C%8A/=]YUS'CSEN#W1\,#7U#!7^N  "DJO"A=L18PXF39
M'KRLSH%U5C$#/*[G*,.@%/R*+[DZ5*7 )0BJQ*\RG$ CUP,?C. ,/H")..80
MOX^#FC']_5_P8_T]=0A8'P2*_NKA+S@ 7[*&"?S?)['VM],$:\N\Y)*%0TQ&
MA8UN!S__WV;O7[VVJ&H/;>=Q#5D;P^J'])@,T*NG1SN.KIA1I0O>_*@,9\K"
M70V3YQ](>@V'CR^P!P6!,0\\_V_L]5<HCBU9CI1Y=$-B*ZR,#O6N]QA^:_U1
M '/KS^"E4,!&'QU8$]F8ZO#9;YX:3(MGCQ])XH$]T:R\2^>C7N?@OPK6=R!8
M_E^]%'^G=1N69$%0'/ZSZ9&L/@+&%=0K!F83A]AKP7L?5RJI'**6;Z6Z2UQ*
M@(^R]O^S]YW-B2OM@M_W5ZCFWKUU3A7X%1EF[IXJ$8W)R=A\H834@(R00('@
M7[_]=+<"R6'&&.RCK;WG]:#4_?238RJ>2D@C:2BG,[%A/!9+#D=R4A[&([%,
M)H9B25',_*!?_1BH'=A?K_"@FM"N%-I<][;0%IJ%7K><ZX2H(Z-<S]T04-"M
MU!O=0@?#NU'O-*KEO- MY(OENE#/E85JIXO_62O4NYUAXJ*[(8NDR^\V./]:
M.7>QG+?:#^2#[UJI6VKC,)4&.0&\QDX.+_"Q(+0[7+Z0*]2R^&QBD1 '2C\G
MU//P1YPLFXK3NCW'RY$^)'*]ESPC6K:!&F/6V0/+%2;R1\.B]105%H_Y:B'9
M&E>K!7&:[%1:/SB$E8,%?H5EV.C#V, !8$^#$4Z?'G[DYVXEN???NM#MM0M<
MH\@UFACENV6,(^>1^$^V:2GC[0OKK8G&#!D<%O18 48VUI/-$%?6I)L0)W)Y
MS$S6(.PEW5CH] BXO\ K D(TRO_*4<V _"ORB],-Y\(:L=_^#G$*5A@X254T
MHH-C-6"".&4^MS4]K&L@H"9;CJD8G+E H"PHSZ!L*!KQP,AHA51] :H#\==
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M7CI6M42B:<I8^\*G2) &@Q<,(ULDV@<&I.5@P"]G$6!Q8DZI8\E*;*I?<!*
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MX[LE- XG--TB&J?-' $AY@40,B(,P>-Y(%0TTYG:P%J DA]EA4S;,(#U&71
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M^59%BQ]5XAH@4X!,'U8!2WGSE>6IE8Y'B7Y^Y2[*?TI/?T!!?^):^%J0^AS
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M( 0*)CZ9BYDH>:K0PO".+1:N'-)@!M7!W(X0N</A3GBK\AFXT6M2V3%;"#D
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MR4YAP@V7U:TINW:@C[N,\[2:Q0'?@$6S%9"L!5NS%'7',M1'EJAH)N4S-"F
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MFS+UC\-:J)4-EA*=X)3[IG&&[T-1J)IN0$Q?'8/X/@04"*-;6(/?AWY@Y[>
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MZF3DPG7UI:K:*[RNQDMMVM X!ZA4\I0$B28U5U(T4]3J*BU1IICO9=)0^YS
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M](2IRE.H^#;K/,I2?SF+>I,=_8Y<ZN@U_*U/A#[WG6#XAY]# 'U3/U2XR1&
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M<121U5 )>Y>*Q0&8^K>H+\25O2D7%(]$MZGEO[<YY! 2& 6<Q/]@NX\0'B?
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M[5C(S\4IHFB#P*^(CA:;TP-\5:[U4CTSTV#2[,?[-K.Z#I>BR.=3[?W)SY5
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MWOE2*NF%%/VMMWB+:E_0Q[_UOJ];O>OFQ;EN5@_PE2PB.[G:_V4OH]_/,6O
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M,ZTP>#V09]#DW8H$VW'E6P)GOY@I[,. JID>EOS>XT?5V2]K#M%=$/M0J9I
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MO??'^7'N77O/\\Q^]LSL>6?66O.^FSY%7P1<-M(WU <PG , &,XN 'T6\ #
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M'3LI4;\GKZURNT/UAJ%#RT)1'86?^EV!)KU@5CAO)\)N*KG HVX#=MNF!)*
M_Y#="^"O(4?KS@QJ]KM](6%05"Z(#L H;;K^V$R,>V#?D'!YYOZ<_K<-$R?8
M2%PQQ8=8$X='<LZ:^;J^LI,KY>U5,MF,/\AV^O!)FO!S\\@,:4P').Y!G8T*
MK3X5?UWVJ2]>]RBA0K="P,3-)>:P%MD'<F2XN7%AS$Y'@#-%#H4,A[] 1#A>
M&:4$^Y8[_'L2$GW?Z?6RIMU]^#0RK\GSU)A\MS6=#CC4(\SV^D1P'\O5&1P@
M.1X?E8N9?>C9&[=0C+][!R4UCQK6,<ZNU'M%#NY0$9<=43A04,%YN$L[_-Z
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M0334+>, @UY!':6X:3TG"\:H@JB3S$5J <&C]M7GCN$LH*=0<,;<E@PRA@[
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M0$WZ-?!\M< L5B;2!K-&:K$;,/QKC;*@[1BG'WJTB@V^%-BG5]&]9-^"WMP
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M(I@_QK[U!JT$: C5F&EIBT/7%7T73KK=@_>/ORV^4WXK],5M(D%AH=1=Z$"
MPCM)TZ9([">UW!S2TOQ!1EK%/!IQ%S^A>=:?=Y(LW4*29>_]M8LFW]B^@&4;
MKH[$U%WA<@2>"G.CJVW"2=U]V)XF&A I+\VAWV#7?L=O_\U&?[$!5V:#R;I4
MVD+B2O8MLC\>&+&G*Q!9'55=F_E*4?DM</T)18.H10=P49R*R'X3VW*R.Z+7
M^F\?Z\$R:-/8"Y/X[G90O<)S]C+7*_.@6Z*?F?O0GY$]S3J/&X=1(L&SKR#!
MFX8/BD7YG)777MJ.56VQE;0/EU0@+!$&:UXKWUYZE=D[*09Q#%(&)]'3=,#B
MA3BB0-NJ2:6.VYBTR/;.4V\)IUH4S %ZYE-)HTN<)[0@JNZ9,+L%HCB10<^+
MC]]O7-:_VIB@5?IADH3LW4F []HU@<]"<1 LTD8'V-(FND+>+12@T&?]K;63
M(ZD)AR',$=819G4]1#.,#C?TWP3S9-W1_.8$LT_];S?4K( 3)0&*7>EH#))W
M!I+^[PX$[GS3*%X5$&@!]H&W*2O@TUH7I#B%:T[?ESW<N#TT&4>;15154>Z0
M0.0B_5H=8L*&Z:.2T,B7]^",8"MC[0*P2GDR_D72C':0&P+YH"W;0D.-)3#L
MPD[C[J1^0F/+.:CK"$TU@'O4]E>B-<%2<KX&]CJ?,?O&9/?.L42V_%FX">FD
MP.QI P@Q9> ';:W:L5S_-/WZYV('/[3N /&,8S;K$9TZO.L+2E2$+]7%J Z4
M(=*L_#=N;/5C,V<SS";S[YT_549/"I%&7O;(FE*#]6.@?]JKRKZ?=Y^0EP3@
MC=ZD99!;,FWR %FN=>F,Y)],4'QQ8HJ.$1T3AR1LNQ27TK\IS"AH:FG]6>A#
M3B;'6YBIZ*8'B_!+KNGLZ C":G07%\OOP8^M-EO?=@ZK"CBW,KS_3U[:945%
M$*0/J V>)V**%$W-#N"^"@B.S7-,6]R9;J<##@/)8B26A5.K! O5P^6QK@R_
M19L4.@#3 S4[D^_CM50*4N],V-PN@0V!+\*N5A04ZA51P_MKOLYJ_I+;FWL3
M\&TTX3!"\==*'*&7TC,;B' *"U34/,DZWB*@G?9^7V[\LUY'!VAL=;?!A74B
M=&HG,;6*^8*4'133[VGJ3L&[.W1 :1IUB;)Y"#R$CWZ?0+N@V:;FOZ<O+)EP
M::C>SW\6?9I]?6#CI8^KU2?>^@(7V,0:M,(L!:-4^H0[I:PBH;NII.(??,LN
M-1;],N[>I#$YHF(!4YS4XIZ2"<UW&6_>7/:<X<0Y=[<K1@>UQ%QW?O/W<[_;
M%"XQ_JUVRKX.A6=I*>'P)DKG/0H4:S?/HQ"COJCC6^$H41[5^7*0)\U,OX+0
M&+,PW]2_ZV;Y]CBMLK/;<JO9;.C[+9F"7'0&YW2")IF:[W:RVAX7-/A D?J=
MF)5[-URB#A@&<R<#VT]. [JZ-"%RI9!&U]!^N3R9.-WC&* 1U45"XD)+"/4[
M'?":,P)X47LX=_/R<4-A >OU2EM]K4Y]P3\2!;"T]F\T:0:C0G $YM3@GE6M
MG2VV09LGTDM#[:2:E +QDG'=G#3MVS7CH@VC.:&^SN50G:&AM98K8XNGHD$S
M5RP#&[@2!Z5^HE\!IT&=<,X#Y.4-F%J<#69EY.'R3VPC(30Y$X;J@3)1$_=W
MHF$*U:17"?@ CR8YS\##\/>R BS>G^/6'1-)+D_)WP2Z,)!7BOWI Y^G.\^E
MAN4N>L>KKRJ/9RRM.S].!:<.4#:Q*\WX\1I/E^71'!S^G5?[2+BJ@%[OPG+"
MS0G_<3K +@N[-5L>H&A;3=+YU"2'JQW"I]@K?1V@_/6"[(WB:T,5:>*4!Q/[
M#OH7/C[==OC\L]57^DJ"W>DJ?BQ;C0S'ES-I,>2 6M.>BSP.ECGB3XMK(PW9
MV) 4<4A,PHPPR)T'G"VCY<0&J*[)EX\D_W5!WRL=Q+5<276(+K;@+E SPP>C
M/(KL[_0Y>H:G\O>/YY2ZJ<2841)ZA8\\IQIQA*-XF+)K[<]_Z8!G(PF(>UW:
M5A+?^X,[$12>-(RYPZ"W_](#E6]O#+\Y/6.1V1!<C=X/;/)<1$QOXMQ4,2(@
M!P\=S3_9 :(/_3D*[\OM5'%(8U9XLYGEFC;&CJS&D]!^ VPJ>B#%%AWQ>M?1
M\5FP2;STDLN')G82>HF6+4%Z>0(K+?SL\IX'59.)"R$7<8I21$D)G>4(8JP
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M9$N;:^#MKR!WW"7U*S:S2C87'#*<[A0;!1CNUGN.;70NOB6O_9B,VX*.GZK
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M_O(SG(?A3V[Y,%AI?G[004Z.">9'FT%4^<<IFT7M!>0]&"V<V%),M"R3\.[
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M.]Q:5X_7YM(*$Z_Y/_\5('WZ_P!02P,$%     @ 3HMR7*>GS?90H@  [ZL
M !@   !M<FMR+3(P,C4Q,C,Q>#$P:S P,BYJ<&?$N'=4T]VV-AH%04! D%Y5
M0!1$!.DM(M)$0$&*0(A()P+2>Z(B(%U 0*G2.U%Z1[J @-1(J*'W))002$AN
MWG?O\YWO['W&..?>?^Y*QLA(?FO--<LSGSEGR'_(BX#+C[1TM0#GS@, YR@O
M 'D&H &@.G_^KS=E45/>%RY>N$!-?8&>EI;FXB7Z2Y<8Z!D8&)E8+S,RL3 Q
M,%SFN,QRA8V=G?T2,R<7!QL7*QL[VU]"SE%1SE!?H+MP@8Z-D8&1[?_U(O\
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M]"5TN""3FD"P&$)6IT4U8*G"U)UC#N_^J+&Q-7&B1^"'K5_,)<X''N]H#+Q
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M252=9Y(8Y]O'GV^LL^RQ\17%"=PU$^NR"9BULDYM:ZW;G%@R5V&N^23"T1@
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M]NU[77[T+6Y,&K>8.VA;E8W/DM1DMP-CAT@YJ.CF[>U4Z1$OCX K_>)9Y;_
MPMD69U($P\8\BBUE!--:]$"[X('XF6V/-3'A+R.^@#F">;'M':3S=8W8V=-N
M:X[QHG %S:E<D;A;=-WF)B\]I=X$!9EEN"SPMX KYYQ3Y4GW)O<J9?I8I_5$
MQO?JD[CFBZIM\4V(N07,$\5CTA#/AQ%BSRO@H0U\\/2X"O?]64C^4E+S=*"
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MV%WJ%E@/;[J[[?9-NUYMOLY0!M%$WI\1G#MO<$7H*E4OHU=O["-O@5L&XV0
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M;33X7(/0)08)M06+M*73YS[NN[I^!BG-ZL;G4WC]/F[1>ZI9F5W#Y"U+'/<
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MP'E:V/$]65&)$->>4I<+9V>VU&=Q A_=D0LYBQ+/-UN?-&XO9>[2+S23XB]
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MY@1="]&][@\U!0P]ZR64DGV;W*@KDN/Y;B'EO\_]A F<]7B)):,7W@V+?H?
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M]I(0(K"72YQN(S?17T2!N#>JRLE&^[)'(8%7.1G>&_P^/'P#?#9W/."C7M:
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MEK],1;ZU3N[*2-%2-P-=],$(POLK"<]_D:NEZ_]!:5ZR=\>WI9RDXQ3:7B%
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M-GPDE=9";_C/5B[].N(V3=,[[)N\Z^^0-#S9VP7;M65SB#S94!.._1*;$$D
M1.!:^U3TCJ.0@C=\;KYJ3'T_DF9RX^?]U NC^''6?.MNI09M_%5 *,6"TAO!
M_7&YO;.%W" [*=)< N"#5?V+'E ,50;+H29*P $3,!UA/VR>1:$G_/SCA?1B
M[[E%F2O6S30)G=(&G2J<S561I]-*M7.4RX74?;G6&18Y1M:.5:ZN3K.]!>\L
M49E6#%R;[5Q2U ;III[6@FDSD!P9JUW1H2/%@!TIB6;BUC@L);ZPQ8L52;60
M+?=[^'S0]D.VI5P0)"DL3P-GX<#2(?9\3\W?(Q_KRB+9AA2%Y[^>MJ*K[\C)
MMG< 6V)B$BT/V) O EO98FM)29IMT.K^(C)7W&./Y9I@CXR1_0C4,K>SJP;E
MQ<<GY3$ISL5SE]S3._&4'V6_3[XNF%59F]H=QF%N\A  Q1\K;C!S,Y=^T'G9
MUN#TU"LS7MY+F76+LXT  +0N;%STE'+3D=EXCSG7)IOD1VP,W3U(?J)K'4 B
M'6PO?8HPKTF:_VG70:\I$. ,X7R.5MFHJ4FX23Z[.H'L7W*(00L]B,D@97<X
M\1H/-'&G;"=M*\=&@GE#4#O\.VQQGU.S0Y5JDFYK1L7Y[CGZ;%Y[U9+<F20=
M1]*KLL%?-2&B;<B%M$DX8'/FJW)H93PLT'([7X-L.8@3 ,X;(/%UNC16=&_;
M^P3[+(S&M'13=AWL85TW[P/YN;XO*ST:[=YM# .\@Y:DMW2=[R[1TNV\F9D9
M^._>.XCX\][!?Q;L.)#$V!( L7)9D'%ER*&0<:HQ^$RD SZ/CX;\>;)"?9^Z
MR1<J7VH!E-NO[SG3]TRZXF27AQU1'^)/X8NN3L"O2G>\6""_0@X*[THWC3SZ
M01VZCPWJV=7Q<BECBE\DSXL.Y'ADAGW2*8@: &>@.S\5*.9;-=\=8J-/K*'8
M&S2KY:[[5*;TTGV6_*+%;./I5BOK1;1"_6GX[,VQY;%LGP.]DYM/8V6*0GX
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M+ZK5X+)+0R$O,G1)?<5;4#_U_VGS+14H[[]XP].5=]J)B_ 36I?2T_WT/][
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M/-FY@+7ZQ-8I@^QF9QW[@>])U%3=*^$3CH:=JFXCCNV!<";;[N[CM?WB!KN
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M,3!K,# S+FIP9^R[9U236[LH&@1%I?<.*BH=1.DME@4("%G4("T*(@+26X!
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M&B+>^$ QM*/]QLBGL?TD7C?MSA"IR% ON:EI5"."&PKOJH9Q$1%/82Z>HC%
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M:[.!91$ER2$DPPX01M*B,453L5F$[T.5>UVR+$)!<(/+15/P8E+:;J%ZV#$
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M]8\5"NL;TLX]NZ2X=7O*^OJ*T;KY<F9A+LJ%;SUZ'/PV)7%DF#'64/Q]$AO
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M?H?.#A_?]B95'=SA<W!VYK>0H_#.(.KE_V#< ER[,TQ[ND@/HD^TG_UM2Q>
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M^WU382 G\A$B-2GM)8X42%>MGL"8JIA2E]J?GZ<@GF\[,*.&K +S:4FC(.V
M]HO@I%_4!R10M X#B1NS"4&7-UNZX/;&U^5A^J["@SQE7J'.F5<M;F]9N:
M$8GZL ;\YHM<%8I02-[,#"61ZL7?E+>B/F9G<E;Z&1[SP^SSK;H/?\R?UCSL
M'W2%2N'3NRJN+G8*3^]H3= 0Y1T/6TPA:Z_M9CL>G!I[$#UT6M"!6Q\0X>=
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MMPU6375E!B<SP\!6QL)A8_85&KM%_Q=[[QW49+NM#T<140&QT$&B@H)40;I
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M+%K8/_S9Y.F&RLLWAQ7'-28A]@ZQHQU9PYJ^I^I\"((ZI_A?/CL\P?;TN#K
M]#\>+/O'8&BG 1Q .^>H$C0  DSY8#++$[>Q/;*!Z%L;OKE_%X,&6&I"?T"T
M30W66@#K*> ZE>L0_&=M,G#/_<PLFBZ9W@%;0\[I('Q(X#T%,_)=DD8>*<>Q
MQ'S1:\/BNO.CG&,_"(W\+)MSPNM%.SK7K33F?HHS0NO3,\.BIM\%E&J\_ @!
M!J"5[?_RZD&"["F9^\Q-2B*FF"GZ3CS.+YN'ATZ<%(EZIME5V215%Q-L=8"4
M%V_F[I-]KYS -U*Z,7PA1_J3584-)B=]1-UR2_68*:=,?D:L9K])U+ )1 ']
M=O*Q21?6M?/=+YR6V8UC;'559YK>!Y[$2,E]&G]0M6>)CILY<7O4;VZ6G$,"
MX<OW<-C(PE+SVY?II6I!5;7@3)!T/SRPOHJ]-^9JC\"S;P/Q%ZS/OL\:UNJ0
M79LM54P7FZ(;OA9'V"=@]Y4"/UM-2IHZ<]S9NH"L.AGB@)!3B'%?9H@46?4M
M0+P",CSND8**"8>X AL3P>$G4B2M@0F"BH+/+L\?^4X)$+N#"7:P6(X'1X8H
M&3WMN>J"2)\9\:HL16%4$'\%V@$"HL=K$Q$).V@^R16B(AW@GE,XFYF[$S3+
M?<?^LRV5P[H_.FR\@NV0SQ4]4C"NX^JUWC>J*\M)[,BQZ_W%6PP7JQ8&(M,[
M4\-4GZ!/AC6*2]P))(SH5@UC/[ZRA5*VR N%OPA!;B&^285N6YU78RLGA0GZ
M5+=?EEQR)1HGP]HNCU?BBFN8\3?KD521A#JJ.(%Q*P:WB782*D&6LYV./%A8
ML:748>A&+Q.JG$I&*A=H .N'_>ELWB9.&[='L3_&B(&6X.,;D+V5G3ZS7\FI
M36K!'JDYD^63V%<_SD6X,)Z-,Y43ZIL)6A_58/=5E*CPK&ORJ$(L+TU<E?!:
MJ]>9RH^0XAJYU0XKE;@E_TS18L5$#L-O*_3.&].Z@NUV^TYX]CZM,@#C&BY?
M/9^RO:[V; ,H..?:F6@+#=@B+VKG>Y56Q3.)6@D_>IA]]HU;W:HH0V_MARN-
M9:4/?DG00T #T*/,IN7D6?3S?>R)'V0R'2M+3$P--N72VEU5L7*6'J'#&E.S
MKIT?'D$IL^0%L*/UDN4;VXR7?]%B0<2@L"D2EXE%W^4=Z?HT )WEF^\[>RT;
M&:JY;&9+$?NBP+V.?:OPFGW1S:)7Y?:Q#']Y=KKS2R-X,'',*4\B/I9!<&I-
M84[GE_%N/P,GPR&'<W<1<+H/A788_<J=,0>Q1T/&-TI_&3M\NV4<E")7U1VX
M8DE_<P=!1[A$1&_QD@;5SI/W[X1ZZU5@B^R/%9^9FXT?)?#M3:W"/VTBVA>)
M;"^ '$545O+=7JBZBVGA6W+^]P.X^WQAD"(E@0F33K?CAB50EER-J>CB34LU
M?^#-M[.@H0_?^V$,O58I5'-X,;N1*M"D%$/,5]6JMZW\6OW:+M10Z7BD#-NT
MXPQ,IA2WO V"Z6A:,K+KW;%69[]WX+]Q'.+R+M\ZZ8LT.6FNGNSZL3YR]U%_
MVBWI-99C-E[+A!@+3'LJ'PDRV35\&M?2Z S&G8&3A6P:=G-[B+6<6\;RY4_%
M'<<?O#K!7"FT>I;06X/!N23E0"_W!"I"%?$N6=TDK;8;7P<*5UP%M./Z6%9$
MP4ZG74?S)CD&-,\]\YE]KC82=O]+I;VQV)*#V8.[UA?U+8Y7/_5M*;-8@/"3
M3^(IR ;72+7+ U CX6 /RI6;7[X$\2P3@QTE#KTM/GBP]_*KTRD_]UIZJ^$G
M?4KT"; 5'OSN6H/ _A=8BKFE+<JHV,?>*7D2>^$=HX4D]9KQV94&SPY P&D6
MPFCCUX;S;7PL^>D'V;K#8U$J%+C:.5+?Y%H=.O@=UGS^*PED6A%Q6_N.,01Y
M0\A!I;+]Y;*26.P+'Z8U7J3=WL,ELTS"P)-"XE(*_Z+.XT1V+P6=0'Q!UA61
MY, E;\9RYV90A.R!S2:34.H@#G?_?&6H*8X&,#VE* [7ZS=)\FG#@<)4G"==
MV4E.UPFUH3&X2[)#4^8O%$_=K[1,N[U:;9H@G(-()5_!+]';WZ.;,4RC/F&3
M19GXJ?NE*.1KJ,,G1S%O9U^QRSH),BZ2-A^CV3ZDW'_&)GM@*]*@1=&&_?59
M8]$1;OZ3_4"_6)0JWCNZQAD_<H.^JTG(8V\E-7!:7:G03C*/2UCQ/J@IJ/'H
MZ8VLL09 OEUJ7.$4<'C$-+AQ7!39'1K'B@XKXAWR6%H2RUV54SIY4SFC&/IF
M.B7_#7GSVR>V/,;&VR81'6!I]BL7)^.8/@M^F: :CIBW^9-NE?>UN)U49#L=
M"FDW:<)R;JYH-\+Q564=/.CB(BDJT![Y)*%8X2._KLO0U#E3+10?S[(_[RZ#
M#HQD "DI2'ACZF#<M^!WU>)5J3_HZPB/O.V=&.$S7S65E&0/++Y6>>8Z<KZ\
M(;2.R8&H%L>122G<O3)BT? LW*ODUN1SM3".=<2K&IGAZ!B\T^1L>H"[:YI/
M[:HGVXE1<]WNUERM+Z]KXM_>>7)528CA^UTC[&OTT9I+>U<7QYD(X(84)16)
MW-&E+3/5\11KP0+EPM*U8ESL>:T2D:L-4X*N9H!=';)VQNWEF+PAL=PZXXIK
MUXE+QH_Z"\^7<H$]CYGSG[QRYR 0G*2(B ^\2.V ,R=-81KVW"><^1L*5,F8
MA6G"4YQJ75*J+D[''OJ()&CGBT.SUF61KNH2NEYZG!$?83L8L5G&^:13:[2%
M[T2T5E3%0^EH$88%1&F]8!2Y?^C< ;ZG#799;-#^L@VN!LA1'P-+$IC 5:\F
M4(Z!2DM$88;9PN3"*'-AJY':XJ#'2E=MQ-.,&BZW*K9H;2&"K63@.*YZQ#%2
M](*7Y2(OU$ 7\&U#.DQPY*GL@:&>WW<#9^&EKUN^T0!<>T.7*>J!D-2R7=B>
M)@W0RD;PIOC"*4=,9@\L616=G@C,GD"=A7VO3R"!MF8Y-K._P4[#ZB_@!1N4
M@Y6T823=6Z?ANW9"Y^4IO"CMW,'=&>>0+Q4?S,,V#IV_6>*]73['LUTTU# L
M!F2+FY42+Q1MM1QN&US XM76,1(%-1=RG5!'>CN?$!',8V-?UE .VBR4P^K0
MS3WN@X%7GM([AE-M<$I\C>EFU/69V,?H*H='EC'G/D8H[YY.U2B[[N#O9JV0
MY.0F45K13+)(M^D[G\7.^S(]H,L1?>)&N4SH!?VO&2-:%-FO(VG&5\$'+$B\
MF$;E7,)8:J[OH^N<2YE?C@MA6Y]\F>)8@S%#-?%9?'RL7 V[U,Q/XXZ\7\'B
MIX9*W]T-QU:_R. YX)\LL+ENSI^<JB.N7R,C_K;Z]N*S@NQ#P'M.:1X!V<:^
M'UC&[W,6:LE@C6N75#=U0((KA;>[M/I58(3\^EV!3YA=*C)[)ZC7Z"1057/L
MU.FH4>>Y\9K\J8*$5 #I)CZA?EM&'HY+4:;7^Z\$W_B6Y\W-M#(%/8.MO8.
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MQ2I%'>"#(8N^IG)"Y0FJR)!A&J Q4)+ <, ];U$_+-$WY9:V4-0WPRC?866
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M:Q/H[[#%<C ]Y" >V$?"$ T0Y.D (RJ,_<:I0#W3DTD#=/\V([<EQ^&DUIY
MKOWESKB5!OC+GR*=H#M=4?&?"2K)EM IA&"I!Q$DS)"LD>2Y=LQO39,?H+\4
MY>A )43H0*?V/>129<.H1QLR@3O)KB \!Z@9U996Z"9@CY[9IB,%#42F4Z'4
M7W$!D;RH<?2P1,WM6^^%-2 ]$+O\"+H2/9@=:?F4QQT)9-0O7Z8_8'-=]#ZL
MG=1(!Z4@^UL.]"MU\J7I='-Q="O9=(Q$(UC!#II,)0M2;]( QE_A.QLD](::
M% BODR)&#1/K(C.""1ETKD\<($2E<=B$*"PJ(%T=M)FM0 / :8"7,'HX!_<_
M.(-Q4>V:L/B5 &%JV-5_J#G]DUJFNLGN0#*LBP:H!TT#%\?_H07'KSB+_:V5
M3CU3F GKGO/]%1VYK11V6*%O%YD&^ UQ'?$71'$@7L=2&+3^MW6["2E&!^QQ
M\KE,DK=6C&W<R_-"BG4V8S&52L)+EHP<LU,ER8&VC& NO58)_1ZG]3O$R[[&
M; >$5>34C(E+NR'L>E:7%NE_KS'^=PX._O6=$S5)IEM!7CFM(*U6M0N MUM\
MB#W<<_F< @A)4X-,LH1AV6'U6J"Y^B4JZ1-KGA@7]93>_HX V6X"XF-C=O#T
MM8H287 ,WW\@[CVL*P1#(6B0A>@30Q*]%@X83BN&35X ;DQZT@!0NN)1^MR"
M,_^OB_]U\;\N_G_JPHR3"^OZ"OU.2%&Q,?A0-V/>__#G=/\[_AN'V%37, /.
MJ]J3L MBP/H,0T+'.:-;A2/TP\63<H]8,7OQO\60G*I)'/Y37<R+J>=U_!L'
M4Q7Q%VHK*XHQ^H^N' :<*LC_3CW7Y6;96Z\E.Z!Q(:^VC+R%?KNH?4!$S\@B
M;KBV;&AG&+->253G(""?8W&P%4OY?%P$F&_41[@>/Z:*@CM9"UCIU/XDI [-
MX8M:)H3I90#W/)!K$_T2I8;6L;M7BMPSAN>]/-:G\?SISZ7U+X+S#EV')S+7
MA$46,=;];3,Z6GVZ>B9.YHB>D5QB$\=&S+()@;D1<J)& ;=#5L_KR.MP*)"K
M8;M\3U_UTPHW0SAL)6:J%O9M2^UP ),A_*Y3AZ.B),NAP'49$]%GRN[TIL@?
M9AT R[+;O$1Q6D2:K/4YP=5[(.?(^OTUKE-2P^%MWX:!48@:*6NUV(1;(^<K
M6$X+!UT=B!)NAI^@ >RP48'<^)C(&GJ=?#0L%'KWKC&RY-:I^[;?K1J*;;NL
M^(9+=Y/<=#0M\T<LT8*0Y07%K*S*9-_"PI7M^[N]X3BJ*$G*@M 5EOZE&ZKG
M/JG=]/Z.JW/Z\28-_ 2F%<0F"PP74"0U3$$.(9L*S094E*]QW6"WD;\?G5)E
MJ->0]^79G-;(&O7V?:B04]][2II%575V^=C);2..#0Y$1 TX/1!#Y<;KM+R2
M="W]4*/ 9]$XP5B9\O"-;(9-4-/U)1,U&9_M1E[@BCJ^X?J7 ;NRGDWN:04O
M^]NM7WRZV .,+7XHC+FS+5YQU],W:TF:0>P [_1 #OTD>Q!0(7O&%@TPQ&C'
MQ$_R;8^/XM.";=<E9R(]EI_")NC%YC!H"AGEC+97*EUC=<*8P<)*D_(EY&<5
MCQS9N,-<_DR9,D,OH# WVO*4<L8<$30 8"E:S\Q(D/%"@2]BUV\QIF8>D02S
MAX<'2E21HB:Q(:F'JG6D3 ?>=57U_SSHC)M;I6HDXM0$S:#&E'AQ>K_(32_;
MW$%11([*.YX2H'N1+(=7LV.O1LX%:7!$7HYV5(C5-9><4Q5'&0GR=5S2GM3=
MAJ6AM>&/>B#G WM@)Z WBZ!W2299/G;-7&KL/62=1\+^.>$AQV:T*L>6 YR2
M"9 (J"^>KX7*&CV"\R:+\SE;;3H7R;;<'PJ*/;R6(.2YE%CQ(%.Q:4.L=*QL
M81UY4\OWT>)MJ91+FO+QM5*#@_,!M>I0)T(U+K Z/[#[M(^8/J$?RZHBYVP?
M.S+6!%30O\R40 8'#BR"2MZ0@K.7E&?A.+83PSY]]2(,#GY$ T&ME;KANH#7
M2]V(6CL5L1 YO59G?Z>=E769W.=QRJ(%&66:(Y9P.R>%&?=Q^[3P294O_\UW
M7?ZG!L,,6S2]V2^54, E4P5(R(DE_YA#FB[ NQB;<CO/P*.,8;I3#*G)[A9,
MRX1//YVP?#4&KO@>SSN!/!8+^G5/MY->7GQ\XW#[KC3WVG.G5?]J9N<;4I*+
MXV*O=E?B&-B^]SC8NEJ?"!\^LC)UYI30,= YJV2W<-EDP3/.SL1-I/MPJ#6O
MQQF1IK%\U]7=$70[*7^"K;F-;<A;>X J0+Y=@NK-^EH3ZW2U$2EUIEXA>_J(
MX& 5\(5V'O0))7,3$2&69;$0R(4LD5?VM[PX6''UQD'5VPRG1]Z(+3&/76S3
M;QE>GJ@<Z>N,E <I%[-(CS07-T;P2AVX]^"8<$1D92:WF;ZQRZ[OD&_(7>B%
M+D6#TMF",2+&7\QS4^T8Y1W:GNTHF:=7Q3+;)P[QJ;)Z8-SG)6=FG4Y%9V!:
M%6SX'4[^+<&]#G9\$WV<DN5T$F?X\N-GD;KW13[$650S]7NQ,%5E@@9 VY O
M->B6G<QCMB^_-,KUX)M:&9A'9W!KD2T)\V,L(MY:':?V-1?E2G HJP;RDK4(
M6W%X]%97'WT]!'R6_5XJ]SKUR-TP=XT73:!&@8LT0&@1B=Y/'H5*9#LR3\8P
M_\!X)V;V'Y85-^7.V:;\9$"K!:&^)X'+*@+61]0%I_A2#LB2)#Z76WYI?"N5
M)G(P>\E-4P[H*V9% V2B]3FMC^3\N+P])6"XEFWI[*HV7;8._W8D!>0$C^S\
M_J.@+50P>*\9D2\J5!YZR<KP-:?&7B?[0:R!Q?O%/<5.>5(<FB^9W6E/Q# $
MT5ZXD ?[O"[5XFR+8J4.IG*1H@KNC[9.:I:BOW3XNO*XL<-K#>!U_7L;T7')
M*JXV>[>I ^-'!E6 C&.#KR?GSQ2MS;S,>)"<[$XZ[K2<GW]'ZJ&TQ4U^@D#N
M^5 FO&R;A'R?SHWR^"\CEZ9?V1QCF['4:VI2]T>M6R!1\41Z@^ZM 61D]/%?
ME+R$U0:)N2+<-[!-@:<J"8<@I:H#I>"M%4'3\@&)#Y>^7Q)_\4KM1SOLV!Q<
MN[\,'+0+C-RT']>Q:1)0XWJG^64ZK>7LPD)-ZZ[)PH.2Y[X5H=*S%!K@/90&
M@)C=M'GR\$Y4C949?]X3;H-%1@_QUDP7JS%H+'*\R+-%T4WSF:>EGU!<^6*O
MW0]0J7-6+CY[:CLD4*(ER\(Q%1B.758.&WI?<DV)KW@A&)/-T4'MA@")V.&;
M]>40MD"^GQ GL_A<S].C6GCVZ#'VN5G5RF;P-<: 0B%-&?:W'-UXH]#K>5MF
MZM')[8/Q3\TY%Q]&2L+.6>";FE5BWTN)+*]M6_KROR\F3N3^\%A3?+*6'3=0
MY9<^!8Z&LRR[J%V!'L:[9#-#'.)W/?P\]IXIY#G?G?;H% ,9XSEBEB,(:YJ#
MH6^J$"\VPTY>&&A_;.HQ='7%IN],X$=$A=4PCZVFE9##Z=5JD0N!H:]7/E?I
MO+L5B[!0#A)-CXX-#S:)2G3<&QNGJK?()D8ZM%K).^2O>8V14[-;(3R!PB0;
M*J?M8!C!O5Z^CR1_G].2#Q(TE/)!P-=MV>]X&%+NQ9Z@V0@PABI<0?*IRH Q
M4UN"7)&^S@IMSS^N57M=G5)"E$J6+FG_O&7"V=UU8C[V[ ,0 [BL)*CY)$>-
M=-V)^;<Y]T '##8K\G23;:K*=_U&*H&0\$_SS6Q&SA2LN3GLHQR];W>8^F_M
MV?]W_(\, <N<P.Y4@;X:C2D)3FW5ZT4U$H^E7,_8Z,2>:SE)'A).)67B:8"5
MDY.NI\GGT:2P[(C<TJ0CJ=I)EN&2-I<&M%:;8?P/47X$,#F.7OQP4;\=)<?7
M9*TWW"/QX%TDM#J55FN 4RL,WZLB^2/,*97&6ZPQF.':^8E<'2$D%'TU'TUB
MZN]KLS>,U"?!I3H).HC.%HR &*5(16[2ON8\]J?:V8''!/G$Q,RX\A3'V!_G
MK9-EUH"7>81Y%@:1:@*!O:DG26\E"QWL!#*S'(<?L;JK)>0-[W!=!;2*5IZE
M>FZTA+I,?B$A]V1UW&2]\(A@C$?L92/@_*IRXCQ*=)'3ZCPEWT-)Y:J*@KN9
M/1=\V-WL\H/3-L['-<KLQ.6D0H3]%?RW7,F1,T&?,^6X DW$L"5^YM/^:G%[
MFCYJ>Y,6-, )R8S*7J)(MG\ 4B]&:=I8K,Q(LU7(K0O#$3RQ-KQ=;R5"D(>G
M01:4:8 024_YD6R=HJ$CYZL7HB*YUY])IZHNS9@_+$<?1+$O<LV;-\2G2J=L
MBD<V<W5Q2ZP\IP$* ]X2V'#@!G]G@WK.Q/EBC*LG<Q.OOOJQ,5G]DXW/65;X
M7\#=M(IX4Q1^I(V-EB^X+D'..TW,][B('C=Y5I8ZBI;P1PN"I\ M;&Q09OQF
M>2&BL+UGM/-L.+.<\=M.F3LLWQZP[>]7,8EV+VND/RT-#A^NQ3FQ/I12/OUY
M*"(TZNEQR"SWTB[O3M\4.DJBQG?OUAF9N6O]9+W)+I8A35>Y\H^ !"[]['&E
MJ9GO17-;(H3V;:M#F)K3N>JJJ9F3K2D/D5667PNKI[,TD(+X7)_[?9]Y"RU7
M-^>W]DKWOL<?9O_24R@R-C^,UD".98][@HZ#G#J8<8'%MK89/AI-$:[NTL%[
MMYT8]\3O*J]Y/CM\%6,PB1X6KO>CM^1D;9R2U91F;RESI?CJ#$K]4!7_F1>:
MG7<F/+<0JI27NH&,$-C/QQL[%Z!CN>86K7BIII)7XY8R(RW.$KLYW]=?ABD)
MQ"$&[#L+%C*=9)$;"KO1 H5^[].2#1_%4T;44OK0SEV,%A S&L#>'G6AN]0<
M>7+$*3$>_K7SAM^9NM<,6*"%B2O.=1A8GWJ*E/F)Q*7G_PJQF?^HLJSV6%9_
MF)VA_DA)O,BU*?YHIV!*AHKK1!MV*-C@SMJRY(.:KZ&JRN/"QC8731X/\ >!
M/B,.85"G+<G:A.T&5Q9'?1V'HB8\[JAUW(?0T%GYC^ECQ&^'XU3DCN6G:C8Y
MHF;0.^\TF$(+@0Y"$[4SM5LFJ#%EN .LOK\7/>G(=B @=6G/?!GDNE&.>%<B
M9*/4Z4,LZD5=I"13SSH&JE(R)ZCC9;&81F7=H-W'G[["^(NE&>E5:##D">:P
M:,R7V+!8E0(7'FL[WH G2;]^+Z1+Y>^'#/+S%J47>&W'B#\Z.$IUKKQ<O!&9
M'&BT40[?\_:16:U7U8*QD,K;-+R8*;D7DZ-<:J8NQ-_\MM7AWQ)% TSK8$!+
M/UPI $PCFJ&&D6"'@RRO.$S6"M_#4\*"RP['7A*JB!I>,(!UK.R:9(>D:SU]
MOTAT<'5>];_/RRZJ'Z=%X34?T? G^LT'L$[%#'<U"!S'>(R)CMS&0'74/C^J
M"JFV]\I7]$GZ7/<TL,:XI0$T;%(/8Y<KO*E>$FS4L]G&S=J>^+C8:5JW)]+V
M_>&S4X*1<ZD?$*DJFA.NITG:6S'XF%#HT;RA8<=AUQ#HJZ(RD8CFQ>PWU^8U
MFYP#.^$.!+MF".]2(*C?-%#8P1B<?4;\VKD0B3"!AR<"8?-\*M,V:3Z.Q][%
MK@1L8LO*KXH^^/(C.!D6O[>4_[6J?-R[>X6('7&]/C@9&R#U+5"A?R7V=L0*
MIY]9&X]UO\NIA[5,C9!2IE R$+^F0_"J/IR>J9XS8>[@/O)P5T-5<+UD&Y4M
ML+F^MMR03AK?GFQ<GX><)JX=6Z#OM=X,>VJSX\)/L9+FXE>Z@''>,)YL9ZXI
MX6\4D\;A]\JI,0=B+VU> [PH>OITCO^X5J!5_Z)U3AZJ4U5J *ON[UBX$UW$
MS)*_)R*!*/'VTADQ<H86^<$:Z"5V/7U;JS'B"K7K*X,?(P7YM)</*E.RWV!$
M9=QY#@5_$V;BF>-I\J0!V*CB\]A3<JZG%H8-3=YV3>YU%5LFY0P89;0]>RG]
M?0=L82S\2NTL624!UQ+BH5U1*.?*.:HAN( Y\0W)YEASRCMRQ[=N[B?F [4M
M<1">22^PIY3'(>9F5WQ>QIW^D0.6\6@MTM1[^?E2LX0]?,JU8B)>('E!-^/!
MU*-$<*=QW_<M, ?9JE<%2&!J$&"K*:]YIT\X3 .4:!^[]%H^2'?]_LEM\#6G
M*Y.N*TR3L BSN5=$9^$5X^'4D$O1N&$"AYDZB^'W#S9QW^OF;]_6.%^#GE*?
MYJ(!RA3J' JSHG&<>[>%7@=?VA%:%?M&YIH<,ZD_BD-$"O":VO77*.&JJRWU
M6]FXE/T/24HO9KXFNY/E>L!'=3W>^6EFNIJ7[=Y?S'R>KA_D/*PCYE7]#A)5
M$&"NL&(]>0=ZZ2+*@V(X?+%\^.AU=G\R_MI8%&FHRV)NN PE0NT9YR-9YIHN
MG!I:3*0!7DFF;:3WRIJ[JCV%CUN_ 5 "\G$CSKH23EN^O"^/M3%B&P65#R]R
M?.2VPQY&/2?9YIKZ>&]5$G:=-M3M_ -L7(:?(.^RJYQ]Q@YO6"\4M;YD4%,P
MALCV-R=WY,T0+[EK=:QO. 0LX]"6X,<D#4)7 XBG$$$#%)LM]NGU)6OX9RY>
MWE&0;YSC2Q!Z,+%^="$XV!0)+ U[61AX10/?,[RTY]8?2!:E)"M9ULN,E%1S
MKXSG+, XJ7QU".BM_E(?B03#[D(RQ<XPZ.<!1</O D^!2MS-5_IY2=&6$+U^
MZ!GOJ<?XK HH1+Z:@A8H+<?.+P%4+E*KG]Y9^&GL\?1M_B7Y1#,S"G;>)K1M
MTLK]641XCQ#6&+$=& ^Z =4@.*GCT8U2QTGRZV+- V7]WF4^Z0;'0EATM\2/
M[&5_DAO&?$^]1!B$3TG%H ^JZ":<5'?PS]:Y<F>50R]<\XWF0A?'IF<H,MLQ
MNM46YNRU*--V*&^:S2#80FY^3Z1!QPPSN"+P6)AMV0;\Z__ D&&1M,KC_^C>
MB_QQ3%$%*'[254/"Q73V#5,'@N_7EB>?OC><?7J4 5WH(3<#+ .3D^:B8$OM
ML/G&0OLFW8R'6\YGN'U$XSX??3(,>6UB0,F% M.6U [W;1Y"E=#/,U2O6+78
M1YOK[&+"1RY<_9JMR'_PL!^N*LH;M_5VDCX9XJV.5Y17!]#++<OK%Z+8&P4C
M3UV_6I*JB$.!"-X-29 ( 5$2QZ1_+N\!_XF$]2R#=OW,FA@^_^<_*@7>[S]=
MJ30(!1/6;O;4Z!SZ0DIH\&.EQD'786T/7XT(,:%,^+>7QFO#@C/;.@1>([>K
M00T&6%]/KN,^J^D7,1T9^X_(O%W>0B-!P=E!3JW0*[B?'CD9TJAL2C+")8/_
ME.DC%;;.VHT&*Z$^*.33SR5E]6&K!63QT4^I:M'9V7WS3K.@H;#&<6 OZ'&4
MEZH+M5/,S2W']XN%5J7MA8IAO]FJM9^.@^N8B>.I+G&]/*XNMF7'I??>G:L3
M:%P57++XF<@^R5-QL=*RUIL&$'S'%Y*N*W=!5^*9ULCX'@WPELA*;S5,)__Q
M$>%3$$^@S +P4(V2<X$3I_=V]ZA%8<'3!4+^=\NJI^VH.*Q).Q89,PR:M"39
M+=LR8K<VD;&/]JHWUN=&%(N2Y10'"KFU'WM-Y-Y&G6>?*[$SG8@9[JM7DR8X
MQX2Z>'3X-_ VD4"/PBR+3XC/P>/NV+2V0!GZ$!P_H3*DEG2R8>_FR(KH\/JX
MA,"6.<_@ H=IJG2L"8O/+JXF!DRZ1!##<37"F'R2< *Y:1K9/M8= RE%;T\S
MQ8/?1S55VYJ@79(Q'P*[K#A)$44.P!,N*L)3S*I,.CI^>!TGM\<7[%PR0EOX
M'YA OQ O\"AJ=9CG.UBB!0=23S,K:AE.OS-&%6:,!#@/MPQ@60(OVZ/9R5=@
M10L]%D/WARRTG:5KC?198+XH8T%^8W!=S+!@/99_5:X:QA91D=W[R"CQ:J.A
M9.&;H@J;N M@B\"R=7"("LQW CS$UFC,N8KAI586C2YXX3AV,AX_N6/(IM="
M/I:"WVB*IP&84%>@H/Y"J%R!C]V-VB\1#54UB2D5KX4_4(:^'C\Z>C+:7\SX
MZ[?; Q*H&K0$E1*5&5>75X.L<DV8R=]$M;7OVK1 REQ#R7RX:OJ),FP?>(Z@
MLYH4G(,*>R@<W24(NLK)_X(&6,JOFEM1GQ@3GC3*CEEIVLI/M["0R GO/;GU
M\OW<S*/'W(+\&U8*>20'3TAXH,J@&B?T)IC9J7N48Y#H_/!L^<;W3U$-3V=T
MV137,(<KI,Z0MER!@3]6US(7JLY0$E[CRA*=)3FBAWT/N&)%^-W[>_@O7%HW
M]3190\2AEHYQ'SN]Y2!<XUJ8FI^''.VSZZ%R4_*>D/40"U46,#:RVT/7[#N<
MJQN:1P_YOSJ0@DP6Z=0D(MP0!TB^Z:2M-LN>[ &4Y()?<WPF=$S^JKW1K'[%
MD2,\3(J( -OCF> ;TDV^'U[5RV@!$8MOIW"36J>UX@JG1\B]*MOZI)5)9Q N
M.F'B4(4_]@1$3%K;N2B>= AW,_5HRUU>HO+.S4;0<2@(O[:52W(X'I*=^;$F
M>G5VUB(^UH'/3;S=5Q5V;!>5XO<T*#C,*"#@_L-<@ZS<*I/2N,U-)^*Q?]G2
M$'!/\(A&_;!59>%"2SU5K-;R_..@Q=46L*;U;:M*U\L/O.<XB!S0J_BB!EQ@
M]A0XP@O%4-&]LCP[*!2]4&;X^&GCB6-3T:EIU?C2W'Z#.-WX)9?LPA>?M0H<
MM1!#2'.7O<4 9AJ ]?I$6Y1"G7)(L)6C?*HXBMI9XG,>T" _HW^!Y5L1<^24
M*JL'2HF$S" Q-5EQ=$NMK,Y4$\XTF)O55EVZ98U,N/""8?;, 41LX"4H=W_@
M27L@(_2*=8$&#7#T$/6B;^<GFW:]T>_XR:#4O&Q^[R87J#H>$Z,"(K1-$ C9
MX84JM[\Z%FZY.3N>6_]BX.7#0Z^8/"G&+Q/=XF.2!H:WYKT#-%B%>6Z8R:EM
M>]56F6>_);(U2]&[#?0A3]9379 ]PW>+7YTCS=*0[RL!U:O6(:TKB?/4<V0#
M_'8#VV'0Z\VV[)B[?(<";_C&WNW:UN.J!"4<BF6$ZA&$&]] K4@(PN&MI0;>
MEM>RU4["/1X?2Y?<1*_+)"<(I:I9#U?ELPGXF.!<E^&9]M@3GLQC FNZ_;A>
MWEWNB%8'C^<[^HK+Q^R46@+==2;2N?N<53%R-7NL,V\B+RD)5\TB4ZND)#ZN
M6C%0\J *4U(<0Z1GV[<(3"\WS?$ZD7Z;,6^0UV!NP0)@])RI7]=*V*>%5+%!
M#V8P$ZG:O*K73GY;QL',#\SMF@.E/C#Y *O7G@*]I %.D9FR?+(MNU'"#KQQ
M/X.:5SYIH$N%8L;%#KP=276/+GL[P7JER80&X$6)PX_[;'75Y57E;.@O<D]O
M1"L*^JRLZ%C;C[462GCFEV^MP+Z5O6@8ZT!XQR^9.*\,TT^CN4$L"_5<$^%*
M0T>^>MKB\*G79E)?E^3';XW:I%2JN _F0(U)/9-KP5OQ; 41(]4=-VYRI*9D
MC>QL*[ H+]^-_GCFSJ*J(PW0<$3."7*LZ3@2IPWC<-04W$F,RA,5._@L/V3J
M[ FQ=Y1/@8(D@\G;;VUP$G8Z9?WDFWRE9K)2O!\C.V(J6N+.R#AU1@J*CKZV
M](+@P;SLDRK@DD@71!IXT\DUON4Z'C$E'(:26MA.X+U4C:PL3FBM[ML\HI*4
MY$WT:&V9T/&6FX27< 5+RB;!3I"2S/N?(*!&N*MO?0,8(_,6'"MV!"<V&0K]
M4^RL+H=H<#^Q#0]1]LSD]9=:H)Y39S=F$OFWO_JK-^J;=E3E>:AS]H-W5]U'
M%%<L" E-0XK(GN(U<319![#_$.XL"4T-(+KN[4G1 *<UDG TP,YV#WIM>?_Z
MO2H2:%*[ ]+(FSS\L':UUD6B[*@"''M;N@5Y7=\1>!0JED<Z+,4XMJ#7-?E=
M3S"ZI_7<P>0BMGL:A>8;4 @-H+:K0*$DT "OTSL(,/+>/'9["T*]6+I5TC?N
MQ^?OF.C?!58;X4>^!CVF <*H$F4]$INJK'81MTO,^4[.RNS<0ZASRQ5.P(-0
M+"1O.W_73_9>6P<W6;Q/2=Z-O<1]MGB.(_L/Z T*]5KB6D?ZLU\5BJPK57M5
M:FN3;DY*"-<9D+3.\#+AR<MK%]XW^!7;Q/JN)3;B0<M8_-[D;$55<]2G%LYT
M;C'V/J4W]:JG05Y5,0I--,#&6CH,.P0C):I@Z25^%XK>DL)L:0"<_=: ..8*
M)L";K<"X-.%J"=:2<@L?UA#%\ WI5S88]5"BR-.THV,Z,T(6T24$S\TR(U_!
MKR1$(6I,&9]'6*""E[<5CC3ZYK8<\EA6ROW/MO\UBCE;[ZJ]1\.,TYTW5#T>
MDO@F5T/PV)L!P(:M&RU@WU2O5])*7LU37=U&E@R3&B$U"AF.NY;Q[X[T;3JD
MXM;'(2F/O?<:@Y>,H7]TDK6H,X:L4"[C<VY=JFR8QWY-:#C#;!YF6([OUU%A
MF[W)W]G%[KR8HRM6E32Y%0**=JZQVM+RW/._:<,QJ&O,7SP2G6**5G;]EU0(
MN$;0 '/8VS0 ^BL-0)#3+]1W67]GVW72++UF%JNS>\(4*H[O3)JJ1G /+[C5
MX?ARR+E%?4%+D<^4[:++!O\X21]/SU3+O)^YZGXU18*CPQ>U_[T; 7Q4:AL-
MT-CS+WKZUWM[+#!_ B9[X-]+U/K;<7ZV4RU80AU]T[RTF/$@_#L>'"3K&I8J
M$'RKVYDQ/NG XSO7A0\EIY8Q_3$(%IVCR.XB!Y%U[/7')-]/75.OH%9;UY;P
M(TF&5://!%5OBQ;2 /5P%D>UJ\'-,@MYJ/.AIUVD!!\6]$Q$%3"Q-ISL0F::
M_F&9Y0_K>*[O>$D8Y92_&\9*CH>E G_N31K/6D]^R7QM4^[-#V^NUD8$HTZ@
M\>(";%4]GZNZSUJH.\F;VWUFRE';A/VSK7]= 94F^6+NF@NS3N)&OB.)SB,=
M'R#'J0=]!"==/LM_GJ3P2&P>-6ASJKS?*@)9#55EZBV6BQD"3V;5%D <$U*!
MIZS&V_NZSGYLWK:)]5'+JOXWJVO3,+DRA7+]87ZN4FXU"OE8,@XO5N<G@0U;
M=99]R[][U#V[\NWKL$!OSZ7M*"<?R"0\3.5,MA.GLE7B&S-'S"E+J\;&KQV"
MSXMT ZXQ< C_,2.2!3,U'Y/S!U)CW\% \%EW8VP)XOD3LC17V&1WNLY%L<F<
MS JO;\DVK)B?QC&-H*#4XZ0T"?"K4I_5N3(^ZPI]?4.!%V&*A> _$7+8<TR8
MG?7>%%OBJ'Q?.4;Q_^ '^P9A6+!BK,6'I+[F* ^#UA5]CGKE\/ULT$K_.J.G
M%Y6S=P5Z!1B&*XGR\"CGC'"*2?@Q@G2=,?SS9I'K*2R!_7@J7Q_&GC1(?W^.
M"[8G 57H)W8H@"NZ#\57/75S3'4/G)=N98";C9%\\: Z++,<7_X:ZP+L065E
M1&L<>?!)UO46X?YCF#_,LD),_H4?TRN+#N(ZONKU!LYJ"<IF8HE_4/BB%!T?
M/EOS1^R?CO^_$?E:8S 9=;79CW$U(G\DHE"9H%+Y69@O]#KU@3'LCVNXSV&,
M58$S<337#I]0O\6+#9.SEQW0IG<.0TFLRI8MVY?C+B&QH8*$M*E)X1 7Z%.J
M5("H-.ZH1$?^6.[9KQRBU\^0%#O^=,(AAL'5RTXK>:[M6\BVXF_J>^>AHM'3
MNE!I]K#VC6,J!8;E[M\[_&;AV2,.QO=,A^K.%!8<$0SG?B^:%OW\6/T?#"<O
M]N<26HO[$<9EM1E)2*]_<X _>O#O3OA_>[VLTV>$OL\33OWH[;/ZRM5M-GJA
M7_1^U%>I,9=+J/\4UW_=? =NZTH2O&QOZP?/1I0HRUU[=8)%A)MAN!+!!%7
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M<T$"5!W:1[_;]]34RW&P$.:4NBTC=%'BGNKZQM_S5]X?.BP77I> 0]G/W,E
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MOSC8M9M^\AW&XE9L6T/>G*RBR,OVGY=[&_0,%-'(*/L.MM'+L3!Q)#Q^?^6
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M;1'Z56;I:>V.%&>MJ?^]P]&(1R8Y^**XVGI/17&Q#J%AT_5.5:;ND\10W&2
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MQJA0S[/3"U$+G"61A,A(BU@"+4X?FM##_:[Z&\=IV#:5"$_YG*>X/K1VA_"
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MVG:JDO.;UNKT)[]BIAAP!0J)GSQ15=$Z[P/DX2'+UZ;*'RUZ+YAZ,@[<!RD
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M7XJ[C,FSL\)UN.0/.>OIK/TP;7C>9QM#X/U(6-R[ZSP0SC[]Q5"IT#'0%>(
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M$=[ <[PF(#L;*SM;'6A88HB>C2;O,WW8UCT9HK9_^3KF?HT"!1"D>#2LX=+
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MYL%S;*Q>ZA8C$)@L4NI^];+7Y<=O7O'/7Y\WO_H2RQ1F??!&[O@JG&[6 ,\
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M9[2>WQ=Y&\OELOOWOB6]7X:2!=KJX.>@_XN3]XYJL@G7O6/%!HB(=%!!0*J
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MH)4BP^@<1?E0')6C);^7IMT\,)D?F7-EK]=)Q+B0^+!, 1KYNJIGU\TXZ?
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MV!Z9&A'PQ#1GIW*HK2EK>4J#G]MZ=]Z,=;<=F'NWEBM26U3Q/<*"&(9=(UO
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MDM^Y>9_\.4P4]J!K55X'5S<U: MHEG-N/?OXBW!!8K<<7JH+=TZQ_-B>DA#
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M9@<#?810D_D1?.;B[^+1]=L1HHC47,'$9[VH\M>+7HF#H::X-(<P(6R5=G]
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M.H_N<C.A;E1G:9<0E4+\,B@;<V/FQNB+D0^&V[<FV?PZ8J+PI)U[1D:(V3,
M)02NFMX$IH; K0*50NHK*D.83*XI-I5T4;:5?Y[/X#PP&Y<$6V;P32U#OK2;
M6?CFP+36]Q QTB@T DP&8=<>]8CR1Z3IOJC]F!NR6*TP2J(?^M%G>JAX!Y\F
M)S*GU6B[X^6?@NF![!&-3U 9- L3DL$>\)")_8F<H>JPE]63R7G!F75#2=]L
MWRU0GP'L-5H]%%FW@L^EN:FSUJLD7L]O (Y<$//[U3=8QSO.S5GMYF)(8\^S
MZFECLX[J^[V&I.L0^A! XS CBU(2K,[_>03F<S-4#!3VXX$+!+6@Z1*_SS/%
M#4['2,S/Z?;PL?HH!'VC&<<+6<@L-X/\)4PB5M&);'8V9 I6]+_//5)G& U(
M\;)G5P^;55GZB=H>N=G4DT<#!20'T-#/)^FTE<L6EB<*77E3T%O/GNU)[3[W
M2IEVQ/BQ+E-4>(0/:/&9FZ&HE!].%2LRHG+7=NS[7LUKF;@?@G9RK"0VCLN$
MNVT:37QM&VX<8>=!/XTA!NH-R.'ETRDG,<A3[MI+\?OP5U6XJ.T@)-T*B:T1
M+&DV#,;6U)+EQX9)$=ZG;+8-9UKJO:A>(QBGW&EYZ<0[(3$2CR$0^S*]ES]!
M_L1W8AAG?+@&H*Y?7^8/2/@G?Y7W #+BRC_9JLXADY].2C<RX%)&FRDU4,9Y
M9'3_<*_DRQF K9"MQ(<NN.$QDCT: LT-TJ\$"Z[UM+%*LLXD[/]R# H*&B,
M(R#NAZZ56E%N>RTI$6NF":?KYLT^;WLNEPF]BAT^\8 G]I07O%Y3]3""!\RH
M-29A1UFIHM3R=)8$>@)UZ@4%FF,T[BKVYL-#/'[=\QSZAD$_N&^A%A9P%\3*
M,+BUO8]BQ4Q.FCT=_ *>U7K_3C2J/66.*%J$Q[S K3DDL?(-81>N\U])^=@9
M_QY1%@V:*\/[V*"V!0283$OT1R8M=%UMC;TI L!]Q.CM7XQ/@9*B#M6N,3^,
MB3_:U"BYAR80XN3'0G9Q\P9Q/NW?]HOH1&[Q:0SMMRBN8:DT_2UJQ1,@ZI5?
MHCM!YB@*W)B=$8RY<7E]<L QFIN[<UE@!D[8E5*\3=2+4$6^!=B;>ZK_;#K5
M5LDEVE3$J=QMVX%5JNEV-F09)Y>*:Q4PQ;U1["U =_([<SU:,F0YA6G'=*&J
MR@J=-6'LDP@X<Q=62ZN121<12^PI1 ?_"*]=*-OBPT ?SH%#3:U"'9T]=>]V
M%=L*UXOE]R724ZABK82A[+&;_.):F(=YT?=@7D&<-2M\F;CHLJ(5)\]"V)OX
MN?6\:<%4^N3;WK%JUIM6V8L(5E#2S)T7QS;3?KL#\H?.$V;*:RY?"@9276F2
M1/,1Y7C]$7D9OG&,P4H1ZBY4HER_2H&FOM'U#" @Z*P9A+^Q%7 'JMY?FE=7
MY73-6"7O)_J3CWM%%3#N*NBG4]RD\5!;5K:YP&F$Y\,CK$)DHU*)$-FZTQSF
MSOB,9Z1"QXO]-\[T;#_1 IH2.H)'EGGHH>(\>SZQ4TI+? +V5!&+:IXV: XR
M#%5I2!LU U<&AK>PW@G#DHTV%,VAFK^> 8(5[NPTCI"*;.1'#N),2A(^D)QI
MLAEBP[!5BHQPK#P #V[Q]H(HZ$!_FU6H3A40HQP@?#K^RLT!(G<*O*);.6Z0
MR:FCL);!_)X.] ]?KB(VEH9\?3V/F<6%/8I>8\-3H#O: OZP[B7^ER8<=I\V
M SD?J4\'AF\0*5\[[8^#<RRJZ;:7)?R$GK(EN-+)A'Q&WJO (7K6S'[CTP_2
MJD+:^:[)/X)P->HQ/.$QOW(ITJ/5G\(D)$$F8 )DXK1Z!KB\X_HE;+1H8W8K
M$P4G4NYQ_]N&CY6U_W<J^6]+O_+CGZQT+/O@/P$Z2.>D&GT&^'B8T4>LUETV
MD5U7:XXZ ]P]E?V+<Q?"I[L&4@P"" <*);5G@!@&V'HRR7#78N@,D-W3MU.]
M!R\1A&';_J;941[G--L AL3T(F5#1D[A70<*,3)>AS#%?HM_=0LYT=[]7SKP
MWW78'-RJ>.E/; I]%8XBD \H>;.TCUCNVAN0CA@%Y^HR>PMW4!>R2E,7/5Q1
M6N/CK;0VHD@=&1++TW^QD$=7J*"!BVF)T.HR81^UI8U3%E4Z1$2E7+^&E0W5
MW.8/Z"B\YR=@H%MG,&33N;S++;Y.$'H/59P[?;@_R<([P<?MSO[DN3"_;WS*
M/(D#2HLC%<U%&6FS-2?:F0M+CD,K%J&GM32X RFO[/L]#%PG(#R;WLUYJB2^
MJ"1W1L5;%G5;0LX?3_=DL,?#0* "':YWW+/OSCB7XN+,]<O1,V/G&'0AH#>%
MDOB $4CD2'&,*+D6.A$KQ%S@F%XCM1I>BU4<KVB>&$VRHWA7!@DXG%D55!@N
M.XZ<A5WG6#"Z\]N5M6_"Q!MQ<'K+$J26$;>-SEO3_P)B8Y@-51LLWI*3GRT.
MJ6U,\]+R"L+?]@00T!6K*1:Y43E*N>-/JPY=5!]$BV$=L-3KZJ0>T$W.ZB_]
M@M@V%YGA^O6-'R;^<LP>(XV8@_[C;AU!2#+HNP6%XL^9"X,!-!-K@RK^[*W^
M;LYOXC;;J./[7U@J)"I26=D',/^.ZUV7I'OI5D(5.7O"N"8>Q35D6>8G.T8<
M8PX$2JU:>COE3N)!;3(EE4)<O_)L+XANW7OSYI(5=XONG2>?A3_/)C#&19II
M[PF8.8Q.:)@>K:D\E!F97SJR<;6SR7LP85_58?>*PHB>G=Z0@81H)AK7@W0I
M:PU"7'^P/4L'U91JS=O&");,C5^^9C&4EE4"J4VIHO :-\/99:4\\71)8+]E
MIO9>O^B1,*_+.):Z7!7W6_\I#[;PQR^:K+DTSH,>K]X>.J_E*XV?/>%]$X;L
M(,MS53@NM>+7OFDC/;<PIR\@-AKEDYYFYUF*-U"J1OF%P1W'@4?ZJ>K7-RA]
M5^^V>@\\+I]^.]3VX5*M\9T@4QEXR ;BJQ8(E&/-4D_V."I:Q:+^_9L*2-BQ
MUSRRC_)]VW.=5#YQ&AK0A.4!HG%DL+&R]I3\8S>N)I*?T^B#39CW4D(J4,?B
MP:#3VF2Y,%%I?MQ#I4)7</3A<O+=H[CC^A='33N6]3D0F4$I;.*6'<KM$A3#
M#PL,7T0RKC JP+]=\LZ=[/-TDGWH_2PUZ!-H\,(-   @<X/@S/+3L%6?<"A>
M4) ]CSCR;CS4QG1E[AH7KXD+5Z[,%9SP?NQ*+BV83.#:YG0"EZ1UW.97OT.C
M1W;AQ<L;CGKMSM?"Q<+NQMUYW$%\6+^"L?+_7<\FU'N _K?VIGW\*[OEI;W1
MS#]$EI].[M*<7M_FZ1]G?>C/2H%\SV-OW+?E0^(0:GT5M:\$']8D8A3. #Z6
M&44*R_PDLH,Q8O!II(Z<]CR8L!MS!E %CDSV0--.F%B0'#M"IS[M?U8/K&6(
MSJ#4FN$N^ :MTW5^L!A8W.JO-(RE7YF3^,'BRZ@[XM?E5.8S*/"T$[9A:[O'
M224,S>0VBL)]R%O>EG:-D*1(SX=B5A-\3]-5WPXN_52[G-Q&H2ZE:+5L8-<=
MMTXRI7_]9BZD2(]OM^T,$(Z:<Q\-D,.'3S9+(&EQ#;R)$V\F40-)BZKJ/Z^S
M]:<C$8O>*3DC^_5+:1W,O 5-^?L #YJ\G:/FE)B6F"MF MG1GB6\R@*5A0%>
MEMBI0%$K>?LS *NS!T] \[P\[8I5\Z[8#SC5'0Q+E)^T64Y@7H>AR9&B8LFF
MZ-/"N;0S0/T(+'D+J/#07[#'>>N-B>G057:1WD6.JV&$HIN10)-,^\2/!9"\
MGQ7PM&PY+4_;2/>J&<_>/OQU\5G6JS%6^)WY2?XQK2R\:I.2?'?YI61A]T!_
M_RM^R%@?YC, -5&[:$'-QN85,Y7(2:&:K/O&-R/C:LV&A=42 ?C7NNKU4]'!
MKAS@]; \3?#,R':YU2 I=ND<..4P5QO4%(.@JB>.U73E]?(W[OZ"6Z9CU'8L
M(F'V@4.&"/:'2P L:UL-^!I$9FB^MZP($M\BT;369"1LJLQMP]*>XZ[ B0>!
MK>=S^^7N^A5P?0OGK(DJ+:/F\1?%I"SH)S 9)#4Z-\)RIE9:%X8K&!J\& ,Z
M]7V+9.6]C29.J_;D-65AY%#%J.V2C<K-^Z%$Q%.FO4V,HB;L@Z,ST0JN-L^W
MDGY+9HKMQR^>XP7K42-20A=1&H<.%H)J%]COY2SEE=BK/!UT$+30\N;-FVD,
MF=^]I3">F_ZB.E D;NM)8;A\#KJNQ-V15O/'B'_5@SRYK%VM;<%M\>8U%%7>
M^9T@?S(X:51;94-7OCW.4J.05UL:JHD:D=-@2%+&G9)R'&0L/M]YBE%UM&WP
M:[%DV,$TH^@A02VQ;X&T$H2O^7O5US,_,-M@G%TC?:U3EB*_K;FY\QVB5OP.
M^%3%CD=(6GD67O)F30J*0W)OCU;SZI/Y<T0T2VON18L>HU4:T)0X=/-M".Q9
MS;DO;(5Q<//_OK1VT]%+/A3AQ6K7"'S88.,/*_+X#Z7XWEQK[9/E4TCZ*^$L
M+7F\9I&<$W,8JP2]S:M/:IFEE^;90L6F)9]6UU66!4Y-]G[X\EFH*UW%6\&N
MT9VP'-S66&0Z96Y>5OX!.IK1M%PFOF>N_"[QU;MTUC1.Z2X5/[_J$Z!_]1"P
M/X>/^3#3*^D(+/>,5?*7OKR((8<2AV->UDV@DO\LW^L>KC270T$=+_\%Q6#W
M.D1N9J:6$W47S9"YPN\6M2LQ@TC31G[5JVD[GS<2XN-&95:'+* #^V([P[F-
MIPRSEH]PGJ38@BFM!;'$K=:$SW;ABTVR-2JJ=MP7'B^D$ (A6XSLAR6"LUSJ
M2_*8SK*0A.^M7A6(O 3>5.(*\#@<;ZYJHO]Y4R?;Z72]%=YL]?.X+IF+,4?'
MUU!LTQ5%N<^&5R-*@LDC=;#=[EN@[$([HPKS2X\HE5(<ZWJ*'=03S%A#D!64
M_!*TD?:\X0,6:,S>U,DU-X/ <%]VWKZG-3%ML>=.-T8BUL>MV/M>M[XP0S,<
M.CH\(U-9,;PX"-5^=:C]A.:6P'1H'RVE*CM"]&?7:066L^XRO]%;LUN_7D/H
M:5I79]A^)&$I/VZ(]SQ98X(P..N-'Q:57H(NUS"<\JU*P<:7QGQ'^*IY]A!7
MJ\O#&S.<;?BL%C-WQ\(1+@<Y<NR:DJ/G#K93HV\1F]&:)=L/?!K.3WU',-F?
MIB5%G\EG"W R$(19-4<W]5BK[T)?Y:PFK0H0)YZ&5;^QI8EGOT'YQ&^^X60V
M+X+XI&C^A,=Y4)O"A)7GF?KE1X$B/U<'2XE<92,>,$KM5X7C.9F!7K<3VMX\
M<8\/WU]](V(^,QBP.:0%]_>GF$ANU9!2%0%Z:Y=4#JDM3]7G0X4&/-.H)IJ.
M68'A5O*E[UO*-:;BMRT\ZP0J[S0ECS,&,TA+7?S^5W+C]56$PS0EE_ 'LSC3
M\K8]U3U#XE\9D8T$%Z.6HI:*_DZ(;"QH//-VQ@'U5QI>E<#_^:O*!HGC'8IS
MKF\Q=#PJE+QM&D /Q4=HGP'@'TB>"88GM;ZBFF!,3,'!2!\1TO7WQ'',5L8I
M%_AH\AB-/K+:P4J>NBMV(J7K8?L%M20)DN>.N3!\$VE5L#^.);'U[;,T##2,
MP/Y*[(Q<:^^<*OMW.>)*%U,/4P_P[\S-/\S_3WQU<YF,Q;75Y>,L:--Y;>G$
MI.'MMM*X8S_S-?0J1GS\+S$<+&#+BQ7>S!U\GK+V!E5^W1I<J_/RC=*<R'I7
M@T,B\G;*91?8VADFVG'B48(%+ V#O]RI/W6P7BJ"/R.@B\_/#\V"V KP[CVO
MB;/V<EZ8,3(D R.@)&Y.^(W*S _Q+DY[TB:[1;)>SEM=7M[-;$:\?0:="*N;
M*S*SW65MI7[O@W1Q?1_VX;<T.!(G;\+;]H9O'#[<_TH>GRQPWWK]AR%# W>V
M3!S_)PFI7ZT^&6M%.8; #_<6ZMV%THI'>M@CLG-Z5]=<TSU@&*O>0@?&SQ*'
M6UK1Z8C:.? 5]HAQ<3-EILKVSN?$*YMF6;\8V62+1W9%]D2D\D)_V1HW/"K1
M27TYO9$]C2Y</!Y;\0FOBN6!<B-26&[X%;S(K_OR^]V197+II$^I79,,2U^H
MDVU5RO:F,/BT"7MJ2C Z2MZV,O@T5_C*K9,:I-*FX9 &]UNO2FD$QL[76OSG
M?6T\N>OV'\.3G^[<TM;W&.W)KSY-/?C^R[U9@2J5A)$!G_I+DL+$"5%6B6>
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M[XG%IWV]U=3!9?4<G6>'3OM@N.1P@\F\DUJKMXQJ2.*=EL0[EM>W::*;QK&
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M<%Y*%Y[OX8#_>O 9-&%V']G##G 9O>7K_U$H*R%*^XIJ6C'[ZQW*8XA!2V>
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MM8?%(O E*9M.V]]OV'ST+?^DKJAI.7L&@""J]R-,@<$<0T1MST*QM57Q2*-
M8>DKLJ/BJ&:?.=S5K+DA'X;$->_/VI5SW@H;K[_F$NT&/7GX2]LR"IISIH6C
M/!E>MI#?EYK0<4<C14Q]^UI %D+/TWLGM8?%/PI\%N\R?LKRDNRD)38^NCG%
M<C'4X>,$9O"A%9[;M'KGXEH=5\FMKST@EIQ!70J<H<PC7U9MNQ78#6>/*#Z5
MRG@]C9EFPW@]'\V]>Z\AA#V+I:AB4Q#!!IEIS9,RZCD5$QE@7798A#"/]8W=
MY*B4VK2:6P.ES" \/:5.!+-LJY"F,<G7I*=?B%E=Q ?.[+:*W[(=M)#I".*=
M-.5WUXY^/TGDZ^?)VYB?;MWD2 @,YRFYV13.\^WBG^/]:#B9*6 '%@3;#3#]
M%^M,LDK,N'H&6"!6HOXAIH(HKGG*(U326M^ &_S(\]1##8O9>'\&8*<+.P.L
M]RJ>4B SX4EG@#>4Q_0-YP!IZ7H&6/$\N,JW/\6-B\7A^[#"WR/UPC>D0G[/
M\TSWJ5R)F3/';#06CLU,0Y):Z(8NY#L VZXEQZA_QHE.IJQRQ/1$]>_;\,(8
M=RB#9#[BCL+DE.9DFQ>G?GGL-M%C>74@1.E2W\H1NXWLC118YM)2 N\KG.X=
M#8LV35(*O+=I74%B+X +G]6,WEZ8.:W3^DS9GBH:T_[V$D[<*PL_A+,@L9NK
M%-L#82]W+C\..)+UCNU?+MO<MK2B;&*+ G;S.XM35Y<K/JQ[E*>;+PUWIXPV
M=G!(Q5:#V&CS!]I)!)H7?GG^E 8X9Y3=/.KNNN\%/5<0.%OW5G>GVP6Y[Z>&
MM42'Q9CF'J'YO.93*JP^,.A%(!NOP)-+'PWL?W9L2:W8RTG/3LO.>C=/_A;(
M)@V@P4@39_6.%*,Y/;_8^'@+[F:G&T<M/4ZSIX_FBC<J\X$G5@9*<9$^(FHD
MM*4?,"DLE9MAI+#X*VK*;US;6Z<RC0[2ZH:IAP6C;O5>($IBK:Y2ED_B>YN6
M+C21(SDN53.C%0O792H@B:-=+;[XA@%HAL2JHRC]X;-9.SF/ W@V@HT*XMWT
MJ"\/;Z515JT%W,T;15P+[N[C=GEW[GGGN*=4?Q3;IJ%\<.R(N-T,4O%_$UMT
MRB*MO&V^'U"A+[?SH18Z<SXR/$?3+XHS+>3F+:!F)\\ G/M2X."4Z[4[:>?>
M@<>D6910\_;%YBO%QTQ?*#1C= [6ZLYA-L=$R]N;M_FR5FU:/9 ]&^3VEO$#
MK1N=/^V\-<AY3^)-Q1?* PJ_0&FCK8>"G9!)+$7HW$-ACQ/#$\_YN\W8K8+#
M$DZIH6 "B.1X<-_D11YOD2=J-FG%,\4Y-!\2^E3AWJBX(0X<_',FKM)O:PM8
M-:+HP3J]%ET[VW<%=*@%%D>%E0I,4L3-.+BV;/E)-"GFR&*/(A/;VPBL81M4
MU C17PQL?%JI0FP;[UM]&O;DNTLX2@?5=;1$.DI<I'AK5OQ\AEUUWZ#@W<<;
MSF]_[!TZ,/?U$:JGD#;YCF+P#Q-1TPN\$Y%N$E:;(DZ-[UB_K#'(C\+9*-;.
M %15%@[HJ+P5\)[**P>,6,18O9%<^H-0C:^ZB7N.W=77J;7N39D8S\6GMS!N
M$.D5RP[28,V9$<UY4\[OT@<4[P70#.BG_ACRF*S?/H5&N4 2(BIM<,AT/^(
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MR.=7/S24UK(IUN_<*MBF 5ZI/%EU*C'QA$4NCT+@-L%"6@3'/=U*HG\'4C
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M:VV"QK8VHZ%GX8).J3KAS1#"=B=TXH92G>&G1OV=Z+UZ^.-MM]7=OA"Y(^L
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MX-7\74/T3"*_WXK\UA'ZF:<K@'.>!JA&=8&987HD>T+NW0'9O,S]]@G'<=3
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M$2*55)G!=N[R3,9K4,A6MY)IFY[>6MUS35&,+EF$Q- &8P\?.P5P4DU*#?!
M%MM595Y1:56+<V#->-?>"^7WTL$/CRP82) #6Q0E=,&RV?-+4)8>:?X=-TC8
M3E]'A,PRPF RXAR/*0D?F$9'XF%O[=E1[+.0=!0_&E'QUM?!-P KF)77V$04
MR+$GF>5^/I8+[YT3)O)7X9A4;$@6,1X:/0[% \+Z?ES];,I^)Y T\PJ]\B+.
M6EUQ#V33*4 'D\*>I+*>U7)TH 3C#.]@HS!TL$%0MR@)7US-4USGW6MCO<PA
M#1?L\A^+"$5$).=:>H,9B$4<GC'A[%97[M>7>%SG>LG:[ 59!5)$!=Z_4M7
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M^Z+A0X?%PW<QZF)3JQ;P(I< 8Q<.7ZWYM?9'3IX43H>]:MS1A@6Q*[(D2DZ
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M&=I8IL]*OSLRA^>OHZZ-0VV^KCO[U6/ZH[6Z[\,GO"W"[]'&'' B$;+S=)3
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MM43*-EXKPGDHX\3Y=GMFE"H\3E4#WRZY+5TP22!(W'2M/N!@5@AXV'UF6.\
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MN)QE(B;=:-+TP.@(,P*L77D_@Y/_?!TM^:5Q$I]H<)3?77%7TY^Q$)_B$WP
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MI&U&7W,$,?2YBGJ]37OHP3^T1_W,KXLL/(8,)3/@3-SJXDX!ZO4/I.KF2N;
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MV>DAS/TQ2Q5VHW.:65)Q]]57,:G>]V-)L1!KZ1$<"BI;M+OJAO:Q4S(3NE\
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M4)XLO [&4+7',\^<8T]-H?T9%TG7?A=D 7STX,BP W2W 0& 6Y42+X8[;+=
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MZ,9PV'EG;QV/<P+%I->D9G/>UQT$P(4+'QP8WYB<U/:_LK_9*>%#H[KXD$)
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M5RS?2+L&=R+Y((@OVKI>>!ZTLQAS&EZ;,B'=&YO(T#1+]]OXH>@NR#;G I&
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MCNX)]RJV4>ZQE8_P5,_\[&Z)?^^#:WJ=F8^UZ,[RR*S&I:V(0X6KIW89;I*
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M2A!(R;0^=E$::Q-H-&HE*=EB'>M27"(<;96K-]J?3+PKEJO'2&W0!:KV_D4
M=^%*OK!FI=(#60A-)@.R]6KY%EWOT_'?HN]U01?A4H#C6M[$N;PRAGE_$^&Z
MVYV+'A_.&56P)0?0:92LLO(#4H(G0=:;\T,&\6?Q-O4#Y'&;+),2AH:K[^TN
M\SWD7BI#<U5L23ZF1C$'UK+J%QQ].BF^K%%I;-1C+9 +[%4N:"*KT[[+#H^Q
MP-(*9@=Z'L6+:*CW2=12JIK>-,5U0+:?40B@0$78II[Z%L=_+&UC^L#G7^^.
MN"///K89Q(G$)7($H&O(H5"'<+K\)JJ'FH0?AW,!_?3MS@-S)5P@!EW.LU2'
M][/9@@N(0B>0<]1EL4'\XC[>'3#1$U:+?Q"2Q]Y K\G@>Z:VR-@5RN0@D9NT
MH&\5]*=DD^+2YRBY4-'93]:MV;+>;0JL@-B[\8LDQH5P4YYN+C##X&DA<=PE
MFNK",9R"U4FIO)[-L1XJ1*\A>GCWWY\&OW,CVB8=<4LZ-\YLTX7DLX;/\B!1
MG;A OC.)"]Q(Y,C@?R$/XV?E><#'57G@=3!\ &?*#5%9-0*A&1Z[XG<=B:D#
MP\"]ABLF!&T2)92@_.*P_6$/M;VYA9+1AD]X*/EV BT^6'G)$F)"U_9P@0F+
MZN(QZ--&.B><S!:%3OO[7-5WJ O^)M@NZA[)KS!ZT)=!^@_<EU?#MXO+<0HN
M3<*50A%SH_FC1.S.P$H=)W.\R.AGC&XO;[R_4#5U3H7H?A%_/SH:1>7'LS.<
MB-74C3A6'>^X2>=5S4@+=E_$0=>%YZYVY3.$[]5((IH2-U<THUL@3]7(MP(4
M%=QC1\_7/X[U7JEH-3G<R5D4SNN@?#Y<"R#FM >OF QSA$#O3^*WR?7U_$(<
MV8@&+G#Z9Y[1NT!LC0V'\-:=(?;0V>;H#\/_('[*0WD^7.#2>^CZ*G51G0MD
M=']D[@_B/QL=?K_Z<3[F >C?NPS^%O-!:L5;GW?N\>0" HGKV=3MCC9._%*?
MH@W]8M;_LUD:6EF#XH.V(W\ +X[?*-H3I[C/ZME\:!+'HNQ(/PAQ_K,)U;JS
M1KV:+6_ESQ[U?RDCX"\:OFCXDVHX9H./45:IRU"-MQB<"CPAFN8GC;=V9ASD
M3STU#^RP\9X;09TL)!/-WD]N1CHKKJ%+Y])]J]&C\BKYXGH__>9B/.F/AD;0
M08\\"*=0)2@F1+LJO;5>5#>0..XZ_1HGQ,QG96X>?6+@"95\8Y3IGB> LG?H
MJ#"3%A<ZKRL45N2=$&.Y\35VDW[5 #/UDT4, E%JE)WY#.76D%Y20%S7[Q,U
M[2>J"^RW,I,!X'_"@2"JYXO$63NHYPOP9E+<9_\ 4$L#!!0    ( $Z+<ERN
M \1!P&<! %N/ 0 8    ;7)K<BTR,#(U,3(S,7@Q,&LP,#8N:G!G[+L'5)/=
MFC8<1$1 1'H3$ %I DJ5&H47$!"0WHE*!Y'>2:(@O2E5J4KO$>DMD2XBO80.
M"=())-0 (?QXULR<]TS[_YDU\_UGUGP[V6LE>9Y][^NZ^W[6ROGD^2+@AJ::
MAAJ Y!( 0'+Q IS/ %0 I)<N_7Y?C,L7;[*K9&27+Y-1DI-?N7J-\MHU*DHJ
M*NKK=#>HK]->IZ*ZP72#EIZ!D9'Q&@TS"Q,#"QT#(\-O(22D%VLNDU&0D5$P
M4%-1,_R'Q_DW .W52_=)L:0DMP&7:$E(:4G..P%<%SC)2/XR /\P2"Y=8+Q"
M?I6"DNKBAMH;@$LDI*27+I/^1GUQ%7QQ'7"9EHR.^_ZC*_1ZS\EO>S"(OWG_
M^2J/<E4;H_XPEE?BA6<(!243,PLK&]\=?@%!(4DI:9D'LG(J?ZBJJ3_6T#0P
M-#(V,34SM[&ULW=P='+V\O;Q]?,/" Q]&Q8>$1D5G9B4G)*:]N%C>FY>?D%A
M47%)Z=?JFMJZ^H;&IO:.SJ[NGN^]/T9&Q\8GD)-3TRCTTJ_EE=6U]0W<[M[^
MP>$1_OCD-R\2 "G)/XY_E1?M!:]+ER^37B;_S8ODDM_O&V@ODW'?OT+W2(_\
MN0?];?$W5QF4WW^N:J/@D=#',K[P'*9DXI5$\>%^4_L+L_]OQ$+^4\S^B=A?
M>4T#KI&27!B/E!8 !)P9Y$8+ '+A(F>-2B+^,]^R9;'P%)2VT19D@=: [1S
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M)W5Z_2@]K,YC*.AW"SPI$E8R/DU2X+PMV6A#WLL6-XT<S:M+4\^!#*07[(1
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M%K&\@$[I.ZF$LY)'G\B@C-^+$VY\':O)$M9N')LQHAWT*'Y&PZ\0F^.<T[-
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M!1T!?_D#2[2R<C3 7(!DJBXRWX&X:-"\FW\20N,>^/O'W O]7TQ!BIX7&FN
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MTKBNMC&RK?2[?8MZ+)=4@B62VEDB(RG"R%57.<Q?^7[LB?R:;?"3EN$#FLC
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M4/FO=8+7/L-B$6=5?P' $;P_+);P^PL,29\_11OJ1,)U\/.I9 8?"],[DG.
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M9P$>ZO$,8#*PF24RC,BUSGEC0@JCJ_.VQZ?"\JP2$S6P?C]VB)3(&><:S%Y
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MGRQ3=?6:9!S4#W @]]^=:_]/$ YK<_=WS)W3*51ND/T>TD5_F]1U"IGABG"
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MJ9892),O$!190*I"?$)JSX!3P<KZ#,XNJ_@C(OUY1MZ=I2F6@!.- R33:&V
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M:DUB%+:+0T$I+-CZ3Y)CQU=K08AP,"MZ<LZ;@^XGS@7]0D3T:0CG6[/^>Q>
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M/$J/Z;HO7?#D;R?EFN=D\91S,EO,]F!^V[C'[,QMG5M*4@%J .C_E/D?(,G
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M5KR0_:#^@FGOIG3V&ZBQ]<3"=MTB)673MFO@U/4?HD::>7$W\\Q65]JV^\)
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MGB>J9CI"DTQ"F]XX_SBGQ<></8998=Y4IP8V<8P+J-$P;'R.5=ER0@8AG"X
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M.W'.]+K.%6 2QV[J*YXSTY$K>._KEK(KFPNG>S=>FJ?(JIO^UY9,"5)R0I'
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M3/Y4L%PDO?-[PG>17'X9??6G=/W<X;"YTDI.#;FG>RWX]6S6>&I+)J1L*']
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M)>?6Y6W?Y^,&Y(E2_B\:DT'[L'ZB>C9Z(HM=<<J>"(45KJ?-M<I42ESD&I3
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MI-ZIF ;WR^]>J@GJJ@G-M12C#5R\_1JN/,88PE^E@MJ$;IL.TB$74J-\W1[
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MYG85Q1L_P7/0K2O*RE-;\(I1AM"6@]?C IZWQAXB.448R=54O_U.NSLWEAO
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M+/XBW4[C3$*PF'5HM<?95<C5]9@8H\DC)OY #E.Z*Z"#%NYU^+;"ZV6'M+"
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MB>%J%GYE;)T,+VY5M)\R2IF2APR66T9Q,PK/FD?[!EJI%NREK@P+=\V"+ZW
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M32Z.OCF(;JM=M8@_0TY!VE,^&G.6#IK)L?=W3[Z;:->34!#?5=5&>P&Z>SU
MZ!=DV,"F5:,MU%"GHZ/0YJ8=L(\U !JI#B1QE4<:2A3>"$P57<SO1 *S3<^S
MP^'P/"G'Y&Q%/D6L7>;;.(3.2^^H0!_R:O!G$>W3IQ^#'K-80RNU((L)F!E1
M@AK]!.T9,-!FS0&D/N:UMOV^-?X$K'9ZQW.G&,*!ODNWH<C2O;1)XD,*JBU_
MK%PYY,R&=ECZH[!K#3]0L5\PU05WO7./F+X?GK[1^>/2EV2A$X(FP9DR1TS%
M4-J"12N8'>,:SX-L-*RCC!272J26/O*W=,U%Q4R]9U1W(:/W$H">.77[X-NF
MPR&\+^\HPY.["M1;<BL:?ADI69Q[/G3IR=I:WP!OI&#L]Y*XCWRY%[78M9Q!
M!<;PB_=IF@"9A GA66H]:+5$YAO&*P7"?!KN#P_.C..6] _+-"175'!<\)F2
MGX_U:#0]+N97:E%BR2/) Z[DSP9WL@7N9&29[B2U"-R44!3?%TVVU_HU9-9G
M<_[8@"_BY0%R!YHKN@O,KMBG"M4Z]7C@[,^:WLG7*W9FLWT32J0SX21I6)/[
MNJ^AS)V):),ZMZ;O^]PW>J2?1'LBC#(,,EUT/B4]R\BRR\Q?+C!XVFQ)$#&:
M.!<3(W)_R#,*2)^W^TB"<#H;4'GGL-&*;$T\<_[3+N_U4FK4*=(_-'C1 QJ2
M%+]R\<"-XH"BY=2<[@8]@?WWISH7=T1+^5X4:69R-MJJO%<;N%1TS8@'BH6:
M[C0ZUN;"W^6K/'B0RO&^GZ<#_1)ECA%$JF>/5,GSNUH30A3!F>-;RK<7G0!P
M?]0@ */./*9J1$J^QEF1I!NY7HX-[H[.@,YG)/?E*:7HM8WK^,.)"_J]3_O6
M%MD@R83\R4,VL]K3;AQO)RYG)UQ8\NJJV_W.A^W9% #>DC!MQ^>57@CD&,L*
M>+Q9?/;3&_N<!8\87-,01<#!]&LIX_Z1<C[@"/YG-K#<=/NAQ^PSZZ8I5M?R
M-'Q(!R&W+;OKO!2O#M;OI\E<>?=:F5Q[J3^E+;8<_8 @IP"-Q7"@6$@?2N6J
MB_^ZO\B=4(^=^PMC>:<=:-%^ =%N=[<?%(<[1<HP^"[&D B\WOU1%EYO?#CN
M]6/QG/B?;P=1RE62//,LOOVT(Z87$K=N9,(]._\/<>\=UE2PM8]&$9"B2.]$
MZ4A3:0*!V&@B1D (/4J'4*27A";2FTA3$) F("72.T@7D-X[! 'I"26$DG#C
M.><[W_=\]_R>^]>]]X]Y=C*9V5E[UEKO>F?O/6M$,DRKE;=A[U'] 2'@RLSP
M1K["03NTN,Z!WI#,I=_SSLX+K1ER6=LJ!GC4!8!J,<@F3&<$!"^$\]"/47ZR
M*E 1]"0;Z#[D3<&]3#P1$%A=D]RQ?<HS<L=I]B3@!UA]_I:PW#<'[GL4(EGB
M03])6H=1G#,1LG9!:KG]2Q".+:ALD<_^-#P<_T%HF^T42H[5)@HC1;"TJ1X7
M@,@J^>+/>Y4M&E)</5/!NERESYT^YR9LK#5&)MN1:^E%<YHB,S^=6@X]V:G+
MT7?6D7KZO2M,E*/PB(P94]/>,L/7&7"CD32'N1JM?,N4L4N_W2,VZ^Z))(!(
M<0&P;W2#$4J:I;TE86E:XT>&-QNK$AS>]WZ6!7^4V:_[*F+%K =ZPIW1[S X
MX?WX'=SE*X]>^9R*S/T]*MG<QAV;G%W_/+]4X,GOS..?^3YW0T3+/#-RN#BP
MX.D<7/*(LH*WZ_W?\>(@-8= 4\.*5V7$_=-(W.E&CE$&;VJAUKS4ZH%8!7,"
M>OUM5_N'7--4 M3]])YDQ>,+ "B!>,)4<L4)8#L6-$0_DIM=7;8Z31_E'?0S
MXM(%P%VG\>[/:=OQN$+V_&&5MS]C7L6HBW)<5@QAXK2-X.]XEZ%Q6[Y0.+O5
M\N[KF(>7F,C&+DVDBK\&[O\%9YV_':);.85U.9*XRSJ%IK,N !D:%P!D9'*D
M&,L3QRM.KL-%]%WJ%"%OI>4-QB$%VCK:?WO,/M$0Y/\+N\*A=W+_B9-^3&T_
MPXW:_HF5G\T?I5%+#.ZN1/HQ%;,\@5F'$7V$"/LB1E<7.7/TNY_%)@DP&8B%
M=S8^?4C_A:]6^V%-Q,>R&!J>W(+_DE2JBMGMSUTMEN]Q)Y:DX2RT)56KOHK^
M.BCN>0'P(B'GO\;YGS\,J>+G.:H5+-V_&'?DTO^]>.9__,',U?D::?O^354[
M?;:A50L]Y2^7(-E1Y/&LTUGKQQJ#9[R?;T6+O(AD.@*\L3O4?E7.>R;-1S3\
M*VD_K0/@;B'9%[Z@?W1@JPGG"G\//%:Y=L5I-E7&^N@FQP?2"#UF(9U6^^5I
M4*3S]/\<4IL$GI%FHQTEU?M?":GT%P QD@:9Q4D2A4K?K0^QU,GYPD?J\7\;
M[(>VX^%+#%*/6CFXBNWSQX3_,1BJCMG\"0P,ONG92;SJQ,W;! J1OZ*2@OO'
MMO^8H6Q_+S( 6!D7JK :&^Y0*A-COT/;9V7_Z'NTAY,O@?R5=QPN?^0042(Q
MT-V>6EKBAW#&)< 9'+Q?>LQ=W7G LZSB:G8=GY:%GVU=Q'PPF'/\KF=Q)R$T
M(F5/E$[;S*_ ?YS(7C&VO8TN:ZX_>*$%"J\UMHURO$[L&**LT3:H(4H/5:;+
M+KYH'G=T*%Y_@=4$99$%;Z1&/<<>AQ[Y",;VF7RO][8XL*0W$76 [/'XOJ @
M,'=N@EE!\C;YL_8W8)T%&R-S-#;UE2Z\3WXO.74_AY>K&=*;JEN]?J_F"_#X
M3TG)287I"'&5-"7<G+!-]EZ-2>Q:N56N.#FX0(F7+-[(O'P.66YZK%4C=RS'
MV&-WJ?5A;7K^3'-,=J \\-W,M?5092Y;#OTO;Q7[C/5B7^J^OUI:_Y?R:#;T
M.>:(!P?ZV1V^H.S7)U[%AD4&V"J!89F/3!D&6HU$9RLD#AO##U7,I@N*E6GQ
ML0,!'!OO[3 S=AS'$>1H'ZW Y+ZWUY4&[4_M(P$GQTMJVT? X*HF+Z/QDMR:
M,<NQU>39WI1C:[[CYS.GU/]CV6:IT(ID"+0+=OW(\<Y&NY[/#:9JR>\59!ET
M%J953)<.]K:;,/DF&,\<-.0&_"V:2D;N94UU?5I_/)]96AH&]:4@^[^V0+V%
M?#+LSX[W7#&8*-6G\4Y,@J'=_I"['T6A811_%B0C[U=%L:'0T:LZVN_I1DJY
M&OLRS87Z>T_DP!+*=Y#:%X"0BI6T)L2VG>4'[O>='*\_(5B.9";Q%!/ MZ=O
ML!E-HMV%)JHZ[>HF:R_4%M[[0A?CSUDQ+UWY4&$.CT6N (7?V*^A, UM,T>]
MD(#LF;G>2/IGX=>'%*E/63^-K+Y<H<A&SKE^:]PM_OJYQ6Q]54K39P5(_]-A
MA[8^-$M>Q/$R%X7%$-W3TVLRQL!IF^5Y7)2+>WU-U!&^)>!K9BJGBG+.1//X
MB#(S7O=A2RRN^U%%37W<;F\\+6KD4^&Y(":YHD#+SR_;:-ZTUW6_-^@C449&
M2L'#*"IJ=6>1"-BPTA,1$A#X=8J[ +SUU\-[/6S&9E2F>J9=2EU;[G$0F643
M^N '0*GB@]#S4JU$RKCE@2070JG%>TV$WTTQOH1ZM3^BAQ -_.ME1ZI5Q#66
MD?%5G>CAKDM\HS)/SIDP&F*0,(>HNSV"MS[ -:PKU_E76:U.XKFR<WG'K$LO
M 'P'X.7%0 %LU:S)H/QHI2B7AD=!\X,'BB)'18NLS8*&^"W=BIJR\-*TO"[Q
MI5H/98<EE[HX7\)=6*@96YRJGX@T_.5WSP6,V"M18(#1($E/0DM!<?A\,>\+
MP-='(:FC;NN)9FF4.!65Z^K]\+J3 TS?@^ ?W]NQE!U>#!NXB6Y9%KMX\5D<
M&W'GC9DP5HRHA/58^R;.HMCTR"&OI/Z5Y2$ NIE<A.EN.YTQ%MB-@8,\^\KY
M;;O&>-J*ILYO83S3?9C'6\*V<S+XZKB>W+LFO/9=QRW1] +P(%E;N_.1E#X!
MD<GF?<>(V&=&5S<ITY#@@DZWO_S>-G"57OULA/IDE[D1&Q9NI,BIJYP5<%?$
MF9KK<O<7GL^3FPLUF/9V'KX6N?KD.$<?5U50SXN[EQ-423-H&-TF%>)UUO2L
MJ=!\$A\@+D\%-'*C<<XX@1CO<>_38#*UAHH?T:9S&!\[BX-@KBV$<1_C,F-D
M:@]<K*EL'<9P?!.-P%9_NO%F07S<-H<[(N]3= HKN0N7Z.=DY:33B()S?DPR
M*D!F9S<,[N9QMZ_O-H6Y?Y6S&MYMN>FRZ,?#'=Z982=6RV8=@(&O3J@-M8NC
MVB*B/#_I>6[VYQ+R<F)#9L8%@%'YENT"%48;;[$LW[QHB6K1&>,G#^Z;$_I2
M:K,,;2M;T94H*QYP1UTE3;4:ZYK\Y5;PNF.I!(Y_Z"_6;;F/5X-D,/WV&ICU
M=M<_\)QTWBF[R-GF7S>N"(U%YGUJN['ZSG1A[\"R\9M;IHR&J'@*A-_?[MP:
MW\+:X?>HMQL2V/IE0P2'N-'[+#8G.F%19NQ<%I.1CLE_5H./69%#(,*)?GQ/
M'SVI:+%VQL'WF/#B2Q^G#9'RYM2?X^:OBSXVQL.74?0]9)L**E7309ZJ_ \>
MT3T0 0UD\N9?K>)I(IF63-+XNH<-_^IHS6$],#E# "M;A+7IEN-(,/:9*<V3
M8%BX^G-K"%KRM3"?^"N#K;XB<LF>1W'BYO[N+:"T?GS\4)S169$&7F]9Z3I1
M<9:;>F!A#=S VW&OY6GL!6"9]9V,YC1*XE!4,^K3\_5D]59S_\KU3Z/I63]/
MH)"M+UE)>B'K W6+L*W"DZ E,)E]"^.Y"B$S7^BTZYZIZ9V.-Y+ZY@@ODF^A
MXSK\6-MYZ.*64]Y9R=7K5>RUC%F1-TXW;!\RG[+GGBM@UD+@'L[Y&[(3\:82
MT^_4+[G\@8LA&3#W_^YJX-J=T5+/M)JJ^WDTT32Y;["!0,[U-??F"E51TV**
MU6EFQB*Y,G4?EF6YRL],-\_[:?MQC5RYE9?%9W$8(<M?P>C\<?)@>[T8 B25
M@U;TL=2Q3$2Q#^;Y1]*1V6IF<;-+3_&-TAE;OF BJ)C'O36C)"-K3[Y_ 2A]
ME&?])@EBIR,^:S5+I(+<+N0PZ_W\H7FOY9QL>7!Z;PE\SN_0+(-]MJZ*J?Z,
M/$Q^7)8G.L@SO@:NBNLRY40OQHQ7*BG?%RM6>U_S"GD,</D /YSM:J%"*JZT
MT*HL$U3'OB8 ->&>=TN5[J-DPG! /.1*S\TA#>&'@%X7&','#6=:U?/T1!!)
M#7'SC;+]]Q'!-F*>,B\S^%[6Z:QJ7@ N0YU'^L9.='$"A/1S#;0D\[3WB'%4
M#*M:N=_//T^K!L_ NY,;]]D >DI U8HAZ5D_,*1&TUC]!K^+ZATFZ@956%#H
MY;B*J(:M3>]&T\[[L6*_S.Y5OC2OC-P!RHT?GY-("^H9_C_DLOY_K9"M[\VH
MM1EEALMPBC@T\LXTB%F]&G<H!:6E&2JZS<-#1AOEL&K+QQ'22OY;3TAV\6U[
MJI*A)JUJ5(G,-]/W=#<2@ '2G M-5-(%F0E]3W^BL(9:,VUJ=(QGE'*: 5,?
M 'F0XF-$03O?:X.AAX@H0Y1#=D5=8V2 L$372?*3O:'4,\D2-?)*_0(=M@D!
MH?L/@QX E9 P/'.!=_GD#P5+S_C-5/_8$(ED_1\.DEQ>*%%P>5CDSK:9.,^(
M.*]71:J\5:0.[6+37%FF>2-T=NP%9=<I-/ HG:S=3*"N%G.*MQ=WLA5W.!35
M7V@VCZ]W-G=)/5ULKW;=.+T64KG3;)OUTE/I)[.KL6V^I1T?U%)>I_V^\KCX
MO]^D_=]%5H.!;4:#C5>X3XH+H*3E]G<I((V=+R-<:LLS<SJ2")UA>-!K7'O%
MHP3";$</;^8:<Q"Z)R;UX\^"KJ/##5^.$\9E8DRV-QCGTS**?)AG:CP3H[HF
MJO9AJM>Q9X K+L (<,:H/B%6M:- LZ.,5BS22)1V[9JFO;WJO;Z=0[Z*:N.\
M*K']NU+]MT=@KVQEF<TJTG,P#\$-8)KF-XA/G^(5[K&^#] M2L(7V@04(.6Q
MS-7)[%54#K\-+A^)QPI?IH%%+= U5HQ+H"=+KC5_5*]__Q,0!QPHGCG7PG0N
MAF1VN&S)=JM 6CQAU"VPIWB;]F;6^HESR>(_D]IUH]LEY/T37Y(%.$3S7G\T
M">A3D8&W-;-A)2,/)6_83GI>=U<RVM2L-'A]MY4?#@1(.JD]!9RY$5F\0@*6
MV2$WTCU_VI:VLASV@LH[EFA/)]4<W9A7&]U^H-4M7_S9=&7C>0==2\,SFJ8L
M/VFA37C23.P.(PHISLAV>5G>5%Y(.N7#$/DH@P[9IFFMQ+)UHN^HWGAC2_;O
M%!_?4DN+[+(V#A9A<P(EN33-&I;W]9B=ZN(B6#E,\]])?IUPR!V3'C/I=^9P
M%@//[SU@18JNB'-VS?@T#3NC6VKTA?O95R%9W$7VS0Z$#WS>'BT\2DG%F5-0
MH[!,\I4.\^L=?N.Z4]2GS_^5Y0(58W8?*]F^>"W=XL%02\T'NE3TE?L>,.TM
MLZB71WZ/^IZ..DE44>6\'9 6%^U]\*)V7;Y$I(I=</P\>E-(6#J]<3#J"XEL
MA2RR)_1CL@S:+]U</!#>,QV,:7'@5E,=VCY7R<(CX<K VA<\WHMK06=%L>/[
M7MU:B#;B+7Q\H1G^^9311DBXPYMR99]7BM0;_N3M'LL[BB\GCNKT%ULE.?EQ
M-=P2:5Q7*%N:_!PP!A[DVH\68/F%V*%N<Y-5C;&6C%2?4Y[Q9;K94R5-6%75
M1"5C_M1S3\X\Y#NA+.5QM^X+0+5S>#,0;CUPT!8EDYOCEW>H8RT_='ASLO.T
M<<++-V]EZI%%>;*.XQ+HNXXW\_; 2AOLRN]1Y)NVW<V]]>%B@S6$-@'M&[2C
M![K.PQ#U8E$S !8AC<5_ZM)VFS7>.$:> A\C>0D5COY\]JP**L2,5-GB/UKO
MDTA362F<#@(JCEZ<]>I8H,"2#\04XT5*G%^9WQELC_V57XN*.Q27U)XX0BB*
M"\H+CO._O_H$["WK+8_*"K"-@3X?)7+;\G!C^8<V%V^4#+%++/'=R3\V.9;Y
M_-W UR/1QREOM"8SZTTWVE[;=;TBSE1F_T@)T1I0K=0=AU1$2O?3LW;@ZN+=
MI_F[,]F(&T>E/,YX8<$2..C]X!(NU#O-(5YQ.3&VZ@ <6.GG;(+5BS;CL8G2
MB6F/2KQO$+AI< J%8;>,AXZ<&8R^IJ_V?S/NX!M#O4;+KW*KE[!0TG%\_IP"
MP5P  JT/:)\5NAU,ERC +P!73A-,"=\E\S!6-1'G,LL7@!T$$Z?S$I2P4X2(
M@_BN5$+PPHIS]LF%!7C;UE>[+(;Q^R]\)R/. 17C#E5]Z8@=T7R\_OS5L845
MPLN-V!=D8ZE+Y_ "V].4R"/-$NJY&=O]WF<W[O:026<%MA\\38LYOP! M ?O
M=!1T9:>C1H\.E?OP46<6<'^*AK=H2=K2G"PS8826*FOO?:6XK()F;N+<L'<#
M-$%SK#)DQ,GFD=AJ_ 7 <\13_[#?VROH8)DNQ"@W0^:U8(C_.[MZR_Q[)^GI
MB" S46='B2P/[JI<B$P'*IPO+GG NU/XU9V#Z.R5&M@6EHMT_0+L(LZCI^=T
MW\\USUSQ":VGXUT)1=YW9LT>N;R] (C^5;7,&%X7UUF/'0QQ6AV1EB&-JM6B
M9CS&"O)2J1]Y@#7:OR:ZW!7S!9]J>R3)]3A48^5F5>7]97ZE?I_)]G2@Z42C
MJ25(D<]X\5&;:@,E%4-L7ER>P-OV@4PY\9))8S">UAD8$6+V')X_JEE$+#A5
MN0 L?3DM9JAT\WZ8\T%VEM\!;]6M;;H> 7:@6<7$9$:"Y):QQ78JCQ:Z4&>S
MAHJA/!E'^ZAN/[>'$TA33MLM3M/';'$OZJ/"UQ,]7HD^7N(NS?NZ*5=_.$EC
ML<QF(5K@ET,P_4E<HBS,-A #5^B]%%\M;8;]OM%M[I>3-QB@)'UP 9":!8$O
M .04<@J=N;[Y8==*T_E"DMV1B91-7D#6 'M'M^6?)*6#%.HG0U"),M7Y9*NN
M 2%-UY"2Z+Z=VQ> #M^8KKA+U2-YB1]O6GR@@/^)"WX$ R!O3NSYW_I9LG2&
M[YVR8^7JW?>TI(S7-28/R^_3?KRZ./KK&]NVBIF]4P#NV!DFZ+E 16A"3U3A
M'3S2Z<[N300D2=2LZ@T^.]/!S^+&L<# JAYI@EK;S1SDQ+&(H,4GQ7NI^+:5
MWOJ&)$=SY]N&=/%75P.%@LS&T50)[6"*K.%S.]Y%>,7[4Q/V7Q,1Q.%#7(E-
M4'N;YMQB_A;1^B4)$=HT!B8F3OT6?R/VVB\ LPJP<!8YG/[I/2-\LHPDW$8Z
M4/PGL(VNQ&6RI6:WYJOIH(W/4E=U8U"D!FW<VUQH+Y%U1,;1"U96.32A.AX5
MS!3/Q3;@CU4*\85T$VPT&C/5RPYXF["FGWF5=+5KNE-$+?+K>"K]U$C.V/A/
M9P3.L'W265NO,$N] +0JIP3,7CXVQMSS#F[WI<0E3K03!3G\+P +[<0A[LXW
M."#F14-R8_"./XN(K0F5(2S);*U1=,DSK:0EBJ+HZUP,6+.2LXJF,&[72'D3
MP0"G07N69,%Y9,9*SY4HI]UKG%@KY#S)AE+Y2*Y8[R1' +7\=/MU5[G_I6Y-
M<NH):NR,#BVT$_P-_Y13"_8,L[G%P][T8@C6<0%POP!X=%L8*I,3&G.P%+6I
M_B79,1+RDPYR OM99V0[9B*8$$M,_EN/&$BG$VMKBDOYXZ^#Q[L"W=?8E)2K
M5NY],YUO](R7$BNGOR+:]RJ#_-F]<]!88>W.>(#QE\*/YA9],N*G :; QUL7
M  [B'%$ <[U!]M,WO)+%&S>F[&>YA=.)Q_V>8,H+@$.MLJBQO8+]E%J^=_J-
MIJ3BP7V3"T Y70ER%,NQN4A2(,7VH22;>FI8Y%2$])'N)P?TH1M!M M)E07/
MX,7J9]HLCR556?!^S.!Z&P;VSFAKH?DE16MF_+&/AGIA0F06TC<.% T?E*)E
MD=?14\J%:8H6'0X[Q:$:'Y[YX>/:4IL&DHKP8M.PV3(-WOCO_CDS#71TQ.GC
M#%G,RV,B<$A_"U;6-V_W[ *@J$;X?70*#?&?X,!%""9\^3,YTOX-CQL0,":H
MSE[R]9O@*T3=Q"MF>T?I8TMR%[@^3VO9MVF@-&:YM..:&@^[I#I=QOI=*EV>
MAU6N04:VB-1GX47I:_>1\/;;I78;V5#HN43]H7(R#"\\D<7]0^-<^(:HN8ID
M*-<!?A*Q0C<KI3UZ+F^#=J;#^WG$7+:Z;,=,1-@I%L4N&N$/5G;KEOL1W1\&
MEZ>2Z&\(S U'\Q_0-6XJDO6[MU0<->&"G0OA]8U]CDN98GESK$#//RLA#T@T
M.]*P668RF7N\GFCE""(H?AH>=&,-SV">6(/]^C R[Z>8L;4LB1?^##TEE#17
MD<)(F=U(=7>MVF!*QKNXIV/XB#,X/FIY#?5[#J^O&*/@LF:XV"EHD2$U%+RU
M [OF'8EN.S9K3M$,^C*Z^BGZ1H8Z*:KO5#\# 3'*:WW=T1+-<UF'IO*#>SN#
MQP?CT)GL6)?8(O;6L5DSN"B2X,N^?'#>6VFOFV3L.G]@:#R\4;$QL3X$O@YV
MBE^I<SKLD0X_)%@ER&J*939\:JF'6)@,U)!P[A*6,O1(,491!^,\+?G*',79
M#*;?@7'\4;#.*H:S)*>^=-7PWZ?C5SD.&J1H"EM9*\R7#'/G!NHD*ZEULX23
M[YSSOQ*\KZKT,X]VG5N73J0^V64K+S.E(*N#/<E![)M"8ZF20XFD> V!+E_:
M>5;AH$N9(N$E!O>VQG<\UNA8T^8$%^"C!'\;1:260Z8(U_ P7XV<>N_<?FD1
MBTIKIK$EWAI#VCAZ?!EP4,DZD'#F0@NO !%>#A95BBNQ5<OS;MU><CS<(>8U
M +%](2JQG+U[L3]2=0?*!J\7W4Y&.%0=P I>HFE[EG/"]7Q,=^"2B'Z[XTPK
M[Q5<_UBE*4-?AR]K6(H!9KXW</+J!4"F,7V\V[G$+8.:Q G#'G[SCAT8-1EJ
MJ3C<^,@WS[?>-_A(+<\;]N.J4Z-,GGW]7KB5 8@"*^TEZ\45U=5]^0[B+!(;
M8ZZIV6^^<_B'0U3>VL*9:O5MPH]O)>D666SZNE7$OIHC:SW_6[_LNC)X9<3[
M<4:P@!SP@V9)XB0/'QY:V'T+T^$;&^0)ZA/78?WE6GBD%&.!5" T+V'-JMV;
MH.I:MS7?B<+?#"8>*%(<4C3NM1DW _T'?=^!&?F-2\ OGOTY?=DMU36U'/9&
M=%6])(-X\JHB8L'0LN.ND'C/DOY4\2)G6"%5EZ^F&12.DMS?=(X9K*"5>>IQ
M2U=#=%^ZM+%Z:[00MQ<5X+3'@ <:9SZ= '&([V:#N"\ 8E$DZ*&H=R8GSM3P
M@#'S>[CGX9F8!*.UA_D:@B!\MVG8Y$SS&WR>!T4$)NWI$,CPMKV9S#.EABP*
M3767-G5$IOW^8FB]8%,)OKX3I#!X/8LS[.SI9[$''M;*28P#=RO+J#,5/_A)
MU[=HU:BZ#59PL.5ISLB+N)>O03>J_YQFK!"I18H,YT"L//0W^CD=/\@A[\6/
M0?U*B-,IDSPTE5A(*%)9!DYN6H.A)-&U,Q)=.Q'"A4]*<UMTLA3EA:^.[2S3
M;T+?1ZN!V@LO%Q,'63B:8LL\2M.2OF.JZND+-5R(W]QW WERAVD7.<H8VNL_
M]]5K0L I+_(SUD29Q42+?C7D5AZ<>"AM/239131GC-F$$J3=7R6XUM JYB\+
MU, "<2.3($JO:QW^['$OAE"L?ADYC*O\/&%#9]!V(JAE^ C,LNFE<*VL<B0W
M\>,MI[:F@!]U&.<V;KU&]R<S+%GL'/I)(H3CM!F5W>SL4)?8@G4-DD\[BN<'
M"*H"E7_9UR=:&<.;X:*B7J,VQW/'+6' FDJS.^-Y(T?<MZ3[/B6P?&@XCQ&R
M<GXV 8ZX #A#Z/%RAIF:XXT<XJ7H^ZMXE^F@75$T@E,S1I4HBF!;T/S$WR$"
M%/^,-5O&^N,FG^$=<_XH\R?) #G;R,2PGZL:3>,'W9YFN,46J>IXB*U,:H(E
MS3J&T;2]U3RN'@[+$[V#?8YG0#VD.*%TL+/EVN:;#06'%_BV<=KW&V[J@#IM
M0ON6F44A*8X_JNIG.45PDL)1FN:LIXC8O6IV VA? %6C#-J9$;^B%=SF[^!;
MZ4II_+'G\@TZL>[O* ,""JFYG&YA.%*\_4NN6:PB7*UHT_/'U;7WU]6X(4V.
M!%1,T3O<^7FI@GME$V@2QI=SYG6G),@[SJY/N(&$,Q"9R;RX+$=2B)Q=9/!F
M//-J][V\R5J=N7]C-(JX?Y>P2J(/GID8[;XRKQOUF.HIN2")R9/ /9CB^=41
MCY-SL]3D>#="IH7-P:)IK\N-*'Q2 U?L> HVS !#K%GI?[35[GD!L![]N!0[
M0")Z/SRO3,A(%;ME<?3F94R43_;[YRN9W?R5P7,_!)JT\+>"!#9VYX\(%1X0
MVJGIK7IP6((!IFDSF'G;^9=CK':WA8$_.<FD@MM+M[ &<(Z;HX[KG R_E?5@
MU7Y%;<U7U< A2+YB>Z+(>Z&@77/+LROG:85W6Z-Y/AZAZ!OHS3;=:-A,5,3R
M?[YS_<'X#Y0IW-?3Q3>34,9FJ%CMQIIT4[KW&.F[YFG%QMA90C>X!ACA#]QR
MM3M->7>#[.#AFW)K^80*D3UC(%V XX;R+;MCG/Z,M.>"0#1K567R,X$??QD?
M<@]=2.*05VX-@^RW M BX0E/P^13!\"XP?PJ[\5@=S^8"98[IO0=OT+F1UIG
M^M9'X/",'[J%GRT*)J-?SD*^II!\F!!9E$F*VD_,O\F+2(;V;A)D%\N.)G)(
MP8=VXC!JNG@/"<3!:PURX]7QMU6\=/RG:V;6@_BPP% D2$9$7.W\6;$<$4>'
M"]P570V8X3,<WK,><7BL@D"GJ;^U]WW'-OT/.EF5@B'3G)SM#-8?E>A*RS.,
MF8F9.W]D3N1WZN:KDDE;L8AP5\J_YZ<#A6'FG\8B/K:S8 :*/OS]_C7=%_C0
M[@* T6X(;0XT\[:P*GPC8!GP2<W--*4#/ N&8A)EZZO3ECO&D3*^65]:8H@;
MNZ@_<'1<E$)-V%$FC[U7!GN5;*IFR\^P+*6?W$$R&P&4$S J;SKH&-)DR5MY
M5U#=?9IXOK\2^E=WA3EI*S;RPQ[.SI4E5LY#T<J(CV.%(%"1V>3Q!WW]S</I
MC&/,))&:W (-9IJU:^8=48VS>N,ION3P[>Y&PPP*:4#X?JZ'2>G0LBC :PA]
M3UNO&.-%=KJP_WFX ;O\K- +N6'#R)S\Z%:XZY10$$Q_TTTR"&P]/MPL^"LU
M--]3[L\,@FO.J/0^_Q'93&7;&GY.1:1+MR*V<<9X^/1P$QX\Z$:KQQ&?]!QZ
MS:>XY _!U]@X(P&SB-N!<)G.;7@I//'U+.0-R/+YX+\+)6XH59CLA8.=!V_@
MH?JUHS(0"D(RCN+VS[WHLSAM&)OMJ=]NR3=CHXVR'O'##Y>H._]!(3)72O,L
MG)=V:)Y,6,7I8,>_Q56:M?G_]E[F.N8M"R6!SB/=?X&.;D;F#6N][R-I1;W_
M!)T+P..-.#K_&59_.1+3/*5XF\)!B#7;TO0Z207O":%&:F5(WA1C3V]R);,-
M<;F:WQ3_>@LF=<XSC'S\#3\PX4SW;,)U)O,>HLWE+[^L/;6H@N&QI=Y>)MC&
M"F]_Y@?A#)O>70QV:@M6/.^&Q;:XQ11*=L0FTL21DYN,)/@ST".Q""//:<0"
M'-*2A1.*)L',O)H6YB@EHA&\O#H!4E((DOYV 5"J_ >/<"4RD,0)[R[8FJB>
MZ0K"B5(9PTWXUE\K4>%0M(2,+TV8H^8\U)9424T0LEIS%I&AO_U/CKE_S1_.
M.>]YJB5!$0Q)MI;%,";K"04]K_:(???:\/GDF2S,=]\"U2&?> M"SY&\=B8N
MD0Y-4%[#AYPYX,.6<<6WZC#%7AS(E5^5S;'/NN_QO /"[!?PW&=O[& ,H*?2
M6KX][J(1^.I/F;_="",(:+_^+Q ?1A7=U_U,(N/0:7B;BW@Z=P% *#T@R3GL
MWD>PT:NJ&+WU 7%B>9GI'<-L1===J*Y"UU )E8BIDH\9,?.W'33<C4O&UU5W
M36<R*<]C-7_)?T*4XL7#*SP/F:K6 RY)@YF\$<NE*5;HK3*?;]FT-3I%L4P9
MOZ'9T(W*KYNZT3-5$X-99\S4L27"8RXNCF:#[DS:*O8.__-^+W._=S=:+@Q$
MQG6M=/.] 7N:@^U.LC/2H[O)O6I_L0.X?0&@\A_RFEF,K2RL,KV\]WR_<B-:
MU2#;(?JK(N,#GD6T9/0"+::8Q753@9 KXIUAR0GS^MB<PSQBZW]KM%$C3Z70
M+B7>S/!I0[+MK&@D/K^3APM+%P4*6-Y:),>K+@Q,2Z?(3M0W*J[0) 0-S@LV
M\2W]@IX*;2^B"VY%(F ,3YQXUJ:R]$)=?0RZC_V$R>:J)",7&$<D2AQWCQH,
MK.K]XB^?,W[VV.G7 G>TT!KC4R7I>HIG2E&W=S4M;O;@3L^@O1< EM>8U<&V
M:]1M,[U0+/_W3M"]3@?+L\>[.L.[VVXF:=.+"^<O*L>JZ*Z;&'M'PSH6I]_>
M\^IB=KN3\/W'Q@.@@W<%FC7L_+ICBM%8=CDBN)K?R9 8J+]3,@9-'C9Y,IL=
M_UC4-Q@F3!R]L3'9?&NX$6KCX5F_FTDF$),SPUZR[J^LHV!=+QD]V2PYJ<R.
M5(R<WW/7)*B>LAW1?UTUNM_+H,9-X?( J!Y*6?O--[;,*E>-*R6%?C8WED_?
M+=#@D!G3E0+L0-% <#%2^I-5HBWW$$\BL9\2>JC5'0(0"U5(RD)[CLPPD'[*
M<7T),3991"0!*N0./5FU$%JL O@U%K-=OGKSD#>Y;B]LQ*1O*9UY]P 7#.<Y
M/QH@=Y?^=Z;@_UD\OHUN5*?([ERI'M8@X_HX?4D7KY<J?"G^R7O5LJXL>E7F
MEZ\N0?Z5!Z4@52O199##J*U0_M>W&Z^)S57\++(3P_S:#[E<OK1]*P!0ITE7
M7KI:$6AS?'?_[K':TZ27MP,! /?+R?^=2T6D7+4\AZ_ _?7;7$OZY]F!-RO+
M:[Z_4W&D??-$?IHCA%GI7Z_IFJAU0D*2 Y@/+4>J:/K2X&*K(_.X/9S,[*3<
MRA[W-%(1<U[?E<.T/]U)_#Z;Y:F]%62DZZ;[/(- ^ZW@OHRN4WYX^]E5_&6A
MZ+75)#;N/))M:*R I\%M_E*QO3-HS2@_Y?[+C^UH'!_NJKD9BIRYGM_UJVVI
M!7RVZ0%!H>C%&8O6YNO#ASMFNVB[RJ*C:\QS]"G/3KG<939Z5DY2Y&1.>4PL
M4FJ;S8P]Y%'4Q$XB&::YP;FP^-Z\QJ6Y^%_3)KC[7[U3<%*8E"B/AABH;GUC
M;7WBN@#^X=2E*;T].O]IV+5&E1(CN^^;KH]E^JZHI=XK3!@5+,$/XLHP:H$R
M)^XQ]II%QKFKD,2GZDV1&>]TUKH/"$6S&* $K ?GXXQ/.)<G?"3A3:_F;(R$
MD-SD56TGJY/4FPA4GJMOV#9XJ<GX16US4WU374-Z5(_8!\L/\!J\V]DS;R Z
M-$\V,\>>')5CVD?;][WEK&[+A%AW9NE-UF[4.9!2V.=CX^>TRA^I?I4WT4PQ
M?>9\7DUX22FU15+R>6<3(TX'DQ)Z+NZ7L_$5H=\(;FY0)6S =H.GH+?!K_8
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M%LYS)2^'>'9D<C/X&I<-/^;Q7=P)V(798-5#23KH'(^)">!-FS/(]&(E[U0
MJO)1??,6\*J?JP><>?-FR>!$(_F"J3V:WT18J2 KUSA)GD=HY>(=,Y-6HT\A
MO_4F]RQ7/R*X%M;FP9_?1F!'W*$L954Q.N4\6Y#^_SHM[Z\8C!] +6F>UXY)
MVMZ<GOF/*E5ZYP!:=0P7*L@!>TI?,3_5_WZB:N@>+,'+X+<ARF2\*'/,O:_0
MX;5IC,GW&\[27'P_45$>X*F]CE*XZ&A&HH8<XSKG/T?-4YZHE8KA9FKFR&\#
M]I0;]%=@9?2<1)\9P\_ST)??WK2_K[?4_<E2#_G;<<'%$M_<7FAN=?.17WZ6
M U^@2FUZ^-F88"W+NCM G^E3K)9I*O^H!##E$KEK8KW(V?F._5*M<BP'WPXU
M8,]W9_IO;\<FB<I(T^VW^*%+>[U1=[[M&RKUJSB=ZA!?ZP:>1(4+!&[30*_#
MOV^9@1>HNMY3(41;G,X!;Y$AJ2P-A)_^>D&&9;77[VX_YL%[6!]L]$.)5HMI
M$97?G(M=W(=S8<X._/65I?'56DS?\"R#"'O*"?/#>KPTZ4X45CAF]91A6S6G
ME6WGZ9>E*]#)?2=];C>-\C'QO67+I^4"&/_*0%6X+-)VAUO[YR"FW8[:7I1J
MAI%[EBOC PQ52>*RD?V.4>(967EBH0R]]4%HL_6Q#$7Y?Y01>Y[TICI@)?JS
MVL=RJ35 +EJ4 &[SFI?'J^5F.$QG)0''9WU9=^\DZ-A3/L)8=5G1PU^'622V
ME_4H<JKN.>S]7J^0"4.[Y!V5;#?YGL6"Z(F%&'J20%7JG=I07_/&%_UO7S^N
M1U.NRF]#US3_K3'?B&&+QPTNF+ 4V1F#VA&);V]%"XVG?\\U4Z]O/.A \(V2
M!#-G<3[9O693+=GSZL#W'_1U'D4#V5BS2X]+"7PFQ%(\JJ/<@;,[I-)0JLJZ
M9B^RQUCQ)G1H7S)T>J%;DEH]2P5K7DS9K0!'UMC_F>+>C>P^*UA$.O!.4Y'9
MU$-8Q&_ONINSB3IW@KR5>O*;V(@\W:UF[\ W2;;W$HP\NQ')KVM-G;.XP=2G
MILH*4BG/LD$)ELCBP8#P:920?NR%*H\VG@/XJ&>6Y#H&+\%2./<LQVBWOC0W
ME-=_T,-[7^89W^$1(<B6$_9:VSM3*0C\VXE842%"GKW>@-HFG>D5>-]2&A>.
MEX7D!"HXS)J?EW_F]#/JA[O> <H/[_P]A]PSS^+"1/QLE-8U_>.1DWM>3X>C
M#QN+?+"J4(^J2 KCQIR/=WQ0OO##SIXZ/W-?3T23>@(1?!A ./H$UV69.RSU
M0][27IF=G*M]" GR'T*[$N1,"+:'<4UR>+FP ZU!>@L2VDCKH;1)+>[:/HHI
M8<F8F+;T\$UUI1QG5;:4BPASVV?=793E!$DE!S$(HFG$)\2^!^JRX A++Q.Y
M?E9=]AM2>%N9KR/BZAKZQT_!G$SE)F+(+Z2AHQOML8&4A'0BORQ4I-9F][G]
M)!::-=8->X"_SA\'#53:#'_:+[!B.N - =,=\ LOB6N]&"H)^FZ;U_E0".=S
MR0\:0(3BEUX0$XO\8B:Y_!0DYR$+O^]_S=77*&E>HNH4%[&\--@"8I^3"W+/
M.4;9ZD,<'GWUI7;^P?(FOQ/:E!:5%Z_1&X#3*'RW4[B[3XK<:4%R JW">#AT
MK^+F!>N&&G0!@MKC,99A#S=C_*#]P*C@OUV2>8GQ196Z-W%Z5E-]:1(.&AH
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MIVI! XXK(H0_E,V"WX+"()98U,V+0X%-T<LUSR^\+Q_WP/KV)R7=2X4,D+H
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MQSA$FPJ8S Z.]G<W6PQ137E62\W/J"J*\0@S*_S:IM=,^ 6GL@8E+L[Q3&R
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M%J+\A;+/R1"S9V$6^?01T,*,^TNH([C[1.2+6(T(_K$$5MGU.VWE2Q^A.J$
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M6$\'GS!'?C.FI^K'L'?GOV&?_QEAZ84;I$&J\'2E@H%F]]"L3(<VCP#US9P
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M_Y6Q_4;0C"&A?U(H1G.IK\Q@UJ[15Q,QCJ1-<U94H6-?Y)P@6&U1+J*N*MN
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ML/C)_)'I!/^"R&37Z^K'"DXZ78V0?[L?V47V$V;D%&#D3R?NN:Q>0VSTAVM
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MN36SG[43MH]+P\H:*U"&94>;(TCQ/FJRF=+&R>'MS;, ]<R"=I@);L\;P1G
M%X,R2D5U 3>2*F<]?.V]#%3 /&]+1NV;KBKQ@:SHT3ZH:5.,[9]-U&5M.EAI
M8W)V2V3_^.S5C(HM)=]+G9*)H7SY\!3QL;PXU<E3L4S+1F"TW<Q];M)P;G?8
M\.R/_Z\[XV-^Z7%3ZW.M08Z>#M#"VS!R7-SYXUF<"GH\C[X!<L6#5V*2S\C@
MW.1I0-SJ[L^;D9*,]\C2!8[95]NWT%8[5E6@O>.G6./8=N'\3=NK]2ZA =6&
M4?UQ ;EO?W&1@I2N?:6A#K.RH(GA 4ZIFQ<J<,E/9D_+PP+R2F"&A]*5F8ON
M_C6>S?,&&O6MMG9GG7W(0ZLLPK"C$%+5"I.EV8Z]&N6;[UC<\+A@UD&B:U:G
M5F@ZJ:L$GQ+Y8\_1[ES: XZ<YR5HV,T"[6>FISU-BA@-[RK?;RM99,Z^O?&U
M3W^%,)ALG2$B-M)X-K=O,E+J#=_T.OHQ%V^ RQ-SFP=J;52(_6I$)!DLSK_+
M9.OJT-)UNXD4=V[],ADQ*J\GZAJ@[CA'=]6_K7DI<^$H#W7&H]&5=QVOZ;GH
M+M7@0^[!L%$9(/4]2<<RS2D\[^:?ZT'^!Z[O/A4;B/1.KAP'[/TJF*QT=/>K
MZ7 IAMO./U?^B)<3.QB:; U5C]\K]3(N<(-E((]1S4U(V1P-$YP#FHL?AKHH
MO'?%;3G#U"DIGO_K_C<!<'?VE6OL<BV+,-2L7!XY6'O\B)["<3V3"'C#%DB(
M\0^J BJAR/)?JF\0^!ZYRHVHQDB7\KJ;C1DWLK6MV*F?*8RL;SMQ(RD47-0O
M^+0C9AL/[/CNFP#ON!$!36N9G6P3<L,QH<,Q>![8K_0FPJW,18'81Z#>KY^W
M?R@Z);YZR&W%%H[5[<ZEO*CKY!?Z\-E37>']QF-*60.5C@\/KCP8O#FG__EK
M'ZE $X7M1G%7\Y3^RXI4^V?+C0E&HR8>)W4>9[,;X_TAG1RW^^DV&IJ"K0Q+
M/1WF4';^.\IB:^<^T_Q=3&!Z."Y&/B.<&<Y67=R3GT_O*[B@L9F*H>Q3J1UK
M E7FT5_VAX&D8#1+QIMVEP4OXT5"6_ET8^_'C+$J[&P961K=9Z\7I'U-=/0L
M7>)9?.Q#?L4NU*45B#:LC>..9+4#?_%S11M]:3-<M=?93K"GV*%17ZL)4!"V
MLZ&:RSM^M![![G'"*?DA8M(V-Y_G,,(0/L3R4% S2.FG/4!&9@;IL A%[:OY
MHZ6B534@"^%.]T=53:M0O(UAMTA @!].#!S:JA!&#9GL)TAM([Y?Y=K] 4T=
M%^N'5J' @,:F8Z33[>=_1!H*U79&CH(<5#;"8?F'<BP'>]W&**@-+LRKVM-*
M@U9.<^%"Z.A%\00,QC04LO\-_$<B1T&/U_IIW=W3I5G9CF?SUB,2<G;/>D<W
M9R4+Q>_T<&C1O.N[VMZ/H]'AS/:8@+9)7#=4"P@*\AX:=-L>ZK>ND"L5?1E:
M?>BY5C'AWBIE J3!:V#8$A$OVJ!,N&DK7&05R$X[TB2SZ^&8;,SM#V2]U("O
M+ZG66I26?>V + &PN'DZA%,>ZP9!'IE^8OZE(UI-P:*VU=?ON-./_(#[R1K,
M[^7+4"N$>'2VIQ;UT<=SJ]N])O4G]FUJQ=Y-JF6K=6E*5L=2R8.E@=5MQPBM
M[7ZQE1WJ;I0?'H2[6^*@535<[8"35QK=D7MNI];YJ.7 JRE/>HA^R#J0-RT3
M 8^:(7!.@#7=,7"K]I$&S][&"2ETI['0]!JJB.F3'T@ <&79^<!^_@][?Y(H
MXVJKL17[GHBVCX0W>F?RS,YS[Z(R)MZ[L@G6-B5T[" 9[JH-GEV:CPV]6H]%
M+(1W![6.CWK^U@M\*M=4YE6]I ,-WMOY_D'D&P'3UZ%9&3$UUKC:%KR8%XU:
MB\<+%CB&QY\XUG]B#LEZ \]@'1TB48O=O)LX:?)3.HV?0I^MM:VC(*,=G38]
MVU@P J^3#<GEI;/?GYHVZ(P[=,@K_738P[+"*X,;J=G(4';F9<-!*D")#AM=
MYIG[Q\#M:0/K'S^25C]0'D#Q!YLJR,B(WPA>,_3)]BN"Y.^K^8M;KZNU7%7%
ME/2>?;#>-;G%V/+PQEKBF4GD3U_K\C%#OUX_DXZQ^N#&T6 [%4<D*__=_/MW
MW6=[%+PL=CIRJD[6P_.U_8]9*>PP+!TI,P;4CNX)UYJ3$* H=.]"N(Y_GBW.
MM9>OW@L9K:Z.XU\\!#*U.\B]0[CX^LLMS<&S&!/EK[SRC7SG)^+2XD43L'F_
M.D*7>?[[[+B9U_J9X 'O70XK6G9]YM/43+OBRB#==3F6?5@406X3<0UL)O7-
MF ZD88]+J 1%R#I5V&_Z%J7TW#QPU+/)H+H^2*6D]'7#*H(#KS\6 (GEX_81
M5]5 AQN8CNP6*K!*>]"7994;*%[S]&8(T5)[^;!/C=Q=%<I(.116*<P7,Y>8
M:>+E[ZC0ZK$U4-B@>[=0F/VHS3B<T[ QS 8U[+.OGE/0?O<[I*'Z8JU'C>UK
MK@3FT=SUB<!*H8Y:E_'"=G9 3G)%Q<<\*I#2VD&-W;'T!*Q1@P'L8C>]5=D3
MV2/31S7S:)02*;%?@PZ"/K4>%H;I1-E.-"R;>)J/IQ8/%!I6#_)_-"VW9-[8
M^H7:K!KM+*_,,S(!"D?\;NU+C!##1XQ$T.)\NJ_CC/4(0X2)"3EJ'3'9N)3]
M-Y2*[ #)>X)UH582E;C@7HU:9#>"U-X6-&^!#8Y4U2TKR0AY6OG#&33[14%2
MC^.; ".T57/(L^G=@XJQ-X&CE8HM.JRAU<">.B]A9W_S0;7LY0FAC9[]%@>W
M"P5WH&5XHS;H./)<JZ\&M(<.CHY^@X&_\>KILL_ZK+VV.[ @.9Q2HIR)\7F'
M:)B/O[1/:CBI'G7V$9]#:@=_RSNSQIYE(F[M+0ZL?[Y8" ^BC.X!O+X->>91
M?W"2ELO7*V819@F:R)"U+T1661 !M(.5JQ\]9%=D]YQGD\/YQ#9&ZG<JQ-8Z
MPHY+)PZKC;4P/= N0V,KW.LP9Y\]L!+YH=:YND0WO0R81>!U-LE,\*UJ^(YO
MP0810,'7I]P7(Y?#N^V8(Z-V=95)4KAU^T,RP$4MV*EV2=627K /)6&&N*MG
MTP,/*RX(OK3W36$E[A?%46U&075M(]7PC=;.2@C_G!OL&H9M1\VW&GQOK)UK
MR?C*)H3^*,?RNGK&\>DHJ.8KAUC+/=0?PO7YR,C7]EP1<PKT^5N<$X@N6MLM
MW1&II-SR,FT(7XJWPHXE68T--/ K*;_$H"=-C'2Y N58V]B.SO"GAJH]UZ#,
MD8Z F;CGS8JZF69[(_.&#A,U53E'&^5':2P'B&@BX 5E(R)6G>TW#$Q;Y98I
M%>]_$5<]]^.5 _;](ZTTLS[!^A^*WRK4^2_JB8#Z(WI&![<\^L8\1IQ&%_SY
ML#F6I^''A^[-E^?\_))L2/Y:13)3&]9G:]L7Z4V=V*::Z3ED9WK'7G',17GD
MRMK:Z/'4<>=D1W7U,=QLP^/2$;N?6^H^11M2=!&N89+VH'+A0'U##\7JW<(&
M[2;?5)5L[EK"WA&Z0VK1]5VC5*PZJX.9!::D?&%Z1.S!F7?59[U>=1=^#K/<
M(KJ8>'1U.OK+H45H;0,P$P&LC_!T.ZH=,>"XWZAKE%V#3('/>T8(/]5FMLH,
MBF(VN4?^'S[X5 EC&I2-T'@^1@*CL5>^;C4.HC_A:.CBZH9O@#NQ!O-_:&>H
M_DI1',87I<X-,OL*NXOS[PJU?'M 6R>?Y\HMV)<O>E4[(,"JV.H.S(K>F&HV
MGVPB[:C-#VFG9M-#(WC;,B?,T13N)5Z=CX6_)I"!]AY>9'9*@QSW-$&!L\&/
M6[*,&LX?"0PEU;O/\'FL4>PQZM6 V7&1RWC!!#-,SUH"F+\0%ZHB8?8]'=5J
MN]-)I?OIY@&+\^.@8(T [-:Q!<LV$5 %J@DQ_*Y^X+?5!I5,4JEF35*9+U^#
M./U>253*C9]5-LAR$#_:*X8F$IC!C-B]-P0&L![FXJ2KFLV\=;PQ/\RS8-.J
M[$4I7)3$>I9.2V@D:5K%3V2>7)T2?Z\.E\."PCU;6XQY;?AV$I6;(!QK5,RS
MI2P#%9$!M[.2N9;,E<H=6S";HU4-M6TQ29L^6/<"6V%)NXU"]X;CI]R9;WE4
M],ZSO.;.4<?[AD)@\L7YJ<C>7(:FE&\G\]<"8%QV$@<ACK=:L-S'DW5V;,/#
MWLE7V -_.*JQ'P #M(MJ\A:=QR1N/#2EONG%S%@K^EEHXK%=\E7 SVI;L1B9
M(5^.PL1*@4RDKH3=EJM0^KR+0,#"_J8BBZ!Q38ZL8[D0(5A5[%@:%XB6BIHG
MVSF48G8OU9^P)*"=O$>+WO(S-JRPOXMH#':\2%;G T'1I7AQL>EPS7;=XQ\^
M\.(E<<<7FO?!'S?VI5AVF"TM[MK;8RU\ ]9^BF8@)":AEAVT3U_G<S)T]:N.
M1%5#)$N'B(#&O"YZ5KQG&T8W\C!+KP!3U!J#.AJT5'("UA<DWJ#J$X]PY0<D
M[@R^U& F ER,.7!6)IB\1#P?&L:$OX>5C"Q_@/VS!1^1'WBQJLDE_YOD*YGK
M>^/B\"3MH*?^>$>Z'&79U)";X9P(!7G\;*"MVV0<]\1^E?HM_W+YTV(OG\8F
MN+&:3_E^U1P%KAR3LN23"+98@%+9X&#ZV(:7@^+!P1M>0EDO/U^NEY^GJ6S/
M@M9N'+&O?2?<!%%W:U CG"\\[V$3Y5'!L8%2''UAM,W-24G?I3D^7*E5\:,O
MH7@L=AC:O,<&OH%QA8*UBK=R;V)V<F$5[I&L&6SZ=OU<<">.;VNYFC #TNYW
M:=8&C(8V?O+H/-F.S(;K[=7+*+M@5UYA8;.W:2)MG9Y"A_;SK/V$L%QZ[/5%
M9+</;<3O7"Y<QL(PK1VH:6;=LWC856+?]B,?F;?X?%=_+HDJX^MO9>J B&%U
M(>,H(H!556+I0E)"&7)]?E# B[M<W*?%2-"PZ#WI0N("1A%6=1NFM/8G(\:<
M^5FFB7T_?C)R%6KG-N]4[6)NX6KQ$Q$W;1#6/UQ\=*1N>9'2>16T]<W6->%H
MGH/DZ9+8M.*AE[R[BUY[EMNS::Z5:^SBU]\AVKBM$D"1Q^ZXO"H<W=S0R=?K
MFYV*C1.$*0@ZH<-/9.Z,8<WC'DRX7XEL66IV+YM^1%2L)N\Z>@/M&O\X:1E]
M["YIX9Q6U #7#0P/OI.K%Y/#_MLOK3 "-3L+#S@ZL'0=#H5T&5^'[23F*H0+
M+F%^8K[_R1J3!1NGJ=L\GF[C]86&'JB1'@=AEQ'DG4JXH*6'=FIFW:%=<^Z^
M@_X<=K'XKPLKUE$_^'J@H>?WXY=*\YZY%Q6RKY=7Y^';P"-;$WLXZ_5T"QVO
MIKD:X])IRW#UI2'"%0-T'LY263LOH5VYDV,B8+WPBYUF0 :OLZ].?%WZH]?-
MD?O+2RP'4>E1V/E%J5[CN#-D9">O]1;*-2[0S)^GYV+;X.-XY_?/CXI<0\Z[
M5*G.C>+[Z+-4U?3'CN^D>NRQ#7J-C<UU;E4^3WM)5272A])3?''I9QI'IT/X
MKA-&E4\2:CHI0) ^7IG&,=7K6(4NY=]M8X?GGFE!R:Q/\F[,]=1W,>8MU,28
MX$AA/>>T!@L[7$9>NCVMK=_*9^T^,<DGHPUB5U/$EVDJ$OT@T9W16,BW/7+<
M>3?G\Q:T%)V-)V?-1WF4O8.($\-L&_L0Y;!JI$-2J.GP10X5,P93__84!6\K
M;'_6Z-4C/U=S KF;Y&)_Y#%455/,"U2SR,Y-;[.TE8SYY2B(TT9O$0$)P'I"
M[=7WH^YS'&./.!L(8*=MV'+!PILI;TV^VW(]N.G%TCBPL,^Y"2[!<HQS3 =9
M51BNO#[ =6TB>%?%(L[>FP]$UWB<]!P'[<KT26@0F^6R;C"XD#F^2]O3\&GZ
M%N_GA4CKQ\-;9JG,Z!93/=1)7?F.+#)L S4?4FQ?D;TD::/2AA!K]@M"S<=A
MYJ/ +%B[)=@W6-0<5597:WA,I 3OY$6[$;QB4+ ]9(HOY23]WC6*-]=(/PR&
ME;Z.X !EZ5[ P"%+7!W2^9BAPJ)O7N[A:SH/ZF['LJ"X7IZ7)E/H'U]:)Y#G
M(TQ$I%/!^J3[T^(IG5OPIL2<VL_K5_7D2HTY\L9K-K^G*?9FIZ95$<93LV;/
MA]-"@C1C^O/U[EL(S13V[Y5.&0HVH1#JVSC7+D1=7S='YQ4[FXMH'K%>6[9$
M 2Q=CDN8LJJ52"RF^$,LA]B'9&7N)268SN]V>JS*$EL?/05NK,^1O0&CGK+(
M7NP9I@A+WO3\.1N4DK9HEK]6(CWDI_ZY('Y&.ZYZ:(7R0-U31:7'T%;/TPL\
MYK'[S5BXT#A-Q[2N<6(B3W)P8ZQ_SK5;66/[%'MU^M@6E[6H!%;=0M,"'3S;
MN*0:[S\:"?F0,PW?X199> ^J.>_EHU0%EN-*CWW;FD90=A"JBB27;BRTCD^2
MY(?$@5_2B?]HY^>"5%P"BU+K.^DVOS -.)TNLJER>)?;+YXQ/CX%)58ZE2&S
M,8_1T,#[G"OBC;'"T>V^I1X$JI2>B#L=XYFK ST9MC//V7=(Q2@_1^4M^[]I
M%KW*G9A(=1ZV>)0T".W:H[/Q8*UV#[F:Y4/>TY!8Y1089Y&:)L#-$'*U550L
MX\Z0YZIYH4Z5J4FP)<(\PW+45H))C^NI#,I:.;G\ZK0':KHMG*D-&1P$=BW"
M*^ VSN6V<F^-=G*ZG0$357DJ'3I6"N9^E0NF(,IDA&\\":8 8 <]0+ %1$\'
MY-@&:YF -M0'LN+F;=OC-R44[84SGK^Q<&)28>$&&-U]_95'Z0P=OYG!@!94
MM C('\IV7AG8T^OS;+LX;OS%:J*G\]@L0\Q0,)SEI"DO<,]IU9/^;:Y$S'$T
M3@NM,,KNULKWULIPW+L=AR7O2Q,]#0OV]K8)>:RKYOD. _T*Y=E U/GT2%':
MKTNQQ38F.:)7>_MV[J3(OGB"FH[<X?@SPZ1L-65N+DX$,*5:B8?/&1$!STR3
MM^:,")92YZ+O.@^067"4OE2I2_[^"R!YNUNGTD6.U%#LO#.F*?NW)U-X@=2A
ME;37-ZZZ&2(@6.ZRMY"#_2[R7K0;+NR1@PP>85GSRCR@X26X:#1!<736/C'N
MZ3..6 "=,G>NY[:'*&*2:A\J:/LX-4QV!ZOOOCXV\O.HWE;V)^%G49ZL\.V!
M5@\B@"K!+E O9-YI&18/H>H4 *6@2_(J03%=3FCA&"XM@\!1\4!-5Q?/LAVN
M9=!L+V[ >6U5D?^=M+T I#ZO&T0$.$L OY9VT:CJ$0'7[G3$CT@N3(GS20W!
M$.P+B4ST/&)[5&*V]@;QA48YBM_E(Q/L]EAW2N5:MYQAX_&?)*A2LE=$'/5*
MX:C&H\8S]^#\O,5S]Q<-M/)S+E.REB,Z6]F+;P"Z:X[2EQUV./8(@2I=A"6(
M-XQIQ#3DJ&]R38^(DE W>Q6Z>_4I\9# @@O::>1E0+;)Y60PP=M;*+W2T_70
MQB_8:LKOQL_S9G:A)!B*+B"3VWPCHAO([NB>1!]]Y" Y-S>$&^!@^E$@T>7F
MU<5E5\8C]DN.[S6"Q7+O^%5>U^_.N#"T 4YHU'MRA]^SF557YE9=DY-X$4V3
M\E(B<JK!JMI8K=LT3_DML(UR,\NR!(UT;*\@ J+><:P$N/):";?G7CAGAJL>
MJM_&A6/$>D)U^Z QZJ)-."_AJ 9#Y8F=1B7!B:>M+<G^7%>;4T_?OK=YQ2ZP
MP$NA?P29 B[FQ47P;@&92[%T'U$!MGVQ11VU3N(^:_>#GQ(L%3<5%>4.R9FQ
MGX[YN8S,*[0%;Y==E.QP*$G8Y\(A+[],67"+CR_,COF4FJ=,2?8- AN$OT%X
MB(#O(R,18F#)3)3/=6O41?2!0?N3\D!Z@2?)).?=# _7B[CC5UY$L.*=+CY'
M".'L;''E)>YS3!A$]*[VMK)%Z@"__2-*_MVVHQO.*5]_D&:>$>+-_;>U.:5+
M\MEN]_3>]9Q/=#@T.M[<1K52?;+@3..>*>Z?G?'9;6IM/-TJWZ>(BV#'6V-<
M>WWB0S/>XL6<T#QB??+/V(^N'9&]?@'-:$B_'RS-X0U8>Q<ZJ3:\?8"]:OQG
M^GLN4XP6$&<@&_YRT]3=;_8!=:_PIU=T7,\?!JJ%NG:$P[0#)/F[>\STLWTH
M*,)4.A\V5YY/3AT^_+D\;I?EGU945%V2/:C@I5(#5S>8 /-C735Q\%+\LY%V
M:J]R#]O.][(7P._#%;W)4ZW9(C;0_J\5-Y=FG#IL<9&8//1);]Y;9:_YN%LC
MLGL\ZZWH+<[G6=Y]_=(WT!Q 7P?\$?=+F9"ES0HQ^IW-D33E]\7DMVV'AO 5
MQ^^J-UR]=[P'->HV&A7[_7S3=FNJ@]M&?(K/A>O4'4;!]%BM)=U>*#FNOB^"
MO1XCG[1((O %U0/.,'.T5P2\M[II=H.;]Y53LI^B%]=Q!.ZUY[DLV ;3WLD;
M@ RL]JHY/->X; -8#GX5N ]*T>S;#2S0:\16-]:7>8<S8(F]Y_M/89>?PH)M
M/I:SN_-I<2':'+-#?EX'#AO!OU+#[!ZD54'3P$",9Z]R;MNYLK%70<,7D/4#
MN63AV/",:PQJ=JOGU9=-HQT%G$KHY:5 MAL6:6%:N]!"&>4>4H%/*V= T7:W
M"Z*FA906;:R"*,"!NSKDX6O:#KR"/;_CWSZK=L4/["@Y8I-#Y<]0TR7:]AGT
M%@?R>_OAS$'NU:;GQ^K&N"Z,OY4GWS7W5LBW<+:>4)VLDB*J@)U0 [&M:Z$?
MT3D_A.[TW<B9^KE@]9G0STN.W7NM>KUL&K2Z:S\<.N:.<CXIV3=4GWEWR_U=
M<+B,+]3?<5[;UVK($_D]W,C7LF-O3Z'C[&=QV.:HX9%RN<MX^3/U6M:]Q@8#
M^(.L_;:@=683;1!%Q>4SX#]]@$W.W<#&6$BDNHC[I"U]G!S/K<'#AK3/#5G/
MV ZXO?F1 *O7EY5U@4LC K2&X$3 :YT.J^,C(B#Y6S$1\.>FQJ$3<K#QA%W4
M?(Z7ML?K#XX[T/9#]Z"(VGG.'EYJ/@YXJ+H%P3&[7>K&.5:,$)/C0P1<27II
M;N536XJOW-6EAU?B]_9<PX@ ZA.TU06]\CR!G%-C,0*O3P3DK]D1 5\+[5F8
MPS@A_9W+O'.P T3'__JZ)MON1(#H^?NP4,00X3@8@4%$"$)^'U03 0LFA02V
MO6[8&6\@ D\E]\U$][\0:.YL$@$JYU-S_Q(E% =$,"'60R:) ,QM)+DV;V_>
M/JR%XO\;7/?+4\%Z0Y!%I<D#(@ HU*Q\^UB6"$@+_Z'6 5R#A*G,_^.L(_\T
MRT)9X9\Q@L7)C>,C2,[%]A[DGV;5_8=9/-\40)V,3ZUF(J<G",$G]1W_3!+?
M/W)20Q6OEJ2Q O2C][$ZG;_<//T#1[*0?V*D6?1_@_W_ ':'H('7TQ8'^U<O
MT.0=%CJ^#E;H.V<_4A+&"M5RAWI_XJWUOSF>X8%J?E95BH/VS]]>?M9^U?S@
M5L"0PI6[0)W9".2P>O*D^R)LCMK)(]G KXJ*TH1?ERO"Q8I)76.Z[P52SL-;
M_MA\;*] N<S"%-%4AO2RZ2GMAB8ESTK4>:K?\4R/-;K)V&_?:T2Z,YW3LJ1V
MUT[9NQ%[8CEZM=BS&I2V8WMMEX'KC<"'FX%Z\B4*K#1?O4B%*7AHU7U0EHR\
MQ2R=40&U0+5?VP? JQ\$<W?%8DC>0&>A8FZ."&F!<=.(D:8]GE-.VGYC?Z$"
M\VKTSH/6#H.:"/N5(*]#I6&6K"3=1D$<9_F8W60&VG\4;(]#T+Y%CH(R>J3_
M=-V,MLN0H2Q\S\W\?/K5U!)%]@3]/Q6?]A(0&C0G@T'$!GP*4!K?M*IW0'WR
M3BW^D/Q41*R1Y>,1N76:<#:IHZ8#\T:OP7Q)RBEWHT>_A)^Y5^B_RQ#ROQ+/
M+_7_P_7TO\'^;["78 E\T#RF1YC(I9P7D;?>J(^':T<4;B3+MGI5MK$&Q5T3
M+E=DP9U2X,%:1(##=2+@/LLY>1'DA^@PH;F4\$9LK1ZD0\5=,4V(&5VNSYXU
M>CXW7^X=?QN6I9Y]NR >@*/X6ZL_S-C9(@($(PV(@"_W(>M]L"S:\%V*"Q1O
MS-I'(N"D(C>_^?JX*;(=A^Q!T$MN'Y$4\]S8V/,$YSV-?"0]J_=R1;T?^\.)
MZPI#-[XK,9$;^29QP;4ZP"RKK&;BG6W#A(*+6(+>:'HK+%KAC.X#^D^C!F/%
M<.F?;W+]-@WJ+UNS;S)J-^!+Q355OC2;7EMM2%DQ1*WZVH_J'RL9-3!1F,6?
M"?&1@T6P5W-J0/F[X&J>&H%/;ZUHR8X_G2LQ] $67QT(4UR,P&]8/IQ49W/[
ML)ENRZ^Y-GN-=_3<]'6-4^,'TSL?79-BK:[ZM,,:OSQ49.FOY4;=1C1O@;P=
M7.1\S+J41Y%Z6,YPWJW>S-16LDKU]!4:/X%;+,_WD;]0K\U)$$'J%L/V-.B6
MULV$UD?+R2M>Y,&Y5#BM\"4(C8/G2X^@('G,L&#G=/%+ZB)'GU]+*_=T^Z]M
M&HFI=.71^;2;Y,M7NI=MU#Z _W8OF4/;L +5GSTP>/7V:5/MT$OI(=&+DZ[A
M6%9Y."?U>FABDVWX>JNT-B6H>VW9QJ(V_8>C])\ EL35O#8.@<%%0UBHB1=]
MRH)K8N$]Q-33&LL0B=6W]EJQSJ8)M47S\!!WEONN04;2]HA85;$*D$75F$7C
M.3?\I<0O$]G8T1"O$YM4)C/U1!*8=E,;[B?+#C*%#B;X"UZG]IT:Y$P$Z(?7
M]&20B1%6K)FN4CD[97Y%JE(O$0$,['N!/&*FXY)>B_)#O%=EM)@! /8%TJXK
M=ZQS2PI8!"$1)J=LRK[P%@[@K\7;U;2>7:B\&*%H'LOO7NKN!3:%[UZ2RC"^
M_[,I0ZDZ&1XHE%NV[%[ZG-G$CG E13.R!_5B3LC]:@+-&YMDQ<1<=^Z*.V0\
M;R_02KWN"LY_T"V9NAJ3Z7#"C1EWJUP5+&UO-+8S2>YPU.9C_IW/L;6B+/2S
M &Z2'6MFX8"/>GY-;^)O5P@8I9+FIK4LA%6K#_2&LO3"5GA$Q?[D;@W'#O"E
M<JW.1*:S[U@1;@/74:5)DKL!C("QS-LZ7OG[A3*4XP_O?5];';YI?CVEP=Q?
MW=L./*AD)2QWMNW78*)M\]$TH+@F;_%=::';/$, US #RFYN_<.L,&JI30<T
MJ;J_PI8^C?2Y<7*UQ#A-P3.-95 @JW9@^?ID>@=]SR4CQ3C70ILI^XT,%!(U
M9Y/4\0F>.<K=;)WP@M?W1;3K<\7OY-S7'4/TF5:M&N.S0QQ2FDVT69X_U7L?
M-G%Q97-RP&&L1JJZH+TN'JV0.^<U+7"OZZ57$;?3:(<=6C<V@F\S@F&R ',R
MY=7(-K&:SE[PA>IY[)"^3.T])TW6JZ1TFN1*LS;ZWC+ZR)8&D7+MGS_%>!6T
MF2U+;FJS^.@X.SS[5I1)#>KI=BEIC1V@ G2)KRNY\(P'<ILZV::>D,Y<UCUH
MND>#=A=\%RWFH!8PG:/Y6=IN=OH/>W%'*N4#LS+&BN^:-@FW%I[ YI7D%H[2
ME%KC=ZPGJ^4,I_0T[A7$BSDQ%,W0^^JK[Q]R0SO&L,<P2">RDY4K:Z]A;N,$
M&7DO=VCN;$S7;2%Y8R+KU_X;J?3-'J='D?MO>NH3G4P+HZI9+V@WQBRD0@0W
M0>3,"3F%:KX&=NSDS*8*LVK&/&6 &35MB7"*100S7FE,HL$Z4"6']#'H<-M^
MIB9Y(,Z@ZZ-\B/WV TAV\M#0@HPSY^F98;0-C1/CKLI5Z?VU=TH[>]9C9:NS
M2TZAJ1.RF<G!7)?$])+H-=.ATSM*OW*>1#[]#5;PJ?9 \>3T5 V+C_+0#"LD
MF]33O.TU;WGQ3*L=//5]YUM_T0S+:$OC;=%W@W^P'F):W5;R)[DW)B0E;KQ!
MC=J5.[)+Q$GK1,59W+^G<N\K!^F&S5'!!(><ZY.">)'81Z]G'M-Y_E%GQB5\
MLP5&%T3VN!HT^X:L?KLVEC#3/7_GJIX\P\AR^>8?:JCXFMP:0:-ES$?5O7*X
MR)"G-TM@^G/Z;3+*+K<A!M$HCF%MCJW7V9;292L*O ZM6?V9B<SC*0BC$O++
M>F,G%_(U<*S$!)OC HO<,L= [1Q'2G,W:4RG&BIJQ6OK*?^\Y(G&Z)&NL%-D
M#A6=\H<!?T]FJQ6UV!F,[[_W'\NTW>X4W[1EK43O:72A9ZLC!JB,Y;)Y'S -
M40S]Y)U *=-%"ER?:T;Y@D>,)H5\5U+T9FX75&WX:;%6/CNYP>72G%1,(R-/
MP56G@LT5C=-VZ.+1YHKV_9!Y0@0PX^H7CY#'T&/MWB2OJI^"\\<.AZB7R9.3
M0LDR;[19UV4>/ZR@\6,6%AS2N8'E2U+GF %%$/KTZ^'O]NVH!]]-BG[1"W"0
MKU6W2;M[WI?@&64?]83<KV(_Z(3C#P9K=3*RL/)*]<,])9@C$? V4@LS']G^
MD7^,>A9G*E\7\N)I\\=-B'OW]*</\5\>+WA_G4X,DNL (TBE!"W#$DHSS:&#
MS;K-B?Q,%EC.S\"T>][9>;;>;4 7?)QU  %UN@[BD0@=^XF!ZV!/(DO&R.!G
M-%XY-HU"'R8(FM&@KS]NQO77F"\\"9T<MUKLS"D'V6X]:KZ[/;XS_UA/=>KQ
M-"#:1YKG'GOXXGU7$60FS M21T"')\'VI!"_]W]KKOM?@@Y$'D'>SHF]0:\N
M__14M30K;F =27"GZ0VA%!]Y4/95.-7IQT:SQJV&:EF-2(+TI)\<=6!G2ZKR
M]'W7^FC%Y*D!L6QR/N6;_0O9[V4,78\2Q/KI=V7/&F<+Y4[R5$>M&NPVYLE7
MFB\N+B;:10):W(J:4P:UV/MK+/1U^(*'IOR:%SA7"0+3H&=2=&ZCH' FN;"M
M$4JF:P*>)BL[,O*D3 (']],!.SWNG#.#DI8=)MEE?CT#GU2"7/.^$0%\#$0
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M(S-?%UB3",^>I9*^,=_5X>95RD/3QZLZ8,)Z,WEA^: !>_F3)NQF4Z9W=9A
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M,M!_[(H:_R)[9H$P+E *&M)EJ-4[@.8!=IW-16-0FY(9^UTNE:R+G#?8R5L
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M>&)^*=Y8$B['#L<USL=K7!/ %;O6;,Y=GWA1:L!C]!LX2)M>+@1@0M'^H;_
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M%-B?00@$U4+)24?=L7!;&\[N$/Y@.RM\6IVG*%C[B]"O!"%;( O;=XG;3!\
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M2+A?_D6\WAE58-/.)79W6EH#>;HHXPYH4S 7@'?YVJ4V;7W4!G^"R@/[:^!
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M-?'KWBOK)ZM8%_G:FP?;LRP2;!9TN(S;#R&TJ1E^ZS$UP1N9KI:OCLFT[RM
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M(8V,/ZYYX,KAUV9(>! ?)J(GQL_!)G>7ES=;JDLCUER;O6_9/D>2.4_MH?(
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M#<WK;TK=5I3/WM<5RKF[XHR\$6FN.7,_$SJOK' .U&_QAY=VO)=PHW8(>!9
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MZ&:3VPJ<K<_54$7B9J6FGABIQ=%*TE+>8GB?.;)HWS[X$W>O93WK/#\3UG4
MRT?OF&4.4N85X1I7QG'!"WX3[J3P9DN/^?#^],3.G+NUE:#P\00@?4Q=.IM#
M?T9):0=>A'%UC!_S4L_U?<?:8Q._6OSML5[H(OO67Z@U=&.[(V*GZ=7YP[S
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M.#L70*SH'.C#^S_[XJ'^?J,Y;_/O<W61I9M0/K;Z!+?SDTD7(.*Q*(NCPA/
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M46\(^"'_Z+WBO]N0%P 3FTCOW%D<J]-^35")46C&^+USJQ*M,I6![I$CN6A
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MKLM(9LR;[-MTLBW&,7-8"3$BP7X%U/R3AHP7[K7*<*GCO_?8>2JY!7RY;.-
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MYXQLI"Q=B!I^%A,!ALI'[GR^:!#RZ+)C@/WU1:F[W$I&3Q=<A$Q%@VX?#GR
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M4N[-^\976G-2]ZT;&ZOCO9/G*VX>[-6VP*)]V8/:PLZU<7"QLN27(;08H97
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M&*6L!B>4RA9)S,OLI*W'>LU?*C;Z-?EU3DW!>K'>^\^. 5QI6QAILOP&+T6
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MS-)S\^A/EL#ZANGJ?NNA]V^/R<LTV8KH=I4^J0Q5C72%6]XAW9?* $)[+_G
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MNJO"P?7*PT$$(#/TU D_$A1[/#4AYDSI,+"L1\N?51\DR?_:["YMG.('14:
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ME.:'S&,G7TN4S19D:U8&-X@*3M?^,J-#PHJR[8PRZM^<YP$;Q[/K(G?=GBP
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MT1@M@^ O1'.BU!96VHR*3_1=E)EF#55YDAT%]%GDT@;D56]M.'A<9Q0:4M1
M!2O6(,^0PQ'OCJ DVU\'P$YUR-67=T[(R5\B'C)V,V;Z4/[LGP42P1#(Q1U%
MY'"[&7O-I!Z9EG9#;=Q 8<%\>+:=C PO^'/PL!0=8[#V%DLY<7N)0X?PME'5
M^4D95!;?Q^K\YA6@&3.]%"'$Q'D$C"Z/GE606D:-:NO[\FVRR-5N6N4O\;K
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MG(V1/ZUFG6JRNJXR:ANO:3VW_&1=P%OIK/$2X%<+^7W# 1H59Y(>_V=J:(O
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MU<8P@H5A\$81V2U:B1I.N)<P0-/EMA=M=[Z<73).'"6WD#/I^951__9UF.E
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M;<]6YB%P2MYSK' #@M0*M#I9T5D&/B<#_O+V["(#PL%G&GTP#88C!V3 !>_
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M$C7XIED6$Z^MT:G*/2I-/#]_(@+JP8O*2:X84"<+\-Z=+SH5#DG$-:"K<\D
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MM'ZJE;!!!KS\B9"HFE@VQEWF2.V>V6P"_B"Z_$WN"C9J8X10','HXK4Q@E2
M34H*\&6-'K5T.1G@8<"3EMZ)K#CJ@)ZQHS.=4!:#6N66RLWRW(GC5_B57EBE
M7S#)<J[$&'K?2..=9U4 ;@;<0;3Z&WTW_2]@V%!\'0$\F\U7,6.KN?G.=Z-"
MA M_*(;,4O*H:[B9$]\ PKYK9B__N9N/I7FBIP5XI_S28RX3<*2L3^K)\FPJ
MG4%G@2?E055H'-)1Q0,(_IONT-L ?*LJA!GL@)^S4Y4;DG"/4H$\"YWQX;_(
M+\_(WLHO+S-.L"%^()@L#G+A/^*UVGTS=M\==/&:S[S_87!-5(-BJPJM-3$]
M5$\7U[ UW"4AU%KPU2]@;&1X9L8/EO-W0*3'BR;H^856FN'?@5 ]M,S^-W@=
M._A_P=O_$'BC7F)YV]."M8G_>XNSK*&.!: <7,J%V98E$8&GG#HH85]".!%&
M!MA+7/2_B!6LZ/2167TK$"E^L,%3+NEUBV7.$@TN;N:9V";H?YYT./'_ A&9
MU/,V\S+B9%]<NJ/?IFD^IY*ZKQ +TI=(:&BT^$&X/"JQ(P,Z39^I,T5MKJJG
MF9BM9$RN?(3I:<I85$OKG-TB"09I'L2P/1N['E.MG.PY*%QD)2_ S"RB06(W
MCH&NZXU3O'-&!P,?4OA267?<GZ[@($)A9"&&2^"32U4( B"1<.M/T[6XUQ7;
MKJ/&^A3&4=2%.+@-@>*IA/"Z?YH.\B[:3JY\+<W_HZ+L/TTS5=H&R_ITS74(
MPG NBI]S2RA^IH$M:OQYKNP7 K.:A[Z4..<]?=K.*XSE:",#KHC!8D4Y+^$M
MU'3$3UAVJ\F #T?4LQYP2V(6VB, BM,;\QB,)G$,^=_%GF6Z+U^I(!H9\&5Y
MUVSY^BMKK67;*V:?C#NGG=MWPTW%MKW2O,(:-?+G-8[$Q<3R(M5.)-^HZ93@
MY5"V$:5Z2R;#RH9%LS?0FA[G2H4\>-\T/V)?-6C?'S=4&-] PW-W:PH5EXR3
M>:JA^05'W>$4.AK:C;_:#<1$\Q$OB_0'GG<X":U;<)[.5+F_ASK6$TF(<KG^
M.O^B^^#3X#UX4GH;XI+%R?QA)?)R%;K>Y_7LASK)#L2<^F;V)%<0LI7OXJNE
MQEBD&E:MWN*,N-$MVWNJOL=O LB ;IG(ULX'*1FO4F9W0*4S" EHY_.3K2X+
M.@JM=WX'!L@XAQR]63<53TL^R7D/%BQ\/IO_@5?SGN61IV9F?K,"_-G$$=],
MGMAP!)+$JN FO,>##M08;W;&\)8L^D$!]EP248%T^'H5HS9#2/H@HVARF4,A
MS NM&=^(D63VX:2Q9>_P=\)*=""B8)?$"2#;1;X+>!=&!FM[9WO&7BSH:XO>
MYEFWQ/CANF1>_<1@ST@]XY&BPPF,C(?5I=R&$<PQGY;WF>F^+G#Y1+"C>QP-
M&$^",+U <<\P<9LX*D(4?KRC%Q#I8W9+_.D&5B3-J5Y+L< O%/CDF-B=5(6F
M.-OZ,25GX>8&<B-3!281\NK/U.FO\.Q;0+[@M5#0T+PT1SXM2IF*SFH)!IG]
M,@QMU.<D0!1U0N;ETC02=,Y#RA]MFV1LYXIV' K$]\#OQW))%];'VN_B"6@\
MSW[A&BVW)X$%WGS&7U0#3[THP:J6!R$#+KYL&$WG$@PM?U5<F<?RHYPJ]F//
M@(;,UFM.1X2SN9/WSPZ--T==!CN<9U5CD'1-@;Z3WDHHFR1+-RNK'._"WJXM
M8D!)I?&%3KG3]5HF?&02)2VUQ?46W<D #K&.U\2,FPRN5U^0 9F6]2%D@&VN
MVR =6O"V8A0(CEAS;JF=6-&\A79N.6()(MT<:[QW>I7T4\_!-*9_OSAYXOQ(
MKUEQ[)6&,[X7#0(-9_V]?RH_*#(A#5C<".(N@C.W0O(?>/F6.X4_'>ZNE%,N
M:X4GBC5289E[NU9[D;]@!9N2QE6''-DKMRY-;C3]TFXU:QB_J!-)_218F\LV
M2CV#.N)ZQ93;<M?"LF3^G!Z+PIF:Y*M^.O:<8KM'.>&& ?-&F<B2P08;^T-X
M#+ 2_LZ=8;)8V:=X0Q8YQ;C#[W-F9G'LRH%R7-X")*P.8QM)XB!U^):F8L\'
MI+SW3AM8++Y9!TH579!J\ZS3:[%EQ ^JLR_":*W'_*^BMM :W<CSA\BKH/D.
M#K1KJ]P,6H#SS"-KY>#@V,^8<\K&QEB-+@[?L+;;@5<I84J)KIR3>#8*K#PT
MU^A@$!R;&_T<I&H)VX$#MP_69#H/?>Z[O/,PCG)^&CF#[(-PGQJ@EH\FL,=\
M9MXI@WP<V_[@Q=TP_:UDX)26BR,J#*MDNO$":7OK)]K:0NE74M)^"D$@Y3(9
M\,VY T2\H;/=T81]%TG[(9^>>_:Z<"F@%S=P5LU_D"\D\%;GE^HXWG34Z##W
MKGUORHU9HM4I(M<83$50TQ:K[/SI_[@> OPX?G_>A<IY]])ISBFJ.C\H^N)3
M^REXG6_UPS)FXW)*'L9])@,@&[F-Q R@;511F/W.RZ&]_4=>2C97!@7V''0F
MZV2T_19VN^;HU",W=PW3GSRP=W[5[:?T$A"LS'6,VF^!7O#@!H$@370=$Y[C
M1>7S].@U]Y" "SKG54*%M;E;H1<;Y5PG%-5C4!DW%U.LM"V9.IB-?WYH[:YR
M/Z7=5HE,:-K%S_9- ^T'G3?'55OQNI@7:P_Q$@O:C]<TL'0=1:<QFN..-YE>
M3SU?ERPJ\TJAPS_Z]?C[0(!Z@+E@\@1N$A_B=MG* _/05>/&2=#DM:-EXS4S
MBTOXK+,P'\O+J:C)8N?G36.%@KV=K[L+XNF8=6JEL8OPR"A@IC2E&B(Z@+;[
M]V=W]Q!KF;[HWVK!=9!F4T'!P!2)M3^J>?!\0I=2"U;KR*D'G:9'G2SG"58_
M$\W2=E'B1?GH$=NFAH[A+OH?=C^\UX#:8Y/S>)T.\'D*N5[?5A4X*R>;*591
M6U>1O.%D(>)<I=XE>SV\Q[S;R?<./#.0VM3,7V$";H,-:[MJU6G$H?LJUMM1
M(':O\YBXS/(V>/#K.C,$CJ]#S30Y+Q#A[6 J2@F'IF0UYQ+AT "X: J'E]3^
MV_CXV'>)Z_*[^D91'FB6D,H3=_-=_//7:08[1Q7@"8+"X5'DCE,)24HHJI(O
M+'&K^J+]#3ME4Y*0[(EN]=ZQ>A1$&!/ [)9V7'/_VSCI.JD+RHHFB-B[>+UN
M%DE8-IV<==XK:;7QE^/\A7[MC8;#<8&_"%9-6C];/!VU,C1H+B_VO5J%#!@C
M(H=3<RC]QS.,J8/+*![5),N=-*-LI&MVOX+1BIF#*E3%86,A27Y#QGTB$ ;\
MK@?_0>*@7+9\\2?776]@U1"M 5YM?"SP1BMKYM2+4P[3T'#3KI$G[H!R':X@
MEKE6 =Y[9C:-JWUZS?BR!>0TAP9&6M87&BLA\R@_0$FKZ6+E4*%PWXIV"#+9
M:)U.B!T[GK$(C$QCAJG$PO*\$=IEM8,9$+N4.YWBZLS+9M3QF\*9B0M\X6FT
M*/,-7[H(][[**Z H$9_%>(V*6S1ZL6?O/AVQ  <<CB,]WJ*XYX%C)9,G;DMK
MH?ZZBRR3SBUIX&A>,/JK1WLSY\J^P-OSWXWD%.1_5;*-I&"$(-=9;8D.9YZ-
M;X_G ]9"A4!^+C>1DKHWW#F7EYJ\!=>"F@4=C+KF]]6QVG-U'P8L:T-1#R5Y
MX97+3JI-#F)2BV1 A\K%$Z4YN7:2P C\Q6"*F[VCLEZ>.C/G+_R1&R?U[D*:
M_1;:B"9*L9"PVF)QV?Z7E#4Q9 !.'M\'"<#U\UN$@8(8<I,B?Z0'+;-]VCM7
M>MIN<;.\&B.WG5Z$S]O6?%6?-*SIX3L35!8NJO;Q1,%"YVD5%HU\URR$[/2Z
M.IZ$:OBX,ZOIFJCQ>DLI-GJ!N+3C9KCC3^G>N*[YKB5*]^Y,:O:/LG?,M_LR
M:!ZISJ':EO?\^0"ZWV'F=.E%DNW5%)WQM76)F+/Y"U&[T:8U!!'.RBV&=(7Q
MHPY%9&24"5CMYF/ENY+?YJ+]/S/5S61".E05O?<M,"G;;A@-G:%#I1))D1F-
M4RW08RO)K[.RU8JQOL8#IG&4-K?%Y=B< <W#UY,!3VNZ$VW=:R3;+Y\]._KJ
M[=ON,T5SW@PHL<.,IMR!8!0H7<LR7&RU)F,I'/HMQQ)Z/O*Y?&MGK^84<L=H
M<W+-O$<ZD91ZPH#)7K3$Z(2K7GXJ#6/UWOU1$;N,;]XUW:M$WWUNU?OH@66$
M*$!_]-O6<PM.S%&$1Y,<KFK87^KN-RS31#C.=/4>FX+='OOS)=K1!3Y<B/\#
MCE#5VZWYH WL!DDB3J?&150VO.;&E4\\H0;K.;SWJ",/6:CQV5VJ//C;6/XV
MKKC@1M!72+-P;4WF58.9[UW\5ZC%T?N)W30V=6OO$AKK1IR0)WI>2(R13(Q=
MDY@C&2#"V\T<4TH XJDP^>W-JOMB_H9N2UI^4=P,4P]3[H(BSKKU""N2/+;&
MY>K-$)4IW3&,DQ3D[QWW["<Z)B/(G)@,FGS(R'ME9?-=,D]L^EOX0(9&*QG
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M6DH97(8B+^XD1L;6N_9N]M3L]$P/; U9G$R.;#[6C[YN*$LT-I>S"$,0_TO
MKM6QM24POFEA93&%INZ"36@Y.Q\K2?4ZYMN8_1>C"XXS#WPR#\W"S7[4_2,=
M#/Z9 _K[*NN4L7SO1]]_FZRQ#WG^Q:W&TE%A >JLYN%K00%%?#^.BJ:YUPS?
M^,%6=/7H[YUPT/M]G\'RE%QZYOBBSNKG4I7E/V5!\"75[<XD+,EP@'+66-[;
M(T^&*RJGW-"NT$$-,J#YZS_-RE_U&UKUF]"Y<6?5>O ?;L_^Q[I"6.JN!F7<
M8/YO/7'@>NU_>.='_X/5/[O)$%;@G<DD;,=?6WOW.">F$\-!C<AU!5XDF B%
MN%?51RYTS(!O7>*)]B"(+&M#.DWSPR6L,U=W[!E+WJ?W 'Q?-(/88CL,B_29
MWD6&5=@K]!D<1*=%/MW5L)F)J0?G%SU^=XE?KP@AZ2O&9UAT:"X!Y4=3VE%$
MO79V&_^8XPKCJ=DQTMUWQ)$DM"&)U&%S>"\J?*G[5OKNVE>"" JXW?2H?2T@
M=JMW"]'WRA L^5!^MB6VJS:Q>[1HD-'L5<9VP9QI/PB?4C5WU#3AR)3P.=O9
MANC3N L-6PXXAJ#Z0%O?2]"ES3]?WE]<\O_::?_/,/HWG"K8'4W'5MW\O/^H
M^C6CX^SKKN;D?96MB5[(B[O,C2[,DL^2$B/M@9YB1;*'VI6'OAL_ESKO9ZAJ
M/-W<,CBD &_I_S:!=_?X@U-3_O'/,H*U^UKKR?H\$KL(Q$)'9(LR;9M>>G>2
M :CW$\"M-BCQ\N@H>^OW8RW< S(@402?00:8BP,/3"?* KOLZ8DP]S.8#O2J
M3M\U(:(E#GZ5^)Y"L7I)0M )K3CBY:HM8%E'0R# CAJX-PPE,HY_["\D V("
M-88MH<NZ9( SO"=SMQQ)"EBDP'$(Z=*K&C( Y@W=I?"T$(-]XOH^<:N];&VV
MYB^7K'\S^S]BP<H,&3#8"#Q"0]L*+"!<XAD225YN>=-]Q)[E".X]F24HCZH8
M>(.K!![<J.2"<[389*FR0-[JJ:@9.#M$/+KV=B,(TK5#<%X@ ^C-3=<3[=[C
MHSK9KM=F@H;-NL*R'R]?U#Q@/YCDB:R63"B>^U"MY;567ZXJ)8GRO<*HW]KI
M]EAX;[PGT!=F_W \L:.\\VIEV9W>>N'R^.U?\K?_TWG]>Q9@X?1VZ(#/TS=A
MGL'N]>:-*\55@+.F,NJ =M6?CUGO='KNIVU4 :?7VE@W?;6;XQT+O".'22MB
MIK@VOH3;(+QL->?D2Z?SS$IIRYTO\<4J&LQ&Z+T:N(ZVQZ$V;RF#8KO5[8("
M$]P\*8-P,#+<?UK:!ST^"B,1X7C=__ A^^*>O^V8*J^#8KEW5]^SL<HZYX_V
M]:41+RM Q?)D@-$**$R_5;_?ER-851#OA:*MZ,MR^#;?:'54W7U;&;S;-6EY
MV"425,I<)?AC;&G. ;'@/W@_5C;&MC<C=XI20@N$V 9K!.&TG0P(G"#<FG*F
MD$X,I9U4D0'G(V\MITGVA/+CJ8[+MF(/VPG:V)>9EX>35T520I_!3[_1\5_5
M]J[]H3-VJ[Y0_.F&B2FZ.F$N=_3P]H/IOF0<$JSF5C3FD0%\Y!TXQ,C =E$@
MY04Z*GHE5K[?T@'&YG_WI>4>W'W#[=I%1G%#O_A.__2<W]Y&(R($FJMJD_<@
M7_2TA/1%O<Y!5]*%7"P0 9C$]J.T*":YIW5E6$9<G[!)9:9U,0?CVVI:?H&7
MV,2W8*6/5L(+J.::R!A!H\=W*\W2$JN^9(SMVNR@:C:RYNXG%),!'MI]2;*'
MU1EHTA.<HT27(M- P=7&Q.=\E>A3T7O&_JD[ZO+LULH:7^:W@"_*3F5^7H]+
MY2IX=F]CI,0_2^ZM/PBSAE85PLI\2O./X-:P&WD:O6<F+WR'/>+XGA7^_"SQ
MD[1(DX9YHK[/2Y"62_3+Q9EK9$#8EKE\@=7K#]FWC/2<7(Q<QLV&C2/]!Z;!
M("4U2-6/C5/A1(=GY15C*L4UOH$-Q.[1&0JZ6YOG.\4A%M7_F1"&.I5^0VNG
M$R.3^SN@/P1)%O3/8BKT(1U0QG/Q__D57=CBU] V#A3/O7/ J0D5?O#Q\OR8
MW^!1L3.7#NRL=S#L.,R, DCSBB*/WJ?_)!BX^G<O$Y<(&Y(!VBQ'R-_^$CFD
M7G'J[#F4?GF2]O@60YEK@#:G:EY"Y)EM,YB^NDY!SI<W#1Q"HT.)F_:W/HO_
M?[FPW.]&X!0+L$L$QXV[2FG5#AC$Z1'X1%<P4'D*VKT,W(TDAA+#H,O3C1(D
MX@3I@R98)I,,.*.*R%;MIL0FWESG!(\X2/;?)P-H%AT1C,HF T"4*^+D.F1+
M1VJ^68V"TMV:D:&J(A24WD9Q2A*\6'DZ^J&SJ4;_O=.O5;_#B3&P;)QLW;%6
M'>1WF%S8[,CKR)/E.O$[)##TGU:>5KB_ I>:;W1&L70U[.(?V6(FWD4#[:M=
MKI)*)'WB9^Z2 <DN^1J)5]U:X$_'J^BEB=S/ZB/D^F@KR[^0 3Y)]-3[[%C;
M8!F1CX$75<L<3)?T,^?]UMR.TCQ%?V@>GFV:S:?3N:"G5UCZI7K?MANK:@V6
M:&NUG,M5,"4V$ 9M$[N,?&7A8I5DP"5E2AE_)FYV\ABS/@Q@%+F@>_!=9B.0
M'O_V9H'+V8R"65.SP=<Q@K'Y+\[/S!<&'$[[Q!I\G^/<=J6_JDJ-O_LU1J=5
MUR(U36MC+7[G4]G<JI-*P-:$DT S5B-H1]I.XF75:&G./?O7L8;)"]J77&KY
MWS_NO\$V"U R'EJ25(0:Q7CW^;F;@@MK5DXV_7>HE4NT.$25=]!S38%D0"L9
MT,YGML$+Q.":BN<V%#UKK/T*IFT'JX)^'=:(K3M3!X]IEC%G:3WBHKESS^\K
M/E2N/)(AB87'/F[^20ONWO>C3A_C( (+ENZ7Y/&]F=; J\-5Z!M3V^,X!2EB
M7DA3\RZU8/K-;X=D -NFJN2XQ&'&_9'ME'=D@ UH6IUDF_P5ZE,9VP [-NY6
ME-X@G8A)-YX<''L<2P>^%1X3-@W6?@S:R*V?VFQLMD\C ^B*M\4<#Y'G3!]>
M;G\VO/*HAD>ZYD+<76NKN0A]/(]GJ95:<Z246,F4B[5GEJ#=9-'#EA5!/07&
M_/>0>KSQ@KENHWV.EO3XB=5Q':M9[V5[-KK7!EL).8>==O[ZS<UX(4B6W8EM
M4&*'D/X^8X0R+>F92_17(1^>PQ;VSOOL+A\S'S_=3ZYO<"B=:3A0$GF<S,:8
MJVO*H"48(%L5X4^-K3YJKT_P=NL:.7XC'SMC=@UP?/K%^;YW^X'*UBC!CP)$
MK/$V]O1@Y)OXY&6>(]ZJ#G\3O.47B;>5CD_]_)H4]5_11"T?%Q;ZT M!4^0'
M<[UGN7@+4*F5,<S['<AIBRLC6H..MH*#"9A:3K,*UUZ O!DV;1];6; J;_KA
MYK%/XM/>(Y"20](T N0Q9X)^[/':@U]>_&7QV/P<?!PI0H*\'X>_'#LL2OV8
M;"\@7'<P0.NIZ-6F68KF3S._]T(\*TC4IWO+3*S[1#9;^#+W\/W7+ C3HQ(&
M@^K:(<?<_7@#=>J72V<1F82'*,:)L.Q0TH##A13)P$T_TS[SN*%RY<O<?+>+
M'S2EN'4W@A:."4*B9S034+??3J_?_;YYKK1B02=T<5Q9K\98GA7$JKX34B1'
MN6+.9A>8FLY\%P"Y"T[I<,<Y?P^LFB4PCKXZ,'_:?;^IPKG:(7DW@''WS<?[
M9^?])B:L#2MXMFZUJ7^QF&[ZE-P7[S?25/V4'G[JPZ/?KIYYLZ:L,5M;\Z Y
M(U ''+]I(8=/M5K@NX@/G#%LJAZI3,<[/4GAX+R2<"?]$E] _[&QPA?23T4U
M$AQ5(U<&MJOFD/5,@VQ@*Q/-M435TF1TC]+YHZG,G8IR'A1Z(]6;(5&> ;+C
M*[P#3Z2C!:>JRB:9PF"^BXW&&#U'J,7X(<2O[_G-6D3YJ.ABPLV]L860;)&;
MP\S</LMNX"IUUL?][D3H=[R) K]+L_S&$=? 6WLKRP"WLUG2/\U[Q[?S6I>>
M=5K3[<1_^G3 ,S:C$S//U0!:0_HP&HV[(;M%<:41/C0B]1IOXO??J(@DE^$5
MH)"\Z6R+2;$?-<87-^EI1,ND]356ZKM<0:^O<A8I=B_$#"3ESL\@-WW-/(WJ
M#<<SK%POC%%HX85P32DEUEJZ*V:VTL>W$_OY*U*62M]>NCS,K?UKY1!W7H3[
M!N/[&=LS*+4N(ZFI.--T8_S28LR-!ZE.NXY)-^PE7I58@+RC/^Z-?6(\,Q-*
MZS:='RKN[&%_$X.(. C?\1"3O"KQ+-3&)$J#Z[U N,C+.XRSO(K&5"5X8W.,
M\;3_A47OTN41Y^F?B3+Q[Q\]^^QI<F\ZFR&!.WXZ?.1=<&KV="+J* S9 <FA
M%R]W4HM G"H%Q#MIMKSIBVGHD>^&<_;K#9$4\58F38\N:LT\S]GO\$KQA%]M
MC*&W%!9]]VO29 =1Y&,-_KH,/'PT=RS*CD[/W##Y>49I301-YC.E:L=Y26Y.
M]E\)5Q+VVZ9O1OA\Y7]@*_MYO]'AGD?=ODO-SSCI0(.ZVW%I&FKVV.ZVH\L3
M%8,JXQGLE6=6M ^+.G'A6K07'YX[;A6@BO5A%PSK<CQSF!TQ3NH]A#L6<W7M
M#65ERM6*7K<Q(IV=#G3Z9$QOA;E\8BZ+&B8#],I"%JLCI]M0O73BC*XBQ0G.
M5@.Z]PQ1E<[-E_!A%IE'9J.'17SXQT_&V4S2O:^8JN$TO'YIR>AO_#[3)-\)
MM-6IK<OQ,!WL@K*LITPD2Q*K_;8@K2\<'4O2- 42>R]FO/&@8M8LI71QKJ;F
M.EE8@-TV;H*AB:% /YKW\QY+&9QZ5/6\=YA!W//ZIE%WQP>ZHS+7OUY9JW(Y
M3UI\T5;^?MV8DY%%96NRF=7;%TIO7W\SS@TJGJ]2> E2$"&ZEHC\Q!RLFA1Z
MXX)!>BR.R&2ON5^4L1:=_DJVJ=F&9-AWG'DX[+U8W6I/VH<*+_M/+[6I'^@V
M7Y_.%O/YG?L9]V?WEP[HI_UV!U.8=N%QI4^E:TB?A6T3KVV3X;[=OMT*0W+C
M[R_ BE:'5H=Z.2@;#]<L;N*QB[NT^('=]FE,W8BIR,.&4/2(NQ<H]OQ##M$?
M],LO*BDH?:6193&O/D@&IE<;[UB<Y10GXBXTZ0%\? SK2"O:2,LIEU[3Q=+
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M,OR&""UWCZ;'Y&DI^7Y)H93$BJ_:IMRFM=G.?+6/:W;,_$#Z=:JDE%'L-]7
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MZAS]TW-:+IEQ'S/O%-;%,JY;<Y"4 U[CG*F]1360=%),B-=*P?"\Q&O]NSW
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M%7!^"5BHX<[.-9$ M.36H^Z>"1!3OU0+64',"<VE!>NRCYF=1>%FW!\T-'E
M5@2_0P^B2L<LK+UP4V-\2TF@9);2$_V@6H3U6K:J$J>&$-BDB+FN3NCN=[YC
M Z7TB"EB=E V(S&D-D]=TE*S:&[ L?+7E4SNY.N?AC)-I!VSQH=%+)[X_;]T
M>^)*WX7*_4N /VA+=DOQ$L WO@ [VD;MYVH?-QZ1: [.60[EG<\B-F#HSDM
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MU SMDHYZ =)9G0O8A?BRDLQ3U5!OD&WT1JN%<Z9<66N>VO=@)ZA^O#^0M8:
MOXC_ ?;"6'+)-X213TI6O(R2D[ON8IK-26#\&],9P2!JY]?%8%J!O45AX[)\
M#@ZM2X"YW@M-CM+QL_XC1$2PM#:5HJR0,N=$<T[DF<CJV4X$7#OZEKZVQ&%*
M\BC)'&J.E?7;R3-WW/H/@A4O 3V7<R1B)4I]_MF<O-$'M..T,_F+=0^7*%/\
M>Y5ZX2OZ*_]"7C)R?G4P7+B[[D*C;E"B5HG^F*@<=Z3R&PU\H%*7DW<6_0,U
MISG. >JHF8:\O@18L1U3S#?V;@<^K)G65;FHE]UE6&VV<UT>;F954>G',O^%
MZ0OU_PR<O.[*#OK?4=76>[4+/'_.RQO#A=R0-2 7QE]I35$;!$;<U%+^B$AO
M5'<N4BNWP=JH,<+AUG():[;07#GV-^+M-!L^"!U2; E+(/=,:H\NDYK9=^NY
MM[MR]B?X,.KOTK@=[F?]6UZ*M!W9*XU*W0P&GP^-9LN1P,A;U [7)_"0D_O.
M9V]J5'@P7V0$%=1I:#X"(XW?GZDYES'>M8G,)>O/??("F+QG$XED"_>8'@.S
MO8M;S6X\*F$5;?#ZYOC!QKRWS31#;O"VXN<#1+$_^ZH:1G!@H!1?<.IUG)-7
MSNP4J^3H-V ],722\6+<HM756N&)DY+RC_NAH%&R6>_!FT8<6;[$=5#!>%G^
M+U9Z3"93JF?\]\JQ:]&I*5L2$=VYO62V:(;DO(VXS71=^+[<.R=NZL_3RNKO
MSN10J4_&^0G*12'5<+#T9O6O$%VMH(?1L(DN/8.6M^7RB*Q6Z>@")48A7,SL
M/G;[K(DZVD]+UZ]ON>;TT,9W7^WYBRA5 ^KO/QSJ@L;HE(A/R&S$6SI]8[M0
M07-TPTH,'@%YF.["#8A4H&::U)?G7K 2RNPRN4,$*Y%MC9.L JJ]HUT3H+%<
M194$DPCI5I_-?+BMJ]VSEI^C"&W@22G+Y&59/.8.;2R0?=>%J3W:JJ]8[)B0
ME(\9_3.63W8#RBU\Y4CY!DA7S7S\O; S_%NHS@B"[Q%E#_77M?:/S'?2[GTR
MA=T.O(?I+)XS=7P)C]P W33--SD?LNU.Q>.M&_+66'W!;N]N44RO'VG_IO'E
M3HQKGY&57E,2N5V/X%EO6"^=FQC?A#9)*]\.O.HC*OZZ2E#7&K-=-@&WT'2
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M0_2"^_E[ZX%QGE/%8Y:'34\R.6>I_-7OE 8X._#F@VIIS+5="3QE-,TE=ZA
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M)*4OM(J:IPR;*1^BU5$9SW8Z7V@+?@!YZ:G#@O>4A??U=?$5-@:$<?QVE@L
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MVA0&,!\;G /&879'ST6SZF?Z[6(^=LJO^1E6/>P9F#5:KI8B^7I3CE2+(N+
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M_2B DF5)2U,(P[Q;3P4I[;/^^QMIX$,?$=^FPP4$\ZY)ARI])3=E?R2!S:4
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M@=_J&YE?-:0.%YE5%SIQ(8O7O>',4 &"1N*6>5# \5LJUL^Q<;$;,(78P[D
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MQWVST@TP"VG1SF%49]3P4Q2Q21J=4%W66?5<]N28'TW+4DCH,#")]*@S'B&
M3/A(V\V\Z#/REH+F>4D\]6SXK&XJ)_^@6(7C2&]?99"[T/9FPV*"'XW0!+07
MC[QBHS8/9!2^K?'9B8OGW>MP\5\V]Y>_^-UBL*,U.D):S-K8?^[\:W*K?LP
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MEP3C"/3 I!V6(N:+O^&K4E6QX+-K&,[+Q;@1P*("]<S[KX)K5W3,KW'5U@L
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M)^7\X;;A>:/]/[; SHM90<GY//]A#)P,_<<8./$"L(9""A(M'@U=GX@C("X
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M (92"K19]0_J6DQV < ^/D7\/HC!\B/7ZGB>G1_\A5VI]F4V)D VM!TI61<
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MZ6PMNP"T:&0;XY/;GAI.V:"8PS*W-%N?75-JB_I!E[9XH EI7[H>^VM=CN;
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M358GE78DQJAA@D$.%';6NI^'JLA?:WE^]'%G*;#T%]]W4,_K U%H\2PC7FU
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M(=V%Z*-O"6.*D#WE=M0DV@:4@32)Z2O3GQ3EH(G4B#-RX<2:JA[L_=E7IR=
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MPY,Z-&/(RGS*#I!119DQ5E&27&CM?K3C0N[%M3A_"3GOUL2-IOK2N3[-3'A
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M@3WJ1Q=9@D^.J3BFNZB:\Q23==L?YG1UQ.YQM?16*H)K@2.DAV_A!*; #&C
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M/4,!_7 JZ>M(%SB6!'+3HD9QIJ%ZUGF4C_@NPEE)B=QS0WK.?R/?A%NO*3U
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MXT()$E#AN,E2[4F=$<G]\WM'9ZR\?T[<*N^E"PH=.C+7CWCDXZ-59K\7%'3
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M9E]L4G ;@A04;8\+.23OQPT=Y3V-F5-5(.QBMV.KO39ZA-K3_18)*O?%I9B
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MO7^A*6-WBS[(.W-T-A'%16N'&3::"XCW#FAEK\'C$U4?YP7>Z:?>4;,)^5S
M,DA_:?H< 3HEI1[OPL.WTWL0NXB6\S6<D3'LH.@O"TJ<%66-1+XM,EKM(%0O
M;MOT6:8B=;S,5.:!K7TL4*L#R[%J%N#]BB&DIYRMM\0!@3Z@*RX3CI3''B\N
M4&3P8QM8/ 87^!A/07J=.5SGY-[=O7(7L4('F[78[VR'1Z5WQH4!P$0=8UW;
M1QE&;T8L]>X4[$\T+.T=&09ZO4,[&7JUP>G#@-;6:VPK<+80($=U%J9F)?8T
MT]7':A:ZBHI"4V/7S=*?K X8<UK-'%14>FXI%,SS!53X[RG+,K.X#;M'J"D)
M^58U%60D%FNBW8U?J3/UAS&NU8^&YTZZVM1$<$S;3(\CTZ[<T#F34,<]#Z\2
M=Y_E;63!BSA^:B]U+Z^7&,SDO,%X2G3J=4]06BR*/R24B"UX1+3M,"/"6F<N
M29463JV6V$#>(Q0[;'=X^0YP#=+OX(!]-8.VV?/&D;FO7&<X?IR%*7N4")W2
MOKL%O5[;[(A]=<#6]E3(]*N3J=ZNSPW$V8]+E+WJVJ//3U]\;#^Q-LG%GK\A
M;M.#>C99^W$MA##?%WL(Y$#QDI2&Y/\TX[99H:A9XQ')A:-G3PNQSSH=[M)V
M%W .]X[Q)L/)-?>PV\2>'.A\RTT(?Y<W%Z:Z<? H$#KA?>TXU>Z-FA6H#;+N
MCI?=T&9ECVQI%*@(V>P\LDOW"'(XV%$+*4BX'N^^SH%.$25UB2)+2V&W<F/$
MYUF_TG;G5__8+A6 8:+H>B6B-Q@"J8!<FZ;3=:!8]4M-A*A6(+=KT,L\\)JR
M4WO):6U,_LSMXJ3Q9_ME?RXER\CEBS[[BI:%<_*(R<9,(XZ V:B+!.G6V+Z)
M"L'37F<=UM65/SCI>FY*7+@?T=NQJR,*2!C!D&P&]X%G2+Q$3B\<61UW'&QO
M\*=N*.:HHM$Z[L@V^&.CXRSWOLO& '[2G&B-AVGCEQJXF(HP<@7&(N'(/XM1
M($UK<!6H)2L89X3&KVUK&01$:8YR'.-[I%J$F-]NSB=%J%JM2H-R5+LGI+%%
MO7:] >@&X3I?NZ+9_&/W$/W?8IWTF\".>=Z=0@RF8'L:N:MN2=C*P?8EAHG2
M4D.D.G>(>AV^,Z9$VG)MZ=AU=& 32_>^.W->1&!L<<['WGB3SN_RAQ.[E<1@
MK!X)*M3O:#5T)3'X#PRJ,,^ <$C9@%>YT+:P4F)MNP,_X;#U2'*/"A!PW2U,
M_H43KG_K.^7=Y:"C9A&M!BASP06T],6.40'\>U[1%/8A7]WJ<[[1I<XUPU(!
MG9<0 9_RZ U.-82G3S)]QD*"^>[EQH5F:;GU[-YL<%T,WD%7C)0BS92)8GOD
MW&2!-%7!>6X7[E!S__JUK&-?9=;P,*$AS^HF?=S07/OLJS(/"9'/\N+%'C%$
MX%KSN#(5H#]'!3@F1MDPM),9VF<4"=EPANC]=;(SQ#]U+_"-G(5V2_A0&N@5
M]SJ0Q1.E.@W]=JXQ$$&T ;%4*&:N3C9NS+^2O<K;YR#^)GP.W(Y\3;DVAL::
MK 5)+D=49T364WZ/<H4[7>7]O2/;<=;G%YUX!Z3[H+]&B)5Q &'J?N&VA8C(
ML^GYWJVA(!6/G-F-Q2#Y?'VSMW9EF1P!;M8[Q:(>%H?#&(+5SU*!N<YFXQC8
MN-5AXI,B&X,;0XLOGM2HO0BOD4TL$"\BQU,!"],A(E2 G2T5<$^^"VI\ "&H
M1^ 1N#/*'57IAPDAUDQ'?4O<-?&)5S6N!*B]8 !<$/]$],%*8\#8J+=R5 "+
M&W] ^,)0B?E70]^-'3:CP&MW61>M1Q]V/E[#4FK/&V.T=O5V=D68[B";LM/6
MZ\RGOO](]T,A;W1^*-;RL=E!H24]^C'$!-"\&HJ?"A@_#5X.<&# HMG79\^A
ME*"3./DO;B1Y+YQ>58_#F3.;"7J7HD#W0,K'+^>QH/CJ65K'WI>X_TAN+_9!
MOU9!Z4'@]XLK[PZCAQ=2_L2&P\'Z&5CD3Z;N1^H2JRB)FIHD X(#0J3]1X+&
MU9UQ%&_"'X6;91B^5,[S40^+;O0$W[BG?T+9L>L*_+J%>K!4_*;MJ;B2AB+:
M[::H1U,[Y.A.29\HT:,(L^X@3<ZO9KKY$=>[;ICMFJ_Y_G?_+XTRH4?#2&?R
M!]0%J+- J\L3Y+J9K4-]YL4X.[U7Q@6VHBOB(^JGP[K5)8C&7T-,AJ0P@SA)
M+Z/4/L,4EZ[WR1^LH)W=AVG[I9/@":/#-G0E,*J1J72J-1^:IYUNVZ R+M"C
MZW3[5_='Y6)Q@'?_W&[,9M&G16*(X8C%#6W?DL,!T^3 4O(8Y,!%[M:CWU42
MJ]6B?-,>Q859R"6D8S$A<2,"O]YVF?_[D$35,'[CP%0;[VX#/?^"\;A\S;CI
M<=AX]JVDGVCZC481IQ"G$9*&L,V#VU.Z=%4A#,ZJ%\(>&I]HUV5!YK8[9V/O
MI-**<W2TKR&H]>)@GMVL6S!J**AH2'T9J<6W;NN@2O[DA1(C/>[O?"<Y0A%P
MM7&MKGXM_<A0]=4%6T_>EWJ]L+=6L5$I8HHQLG]D8DK<ZHRZ=CT@PM-E"Y0^
MI])$HXHBTWA=[*W>"_[Q,]FU^@=Z?HKH"?=@V.O9RWY40$17L6:1:WU/B4UD
MAO>E]6N?1U5__!(^??>](^4SLO0YZ185D+1-?$<%.-RD K[HF)(TR'$>C2+%
M4-LV]+GG:<9C>Z4:+MDJF_>L]'(O[?LK-O/^[- $ZH>W@<Y19*$!\]OO5&%S
ML8+T218QBF_<D[8Q*)NSO/2!S.=Z@F3;'I</%3ND^.;;),4N5X%5G;C]RP:7
M]$^:/K?S*Y9(N UF71]1SNQ.W;$K5>.L:,J&>^_W<"\!SY:%2=@9%%$!+=U5
M_:5YC/"GRC+/DY+08=;HB<YY!S@X_:EKJ$UQ_I]\S_( <.#!L/N)Z\V=ZK!X
M:W*S%I>5S(___('4JGM&G":/@$\COUJD&((?CKV#S)[WV]0\R.L/"62\ZRN@
M)K,IXGB#P^MJ><3VL!4Z:12A[3>M)Q+DHT_&#(3TB<H@E#]\_8)T:R<EC<"O
M0H7:E ];@'%A,L0TYQY0Y!S!HN-#R>25!2WADN:^&AV&<KK1)@%L!P)20DP[
MB$.79TF52CU/?U00MVAO_?(<\C'1\$1M9K7>I3U>J/U@=&<U6V+$N>[UT_=*
M.YFH\Y1UYC=JZQ%$OA,Q:"W6(9$@JU\?K/+)+T.A>JA KRZI;' >*,W;$Q8>
MW?.2=*_L:+ P11$Q:-(H<MA> $_+(>R]X*V7^KCHR=)332H;!/NFH,+RJ !G
M]"N'<\2<$[E53>M^#V%TO?78B8899Y[GXQ*!,IV],OC!>8(\I1KO3P48H7^D
M;I_P6*;_GK$.O"98^+ON0&+V4QGP)YP9YB9]AJ2>^!/S"%\#_YK\D3U4.*+L
MFI6HSUEF;6TC=3/P/4H?%<#@03E+4JC$3P6 /1MNJXULSMRZGD7X\7H<P*U3
MD;#4^&";VWC\:8[JO:)-L9L:HCV_T^1GG7P'R]><DD4W7?7E,I6N#&=8-@QV
M]XYZ+N<-:'$?#1QH_*^[M,Y9_,/@6 ,KHIO\GG:PXKX>OVO+UM2G!W$!\]6T
M&B)ZK!7-&29'Y*:P0U5,!CQ+D!RVY+O6&8\:OVA<V4WXO#ZFB,RA MQIB>H:
ML;R(>"&44<5-:*":T\_OX-V;$+CH@_T5R,Q%.<T4"[,-\3U^I6D)M&2K=OI2
M8<K],?F/2UZX^.J!:?N\!3&G%!DH9B=C,?Q%P.+(A"3<6!9G:_PN"-X*QK3B
M0GLSYLAF[=LOWN>UYA=)GKNT]?SFW&A4,Y+?@7AR,#:R'TP%L(*A3[$D=;;5
MXU?7+)@67W5>>1&6L@&\@.)<G^$C?R'!YIF&7[D>#YN(% OG9*:H+@9;AAZV
MP"Y.4 ;#A(@1B$E,WQ/U5\]+!K9.-]B=>7A*,-)\U]Y"ABB6/9II;IYUKA/^
M>6V3OAN"6=_N;U%\8!YX?7+1PG:QYO?.Z D5T)I-?Z)]%^1J'*=^8^C+J.2&
MA"I? 6CB3]IYWO3M;6Z[;&/>^<&F!BS\G3P0PWI@U% ^M*U5&SUKG&20:CK>
MMB+3)4C'[+,RTD.2(D>IJ@5^F9HE&0U-FA$\]J=J>3@P:[+7 )U70A).+:2K
M\IV($Q.;QV <(4(%,S!G*&O;K:-TIP6%YRZ56;HW4WJ7>+%U"])-OD\)@4YV
MJB]\(=;8*3O;F,6!?!5(H/W):$53E4PKEE"U;L!NFC+B)#SH>;PNL+HUB6V:
M68YLP3"\"F%B?8T2"Q%!#UP^S4ZR*M!F?KL])3S[IL3H+A;-N 5SSR@5497%
M&WD(&^,V!9W!E7FDG1EM0,ME)=$"&7NMOE8X1NH0BR")9WPB2?OD!X(FEFW2
M37<SO'?B%G:\9YUAE]VWVUDG$CLN4LX3GWPEBAE(:I^TF/)E0XY4JP)E&Q3G
MA?RA??I[*'3$\31_-43+(-T#X]&,.%M7/<KC;XGNUHQ=2Z$@33-OZD^5S]PT
MT),.,!1Q"@CF41> )NH.D_QR)T4WC@JA;C-SW".(*DSJU].:2=\=/ZR##: Q
M@O?F[PU?&W1.F#6#"GKD)SN9WE,W#7V-I.^79\6X5?<H^7DH-!?G"WQJG]1
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M</%E:92C].J%F0\XII!;PIV?M->6W0D\.,O*5#!C%U[F]B"?$O,=KE;S6U2
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M!,LHZD34C\2 Z6F;EEB.IFT-HXA/A4M[V4ER0\7/+^"2Z*[Z>P$I6F[(%@X
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MK>N6^-/,"*1;)O(\K7K:FA1PIW*@QM%=N+-VHM1#B__/PORZ-XH_0"91CCB
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M6V3)9.K1Q3[;%N\OR\:Z+F>AM7#Y:^GII^>$#T#B7-*-*8XM']:]W?AT!S3
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MEC/PTFS C#S)2I;5W[CSM\8IG#9ZQ&_KD=V,9B44?<V0=2X=/@)M(K$!5U.
M+'HBQ_ZQY=E9S)R(-?P4:[S9%^I.G@VJMU5T90,:5W38 /P\AZF<"C,$^8BX
M*=Y+6*]$T=#T5#08=U7S]WL+$5TK:Z 3\!%@LP*'9Z?HWSPS40T 6EW5RMB5
M/24"0RN0R%DM'U)7UH#47]>KZ+$AG#R8"))_AC_7Q\-D<@1<1$U/VEYXAK_0
M%][[A%-V6=N390TT[C .,LNC60X[4M."-%_(:_%U1)X!\-X<9Z; TS_]9[TI
MSU)!;W19PCN!0BCGQX2/Y-O,\A@6O [(PP8TE'O[K,R*G]TJ\]1AJ%L;PVMG
M]8VV2NV9+NN'+_Z-OL,:;T&!IPBMN] IPU7%3*0\Y9/MN2&<$T-+,[OS*]!Q
MY&T;<_.=AX[SWA>T?!C._T.$IZFO8]+K)O.F[M32PGJT;/Z1!__USV;_\Y1?
M3KD?+2[L9MYIX<WMS3&6?DT!9&\VJF65 %VZ!;R-JK?\P@;T6+6SV  LK9<-
M./0TD@VX[:)(9Q%FH6J]MX!:_T#^@?P#^0?R#^0?R/\D9+!=X7ZWL;F+?O8S
M,_\/GU3 <KN9M="I;H;?,G =N_%94)<3P+C8H_\+4$L#!!0    ( $Z+<EP[
MD] P0!0  #**   8    ;7)K<BTR,#(U,3(S,7AE>#$T9#$N:'1M[5UM<]LV
MMOXKV'2Z369D^359K^QFQK7=NY[;I-G4V7[8V0\@"4FH*8(+@%9T?_T]YP @
M05JRE<2695>=J2-1% B<U^>\ #K^R];6>3'F12HR]H_+=[^P3*751!26I5IP
M"U>GTH[9I2I+7K!W0FN9Y^PG+;.18&QWM[_7W^GO[6YMO3V&H4[]=U0Q8/O;
MNX?;>SM[;]C.X6#O[X.]'?;A'7OYZ?+T%=X]MI,<_@J>O3V>",M9.N;:"/OC
MBT^7/V\=OGA[;*7-Q=OC[?"ONS=1V>SM<2:OF;&S7/SX8L+U2!9;5I6#_9W2
M'L$WM^'CSCV?MZ8RL^/![L[.]T<ESS)9C+9R,;2#U_W#P^:2EJ-Q?4T9:26L
M18N<6WDM<.QHU#077 \29<='W0?,^V89OC=4A=T:\HG,9X,?+N5$&/9>3-E'
M->'%#SUW!?XU0LOA#T=TMY'_)V!H6)X5G^T6S^4(!L>Y'KGU#^ SAO_O[KD7
M^,2D]<2IH+4E*L_@P_//8YE(N/^@OWN\G0#1R@>88@J2)/37SO$=UU="L\NQ
MT+P4E96IZ;&+(NVOZX1/52:8&K)S.X:Y,EYD[*?*R$(8PTY5D56IO>>I+Y[H
M;O^OW^V^V3DZKL*#:)F92)7F*)Q;J<J5'GRW0_\==3_-8=J#JLB$QE<W/J8Q
M!T;E$A=^45BM<'GPT?%V];;_,-SYHS)6#F?NDH2Y%7:P>W@'&78='=Q?D"7V
MD^(Z0S:=22U2J[3!-PN%C;VT:B0L7'>V4%K#3)48F4FNI8"[X#/VU^\.]_:
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M;F@Y-,W,K0Z_-50Y/!OGT$)K"/9V_W9D/,KC(T*A?F$01R",P&Q5QU.!M.2
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M]X(C,B_;(<7F9L*E!K4+:SVI,H 95-*$T5:9?+PC$7QVEUI2BH'4H"M,\[7
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M81BD<5LN!-6:MAB6W+I(B:[#&C'$<PBTG!'GVE%4;9SP'KQ=4!P&V Q+7Z(
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MG70K;$E27=>@R R-$5*26R-X@80$@1=ZOA<&E(X2%VI\\-&*D>MA$ U#/_Q
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MYKVN4VBL*TR?8VU"5X)W"CF7U&DX$W0M+S'EC:$[U! 7J%F%&\/3N@<SF=K
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M#CN#=>$5VGK^>\_P46C7?U/Z/U!+ P04    " !.BW)<$0O(;W4(  #=*@
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M!>&DZ\C;'Z".T7]_X'_0B.'&B'/A; M5%J/R]":5H;3L$"X<=T-,6OD(*D9
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M%D(J$ E<$OF!2EBD5)*"KA2+RBY<Y)$-!WK]]R\&GN<$$Y$A"6W,FQL<(LO
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M=[AAKFK,,;=+U154S]Q@_0%02P$"% ,4    " !.BW)<;R<E2E(2  !;L@
M$0              @ $     ;7)K<BTR,#(U,3(S,2YX<V102P$"% ,4
M" !.BW)<$1UH0X,+   ^F0  %0              @ &!$@  ;7)K<BTR,#(U
M,3(S,5]C86PN>&UL4$L! A0#%     @ 3HMR7,(8*DDU+0  :,$" !4
M         ( !-QX  &UR:W(M,C R-3$R,S%?9&5F+GAM;%!+ 0(4 Q0    (
M $Z+<EQ!5'D&G&<  &V#!@ 5              "  9]+  !M<FMR+3(P,C4Q
M,C,Q7VQA8BYX;6Q02P$"% ,4    " !.BW)<!UI0%EQ%  #>WP0 %0
M        @ %NLP  ;7)K<BTR,#(U,3(S,5]P<F4N>&UL4$L! A0#%     @
M3HMR7/#!="V5:0, J'T> !4              ( !_?@  &UR:W(M,C R-3$R
M,S%X,3!K+FAT;5!+ 0(4 Q0    ( $Z+<EP^A%#*?C,  ' T   8
M      "  <5B! !M<FMR+3(P,C4Q,C,Q>#$P:S P,2YJ<&=02P$"% ,4
M" !.BW)<IZ?-]E"B  #OJP  &               @ %YE@0 ;7)K<BTR,#(U
M,3(S,7@Q,&LP,#(N:G!G4$L! A0#%     @ 3HMR7(D#5(2AFP  <;T  !@
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M-RYJ<&=02P$"% ,4    " !.BW)<"/\3-!L= 0"I-@$ &
M@ $>3@H ;7)K<BTR,#(U,3(S,7@Q,&LP,#@N:G!G4$L! A0#%     @ 3HMR
M7/F6;#SGL   Y=\  !@              ( !;VL+ &UR:W(M,C R-3$R,S%X
M,3!K,# Y+FIP9U!+ 0(4 Q0    ( $Z+<EP[D] P0!0  #**   8
M      "  8P<# !M<FMR+3(P,C4Q,C,Q>&5X,31D,2YH=&U02P$"% ,4
M" !.BW)<.@P[!Q4"  !A!0  &               @ $",0P ;7)K<BTR,#(U
M,3(S,7AE>#(Q9#$N:'1M4$L! A0#%     @ 3HMR7!MN#)\+ P  /P<  !@
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M,2YH=&U02P$"% ,4    " !.BW)<3"&"I!L%  !!$P  &
M@ %\4 P ;7)K<BTR,#(U,3(S,7AE>#,R9#(N:'1M4$L%!@     7 !< - 8
' ,U5#     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>mrkr-20251231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mrkr="http://www.tapimmune.com/20251231"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mrkr-20251231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2025_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember__a5PjJFdNkGHBThsnBK4rA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_jAeiudl5qEe8J-4VzRHRzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XT2HAsu1XEKincjWBVb39A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_19_2024_To_12_19_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8VZRCOP4d0-aokYe1ivjTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-19</startDate>
            <endDate>2024-12-19</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gV71OOam90epk_Du2IQJ0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HXX7qp5MoUuH8nof-BnwCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E0qy7Vq1QkiOgpqHJZmV-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ewnb_9qGskmiSR_2gvsz1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_84AY7Y29u0Wa9RpjQCDF4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oPOrqZBAU0ezQq1EPL4X1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_QeGMQYKwNUKt8wiYv26-mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_26_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_pn_qg4MJb0i_SQXgwMffCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-26</instant>
        </period>
    </context>
    <context id="As_Of_12_19_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_NdnoCXF10U2RaVtcYYPkIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-19</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_H1iRzvGfK0C3IBU4YuN-sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IyxgTtJMsUeI7g0JQzRu5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tksY2KuphU-6mtLP78kkWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_12_2025_To_2_12_2025_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_RyHxP5Ri-UCIy9cqONYc_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentiveAward2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-12</startDate>
            <endDate>2025-02-12</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_M_rPwQol10ywKLcDBKqTtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_17_2025_To_11_17_2025_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_0n8Ce_-UXUS8UIExWuVJBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentiveAward2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-17</startDate>
            <endDate>2025-11-17</endDate>
        </period>
    </context>
    <context id="As_Of_2_12_2025_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_br-AgiIl10O-PTuaEnCrgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentiveAward2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-12</instant>
        </period>
    </context>
    <context id="As_Of_2_12_2025_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_-zpixAd6L0ukz7Q5PRFHjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentiveAward2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-12</instant>
        </period>
    </context>
    <context id="Duration_5_19_2020_To_5_19_2020_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_-5xby4R-iU6ab24NiQ858Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-19</startDate>
            <endDate>2020-05-19</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2025_To_11_1_2025_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_m9FesoReQ0m7x7fy6w2Hag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentiveAward2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-11-01</endDate>
        </period>
    </context>
    <context id="Duration_10_31_2025_To_10_31_2025_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_qkF9ZLP_WkaIr8Qab56IzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentiveAward2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-31</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_Y5VZDx-btUSB5iQ3XO7H4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_26_2025_To_8_26_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_dZBSMZhgiU-56Poy6Ff-Yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-26</startDate>
            <endDate>2025-08-26</endDate>
        </period>
    </context>
    <context id="Duration_7_17_2025_To_7_21_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_bAz_p3gArkWolV47xKRr_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-17</startDate>
            <endDate>2025-07-21</endDate>
        </period>
    </context>
    <context id="Duration_12_23_2024_To_12_23_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_uXfGzxM0uEOSkZZ_6NldVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-23</startDate>
            <endDate>2024-12-23</endDate>
        </period>
    </context>
    <context id="Duration_12_19_2024_To_12_19_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_O2p_zKEtQUqaRKBbLOCA1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-19</startDate>
            <endDate>2024-12-19</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_us-gaap_GrantMember_6LnqjjsZJEiYA6ZxeN_-8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_CpritPancreaticGrantMember_YmkzplPQXEqeidRVY8TO_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:CpritPancreaticGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_tIJI_NC6ykGWgCWOPj17jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_GrantMember_UiYnDW3Fo0WMqnl0BxBg_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_RRTLLDVCo0iNI2tLPudd5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_CkarEX95-0qd9acV3OWC_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_dJoyNhvuRUeMzzqqNeKOvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_qobRXgqC6kWkIYzc8lU_ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthNationalCancerInstituteGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_AKZHg4JWuUyRUOYrneJE0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:FdaGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_bMeEXnqqVEGomKtJCoNZAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_L0Z_1a2Gv0qiuiDAeZfKZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_7bCo5DiTM02jrNls_29_eA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_Wv20gcHvB0KjVifO_1x-LQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCoAndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_F38uZMcfxU2b3xquA6y5bA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_mrkr_CellReadyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_AVpatNJHyUqIpBAODzA4gA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CellReadyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_mrkr_CellReadyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__-jgDBmfiUmEu0GZmK8-5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CellReadyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_SpvmUFoDl0q5J75fLE_V5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ESA9zEAYIUOC4PrJsuQIKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_18qBhBV9dU2bbek_wtQbrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_1TeDARXsOkC9hEbasgXmxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_Ek7VnObDF0qwBQZljA5lrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_CellReadyMember_EXj1TZHoG0iefhOIN4rydg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:CellReadyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_y1zLnl6EqUepjN6-dcbOxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_CellReadyMember_4FOpwyVQrECS-MHeaC1tvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:CellReadyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Sob6q5KlDEqJgHe6539l1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Odf2gYh8fUCDHWMqpklBpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalTaxJurisdictionOtherMember_X-zB0CIm-UCdX3pra_QnCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalTaxJurisdictionOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_stpr_TX_Rjqllw7i7k-FAGtEiFvgPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalTaxJurisdictionOtherMember_RP8A9ma7LU69CXCfisa1tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalTaxJurisdictionOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_stpr_TX_B-Dm5j-e00KX7oWR9bXJxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_hpcaPdhzZESFYUuK8cOwRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_XnQVMZBaJUW4WC5UTNTybw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_ka9khI5BP0KG3WlDMZO44g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_irhoM80iL0yHiHWgBsAv_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mrkr:NationalInstitutesOfHealthNationalCancerInstituteGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_FdaGrantMember_faf3JBchfUmF26_0A8acNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mrkr:FdaGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_mrLGat3Upk2fb1jB4KArIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mrkr:CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_-Zh_8JjoQEG-VAt8uJFkjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_mMsw9pTVxUmPUqQGanMoDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_WeW3pJ_MmkC27F7VxYyoRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mrkr:NationalInstitutesOfHealthNationalCancerInstituteGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_YiV5PV-xXEmJq6NEHauChA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">mrkr:CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_X_oxJZvmIEKv7qs6HvnyNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_cca_sB7gSU6dxZHLZj013g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PrivatePlacementWarrantMember_cafAhZMIDkSljx-lvFkWag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mrkr:PrivatePlacementWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_Nng2hqeyCUeMaAu9fclCqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mrkr:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_19_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PrivatePlacementWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_On3uaIjHpUqZni5K7dWfLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mrkr:PrivatePlacementWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-19</instant>
        </period>
    </context>
    <context id="As_Of_12_19_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8uiS2_V-yU681VJlw1Q9uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mrkr:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-19</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PrivatePlacementWarrantMember_A7nPIRhbOkCSTYcVdsqkJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mrkr:PrivatePlacementWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_jieysXAEz0G_tGMRFzVAhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mrkr:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_jtXp7bckLE2CuJhkJ9PNfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_MqvvcKTOj0eV0u3Nau83Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aSuKfM4-akyKvKZsn6tCGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_aIjiS1PliUO1FmEZTPTlFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_B2nRyEV--0GS0eskNh548A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Ey1Xk4v6f0yORZDZoGT7FA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1iM8joIEOEKotgV079FgPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_j5D-je0g6E6fJSRo58Oxow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Cf4uLI9Y-kqC1zLcm3sQTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pYHphuyyu066BcjVFoJ8QA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xtMtVYunjEei0jSpfl8XCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C8n1YFIWQkCqU7lJuKSmFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_oLyCD0BiIEeiK_BggHiIyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_17_2025_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_XfMX7dcV3UWRP3Ne6O4l6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentiveAward2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-17</instant>
        </period>
    </context>
    <context id="As_Of_2_12_2025_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_K5BoRY6DdkuHU8WoQnkViA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentiveAward2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-12</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_FwxvILLeMU2KaVIewcISUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_at2LqTEclEeq_pEAvIINhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_22_2024_To_2_22_2024_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_66lUgXxPyUi3q214hjo-SQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:CellReadyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-22</startDate>
            <endDate>2024-02-22</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineLicenseAgreementMember_Eej9dmqQ10SaSsQkQOu8NQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrkr:BaylorCollegeOfMedicineLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineLicenseAgreementMember_mKK3QAV17UG31xtSaZ_jxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrkr:BaylorCollegeOfMedicineLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_WilsonWolfManufacturingCorporationMember_SnKdFpBTG0ewLmW3QKOiwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_zGmyKdpTO0WFcYUPxTzPtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:CellReadyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineMember_ip2nTF_Fk0CYXX-yEMZW9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrkr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mrkr_WilsonWolfManufacturingCorporationMember_88XPTdVeZEeIbHu_8g-p9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_c3M_pD1k30WAzZa10zvfBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:CellReadyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineMember_-usF9LGyt0GIxeKFzPNwug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrkr:BaylorCollegeOfMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_K0kZGOM0S0iI7apUnHkXog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrkr:CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2024_To_8_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_he6YWLaAFUG7GJ38OI7D1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2024_To_8_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember__Ch-QALgtkqd7AZY24MzHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_WnNM8CWplk24UBwBqIF4_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_MnQUj6Ma20ugl93GMps1dw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:FdaGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_us-gaap_RelatedPartyTransactionAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_AFB5466R20GWPhFeBp81GQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrkr:CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_mjoYIWkR20GbZX_dLT8n1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthNationalCancerInstituteGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_J7SfSASjZE-svWLtQE3gbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrkr:CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_27_2025_To_3_27_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_CellReadyAgreementMember_JD_kClq_cE2FGVMW6U031Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrkr:CellReadyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-27</startDate>
            <endDate>2025-03-27</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_ziCCxC0XiEqj3xjfTYljxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_670n_eqWFEyvZOe0MstmvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_v3gveAJvr0u79DQtC91MKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_qnTBapqjVEaOu5WEAR6N1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:NationalInstitutesOfHealthNationalCancerInstituteGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_ZoSbOHwhNE-hXUpvIJbwbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:FdaGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_AdditionalCpritGrantMember_nxUvKve8xkGalcxFRXPFew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrkr:AdditionalCpritGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2024_To_11_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_nPc36OB43EulxDCPK9rlUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCoAndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_Rn5SiIOVNEaGW-wHHWjNLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_U2becBy6kUyXW95FuWcLrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mrkr:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2025_To_12_31_2025_Ivl427bMU0uiB1nIEy7zew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2025_7SBk-9LcdEuP16DOVYgcxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_16_2026_adwy4cFtS0uxZ5Iqr7vnRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2026-03-16</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      id="Hidden_rTRE-7XNW0K4cyqC2oQcTw">http://fasb.org/us-gaap/2025#RelatedPartyMember</us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration>
    <us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      id="Hidden_93Ikgu4vrE69qFMe0Zr1Lg">http://fasb.org/us-gaap/2025#RelatedPartyMember</us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      id="Hidden_88CJo7lppUKf_UurEb1KRQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      id="Hidden_WjgPJmQyyEWPfo3nuOI25g"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      id="Hidden_dTBoH9MfTE64AKs-oLTQIA">http://fasb.org/us-gaap/2025#RelatedPartyMember</us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration>
    <us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      id="Hidden_SzDJsYRNAk-RRfM_aKodzg">http://fasb.org/us-gaap/2025#RelatedPartyMember</us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tc_bZHKzMsyNEK5R2EWwRW9hQ_2_1">0001094038</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tc_-1MWiyMaqUCculqnyPQZKw_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tc_wyaARvKeb0qHDOA5Lg-8VQ_4_1">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tc_u5ge9XNLPUCKcLAEGhMKsw_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tc_YaiGqrT_bkCiR0_lboPU5w_6_1">false</dei:AmendmentFlag>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Hidden_8t_mC5yobUSo0_SotysiiQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">62159</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_19_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PrivatePlacementWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_On3uaIjHpUqZni5K7dWfLQ"
      decimals="3"
      id="Hidden_vlSFv0gqUE-B3bsGUvHgiw"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">3.199</us-gaap:SharesIssuedPricePerShare>
    <dei:DocumentType
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_cW-lt-6BGESoOgExXsfKlA">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tc_BU7EjmJXYUeFsiXijaGYuw_0_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_VidWjcGnZkq90dJCi8gO5Q">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tc_iQ1NGIm8WkST-eEs3UduaQ_6_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_gS8P3WhvOkm26eJHl37zyw">001-37939</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_LsLoK0LDX0qEx-W28Ge3Bw">MARKER THERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tc__z8gOWLMIUujU1vBW5so1w_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tc_2ScVrPbnnkW8pCYiJHGS2g_0_2">45-4497941</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_TwQp7eXGaUq0o1aB_UnqTw">2450 Holcombe Blvd, TMC Partners Office 1.311</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_HjRROSup5kyvc95eEXhNzw">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_boyqoD_xwU6OKHqr1UwzTQ">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tc_MOf6ur2NvUuwv2COBR7Q-g_3_2">77021</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_GHakC3a0ak21fxttkg_S2w">713</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_G9e8r8P24UuvZzZO3S5I3w">400-6400</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tc_frmzYKUC2k6Koo-9ixCziA_1_0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tc_VMLt_vG8pkO4gnCyQg5wvA_1_2">MRKR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_tR_8331b50OIYzWw7JtmvA">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_otiVyJxaD0qpDdFoRucp5g">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_L7wrfVJX8USN4EpW9urVYQ">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_d_hi4FfSwUW_wO4-r5HauQ">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_GvfnUgIqlEG3M0jFp_UigQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tc_vRGKFz588k6yPNRdKbtHkw_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tc_tKeigqAj4kS6h_p6fN2yaQ_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tc_3t3owbm8WUilkEUfsitfQw_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_YjWuHgfUjUuE7r_VgJrOPQ">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_rW4n31Hfp0WZPqnlEsYl9Q">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_pX9FSev7gkWW8hGbzymHWg">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2025_7SBk-9LcdEuP16DOVYgcxw"
      decimals="0"
      id="Narr_SpVhx60BzE6tVNaUmY9Aew"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">17312000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_16_2026_adwy4cFtS0uxZ5Iqr7vnRw"
      decimals="INF"
      id="Narr_OcOGn227ekS3S6QI8T1jPw"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">16673127</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_H2llRE63FEqvchuwT7LraA">&lt;span style="font-size:7pt;"&gt;Portions of the registrant&#x2019;s proxy statement relating to registrant&#x2019;s 2025 Annual Meeting of Stockholders (the &#x201c;Proxy Statement&#x201d;) to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than 120&#160;days after the close of the registrant&#x2019;s fiscal&#160;year, are incorporated by reference in Part&#160;III of this Annual Report on Form&#160;10-K. Except with respect to information specifically incorporated by reference in this Annual Report on Form&#160;10-K, the Proxy Statement is not deemed to be filed as part of this Annual Report on Form&#160;10-K&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_hlO_rRF38U6Cu1innGqY4g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;We operate in the biotechnology sector, which is subject to various cybersecurity risks that could adversely affect our business, financial condition, and results of operations, including intellectual property theft&#x37e; fraud&#x37e; extortion&#x37e; harm to employees or customers&#x37e; violation of privacy laws and other litigation and legal risk&#x37e; and reputational risk. We have implemented a risk-based approach to identify and assess the cybersecurity threats that could affect our business and information systems. Our cybersecurity program is aligned with industry standards and best practices, such as the National Institute of Standards and Technology (&#x201c;NIST&#x201d;) Cybersecurity Framework. We expect the third-party vendors that provide our IT services to use various tools and methodologies to manage cybersecurity risk and to monitor and evaluate our cybersecurity posture and performance on an ongoing basis through regular vulnerability scans, penetration tests and threat intelligence feeds. We expect to require third-party service providers with access to personal, confidential or proprietary information to implement and maintain cybersecurity practices consistent with applicable legal standards and industry best practices.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Our business depends on the availability, reliability, and security of our information systems, networks, data, and intellectual property. Any disruption, compromise, or breach of our systems or data due to a cybersecurity threat or incident could adversely affect our operations, customer service, product development, and competitive position. They may also result in a breach of our contractual obligations or legal duties to protect the privacy and confidentiality of our stakeholders. Such a breach could expose us to business interruption, lost revenue, ransom payments, remediation costs, liabilities to affected parties, cybersecurity protection costs, lost assets, litigation, regulatory scrutiny and actions, reputational harm, customer dissatisfaction, harm to our vendor relationships, or loss of market share.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_9DwI1SofM0mp5gAWgbZU6g">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_3Tte3TeNvEO0HFMQMkaRog">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_Z18Kq6VX_kOYzTddN7SIWA">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_mRn91iVOlUGa0Ad2g_dqHA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Our board of directors addresses our cybersecurity risk management as part of its general oversight function.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by various members of our management team, third party service providers and other employees, who we believe have a combination of relevant expertise, experience, education and training.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Certain members of our management team are responsible for hiring appropriate personnel and third-party IT service providers, helping to integrate cybersecurity risk considerations into our overall risk management strategy, communicating key priorities to relevant personnel, approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including in some cases to our executive team. Our cybersecurity incident management team, and other individuals as needed, work to help us mitigate and remediate cybersecurity incidents of which we are notified. In addition, our incident response processes include a procedure for reporting certain cybersecurity incidents to the board of directors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The board of directors receives regular reports from management concerning our cybersecurity risk management program. The board also receives various summaries and/or presentations related to cybersecurity threats, risks and mitigation.&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_9byzhs_OX0qwR74nHpJY7Q">board of directors</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_HegNGGY990u_Q5hDC4y5yg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by various members of our management team, third party service providers and other employees, who we believe have a combination of relevant expertise, experience, education and training.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Certain members of our management team are responsible for hiring appropriate personnel and third-party IT service providers, helping to integrate cybersecurity risk considerations into our overall risk management strategy, communicating key priorities to relevant personnel, approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including in some cases to our executive team. Our cybersecurity incident management team, and other individuals as needed, work to help us mitigate and remediate cybersecurity incidents of which we are notified. In addition, our incident response processes include a procedure for reporting certain cybersecurity incidents to the board of directors.&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_A2BLiH9JXU2_V6IOiKf8_A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by various members of our management team, third party service providers and other employees, who we believe have a combination of relevant expertise, experience, education and training.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_2gN6k0_6PUCktf9n2sTf0g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by various members of our management team, third party service providers and other employees, who we believe have a combination of relevant expertise, experience, education and training.&lt;/p&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_nf2IInDCO0qfMgj6vHedUA">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_4gzHWrSeP028KfrYd7Ah0A">members of our management team</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_sw9eeOHTjE6CZ4ZXVeDMhg">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_bAvuC0xiqEyM5uu-kHzeMg">Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including in some cases to our executive team. Our cybersecurity incident management team, and other individuals as needed, work to help us mitigate and remediate cybersecurity incidents of which we are notified. In addition, our incident response processes include a procedure for reporting certain cybersecurity incidents to the board of directors</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb__H_a-9_z-ESHnFD-2o3pFg">The board of directors receives regular reports from management concerning our cybersecurity risk management program.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_cmIXVEyI-EialjQpg2CfuQ">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_Ivl427bMU0uiB1nIEy7zew"
      id="Narr_PkZCWaIiakmv_lgry3zSUA">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_Ivl427bMU0uiB1nIEy7zew"
      id="Narr_ZF7VZrFKgUe7dafG_MK6HQ">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_Ivl427bMU0uiB1nIEy7zew"
      id="Narr_iDv5JAQC10mOpy1k9xjvdg">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_Ivl427bMU0uiB1nIEy7zew"
      id="Narr_3yt9t5-xhkalWUs5unbIrQ">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_iYvuBwbgGUOCqR7Vp6rM7g">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_Mgw10Jdqa0ywQboxWkRqow">688</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_WHCzMS8Lgka1O8ZPZRHwOA">Marcum LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_zM0XibSmyUaZ03RooY-7KQ">Houston, TX</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_ecJ6Gf0NKUmpb4PFjSqSjw_5_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">16068048</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_NeHvui_X6kGpGzx_FhE3TQ_5_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">19192440</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_pW0jHLGRjUOFAYSdDjOZsA_6_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">974799</us-gaap:RestrictedCashCurrent>
    <mrkr:PrepaidExpenseAndDepositsCurrent
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_MDpaBJ7b506Lg7y-_bYoXw_7_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">658750</mrkr:PrepaidExpenseAndDepositsCurrent>
    <mrkr:PrepaidExpenseAndDepositsCurrent
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_d6Pa2lzgj0iLHY89vWZitA_7_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">483717</mrkr:PrepaidExpenseAndDepositsCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_SJZeJFkKqUSyfQrDXTDFmg_8_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1369400</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_xlk7_Vj2mkOU4ke8NmWL5w_8_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">2346703</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_GDnHTmWAokaHsZfbntmQHQ_9_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">19070997</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_Z9QFL934nEal0v0PwxiuDg_9_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">22022860</us-gaap:AssetsCurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_RUvsOR9xmEWAS1QDf-MqhQ_10_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">19070997</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_bfzsCoyXtU28rL0eN7hr1A_10_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">22022860</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_pTxqtAjOEUaH2RUrFrIHtA_14_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1299384</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_aQ9TrJWsVkqWzCy_16YNTQ_14_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1753954</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_V_cYeq-DOkGjD3cg9zabDw_15_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1710500</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_pIGHiEwE50WbLUR___T8sw_16_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">974799</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_-IoLOEtBKUSiZBgIb2URYg_17_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">2274183</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_mqy6yiSB50Oo7ER3NZz6Uw_17_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">3464454</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_39W2qFHZO0ORio4-qx2zXQ_18_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">2274183</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_OMogS1metESy2lPSN-L-NA_18_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">3464454</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="INF"
      id="Narr_gtY4G74am0GjCBp-AVkBPw"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="INF"
      id="Narr_6CeaBFH7UE2k9LUX-p2scw"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="-6"
      id="Narr_zTogDxxK-ESHIaN41LgRfQ"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="-6"
      id="Narr_d_Avsni2VEiw4VVXgnIZeA"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="-6"
      id="Narr_F6FIorjHFk6CQs6gvY0ShA"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="-6"
      id="Narr_uj5yAzXR9EWzO4J-jUIRIA"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="-6"
      id="Narr_5ZTA8xPLXkOOii54CHkW9Q"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="-6"
      id="Narr_WxXC4T3v5k6gEcYu_9cr4w"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="INF"
      id="Narr_8u_X-lPoVEyY-2ImB9uF0A"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="INF"
      id="Narr_4hLj0xE_YUWIRLK_0KeOIA"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="-6"
      id="Narr_ShF1VlBtykizk1mZYHx1Yw"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="-6"
      id="Narr_2ZJU4iAs50K7rFinFVTgzA"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="-5"
      id="Narr_9WucUPsjsE-hGSQu2xwBzg"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">16700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="-5"
      id="Narr_LoGvmiCZ50K1LOWL1H50rQ"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">16700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="-5"
      id="Narr_Hwbf6_NMvkuxCMLvqUM3hA"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">10700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="-5"
      id="Narr_JrvyoQtw_kurFPNEYtRYNQ"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">10700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_UtBgvpX9tE6v2QkqDqKGng_22_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">16672</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_s2w0bb1W4EuNNbXsCPxoKQ_22_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">10708</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_jjPolNdKQkKm-0p7o8F6KQ_23_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">475960940</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc__8D-GtvxpU6GxTzfjxXHoA_23_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">465564876</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_zAr_S9IcPEGzrk--tW-saQ_24_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-459180798</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_OoZoXM9Aak-j8G8jrBNAYw_24_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-447017178</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_I6LClqHHWEqHPU-C0nFm_w_25_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">16796814</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_S1Ab77yjq02d-fJ4HedVVA_25_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">18558406</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_y9RxYmgvBUC_4DqpYt-kBg_26_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">19070997</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_7IHY8BYAyku8vTk9KBoX_A_26_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">22022860</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_us-gaap_GrantMember_6LnqjjsZJEiYA6ZxeN_-8Q"
      decimals="0"
      id="Tc_RvBDLkxY9E-4qmIKYKD3gQ_5_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">3546669</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_GrantMember_UiYnDW3Fo0WMqnl0BxBg_w"
      decimals="0"
      id="Tc_GsWmZESBCEixQqEkTy2h6Q_5_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">6591080</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_8YsX6fCEzE6jwiDhs_ynuA_6_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">3546669</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_sXWKaFlxCECcKyBEoq8Emg_6_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">6591080</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_grQpKZAm7kCon9Y0GNtIWQ_8_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">11799154</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_54n0yvjXTkO8MVCQZ7Vrwg_8_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">13467845</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_SbjyK_6ASEmg9dd1ShEFvA_9_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">4184806</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_sTcLrvosUkGg_NYgE8i9Fw_9_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">4241607</us-gaap:GeneralAndAdministrativeExpense>
    <mrkr:GainLossOnEarlyTerminationOfVendorAgreement
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_brLzJKPcdUmGmU808-7Dxw_10_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-453135</mrkr:GainLossOnEarlyTerminationOfVendorAgreement>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_aaL8irJ-ok2nhin2B5iu3A_11_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">16437095</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_6jaAvPmpR0WMU8yHb_U62w_11_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">17709452</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_8qVAxceYUk-kjC67mSmZTw_12_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-12890426</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_pH7PwNCuwEuDAtRPNa-ICw_12_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-11118372</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_qKVBnZhxJkW_Fz2SyN56rA_14_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">594206</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_9PJPjW485E-bVV0PeX44tQ_14_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">437010</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_uy1A9YIoDkC8DZg1S5Y5_Q_15_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">117444</us-gaap:OtherNonoperatingIncome>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_SdH9W6uSJ0WxAIQLCLJLmg_16_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-12178776</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_xT88g5WZkkOBAEk3nsPMeg_16_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-10681362</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_qajmBkwVKEueZ6_a__gviA_17_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-15156</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_rIz2NtmnQkyPdCkBAef_Sw_17_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">49953</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_qGYfW9g3PEe8EcL_h0hyuw_18_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-12163620</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_5TxrBhuop0K6btObzJfXzg_18_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-10731315</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="2"
      id="Tc_ALr4EYNwbk-3InkqLhmkCw_20_3"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">-0.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="2"
      id="Tc_ALr4EYNwbk-3InkqLhmkCw_20_3_2"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">-0.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="2"
      id="Tc_w7G9UutHb0Gi564kFykLyw_20_6"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">-1.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="2"
      id="Tc_w7G9UutHb0Gi564kFykLyw_20_6_2"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">-1.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_NmBRhDCOyEeNsKdN9ZbZkA_23_3"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">15310308</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_d4eU-_hXw0m4ulDkYbT37w_23_6"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">8980207</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_ENrzgHso5kGPU_3khRzmQQ_24_3"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">15310308</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_CZ_6diWb3U2GTvQQmnYu7g_24_6"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">8980207</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tksY2KuphU-6mtLP78kkWg"
      decimals="INF"
      id="Tc_MMATFSdJ006I8BVyPWnPsw_4_2"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">8891420</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tksY2KuphU-6mtLP78kkWg"
      decimals="0"
      id="Tc_pC1fyMTYg0ylNcNaXdWtWw_4_5"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">8891</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oPOrqZBAU0ezQq1EPL4X1A"
      decimals="0"
      id="Tc_JphcB_G0ukqVfL7BiyLQJg_4_8"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">450329515</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_84AY7Y29u0Wa9RpjQCDF4A"
      decimals="0"
      id="Tc_d6QgzlS9t06nADqy85JXGQ_4_11"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-436285863</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_jtXp7bckLE2CuJhkJ9PNfg"
      decimals="0"
      id="Tc_BP2MXr2G5kWh38eeGzXdMQ_4_14"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">14052543</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C8n1YFIWQkCqU7lJuKSmFQ"
      decimals="INF"
      id="Tc_JDzWCjLM0EiTTKQkmj01UA_5_2"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">8178</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C8n1YFIWQkCqU7lJuKSmFQ"
      decimals="0"
      id="Tc_GdqifS6S_UGgczpKK6Oyrg_5_5"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">8</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xtMtVYunjEei0jSpfl8XCA"
      decimals="0"
      id="Tc_41nJxvqdrkOCUX2d0Asiqw_5_8"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">36894</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_nGTBz3NQwEuF59vXKpIBBw_5_14"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">36902</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C8n1YFIWQkCqU7lJuKSmFQ"
      decimals="INF"
      id="Tc_GKnimRz_b0ehGEfZ7ag-Lw_6_2"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">25602</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C8n1YFIWQkCqU7lJuKSmFQ"
      decimals="0"
      id="Tc_A-T2cdfKLU-aQh8Sk1BXng_6_5"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">25</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xtMtVYunjEei0jSpfl8XCA"
      decimals="0"
      id="Tc_oLU-XqiRj0W8H4_9ro7lEQ_6_8"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">62134</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_Ugdi7UJf4UKII8elAVMtiA_6_14"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">62159</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="-5"
      id="Narr_kFmCkVW0L0u1ga0gHNBLbQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <mrkr:StockAndWarrantsIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C8n1YFIWQkCqU7lJuKSmFQ"
      decimals="INF"
      id="Tc_qOzPbs1dLEuPzx2cmi8eEA_7_2"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">1783805</mrkr:StockAndWarrantsIssuedDuringPeriodSharesNewIssues>
    <mrkr:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_C8n1YFIWQkCqU7lJuKSmFQ"
      decimals="0"
      id="Tc_J1perH4Vk0mEH_r9vYM8Kg_7_5"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1784</mrkr:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <mrkr:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xtMtVYunjEei0jSpfl8XCA"
      decimals="0"
      id="Tc_m-pdauX2zEK-Ysi31SYGOw_7_8"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">14890469</mrkr:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <mrkr:StockAndWarrantsIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_q_JsCuDj4kies63ljImM9A_7_14"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">14892253</mrkr:StockAndWarrantsIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_xtMtVYunjEei0jSpfl8XCA"
      decimals="0"
      id="Tc_qAU4psrSwEeEvpql1kbGSA_8_8"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">245864</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_8rrvZ9j9F0y-P9RhypBaTg_8_14"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">245864</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Odf2gYh8fUCDHWMqpklBpg"
      decimals="0"
      id="Tc_LdaxXnTHT0WbTZe7zyWWJA_9_11"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-10731315</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_BCV_arOBgUm6j17scszj4A_9_14"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-10731315</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IyxgTtJMsUeI7g0JQzRu5w"
      decimals="INF"
      id="Tc_GVL9a_OYzUmuP4SGpcPCsg_10_2"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">10709005</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IyxgTtJMsUeI7g0JQzRu5w"
      decimals="0"
      id="Tc_xhgjdkR3Z0SIMQk2-ZBBzw_10_5"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">10708</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ewnb_9qGskmiSR_2gvsz1A"
      decimals="0"
      id="Tc_g7Yz1DmjEE-JgXbjts0maw_10_8"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">465564876</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E0qy7Vq1QkiOgpqHJZmV-A"
      decimals="0"
      id="Tc_jcSxRedNMEKgkdB4M-lFug_10_11"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-447017178</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_iFDplPxI60iNwy8vq4pugw_10_14"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">18558406</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pYHphuyyu066BcjVFoJ8QA"
      decimals="INF"
      id="Tc_RB-gOypkYESzPJlBLUhY7Q_11_2"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">5358292</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pYHphuyyu066BcjVFoJ8QA"
      decimals="0"
      id="Tc_aYPFkkaN3EOA0DjV4e35CQ_11_5"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">5359</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XT2HAsu1XEKincjWBVb39A"
      decimals="0"
      id="Tc_0D1sBBcWJUOTdea38SKemw_11_8"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">9858524</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc__LrFyXTmA024OPhs0fVoLg_11_14"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">9863883</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mrkr:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pYHphuyyu066BcjVFoJ8QA"
      decimals="INF"
      id="Tc_fYmjNV3UF0yfb6jgGdcofA_12_2"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">605830</mrkr:StockIssuedDuringPeriodSharesWarrantsExercised>
    <mrkr:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pYHphuyyu066BcjVFoJ8QA"
      decimals="0"
      id="Tc_M5Q3RwaqxUe8VDJbnAztBA_12_5"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">605</mrkr:StockIssuedDuringPeriodValueWarrantsExercised>
    <mrkr:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_LHGrURqmz0OU61e-zHkY-A_12_14"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">605</mrkr:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XT2HAsu1XEKincjWBVb39A"
      decimals="0"
      id="Tc_HsoeN6Y3FE2-iakctE8sgA_13_8"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">537540</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_hIlJl5WUYEemK9hVaOyp-A_13_14"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">537540</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Sob6q5KlDEqJgHe6539l1A"
      decimals="0"
      id="Tc_sfRWjHB45kOHfyMcXEM9_g_14_11"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-12163620</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_1gwrRS-MHUiAseZ02y9scA_14_14"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-12163620</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_H1iRzvGfK0C3IBU4YuN-sg"
      decimals="INF"
      id="Tc_keeaFMMADE6FGGMpja1EKg_15_2"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">16673127</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_H1iRzvGfK0C3IBU4YuN-sg"
      decimals="0"
      id="Tc_-d-ZIvtQaEy0kZTXuHqdYg_15_5"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">16672</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HXX7qp5MoUuH8nof-BnwCA"
      decimals="0"
      id="Tc_flRbrhCapUijuuA3L6AF4g_15_8"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">475960940</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gV71OOam90epk_Du2IQJ0A"
      decimals="0"
      id="Tc_IhlqStQ4g0au-nJKjPO6Hg_15_11"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-459180798</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_mMSOoeexRESxRLsRPpHZVQ_15_14"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">16796814</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_9QxzdRkuGkqpm8xTTVrxsg_5_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-12163620</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_kUTSH1cx906e4hupFEpE-A_5_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-10731315</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_vvm4YQwJtUWYF7t3nomy2w_7_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">537540</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_a-MqfkfkOU66K35-gMr07w_7_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">245864</us-gaap:ShareBasedCompensation>
    <mrkr:IncreaseDecreaseInPrepaidExpenseAndDeposits
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_-kmPZvwYN0qta8eHpDWwdA_9_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">175033</mrkr:IncreaseDecreaseInPrepaidExpenseAndDeposits>
    <mrkr:IncreaseDecreaseInPrepaidExpenseAndDeposits
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_XttCq-E810SpT2qzdHYDmA_9_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-504409</mrkr:IncreaseDecreaseInPrepaidExpenseAndDeposits>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_fta45bhhLEGiRYr74shQzA_10_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-977303</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_rE3PVitleU6HN8r6_hHAeQ_10_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1318888</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_juhykJpTkEGUT5YMU1-dyA_11_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-1710500</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_0ipcakS_W0GOSt6vm8jX1g_11_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">380845</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_sJ76207CcEq_PDv5ldsRKw_12_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-454570</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_zkv0yNcFPUyIG3Q1zFzhpg_12_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">8761</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_GXmJsXHbUke1dLNDJmi-0Q_13_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">974799</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_0ip_XSWStkef3Z7uutnY7w_14_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-12014081</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_6vvhndHvVkG8TsSUc4Fpwg_14_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-10910324</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_UuzZPDiZxEKU8a7apK-lpQ_16_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">9863883</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_A641OrpkkESTMaucWh7Cig_16_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">14929155</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mrkr:ProceedsFromWarrantsAndStockOptionsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_FC-WNt1-UUaTV_XadijVrQ_17_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">605</mrkr:ProceedsFromWarrantsAndStockOptionsExercised>
    <mrkr:ProceedsFromWarrantsAndStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_6YNFkcGFREe4mMrNuLkP7A_17_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">62159</mrkr:ProceedsFromWarrantsAndStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_3BAZeDtFrEKktXU0vXj1ew_18_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">9864488</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_kUR934ByaEqlPwNjwR_Szw_18_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">14991314</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_taRqS-nVik-UvJZm3xpFJA_19_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-2149593</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_Ps7QaXDfAky88kCY5XSDNw_19_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">4080990</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_-tfqTbbsHEG6g5ANPCuLIw_20_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">19192440</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_jtXp7bckLE2CuJhkJ9PNfg"
      decimals="0"
      id="Tc_yuw9EofJQ02RvoShQlBMvg_20_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">15111450</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_IwTOM66aJUWPgZ49sF-NOg_21_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">17042847</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_QHU-qJr_0UWshZpIb-CoIw_21_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">19192440</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_Ftj2ApYDLE6QfLLEah6SKQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;1:&#160;&#160;&#160;&#160;NATURE OF OPERATIONS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Marker Therapeutics, Inc., a Delaware corporation (the &#x201c;Company&#x201d; or &#x201c;we&#x201d;), is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company&#x2019;s multi antigen recognizing (&#x201c;MAR&#x201d;)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Currently, the Baylor College of Medicine (&#x201c;BCM&#x201d;) supplies the Company with MT-601, the Company&#x2019;s lead Multi-Antigen Recognizing (MAR)-T cell therapy in anticipation of the commencement of the Company&#x2019;s larger pivotal trial for Lymphoma.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On June 16, 2025, the Company entered into a Statement of Work (the &#x201c;SOW&#x201d;) with Cellipont Bioservices (&#x201c;Cellipont&#x201d;), a leading cell therapy Contract Development and Manufacturing Organization (&#x201c;CDMO&#x201d;), for the manufacturing of MT-601. Pursuant to the SOW, Cellipont will provide technology transfer and cGMP manufacturing services to support the scale-up and production of MT-601 for the Company&#x2019;s APOLLO study.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_W0euYb2vxEaUbVoZYZ4hlA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;2:&#160;&#160;&#160;&#160;FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;As of December 31, 2025, the Company had cash, cash equivalents,&lt;/span&gt; &lt;span style="font-style:normal;font-weight:normal;"&gt;and restricted cash of approximately &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$17.0&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; million. The Company&#x2019;s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company&#x2019;s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing; successfully progress its product candidates through preclinical and clinical development; obtain regulatory approval of one or more of its product candidates; maintain and enforce intellectual property rights; develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity, debt financings and grants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In August 2021, the Company entered into a Controlled Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement (the &#x201c;ATM Agreement&#x201d;) with Cantor Fitzgerald &amp;amp; Co. and RBC Capital Markets, LLC (the &#x201c;Sales Agents&#x201d;), pursuant to which the Company could offer and sell, from time to time at its sole discretion through the Sales Agents, shares of its common stock having an aggregate offering price of up to $75.0 million. Any shares of its common stock sold were issued pursuant to the Company&#x2019;s shelf registration statement on Form S-3 (File No. 333-258687), which the SEC declared effective on August 19, 2021. However, our use of the shelf registration statement on Form S-3 was limited for so long as we were subject to General Instruction I.B.6 of Form S-3, which limited the amounts that we could sell under the registration statement and in accordance with the ATM agreement. The Sales Agents were entitled to compensation under the Sales Agreement at a commission rate equal to 3.0% of the gross sales price per share sold under the ATM Agreement, and we provided each of the Sales Agents with indemnification and contribution rights. During the year ended December 31, 2024, the Company sold 8,178 shares of its common stock under the ATM Agreement for proceeds of $0.04 million. On June 10, 2024, the Company provided notice of its termination of the ATM Agreement with Cantor Fitzgerald &amp;amp; Co. and RBC Capital Markets, LLC. The Company is not subject to any termination penalties related to the termination of the ATM Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In November 2024, the Company entered into an At The Market Offering Agreement, or the Sales Agreement, with H.C. Wainwright &amp;amp; Co. LLC, relating to the sale of shares of its common stock having an agreement offering price of up to $11,431,713 from time to time through H.C. Wainwright &amp;amp; Co. LLC. Any shares of common stock sold will be issued pursuant to the Company&#x2019;s shelf registration statement on Form S-3 (File No. 333-283512), which the SEC declared effective on December 6, 2024. However, the Company&#x2019;s use of the shelf registration statement on Form S-3 will be limited for so long as it is subject to General Instruction I.B.6 of Form S-3, which limits the amounts that the Company may sell under the registration statement and in accordance with the ATM agreement. H.C. Wainwright &amp;amp; Co. LLC will be entitled to compensation under the Sales Agreement at a commission rate equal to 3.0% of the gross sales price per share sold under the ATM Agreement, and the Company&#x2019; has provided H.C. Wainwright &amp;amp; Co. LLC with indemnification and contribution rights. Between July 17 and 21, 2025, the Company sold 1,624,075 shares of common stock pursuant to the ATM &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Agreement for net proceeds of $4.5 million, after deducting agent commissions, at an average price of $2.87 per share. On August 26, 2025, the Company sold an additional 3,734,217 shares of common stock pursuant to the ATM Agreement with H.C. Wainwright &amp;amp; Co., LLC for net proceeds of $5.4 million, after deducting agent commissions, at an average price of $1.48 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from the CPRIT to support the Company&#x2019;s clinical investigation of MT-401 (the &#x201c;CPRIT AML Grant&#x201d;). Through the date of this filing, the Company has received $11.8 million in funds from the CPRIT AML Grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In September 2022, the Company received notice from the FDA that it had awarded the Company a $2.0 million grant from the FDA&#x2019;s Orphan Products Grant program to support the clinical investigation of MT-401 for the treatment of post-transplant AML (the &#x201c;FDA Grant&#x201d;). Through the date of this filing, the Company has received $1.2 million in funds from the FDA Grant. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In May 2023, the Company announced that it had received a $2.0 million grant from the National Institutes of Health (&#x201c;NIH&#x201d;) Small Business Innovation Research (&#x201c;SBIR&#x201d;) program to support the development and investigation of MT-401 for the treatment of AML patients following standard-of-care therapy with hypomethylating agents (the &#x201c;SBIR AML Grant&#x201d;). Through the date of this filing, the Company has received $1.7 million in funds from the SBIR AML Grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The above funding agencies have agreed to continue their financial support and to shift funds to the MT-401-OTS program.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In June 2024, the Company received notice of a $2.0 million grant over a 2-year period from the National Institutes of Health SBIR program to support control over tumor immune escape in pancreatic cancer using a dual T cell product strategy (the &#x201c;Decoy Grant&#x201d;). Through the date of this filing, the Company has received approximately $0.5 million in funds from the Decoy Grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In August 2024, the Company received notice of a $2.0 million grant from the NIH SBIR program to support the clinical investigation of MT-601 in patients with non-Hodgkin&#x2019;s lymphoma (&#x201c;NHL&#x201d;) who have relapsed following anti-CD19 chimeric antigen receptor (CAR) T cell therapy (the &#x201c;SBIR NHL Grant&#x201d;). Through the date of this filing, the Company has received $1.3 million in funds from the SBIR NHL Grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In August 2024, the Company received another $2.0 million grant from the NIH SBIR program to support the advancement of MT-601 in patients with pancreatic cancer (the &#x201c;PANACEA Grant&#x201d;). Through the date of this filing, the Company has received approximately $0.4 million in funds from the PANACEA Grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In December 2024, the Company received notice of an additional $9.5 million grant from CPRIT to support the clinical investigation of MT-601 in patients with metastatic pancreatic cancer (the &#x201c;CPRIT Pancreatic Grant&#x201d;). Through the date of this filing, the Company has received $1.5 million in funds from this grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Refer to Note 5 and Note 9 for grant income receivable and grant income recorded for each grant, respectively, for the periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;On December 19, 2024, the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;), pursuant to which the Company issued and sold in a private Placement the following securities: (i)&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;1,783,805&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; shares of common stock, (ii) Series B Warrants, or Pre-Funded Warrants, to purchase an aggregate of &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;3,247,445&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; shares of common stock in lieu of shares of common stock and (iii) Series A Warrants, or Private Placement Warrants, to purchase an aggregate of &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;5,031,250&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; shares of common stock. The purchase price per share of common stock and accompanying Private Placement Warrant to purchase a share of common stock was &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$3.20&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;, and the purchase price per Pre-Funded Warrant and accompanying Private Placement Warrant to purchase a share of common stock was &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$3.199&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;. The transaction closed on December 23, 2024, with net proceeds from the sale of securities in the Private Placement of approximately &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$14.9&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; million, which does not include any proceeds that may be received upon exercise of any warrants issued in the Private Placement. Both the Pre-Funded Warrants and the Private Placement Warrants were not exercisable until the Company obtained shareholder approval, which was received on March 21, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The Company expects to continue to incur substantial losses over the next several years during its development phase.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Based on the Company&#x2019;s lack of recurring revenues, anticipated uses of cash and historical recurring cash losses from operating activities, and cash, cash equivalents, and restricted cash as of December 31, 2025, and taking into consideration the net proceeds received in July and August of 2025 through the sale of Common Stock pursuant to its ATM Agreement with H.C. Wainwright &amp;amp; Co., &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;LLC (see Note 7), the Company anticipates that it will be able to fund its operating expenses and capital expenditure requirements through the fourth quarter of 2026, assuming no additional grant funds are received, either from new grants or from existing awarded grants. These factors raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Management is considering raising additional capital through the issuance of securities and intends to apply for additional grant funds, which could enable the Company to fund its operating expenses and capital expenditure requirements beyond the fourth quarter of 2026, although no assurance can be given that such capital or existing awarded grants will be earned or future grants will be awarded. The Company&#x2019;s future cash requirements are based on the Company&#x2019;s clinical and research and development plans, timing expectations related to the progress of its programs, and is subject to the Company&#x2019;s ability to effectively manage its costs, raise additional capital, and receive additional grant funds, of which there can be no assurances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The Company&#x2019;s assumptions may prove to be wrong, and the Company could utilize its available capital resources sooner than it currently expects. Furthermore, the Company&#x2019;s operating plan may change, and it may need additional funds sooner than planned in order to meet operational needs and capital requirements for product development and commercialization. Because of the numerous risks and uncertainties associated with the development and commercialization of the Company&#x2019;s product candidates and the extent to which the Company may enter into additional collaborations with third parties to participate in their development and commercialization, the Company is unable to estimate the amounts of increased capital outlays and operating expenditures associated with its current and anticipated clinical trials. The Company&#x2019;s future funding requirements will depend on many factors, as it:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Initiates, continues, or accelerates clinical trials of its product candidates;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;continues the research and development of its product candidates and seeks to discover additional product candidates;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;seeks regulatory approvals for any product candidates that successfully complete clinical trials;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;maintains and enforces intellectual property rights;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;enters into contract manufacturing arrangements with contract manufacturing organizations for clinical manufacturing supply;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;establishes sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates that may receive regulatory approval;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;evaluates strategic transactions the Company may undertake; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;enhances operational, financial and information management systems and hires additional personnel, including personnel to support development of product candidates and, if a product candidate is approved, commercialization efforts.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company&#x2019;s financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In addition to the foregoing, high inflation and concerns about an economic recession in the United States or other major markets have resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company&#x2019;s ability to access capital, which could in the future negatively affect the Company&#x2019;s liquidity. In addition, a recession or market correction due to these factors could materially affect the Company&#x2019;s business and the value of its common stock.&lt;/p&gt;</mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="-5"
      id="Narr_7zrkNozAC0eajQx6PFRiEg"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">17000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="As_Of_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_cca_sB7gSU6dxZHLZj013g"
      decimals="-5"
      id="Narr_tSPWTDQ32kmJ2tjcjz68GQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">75000000</us-gaap:CommonStockSharesSubscriptions>
    <mrkr:CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent
      contextRef="Duration_8_1_2021_To_8_31_2021_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCoAndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_Rn5SiIOVNEaGW-wHHWjNLA"
      decimals="3"
      id="Narr_W8s_TIcvgUi18PeKh330jg"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">0.03</mrkr:CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCoAndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_F38uZMcfxU2b3xquA6y5bA"
      decimals="INF"
      id="Narr_k4jX8bBs8kyeMGAAWr1H-A"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">8178</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCoAndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_F38uZMcfxU2b3xquA6y5bA"
      decimals="-4"
      id="Narr_kfCNdtqCOkyFhp__dHptew"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">40000.00</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="As_Of_11_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_X_oxJZvmIEKv7qs6HvnyNQ"
      decimals="0"
      id="Narr_aNqxrkEwBUGgzd6dpwwe_w"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">11431713</us-gaap:CommonStockSharesSubscriptions>
    <mrkr:CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent
      contextRef="Duration_11_1_2024_To_11_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_nPc36OB43EulxDCPK9rlUA"
      decimals="3"
      id="Narr_lGcEotf7LkqRTVyoQVO0nw"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">0.03</mrkr:CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_17_2025_To_7_21_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_bAz_p3gArkWolV47xKRr_g"
      decimals="INF"
      id="Narr_YAAOTN9ETE24FoiveVE9Ow"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">1624075</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_7_17_2025_To_7_21_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_bAz_p3gArkWolV47xKRr_g"
      decimals="-5"
      id="Narr_ntVdPANX2Ua5qHDiqrgUPw"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">4500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_QeGMQYKwNUKt8wiYv26-mg"
      decimals="2"
      id="Narr_V6I2fYV7pkyzuSBePLCFDA"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">2.87</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_26_2025_To_8_26_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_dZBSMZhgiU-56Poy6Ff-Yw"
      decimals="INF"
      id="Narr_F8p3jjXA0U-mthd3VLZ1lw"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">3734217</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_8_26_2025_To_8_26_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_dZBSMZhgiU-56Poy6Ff-Yw"
      decimals="-5"
      id="Narr_mGRrtzwIpkGMhxlfDpZ0kA"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">5400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_8_26_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_pn_qg4MJb0i_SQXgwMffCA"
      decimals="2"
      id="Narr_0lOtD7xOfEybXeJHw5dFLw"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">1.48</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="Duration_8_1_2021_To_8_31_2021_L0Z_1a2Gv0qiuiDAeZfKZw"
      decimals="-5"
      id="Narr_8n71SqIZCkW8e1W2wi1Z2w"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">13100000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <mrkr:FundsReceivedFromCpritGrant
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="-5"
      id="Narr_MpyXEealt0iv1L58c3icWg"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">11800000</mrkr:FundsReceivedFromCpritGrant>
    <mrkr:GrantReceived
      contextRef="Duration_9_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_MnQUj6Ma20ugl93GMps1dw"
      decimals="-5"
      id="Narr_22uVIIc29UemfZcUfiOLqQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">2000000</mrkr:GrantReceived>
    <mrkr:FundsReceivedFromGrant
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_ZoSbOHwhNE-hXUpvIJbwbg"
      decimals="-5"
      id="Narr_i3wNx8BeLkq9RqJXJ-ZNYA"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1200000</mrkr:FundsReceivedFromGrant>
    <mrkr:GrantReceived
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_WnNM8CWplk24UBwBqIF4_g"
      decimals="-5"
      id="Narr_8QzEfmbEZUmrMSEuv5Pi_w"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">2000000</mrkr:GrantReceived>
    <mrkr:FundsReceivedFromGrant
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_ziCCxC0XiEqj3xjfTYljxg"
      decimals="-5"
      id="Narr_Ozveb9iL0Eao0POHN5n3vg"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1700000</mrkr:FundsReceivedFromGrant>
    <mrkr:GrantReceived
      contextRef="Duration_6_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_mjoYIWkR20GbZX_dLT8n1g"
      decimals="-5"
      id="Narr_nDUL4GG00UKafv57MAB9kQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">2000000</mrkr:GrantReceived>
    <mrkr:GrantAssistanceTerm
      contextRef="Duration_6_1_2024_To_6_30_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_mjoYIWkR20GbZX_dLT8n1g"
      id="Narr_-Kf8Ay-H7060eYwnfhIWdA">P2Y</mrkr:GrantAssistanceTerm>
    <mrkr:FundsReceivedFromGrant
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_qnTBapqjVEaOu5WEAR6N1A"
      decimals="-5"
      id="Narr__Avyc6b830KhC99kJHdkGw"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">500000</mrkr:FundsReceivedFromGrant>
    <mrkr:GrantReceived
      contextRef="Duration_8_1_2024_To_8_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember__Ch-QALgtkqd7AZY24MzHg"
      decimals="-5"
      id="Narr_h0beQeSdzUGgPomApJa9oQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">2000000</mrkr:GrantReceived>
    <mrkr:FundsReceivedFromGrant
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_v3gveAJvr0u79DQtC91MKA"
      decimals="-5"
      id="Narr_AZUS0-O_mEmSPyzmJ14JLA"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1300000</mrkr:FundsReceivedFromGrant>
    <mrkr:GrantReceived
      contextRef="Duration_8_1_2024_To_8_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_he6YWLaAFUG7GJ38OI7D1Q"
      decimals="-5"
      id="Narr_gckctDhVuUCkOqmmzcS2uQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">2000000</mrkr:GrantReceived>
    <mrkr:FundsReceivedFromGrant
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_670n_eqWFEyvZOe0MstmvA"
      decimals="-5"
      id="Narr_JdM3AfTjgkqAGY6eSzGbEg"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">400000</mrkr:FundsReceivedFromGrant>
    <us-gaap:GrantsReceivable
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="-5"
      id="Narr_kVqatp8M1kKHkvKm7KG-zA"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">9500000</us-gaap:GrantsReceivable>
    <mrkr:FundsReceivedFromGrant
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_AdditionalCpritGrantMember_nxUvKve8xkGalcxFRXPFew"
      decimals="-5"
      id="Narr_GbuSZiUJ30-15E2cfpZuOQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1500000</mrkr:FundsReceivedFromGrant>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_19_2024_To_12_19_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8VZRCOP4d0-aokYe1ivjTA"
      decimals="INF"
      id="Narr_Kxfc4M30UUmOfYSSfs9EOg"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">1783805</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_19_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8uiS2_V-yU681VJlw1Q9uw"
      decimals="INF"
      id="Narr_cRQS0twFoku5WBOPuVhQTA"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">3247445</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_19_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PrivatePlacementWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_On3uaIjHpUqZni5K7dWfLQ"
      decimals="INF"
      id="Narr_umDqUJBWaUS8Q97wi4snrw"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">5031250</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_19_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_NdnoCXF10U2RaVtcYYPkIQ"
      decimals="2"
      id="Narr_Ne6PagSoPEqsguywpJjAKg"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">3.2</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_19_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8uiS2_V-yU681VJlw1Q9uw"
      decimals="3"
      id="Narr_6U-rpc_W9kSWHbTFH02jcA"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">3.199</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_12_23_2024_To_12_23_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_uXfGzxM0uEOSkZZ_6NldVg"
      decimals="-5"
      id="Narr_ZYC-XtA_20O_PXz3Qnpx1A"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">14900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_l3PloWcpf0Wwvh886VQO6w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;3:&#160;&#160;&#160;&#160;SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the Securities Exchange Commission (&#x201c;SEC&#x201d;). Any reference &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;in these footnotes to applicable guidance is meant to refer to the authoritative U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy,&#160;Inc. and GeneMax Pharmaceuticals&#160;Inc.&#160;&#x2013; a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada,&#160;Inc. All significant intercompany balances and transactions are eliminated upon consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accordingly, actual results may differ materially from those estimates. Management considers many factors in selecting appropriate financial accounting policies, controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation expense and income taxes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash, Cash Equivalents, Restricted Cash, and Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash, cash equivalents, and restricted cash at December 31, 2025 consisted of cash and certificates of deposit in institutions in the United States. The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insured limits of $250,000. As of December 31, 2025, the Company had approximately $1.6 million in cash at financial institutions, including $1.0 million of restricted cash at financial institutions, and approximately $15.4 million in U.S. government agency securities, for aggregate cash, cash equivalents, and restricted cash of $17.0 million. As of December 31, 2024, the Company had approximately $1.1 million in cash at financial institutions and approximately $18.1 million in U.S. government agency securities, for aggregate cash and cash equivalents of $19.2 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In the event cash is received from grants in advance of incurring qualifying costs, it is recorded as restricted cash until it is earned and recorded to grant income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Modification of Stock Options &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2025, the Company recorded incremental stock-based compensation expense of $0.3 million pertaining to the modification of stock options in connection with certain consultants. The modification provided for an acceleration of unvested options, resulting in $0.3 million in compensation expense that was immediately recognized, and is reflected in operating expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Patents and Patent Application Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company incurs stock-based compensation expense related to the issuance of common stock and stock options. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Term&lt;/i&gt; &#x2014; The expected life of stock options was estimated using the &#x201c;simplified method,&#x201d; as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Volatility&lt;/i&gt; &#x2014; The Company computes stock price volatility over expected terms based on its historical common stock trading prices. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-Free Interest Rate&lt;/i&gt; &#x2014; The Company bases the risk-free interest rate on the implied yield available on U.S. Treasury zero-coupon issues with an equivalent remaining term. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Dividend&lt;/i&gt; &#x2014; The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company amortizes the fair value of the awards expected to vest on a straight-line basis over the requisite service period of the awards. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received as if the Company had paid cash for those services. Forfeitures are accounted for as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Research and development expenses consist of costs associated with clinical trial programs. Costs incurred by third parties are expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the clinical trial or project and the invoices received from its external service providers. The Company estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each project and total project spending. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone events are achieved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable income in the years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the date of allowances against deferred tax assets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for &#x201c;unrecognized tax benefits&#x201d; is recorded for any tax benefits claimed in the Company&#x2019;s tax returns that do not meet these recognition and measurement standards. As of December 31, 2025 and 2024, no liability for unrecognized tax benefits was required to be reported. The guidance also discusses the classification of related interest and penalties on income taxes. The Company&#x2019;s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the years ended December 31, 2025 and 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Grant Income&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Grant Income represents funding under cost reimbursement programs from government agencies and non-profit foundations for qualified research and development activities performed by the Company. In applying the provisions of ASC Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;), the Company determined that grants and awards are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#x201c;customer&#x201d;, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to each grant or award, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (&#x201c;ASC 808&#x201d;). For grant and awards outside the scope of ASC 808, the Company applies either ASC 606 or IAS 20 by analogy depending on if the arrangement is considered an exchange or non-exchange transaction, respectively. Under both accounting frameworks, revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract. During the two years ended December 31, 2025, the Company did not participate in any collaboration agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Loss per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basic loss per share includes only the weighted average common shares outstanding, without consideration of potentially dilutive securities. Diluted loss per share includes the weighted average common shares outstanding and any potentially dilutive common stock equivalent shares in the calculation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of an entity for which separate discrete financial information is made available and that is regularly evaluated by the chief operating decision maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. The Company is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company&#x2019;s operations are organized and reported as a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its products. The Company&#x2019;s CODM, its chief executive officer, reviews operating results on an aggregate basis and manages the operations as a single operating segment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The accounting policies of the Company&#x2019;s single operating and reportable segment are the same as those described in the summary of significant accounting policies. The measure of segment assets is reported on the consolidated balance sheets as total assets. The CODM evaluates performance and allocates resources based on consolidated net income (loss) that also is reported on the consolidated statements of operations as net loss, and consolidated cash used in operations. The CODM makes operating decisions based on the availability of cash and the allocation of cash to the required expenditures. The significant expenses regularly reviewed by the CODM are consistent with those reported on the Company&#x2019;s consolidated statements of operations, and expenses are not regularly reviewed on a more disaggregated basis for purposes of assessing segment performance and deciding how to allocate resources.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;New Accounting Standards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recently Adopted Accounting Standards&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Improvements to Income Tax Disclosures&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. Effective January 1, 2025, the Company adopted the new standard and applied it retrospectively to prior periods presented. The Company does not believe the new disclosure requirements had a material impact to its financial positions, results of operations and cash flows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In December 2025, the FASB issued ASU 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities. The new standard is intended to establish authoritative guidance on the accounting for government grants received by business entities and reduce diversity in practice. The amendments establish the timing and methods of recognition of both (1) a grant related to an asset and (2) a grant related to income. The amendments also require certain disclosures including the nature of the grant received, the accounting policies used to account for the grant, and significant terms and conditions for the grant. The new guidance is effective for annual reporting periods beginning after December 15, 2028, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The new guidance may be applied on a modified prospective basis, modified retrospective basis, or full retrospective basis. The Company is currently evaluating the impact of ASU 2025-10 on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Income Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures, to improve transparency in financial reporting by requiring entities to present more detailed information about the nature of expenses included within the Income Statement. The guidance will be effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. The Company is in the process of assessing the impact of ASU 2024-03 on its disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;U.S Tax Law Changes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was enacted, introducing significant changes to U.S. tax law, including provisions related to bonus depreciation, interest expense limitations, and the treatment of domestic research and development expenditures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company evaluated the legislation in accordance with ASC 740 and determined that the enactment did not have a material impact on its financial statements for the year ended December 31, 2025.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_4ddmGY66IkKi4U_vh3yWJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the Securities Exchange Commission (&#x201c;SEC&#x201d;). Any reference &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;in these footnotes to applicable guidance is meant to refer to the authoritative U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_irRF92OIR0u6GqNTcmvHVw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy,&#160;Inc. and GeneMax Pharmaceuticals&#160;Inc.&#160;&#x2013; a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada,&#160;Inc. All significant intercompany balances and transactions are eliminated upon consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_cWoKlkIvvES69bkIbxsO-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accordingly, actual results may differ materially from those estimates. Management considers many factors in selecting appropriate financial accounting policies, controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: stock-based compensation expense and income taxes.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_9cnjHORe9ESSvft9mQjoUg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash, Cash Equivalents, Restricted Cash, and Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash, cash equivalents, and restricted cash at December 31, 2025 consisted of cash and certificates of deposit in institutions in the United States. The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insured limits of $250,000. As of December 31, 2025, the Company had approximately $1.6 million in cash at financial institutions, including $1.0 million of restricted cash at financial institutions, and approximately $15.4 million in U.S. government agency securities, for aggregate cash, cash equivalents, and restricted cash of $17.0 million. As of December 31, 2024, the Company had approximately $1.1 million in cash at financial institutions and approximately $18.1 million in U.S. government agency securities, for aggregate cash and cash equivalents of $19.2 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In the event cash is received from grants in advance of incurring qualifying costs, it is recorded as restricted cash until it is earned and recorded to grant income.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Narr_DXcM0RwwEUO_k8P8ZXrvEw"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">250000</us-gaap:CashFDICInsuredAmount>
    <mrkr:CashAtFinancialInstitutions
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="-5"
      id="Narr_0UbuzpZaukmtD9-QCkQrjQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1600000</mrkr:CashAtFinancialInstitutions>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="-5"
      id="Narr_w0SW3x9s5kmgHCVHEFlQ5g"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:USGovernmentAgenciesSecuritiesAtCarryingValue
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="-5"
      id="Narr_jA0Bu8u86kiseEK1AdKhGQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">15400000</us-gaap:USGovernmentAgenciesSecuritiesAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="-5"
      id="Narr_KzDkVdZ1NkaUtxJSH0Jm3w"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">17000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <mrkr:CashAtFinancialInstitutions
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="-5"
      id="Narr_DCWr5MEEEEGd1q7cvVCDuQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1100000</mrkr:CashAtFinancialInstitutions>
    <us-gaap:USGovernmentAgenciesSecuritiesAtCarryingValue
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="-5"
      id="Narr_SKyub4Rw6kueiQN69QV3MQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">18100000</us-gaap:USGovernmentAgenciesSecuritiesAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="-5"
      id="Narr_tJJOC8HM0k6d-67Qrswg7Q"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">19200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_dcKNYSeP9kKE-yCmkd1qUA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Modification of Stock Options &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2025, the Company recorded incremental stock-based compensation expense of $0.3 million pertaining to the modification of stock options in connection with certain consultants. The modification provided for an acceleration of unvested options, resulting in $0.3 million in compensation expense that was immediately recognized, and is reflected in operating expenses.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="-5"
      id="Narr_8LUDRupSyEWznFZ7QwedQg"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="-5"
      id="Narr_O-013-t2bEWsqddPRTpfgw"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_TpbBq8AkYk6Nb6ai-c0x1g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Patents and Patent Application Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred. &lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_tGQRacG07Eu0BkbDKyiIFA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company incurs stock-based compensation expense related to the issuance of common stock and stock options. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Term&lt;/i&gt; &#x2014; The expected life of stock options was estimated using the &#x201c;simplified method,&#x201d; as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Volatility&lt;/i&gt; &#x2014; The Company computes stock price volatility over expected terms based on its historical common stock trading prices. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-Free Interest Rate&lt;/i&gt; &#x2014; The Company bases the risk-free interest rate on the implied yield available on U.S. Treasury zero-coupon issues with an equivalent remaining term. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Dividend&lt;/i&gt; &#x2014; The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company amortizes the fair value of the awards expected to vest on a straight-line basis over the requisite service period of the awards. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received as if the Company had paid cash for those services. Forfeitures are accounted for as incurred.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_yZN38wyKL0qmnh--bhuzSw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Research and development expenses consist of costs associated with clinical trial programs. Costs incurred by third parties are expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the clinical trial or project and the invoices received from its external service providers. The Company estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each project and total project spending. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone events are achieved.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_rwQg16a7skCliOGR7xSaxQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable income in the years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the date of allowances against deferred tax assets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for &#x201c;unrecognized tax benefits&#x201d; is recorded for any tax benefits claimed in the Company&#x2019;s tax returns that do not meet these recognition and measurement standards. As of December 31, 2025 and 2024, no liability for unrecognized tax benefits was required to be reported. The guidance also discusses the classification of related interest and penalties on income taxes. The Company&#x2019;s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the years ended December 31, 2025 and 2024.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Narr_3g1Vv1SHRkG7qavki1vpFg"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Narr_RW28YNm1zkKSIf2yKr9XPg"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Narr_bdZUdpLvK0G2A53e1XYrPQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Narr_5XSP6Gu6YUGhiJPzUultjA"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <mrkr:GrantIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_55mza7XzS0WfLYqkxDkL4A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Grant Income&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Grant Income represents funding under cost reimbursement programs from government agencies and non-profit foundations for qualified research and development activities performed by the Company. In applying the provisions of ASC Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;), the Company determined that grants and awards are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#x201c;customer&#x201d;, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to each grant or award, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (&#x201c;ASC 808&#x201d;). For grant and awards outside the scope of ASC 808, the Company applies either ASC 606 or IAS 20 by analogy depending on if the arrangement is considered an exchange or non-exchange transaction, respectively. Under both accounting frameworks, revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract. During the two years ended December 31, 2025, the Company did not participate in any collaboration agreements.&lt;/p&gt;</mrkr:GrantIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_cgi2zQeZn065USZK_SGcNQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Loss per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basic loss per share includes only the weighted average common shares outstanding, without consideration of potentially dilutive securities. Diluted loss per share includes the weighted average common shares outstanding and any potentially dilutive common stock equivalent shares in the calculation.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_aYzM62BFmUiSbpSJ-ryQrg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of an entity for which separate discrete financial information is made available and that is regularly evaluated by the chief operating decision maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. The Company is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company&#x2019;s operations are organized and reported as a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its products. The Company&#x2019;s CODM, its chief executive officer, reviews operating results on an aggregate basis and manages the operations as a single operating segment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The accounting policies of the Company&#x2019;s single operating and reportable segment are the same as those described in the summary of significant accounting policies. The measure of segment assets is reported on the consolidated balance sheets as total assets. The CODM evaluates performance and allocates resources based on consolidated net income (loss) that also is reported on the consolidated statements of operations as net loss, and consolidated cash used in operations. The CODM makes operating decisions based on the availability of cash and the allocation of cash to the required expenditures. The significant expenses regularly reviewed by the CODM are consistent with those reported on the Company&#x2019;s consolidated statements of operations, and expenses are not regularly reviewed on a more disaggregated basis for purposes of assessing segment performance and deciding how to allocate resources.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_B2O5C0UWCESk34m_y7NFBg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;New Accounting Standards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption. &lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <mrkr:RecentlyIssuedAccountingStandardsAdoptedPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_fs28hrD8WUij9O1kBsFRzw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recently Adopted Accounting Standards&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Improvements to Income Tax Disclosures&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. Effective January 1, 2025, the Company adopted the new standard and applied it retrospectively to prior periods presented. The Company does not believe the new disclosure requirements had a material impact to its financial positions, results of operations and cash flows.&lt;/p&gt;</mrkr:RecentlyIssuedAccountingStandardsAdoptedPolicyTextBlock>
    <mrkr:RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_H0s0YInT9kOSrbKpJ4hLqw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In December 2025, the FASB issued ASU 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities. The new standard is intended to establish authoritative guidance on the accounting for government grants received by business entities and reduce diversity in practice. The amendments establish the timing and methods of recognition of both (1) a grant related to an asset and (2) a grant related to income. The amendments also require certain disclosures including the nature of the grant received, the accounting policies used to account for the grant, and significant terms and conditions for the grant. The new guidance is effective for annual reporting periods beginning after December 15, 2028, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The new guidance may be applied on a modified prospective basis, modified retrospective basis, or full retrospective basis. The Company is currently evaluating the impact of ASU 2025-10 on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Income Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures, to improve transparency in financial reporting by requiring entities to present more detailed information about the nature of expenses included within the Income Statement. The guidance will be effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. The Company is in the process of assessing the impact of ASU 2024-03 on its disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;U.S Tax Law Changes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was enacted, introducing significant changes to U.S. tax law, including provisions related to bonus depreciation, interest expense limitations, and the treatment of domestic research and development expenditures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company evaluated the legislation in accordance with ASC 740 and determined that the enactment did not have a material impact on its financial statements for the year ended December 31, 2025.&lt;/p&gt;</mrkr:RecentlyIssuedAccountingStandardsNotYetAdoptedPolicyTextBlock>
    <us-gaap:MinorityInterestDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_uiDElW5QZ0aqZobQJXvVAw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;4:&#160;&#160;&#160;&#160;NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table sets forth the computation of net loss per share for the years ended December 31, 2025 and 2024, respectively:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,163,620)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,731,315)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average common shares outstanding, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,310,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8,980,207&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average common shares outstanding, diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,310,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8,980,207&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net earnings (loss) per share:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.79)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.19)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,762,878&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 587,704&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock purchase warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,031,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,278,695&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Potentially dilutive securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,794,128&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,866,399&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_7ZzGIoFH20qqmMWTHPpcLQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,163,620)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,731,315)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average common shares outstanding, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,310,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8,980,207&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average common shares outstanding, diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,310,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8,980,207&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net earnings (loss) per share:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.79)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.19)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_Ken_dK3nzEyD-72w7HxzSA_5_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-12163620</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_HP_Ggt4M0Uy0e06ZpXb9nQ_5_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-10731315</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc__H2cqDZU5ku1DRZBBWPkVA_8_3"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">15310308</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_mcGWLCmd9kaqnQte5ZBggg_8_6"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">8980207</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_IGEjDXFB5U-Dz-MRtzRWgA_9_3"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">15310308</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_XgvVJgIe90SJ7pf2CDUAMA_9_6"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">8980207</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="2"
      id="Tc_cLpkEFg1H0Cl1CgQL7uPvQ_12_3"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">-0.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="2"
      id="Tc_cLpkEFg1H0Cl1CgQL7uPvQ_12_3_2"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">-0.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="2"
      id="Tc_ZZLW814dd0ezkVBd936qOQ_12_6"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">-1.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="2"
      id="Tc_ZZLW814dd0ezkVBd936qOQ_12_6_2"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">-1.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_-nqNax1nMEWQ_8jFxyAU7A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,762,878&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 587,704&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock purchase warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,031,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,278,695&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Potentially dilutive securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,794,128&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,866,399&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aSuKfM4-akyKvKZsn6tCGA"
      decimals="INF"
      id="Tc_oG5wFeCIb0Olxzrb28R3Hg_4_2"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">1762878</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_B2nRyEV--0GS0eskNh548A"
      decimals="INF"
      id="Tc_llG9TFW2IEOycnriagLRgg_4_4"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">587704</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_MqvvcKTOj0eV0u3Nau83Wg"
      decimals="INF"
      id="Tc_8L0QiT6aR0OfZ8kLgpOx2w_5_2"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">5031250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_aIjiS1PliUO1FmEZTPTlFQ"
      decimals="INF"
      id="Tc_UvYBun7DUEmOeT3WKmQHiw_5_4"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">8278695</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="INF"
      id="Tc_Q3J1i2neiEWsSxj0f-PMLg_6_2"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">6794128</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="INF"
      id="Tc_rUaZs8qkaUGM2Q85Wip48g_6_4"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">8866399</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_IhoOTUvo6EOlIAcx9iglGg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 5:&#160;&#160;&#160;&#160;&#160;OTHER RECEIVABLE&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Other receivable mainly consists of grant income receivable. Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. The following table summarizes the Company&#x2019;s other receivable balance as of December 31, 2025 and 2024, respectively:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant income receivable:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;CPRIT AML Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 815,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,059,457&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;FDA Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,678&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;SBIR AML Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 162,897&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 244,810&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Decoy Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 59,501&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,822&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;SBIR NHL Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87,417&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;PANACEA Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 190,052&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,502&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total grant income receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,318,981&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,316,591&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,419&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,112&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total other receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,369,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,346,703&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Refer to Note 2 for details related to awarded grants and Note 9 for more information on grant income.&lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <mrkr:ScheduleOfOtherReceivablesCurrentTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_0y2oho4Ur0yulk4GbLZXmw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant income receivable:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;CPRIT AML Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 815,436&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,059,457&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;FDA Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,678&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;SBIR AML Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 162,897&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 244,810&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Decoy Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 59,501&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,822&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;SBIR NHL Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87,417&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;PANACEA Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 190,052&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,502&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total grant income receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,318,981&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,316,591&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,419&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,112&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total other receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,369,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,346,703&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrkr:ScheduleOfOtherReceivablesCurrentTableTextBlock>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_mrLGat3Upk2fb1jB4KArIQ"
      decimals="0"
      id="Tc_ySCVtG4zwUy-umvCU8g_oA_4_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">815436</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_YiV5PV-xXEmJq6NEHauChA"
      decimals="0"
      id="Tc_Ceby3NBIkUySHS8QRXUfKg_4_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">2059457</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_FdaGrantMember_faf3JBchfUmF26_0A8acNw"
      decimals="0"
      id="Tc_7ZKGbqgAB0uwixYSGf7avw_5_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">3678</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_hpcaPdhzZESFYUuK8cOwRw"
      decimals="0"
      id="Tc_WBXzywEiaky3u9FjeRDFBg_6_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">162897</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_-Zh_8JjoQEG-VAt8uJFkjw"
      decimals="0"
      id="Tc_6I9-YqC9W06xmL5qPiIDAg_6_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">244810</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_irhoM80iL0yHiHWgBsAv_Q"
      decimals="0"
      id="Tc_P8qwqyPDNkKYrqJtNYr0Sg_7_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">59501</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_WeW3pJ_MmkC27F7VxYyoRA"
      decimals="0"
      id="Tc_FVN-Id22lUu7tKQ2QzJEkw_7_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">5822</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_ka9khI5BP0KG3WlDMZO44g"
      decimals="0"
      id="Tc_scDkXw6A_UOFSRv2CV6A5Q_8_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">87417</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2025_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_XnQVMZBaJUW4WC5UTNTybw"
      decimals="0"
      id="Tc_urPBM7Adp0ebNR1-IPetew_9_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">190052</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2024_us-gaap_GovernmentAssistanceTypeAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_mMsw9pTVxUmPUqQGanMoDw"
      decimals="0"
      id="Tc_B7725zI5yEmJa_toYJ1hlw_9_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">6502</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_Y08aQd6GVUqs0NnxUXiWqw_10_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1318981</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_lgFfX9n_aUyf6SP5tDS4eQ_10_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">2316591</us-gaap:GrantsReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_5Rgt1e0SsUCw-cnIx8hblQ_11_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">50419</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_hYchkyZ9nE6A5M6F6nppiw_11_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">28112</us-gaap:InterestReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_SykhWgcKi0qB7vfFQepOUA_12_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">2000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_HN6P9lA2tEqqCqcaPI8IXw_13_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1369400</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_WJbmJX1zHEu-N6-AF0kOew_13_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">2346703</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_LDXzrlUy5kKHpNC9jYLcyg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE 6:&#160;&#160;&#160;&#160;ACCOUNTS PAYABLE, ACCRUED LIABILITIES, AND RELATED PARTY PAYABLE&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Accounts payable, accrued liabilities, and related party payable consist of the following as of December 31, 2025 and 2024, respectively:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 793,727&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,066,395&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87,083&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 86,350&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 160,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 293,189&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_dTBoH9MfTE64AKs-oLTQIA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Related party payable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,710,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,638&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 104,591&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 203,928&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 203,429&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,299,384&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,464,454&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The $1.7 million related-party payable as of December 31, 2024 reflects amounts for outsourced product development and manufacturing services. See Note 11: Related Party Transactions.&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_j6Bwm-MrSk-dmgcK6uxNtQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 793,727&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,066,395&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87,083&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 86,350&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 160,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 293,189&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_dTBoH9MfTE64AKs-oLTQIA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Related party payable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,710,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,638&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 104,591&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 203,928&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 203,429&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,299,384&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,464,454&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_4n_qvoZYMUuCY2kgdBpWTQ_3_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">793727</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_rKsQsnCOMkKRKxftJWgFyg_3_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1066395</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_If-k0cyw10O2xc0WGfd6Vw_4_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">87083</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_SFGVjvmaeUOMHFO40GSmeg_4_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">86350</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_JFLQmNe-dUCtjGbk3s801A_5_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">160008</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_kiw4xTwIfEibyjZKOrA5nA_5_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">293189</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_8MvKOFd8IE6N2METRILIdQ_6_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1710500</us-gaap:OtherLiabilitiesCurrent>
    <mrkr:TaxFeesPayable
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_mWLmZYqasEGlIhw4hcE_Dg_7_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">54638</mrkr:TaxFeesPayable>
    <mrkr:TaxFeesPayable
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_iKV6STwixEuxxR-37RmfZQ_7_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">104591</mrkr:TaxFeesPayable>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_stEyeq1sqUi5VigA-u8fbw_8_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">203928</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_K4dq6Yd62EGXKMVdRjiuLg_8_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">203429</us-gaap:OtherAccruedLiabilitiesCurrent>
    <mrkr:AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_OeBCYqvjJEqjyo9E26NrzA_9_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1299384</mrkr:AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent>
    <mrkr:AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_RZHrXshV9ESDd6T2Cq8B-Q_9_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">3464454</mrkr:AccountsPayableAndAccruedLiabilitiesIncludingRelatedPartyPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_SpvmUFoDl0q5J75fLE_V5A"
      decimals="-5"
      id="Narr_PrDyfw8y4kii8_1ICOIl7w"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1700000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_sIUG6n1DO0GZ5lQ2-DzjaQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;7:&#160;&#160;&#160;&#160;STOCKHOLDERS&#x2019; EQUITY&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Common Stock Transactions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has authorized up to 30,000,000 shares of common stock, $0.001 par value per share, for issuance. Significant 2025 and 2024 common stock transactions were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Issuance of Common Stock Pursuant to ATM Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2025, the Company sold 5,358,292 shares of its common stock under the ATM Agreement for gross proceeds of $9.9 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2024, the Company sold 8,178 shares of its common stock under the ATM Agreement for gross proceeds of $37,000. On June 10, 2024, the Company provided notice of its termination of the ATM Agreement with Cantor Fitzgerald &amp;amp; Co. and RBC Capital Markets, LLC. In November 2024, the Company entered into an ATM Agreement with H.C. Wainwright &amp;amp; Co., LLC.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Private Placement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On December 19, 2024, the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;), pursuant to which the Company issued and sold in a private Placement the following securities: (i) 1,783,805 shares of common stock, (ii) Series B Warrants, or Pre-Funded Warrants, to purchase an aggregate of 3,247,445 shares of common stock in lieu of shares of common stock and (iii) Series A Warrants, or Private Placement Warrants, to purchase an aggregate of 5,031,250 shares of common stock. The purchase price per share of common stock and accompanying Private Placement Warrant to purchase a share of common stock was $3.20, and the purchase price per Pre-Funded Warrant and accompanying &lt;span style="-sec-ix-hidden:Hidden_vlSFv0gqUE-B3bsGUvHgiw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Private Placement&lt;/span&gt;&lt;/span&gt; Warrant to purchase a share of common stock was $3.199. Net proceeds from the sale of securities in the Private Placement was approximately $14.9 million, which does not include any proceeds that may be received upon the exercise of any warrants issued in the Private Placement. Both the Pre-Funded Warrants and the Private Placement Warrants are not exercisable until the Company obtains shareholder approval. On March 21, 2025, the Company obtained shareholder approval for the exercise of such warrants. The transaction closed on December 23, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Exercise of Stock Options&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2024, certain outstanding options were exercised for 25,602 shares of common stock providing aggregate proceeds to the Company of approximately &lt;span style="-sec-ix-hidden:Hidden_8t_mC5yobUSo0_SotysiiQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$62,000&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Exercise of Pre-funded Warrants&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2025, certain outstanding pre-funded warrants were exercised for 605,830 shares of common stock providing aggregate proceeds to the Company of $605.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has authorized up to 5,000,000 shares of preferred stock, $0.001 par value per share, for issuance. The preferred stock will have such rights, privileges and restrictions, including voting rights, dividend conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company&#x2019;s board of directors upon its issuance. To date, the Company has not issued any preferred shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Warrant Summary&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes the total warrants outstanding at December 31, 2025:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; as of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; as of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price Per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;New&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issue Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercised&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:34.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Private placement warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;"&gt;5 years&lt;/span&gt;&lt;span style="font-size:8pt;"&gt; from shareholder approval&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,031,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,031,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:34.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pre-funded warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;"&gt;5 years&lt;/span&gt;&lt;span style="font-size:8pt;"&gt; from shareholder approval&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,247,445&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (605,830)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,641,615&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:34.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,278,695&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (605,830)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,672,865&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="INF"
      id="Narr_nQgYxKNeA0CyH0vpgi_Gpw"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="INF"
      id="Narr_VP5fNUS1FkKn0ijWgVtAtA"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_7bCo5DiTM02jrNls_29_eA"
      decimals="INF"
      id="Narr_-IwYwNL6D0S078SlimIslg"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">5358292</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_7bCo5DiTM02jrNls_29_eA"
      decimals="-5"
      id="Narr_9gqN5vv6mkaujJzeUD2Fig"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">9900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_Wv20gcHvB0KjVifO_1x-LQ"
      decimals="INF"
      id="Narr_1--iqg9o-U6FvTW57n0j-A"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">8178</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtMarketOfferingMember_Wv20gcHvB0KjVifO_1x-LQ"
      decimals="0"
      id="Narr_I7Rvdk0Mq0Sjdv8pNAp8uQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">37000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_19_2024_To_12_19_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8VZRCOP4d0-aokYe1ivjTA"
      decimals="INF"
      id="Narr_RyxkOlCioEKrs88BO-4ZKg"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">1783805</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_19_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8uiS2_V-yU681VJlw1Q9uw"
      decimals="INF"
      id="Narr_dwtFobvq-0u-rGsbc2c8AA"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">3247445</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_19_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PrivatePlacementWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_On3uaIjHpUqZni5K7dWfLQ"
      decimals="INF"
      id="Narr_xUP0gE4YAkevAvIknbAm7w"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">5031250</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_19_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_NdnoCXF10U2RaVtcYYPkIQ"
      decimals="2"
      id="Narr_y9H5If8i8kipkTX9qPPOVg"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">3.2</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_19_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8uiS2_V-yU681VJlw1Q9uw"
      decimals="3"
      id="Narr_gXHaHKbSuE6npwEtoiLtIQ"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">3.199</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_12_19_2024_To_12_19_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_O2p_zKEtQUqaRKBbLOCA1g"
      decimals="-5"
      id="Narr_0dU_riRlQEqv9DEuzXOm_A"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">14900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="INF"
      id="Narr_o-1rcVEOt0WJi5wmjqb2Ew"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">25602</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <mrkr:ClassOfWarrantOrRightExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_U2becBy6kUyXW95FuWcLrQ"
      decimals="INF"
      id="Narr_Sx2eO7z4QkyR2yvf9MFidQ"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">605830</mrkr:ClassOfWarrantOrRightExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_U2becBy6kUyXW95FuWcLrQ"
      decimals="0"
      id="Narr_DjQKJsq6gEemKgfDMHrRyg"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">605</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="INF"
      id="Narr_tPEvDDGLnkqh8FdDPdawxA"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="INF"
      id="Narr_75XLY8u260q1ZgZiXfyrcw"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_L2qk2PI_d0GIDLesvhY3hw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; as of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; as of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price Per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;New&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:34.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issue Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercised&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:34.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Private placement warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;"&gt;5 years&lt;/span&gt;&lt;span style="font-size:8pt;"&gt; from shareholder approval&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,031,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,031,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:top;width:34.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pre-funded warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;"&gt;5 years&lt;/span&gt;&lt;span style="font-size:8pt;"&gt; from shareholder approval&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,247,445&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (605,830)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,641,615&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:34.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,278,695&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (605,830)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,672,865&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PrivatePlacementWarrantMember_A7nPIRhbOkCSTYcVdsqkJQ"
      decimals="2"
      id="Tc_qjeQZiyDz0SoYoCb-x_2Vg_5_5"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PrivatePlacementWarrantMember_A7nPIRhbOkCSTYcVdsqkJQ"
      id="Narr_FHzcfSMAfkGdFy7HIwPHIQ">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PrivatePlacementWarrantMember_cafAhZMIDkSljx-lvFkWag"
      decimals="INF"
      id="Tc_1ZNEGNpo3UCdZSucx2wT_w_5_9"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">5031250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PrivatePlacementWarrantMember_A7nPIRhbOkCSTYcVdsqkJQ"
      decimals="INF"
      id="Tc_JThG7gzDeECYO9gSIhohCA_5_15"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">5031250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_jieysXAEz0G_tGMRFzVAhw"
      decimals="3"
      id="Tc_3D5rLukktU6VJCIJayBpag_6_5"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_jieysXAEz0G_tGMRFzVAhw"
      id="Narr_Xq_jKj9LeUu5Z4KqBPi93Q">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_Nng2hqeyCUeMaAu9fclCqA"
      decimals="INF"
      id="Tc_3f3LdvZQvkSdLqqBMO-WGA_6_9"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">3247445</us-gaap:ClassOfWarrantOrRightOutstanding>
    <mrkr:ClassOfWarrantOrRightExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_U2becBy6kUyXW95FuWcLrQ"
      decimals="INF"
      id="Tc_CDz1ymQxC0irdKHNqgAZeA_6_13"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">605830</mrkr:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mrkr_PreFundedWarrantMember_jieysXAEz0G_tGMRFzVAhw"
      decimals="INF"
      id="Tc_I3NXJYs19UWInIl5_aDKfQ_6_15"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">2641615</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="INF"
      id="Tc_6f2XQzgA_EKoT_H5FDOGgA_7_9"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">8278695</us-gaap:ClassOfWarrantOrRightOutstanding>
    <mrkr:ClassOfWarrantOrRightExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="INF"
      id="Tc_Kd3OizEM_EGmKooXMmYL3w_7_13"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">605830</mrkr:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="INF"
      id="Tc_VHMFqwxbNUit821WkvnWNA_7_15"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">7672865</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_tb-C8hXda06dFlIWgW5yoQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;8:&#160;&#160;&#160;&#160;STOCK BASED COMPENSATION&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On May 19, 2020, the Board adopted the 2020 Equity Incentive Plan (&#x201c;2020 Equity Incentive Plan&#x201d;) which replaced the 2014 Omnibus Stock Option Plan. The 2020 Plan was further amended effective May 2022 to increase the number of shares of common stock authorized for issuance under the plan by 850,000 shares. The 2020 Equity Incentive Plan allows for grants of stock options, restricted shares, stock bonuses and other equity-based awards to employees and non-employee directors of the Company. Awards under the 2020 Equity Incentive Plan may be at prices and for terms as determined by the Company&#x2019;s board of directors and may have vesting requirements as determined by the Board, provided that the exercise price for any stock option must be at least equal to the fair market value (as defined in the 2020 Plan) of a share of the stock on the grant date. Once granted, the exercise price of an option may not be reduced without the approval of the Company&#x2019;s stockholders, other than under certain limited circumstances such as a stock split or take any other action with respect to a stock option that would be treated as a repricing under the rules and regulations of the Nasdaq Stock Exchange.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Options granted under the 2020 Equity Incentive Plan have a maximum term of ten years from the date of grant and generally vest over four years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;2025 Equity Incentive Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On February 12, 2025, pursuant to the Company&#x2019;s 2020 Equity Incentive Plan, as amended, the compensation committee of the Company&#x2019;s board of directors approved 50,000 options to purchase the Company&#x2019;s common stock as equity-based incentive awards to the Company&#x2019;s Chief Executive Officer and President, Dr. Juan Vera, and 30,000 options to purchase the Company&#x2019;s common stock as equity-based incentive awards to each Non-Employee Director. Each option award was granted with an exercise price of $1.59 per share, the closing price of the Company&#x2019;s common stock on the Nasdaq Capital Market on February 12, 2025, with the option award vesting in three annual installments, subject to such Optionee&#x2019;s continued service on the applicable vesting date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On October 31, 2025, the board of directors (the &#x201c;Board&#x201d;) of the Company appointed Ms. Kathryn Penkus Corzo to the Company&#x2019;s Board, effective November 1, 2025. In connection with the appointment of Kathryn Penkus Corzo to the Company&#x2019;s Board and pursuant to the Company&#x2019;s 2020 Equity Incentive Plan, the Company granted Ms. Corzo 147,611 stock options to purchase shares of the Company&#x2019;s common stock at an exercise price per share equal to the fair market value per share on the date she was appointed to the Board. The options will vest evenly over thirty-six (36) months and are subject to her continued service as a director.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On October 31, 2025, the Compensation Committee and Board approved a discretionary award of 250,000 stock options at an exercise price per share equal to the fair market value per share on the date of the grant (the &#x201c;CEO Options&#x201d;) to Dr. Juan Vera under the Company&#x2019;s 2020 Plan. The CEO Options vest annually over four years beginning on the anniversary of the grant date of the CEO Options and are subject to the terms and conditions of the 2020 Plan and the Company&#x2019;s form of option award agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 17, 2025, the Compensation Committee of the Board approved additional grant awards to each Non-Employee Director apart from Ms. Corzo. The Company granted each Non-Employee Director a total of 221,741 stock options to purchase shares of the Company&#x2019;s common stock at an exercise price per share equal to the fair market value per share on the grant date, or $0.9548. The options vest fully in one annual installment, subject to such Optionee&#x2019;s continued service through the vesting date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2025, approximately 0.1 million shares of common stock are available to be issued under the 2020 Equity Incentive Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock Options &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A summary of the Company&#x2019;s stock option activity for the years ended December 31, 2025 and December 31, 2024, is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Intrinsic Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life (in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 737,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,317,234&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (25,602)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Canceled/Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (124,589)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 587,704&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 377,767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,202,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Canceled/Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (27,660)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,762,878&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 563,368&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options vested and exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 461,202&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,619&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Black-Scholes option pricing model is used to estimate the fair value of stock options granted under the Company&#x2019;s share-based compensation plans. The weighted average assumptions used in calculating the fair values of stock options that were granted during the years ended December 31, 2025 and 2024, respectively, were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected stock price volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 104.82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table sets forth stock-based compensation expenses recorded during the respective periods:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock Compensation expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 308,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 229,472&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230,617&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock compensation expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 537,540&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 245,864&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the year ended December 31, 2025, the Company recorded incremental stock-based compensation expense of $0.3 million pertaining to the modification of stock options in connection with certain consultants. The modification resulted in an acceleration of $0.3 million in compensation expense that was immediately recognized, and is reflected in operating expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;At December 31, 2025, the total stock-based compensation cost related to unvested awards not yet recognized was $0.9 million. The expected weighted average period for compensation costs to be recognized was 1.8 years. Future option grants will impact the compensation expense recognized.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_5_19_2020_To_5_19_2020_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_-5xby4R-iU6ab24NiQ858Q"
      decimals="INF"
      id="Narr_G7dHydvS8EqokcjtibbOwQ"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_Y5VZDx-btUSB5iQ3XO7H4w"
      id="Narr_5lM0HN6z-kurPmbgWLjwnQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_Y5VZDx-btUSB5iQ3XO7H4w"
      id="Narr_YMWVL0xVy0aH4gxXGao1hw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_2_12_2025_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_-zpixAd6L0ukz7Q5PRFHjw"
      decimals="INF"
      id="Narr_rUQ11NnKKkK5gWtXd5TLVg"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_2_12_2025_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_br-AgiIl10O-PTuaEnCrgA"
      decimals="INF"
      id="Narr_UKcbdkycjESUGCA_vawrVA"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_2_12_2025_To_2_12_2025_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_RyHxP5Ri-UCIy9cqONYc_Q"
      decimals="2"
      id="Narr_HiOR67TLzkW0yyL16peS1w"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">1.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <mrkr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments
      contextRef="As_Of_2_12_2025_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_K5BoRY6DdkuHU8WoQnkViA"
      decimals="INF"
      id="Narr_PfATHC2PQkuiUcRLy5g6rw"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">3</mrkr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_11_1_2025_To_11_1_2025_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_m9FesoReQ0m7x7fy6w2Hag"
      decimals="INF"
      id="Narr_SPs0ZYLRREuKHoOqdz6YjA"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">147611</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_11_1_2025_To_11_1_2025_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_m9FesoReQ0m7x7fy6w2Hag"
      id="Narr_Cr8w0wnTlky9XEUDhTitTQ">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_10_31_2025_To_10_31_2025_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_qkF9ZLP_WkaIr8Qab56IzA"
      decimals="INF"
      id="Narr_iGnkLDMFG0aydbodJuckeg"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_10_31_2025_To_10_31_2025_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_qkF9ZLP_WkaIr8Qab56IzA"
      id="Narr_R3yGpcO_R02KR-w1SD0U2w">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_11_17_2025_To_11_17_2025_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_0n8Ce_-UXUS8UIExWuVJBg"
      decimals="INF"
      id="Narr_HzViOKsBOkGY0FeXzkjd5g"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">221741</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_11_17_2025_To_11_17_2025_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_0n8Ce_-UXUS8UIExWuVJBg"
      decimals="4"
      id="Narr_ZoL7TWujc0yGQKwZq01cig"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">0.9548</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <mrkr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments
      contextRef="As_Of_11_17_2025_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAward2025Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_XfMX7dcV3UWRP3Ne6O4l6Q"
      decimals="INF"
      id="Narr_2wcZaf5vv0uRyI4PubZROA"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1</mrkr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualVestingInstallments>
    <mrkr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_oLyCD0BiIEeiK_BggHiIyw"
      decimals="-5"
      id="Narr_AyZXNtCaYku15ctuJJZsww"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">100000</mrkr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_-bVEXW-w_EGwpCQOIUK8cg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Intrinsic Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life (in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 737,895&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,317,234&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (25,602)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Canceled/Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (124,589)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 587,704&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 377,767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,202,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Canceled/Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (27,660)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,762,878&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 563,368&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:31.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options vested and exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 461,202&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,619&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_jtXp7bckLE2CuJhkJ9PNfg"
      decimals="INF"
      id="Tc_Yyw3E7xtOE6LS0_FlelPqg_5_2"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">737895</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_jtXp7bckLE2CuJhkJ9PNfg"
      decimals="2"
      id="Tc_9I1lO55SfkiuCDoDtOnk9A_5_5"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">25.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2023_jtXp7bckLE2CuJhkJ9PNfg"
      decimals="0"
      id="Tc_0x-P4YvqMkueaO6Mk9qFgQ_5_8"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1317234</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_M_rPwQol10ywKLcDBKqTtw"
      id="Tc_t8s0KTS7z02L0vR7CEoftw_5_10">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="INF"
      id="Tc_pT-Ovwjx9k25wZgP3boquA_7_2"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">25602</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="2"
      id="Tc_UID0De8rnUmuEpZUKmESow_7_5"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">2.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="INF"
      id="Tc_IqQjN7bHnEuX58NQ9hdH-w_8_2"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">124589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="2"
      id="Tc_Blx4wbvgPkKUiaIy99pVCg_8_5"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">42.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="INF"
      id="Tc_CVuoYcFRgUG8YYGubJnG3A_9_2"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">587704</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="2"
      id="Tc_OgrKgrPsSUKNLaxbNH--MA_9_5"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">22.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_bzR54-rgXk6iMSqbtiP5JA_9_8"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">377767</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      id="Tc_YYcDztqRv0a7hAfLMAzPIw_9_10">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="INF"
      id="Tc_EBBBwThXzEOuYqufw5w_yw_10_2"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">1202834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="2"
      id="Tc_qW1g1qByc0a8Auo7qkYkzg_10_5"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">1.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="INF"
      id="Tc_l7HV6_z6hke_x53wk1DenQ_12_2"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">27660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="2"
      id="Tc_0Q3XHRjqZk6ApvWmWcURVQ_12_5"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">35.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="INF"
      id="Tc_4C11Rtt3R0qdEEmc3wkbBw_13_2"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">1762878</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="2"
      id="Tc_CFpU3a0-90-SjE7B1xnfiQ_13_5"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">7.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_9q1st-XWZEanAOJQTHSFiA_13_8"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">563368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tc_eaGs3H7FF06u3IUxVZTjmA_13_10">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="INF"
      id="Tc_4TL2L3B1Hk6LPl73--VljA_14_2"
      unitRef="Unit_Standard_shares_TTeo_ZnuZ0CTHYgSUpciwg">461202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="2"
      id="Tc_4zmv2mqBpU2tybaS2JPf4Q_14_5"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">26.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_WueNICkGu0OWbojy3_RsQw_14_8"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">7619</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tc_dBdIwfLxaEmHzYC0_HM1Jw_14_10">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_z4h7oCPcUkKXLP9An3jeOA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected stock price volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 104.82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="2"
      id="Tc_G4XyQ5fib06bgS8qOnI-Sg_4_3"
      unitRef="Unit_Divide_USD_shares_MlUSflOOPEWxsXEzI_klFQ">1.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tc_woNECRzzm0iVBSvXWLQhFw_5_3">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="4"
      id="Tc_soFZ-AF3ck2CvnwXEobz_g_6_3"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">1.0482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="4"
      id="Tc_m4Go3y9hUkqOq1iBNKiggw_7_3"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">0.0388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="4"
      id="Tc_3GLAvOT7lUuzqbETBNOk0A_8_3"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <mrkr:StockBasedCompensationExpensesTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_SiaGONfMokyFbOmDDsKpzg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock Compensation expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 308,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 229,472&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230,617&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock compensation expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 537,540&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 245,864&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrkr:StockBasedCompensationExpensesTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Ey1Xk4v6f0yORZDZoGT7FA"
      decimals="0"
      id="Tc_GAEaOs_zq0S4h18XcWGPYQ_5_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">308068</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_j5D-je0g6E6fJSRo58Oxow"
      decimals="0"
      id="Tc_0xXHs0-21kmZtyOEUU47oQ_5_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">15247</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1iM8joIEOEKotgV079FgPg"
      decimals="0"
      id="Tc_CNa1Uw8R1EqlwznCQ9Qb-Q_6_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">229472</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Cf4uLI9Y-kqC1zLcm3sQTg"
      decimals="0"
      id="Tc_ZTabiZjBO0qJD8ZtZo0fkQ_6_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">230617</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_UtOzJxUfJkCT1wurwuETNw_7_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">537540</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_tltEeNH2bU2YWzm0USLjjA_7_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">245864</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="-5"
      id="Narr_4J_LuPtGL0GCvt44jwhNew"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="-5"
      id="Narr_niKREVLXQ06FAZlB27W0QQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="-5"
      id="Narr_TseiLtlB6Uex5ek5UtlWfA"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_-on7TYrgzUSy3es3psK7Sw">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_2sWgtwp-002F-4IEh8EOkw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 9: GRANT INCOME&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Grant Income represents funding under cost reimbursement programs from government agencies and non-profit foundations for qualified research and development activities performed by the Company. Revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract (see Note 3). If restricted cash is received from grants in advance of incurring qualifying costs, it is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. The Company had $1.0 million of restricted cash recorded as of December 31, 2025, and none recorded as of December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes grant income recorded for the years ended December 31, 2025 and 2024, by grant:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;CPRIT AML Grant&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;1&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 900,014&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,411,149&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;FDA Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 118,478&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 519,750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;SBIR AML Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 472,208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 982,182&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Decoy Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 391,305&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,822&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;SBIR NHL Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 665,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 665,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;PANACEA Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 425,670&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;CPRIT Pancreatic Grant&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;1&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 573,994&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total grant income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,546,669&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,591,080&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;(1)&lt;/span&gt;&lt;/span&gt;Both CPRIT grants are subject to certain revenue-sharing arrangements, as per the grant agreements (see Note 10).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;If qualifying grant income is earned in advance of cash received from grants, it is recognized as revenue and recorded as other receivable (see Note 5).&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="-5"
      id="Narr_dHomlHE6gkORZiEQiJO-VQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="-5"
      id="Narr_2rxkV7zfqEiI1g4Yo2sGwg"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_d8id3eAPmk-qpKuyOO-Vrw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;CPRIT AML Grant&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;1&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 900,014&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,411,149&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;FDA Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 118,478&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 519,750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;SBIR AML Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 472,208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 982,182&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Decoy Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 391,305&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,822&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;SBIR NHL Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 665,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 665,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;PANACEA Grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 425,670&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;CPRIT Pancreatic Grant&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;1&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 573,994&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total grant income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,546,669&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,591,080&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;(1)&lt;/span&gt;&lt;/span&gt;Both CPRIT grants are subject to certain revenue-sharing arrangements, as per the grant agreements (see Note 10).&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_tIJI_NC6ykGWgCWOPj17jw"
      decimals="0"
      id="Tc_yMPtymiv7Eux2UgikIAOSg_5_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">900014</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasAcuteMyeloidLeukemiaMember_bMeEXnqqVEGomKtJCoNZAA"
      decimals="0"
      id="Tc_T3O_SE5mzECZaj57eCNIww_5_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">4411149</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_ZoSbOHwhNE-hXUpvIJbwbg"
      decimals="0"
      id="Tc_W3CFakxwXEeW9oMznZ2Htw_6_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">118478</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_FdaGrantMember_AKZHg4JWuUyRUOYrneJE0A"
      decimals="0"
      id="Tc_NsI_u1J_fkKByFidUBIYFQ_6_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">519750</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_ziCCxC0XiEqj3xjfTYljxg"
      decimals="0"
      id="Tc__60z81sln0KnioTX0kwSFA_7_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">472208</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchMember_RRTLLDVCo0iNI2tLPudd5w"
      decimals="0"
      id="Tc_1ejyCffK00CtT7UlOA1DQQ_7_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">982182</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_qnTBapqjVEaOu5WEAR6N1A"
      decimals="0"
      id="Tc_HTGNQ3k8nki3Kw_U0t3yLA_8_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">391305</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthNationalCancerInstituteGrantMember_qobRXgqC6kWkIYzc8lU_ag"
      decimals="0"
      id="Tc_sP5-Gn6hkUC7nONzwyJdrA_8_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">5822</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_v3gveAJvr0u79DQtC91MKA"
      decimals="0"
      id="Tc_ZDMg7ietCke0C4YVOLer8w_9_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">665000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForLymphomaGrantMember_dJoyNhvuRUeMzzqqNeKOvQ"
      decimals="0"
      id="Tc_u1bJ4sSrU0aGN1PKLKrBOA_9_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">665000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_670n_eqWFEyvZOe0MstmvA"
      decimals="0"
      id="Tc_Pd-VVFCJck2oDpQq7Rmofg_10_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">425670</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_mrkr_NationalInstitutesOfHealthSmallBusinessInnovationResearchForPancreaticCancerMember_CkarEX95-0qd9acV3OWC_Q"
      decimals="0"
      id="Tc_y10XtJyvAE6sek46jxqnTQ_10_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">7177</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_mrkr_CpritPancreaticGrantMember_YmkzplPQXEqeidRVY8TO_g"
      decimals="0"
      id="Tc_D677NjDBA0aYRXrbE2BR-w_11_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">573994</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_ProductOrServiceAxis_us-gaap_GrantMember_6LnqjjsZJEiYA6ZxeN_-8Q"
      decimals="0"
      id="Tc_oMIlyEWjZEm8sgiZo9KPQQ_12_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">3546669</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_GrantMember_UiYnDW3Fo0WMqnl0BxBg_w"
      decimals="0"
      id="Tc_n6CewRpxm0KwntaOYK0Nuw_12_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">6591080</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_10R4yNOTBUWrvqfiEKgGVw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;10:&#160;&#160;&#160;&#160;COMMITMENTS AND CONTINGENCIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cancer Prevention and Research Institute of Texas&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from CPRIT to support the Company&#x2019;s clinical investigation of MT-401 (the &#x201c;CPRIT AML Grant&#x201d;). In December 2024, the Company received notice of an additional $9.5 million grant from CPRIT to support the clinical investigation of MT-601 in patients with pancreatic &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;cancer (&#x201c;the CPRIT Pancreatic Grant&#x201d;). Both CPRIT grants contain identical terms surrounding intellectual property and revenue sharing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Per the CPRIT grant agreements, the Company will retain ownership over any intellectual property developed under the contracts (the &#x201c;Project Results&#x201d;). With respect to non-commercial use of any Project Results, the Company agreed to grant to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with the right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, solely for academic, research, and other non-commercial purposes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;If the Company&#x2019;s products become commercially saleable, the Company is obligated to make payments to CPRIT, with respect to net sales of any product covered in the contract, equal to a percentage of revenue ranging from the low-to-mid single digits. These payments will continue up to and until CPRIT receives an aggregate amount of 400% of the sum of all monies paid to the Company by CPRIT under the grant agreements. If the Company is required to obtain a license from a third party to sell any such product, the revenue sharing percentages may be reduced. In addition, once the Company has paid CPRIT 400% of the monies received under the grant agreements, the Company will continue to pay CPRIT a revenue-sharing percentage of 0.5% for the remainder of the Revenue Term as specified in the grant agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;License Agreement with the Baylor College of Medicine&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In March 2018, the Company entered into an exclusive license agreement with BCM under which the Company acquired a worldwide, exclusive license to BCM&#x2019;s rights in and to certain intellectual property rights, including a European patent to develop and commercialize MAR-T cell product candidates (the &#x201c;BCM License Agreement&#x201d;). In exchange for the license, the Company issued shares of its common stock to BCM valued at approximately $5.0 million at the time of issuance, agreed to make royalty payments to BCM upon commercial sales according to the royalty schedule in the BCM License Agreement, under which the royalty percentages increase in proportion to the aggregate net sales, and agreed to pay BCM certain milestone payments up to an aggregate of $64.85 million. The milestone payments are based upon the occurrence of nine particular milestones relating to completion of the first dosing in clinical trials for a first and second distinct product, FDA approval, and achievement of certain net sales goals. The Company is also responsible for sublicensing fees and for reimbursing BCM for related-party expenses. In addition, upon a liquidity event (as defined in the BCM License Agreement) of the Company, BCM will receive a one-time liquidity incentive payment of 0.5% of the liquidity event proceeds (as defined in the BCM License Agreement).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, we may become involved in legal proceedings, including those arising in the ordinary course of our business. We are not currently a party to any material legal proceedings that we believe could have an adverse effect on our business, operating results or financial condition.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <mrkr:GrantReceived
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_RelatedPartyTransactionAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_AFB5466R20GWPhFeBp81GQ"
      decimals="-5"
      id="Narr_daOWZMHXz029-oWjnqnRRQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">13100000</mrkr:GrantReceived>
    <mrkr:GrantReceived
      contextRef="Duration_12_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_K0kZGOM0S0iI7apUnHkXog"
      decimals="-5"
      id="Narr_4QMteHQU1EC0JVi3ajplTA"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">9500000</mrkr:GrantReceived>
    <mrkr:GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_J7SfSASjZE-svWLtQE3gbg"
      decimals="2"
      id="Narr_EvEBdAU1qUSKNUFcBoIpNw"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">4</mrkr:GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived>
    <mrkr:GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_J7SfSASjZE-svWLtQE3gbg"
      decimals="2"
      id="Narr_Ez7DVfHIK0q_wNcDlzsaLA"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">4</mrkr:GrantAgreementPaymentsRequiredPercentageOfNetSalesToGrantsReceived>
    <mrkr:GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasGrantAgreementMember_J7SfSASjZE-svWLtQE3gbg"
      decimals="3"
      id="Narr_80LID4UOCEua73lKlhJ2rQ"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">0.005</mrkr:GrantAgreementRevenueSharingPercentageRemainderOfRevenueTerm>
    <mrkr:SaleOfStockValueOfSharesIssuedInTransaction
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineLicenseAgreementMember_mKK3QAV17UG31xtSaZ_jxQ"
      decimals="-5"
      id="Narr_ObvtPPNRGku-BuXIVxLL3A"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">5000000</mrkr:SaleOfStockValueOfSharesIssuedInTransaction>
    <mrkr:LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineLicenseAgreementMember_Eej9dmqQ10SaSsQkQOu8NQ"
      decimals="-4"
      id="Narr_ZNta5IsqfUqMVRVDocJw-g"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">64850000</mrkr:LicenseAgreementMaximumMilestonePaymentsAgreedToBePaid>
    <mrkr:LicenseAgreementLiquidityIncentivePaymentPercentage
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineLicenseAgreementMember_mKK3QAV17UG31xtSaZ_jxQ"
      decimals="3"
      id="Narr_95e8PFNEvUa655Z206E37w"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">0.005</mrkr:LicenseAgreementLiquidityIncentivePaymentPercentage>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_glWwU1366U69zDcrYjWj8Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;11:&#160;&#160;&#160;&#160;RELATED PARTY TRANSACTIONS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table sets forth related party transaction expenses recorded for the years ended December 31, 2025 and 2024, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Baylor College of Medicine&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,218,138&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,723&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cell Ready&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,266,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,846,456&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Wilson Wolf Manufacturing Corporation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,543&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,568,485&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,853,179&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;"&gt;As of December 31, 2025 and 2024, nil and $1.7 million, respectively, of related party transactions are included in accounts payable and accrued liabilities. See Note 6 for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Agreements with The Baylor College of Medicine (&#x201c;BCM&#x201d;)&lt;/i&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In November&#160; 2018, January 2020 and February 2020, the Company entered in Sponsored Research Agreements with BCM, which provided for the conduct of research for the Company by credentialed personnel at BCM&#x2019;s Center for Cell and Gene Therapy. On April 1, 2025, the Company sighed Amendment #1 to the Sponsored Research and Product Development Agreement with BCM to perform research on &#x201c;Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T-Cell Product Strategy.&#x201d;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In September 2019, May 2020 and July 2021, the Company entered into Clinical Supply Agreements with BCM, which provided for BCM to provide to the Company multi tumor antigen specific products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In October 2019, the Company entered in a Workforce Grant Agreement with BCM, which provided for BCM to provide to the Company manpower costs of projects for manufacturing, quality control testing and validation run activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In August 2020, the Company entered in a Clinical Trial Agreement with BCM, which provided for BCM to provide to the Company investigator-initiated research studies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has also entered into a Clinical Site Agreement and Laboratory Service Agreement with BCM, pursuant to which BCM conducts clinical trials for the Company and testing of Marker&#x2019;s product candidates to develop an optimized potency assay.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;BCM is also a shareholder of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the years ended December 31, 2025 and 2024, the Company incurred $3.2 million and $7,000 in expenses related to services and manufacturing costs and paid BCM approximately $3.0 million and $0.1 million for invoices received, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Purchases from Wilson Wolf&lt;/i&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In 2025, the Company utilized Wilson Wolf for the purchases of cell culture devices. Mr. John Wilson is a former director of the Company and is serving as the CEO of Wilson Wolf Manufacturing Corporation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the years ended December 31, 2025 and 2024, the Company incurred approximately $0.1 million and nil, respectively, in expenses related to cell culture devices and paid Wilson Wolf approximately $0.1 million and nil respectively, for invoices received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Purchases from Cell Ready, LLC.&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company has utilized Cell Ready, LLC for clinical manufacturing supply and product development. Cell Ready, which is owned by a former director, Mr. John Wilson, is a contract development and manufacturing organization (&#x201c;CDMO&#x201d;). On February 22, 2024, the Company entered into a 3-year Master Services Agreement for Product Supply (the &#x201c;MSA&#x201d;) with Cell Ready. During the years ended December 31, 2025 and 2024, the Company incurred $0.8 million and $5.8 million in expenses related to services and manufacturing costs, respectively, and paid $2.6 million and $5.5 million for invoices received, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On March 27, 2025, the Company mutually agreed with Cell Ready to terminate the MSA. In connection therewith, the Company entered into a settlement and release agreement with Cell Ready pursuant to which the Company paid Cell Ready approximately $453,000 and the parties provided one another with mutual releases of all claims associated with any and all agreements between the Company and Cell Ready.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_c2QgrlEFNkO2Ek7C015O_g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Baylor College of Medicine&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,218,138&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,723&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cell Ready&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,266,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,846,456&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Wilson Wolf Manufacturing Corporation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,543&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:70.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,568,485&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,853,179&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_Ek7VnObDF0qwBQZljA5lrg"
      decimals="0"
      id="Tc_HnqVc_nqNEyi-7byVsCK7A_4_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">3218138</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_y1zLnl6EqUepjN6-dcbOxA"
      decimals="0"
      id="Tc_LRmXRn9Ot0eDmn9SWEP00A_4_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">6723</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_CellReadyMember_EXj1TZHoG0iefhOIN4rydg"
      decimals="0"
      id="Tc_ZKCw8hn8nkSgUX44w_-tPQ_5_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1266804</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_CellReadyMember_4FOpwyVQrECS-MHeaC1tvw"
      decimals="0"
      id="Tc_UX1M1pIJ8keM4y7AOCqwMQ_5_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">5846456</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_1TeDARXsOkC9hEbasgXmxA"
      decimals="0"
      id="Tc_o5tH_5JUGkW07kt8zPAkAw_6_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">83543</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_UKMKS0Yvc02qtM-M8XGg3g_7_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">4568485</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_96y7kUIxgkOv4kKf7QMkXw_7_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">5853179</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_mrkr_CellReadyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_AVpatNJHyUqIpBAODzA4gA"
      decimals="-5"
      id="Narr_HE_5v1gfQ0-4Sy3GiZ7Qow"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_mrkr_CellReadyMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__-jgDBmfiUmEu0GZmK8-5g"
      decimals="-5"
      id="Narr_fPhcHiHneE-qQzlzCEKlhw"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1700000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineMember_ip2nTF_Fk0CYXX-yEMZW9Q"
      decimals="-5"
      id="Narr_YM0F_sNkiUqhR9fFseD2Yw"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">3200000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineMember_-usF9LGyt0GIxeKFzPNwug"
      decimals="0"
      id="Narr_6Z035kpvtEGOAvT76251Ow"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">7000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <mrkr:InvoicesReceivedForServicesAndManufacturingCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineMember_ip2nTF_Fk0CYXX-yEMZW9Q"
      decimals="-5"
      id="Narr_az-t6fEtVUGb7vIc7nTMGQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">3000000</mrkr:InvoicesReceivedForServicesAndManufacturingCosts>
    <mrkr:InvoicesReceivedForServicesAndManufacturingCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mrkr_BaylorCollegeOfMedicineMember_-usF9LGyt0GIxeKFzPNwug"
      decimals="-5"
      id="Narr_qXupcb4gj0KFWgS59XBJEA"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">100000</mrkr:InvoicesReceivedForServicesAndManufacturingCosts>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_WilsonWolfManufacturingCorporationMember_SnKdFpBTG0ewLmW3QKOiwA"
      decimals="-5"
      id="Narr_4QC5R65SWkmDJrZGyYSGjQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">100000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mrkr_WilsonWolfManufacturingCorporationMember_88XPTdVeZEeIbHu_8g-p9A"
      decimals="-5"
      id="Narr_g2dY_kuybEKii6dHHRl8ew"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">0</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <mrkr:InvoicesReceivedForServicesAndManufacturingCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_WilsonWolfManufacturingCorporationMember_SnKdFpBTG0ewLmW3QKOiwA"
      decimals="-5"
      id="Narr_Lff3FCrPAEedL0Xgal8xNQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">100000</mrkr:InvoicesReceivedForServicesAndManufacturingCosts>
    <mrkr:InvoicesReceivedForServicesAndManufacturingCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mrkr_WilsonWolfManufacturingCorporationMember_88XPTdVeZEeIbHu_8g-p9A"
      decimals="-5"
      id="Narr_-LAVEXBfQ0KN0OnK9Z4eqQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">0</mrkr:InvoicesReceivedForServicesAndManufacturingCosts>
    <mrkr:MasterServicesAgreementTerm
      contextRef="Duration_2_22_2024_To_2_22_2024_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_66lUgXxPyUi3q214hjo-SQ"
      id="Narr_bMbIwE3oEUyiyz1wthRLiw">P3Y</mrkr:MasterServicesAgreementTerm>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_zGmyKdpTO0WFcYUPxTzPtA"
      decimals="-5"
      id="Narr_yAFXd2PtQ0q744Cj3JIYfQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">800000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_c3M_pD1k30WAzZa10zvfBQ"
      decimals="-5"
      id="Narr_83_qcav76keDMivcT9FL6w"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">5800000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <mrkr:InvoicesReceivedForServicesAndManufacturingCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_zGmyKdpTO0WFcYUPxTzPtA"
      decimals="-5"
      id="Narr_-9zKnJZzxUOGelbTSbwgvw"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">2600000</mrkr:InvoicesReceivedForServicesAndManufacturingCosts>
    <mrkr:InvoicesReceivedForServicesAndManufacturingCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_mrkr_CellReadyAgreementMember_c3M_pD1k30WAzZa10zvfBQ"
      decimals="-5"
      id="Narr_RwG-wgYVsECANdZjVp6Baw"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">5500000</mrkr:InvoicesReceivedForServicesAndManufacturingCosts>
    <mrkr:GainLossOnEarlyTerminationOfVendorAgreement
      contextRef="Duration_3_27_2025_To_3_27_2025_us-gaap_RelatedPartyTransactionAxis_mrkr_CellReadyAgreementMember_JD_kClq_cE2FGVMW6U031Q"
      decimals="0"
      id="Narr_X6PlNOYbjku3iaP5r2ghcw"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">453000</mrkr:GainLossOnEarlyTerminationOfVendorAgreement>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_wmeUJiu0O0uzhUECRFjxtg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;12:&#160;&#160;&#160;&#160;INCOME TAXES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has no federal income tax expense due to operating losses incurred for the years ended December 31, 2025, and 2024, respectively. The Company recognized ($15,156) and $49,953 in state tax (benefit) expense for the years ended December 31, 2025 and 2024, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The effects of temporary differences that give rise to significant portions of the deferred tax assets as of December 31, 2025 and 2024 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred Tax Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net Operating Loss Carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,896,185&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,724,771&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock Compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,548,803&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,670,477&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Capitalized R&amp;amp;E&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,777&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,868,640&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Reserves&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,072&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and Development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 811,961&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 733,328&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,325,798&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,997,216&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Valuation Allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (43,325,798)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;(40,997,216)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Deferred Tax Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Deferred Tax Liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Deferred Tax Assets/(Liabilities)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the history of losses, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized and has established a full valuation allowance for the years ended December 31, 2025 and 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;The Company has approximately $186.8 million of federal and $38.6 million of state Net Operating Losses (&#x201c;NOL&#x201d;s) that may be available to offset future taxable income, if any. The federal net operating loss carryforwards of $38.4 million, if not utilized, will expire between 2030 and 2037. The federal net operating loss carryforwards of $148.4 million generated in 2018 and thereafter are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely. The state net operating loss carryforwards of $21.9 million, if not utilized, will begin to expire in 2035. The state net operating loss carryforwards of $16.7 million generated in 2018 and thereafter are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company has federal and state research and development tax credit carryforwards of $0.7 million and $0.1 million, respectively, available to offset future federal income taxes. The research and development tax credit carryforwards begin to expire in 2030.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;In accordance with Section&#160;382 of the Internal Revenue code, the usage of the Company&#x2019;s net operating loss carryforwards may be limited in the event of a change in ownership. A full Section&#160;382 analysis has not been prepared and NOLs could be subject to limitation under Section&#160;382.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;On July 4, 2025, the One Big Beautiful Bill Act (&#x201c;OBBBA&#x201d;) was signed into law. Key corporate tax provisions include the restoration of 100% bonus depreciation, immediate expensing for domestic research and experimental expenditures, changes to Section 163(j) interest limitations, updates to Global Intangible Low-Taxed Income and Foreign-Derived Intangible Income rules, amendments to energy credits, and expanded Section 162(m) aggregation requirements. In accordance with Accounting Standards Codification 740, Income Taxes (&#x201c;ASC 740&#x201d;), the effects of the new tax law were recognized in the period of enactment. Due to the Company&#x2019;s valuation allowance position, the provisions of the OBBBA did not have an impact on the Company&#x2019;s income tax provision.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;The Company&#x2019;s income tax returns for 2022 to 2024 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;For the years ended December 31, 2025, and 2024, the expected tax (benefit) expense based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:43.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percent of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percent of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Pretax Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Pretax Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,557,543)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,243,086)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (15,156)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,953&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.50)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,336,604&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19.30)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,271,570&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11.90)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Nontaxable or nondeductible items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 90,207&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.70)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.30)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;SBC cancellations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 130,732&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 943,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8.77)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax provision/(benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (15,156)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.00)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,953&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.47)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognized approximately $15,156 in state tax benefit for the year ended December 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In accordance with ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, the Company updated the presentation of its effective tax rate reconciliation to reflect the standardized categories required by the new guidance. The effective tax rate reconciliation for the year ended December 31, 2024 has been recast for comparative purposes to conform to the current-year presentation. The recast was solely for presentation purposes and did not result in any changes to the Company&#x2019;s previously reported income tax expense, effective tax rate, or other financial statement amounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. As of December 31, 2025, and 2024, there were no unrecognized tax benefits. The Company recognizes accrued interest and penalties as income tax expense. No amounts were accrued for the payment of interest and penalties at December 31, 2025 and 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position in the next year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table sets forth a summary of income tax payments made and income tax refunds received during the year ended December 31, 2025, and 2024 as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.12%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Payment (Refund)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Payment (Refund)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Jurisdiction&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Texas&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 37,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 64,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other US States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,150&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Income Taxes Paid&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 72,150&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Narr_AxfM-SKCGESuBcrI89d3uA"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Narr_zXg6vz7PAUiqqbI2Gc4cDw"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Narr_CPAw3LC7mEWWGEJ541xKww"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-15156</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Narr_2TYrSoMybUiArZKBTUCzTg"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">49953</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_tX6gvHw7s0WjMSuTFXzNmg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred Tax Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net Operating Loss Carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,896,185&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,724,771&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock Compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,548,803&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,670,477&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Capitalized R&amp;amp;E&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,777&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,868,640&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Reserves&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,072&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and Development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 811,961&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 733,328&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,325,798&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,997,216&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Valuation Allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (43,325,798)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;(40,997,216)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Deferred Tax Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Deferred Tax Liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:69.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Deferred Tax Assets/(Liabilities)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_yQPQ5yTROEWEcSY2q-4ryw_5_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">40896185</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_hrQ-8x1Cu0eLsPfuZlhtUA_5_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">30724771</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <mrkr:DeferredTaxStockBasedCompensation
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_vX2wr9O1g0CMJfqYb_OQFg_6_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1548803</mrkr:DeferredTaxStockBasedCompensation>
    <mrkr:DeferredTaxStockBasedCompensation
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_KwzotfrTb0i3pkJDMB6K_Q_6_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1670477</mrkr:DeferredTaxStockBasedCompensation>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_au2XIrkIrECuYwlJysakcg_7_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">29777</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_xGPFqoAhDU6qHElTB7TNUg_7_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">7868640</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_LmY2x5fVdUGbJW_A7z4e1Q_8_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">18072</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_3JXnmvl16ESZwWHevWgCKQ_9_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">21000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_EwKAxqToF0OnH1tMUMVhKw_10_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">811961</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_aL4w5-NAMUuYOlOh6eTpNw_10_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">733328</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_23PAEXaYJkupbbMgUXD6gQ_11_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">43325798</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_qW7KQSkeikCfa-MdpW_sRA_11_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">40997216</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Tc_oSRz5vcgOUWvwI9e__LefA_12_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">43325798</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Tc_oO2mRTCrSUWOPM18u8c--w_12_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">40997216</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="-5"
      id="Narr_BPX9IOX_NkGYtVJgrgVi_w"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">186800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="-5"
      id="Narr_mPc0xG4F4EWBY9o-ohSPgg"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">38600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="-5"
      id="Narr_TMOSOvMCLUG_j7NW3admQg"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">38400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <mrkr:TaxCreditCarryforwardsExpirationPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_C8Y2A7owIk2faRvV8W-FhA">2030</mrkr:TaxCreditCarryforwardsExpirationPeriod>
    <mrkr:TaxCreditCarryForwardExpirationYearRangeEnd
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Narr_t2k6JS1EZEaW0Br8gmFAnQ">2037</mrkr:TaxCreditCarryForwardExpirationYearRangeEnd>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_18qBhBV9dU2bbek_wtQbrg"
      decimals="-5"
      id="Narr_h_OckOZ5VUC0GBe07cupiw"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">148400000</us-gaap:OperatingLossCarryforwards>
    <mrkr:OperatingLossCarryforwardsLimitationPercentage
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_at2LqTEclEeq_pEAvIINhA"
      decimals="2"
      id="Narr_fOFlYKK9EkWjqHjraFYWLQ"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">0.80</mrkr:OperatingLossCarryforwardsLimitationPercentage>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="-5"
      id="Narr_wbZRJ19bski-mmaf_s1MFg"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">21900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ESA9zEAYIUOC4PrJsuQIKw"
      decimals="-5"
      id="Narr_Qhp-9FylO0mK4JvtR-9utg"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">16700000</us-gaap:OperatingLossCarryforwards>
    <mrkr:OperatingLossCarryforwardsLimitationPercentage
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_FwxvILLeMU2KaVIewcISUw"
      decimals="2"
      id="Narr_JyQwVY8mQECpLphNpzZeDg"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">0.80</mrkr:OperatingLossCarryforwardsLimitationPercentage>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2025_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember__a5PjJFdNkGHBThsnBK4rA"
      decimals="-5"
      id="Narr_Q_qESbvC20S1CGR0dW8aCg"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_jAeiudl5qEe8J-4VzRHRzg"
      decimals="-5"
      id="Narr_w_nawXy6Z0mB9d3dPmh6hw"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_3epxXl08pE2GjPeG6cNeQQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:43.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percent of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percent of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Pretax Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Pretax Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,557,543)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,243,086)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (15,156)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,953&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.50)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,336,604&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19.30)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,271,570&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11.90)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Nontaxable or nondeductible items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 90,207&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.70)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.30)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;SBC cancellations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 130,732&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 943,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8.77)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax provision/(benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (15,156)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.00)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,953&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.47)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_jVqAs_8wWU2rKECzfRfrog_5_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-2557543</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="4"
      id="Tc_rjvCUaRBVkCr-oYRaDukZw_5_5"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_XdFCwprrH0iFSitUCqvI4w_5_8"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-2243086</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="4"
      id="Tc_IpsPGI_wu0-oA1B5C2hchA_5_10"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_4I1XiwFDfkCGWjGzQ9O3hQ_6_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-15156</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="4"
      id="Tc_W6Zb36M_MEesUcVHWcsUfQ_6_5"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_ESYHQBbuOEKyZkvoDPD8Lw_6_8"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">49953</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="4"
      id="Tc_RzLcm1miNkGBI8dtcqqiBw_6_10"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_xqQxiitbE0KmloMdz0aXLg_7_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">2336604</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="4"
      id="Tc_5GigfI-FUUCkPehh7xQ0-g_7_5"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">-0.193</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_xiouXU5E7EKVRJuyanWY5A_7_8"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">1271570</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="4"
      id="Tc_WqNXy38dckevoh1F8xbo5w_7_10"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">-0.119</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_pLX2jGp2FEi73L4nN8bdTA_8_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">90207</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="4"
      id="Tc_OxVDNzUzhkWKxVx18QpcoQ_8_5"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_P3PY2d9HhkqMVsocV9V_fw_8_8"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">27712</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="4"
      id="Tc_4n_ZTpw9YUqbZgPdfm3HrA_8_10"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_kuwGx6MhTU2CZomSJ9EP6A_10_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">130732</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="4"
      id="Tc_Avo_OOunyUGxNUcMQfdMgQ_10_5"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_YMsqNcF3vEOSlIDayq6qNQ_10_8"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">943804</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="4"
      id="Tc_YaetVGJTkkSmRmQ92WRRfQ_10_10"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">-0.0877</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_KbJiq_X3XUCK22tfxDcLwg_11_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-15156</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="4"
      id="Tc_7ICJ-t6tFUKTE5rYDf3CLw_11_5"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_NxBZQqcNbUeMS2w4zHW-Ag_11_8"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">49953</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="4"
      id="Tc_rI_MMROxGE2XoSzSsymgyQ_11_10"
      unitRef="Unit_Standard_pure_Efb4QY58r0S9DYVZFzNQ4A">-0.0047</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Narr_xvVtk5BsqECWotnKZGPPEA"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">-15156</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Narr_bjA_Hq3sA0awSDBePBYiiQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Narr_skacmqmp4EKiN3Ca5EE49g"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2024_7uJsmx0v9UOFjlJkA_EIpw"
      decimals="0"
      id="Narr_KufL0WNZY0q4SqAxlWTyAg"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2025_hsyZl0T1CUGpMgW5jutAcw"
      decimals="0"
      id="Narr_cM6H-WcG9UGMB1hiFR8JwQ"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <mrkr:IncomeTaxPaymentsByJurisdictionTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_IbgbJtLgSkCHlERBkyDvvA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.12%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Payment (Refund)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Payment (Refund)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Jurisdiction&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Texas&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 37,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 64,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other US States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,150&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Income Taxes Paid&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 72,150&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</mrkr:IncomeTaxPaymentsByJurisdictionTableTextBlock>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_stpr_TX_Rjqllw7i7k-FAGtEiFvgPQ"
      decimals="0"
      id="Tc_U2VzoHSKeEmWogR3_FO6Uw_8_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">37000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_stpr_TX_B-Dm5j-e00KX7oWR9bXJxw"
      decimals="0"
      id="Tc_yqUfMWmTtEG0dxHL6OHlHg_8_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">64000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalTaxJurisdictionOtherMember_X-zB0CIm-UCdX3pra_QnCw"
      decimals="0"
      id="Tc_pnYjz01yoEym0IrlYLA06A_9_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">5000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalTaxJurisdictionOtherMember_RP8A9ma7LU69CXCfisa1tw"
      decimals="0"
      id="Tc_KN-akuz9cUKJOKqBDFHkRg_9_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">8150</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      decimals="0"
      id="Tc_9HU9Wo2oaEylFzWbeqXrJw_10_3"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">42000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2024_To_12_31_2024_oDR_LTFH3UeMVQk0mJbG0g"
      decimals="0"
      id="Tc_Y05CidBVLkqEPYLVaPrrNQ_10_6"
      unitRef="Unit_Standard_USD_tjPF0vFJskW5_3-_acRu5A">72150</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_pShaFqdikUGSsQD9KGt9rw"
      id="Tb_RgSF50x5kkmFYJl-ntxc8A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 13:&#160;&#160;&#160;&#160;SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company has evaluated subsequent events and transactions that occurred up to the date these consolidated financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment to or disclosure in the unaudited condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
